<SEC-DOCUMENT>0001564590-21-028010.txt : 20210514
<SEC-HEADER>0001564590-21-028010.hdr.sgml : 20210514
<ACCEPTANCE-DATETIME>20210514160640
ACCESSION NUMBER:		0001564590-21-028010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210514
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ImmunityBio, Inc.
		CENTRAL INDEX KEY:			0001326110
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				431979754
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37507
		FILM NUMBER:		21924574

	BUSINESS ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 633-0300

	MAIL ADDRESS:	
		STREET 1:		3530 JOHN HOPKINS COURT
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NantKwest, Inc.
		DATE OF NAME CHANGE:	20150713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Conkwest, Inc.
		DATE OF NAME CHANGE:	20140416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZelleRx Corp
		DATE OF NAME CHANGE:	20050504
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ibrx-10q_20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4046635+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ibrx="http://www.immunitybio.com/20210331" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ibrx-10q_20210331.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001326110_20210101_20210331">10-Q</ix:nonNumeric>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001326110_20210101_20210331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001326110_20210101_20210331">2021</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001326110_20210101_20210331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001326110_20210101_20210331">0001326110</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001326110_20210101_20210331">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000013" name="dei:EntityCurrentReportingStatus" contextRef="C_0001326110_20210101_20210331">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000014" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001326110_20210101_20210331">Yes</ix:nonNumeric>
			<ix:nonNumeric id="F_000959" name="ibrx:OptionExpirationDateExtendedPeriod" contextRef="C_0001326110_20210101_20210331">P30D</ix:nonNumeric>
			<ix:nonNumeric id="F_000962" name="ibrx:ModifiedOptionsExercisablePeriod" contextRef="C_0001326110_20210101_20210331">P90D</ix:nonNumeric>
			<ix:nonNumeric id="F_001016" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">P70M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210331" decimals="INF">0</ix:nonFraction>
			<ix:nonNumeric id="F_000742" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210331">P10Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000741" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210331">P2Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000744" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000743" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210331">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000837" name="ibrx:RelatedPartyTransactionInitialTermOfAgreement" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000838" name="ibrx:RelatedPartyAgreementRenewalTerm" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000854" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000868" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000873" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000874" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">P7Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000875" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000890" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_001015" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000816" name="ibrx:InitialTermOfAgreement" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">P1Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000828" name="ibrx:RelatedPartyTransactionInitialTermOfAgreement" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000876" name="ibrx:PeriodOfExtendedLeaseTerm" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">P5Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20210331" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075_2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20210331" decimals="-3">0</ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076_2" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001326110_20201231" decimals="-3">0</ix:nonFraction>
			<ix:nonNumeric id="F_000607" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210101_20210331">P2M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000608" name="ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210331">P5Y1M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000978" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P4Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P5Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000980" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P4Y2M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000990" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">P6Y</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ibrx-20210331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001326110_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210512">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-05-12</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ibrx:MarketableDebtAndEquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantKwestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20201221_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-21</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-30</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:OutstandingStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:OutstandingStockOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-09</xbrli:startDate>
					<xbrli:endDate>2021-03-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_20170331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-01</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-09-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190130_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-30</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_ibrxInterestAndInvestmentIncomeNetMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ibrx:InterestAndInvestmentIncomeNetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:SunesisPharmaceuticalsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-25</xbrli:startDate>
					<xbrli:endDate>2021-02-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxSecurity">
				<xbrli:measure>ibrx:Security</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-02</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-02</xbrli:startDate>
					<xbrli:endDate>2018-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:ClinicalTrialActivitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:ClinicalTrialActivitiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-04-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-04-10</xbrli:startDate>
					<xbrli:endDate>2015-04-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-06-15</xbrli:startDate>
					<xbrli:endDate>2015-06-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableAtDecember312022Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableBeforeDecember312026Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndPelatedPartyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-11-01</xbrli:startDate>
					<xbrli:endDate>2015-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-09-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxOfficer">
				<xbrli:measure>ibrx:Officer</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20151130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantBioScienceMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_deiLegalEntityAxis_ibrxSorrentoMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:SorrentoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-08-01</xbrli:startDate>
					<xbrli:endDate>2018-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:BioreactorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:BioreactorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-02-01</xbrli:startDate>
					<xbrli:endDate>2017-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxTerm">
				<xbrli:measure>ibrx:Term</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20170630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20180831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210226_20210226">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-26</xbrli:startDate>
					<xbrli:endDate>2021-02-26</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithResignationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:NonEmployeeDirectorMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-18</xbrli:startDate>
					<xbrli:endDate>2021-03-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxDirector">
				<xbrli:measure>ibrx:Director</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-29</xbrli:startDate>
					<xbrli:endDate>2021-03-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ibrxAward">
				<xbrli:measure>ibrx:Award</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:FirstRSUAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:SecondRSUAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-05</xbrli:startDate>
					<xbrli:endDate>2021-02-05</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-04</xbrli:startDate>
					<xbrli:endDate>2021-03-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-04</xbrli:startDate>
					<xbrli:endDate>2021-03-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:WorkOrderOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderTwoMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001326110</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:WorkOrderTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="line-height:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10&#8209;Q</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:DocumentQuarterlyReport" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the quarterly period ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001326110_20210101_20210331" format="ixt:datemonthdayyearen">March&#160;31, 2021</ix:nonNumeric></p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentTransitionReport" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000018" name="dei:EntityFileNumber" contextRef="C_0001326110_20210101_20210331">001-37507</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:6pt;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001326110_20210101_20210331">IMMUNITYBIO, INC.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter)</p>
<p style="text-align:center;margin-top:3pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001326110_20210101_20210331">43-1979754</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressAddressLine1" contextRef="C_0001326110_20210101_20210331">3530 John Hopkins Court</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityAddressCityOrTown" contextRef="C_0001326110_20210101_20210331">San Diego</ix:nonNumeric><span style="font-family:Times New Roman Bold;">, <ix:nonNumeric id="F_000023" name="dei:EntityAddressStateOrProvince" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressPostalZipCode" contextRef="C_0001326110_20210101_20210331">92121</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: <span style="font-size:9pt;">(<ix:nonNumeric id="F_000025" name="dei:CityAreaCode" contextRef="C_0001326110_20210101_20210331">858</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000026" name="dei:LocalPhoneNumber" contextRef="C_0001326110_20210101_20210331">633-0300</ix:nonNumeric></span></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:5.33%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title&#160;of each class </p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:45%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;width:38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:Security12bTitle" contextRef="C_0001326110_20210101_20210331">Common Stock, par&#160;value&#160;$0.0001 per share</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:15%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001326110_20210101_20210331">IBRX</ix:nonNumeric></p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;width:45%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:SecurityExchangeName" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:exchnameen">The Nasdaq </ix:nonNumeric>Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant&#160;(1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of&#160;1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and&#160;(2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;YES&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:entityfilercategoryen">Non-accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntitySmallBusiness" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:4.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:25%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging&#160;growth&#160;company</p></td>
<td valign="top" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="top" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:3.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0001326110_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;NO&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of the Registrant&#8217;s common stock outstanding as of May 12, 2021 was <ix:nonFraction unitRef="U_xbrlishares" id="F_000012" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001326110_20210512" decimals="INF" format="ixt:numdotdecimal">383,905,840</ix:nonFraction> (excluding 163,800&#160;shares held by a majority owned subsidiary of ours which are treated as treasury shares for accounting purposes).</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="TABLE_CONTENTS">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION"><span style="text-decoration:underline;">Part I&#8212;FINANCIAL INFORMATION</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Financial Statements</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Combined Consolidated Balance Sheets &#8211; <br />&#160;&#160; As of March&#160;31, 2021 and December&#160;31, 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_INCOME_STATEMENT"><span style="text-decoration:underline;">Condensed Combined Consolidated Statements of Operations &#8211; <br />&#160;&#160; For the three months ended March&#160;31, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.19%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_COMPREHENSIVE_INCOME"><span style="text-decoration:underline;">Condensed Combined Consolidated Statements of Comprehensive Loss &#8211; <br />&#160;&#160; For the three months ended March&#160;31, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5.19%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_EQUITY"><span style="text-decoration:underline;">Condensed Combined Consolidated Statements of Stockholders&#8217; (Deficit) Equity &#8211; <br />&#160;&#160; For the three months ended March&#160;31, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:6.67%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_CASH_FLOWS"><span style="text-decoration:underline;">Condensed Combined Consolidated Statements of Cash Flows &#8211; <br />&#160;&#160; For the three months ended March&#160;31, 2021 and 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FS_FOOTNOTES"><span style="text-decoration:underline;">Notes to Unaudited Condensed Combined Consolidated Financial Statements</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures about Market Risk</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II_OR_INFORMATION"><span style="text-decoration:underline;">Part II&#8212;OTHER INFORMATION</span></a></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:6.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:89.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
</tr>
<tr style="height:14.4pt;">
<td valign="top" style="width:6.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="top" style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:88.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a><span style="text-decoration:none;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
</tr>
<tr style="height:14.4pt;">
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="top" style="width:0.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i-</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I&#8212;FINANCIAL INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">ITEM 1. FINANCIAL STATEMENTS.</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_BALANCE_SHEETS">Condensed Combined Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000029" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">38,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AssetsCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">99,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,713</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, noncurrent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:MarketableSecuritiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">80,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-marketable equity investment (Note 4)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible asset, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,463</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible note receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="ibrx:ConvertibleNoteReceivableNonCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,191</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="ibrx:ConvertibleNoteReceivableNonCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets, net (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">18,447</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:Assets" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">209,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">221,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,097</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related parties</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,817</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">79,863</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,134</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">297,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities, less current portion (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,554</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001326110_20210331" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_0001326110_20201231" decimals="-3" scale="3">170</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:Liabilities" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">394,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:Liabilities" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">339,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 8)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000075">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000076">&#160;</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; deficit:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000093" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20201231" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001326110_20210331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001326110_20210331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_20210331" decimals="INF" format="ixt:numdotdecimal">383,067,321</ix:nonFraction></ix:nonFraction> and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal">382,243,142</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March 31, 2021 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020, respectively&#59; excluding treasury stock, <ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:TreasuryStockShares" contextRef="C_0001326110_20210331" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:TreasuryStockShares" contextRef="C_0001326110_20201231" decimals="INF" format="ixt:numdotdecimal">163,800</ix:nonFraction></ix:nonFraction> shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; outstanding as of March 31, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommonStockValue" contextRef="C_0001326110_20210331" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommonStockValue" contextRef="C_0001326110_20201231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,508,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,694,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210331" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total ImmunityBio stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:StockholdersEquity" contextRef="C_0001326110_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:StockholdersEquity" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,808</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:MinorityInterest" contextRef="C_0001326110_20210331" decimals="-3" scale="3">451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:MinorityInterest" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">118,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">209,428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">221,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_INCOME_STATEMENT">Condensed Combined Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:Revenues" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:Revenues" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with related parties)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">41,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts with related parties)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">45,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">86,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:OperatingExpenses" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,702</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:InvestmentIncomeInterestAndDividend" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:InterestExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:InterestExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes and noncontrolling interests</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,475</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,409</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to noncontrolling interests, net of tax</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to ImmunityBio common stockholders</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:NetIncomeLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,038</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per ImmunityBio common share &#8211; basic and diluted</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000131" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20210101_20210331" decimals="2" sign="-">0.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000132" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001326110_20200101_20200331" decimals="2" sign="-">0.10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average number of common shares used in computing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net loss per share &#8211; basic and diluted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20210101_20210331" decimals="0" format="ixt:numdotdecimal">382,741,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000134" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001326110_20200101_20200331" decimals="0" format="ixt:numdotdecimal">371,989,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_COMPREHENSIVE_INCOME">Condensed Combined Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive (loss) income, net of income taxes:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized losses on available-for-sale securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of net realized losses on available-for-sale</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; securities included in net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other comprehensive (loss) income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss attributable to noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss attributable ImmunityBio common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,774</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_EQUITY">Condensed Combined Consolidated Statements of (Deficit) Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income&#160;(Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">382,243,142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,495,163</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,615,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">119,808</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">118,490</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000167" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">690,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of restricted stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; units (RSUs)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000175" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">235,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSUs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; vesting</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000183" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">102,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" sign="-" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" sign="-" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">160</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">79,614</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331" decimals="-3" sign="-" scale="3">867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal">383,067,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,508,958</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,694,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331" decimals="-3" sign="-" scale="3">38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331" decimals="-3" scale="3">451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">185,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Deficit)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000215" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">371,976,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,406,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,393,280</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,326</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of RSUs</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000231" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">63,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSUs</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; vesting</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000239" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">25,722</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331" decimals="-3" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.92%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,038</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,038</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:ProfitLoss" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331" decimals="-3" sign="-" scale="3">389</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,427</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:24.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance as of March 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000263" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" format="ixt:numdotdecimal">372,015,023</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,406,359</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,430,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331" decimals="-3" sign="-" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">23,962</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,265</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.92%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0001326110_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">20,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_CASH_FLOWS">Condensed Combined Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating activities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:ShareBasedCompensation" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:ShareBasedCompensation" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized (gains) losses on equity securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,834</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash interest items, net (including amounts with related parties)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="ibrx:NonCashInterestIncomeExpenseFromOperatingActivities" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,965</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense related to operating lease right-of-use assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of net premiums and discounts on marketable debt securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,067</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">125</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">934</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,020</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">693</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related parties</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,597</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,411</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="ibrx:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,474</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="ibrx:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">60,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">31,107</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing activities:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property, plant and equipment</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,083</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable debt securities, available-for-sale</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,300</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable debt securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">31,925</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">23,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sales of marketable debt securities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">7,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">31,845</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing activities:</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of related-party promissory notes</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">40,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercises of stock options</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net share settlement for RSUs vesting</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) financing activities</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">38,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">123</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">89</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents, and restricted cash</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">17,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, beginning of period</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">35,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">75,980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">58,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">, Inc.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> and Subsidiaries</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Condensed Combined Consolidated Statements of Cash Flows (Continued)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of cash, cash equivalents, and restricted cash, end of period:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000330" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001326110_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">58,654</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (Note 3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" contextRef="C_0001326110_20200331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, and restricted cash, end of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001326110_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">58,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of cash flow information:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid during the period for:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:InterestPaidNet" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:InterestPaidNet" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment purchases included in accounts payable, accrued expenses,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and due to related parties</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">367</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,388</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains on marketable debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">14</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these condensed combined consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc. and Subsidiaries</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FS_FOOTNOTES">Notes to Unaudited Condensed Combined Consolidated Financial Statements</p><ix:nonNumeric id="F_000345" name="us-gaap:NatureOfOperations" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000345_dcnt_7a02ff51-e35d-423d-bef8-f5b4243bd19a">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N1___DESCRIPTION_BUSINESS">1. &#160;&#160;&#160;&#160;Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We were </span>incorporated in Illinois on October&#160;7,&#160;2002 under the name ZelleRx Corporation. On January&#160;22,&#160;2010, we changed our name to Conkwest,&#160;Inc. In March&#160;2014, we formed Conkwest, Inc., our wholly-owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March&#160;2014, we merged with an into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July&#160;10,&#160;2015, we changed our name to NantKwest,&#160;Inc. On March 9,&#160;2021, we completed a merger with NantCell,&#160;Inc. (formerly known as ImmunityBio, Inc., a private company) and we changed our name to ImmunityBio,&#160;Inc. Our principal executive offices are located in San&#160;Diego, California. In these notes to unaudited condensed combined consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio and subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We established ImmunityBio to advance the next-generation immunotherapies and to address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our four&#160;key modalities:&#160;(1)&#160;activating natural killer, or NK, and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4)&#160;off-the-shelf natural killer cells from the NK&#8209;92 cell line and memory-like cytokine-enhanced natural killer cells (m&#8209;ceNK) from allogenic and autologous donors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL&#8209;15 superagonist&#160;(N&#8209;803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator&#160;(aldoxorubicin), second-generation adenovirus&#160;(hAd5) and yeast vaccine technologies&#160;(targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK cell product for cancer that is an autologous Memory cytokine enhanced Natural Killer cells, macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD&#8209;L1, TGF&#8209;</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">b</span></span><span style="Background-color:#FFFFFF;"> and IL&#8209;12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the </span>United States, or U.S., Food and Drug Administration<span style="Background-color:#FFFFFF;">, or FDA, granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#233;rin, or BCG, unresponsive carcinoma in situ non-muscle invasive bladder cancer. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On <ix:nonNumeric id="F_000389" name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331" format="ixt:datemonthdayyearen">December&#160;21, 2020</ix:nonNumeric>, we and NantCell, Inc.&#160;(formerly known as ImmunityBio,&#160;Inc., a private company)&#160;(&#8220;NantCell&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell&#160;(the&#160;&#8220;Merger&#8221;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On <ix:nonNumeric id="F_000393" name="us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1" contextRef="C_0001326110_20210101_20210331" format="ixt:datemonthdayyearen">March&#160;9, 2021</ix:nonNumeric>, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#8220;Effective Time&#8221;), each share of NantCell common stock</span>, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000390" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3">0.001</ix:nonFraction>&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000391" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>&#160;(the &#8220;Exchange Ratio&#8221;) newly</span> issued shares of common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000392" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="4">0.0001</ix:nonFraction>&#160;per share, of the company&#160;(&#8220;Company Common Stock&#8221;), with cash paid in lieu of any fractional shares.<span style="Background-color:#FFFFFF;"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000345_dcnt_7a02ff51-e35d-423d-bef8-f5b4243bd19a" continuedAt="F_000345_dcnt_bc807965-3243-4915-bced-4c79c286401d">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000394" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3" scale="-2">71.5</ix:nonFraction>%&#160;of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000395" name="ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" contextRef="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309" decimals="3" scale="-2">28.5</ix:nonFraction>%&#160;of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially own, in the aggregate, approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000396" name="ibrx:OwnershipPercentageByKeyExecutives" contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309" decimals="3" scale="-2">81.8</ix:nonFraction>%&#160;of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company&#8217;s common stock are now listed on the Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We incurred costs totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:PaymentsForMergerRelatedCosts" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20201221_20210331" decimals="-5" scale="6">23.2</ix:nonFraction>&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:PaymentsForMergerRelatedCosts" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331" decimals="-5" scale="6">12.9</ix:nonFraction>&#160;million was recorded during the three&#160;months ended March&#160;31,&#160;2021. Merger-related costs are</span><span style="Background-color:#FFFFFF;color:#000000;"> reported in </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">selling, general and administrative expense</span><span style="Background-color:#FFFFFF;color:#000000;">, on the condensed combined consolidated statements of operations.</span></p><ix:nonNumeric id="F_000360" name="us-gaap:BusinessCombinationsPolicy" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of each of the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric id="F_000371" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000371_dcnt_e46b17f1-13df-44b6-8ed4-904ac7c0dfc7">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March&#160;31, 2021 and 2020 (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" scale="3">183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000400" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000401" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">44</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:Revenues" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000404" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">19,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000405" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">106</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000406" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">41,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000407" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">24,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000408" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">20,903</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000409" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" sign="-" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000410" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">45,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">45,708</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">40,628</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000414" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">86,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" scale="3">848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,637</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">33,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331" decimals="-3" scale="3">72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">80,481</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" scale="3">168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" scale="3">21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:Revenues" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" sign="-" scale="3">24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:Revenues" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,234</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" sign="-" scale="3">112</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">27,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,120</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,373</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">9,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">36,702</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" sign="-" scale="3">910</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" scale="3">203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">18</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">19,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,383</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:ProfitLoss" contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331" decimals="-3" scale="3">88</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:ProfitLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">37,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000345_dcnt_bc807965-3243-4915-bced-4c79c286401d"><ix:continuation id="F_000371_dcnt_e46b17f1-13df-44b6-8ed4-904ac7c0dfc7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000346" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000346_dcnt_6dd59857-0f67-4401-8719-6f6ce0e4cac5">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI">2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p><ix:nonNumeric id="F_000361" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the company had an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001326110_20210331" decimals="-8" sign="-" format="ixt:numdotdecimal" scale="9">1.7</ix:nonFraction>&#160;billion. We also had negative cash flows from operations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001326110_20210101_20210331" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">60.5</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements are derived from the company&#8217;s and NantCell&#8217;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December&#160;31,&#160;2020 included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000457" name="ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="INF" scale="6">500.0</ix:nonFraction>&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</p></ix:nonNumeric><ix:nonNumeric id="F_000362" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000362_dcnt_fa6c2e21-8bfe-446e-a7b9-65cf806ec66b">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_6dd59857-0f67-4401-8719-6f6ce0e4cac5" continuedAt="F_000346_dcnt_2945d5d5-fc17-4ca1-b7db-235752cb5d4a"><ix:continuation id="F_000362_dcnt_fa6c2e21-8bfe-446e-a7b9-65cf806ec66b">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under ASC Topic&#160;810,&#160;<span style="font-style:italic;">Consolidation</span>, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#8217;s most significant economic activities and the ability to participate in the entity&#8217;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of <ix:nonFraction unitRef="U_xbrlipure" id="F_000458" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210331" decimals="2" scale="-2">20</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210331" decimals="2" scale="-2">50</ix:nonFraction>% interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed combined consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, <span style="font-style:italic;">Fair Value Measurement</span>, or ASC&#160;820, we will apply the measurement alternative under ASC Topic&#160;321, <span style="font-style:italic;">Investments&#8212;Equity Securities</span>, or ASC&#160;321, pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#8217;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p></ix:continuation><ix:nonNumeric id="F_000363" name="us-gaap:UseOfEstimates" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000363_dcnt_28e7f770-e284-4659-99cd-45e3b00dcc0c">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_2945d5d5-fc17-4ca1-b7db-235752cb5d4a" continuedAt="F_000346_dcnt_6c18e814-f443-4390-8cbf-f3e6fa4a2195"><ix:continuation id="F_000363_dcnt_28e7f770-e284-4659-99cd-45e3b00dcc0c">
</ix:continuation><ix:nonNumeric id="F_000364" name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p></ix:nonNumeric><ix:nonNumeric id="F_000365" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p></ix:nonNumeric><ix:nonNumeric id="F_000366" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p></ix:nonNumeric><ix:nonNumeric id="F_000367" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span>, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p></ix:nonNumeric><ix:nonNumeric id="F_000368" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000368_dcnt_1e4f7d74-37ff-4d4c-883c-78b10bb00903">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_6c18e814-f443-4390-8cbf-f3e6fa4a2195" continuedAt="F_000346_dcnt_cae857ac-2375-4c76-bfad-a4ca5fe10e87"><ix:continuation id="F_000368_dcnt_1e4f7d74-37ff-4d4c-883c-78b10bb00903">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. </span><ix:nonNumeric id="F_000372" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000372_cnt_1"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table details those securities that have been excluded from the computation of p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otentially dilutive securities:</span></ix:nonNumeric></p><ix:continuation id="F_000372_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000460" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">4,978,314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000461" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20200101_20200331" decimals="0" format="ixt:numdotdecimal">6,080,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000462" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">7,636,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000463" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331" decimals="0" format="ixt:numdotdecimal">1,102,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding related-party warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000464" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">1,638,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000465" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331" decimals="0" format="ixt:numdotdecimal">1,638,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000466" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_20210101_20210331" decimals="0" format="ixt:numdotdecimal">14,252,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000467" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001326110_20200101_20200331" decimals="0" format="ixt:numdotdecimal">8,821,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#8220;2015&#160;Plan&#8221;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#8220;2014&#160;Plan&#8221;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#8220;NC&#160;2015&#160;Plan&#8221;) that, in the case of March&#160;31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March&#160;31, 2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted <span style="Background-color:#FFFFFF;color:#000000;">using the Merger Exchange Ratio of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000468" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309" decimals="4">0.8190</ix:nonFraction></span>). See <a href="#N11___STOCKBASED_COMPENSATION"><span style="text-decoration:underline;">Note&#160;11</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Stock-Based Compensation</span>, for further information.</p></ix:continuation><ix:nonNumeric id="F_000369" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000369_dcnt_a4f62577-5ea5-4a67-a7cc-59e27b034d4c">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued Accounting Standards Update, or ASU, 2016&#8209;13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments</span>, or ASU&#160;2016-13. The FASB subsequently issued amendments to ASU&#160;2016&#8209;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements and we do not intend to early adopt this new standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended March&#160;31,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000346_dcnt_cae857ac-2375-4c76-bfad-a4ca5fe10e87"><ix:continuation id="F_000369_dcnt_a4f62577-5ea5-4a67-a7cc-59e27b034d4c">
</ix:continuation></ix:continuation><ix:nonNumeric id="F_000347" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000347_dcnt_ec953b14-8947-435a-9a03-35499813099f">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N3___FINANCIAL_STATEMENT_DETAILS">3. &#160;&#160;&#160;&#160;Financial Statement Details</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p><ix:nonNumeric id="F_000373" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,648</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,932</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:InsuranceSettlementsReceivableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,518</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="ibrx:PrepaidServices" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="ibrx:PrepaidServices" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="ibrx:PrepaidLicenseFees" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="ibrx:PrepaidLicenseFees" contextRef="C_0001326110_20201231" decimals="-3" scale="3">801</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:PrepaidInsurance" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:PrepaidInsurance" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="ibrx:InsurancePremiumFinancingAsset" contextRef="C_0001326110_20210331" decimals="-3" scale="3">571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="ibrx:InsurancePremiumFinancingAsset" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:PrepaidRent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">569</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:PrepaidRent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment deposits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="ibrx:EquipmentDepositsCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">375</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="ibrx:EquipmentDepositsCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">66</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant improvement receivables &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:LeaseIncentiveReceivableCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:LeaseIncentiveReceivableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="ibrx:PrepaidEquipmentMaintenance" contextRef="C_0001326110_20210331" decimals="-3" scale="3">239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="ibrx:PrepaidEquipmentMaintenance" contextRef="C_0001326110_20201231" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable <span style="font-size:9pt;">&#8211;</span> marketable debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:InterestReceivableCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">473</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies &#8211; with related party (Note 9)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="ibrx:PrepaidSuppliesWithRelatedParty" contextRef="C_0001326110_20210331" decimals="-3" scale="3">131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="ibrx:PrepaidSuppliesWithRelatedParty" contextRef="C_0001326110_20201231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:OtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">14,242</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,649</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. <span style="color:#000000;">Our insurance claims receivable as of March&#160;31,&#160;2021 and December&#160;31, 2020 are the result of the recovery of legal costs, which had been previously charged in prior periods to s</span><span style="font-style:italic;color:#000000;">elling, general and administrative expense, </span><span style="color:#000000;">on the condensed combined consolidated statements of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p><ix:nonNumeric id="F_000374" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">52,200</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">38,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">22,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,690</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,333</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &#38; fixtures</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property, plant and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">125,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">114,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,545</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">80,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">72,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress at March&#160;31,&#160;2021 is related primarily to expansion of our hAd5 pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El&#160;Segundo, California<span style="color:#1F497D;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense related to property, plant and equipment totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20210101_20210331" decimals="-5" scale="6">3.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001326110_20200101_20200331" decimals="-5" scale="6">3.5</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000347_dcnt_ec953b14-8947-435a-9a03-35499813099f" continuedAt="F_000347_dcnt_27d1d09a-ab3c-4af0-839a-c413a7ec8b18">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other assets</p><ix:nonNumeric id="F_000375" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000375_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands):</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000375_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:ValueAddedTaxReceivableNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:ValueAddedTaxReceivableNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">864</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_20210331" decimals="-3" scale="3">319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_20201231" decimals="-3" scale="3">634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software license fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="ibrx:PrepaidSoftwareLicenseFeesInOtherAssets" contextRef="C_0001326110_20210331" decimals="-3" scale="3">227</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="ibrx:PrepaidSoftwareLicenseFeesInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" scale="3">455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">54</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:DueFromRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" contextRef="C_0001326110_20201231" decimals="-3" scale="3">92</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">316</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:OtherAssetsMiscellaneousNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,905</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,598</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p><ix:nonNumeric id="F_000376" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000533" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,947</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="us-gaap:AccruedBonusesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dissenting shares (Note 8)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="ibrx:AccruedDissentingShares" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="ibrx:AccruedDissentingShares" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,656</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000540" name="ibrx:AccruedPreclinicalAndClinicalTrialCosts" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,349</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:AccruedSalariesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="ibrx:AccruedResearchAndDevelopmentCosts" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="ibrx:AccruedResearchAndDevelopmentCosts" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:ConstructionPayableCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:ConstructionPayableCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contingent consideration payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">822</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="ibrx:AccruedLaboratoryEquipmentAndSupplies" contextRef="C_0001326110_20210331" decimals="-3" scale="3">681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="ibrx:AccruedLaboratoryEquipmentAndSupplies" contextRef="C_0001326110_20201231" decimals="-3" scale="3">641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation <span style="font-family:Calibri;">&#8211;</span> current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="us-gaap:AccruedInsuranceCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:AccruedInsuranceCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,421</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_20210331" decimals="-3" scale="3">263</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_20201231" decimals="-3" scale="3">270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales, use and property taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="C_0001326110_20201231" decimals="-3" scale="3">103</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued capital expenditures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000557" name="ibrx:AccruedCapitalExpenditures" contextRef="C_0001326110_20210331" decimals="-3" scale="3">16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="ibrx:AccruedCapitalExpenditures" contextRef="C_0001326110_20201231" decimals="-3" scale="3">337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" scale="3">759</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,186</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">36,793</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,771</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and investment income, net</p><ix:nonNumeric id="F_000377" name="us-gaap:InterestAndOtherIncomeTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net consists of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains (losses) from equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">198</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">339</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">322</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment amortization expense, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized losses on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20210101_20210331" decimals="-3" sign="-" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:RealizedInvestmentGainsLosses" contextRef="C_0001326110_20200101_20200331" decimals="-3" sign="-" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:InvestmentIncomeNet" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,944</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:InvestmentIncomeNet" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000347_dcnt_27d1d09a-ab3c-4af0-839a-c413a7ec8b18">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p></ix:continuation><ix:nonNumeric id="F_000348" name="us-gaap:InvestmentTextBlock" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331" escape="true" continuedAt="F_000348_dcnt_05ba1061-5267-4ce8-8ded-cfcd48fcc9f9">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT">4. &#160;&#160;&#160;&#160;Equity Investment in Viracta Therapeutics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20170331" decimals="-5" scale="6">8.5</ix:nonFraction>&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company, which was initially recorded at cost. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2018, Viracta executed a 2018&#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="ibrx:PurchaseOfConvertibleNoteUponConversion" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common stock. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="ibrx:PurchaseOfConvertibleNoteUponConversion" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common stock. Effective January&#160;31,&#160;2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#8217;s Series&#160;B convertible preferred stock of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190130_20190131" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million. In May&#160;2019, we exercised warrants to acquire <ix:nonFraction unitRef="U_xbrlishares" id="F_000577" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531" decimals="INF" format="ixt:numdotdecimal">253,120</ix:nonFraction>&#160;shares of Viracta common stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the level of equity investment at risk, Viracta was not a VIE and therefore was not consolidated under the VIE model. In addition, we did not hold a controlling financial interest in Viracta, and therefore we did not consolidate Viracta under the voting interest model. As the preferred stock was not considered in-substance common stock, the investment was not within the scope of accounting for the investment under the equity method. As the preferred stock did not have a readily determinable fair value and did not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we had elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measured our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our fair value assessment indicated that the offering of Viracta&#8217;s Series&#160;E preferred stock in November&#160;2020, at a lower offering price per share than the per share carrying amount of our investment in Viracta, was a directional indicator representing an observable price change in an orderly transaction for a similar investment. On December&#160;31,&#160;2020, we reduced the carrying value by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_ibrxInterestAndInvestmentIncomeNetMember_20200101_20201231" decimals="-5" scale="6">1.4</ix:nonFraction>&#160;million due to the observable price change, which was included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed combined consolidated statements of operations for the year ended December&#160;31,&#160;2020. As of December&#160;31,&#160;2020, the carrying value of our investment in Viracta, which was reflected in <span style="font-style:italic;">non-marketable equity investment,</span> on the condensed combined consolidated balance sheets, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" contextRef="C_0001326110_20201231" decimals="-5" scale="6">7.8</ix:nonFraction>&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;24,&#160;2021, Sunesis Pharmaceuticals, Inc., a public company, completed a business combination with Viracta. In connection with this business combination, our preferred stock investment in Viracta was converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000580" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225" decimals="INF" format="ixt:numdotdecimal">1,562,604</ix:nonFraction>&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. As of March&#160;31,&#160;2021, the carrying value of our investment in Viracta, which is reflected in <span style="font-style:italic;">marketable securities</span>, on the condensed combined consolidated balance sheets totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331" decimals="-5" scale="6">14.5</ix:nonFraction>&#160;million (including an unrealized gain of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331" decimals="-5" scale="6">6.6</ix:nonFraction>&#160;million). </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000348_dcnt_05ba1061-5267-4ce8-8ded-cfcd48fcc9f9">
</ix:continuation><ix:nonNumeric id="F_000349" name="us-gaap:InvestmentTextBlock" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331" escape="true" continuedAt="F_000349_dcnt_adc1a2b2-3172-48a5-b749-c9b2e3606fb3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N5___FINANCIAL_INSTRUMENTS">5. &#160;&#160;&#160;&#160;Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Debt Securities</p><ix:nonNumeric id="F_000378" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000378_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.2</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000589" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000601" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000590" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000602" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,576</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">5.1</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_20210331" decimals="-3" scale="3">142</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,575</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:continuation id="F_000378_cnt_1">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,<span style="color:#000000;">&#160;</span>2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000609" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000615" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000610" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">35</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000611" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,824</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,809</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000612" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">89</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000613" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">861</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">89</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000631" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000614" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,685</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">93</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0001326110_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,759</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000379" name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000379_cnt_1">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands):</p></ix:nonNumeric><ix:continuation id="F_000379_cnt_1" continuedAt="F_000379_dcnt_938b8574-e28a-4f94-a549-7adfd2819fbf">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">13,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_20210331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000641" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000643" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000642" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,762</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="C_0001326110_20201231" decimals="-3" scale="3">19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:continuation></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000349_dcnt_adc1a2b2-3172-48a5-b749-c9b2e3606fb3"><ix:continuation id="F_000379_dcnt_938b8574-e28a-4f94-a549-7adfd2819fbf">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, a total of <ix:nonFraction unitRef="U_ibrxSecurity" id="F_000649" name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210331" decimals="INF">14</ix:nonFraction> of the securities were in unrealized loss positions. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment losses during the three&#160;months ended March&#160;31,&#160;2021. Realized gains and losses on sales of available-for-sale debt securities during the three&#160;months ended March&#160;31,&#160;2021 and 2020 were not material.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We held investments in marketable equity securities with readily determinable fair values of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331" decimals="-5" scale="6">23.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-5" scale="6">6.3</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Unrealized gains recognized on equity securities with readily determinable fair values totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331" decimals="-5" scale="6">8.8</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2021, while unrealized losses recognized on equity securities with readily determinable fair values totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000654" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331" decimals="-5" sign="-" scale="6">0.2</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2020. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000655" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="us-gaap:DebtAndEquitySecuritiesRealizedGainLoss" contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> realized gains or losses on sales of equity securities for the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p></ix:continuation><ix:nonNumeric id="F_000350" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000350_dcnt_0ddfa2f9-2d7b-4e2d-b43f-5aa9be3ec8b3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N6___FAIR_VALUE_MEASUREMENTS">6. &#160;&#160;&#160;&#160;Fair Value Measurements</p><ix:nonNumeric id="F_000370" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000370_dcnt_0bdf5375-3b20-42ab-bfce-6a9475d6dbe1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000350_dcnt_0ddfa2f9-2d7b-4e2d-b43f-5aa9be3ec8b3" continuedAt="F_000350_dcnt_e51cb176-fe62-4219-b789-b48674a8fa1b"><ix:continuation id="F_000370_dcnt_0bdf5375-3b20-42ab-bfce-6a9475d6dbe1">
</ix:continuation>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recurring Valuations</p><ix:nonNumeric id="F_000380" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of March 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000658" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">44,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities (1)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">23,019</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">23,019</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">84,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">68,735</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,538</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">34,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" scale="3">950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,011</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">42,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">54,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our equity securities include our investment in Viracta totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="us-gaap:AvailableForSaleSecuritiesEquitySecurities" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331" decimals="-5" scale="6">14.5</ix:nonFraction>&#160;million, which was previously accounted for by applying the measurement alternative under ASC&#160;321. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into <ix:nonFraction unitRef="U_xbrlishares" id="F_000714" name="us-gaap:ConversionOfStockSharesConverted1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225" decimals="INF" format="ixt:numdotdecimal">1,562,604</ix:nonFraction>&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. See </span><a href="#N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT"><span style="text-decoration:underline;color:#000000;">Note&#160;4</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Equity Investment in Viracta Therapeutics</span><span style="Background-color:#FFFFFF;color:#000000;">, for additional information.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.63%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;color:#000000;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Commitments and Contingencies,</span><span style="color:#000000;"> for additional information.</span></p></td></tr></table></div></ix:nonNumeric><ix:nonNumeric id="F_000381" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000381_dcnt_8ef87492-c8ab-495e-9b2a-631edba76146">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, beginning of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" sign="-" scale="3">972</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in fair value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210331" decimals="-3" scale="3">128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200331" decimals="-3" sign="-" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331" decimals="-3" sign="-" scale="3">844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000720" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,727</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000350_dcnt_e51cb176-fe62-4219-b789-b48674a8fa1b"><ix:continuation id="F_000381_dcnt_8ef87492-c8ab-495e-9b2a-631edba76146">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-recurring Valuations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p></ix:continuation><ix:nonNumeric id="F_000351" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000351_dcnt_a91ff65e-b7c4-4d04-8a03-e7a0f46268d3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N7___COLLABORATION_LICENSE_AGREEMENTS">7. &#160;&#160;&#160;&#160;Collaboration and License Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">National Cancer Institute</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, Etubics Corporation, or Etubics, entered into a Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services as represented by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA, NIH provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the CRADA, we are required to make annual payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000721" name="ibrx:AnnualPaymentForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million to the NIH for support of research activities. We made a payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="ibrx:AnnualPaymentForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The&#160;CRADA expires in May&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into an amendment to a CRADA with NIH that was originally executed between NIH and Amgen,&#160;Inc., or Amgen, in May&#160;2012 and subsequently assigned by Amgen to the company effective as of December&#160;17,&#160;2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor&#160;one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing February&#160;20,&#160;2018 and expiring on February&#160;20,&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the agreement, we are required to make minimum annual payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="ibrx:MinimumAnnualPaymentsForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million to NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="ibrx:EstimatedUnpaidResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="ibrx:EstimatedUnpaidResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2021, we entered into a CRADA with NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant natural killer&#160;(NK) cells and/or monoclonal antibodies&#160;(mAbs) alone or in combination for the treatment of cancer and to pre-clinically study such agents. The CRADA has a two-year term commencing February&#160;22, 2021 and expiring on February&#160;22, 2023. During the term of the agreement, we are required to provide $<ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="ibrx:AnnualPaymentForSupportOfResearchActivities" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million per year to NIH for support of research activities. We have $<ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="ibrx:PayableOutstanding" contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210331" decimals="0" format="ixt:numdotdecimal">8,000</ix:nonFraction> payable outstanding as of March&#160;31, 2021 in connection with this CRADA agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All CRADA agreements may be terminated at any time upon the mutual written consent of the company and NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60&#160;days before the desired termination date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000351_dcnt_a91ff65e-b7c4-4d04-8a03-e7a0f46268d3">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Royalties and In-licensing Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">iosBio Ltd. Exclusive License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. (&#8220;iosBio&#8221;), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio&#8217;s intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants to iosBio and its affiliates a non-exclusive, worldwide license under the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="ibrx:AccruedReimbursableCostsPayable" contextRef="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="ibrx:AccruedReimbursableCostsPayable" contextRef="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million payable, respectively, to iosBio for reimbursable costs related to the clinical trial activities initiated by iosBio.</p></ix:continuation><ix:nonNumeric id="F_000352" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000352_dcnt_e7cb8685-6e8c-43ba-a4fc-a6d962dbb375">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N8___COMMITMENTS_CONTINGENCIES">8. &#160;&#160;&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Consideration Related to Business Combinations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">VivaBioCell, S.p.A.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;10, 2015, NantWorks, a related party, acquired a <ix:nonFraction unitRef="U_xbrlipure" id="F_000730" name="ibrx:PercentageOfWhollyOwnedSubsidiary" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410" decimals="INF" scale="-2">100</ix:nonFraction>%&#160;interest in VivaBioCell, S.p.A., or VivaBioCell, through its wholly-owned subsidiary, VBC&#160;Holdings, LLC, or VBC&#160;Holdings, for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million, less working capital adjustments. On June&#160;15,&#160;2015, NantWorks contributed its equity interest in VBC&#160;Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615" decimals="-5" scale="6">3.7</ix:nonFraction>&#160;million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $<ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="ibrx:ChangeInContingentConsideration" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million during the three&#160;months ended March&#160;31,&#160;2021 to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="ibrx:FairValueOfContingentConsiderationObligation" contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210331" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience Corporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our July&#160;2017 acquisition of Altor BioScience Corporation, or Altor, we issued contingent value rights, or CVRs, under which we agreed to pay the prior stockholders of Altor approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210331" decimals="-5" scale="6">304.0</ix:nonFraction>&#160;million upon successful approval of the Biologics License Application, or BLA, or foreign equivalent, for Anktiva by December&#160;31,&#160;2022 and approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210331" decimals="-5" scale="6">304.0</ix:nonFraction>&#160;million upon the first calendar year before December&#160;31,&#160;2026 in which worldwide net sales of Anktiva exceed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="ibrx:MinimumNetSalesMilestoneContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_20210101_20210331" decimals="-8" scale="9">1.0</ix:nonFraction>&#160;billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="ibrx:ContingentValueRightsPayable" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210331" decimals="-5" scale="6">279.5</ix:nonFraction>&#160;million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_e7cb8685-6e8c-43ba-a4fc-a6d962dbb375" continuedAt="F_000352_dcnt_85e954f4-2777-4ba3-ba29-16f5beb6fcb7">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience, LLC </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first action, Gray v.&#160;Soon-Shiong, et al.&#160;(Delaware Chancery Court, Case No.&#160;2017-466-JRS), was filed on June&#160;21,&#160;2017, by plaintiffs Clayland Boyden Gray, or Gray, and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for&#160;(1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion on July&#160;25,&#160;2017, and permitted the merger to close. On September&#160;1,&#160;2017, plaintiffs (joined by two&#160;additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson, or Henderson) filed a second&#160;amended complaint, asserting claims for (1)&#160;appraisal&#59; (2)&#160;quasi-appraisal&#59; (3)&#160;breach of fiduciary duty&#59; and (4)&#160;aiding and abetting breach of fiduciary duty. On September&#160;18,&#160;2017, defendants moved to dismiss the second&#160;amended complaint, raising grounds that included a &#8220;standstill&#8221; agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman, or the Waldman&#8217;s, agreed not to bring the lawsuit. In the second&#160;action, Dyad Pharmaceutical Corp. v.&#160;Altor BioScience,&#160;LLC&#160;(Delaware Chancery Court, Case No.&#160;2017-848-JRS), commenced November&#160;28,&#160;2017, Dyad Pharmaceutical Corporation, or Dyad, filed a petition for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition on January&#160;26,&#160;2018, arguing in part that the petition was barred by the same &#8220;standstill&#8221; agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;23,&#160;2018, the court heard oral arguments on the motions to dismiss in both consolidated cases, and on June&#160;26,&#160;2018, the court converted the motions to dismiss into motions for summary judgment with regard to the &#8220;standstill&#8221; agreement argument, or the Converted Motions. The court permitted discovery into the meaning and intended scope of the &#8220;standstill&#8221; agreements, which the parties completed on December&#160;19,&#160;2018. The parties completed a briefing on the Converted Motions on March&#160;15,&#160;2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The court heard an oral argument on the Converted Motions on May&#160;7,&#160;2019, and issued an oral ruling on May&#160;15,&#160;2019. The court&#160;(1)&#160;dismissed all claims brought by Gray and the Waldman&#8217;s except for their appraisal claims&#59; (2)&#160;dismissed all plaintiffs&#8217; quasi-appraisal claims&#59; (3)&#160;dismissed the disclosure-based breach of fiduciary duty claims&#59; and (4)&#160;dismissed Altor BioScience from the action. The following claims remain: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience, LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;14,&#160;2019, the defendants answered the second&#160;amended complaint, and the respondent answered Dyad&#8217;s appraisal petition. In their answer, defendants asserted counterclaims against Gray and the Waldman&#8217;s for breach of the &#8220;standstill&#8221; agreements and are seeking as damages the attorneys&#8217; fees and costs they were forced to expend as a result of the breach. On June&#160;20,&#160;2019, the court issued a written order implementing its ruling on the Converted Motions, or the Implementing Order. In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. On July&#160;11,&#160;2019, Gray and the Waldman&#8217;s filed answers denying the counterclaims and asserting defenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;30,&#160;2019, plaintiffs moved for leave to file a third&#160;amended complaint. The proposed amendment sought to add two&#160;former Altor stockholders as plaintiffs and to add a fiduciary duty claim on behalf of a purported class of former Altor stockholders. On October&#160;25,&#160;2019, the defendants opposed the motion, and a briefing was completed on February&#160;28,&#160;2020. The court heard an oral argument on March&#160;12,&#160;2020, and granted the motion. The plaintiffs filed the third&#160;amended complaint on June&#160;8,&#160;2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;29,&#160;2020, defendants answered the third&#160;amended complaint and asserted counter claims against the plaintiffs. As damages, defendants seek the attorneys&#8217; fees and costs incurred as a result of these breaches. On July&#160;14,&#160;2020, the plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date, and when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had accrued $<ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="ibrx:AccruedPaymentForDissentingShares" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210331" decimals="-5" scale="6">6.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="ibrx:AccruedPaymentForDissentingShares" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231" decimals="-5" scale="6">6.8</ix:nonFraction>&#160;million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic&#160;450, <span style="font-style:italic;">Contingencies</span>, after considering the reasonable outcomes for settling the dissenting shareholder dispute along with any accrued statutory interest. We cannot reasonably estimate a range of loss beyond the amounts recorded as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, as the dissenting stockholders have not yet provided a quantified value of their claim and, therefore, an upper end of the range of loss cannot be determined. We reassess the reasonableness of the recorded amount at each reporting period. We believe the claims lack merit and intend to continue defending the case vigorously.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_85e954f4-2777-4ba3-ba29-16f5beb6fcb7" continuedAt="F_000352_dcnt_af7de430-cf35-46b7-982e-6489f5aab28a">

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. v. NantCell, Inc., et al. Sorrento Therapeutics, Inc., or Sorrento, derivatively on behalf of NANTibody, LLC, or NANTibody, filed an action in the Superior Court of California, Los&#160;Angeles County, or the Superior Court, against the company, Dr.&#160;Soon-Shiong and Charles&#160;Kim. The action alleges that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. from our affiliate NantPharma,&#160;LLC, or NantPharma, and seeks to have the transaction undone, and seeks to have the purchase amount returned to NANTibody. Sorrento filed a related arbitration proceeding, or the Cynviloq arbitration, against Dr.&#160;Soon-Shiong and NantPharma&#59; the company is not named in the Cynviloq arbitration. On May&#160;15,&#160;2019, we filed a demurrer to several causes of action alleged in the Superior Court action. On July&#160;18,&#160;2019, Sorrento filed an amended complaint, eliminating Charles&#160;Kim as a defendant and dropping the causes of action we had challenged in its demurrer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;24,&#160;2019, we and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. We and Dr.&#160;Soon-Shiong allege that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;9,&#160;2019, the Superior Court ruled that our claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;13,&#160;2020, after a full briefing, the Superior Court heard oral argument and granted Dr.&#160;Soon-Shiong&#8217;s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr.&#160;Soon-Shiong in the Superior Court on March&#160;3,&#160;2020, and at Sorrento&#8217;s request, the arbitrator entered an order dismissing Sorrento&#8217;s claims against Dr.&#160;Soon-Shiong in the Cynviloq arbitration on March&#160;6,&#160;2020. The hearing in the Cynviloq arbitration has been scheduled to commence in June&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;24,&#160;2019, we, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration on May&#160;4,&#160;2020, and requested leave to file a dispositive motion on May&#160;1,&#160;2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;29,&#160;2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter on April&#160;10,&#160;2020, purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements. We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time. The hearings in the antibody arbitration commenced in April&#160;2021 and are anticipated to be concluded in late July or early August&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shenzhen Beike Biotechnology Corporation Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation, or Beike. The arbitration relates to a license, development, and commercialization agreement that Altor&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC, or Altor) entered into with Beike in September&#160;2014, which agreement was amended and restated in September&#160;2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by May&#160;31,&#160;2021 of any further developments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_af7de430-cf35-46b7-982e-6489f5aab28a" continuedAt="F_000352_dcnt_d122ae43-9b40-431d-bc3f-cbf6a6c064dc">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Litigation</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;21,&#160;2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San&#160;Diego County, California, naming Fox&#160;Chase Cancer Center Foundation and Institute for Cancer Research as the defendants&#160;(hereafter collectively &#8220;Fox&#160;Chase&#8221;). This litigation relates to the license with Fox&#160;Chase and includes various intellectual property rights (the&#160;&#8220;2004&#160;License&#8221;). Our initial court filing requested that the Court find that we have not breached any material obligation under the 2004&#160;License and that Fox&#160;Chase has not and cannot terminate the 2004&#160;License. Fox&#160;Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. See Part&#160;II, Item&#160;1A.,&#160;&#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; of this Quarterly Report on Form&#160;10-Q for a more detailed discussion. While the litigation is in the early stage, its outcome cannot be predicted. We do not consider the 2004&#160;License to be material to our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation Related to the Merger with ImmunityBio, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger with <span style="letter-spacing:-0.05pt;">NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest&#160;(the &#8220;Merger&#160;Sub&#8221;), </span>seven&#160;complaints have been filed as individual actions in United States District Courts. Three&#160;complaints have been filed in the United States District Court for the District of Delaware against NantKwest and its directors and are captioned&#160;<span style="font-style:italic;">Hargett v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00197&#160;(filed February&#160;11,&#160;2021) (the &#8220;Hargett Complaint&#8221;),&#160;<span style="font-style:italic;">Franchi v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00218&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Franchi Complaint&#8221;), and <span style="font-style:italic;">Gross&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00223&#160;(filed February&#160;17,&#160;2021) (the &#8220;Gross Complaint&#8221;). One&#160;complaint has been filed in the United States District Court for the Southern District of New York and is captioned <span style="font-style:italic;">Leaman&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;01351&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Leaman Complaint&#8221;). Two&#160;complaints have been filed in the United States District Court for the Southern District of California and are captioned <span style="font-style:italic;">Weiss&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00280&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Weiss Complaint&#8221;) and <span style="font-style:italic;">Carlisle&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00304&#160;(filed February&#160;19,&#160;2021) (the&#160;&#8220;Carlisle Complaint&#8221;). One&#160;complaint has been filed in the United States District Court for the Eastern District of New York and was captioned <span style="font-style:italic;">Shenk&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00871&#160;(filed February&#160;18,&#160;2021) (the &#8220;Shenk Complaint,&#8221; and collectively with the Hargett Complaint, the Franchi Complaint, the Gross Complaint, the Leaman Complaint, the Weiss Complaint, and the Carlisle Complaint, the &#8220;Merger Actions&#8221;). The Shenk Complaint was voluntarily dismissed on March&#160;10,&#160;2021. The Franchi Complaint was voluntarily dismissed on May&#160;6,&#160;2021. The Leaman Complaint was voluntarily dismissed on May&#160;7,&#160;2021. The Hargett Complaint and the Gross Complaint also bring claims against ImmunityBio, and Merger&#160;Sub. The Merger Actions generally allege that the Definitive Proxy Statement filed with the SEC on February&#160;2,&#160;2021 misrepresents and/or omits certain purportedly material information relating to financial projections, analysis performed by the financial advisor to NantKwest&#8217;s Special Committee, alleged past engagements of the Special Committee&#8217;s financial advisor and industry consultant, and the terms of the engagement of such consultant. The Merger Actions assert violations of Sections&#160;14(a) of the Securities Exchange Act of&#160;1934, as amended (the&#160;&#8220;Exchange Act&#8221;), and Rule&#160;14a-9 promulgated thereunder against all defendants and violations of Section&#160;20(a) of the Exchange Act against NantKwest&#8217;s directors. The Merger Actions seek, among other things, an injunction enjoining the stockholder vote on the Merger and the consummation of the Merger unless and until certain additional information is disclosed to NantKwest&#8217;s stockholders, costs of the action, including plaintiffs&#8217; attorneys&#8217; fees and experts&#8217; fees, and other relief the Court may deem just and proper. Neither the stockholder vote on the Merger nor the Merger were enjoined and occurred on March&#160;8 and March&#160;9,&#160;2021, respectively. The company cannot predict the outcome of the Merger Actions. The company believes the Merger Actions are without merit and the company and the individual defendants intend to vigorously defend against the Merger Actions and any subsequently filed similar actions. If additional similar complaints are filed, absent new or significantly different allegations, the company will not necessarily disclose such additional filings.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El&#160;Segundo, California&#160;(general corporate and administrative activities, research and development and regulatory from related parties)&#59; San&#160;Diego, California&#160;(research facility and office space)&#59; Culver&#160;City, California&#160;(research and manufacturing space from a related party)&#59; Torrance, California&#160;(a research facility from a related party)&#59; Miramar, Florida&#160;(clinical development)&#59; Seattle, Washington&#160;(research and development)&#59; Louisville, Colorado&#160;(research and development and manufacturing)&#59; Woburn, Massachusetts&#160;(research facility)&#59; and Udine and Tavangnacco, Italy&#160;(GMP-in-a-Box, research facility and office space). See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:F_000741">two to ten&#160;years</span> and often include one&#160;or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:F_000743">one to five&#160;years</span>, and are included in the lease term when it is reasonably certain that we will exercise the option.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_d122ae43-9b40-431d-bc3f-cbf6a6c064dc" continuedAt="F_000352_dcnt_e1bdbfcd-4c30-4006-b13c-f0200a355f61">
<ix:nonNumeric id="F_000382" name="us-gaap:LeaseCostTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000382_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our leases is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000745" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001326110_20210331" format="ixt-sec:duryear">4.6</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000746" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001326110_20201231" format="ixt-sec:duryear">3.9</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000747" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001326110_20210331" decimals="2" scale="-2">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000748" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001326110_20201231" decimals="2" scale="-2">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000382_cnt_1" continuedAt="F_000382_cnt_2">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:5pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,147</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:OperatingLeaseCost" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,782</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20210101_20210331" decimals="-3" scale="3">666</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="us-gaap:VariableLeaseCost" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:LeaseCost" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:LeaseCost" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000382_cnt_2">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows for operating leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:OperatingLeasePayments" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,679</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:OperatingLeasePayments" contextRef="C_0001326110_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000383" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments as of March&#160;31,&#160;2021, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" contextRef="C_0001326110_20210101_20210331" decimals="-5" scale="6">4.9</ix:nonFraction>&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (excluding the three months ended March 31, 2021)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,622</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,183</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000763" name="ibrx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000764" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">26,509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000765" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">21,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional three-year&#160;term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of 3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000352_dcnt_e1bdbfcd-4c30-4006-b13c-f0200a355f61">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not enter into any significant contracts during the three&#160;months ended March&#160;31,&#160;2021, other than those disclosed in these condensed combined consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p></ix:continuation><ix:nonNumeric id="F_000353" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000353_dcnt_0230acd1-e457-42bd-bd7d-5d57c73b1210">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N9___RELATED_PARTY_AGREEMENTS">9. &#160;&#160;&#160;&#160;Related Party Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business with several affiliates under written agreements and informal arrangements. <ix:nonNumeric id="F_000384" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000384_cnt_1">Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):</ix:nonNumeric></p><ix:continuation id="F_000384_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;width:14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantBio</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000768" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,294</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantOmics</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210331" decimals="-3" scale="3">591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231" decimals="-3" scale="3">591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties &#8211; Various</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210331" decimals="-3" scale="3">172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231" decimals="-3" scale="3">118</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.25pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due from related parties</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000774" name="us-gaap:DueFromRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantWorks</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000775" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">12,799</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000776" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,650</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Duley Road</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,787</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantBio</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331" decimals="-3" scale="3">943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231" decimals="-3" scale="3">943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Immuno-Oncology Clinic</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210331" decimals="-3" scale="3">503</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231" decimals="-3" scale="3">271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Nant Capital</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-3" scale="3">224</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-3" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantPharma</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000785" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000786" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231" decimals="-3" scale="3">187</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due to related parties</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000787" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">17,817</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000788" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,838</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; Nant Capital</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000789" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">150,695</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000790" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">109,246</ix:nonFraction></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantMobile</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000791" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">57,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000792" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantWorks</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000793" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">52,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000794" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,546</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NCSC</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000795" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">37,348</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000796" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,901</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total related-party notes payable</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">297,286</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="us-gaap:DueToRelatedPartiesNoncurrent" contextRef="C_0001326110_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">254,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantWorks</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000799" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331" decimals="-5" scale="6">1.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000800" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331" decimals="-5" scale="6">1.5</ix:nonFraction>&#160;million, respectively, in <span style="font-style:italic;">selling, general and administrative expense</span>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000801" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331" decimals="-5" scale="6">1.0</ix:nonFraction>&#160;million, respectively, of expense reimbursements under this arrangement in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000353_dcnt_0230acd1-e457-42bd-bd7d-5d57c73b1210" continuedAt="F_000353_dcnt_47bd5d80-bf49-4b8c-9147-854d3e467d96">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31, 2020, we owed NantWorks a net amount of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331" decimals="-5" scale="6">12.8</ix:nonFraction>&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000804" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6">10.7</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively, for all agreements between the two affiliates, which is included in </span><span style="font-style:italic;">due to related parties</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also recorded $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000805" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331" decimals="-5" scale="6">1.3</ix:nonFraction>&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000806" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and December&#160;31,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, respectively, which are included in </span><span style="font-style:italic;">prepaid expenses and other current assets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks&#160;LLC, or NantWorks, a related party, for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000807" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130" decimals="INF" format="ixt:numdotdecimal">9,500</ix:nonFraction>&#160;square feet of office space in Culver&#160;City, California, which has been converted to a research and development laboratory and a cGMP&#160;manufacturing facility. The initial license was effective from May&#160;2015 through December&#160;2020. Base monthly rent for the initial lease term was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000808" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130" decimals="0" format="ixt:numdotdecimal">47,000</ix:nonFraction>, with annual increases of 3% beginning in January&#160;2017. In September&#160;2020, we amended this agreement to extend the term of this lease through <ix:nonNumeric id="F_000812" name="ibrx:LeaseAgreementExtendedPeriod" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930" format="ixt:datemonthdayyearen">December&#160;31,&#160;2021</ix:nonNumeric>. Commencing January&#160;1,&#160;2021, the monthly rent increased by 3% to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000809" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101" decimals="0" format="ixt:numdotdecimal">54,500</ix:nonFraction>. Subsequent to December&#160;31,&#160;2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30&#160;days&#8217; prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December&#160;31,&#160;2022. If we exercise the option to extend the lease through December&#160;31,&#160;2022, or continue on a month-to-month basis, the monthly rent will increase by <ix:nonFraction unitRef="U_xbrlipure" id="F_000810" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101" decimals="2" scale="-2">3</ix:nonFraction>% annually commencing on January&#160;1 of each year. On the date of amendment, we recognized an increase of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000811" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930" decimals="-5" scale="6">1.2</ix:nonFraction>&#160;million in both <span style="font-style:italic;">operating lease right-of-use assets</span>, and <span style="font-style:italic;">operating lease liabilities</span>, on the condensed combined consolidated balance sheets, reflecting our belief that we will extend the term of this lease through December&#160;31,&#160;2022. Lease expense for this facility totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000813" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000814" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, was recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic (dba&#160;Chan Soon-Shiong Institutes for Medicine, in El&#160;Segundo, California), to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by <ix:nonFraction unitRef="U_ibrxOfficer" id="F_000815" name="ibrx:NumberOfOfficers" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20151130" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> officer of the company and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30,&#160;2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the Clinic (the Clinic Agreement), which became effective on July&#160;1,&#160;2019. The Clinic Agreement, as amended on March&#160;31,&#160;2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1,&#160;2019, and prospective clinical trials and research projects. The Clinic Agreement also specifies certain services and related costs that are excluded from the Clinic Agreement. Prior to commencing any work under the Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July&#160;1,&#160;2019, fees incurred for services performed after July&#160;1,&#160;2019 are covered under the Clinic Agreement and applied towards the below-mentioned prepayments. The Clinic Agreement allows for automatic renewal and additional extensions beyond the initial <span style="-sec-ix-hidden:F_000816">one-year</span> term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the Clinic Agreement, as amended on March&#160;31,&#160;2020, we agreed to make payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000817" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731" decimals="-5" scale="6">7.5</ix:nonFraction>&#160;million to the Clinic, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000818" name="ibrx:RelatedPartyInstallmentPayment" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731" decimals="-4" scale="6">3.75</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000819" name="ibrx:RelatedPartyInstallmentPayment" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031" decimals="-4" scale="6">1.88</ix:nonFraction>&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. As amended, a conditional payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000820" name="ibrx:RelatedPartyTransactionConditionalPayment" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731" decimals="-4" scale="6">1.88</ix:nonFraction>&#160;million shall be due and payable at such time, if any, that the payments made in July&#160;2019 and October&#160;2019 have been earned by the Clinic through the performance of services. On a quarterly basis, our prepayment is increased by an interest credit computed in accordance with terms specified in the Clinic Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the Clinic Agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the Clinic Agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the Clinic Agreement for up to three additional one&#160;year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within <ix:nonNumeric id="F_000821" name="ibrx:NewAgreementTerminationNoticePeriod" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331" format="ixt-sec:durday">60</ix:nonNumeric>&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we executed a clinical trial work order under the Clinic Agreement for an open-label, Phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July&#160;2020, but effective on June&#160;22,&#160;2020, we and NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company) executed a clinical trial work order under our existing master agreement with the Clinic for an open-label, randomized, comparative Phase&#160;II study of NantCell&#8217;s proprietary IL&#8209;15 superagonist (N&#8209;803) and Aldoxorubicin Hydrochloride&#160;(Aldoxorubicin) and our PD&#8209;L1.t&#8209;haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000353_dcnt_47bd5d80-bf49-4b8c-9147-854d3e467d96" continuedAt="F_000353_cnt_1">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three&#160;months ended March&#160;31,&#160;2021 and 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, respectively, was recognized in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations related to clinical trial and research-related activities conducted for us by the Clinic. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we owed the Clinic $<ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331" decimals="-5" scale="6">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million, respectively, for services excluded from the Clinic Agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had prepaid balances related to the Clinic Agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="ibrx:PrepaidBalance" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331" decimals="-5" scale="6">4.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000827" name="ibrx:PrepaidBalance" contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231" decimals="-5" scale="6">4.7</ix:nonFraction>&#160;million, respectively. We anticipate that the remaining prepayment amount as of March&#160;31,&#160;2021 will be utilized in future periods as the Clinic provides additional services pursuant to the Clinic Agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantBio, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio and the National Cancer Institute, or the NCI, entered into a cooperative research and development agreement. The initial <span style="-sec-ix-hidden:F_000828">five-year</span> agreement covered NantBio and its affiliates, including us. Under the agreement, the parties collaborated on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and combination immunotherapies. In each of the contractual years under the agreement we paid $<ix:nonFraction unitRef="U_iso4217USD" id="F_000832" name="ibrx:PrepaymentOfFundingAmount" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331" decimals="-5" scale="6">0.6</ix:nonFraction>&#160;million to the NCI as a payment for services under the agreement. We recognized research and development expense related to this agreement ratably over a <ix:nonNumeric id="F_000829" name="ibrx:ResearchAndDevelopmentExpenseRatablePaymentPeriod" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331" format="ixt-sec:durmonth">12</ix:nonNumeric>-month period for each funding year and recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000831" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction>&#160;million of expense related to this agreement in each of the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000833" name="ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210331" decimals="-6" scale="6">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000834" name="ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, respectively, in <span style="font-style:italic;">prepaid expenses</span> <span style="font-style:italic;">and other current assets</span>, on the condensed combined consolidated balance sheets related to this agreement.</p></ix:continuation><ix:continuation id="F_000353_cnt_1" continuedAt="F_000353_dcnt_a040ecb5-8cef-47c7-8cd3-dd066de83395">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC, or NCSC, a <ix:nonFraction unitRef="U_xbrlipure" id="F_000835" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantBioScienceMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831" decimals="2" scale="-2">60</ix:nonFraction>% owned subsidiary of NantBio (with the other <ix:nonFraction unitRef="U_xbrlipure" id="F_000836" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="C_0001326110_deiLegalEntityAxis_ibrxSorrentoMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831" decimals="2" scale="-2">40</ix:nonFraction>%&#160;owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of <span style="-sec-ix-hidden:F_000837">five&#160;years</span> and renews automatically for successive <span style="-sec-ix-hidden:F_000838">one-year</span> terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. <ix:nonFraction unitRef="U_iso4217USD" id="F_000839" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210101_20210331" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20200101_20200331" decimals="-6" format="ixt-sec:numwordsen" scale="6">No</ix:nonFraction></ix:nonFraction> revenue was recognized during the three&#160;months ended March&#160;31,&#160;2021 and 2020. We recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million of deferred revenue for bioreactors that were delivered but not installed as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000844" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331" decimals="-5" scale="6">0.9</ix:nonFraction></ix:nonFraction>&#160;million in <span style="font-style:italic;">due to related parties</span>, on the condensed combined consolidated balance sheets related to this agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio&#8217;s business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a net receivable from NantBio of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331" decimals="-5" scale="6">1.3</ix:nonFraction></ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331" decimals="-5" scale="6">1.0</ix:nonFraction></ix:nonFraction>&#160;million for employee bonuses and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331" decimals="-5" scale="6">0.3</ix:nonFraction></ix:nonFraction>&#160;million for vendor costs we paid on behalf of NantBio.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantOmics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC, or NantOmics, a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December&#160;31,&#160;2020 and recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:DueFromRelatedParties" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210331" decimals="-5" scale="6">0.6</ix:nonFraction></ix:nonFraction>&#160;million receivable from NantOmics as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">605&#160;Doug&#160;St,&#160;LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman, for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000853" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331" decimals="0" format="ixt:numdotdecimal">24,250</ix:nonFraction>&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional <span style="-sec-ix-hidden:F_000854">three-year</span> term through July&#160;2026. The monthly rent is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million with annual increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_000856" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331" decimals="2" scale="-2">3</ix:nonFraction>% which began in July&#160;2017. Lease expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200331" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction>&#160;million for this facility for each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, is recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, there were <ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000860" name="us-gaap:RelatedPartyTransactionDueFromToRelatedParty" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20201231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction> balances due between the parties.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000353_dcnt_a040ecb5-8cef-47c7-8cd3-dd066de83395" continuedAt="F_000353_dcnt_05d1563f-1aba-45fa-a6d5-5a4059c24245">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Duley Road, LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2017, Altor BioScience Corporation&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC), or Altor, through its wholly-owned subsidiary, entered into a lease agreement with Duley Road,&#160;LLC, or Duley Road, a related party, that is indirectly controlled by our Executive Chairman, for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000861" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170228" decimals="INF" format="ixt:numdotdecimal">12,000</ix:nonFraction>&#160;square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. <ix:nonNumeric id="F_000870" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for <ix:nonFraction unitRef="U_ibrxTerm" id="F_000869" name="ibrx:OptionsToExtendNumberOfTerms" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction>&#160;consecutive <span style="-sec-ix-hidden:F_000868">five-year</span> periods through July&#160;2034. The monthly rent is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000862" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228" decimals="0" format="ixt:numdotdecimal">40,700</ix:nonFraction> with annual increases of <ix:nonFraction unitRef="U_xbrlipure" id="F_000863" name="ibrx:AnnualPercentageIncreasesToMonthlyFixedCharge" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228" decimals="2" scale="-2">3</ix:nonFraction>% which began in November&#160;2018.</ix:nonNumeric> As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded rent payable to Duley Road of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000864" name="us-gaap:AccruedRentCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="-5" scale="6">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000865" name="us-gaap:AccruedRentCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231" decimals="-5" scale="6">1.0</ix:nonFraction>&#160;million, respectively. For the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded rent expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000866" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="-5" scale="6">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000867" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, respectively, which is reflected in <span style="font-style:italic;">research</span> <span style="font-style:italic;">and development expense</span>, on the condensed combined consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second building located in El&#160;Segundo, California. The first lease is for the first floor of the building with approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000871" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="0" format="ixt:numdotdecimal">5,650</ix:nonFraction>&#160;square feet. The lease has a <span style="-sec-ix-hidden:F_000873">seven-year</span>&#160;term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000872" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="0" format="ixt:numdotdecimal">6,488</ix:nonFraction>&#160;square feet. The lease has a <span style="-sec-ix-hidden:F_000874">seven-year</span> term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive <span style="-sec-ix-hidden:F_000875"><span style="-sec-ix-hidden:F_000876">five-year</span></span> periods through 2036. The monthly rent for the two&#160;leases is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000877" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000878" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">35,800</ix:nonFraction></ix:nonFraction>, which increases at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000879" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="2" scale="-2"><ix:nonFraction unitRef="U_xbrlipure" id="F_000880" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="2" scale="-2">3</ix:nonFraction></ix:nonFraction>%&#160;per year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000881" name="ibrx:LeaseholdImprovementPayables" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="-5" scale="6">0.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000882" name="ibrx:LeaseholdImprovementPayables" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231" decimals="-5" scale="6">0.7</ix:nonFraction>&#160;million of leasehold improvement payables, respectively, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000883" name="ibrx:LeaseRelatedPayables" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000884" name="ibrx:LeaseRelatedPayables" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million of lease-related payables to Duley Road, which were included in <span style="font-style:italic;">due to related parties</span>, on the condensed combined consolidated balance sheets. For each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000885" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000886" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction>&#160;million of rent expense for the two&#160;leases, which is included in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. The security deposits for the leases totals $<ix:nonFraction unitRef="U_iso4217USD" id="F_000887" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000888" name="us-gaap:SecurityDeposit" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, which are included in <span style="font-style:italic;">other assets</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">605 Nash, LLC</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000889" name="ibrx:NumberOfSquareFootOfFacilityLeased" contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228" decimals="INF" format="ixt:numdotdecimal">6,883</ix:nonFraction>&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional <span style="-sec-ix-hidden:F_000890">three-year</span> term through December&#160;2030. Base rent for the term of the lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000891" name="ibrx:BaseMonthlyRent" contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="0" format="ixt:numdotdecimal">20,300</ix:nonFraction>&#160;per month with an annual increase of&#160;<ix:nonFraction unitRef="U_xbrlipure" id="F_000892" name="ibrx:AnnualPercentageIncreasesToBaseRent" contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228" decimals="2" scale="-2">3</ix:nonFraction>% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are responsible for the build out of the facility space and have incurred costs of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000893" name="us-gaap:ConstructionInProgressGross" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331" decimals="-5" scale="6">7.0</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021, which is reflected as construction in progress within </span><span style="font-style:italic;Background-color:#FFFFFF;">property, plant and equipment, net</span><span style="Background-color:#FFFFFF;">, on the condensed combined consolidated balance sheets. We are also entitled to a tenant improvement allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000894" name="us-gaap:TenantImprovements" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331" decimals="-5" scale="6">0.3</ix:nonFraction>&#160;million associated with the buildout costs, which is recorded in </span><span style="font-style:italic;Background-color:#FFFFFF;">prepaid expenses and other current assets</span><span style="Background-color:#FFFFFF;"> on the condensed combined consolidated balance sheets. For the three months ended March&#160;31,&#160;2021, we recorded rent expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million, which is reflected in </span><span style="font-style:italic;Background-color:#FFFFFF;">research and development expense</span><span style="Background-color:#FFFFFF;"> on the condensed combined consolidated statements of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantPharma</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, Altor BioScience, LLC and GlobeImmune, Inc. purchased a total of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20180101_20181231" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million in laboratory equipment from NantPharma. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction>&#160;million payable to NantPharma.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Notes Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, we executed a demand promissory note with Nant Capital. The note bears interest at a per annum rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000899" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20151231" decimals="INF" scale="-2">5.0</ix:nonFraction>%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020 and August&#160;2020, we borrowed $<ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200731" decimals="-5" scale="6">10.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200831" decimals="-5" scale="6">3.7</ix:nonFraction>&#160;million from Nant Capital, respectively. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. The principal amount of advances made by the related party pursuant to these notes totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6">55.2</ix:nonFraction></ix:nonFraction>&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Accrued and unpaid interest on this note totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-5" scale="6">3.3</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes</span> <span style="font-style:italic;">payable</span>, on the condensed combined consolidated balance sheets.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000353_dcnt_05d1563f-1aba-45fa-a6d5-5a4059c24245" continuedAt="F_000353_dcnt_b6713107-b32d-4d30-afd4-0a25be10a948">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, we executed a demand promissory note with NantWorks. The note bears interest at a per annum rate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000906" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20170630" decimals="INF" scale="-2">5.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantWorks. All outstanding amounts under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231" decimals="-5" scale="6">43.4</ix:nonFraction></ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, all of which was outstanding</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note totaled $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331" decimals="-5" scale="6">8.8</ix:nonFraction><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231" decimals="-5" scale="6">8.1</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due under this promissory note are included in </span><span style="font-style:italic;">related-party</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-style:italic;">notes payable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed combined</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> consolidated balance sheets.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we executed a demand promissory note with NCSC. The note bears interest at a per annum rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000911" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20180831" decimals="INF" scale="-2">5.0</ix:nonFraction>%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $<ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-5" scale="6">33.0</ix:nonFraction></ix:nonFraction>&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331" decimals="-5" scale="6">4.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231" decimals="-5" scale="6">3.9</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we executed a demand promissory note with NantMobile. The note bears interest at a per annum rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000916" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20191231" decimals="INF" scale="-2">3.0</ix:nonFraction>%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantMobile. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount advanced by the related party pursuant to this note was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000917" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000918" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231" decimals="-5" scale="6">55.0</ix:nonFraction></ix:nonFraction>&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000919" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331" decimals="-5" scale="6">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000920" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231" decimals="-5" scale="6">1.7</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we executed a promissory note with Nant Capital for an advance of the principal of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000922" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000923" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000924" name="us-gaap:NotesPayableRelatedPartiesNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-5" scale="6">50.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020. The note bears interest at a per annum rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000921" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930" decimals="INF" scale="-2">6.0</ix:nonFraction>%, compounded annually and computed on the basis of 365 or 366 days. The outstanding principal and accrued and unpaid interest are due and payable on September&#160;30,&#160;2025. Accrued and unpaid interest on this note amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000925" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000926" name="us-gaap:InterestPayableCurrentAndNoncurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we executed a promissory note with Nant Capital. The outstanding principal amount of each advance made by Nant Capital bears interest at a per annum rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000927" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210228" decimals="INF" scale="-2">6.0</ix:nonFraction>%, compounded annually and computed based on 365 or 366 days. On February&#160;26,&#160;2021, we received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000928" name="ibrx:AmountOfAdvanceReceivedOnNote" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210226_20210226" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000929" name="ibrx:AmountOfAdvanceReceivedOnNoteOutstanding" contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6">40.0</ix:nonFraction></ix:nonFraction>&#160;million advance pursuant to this promissory note, all of which is outstanding as of March&#160;31,&#160;2021. The accrued interest shall be paid quarterly commencing on June&#160;30,&#160;2021. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;30,&#160;2025. We may prepay the outstanding principal amount and accrued interest at any time without premium or penalty and the prior consent of Nant Capital. Accrued interest payable on this note amounted to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000930" name="us-gaap:InterestPayableCurrent" contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331" decimals="-5" scale="6">0.2</ix:nonFraction>&#160;million as of March&#160;31,&#160;2021, and was included in <span style="font-style:italic;">due to</span> <span style="font-style:italic;">related parties</span>, on the condensed combined consolidated balance sheets. The principal amount due under this promissory note is included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All demand promissory notes have no equity or equity-linked convertible rights.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000353_dcnt_b6713107-b32d-4d30-afd4-0a25be10a948">
</ix:continuation><ix:nonNumeric id="F_000355" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N10___STOCKHOLDERS_DEFICIT">10. &#160;&#160;&#160;&#160;Stockholders&#8217; Deficit</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger with NantCell</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock</span>, par value $0.001&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive <ix:nonFraction unitRef="U_xbrlipure" id="F_000931" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>&#160;newly issued shares of common stock</span>, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000932" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="INF">0.0001</ix:nonFraction>&#160;per share, resulting in the issuance of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000933" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_20210309_20210309" decimals="-5" scale="6">273.7</ix:nonFraction>&#160;million shares of Company Common Stock.<span style="Background-color:#FFFFFF;"> </span>From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. <span style="Background-color:#FFFFFF;">At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed combined consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company&#8217;s par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000934" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210331" decimals="INF">0.0001</ix:nonFraction>&#160;per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved a share repurchase program, or the 2015&#160;Share Repurchase Program, allowing the Chief Executive officer, or CEO, or Chief Financial Officer, or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000935" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="C_0001326110_20210331" decimals="-5" scale="6">50.0</ix:nonFraction>&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through board approval upon repurchase. <ix:nonFraction unitRef="U_xbrlishares" id="F_000937" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="C_0001326110_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000938" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" contextRef="C_0001326110_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction>&#160;shares were repurchased during the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000936" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="C_0001326110_20210331" decimals="-5" scale="6">18.3</ix:nonFraction>&#160;million remained authorized for repurchase under the 2015&#160;Share Repurchase Program. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, a total of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000939" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_20210331" decimals="-5" scale="6">12.6</ix:nonFraction>&#160;million shares of common stock were reserved for issuance, <span style="Background-color:#FFFFFF;color:#000000;">including awards issued under the NC&#160;2015&#160;Plan that were outstanding immediately prior to the Effective Time of the Merger. </span>At the Effective Time, all outstanding equity awards granted under the NC&#160;2015&#160;Plan to purchase NantCell common stock were converted into equity awards to purchase shares of Company Common Stock (using the Merger Exchange Ratio of <ix:nonFraction unitRef="U_xbrlipure" id="F_000940" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction>), on the same terms and conditions as immediately prior to the Effective Time. As of March&#160;31,&#160;2021, there were approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000941" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331" decimals="-5" scale="6">7.0</ix:nonFraction>&#160;million RSUs and <ix:nonFraction unitRef="U_xbrlishares" id="F_000942" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331" decimals="-5" scale="6">1.3</ix:nonFraction>&#160;million stock options outstanding under the NC&#160;2015&#160;Plan, and there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000943" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> additional shares available for future grant.</p></ix:nonNumeric><ix:nonNumeric id="F_000356" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000356_dcnt_bd512e9e-a1bc-4d1b-a33f-1b04c7dd2b82">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N11___STOCKBASED_COMPENSATION">11. &#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2015, the company&#8217;s board of directors adopted, and the company&#8217;s stockholders approved the 2015&#160;Plan. As of March&#160;31,&#160;2021, the 2015&#160;Plan is the only equity plan of the company available for grant of equity awards to employees, directors and consultants of the company. As of March&#160;31,&#160;2021, a total of approximately <ix:nonFraction unitRef="U_xbrlishares" id="F_000944" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210331" decimals="INF" scale="6">6.2</ix:nonFraction>&#160;million shares were available for future grant under the 2015&#160;Plan.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000356_dcnt_bd512e9e-a1bc-4d1b-a33f-1b04c7dd2b82" continuedAt="F_000356_dcnt_995d3881-c4bc-4d6a-94f5-4959f4e79a93">

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based Compensation</p><ix:nonNumeric id="F_000385" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200331" decimals="-3" scale="3">130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">8,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331" decimals="-3" scale="3">350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,888</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331" decimals="-3" scale="3">161</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">12,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331" decimals="-3" scale="3">319</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">15,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_20200101_20200331" decimals="-3" scale="3">480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;18,&#160;2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30)&#160;days following our registration statement effective date. We recognized incremental stock-based compensation expense of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318" decimals="-5" scale="6">2.7</ix:nonFraction>&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;29,&#160;2021, in connection with the resignation of <ix:nonFraction unitRef="U_ibrxDirector" id="F_000960" name="ibrx:NumberOfBoardOfDirectors" contextRef="C_0001326110_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction>&#160;former directors, the Board of Directors approved the acceleration of vesting of <ix:nonFraction unitRef="U_xbrlishares" id="F_000961" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329" decimals="INF" format="ixt:numdotdecimal">83,333</ix:nonFraction>&#160;shares of unvested stock options of each of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90)&#160;days after the date of the modification. We recognized incremental stock-based compensation expense of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210331" decimals="-5" scale="6">2.3</ix:nonFraction>&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recognized in <span style="font-style:italic;">selling, general and administrative expenses</span>, on the condensed combined consolidated statements of operations during the three&#160;months ended March&#160;31,&#160;2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p><ix:nonNumeric id="F_000386" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity and related information for three&#160;months ended March&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000963" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,996,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000969" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="2">9.96</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000978">4.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000964" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000970" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2">23.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000965" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">752,310</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000971" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2">2.39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000966" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">15,660</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000972" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="2">6.27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000967" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="INF" format="ixt:numdotdecimal">4,978,314</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000973" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2">13.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">54,279</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000979">5.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:10.05pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000968" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="INF" format="ixt:numdotdecimal">3,815,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000974" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2">12.07</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">46,363</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000980">4.2</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000356_dcnt_995d3881-c4bc-4d6a-94f5-4959f4e79a93" continuedAt="F_000356_dcnt_266bc9d7-ed44-48a5-826e-f85f30c2fe5f">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,&#160;2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Richard<span style="letter-spacing:-0.15pt;"> </span>Adcock,<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer, a stock option award</span><span style="letter-spacing:-0.15pt;"> </span>(the<span style="letter-spacing:-0.15pt;"> &#8220;</span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant&#8221;)<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>purchase<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_000983" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">750,000</ix:nonFraction><span style="letter-spacing:-0.15pt;">&#160;</span>shares<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>common<span style="letter-spacing:-0.15pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>2015&#160;Plan.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.15pt;"> </span>Grant<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>exercise<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000984" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF">23.72</ix:nonFraction>&#160;per share,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>closing<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>reported<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> the </span>Nasdaq<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>date<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>grant.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>addition,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>schedule:&#160;<ix:nonNumeric id="F_000985" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">one-third<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant<span style="letter-spacing:-0.15pt;">&#160;</span><span style="letter-spacing:-0.05pt;">(i.e.,</span><span style="letter-spacing:-0.1pt;">&#160;</span>250,000<span style="letter-spacing:-0.1pt;"> </span>options)<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>anniversaries<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of </span>grant,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:1.05pt;"> </span>defined<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.15pt;"> </span>through<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>dates.</ix:nonNumeric> This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, the unrecognized compensation cost related to outstanding stock options was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="-5" scale="6">13.9</ix:nonFraction>&#160;million, which is expected to be recognized over a remaining weighted-average period of <ix:nonNumeric id="F_000982" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" format="ixt-sec:duryear">2.8</ix:nonNumeric>&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of stock options exercised during the three&#160;months ended March&#160;31,&#160;2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="-5" scale="6">11.1</ix:nonFraction>&#160;million. Cash proceeds received from stock option exercises during the three&#160;months ended March&#160;31,&#160;2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000988" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> stock options exercised during the three&#160;months ended March&#160;31,&#160;2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,&#160;2020, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000989" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">4,345,497</ix:nonFraction>&#160;vested and exercisable shares were outstanding.</p><ix:nonNumeric id="F_000387" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000990">6.0</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000991" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="3" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000992" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="3" scale="-2">100.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000993" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000994" name="ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331" decimals="2">18.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future. There were <ix:nonFraction unitRef="U_xbrlishares" id="F_000995" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> stock options granted during the three&#160;months ended March&#160;31,&#160;2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p><ix:nonNumeric id="F_000388" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity for the three&#160;months ended March&#160;31,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000996" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="INF" format="ixt:numdotdecimal">466,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231" decimals="2">2.52</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000997" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">7,521,110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001002" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="2">25.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000998" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">235,725</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001003" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="2">16.34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000999" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">116,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001004" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" decimals="2">25.49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_001000" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="INF" format="ixt:numdotdecimal">7,636,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001005" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="2">24.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_001006" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331" decimals="-5" scale="6">179.2</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric id="F_001007" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331" format="ixt-sec:duryear">3.9</ix:nonNumeric>&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000356_dcnt_266bc9d7-ed44-48a5-826e-f85f30c2fe5f" continuedAt="F_000356_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,<span style="letter-spacing:-0.15pt;"> </span>2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Mr.&#160;Adcock<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_ibrxAward" id="F_001009" name="ibrx:NumberOfAwardsGranted" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="letter-spacing:-0.1pt;">&#160;</span>awards<span style="letter-spacing:-0.15pt;"> </span>totaling<span style="letter-spacing:-0.15pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001008" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">400,000</ix:nonFraction><span style="letter-spacing:-0.15pt;">&#160;</span>RSUs<span style="letter-spacing:-0.15pt;"> </span>(each<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Award&#8221;</span><span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">collectively,</span><span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Awards&#8221;) </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.15pt;">Awards </span>are<span style="letter-spacing:-0.1pt;"> </span>comprised<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>two&#160;separate<span style="letter-spacing:-0.15pt;"> </span>awards,<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>settled<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.15pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001010" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction><span style="letter-spacing:-0.1pt;">&#160;</span>shares<span style="letter-spacing:1.05pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>settled<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.1pt;"> </span><ix:nonFraction unitRef="U_xbrlishares" id="F_001011" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction><span style="letter-spacing:-0.15pt;">&#160;</span>shares<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:-0.15pt;"> </span>vesting.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>vested<span style="letter-spacing:1.15pt;"> </span>immediately<span style="letter-spacing:1.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> c</span>ompany<span style="letter-spacing:-0.15pt;"> </span>retaining<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>withholding<span style="letter-spacing:-0.15pt;"> </span>obligations. The<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.15pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>vest<span style="letter-spacing:1.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>schedule:<span style="letter-spacing:-0.1pt;">&#160;</span>one-third<span style="letter-spacing:-0.15pt;"> </span>(i.e.<span style="letter-spacing:-0.1pt;">&#160;</span><ix:nonFraction unitRef="U_xbrlishares" id="F_001012" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205" decimals="INF" format="ixt:numdotdecimal">83,333</ix:nonFraction>)<span style="letter-spacing:-0.15pt;">&#160;</span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>annual<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third&#160;anniversaries<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>shall<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of g</span>rant,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.1pt;"> </span>to <span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>defined<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.1pt;"> </span>vesting<span style="letter-spacing:-0.15pt;"> </span>dates.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4,&#160;2021, prior to the Merger, NantCell awarded <ix:nonFraction unitRef="U_xbrlishares" id="F_001013" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304" decimals="INF" format="ixt:numdotdecimal">7,121,110</ix:nonFraction>&#160;RSUs (adjusted for the exchange ratio of <ix:nonFraction unitRef="U_xbrlipure" id="F_001014" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304" decimals="4">0.8190</ix:nonFraction>) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC&#160;2015&#160;Plan. These RSU awards were subject to a performance condition in connection with a &#8220;Liquidity Event&#8221;, defined as either (i)&#160;NantCell&#8217;s registration of shares for issuance on a securities offering or (ii)&#160;the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March&#160;9,&#160;2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March&#160;4,&#160;2021 and was derived primarily from the estimated probabilities of the Merger close on March&#160;9, 2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March&#160;9, 2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from <span style="-sec-ix-hidden:F_001015">six-month</span> to seventy&#160;(70)-month vesting periods. During the three&#160;months ended March&#160;31,&#160;2021, we recognized approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001017" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331" decimals="-5" scale="6">5.1</ix:nonFraction>&#160;million of stock-based compensation expense related to these awards, of which approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001018" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-5" scale="6">2.9</ix:nonFraction>&#160;million was recorded in <span style="font-style:italic;">research and development expense</span>, and approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331" decimals="-5" scale="6">2.2</ix:nonFraction>&#160;million was recorded in <span style="font-style:italic;">selling, general and administrative expense</span>, respectively, on the condensed combined consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU&#160;2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic&#160;718)</span>, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" contextRef="C_0001326110_20210101_20210331" decimals="-5" scale="6">4.0</ix:nonFraction>&#160;million and recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_001021" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" contextRef="C_0001326110_20210101_20210331" decimals="-5" scale="6">0.1</ix:nonFraction>&#160;million of deemed dividends for the three&#160;months ended March&#160;31,&#160;2021, which was recorded in <span style="font-style:italic;">additional paid in capital,</span> on the condensed combined consolidated balance sheets, with a corresponding credit to stock compensation expense.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrants</p></ix:continuation><ix:continuation id="F_000356_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_001022" name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210331" decimals="INF" format="ixt:numdotdecimal">1,638,000</ix:nonFraction>&#160;warrants with an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001023" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001326110_20210331" decimals="2">3.24</ix:nonFraction>&#160;per share, with vesting subject to the achievement of a certain performance condition pertaining to building manufacturing capacity, were outstanding as of March&#160;31,&#160;2021. The fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001024" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" contextRef="C_0001326110_20210331" decimals="-5" scale="6">18.0</ix:nonFraction>&#160;million assigned to the unvested warrants will be recognized upon achievement of a performance-based vesting condition <span style="color:#000000;">pertaining to building manufacturing capacity to support supply requirements for one of our product candidates</span>. </p></ix:continuation><ix:nonNumeric id="F_000358" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000358_dcnt_651f1f70-ff20-45ab-a2ab-b3f2100c5f6f">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N12___INCOME_TAXES">12. &#160;&#160;&#160;&#160;Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;9, 2021, the company completed the Merger with NantCell. The merger is accounted for as a transaction between entities under common control. The Merger is also considered a nontaxable transaction for U.S. income tax purposes and it is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of&#160;1986, as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S.&#160;activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. <ix:nonFraction unitRef="U_iso4217USD" id="F_001025" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_001026" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_001027" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000358_dcnt_651f1f70-ff20-45ab-a2ab-b3f2100c5f6f">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The difference between the federal statutory tax rate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001028" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001326110_20210101_20210331" decimals="2" scale="-2">21</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the company&#8217;s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_001029" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001326110_20210101_20210331" decimals="2" scale="-2">0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% tax rate is due to losses from which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cannot benefit.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is no longer subject to income tax examination by the U.S.&#160;federal, state or local tax authorities for years ended December&#160;31,&#160;2015 or prior&#59; however, its tax attributes, such as net operating loss&#160;(&#8220;NOL&#8221;) carryforwards and tax credits, are still subject to examination in the year they are used.</p></ix:continuation><ix:nonNumeric id="F_000359" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001326110_20210101_20210331" escape="true" continuedAt="F_000359_dcnt_3b3f7a20-c3fc-4e98-8bbc-07a30e4705ad">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N13___SUBSEQUENT_EVENTS">13. &#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc. Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During April&#160;2021, ImmunityBio executed two&#160;work orders under an existing master agreement with <span style="Background-color:#FFFFFF;color:#000000;">Immuno-Oncology Clinic,&#160;Inc.&#160;(the &#8220;Clinic&#8221;), a related party. Under these work orders, the parties agreed that the Clinic would serve as a site for the following multi-site clinical trials:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike &#38; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"></span><span style="color:#000000;"></span><span style="Background-color:#FFFFFF;color:#000000;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of a supplemental spike &#38; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;color:#000000;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our existing agreement with the Clinic, our share of qualifying expenses shall be deducted from amounts previously paid to the Clinic as described in further detail in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="Background-color:#FFFFFF;">, </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Related Party Agreements</span><span style="Background-color:#FFFFFF;color:#000000;">. We expect to incur up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_001030" name="ibrx:ExpectedClinicalTrialExpense" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_001031" name="ibrx:ExpectedClinicalTrialExpense" contextRef="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderTwoMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430" decimals="-5" scale="6">0.2</ix:nonFraction></ix:nonFraction>&#160;million of qualifying clinical trial expenses under each work order, subject to changes dependent on clinical trial enrollments and progress.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Open Market Sale Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;30, 2021, we entered into an Open Market Sale Agreement&#160;(the &#8220;Sale Agreement&#8221;) with respect to an at-the-market&#160;(&#8220;ATM&#8221;) offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_001032" name="ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="INF" scale="6">500.0</ix:nonFraction>&#160;million through our sales agent. We will pay our sales agent a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_001033" name="ibrx:PercentageOfSalesAgentCommission" contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430" decimals="3" scale="-2">3.0</ix:nonFraction>%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not obligated to sell any shares under the Sale Agreement and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000359_dcnt_3b3f7a20-c3fc-4e98-8bbc-07a30e4705ad">
</ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.46%;text-indent:-7.46%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_MANAGEMENTS_DISCUSSION_ANALYSIS_F">ITEM 2.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read together with our condensed combined consolidated financial statements and the notes to those statements included elsewhere in this Quarterly Report on Form&#160;10-Q. This Quarterly Report on Form&#160;10-Q contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of&#160;1933, as amended, or Securities Act, and Section&#160;21E of the Securities Exchange Act of&#160;1934, as amended, or Exchange Act, that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained in this Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations. Forward-looking statements include, but are not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to pioneer immunotherapy, harness the power of the innate immune system, implement precision cancer medicine and change the current paradigm of cancer care&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to implement and support our COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19 vaccine and therapeutic programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any impact of the coronavirus pandemic, or responses to the pandemic, on our business, clinical trials or personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the potential benefits of our strategy and technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the operation of our product candidates and related benefits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to utilize multiple modes to induce cell death&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the benefits and perceived limitations of competing approaches, and the future of competing technologies and our industry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">details regarding our strategic vision and planned product candidate pipeline, including that we eventually plan to advance therapies for virally induced infectious diseases&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the success, cost and timing of our product candidate development activities and current and future clinical trials and studies, including study design&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding our ability to utilize the Phase&#160;I and II&#160;aNK and haNK clinical trials data to support the development of our product candidates, including our haNK, taNK, t&#8209;haNK, MSC and ceNK product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the development, application, commercialization, marketing, prospects and use generally of our product candidates, including Anktiva, hAd5 and aldoxorubicin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing or likelihood of regulatory filings or other actions and related regulatory authority responses, including any planned investigational new drug, or IND&#59; Biologics License Application, or BLA&#59; or New Drug Application, or NDA, filings or pursuit of accelerated regulatory approval pathways or orphan drug status and Breakthrough Therapy designations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to implement an integrated discovery ecosystem and the operation of that planned ecosystem, including being able to regularly add neoepitopes and subsequently formulate new product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability and willingness of strategic collaborators, including certain affiliates of NantWorks,&#160;LLC, or NantWorks, to share our vision and effectively work with us to achieve our goals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability and willingness of various third parties to engage in research and development activities involving our product candidates, and our ability to leverage those activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract additional third-party collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the ease of administration associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the patient compatibility associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the potential markets for our product candidates and our ability to serve those markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to produce an &#8220;off-the-shelf&#8221; therapy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our beliefs regarding the potential manufacturing and distribution benefits associated with our product candidates, and our ability to scale up the production of our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our plans regarding our manufacturing facilit</span><span style="color:#000000;">ies</span><span style="color:#000000;"> and our belief that our manufacturing is capable of being conducted in</span><span style="color:#000000;">&#8209;house&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our belief in the potential of our antibody cytokine fusion protein, vaccine technology and NK-92 and ceNK cell therapy technology, and the fact that our business is based upon the success individually and collectively of our platforms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our antibody cytokine fusion protein, vaccine technology and NK-92 and ceNK cell therapy technology along with other product candidate families, will require significant additional clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">even if we successfully develop and commercialize specific product candidates like our Anktiva or haNK and t&#8209;hank, we may not be successful in developing and commercializing our other product candidates either alone or in combination with other therapeutic agents&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to obtain and maintain regulatory approval of any of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to commercialize any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate and degree of market acceptance of any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the accuracy of our estimates regarding our future revenue, as well as our future operating expenses, capital requirements and needs for additional financing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain funding for our operations, including funding necessary to complete further development and any commercialization of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain, maintain, protect and enforce intellectual property protection for our product candidates and technology and not infringe upon, misappropriate or otherwise violate the intellectual property of others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and conditions of licenses granted to us and our ability to license additional intellectual property relating to our product candidates and technology&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact on us, if any, if the contingent value rights, or CVRs, held by former Altor stockholders become due and payable in accordance with their terms&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments in the United States, or U.S., and foreign countries.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Forward-looking statements include statements that are not historical facts and can be identified by terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; or similar expressions and the negatives of those terms. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Quarterly Report on Form&#160;10-Q, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part&#160;II, Item&#160;1A. &#8220;Risk Factors&#8221; of this Quarterly Report <span style="color:#000000;">on Form&#160;10-Q</span>. Given these uncertainties, you should not place undue reliance on these forward-looking statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame. Also, forward-looking statements represent our management&#8217;s beliefs and assumptions only as of the date of this Quarterly Report <span style="color:#000000;">on Form&#160;10-Q</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Quarterly Report on Form&#160;10-Q completely and with the understanding that our actual future results may be materially different from what we expect.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">This </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Quarterly Report</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> on Form&#160;10-Q</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Quarterly Report</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> on Form&#160;10-Q</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">, including logos, artwork and other visual displays, may appear without the </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> or </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup></span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">,</span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"> by any other companies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form&#160;10-Q, &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio,&#160;Inc. and its subsidiaries.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We established ImmunityBio to advance the next-generation of immunotherapies and to address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our&#160;four key modalities:&#160;(1)&#160;activating NK and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4)&#160;off-the-shelf natural killer cells from the NK-92 cell line and memory-like cytokine-enhanced natural killer cells&#160;(m-ceNK) from allogenic and autologous donors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL-15 superagonist (N-803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator&#160;(aldoxorubicin), second-generation adenovirus&#160;(hAd5) and yeast vaccine technologies (targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), </span><span style="Background-color:#FFFFFF;">patient specific NK cell product for cancer that is an autologous Memory cytokine enhanced Natural Killer cells, </span><span style="Background-color:#FFFFFF;">macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD-L1, TGF-</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">b</span></span><span style="Background-color:#FFFFFF;"> and IL-12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December&#160;2019, the </span><span style="color:#000000;">U.S. Food and Drug Administration</span><span style="Background-color:#FFFFFF;">, or FDA, granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#233;rin, or BCG, unresponsive carcinoma in situ non-muscle invasive bladder cancer. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December&#160;21,&#160;2020, we and NantCell,&#160;Inc.&#160;(formerly known as ImmunityBio,&#160;Inc., a private company) (&#8220;NantCell&#8221;) entered into an Agreement and Plan of Merger&#160;(the &#8220;Merger Agreement&#8221;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell&#160;(the&#160;&#8220;Merger&#8221;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March&#160;9,&#160;2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#8220;Effective Time&#8221;), each share of NantCell common stock</span>, par value $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000390_2" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309" decimals="3">0.001</ix:nonFraction></span>&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;</span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000391_2" name="ibrx:MergerExchangeRatio" contextRef="C_0001326110_20210309_20210309" decimals="4">0.8190</ix:nonFraction></span><span style="Background-color:#FFFFFF;">&#160;(the &#8220;Exchange Ratio&#8221;) newly</span> issued shares of common stock, par value $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000392_2" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001326110_20210309" decimals="4">0.0001</ix:nonFraction></span>&#160;per share, of the company&#160;(&#8220;Company Common Stock&#8221;), with cash paid in lieu of any fractional shares.<span style="Background-color:#FFFFFF;"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;</span><span style="Background-color:#FFFFFF;">7</span><span style="Background-color:#FFFFFF;">1</span><span style="Background-color:#FFFFFF;">.</span><span style="Background-color:#FFFFFF;">5</span><span style="Background-color:#FFFFFF;">%</span><span style="Background-color:#FFFFFF;"> of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately</span><span style="Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">28</span><span style="Background-color:#FFFFFF;">.5</span><span style="Background-color:#FFFFFF;">%</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our </span><span style="Background-color:#FFFFFF;">E</span><span style="Background-color:#FFFFFF;">xecutive </span><span style="Background-color:#FFFFFF;">C</span><span style="Background-color:#FFFFFF;">hairman, and his affiliates beneficially own, in the aggregate, </span><span style="Background-color:#FFFFFF;">approximately&#160;</span><span style="Background-color:#FFFFFF;">8</span><span style="Background-color:#FFFFFF;">1.8</span><span style="Background-color:#FFFFFF;">%</span><span style="Background-color:#FFFFFF;">&#160;</span><span style="Background-color:#FFFFFF;">of the outstanding shares of Company Common Stock.</span><span style="Background-color:#FFFFFF;"> </span><span style="Background-color:#FFFFFF;">Following the consummation of the Merger, shares of the company&#8217;s common stock are now listed on the Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We incurred costs totaling $23.2&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $12.9&#160;million was recorded during the three&#160;months ended March&#160;31,&#160;2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:2.54%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board Accounting Standards Codification Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon&#8209;Shiong <span style="color:#000000;">and his affiliates were the controlling stockholders of each of the company and </span>NantCell for all the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior <span style="color:#000000;">period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the condensed consolidated financial statements presented in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q. All</span> material intercompany accounts and transactions have been eliminated in consolidation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Coronavirus Pandemic</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease (SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given the unprecedented and continuously evolving nature of the pandemic, the future impact of these changes and potential changes on the company are unknown at this time. To date, we have seen no material adverse impact to our business from the pandemic. We anticipate, however, that enrollment of patients in certain studies will likely take longer than forecasted in prior Securities and Exchange Commission, or SEC, filings and that our clinical trials may require additional time to complete which would in turn impact the timeline in which we were previously forecasting BLA submissions of our product candidates and subsequent revenue generation. These factors have been accounted for in the company&#8217;s anticipated upcoming milestones. During any such delays in our clinical trials, we will continue to incur fixed costs such as selling, general and administrative expenses and operating expenses related to our laboratory, Good Manufacturing Practice, or GMP, manufacturing, and office facilities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our office-based employees have been working from home since mid-March&#160;2020. Essential staffing levels for our research and development operations remain in place, including maintaining key personnel in our laboratory and GMP&#160;manufacturing facilities. It is likely that the pandemic and resulting mitigation efforts could have an impact in the future on our third-party suppliers who manufacture laboratory supplies required for our in-house manufacturing process, which in turn could have an impact on having sufficient clinical product supply available for our clinical trials. We have addressed this in part by ensuring that we have sufficient supplies on hand to weather interruptions in our supply chain.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty about the progression and ultimate impact of the pandemic on our business and operations. While the pandemic did not materially impact our results during the periods presented in this Quarterly Report on Form&#160;10-Q, we anticipate that it could impact our business in the future due to factors such as fewer patients accessing treatment for cancer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Results</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> minimal </span>revenue<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.1pt;">g</span>reements<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">n</span>es,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>bioreactors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>related consumables<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. We have incurred net losses in each year since our inception and, as of March&#160;31,&#160;2021, we had an accumulated deficit of $1.7&#160;billion. Our net losses attributable to ImmunityBio common stockholders were $79.6&#160;million and $37.0&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, and $221.9&#160;million and $157.8&#160;million for the years ended December&#160;31,&#160;2020 and 2019, respectively. Substantially all of our net losses resulted principally from costs incurred in connection with our ongoing clinical trials and operations, our research and development programs, and from selling, general and administrative costs associated with our operations, including stock-based compensation expense.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, we had 475&#160;employees. Personnel of related companies who provide corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy and other support services under our shared services agreement with NantWorks are not included in this number. For additional information, see <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-style:italic;">&#160;Related Party Agreements,</span> of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears</span> in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of this Quarterly Report<span style="color:#000000;"> on Form&#160;10-Q</span>. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future, which may fluctuate significantly from quarter-to-quarter and year-to-year. See &#8220;&#8212;<span style="font-style:italic;">Future Funding Requirements</span>&#8221; below for a discussion of our anticipated expenditures and sources of capital we expect to access to fund these expenditures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that strategic collaborations will become an integral part of our operations, providing opportunities to leverage our partners&#8217; expertise and capabilities to further expand the potential of our technologies and product candidates. We believe we are well positioned to become a leader in immunotherapy due to our broad and vertically integrated platform and through complementary strategic partnerships. We may also enter into supply arrangements for various investigational agents to be used in our clinical trials. See&#160;<a href="#N7___COLLABORATION_LICENSE_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;7</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Collaboration and License Agreements</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q</span> for a more detailed discussion regarding our existing collaboration and license agreements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Agreements with Related Parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business with several affiliates under written and informal arrangements. Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. We have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new immunotherapies for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, we have outstanding promissory notes with certain entities affiliated with Dr.&#160;Soon-Shiong in an aggregate amount of $297.5&#160;million, including accrued interest. The notes bear interest at a per annum rate ranging from 3.0% to 6.0%. As of March&#160;31,&#160;2021, the notes provide that all outstanding principal is due and payable on September&#160;30,&#160;2025, and accrued and unpaid interest is payable on either the maturity date or, with respect to one of the notes, on a quarterly basis beginning June&#160;30,&#160;2021. We may prepay the outstanding amount of any advance under such notes, together with accrued and unpaid interest, at any time, in whole or in part, without premium or penalty.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">605 Nash, LLC</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, but effective on January&#160;1, 2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional three-year term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of&#160;3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Promissory Note with Nant Capital</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we executed a promissory note with Nant Capital. The outstanding principal amount of each advance made by Nant Capital bears interest at a per annum rate of 6.0%, compounded annually and computed based on 365 or 366 days. On February&#160;26,&#160;2021, we received a $40.0&#160;million advance pursuant to this promissory note, all of which is outstanding as of March&#160;31,&#160;2021. The accrued interest shall be paid quarterly commencing on June&#160;30,&#160;2021. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;30, 2025. We may prepay the outstanding principal amount and accrued interest at any time without premium or penalty and the prior consent of Nant Capital. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related Party Agreements</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; that appears in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q for a more detailed discussion regarding our related party agreements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of our Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> minimal </span>revenue<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.1pt;">g</span>reements<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">n</span>es,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>bioreactors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>related consumables<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>programs. We have no clinical products approved for commercial sale and have not generated any revenue from therapeutic and vaccine product candidates that are under development. If we fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval for them, we may never be able to generate substantial future revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally classify our operating expenses into research and development, and selling, general and administrative expenses. Personnel costs, including salaries, benefits, bonuses, and stock-based compensation expense comprise a significant component of our research and development, and selling, general and administrative expense categories. We allocate expenses associated with our facilities and information technology costs between these two&#160;categories based on the nature of each cost.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense consists of expenses incurred while performing research and development activities to discover and develop our technology and product candidates. This includes conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for product candidates. We recognize research and development expenses as they are incurred. Our research and development expense primarily consists of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial and regulatory-related costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under agreements with investigative sites and consultants that conduct our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses incurred under collaborative agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing and testing costs and related supplies and materials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">employee-related expenses, including salaries, benefits, travel and stock-based compensation&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">facility expenses dedicated to research and development.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external consultant costs to specific product candidates or development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to continue to increase significantly for the foreseeable future as we advance our product candidates through clinical development, including the conduct of our ongoing and any future clinical trials. The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. The successful development of product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs required to complete the remaining development of any product candidates. This is due to the numerous risks and uncertainties associated with the development of product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The costs of clinical trials may vary significantly over the life of a project owing to, but not limited to, the following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">per patient trial costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of sites included in the clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the countries in which the clinical trials are conducted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the length of time required to enroll eligible patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of patients that participate in the clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number of doses that patients receive&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of comparative agents used in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the drop-out or discontinuation rates of patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential additional safety monitoring or other studies requested by regulatory agencies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the duration of patient follow-up&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efficacy and safety profile of the product candidate.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not expect any of our product candidates to be commercially available for at least the next 12&#160;to 24&#160;months, if ever.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Selling, General and Administrative</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense consists primarily of salaries and personnel-related costs, including employee benefits and any stock-based compensation, for employees performing functions other than research and development. This includes personnel in executive, finance, human resources, information technology, legal, and administrative support functions. Other selling, general and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees for auditing, tax and legal services, advertising costs, expenses associated with strategic business transactions and business development efforts, obtaining and maintaining patents, consulting costs, royalties and licensing costs, and costs of our information systems.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our selling, general and administrative expenses will increase for the foreseeable future as we expand operations, build out information systems and increase our headcount to support continued research activities and the development of our clinical programs. We have incurred and expect that we will continue to incur in the future, additional costs associated with operating as a public company, including costs to comply with stock exchange listing and SEC&#160;requirements, future funding efforts, corporate governance, internal controls, investor relations, disclosure and similar requirements applicable to public companies. Additionally, if and when we believe that a regulatory approval of a product candidate appears likely, we expect to incur significant increases in our selling, general and administrative expenses relating to the sales and marketing of the approved product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Other Income and Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income and expense consists primarily of interest income, interest expense, unrealized gains and losses on investments in equity securities, realized gains and losses on both debt and equity securities, and gains and losses on foreign currency transactions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S.&#160;activities are subject to local country income tax. To date, we have not been required to pay U.S.&#160;federal income taxes or foreign income taxes because of our or our subsidiaries&#8217; current and accumulated net operating losses.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparison of the three months ended March&#160;31, 2021 and 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited, $ in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,128</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,374</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,754</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,275</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,493</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,782</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">377</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,403</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,867</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,536</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,264</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,702</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49,562</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,944</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,866</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11367</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense (including amounts with related parties)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,168</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,889</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,279</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,104</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,091</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,789</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(707</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,496</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(919</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes and noncontrolling interests</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,475</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,409</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,066</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,481</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,427</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,054</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expense increased $13.8&#160;million during the three&#160;months ended March&#160;31,&#160;2021, as compared to the three&#160;months ended March&#160;31,&#160;2020. The increase in research and development expense was primarily driven by higher laboratory supply expenses of $4.9&#160;million mainly driven by our COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs, increased stock compensation expense of $2.7&#160;million due to new grants issued, higher compensation related expenses including shared services costs of $1.9&#160;million driven by additional headcount needed to support our business activities, increased clinical trial expenses and regulatory costs of $1.7&#160;million related to our COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs, higher third party testing services of $1.3&#160;million driven by release testing related to various product candidates, and higher manufacturing costs, including facilities expenses and equipment maintenance costs of $1.1&#160;million related to our Anktiva and COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 programs.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expense to increase significantly for the foreseeable future as we advance our product candidates through clinical development and conduct our ongoing and planned clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Selling, General and Administrative Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative expense increased $35.8&#160;million during the three&#160;months ended March&#160;31,&#160;2021, as compared to the three&#160;months ended March&#160;31,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">The increase in selling, general and administrative expense was primarily attributable to </span>higher financial advisory, legal, public company and other professional fees of $21.0&#160;million related to our merger which was announced in December&#160;2020 and closed in March&#160;2021 as well as higher costs associated with ongoing litigation, contracting, trademark, and patent related legal fees and other matters, higher stock compensation expense of $12.1&#160;million driven by stock options and RSUs granted as well as stock option modifications resulting in incremental stock based compensation expense in the first quarter of 2021, increased insurance costs of $2.0&#160;million due mostly to higher directors&#8217; and officers&#8217; renewal rates and increased coverage related to the combined company, and higher compensation related expenses including shared services costs of $0.6 million.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Inc</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ome</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Expense</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income increased $6.5<span style="color:#000000;">&#160;</span>million during the three&#160;months ended March&#160;31,&#160;2021, as compared to the three months&#160;ended March&#160;31,&#160;2020. <span style="Background-color:#FFFFFF;color:#000000;">This increase was mainly due to unrealized gains of $8.8&#160;million related to our equity investments. These gains were partially offset by a $1.3&#160;million increase in interest expense driven primarily by additional related party borrowings and a decrease in other income of $1.1&#160;million related to Receptome,&#160;LLC.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal sources of liquidity are our existing cash, cash equivalents, and marketable securities. We have historically invested our cash primarily in investment grade short- to intermediate-term corporate debt securities, commercial paper, government-sponsored securities, U.S.&#160;treasury securities, and foreign government bonds and classify these investments as available-for-sale. Certain of these investments are subject to general credit, liquidity and other market risks. The general condition of the financial markets and the economy may increase those risks and may affect the value and liquidity of investments and restrict our ability to access the capital markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, we had cash and cash equivalents, and marketable securities of $84.3&#160;million compared to $97.0&#160;million as of December&#160;31,&#160;2020. In order to complete the development of our current product candidates, and implement our business plan, we will require substantial additional funding. Furthermore, changing circumstances may cause us to increase our spending significantly faster than we currently anticipate, and we may need to raise even greater amounts of funds sooner if we choose to expand more rapidly than we presently anticipate. Moreover, our fixed expenses such as rent and other contractual commitments are substantial and are expected to increase in the future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Uses of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the cash used to fund our operating activities discussed in &#8220;<span style="font-style:italic;">&#8212;Future Funding Requirements</span>&#8221; below, we will require cash to settle the following obligations:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, we had related-party notes payable together with accrued interest thereon of $297.5&#160;million compared to $254.4&#160;million as of December&#160;31,&#160;2020. During the three&#160;months ended March&#160;31&#160;2021, we received a $40.0&#160;million advance pursuant to a related-party promissory note. Such notes bear interest at 3% to 6% per year and may be prepaid by us without penalty. The notes allow for additional advances as we may request with the consent of the applicable lender. With the exception of interest on the recent $40.0&#160;million advance, all outstanding principal and accrued and unpaid interest on these notes are due and payable on September&#160;30,&#160;2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our acquisition of Altor, we issued CVRs under which we have agreed to pay the prior stockholders of Altor approximately $304.0&#160;million upon successful approval of the BLA or foreign equivalent for Anktiva by December&#160;31,&#160;2022 and approximately $304.0&#160;million upon the first calendar year prior to December&#160;31,&#160;2026 in which worldwide net sales of Anktiva exceed $1.0&#160;billion (with payments payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately $279.5&#160;million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of common stock in satisfaction of their CVRs. We may need to seek additional sources of capital to satisfy the CVR obligations if they are achieved.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth our primary sources and uses of cash for periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended <br />March 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(60,469</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,107</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,845</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,994</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,497</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(123</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effect of exchange rate changes on cash, cash equivalents,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in cash, cash equivalents, and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,764</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,147</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended March&#160;31,&#160;2021, net cash used in operating activities of $60.5&#160;million consisted of a<span style="letter-spacing:0.25pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">l</span>oss<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>$80.5&#160;m<span style="letter-spacing:0.05pt;">i</span>llion, part<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">l</span>ly<span style="letter-spacing:1.25pt;"> </span>o<span style="letter-spacing:0.05pt;">f</span>fset<span style="letter-spacing:0.85pt;"> </span>by<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">$14.5&#160;m</span>illi<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>ad<span style="letter-spacing:0.05pt;">j</span>us<span style="letter-spacing:0.05pt;">t</span>ments<span style="letter-spacing:1.7pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.5pt;"> </span>no<span style="letter-spacing:0.05pt;">n</span>-cash<span style="letter-spacing:1.4pt;"> </span>items<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">$5.5&#160;m</span>ill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>cash<span style="letter-spacing:0.7pt;"> </span><span style="letter-spacing:0.05pt;">p</span>rovi<span style="letter-spacing:0.05pt;">d</span>ed<span style="letter-spacing:1.3pt;"> </span>by<span style="letter-spacing:0.45pt;"> </span>net<span style="letter-spacing:0.55pt;"> </span>work<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:1.25pt;"> </span>capital<span style="letter-spacing:1pt;"> </span>chan<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:1.3pt;"> </span>A<span style="letter-spacing:0.05pt;">d</span>justmen<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:1.8pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>tems<span style="letter-spacing:0.85pt;"> </span>pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:1.35pt;"> </span>consisted<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$15.3&#160;mil<span style="letter-spacing:0.05pt;">l</span>ion<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>ock<span style="letter-spacing:0.8pt;"> </span>compe<span style="letter-spacing:0.05pt;">n</span>sati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:2pt;"> </span>expense,<span style="letter-spacing:1.3pt;"> </span>$3.4&#160;mill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>terest<span style="letter-spacing:1.1pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>ri<span style="letter-spacing:0.05pt;">m</span>a<span style="letter-spacing:0.05pt;">r</span>ily<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>related<span style="letter-spacing:1.05pt;"> </span>party<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">l</span>oans,<span style="letter-spacing:0.9pt;"> </span>$3.0&#160;mill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>depreciati<span style="letter-spacing:0.1pt;">o</span>n<span style="letter-spacing:1.8pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>amo<span style="letter-spacing:0.05pt;">r</span>tizati<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:1.9pt;"> </span>$1.6&#160;<span style="letter-spacing:0.05pt;">m</span>ill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>non<span style="letter-spacing:0.05pt;">-</span>cash<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">l</span><span style="letter-spacing:-0.05pt;">e</span>ase<span style="letter-spacing:0.8pt;"> </span>expense<span style="letter-spacing:1.2pt;"> </span>related<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>operat<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:1.4pt;"> </span>lease<span style="letter-spacing:0.85pt;"> </span>righ<span style="letter-spacing:0.05pt;">t</span>-of-use assets,<span style="letter-spacing:1pt;"> </span>and $0.2&#160;<span style="letter-spacing:0.05pt;">m</span>ill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">m</span>or<span style="letter-spacing:0.05pt;">t</span>iza<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:1.8pt;"> </span>of<span style="letter-spacing:0.45pt;"> net </span>premiums and discounts on<span style="letter-spacing:0.5pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>e<span style="letter-spacing:0.05pt;">t</span>a<span style="letter-spacing:0.05pt;">b</span>le<span style="letter-spacing:1.6pt;"> </span>debt<span style="letter-spacing:0.7pt;"> </span>securi<span style="letter-spacing:0.05pt;">t</span>ies, reduced<span style="letter-spacing:1.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:0.45pt;"> </span><span style="letter-spacing:0.05pt;">$8.8&#160;m</span>illion<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>realized<span style="letter-spacing:1.5pt;"> </span>gains<span style="letter-spacing:0.8pt;"> </span>on<span style="letter-spacing:0.5pt;"> </span>marketa<span style="letter-spacing:0.05pt;">b</span>le<span style="letter-spacing:1.6pt;"> </span>e<span style="letter-spacing:0.05pt;">q</span>u<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:0.95pt;"> </span>secur<span style="letter-spacing:0.05pt;">i</span>ties<span style="letter-spacing:1.4pt;"> </span>dri<span style="letter-spacing:0.05pt;">v</span>en pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:0.35pt;"> </span>by<span style="letter-spacing:0.45pt;"> </span>an<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span>ncrease<span style="letter-spacing:1.2pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span>val<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>in<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:0.05pt;">m</span>ents.<span style="letter-spacing:1.45pt;"> </span>The<span style="letter-spacing:0.65pt;"> </span>change<span style="letter-spacing:1.05pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>working<span style="letter-spacing:1.25pt;"> </span>capi<span style="letter-spacing:0.05pt;">t</span>al<span style="letter-spacing:1.05pt;"> </span>co<span style="letter-spacing:0.1pt;">n</span>sisted<span style="letter-spacing:1.35pt;"> </span>pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:1.35pt;"> </span>of increases<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>accoun<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:1.3pt;"> </span>pa<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">b</span>le<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">$6.5&#160;</span>m<span style="letter-spacing:0.05pt;">i</span>llio<span style="letter-spacing:0.05pt;">n,</span> amounts due<span style="letter-spacing:0.6pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>rties<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$2.6&#160;<span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n, and <span style="letter-spacing:0.05pt;">o</span>ther<span style="letter-spacing:0.8pt;"> </span><span style="letter-spacing:0.05pt;">l</span>ong-term<span style="letter-spacing:1.45pt;"> </span>asse<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f $0.7&#160;mill<span style="letter-spacing:0.05pt;">i</span>on.<span style="letter-spacing:1.25pt;"> </span>T<span style="letter-spacing:0.05pt;">h</span>ese increases<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>wo<span style="letter-spacing:0.05pt;">r</span>king<span style="letter-spacing:1.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">p</span>ital<span style="letter-spacing:1pt;"> </span>were<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span>tially<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:0.05pt;">f</span><span style="letter-spacing:-0.05pt;">s</span>et<span style="letter-spacing:0.85pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:0.45pt;"> de</span>creases<span style="letter-spacing:1.4pt;"> </span><span style="letter-spacing:0.05pt;">in accrued expenses</span> and other liabilities<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">$1.9</span>&#160;<span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:2.05pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>e<span style="letter-spacing:0.05pt;">r</span>ating<span style="letter-spacing:1.45pt;"> </span>lease<span style="letter-spacing:0.8pt;"> </span>liab<span style="letter-spacing:0.05pt;">i</span>lities<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$1.5&#160;<span style="letter-spacing:0.05pt;">m</span>ill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>prepaid<span style="letter-spacing:1.15pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">x</span>pens<span style="letter-spacing:-0.05pt;">e</span>s and <span style="letter-spacing:0.05pt;">o</span>ther<span style="letter-spacing:0.8pt;"> </span>current<span style="letter-spacing:1.05pt;"> </span>assets<span style="letter-spacing:0.95pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>$0.9&#160;m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>includ<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:1.45pt;"> </span>changes<span style="letter-spacing:1.2pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o insurance<span style="letter-spacing:1.4pt;"> </span>claim<span style="letter-spacing:0.9pt;"> </span>receivables<span style="letter-spacing:1.65pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>prepaid<span style="letter-spacing:1.1pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span>ufacturing<span style="letter-spacing:2.1pt;"> </span>serv<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">c</span>es.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended March&#160;31,&#160;2020, net cash used in operating activities of $31.1&#160;million consisted of a<span style="letter-spacing:0.25pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">l</span>oss<span style="letter-spacing:0.65pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>$37.4&#160;m<span style="letter-spacing:0.05pt;">i</span>llion, partially offset by $6.3&#160;mil<span style="letter-spacing:0.05pt;">l</span>ion<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:0.35pt;"> </span>adjustmen<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:1.7pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or<span style="letter-spacing:0.55pt;"> </span>non-cash<span style="letter-spacing:1.35pt;"> </span>i<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:0.05pt;">m</span>s and $0.1&#160;million<span style="letter-spacing:1.1pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>cash<span style="letter-spacing:0.75pt;"> provided </span>by<span style="letter-spacing:0.45pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>w<span style="letter-spacing:0.05pt;">o</span>rki<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:1.25pt;"> </span>capital<span style="letter-spacing:1pt;"> </span>changes.<span style="letter-spacing:1pt;"> </span>Adjust<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts<span style="letter-spacing:1.85pt;"> </span>for<span style="letter-spacing:0.5pt;"> </span>non-cash items<span style="letter-spacing:0.85pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ima<span style="letter-spacing:0.05pt;">r</span>ily<span style="letter-spacing:1.35pt;"> </span>consisted<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>$3.5&#160;m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>dep<span style="letter-spacing:0.05pt;">r</span>ec<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:1.8pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>a<span style="letter-spacing:0.05pt;">m</span>ort<span style="letter-spacing:0.05pt;">i</span>za<span style="letter-spacing:0.05pt;">t</span>ion,<span style="letter-spacing:1.9pt;"> </span><span style="letter-spacing:0.05pt;">$2.0&#160;m</span>illion<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>n-cash<span style="letter-spacing:1.35pt;"> </span>inte<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>st items, $1.2&#160;m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">n</span>on-cash<span style="letter-spacing:1.35pt;"> </span>lease<span style="letter-spacing:0.8pt;"> </span>ex<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:1.2pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">l</span>ated<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>e<span style="letter-spacing:0.05pt;">r</span>ating<span style="letter-spacing:1.45pt;"> </span>lease ri<span style="letter-spacing:0.05pt;">g</span>ht-<span style="letter-spacing:0.05pt;">o</span>f-<span style="letter-spacing:0.05pt;">u</span>se<span style="letter-spacing:1.7pt;"> </span>assets,<span style="letter-spacing:1pt;"> </span>$0.5&#160;m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>stock<span style="letter-spacing:0.8pt;"> </span>co<span style="letter-spacing:0.05pt;">m</span>pensa<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:2pt;"> </span>expense, and $0.2&#160;million in unrealized losses<span style="letter-spacing:0.9pt;"> </span>on<span style="letter-spacing:0.5pt;"> </span>marketab<span style="letter-spacing:0.05pt;">l</span>e<span style="letter-spacing:1.6pt;"> </span>e<span style="letter-spacing:0.05pt;">q</span>uity<span style="letter-spacing:0.95pt;"> </span>secur<span style="letter-spacing:0.05pt;">i</span>ties, partially offset by a $1.1&#160;million change in deferred tax liability.<span style="letter-spacing:1.25pt;"> </span>The<span style="letter-spacing:0.65pt;"> changes</span><span style="letter-spacing:1.25pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>net wor<span style="letter-spacing:0.05pt;">k</span>ing<span style="letter-spacing:1.25pt;"> </span>capi<span style="letter-spacing:0.05pt;">t</span>al<span style="letter-spacing:1.05pt;"> </span>consis<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:1.35pt;"> </span>pr<span style="letter-spacing:0.05pt;">i</span>mari<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.45pt;"> in</span>c<span style="letter-spacing:0.05pt;">r</span>eases<span style="letter-spacing:1.4pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>acc<span style="letter-spacing:0.05pt;">r</span>ued<span style="letter-spacing:1.15pt;"> </span>expenses<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>$8.2<span style="letter-spacing:0.85pt;">&#160;</span><span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n and<span style="letter-spacing:1.15pt;"> </span>other<span style="letter-spacing:0.85pt;"> </span>assets<span style="letter-spacing:0.9pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$0.3<span style="letter-spacing:0.7pt;">&#160;</span>million, partially offset by decreases in prepaid<span style="letter-spacing:1.15pt;"> </span>expenses<span style="letter-spacing:1.35pt;"> </span>and<span style="letter-spacing:1.15pt;"> </span>other<span style="letter-spacing:0.8pt;"> </span>current<span style="letter-spacing:1.1pt;"> </span>assets<span style="letter-spacing:0.9pt;"> </span>of $4.0&#160;mill<span style="letter-spacing:0.05pt;">i</span>on, d<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.65pt;"> </span>to<span style="letter-spacing:0.35pt;"> </span>related<span style="letter-spacing:1.05pt;"> </span>parties<span style="letter-spacing:1pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$2.4&#160;<span style="letter-spacing:0.05pt;">m</span>ill<span style="letter-spacing:0.05pt;">i</span>on,<span style="letter-spacing:1.15pt;"> </span>accou<span style="letter-spacing:0.05pt;">n</span>ts<span style="letter-spacing:1.35pt;"> </span>payable<span style="letter-spacing:1.15pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$1.7&#160;<span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n, and ope<span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">t</span>ing<span style="letter-spacing:1.4pt;"> </span>lease liabi<span style="letter-spacing:0.05pt;">l</span>ities<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">$0</span>.3&#160;<span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three months&#160;ended March&#160;31,&#160;2021, net cash provided by investing activities was $31.8&#160;million, which included cash inflows of $3<span style="letter-spacing:0.05pt;">1</span>.9<span style="letter-spacing:0.85pt;">&#160;</span>m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d $7.1<span style="letter-spacing:0.75pt;">&#160;</span>mill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">f</span>rom<span style="letter-spacing:0.8pt;"> </span>matu<span style="letter-spacing:0.05pt;">r</span>ities<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>sales<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span>ketable<span style="letter-spacing:1.6pt;"> </span>sec<span style="letter-spacing:0.05pt;">u</span>rit<span style="letter-spacing:0.05pt;">i</span>es,<span style="letter-spacing:1.45pt;"> </span><span style="letter-spacing:0.05pt;">respectively, partially offset</span><span style="letter-spacing:1.5pt;"> by</span>$7.1<span style="letter-spacing:0.85pt;">&#160;</span>mil<span style="letter-spacing:0.05pt;">l</span>ion<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">p</span>urchases<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>opert<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:1.35pt;"> </span>plant<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>equip<span style="letter-spacing:0.05pt;">m</span>ent,<span style="letter-spacing:1.6pt;"> </span>Our<span style="letter-spacing:0.7pt;"> </span>invest<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts<span style="letter-spacing:1.75pt;"> </span>in<span style="letter-spacing:0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>opert<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:1.35pt;"> </span>plant<span style="letter-spacing:0.8pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:0.6pt;"> </span>equip<span style="letter-spacing:0.05pt;">m</span>ent<span style="letter-spacing:0.85pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>ri<span style="letter-spacing:0.05pt;">m</span>a<span style="letter-spacing:0.05pt;">r</span>ily<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>acquisiti<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>equ<span style="letter-spacing:0.05pt;">i</span>pment<span style="letter-spacing:1.55pt;"> </span><span style="letter-spacing:0.05pt;">w</span>hich<span style="letter-spacing:0.95pt;"> </span>wi<span style="letter-spacing:0.05pt;">l</span>l<span style="letter-spacing:0.65pt;"> </span>be<span style="letter-spacing:0.4pt;"> </span>used<span style="letter-spacing:0.7pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.5pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">m</span>anufactu<span style="letter-spacing:0.05pt;">r</span>ing<span style="letter-spacing:2.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oduct<span style="letter-spacing:1.15pt;"> </span>cand<span style="letter-spacing:0.05pt;">ida</span>te<span style="letter-spacing:-0.05pt;">s and expenditures related to the build out of our manufacturing facilities</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended March&#160;31,&#160;2020, net cash provided by investing activities was $14.0&#160;million, which included cash inflows of $23.1<span style="letter-spacing:0.85pt;">&#160;</span>m<span style="letter-spacing:0.05pt;">i</span>llion<span style="letter-spacing:1.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d $1.5<span style="letter-spacing:0.75pt;">&#160;</span>mill<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">f</span>rom<span style="letter-spacing:0.8pt;"> </span>matu<span style="letter-spacing:0.05pt;">r</span>ities<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:0.6pt;"> </span>sales<span style="letter-spacing:0.75pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span><span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">r</span>ketable<span style="letter-spacing:1.6pt;"> </span>sec<span style="letter-spacing:0.05pt;">u</span>rit<span style="letter-spacing:0.05pt;">i</span>es,<span style="letter-spacing:1.45pt;"> </span><span style="letter-spacing:0.05pt;">re</span>spect<span style="letter-spacing:0.05pt;">i</span>vely,<span style="letter-spacing:1.5pt;"> </span>partially offset by $10.3&#160;million of purchases of marketable debt securities and $0.3<span style="letter-spacing:0.85pt;">&#160;</span>mil<span style="letter-spacing:0.05pt;">l</span>ion<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">f</span>or<span style="letter-spacing:0.5pt;"> </span><span style="letter-spacing:0.05pt;">p</span>urchases<span style="letter-spacing:1.45pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>opert<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:1.35pt;"> </span>plant<span style="letter-spacing:0.8pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>equip<span style="letter-spacing:0.05pt;">m</span>ent.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended March&#160;31,&#160;2021, net cash provided by financing activities was $38.5&#160;million, which consisted of net proceeds <span style="letter-spacing:0.05pt;">f</span>rom<span style="letter-spacing:0.8pt;"> </span>iss<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>es<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>related<span style="letter-spacing:1pt;"> </span>party notes<span style="letter-spacing:0.8pt;"> </span>of $40&#160;million<span style="letter-spacing:1.45pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:0.6pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oceeds<span style="letter-spacing:1.3pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$1.1&#160;mil<span style="letter-spacing:0.05pt;">l</span>ion<span style="letter-spacing:1.1pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>su<span style="letter-spacing:0.05pt;">l</span>ting<span style="letter-spacing:1.3pt;"> </span><span style="letter-spacing:0.05pt;">f</span>rom<span style="letter-spacing:0.8pt;"> </span>exercises<span style="letter-spacing:1.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:0.4pt;"> </span>stock<span style="letter-spacing:0.8pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>tions.<span style="letter-spacing:1.2pt;"> </span>Net<span style="letter-spacing:0.65pt;"> </span>cash<span style="letter-spacing:0.7pt;"> </span>used<span style="letter-spacing:0.7pt;"> </span>in<span style="letter-spacing:0.4pt;"> </span>financi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:1.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ctivi<span style="letter-spacing:0.05pt;">t</span>ies<span style="letter-spacing:0.85pt;"> </span>consisted<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>$2.6&#160;<span style="letter-spacing:0.05pt;">m</span>illi<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:1.1pt;"> </span>related<span style="letter-spacing:1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:0.35pt;"> </span>net<span style="letter-spacing:0.5pt;"> </span>share<span style="letter-spacing:0.8pt;"> </span>settle<span style="letter-spacing:0.05pt;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:1.5pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>ves<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:1pt;"> </span>RSUs<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:0.55pt;"> </span>pay<span style="letter-spacing:0.05pt;">m</span>e<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:0.4pt;"> </span>e<span style="letter-spacing:0.05pt;">m</span>ployee<span style="letter-spacing:1.4pt;"> </span>pay<span style="letter-spacing:0.05pt;">r</span>oll<span style="letter-spacing:1.05pt;"> </span><span style="letter-spacing:0.05pt;">t</span>a<span style="letter-spacing:0.05pt;">x</span>e<span style="letter-spacing:-0.05pt;">s</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the three&#160;months ended March&#160;31,&#160;2020, net cash used in financing activities was minimal.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future Funding Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generated minimal revenue, and we have no products approved for commercial sale and have not generated any revenue from product sales. We do not expect to generate significant revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates, and we do not know when, or if, this will occur. In addition, we expect our expenses to significantly increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our product candidates. We have also incurred and expect that we will continue to incur in the future additional costs associated with operating as a public company as well as costs related to future fundraising efforts. In addition, subject to obtaining regulatory approval of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations. We expect that our expenses will increase substantially if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue research and development, including preclinical and clinical development of our existing product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potentially seek regulatory approval for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to discover and develop additional product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">establish a commercialization infrastructure and scale up our manufacturing and distribution capabilities to commercialize any of our product candidates for which we may obtain regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek to comply with regulatory standards and laws&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain, leverage and expand our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">hire clinical, manufacturing, scientific and other personnel to support our product candidates&#8217; development and future commercialization efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">add operational, financial and management information systems and personnel&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">incur additional legal, accounting and other expenses in operating as a public company.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. To date, we have in part relied on borrowings from entities affiliated with our Executive Chairman and principal stockholder, Dr. Soon-Shiong, to fund our capital requirements. We have no lines of credit or committed sources of financing&#59; however, we may have access to incremental draws on the promissory notes we have with entities associated with Dr.&#160;Soon-Shiong. We believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the condensed combined consolidated financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We have based this estimate on assumptions that may prove to be incorrect, and we may use our available capital resources sooner than we currently expect. The successful development of any product candidate is highly uncertain. Due to the numerous risks and uncertainties associated with the development and commercialization of our product candidates, if approved, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to obtain additional financing to fund our future operations, including completing the development and commercialization of our product candidates. Our future capital requirements will depend on many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">progr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">s, timing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">scope and costs of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our clinical tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">luding</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">bil</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">im</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enro</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sub</span><span style="letter-spacing:-0.25pt;color:#000000;">j</span><span style="color:#000000;">ec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nufac</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ure Anktiva</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">treat</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">oing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd po</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory approvals </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regula</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">uthori</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">xe</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ute</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">als&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">manufact</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">red</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">consistent</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">European Medicines Agency regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">mount</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercialize,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prices</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availabi</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cover</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ge</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;line-height:10pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th commercializing</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pab</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">staffing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">validating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">facilities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> U.S.</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">erms and timing of our current and any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pote</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">future collaborations, </span><span style="letter-spacing:-0.5pt;color:#000000;">CVRs</span><span style="color:#000000;">,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lestones,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">yalti</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">licensing or other arrangements that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">established</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ash requirements of any fut</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">acquisitions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t of other product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to respond</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">technological,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">regulatory,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of filing, prosecuting, maintaining, defending and enforcing any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual property rights&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with any po</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product acquis</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">tions,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">collaborations,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">licensing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">agreements or other arrangements that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless and until we can generate a sufficient amount of revenue, we expect to seek to finance future cash needs through public or private equity offerings, license agreements, debt financings, credit facilities, collaborations, strategic alliances and marketing or distribution arrangements. In that connection we intend to issue additional shares in one or more future capital raising transactions, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, or the ATM. Additional funds may not be available when we seek to raise capital or need funds on terms that are acceptable to us, or at all. We have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay or reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts. Our current license agreements may also be terminated if we are unable to meet the payment obligations under those agreements. As a result, we may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of additional equity or convertible debt securities, including through the ATM or other offerings, the ownership interest of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. The incurrence of additional indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on unfavorable terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;30,&#160;2021, we entered into an Open Market Sale Agreement (the &#8220;Agreement&#8221;) with respect to an at-the-market (&#8220;ATM&#8221;) offering program under which we may offer and sell, from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to $500&#160;million. See <a href="#N13___SUBSEQUENT_EVENTS"><span style="text-decoration:underline;">Note&#160;13</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Subsequent Events</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; that appear in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10-Q.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations, Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Commitments and Contingencies &#8211; Lease Arrangements</span>,<span style="font-style:italic;"> </span>and<span style="font-style:italic;"> </span><a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related Party Agreements</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; <span style="color:#000000;">that appear </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q.</span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. <span style="Background-color:#FFFFFF;color:#000000;">We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. </span>Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio,&#160;Inc. filed as </span><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex993.htm"><span style="text-decoration:underline;">Exhibit&#160;99.3</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8-K/A filed with the SEC on April&#160;22,&#160;2021, we have disclosed those accounting policies that we consider to be significant in determining our results of operations and financial condition. There have been no material changes to those policies that we consider to be significant since the filing of our Current Report on Form&#160;8-K/A on April&#160;22,&#160;2021. The accounting principles used in preparing our condensed combined consolidated financial statements conform in all material respects </span><span style="Background-color:#FFFFFF;color:#000000;">with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, and fair value measurements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span>, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to <a href="#N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI"><span style="text-decoration:underline;">Note&#160;2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Summary of Significant Accounting Policies</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; <span style="color:#000000;">that appears </span>in Item&#160;1.&#160;&#8220;Financial Statements&#8221; of <span style="color:#000000;">this Quarterly Report on Form&#160;10-Q</span> for a discussion of recent accounting pronouncements or changes in accounting pronouncements that are of significance, or potential significance, to us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial market risks related to interest rates, equity investments, foreign currency exchange rates and inflation are described in the Combined Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of ImmunityBio,&#160;Inc. filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex993.htm"><span style="text-decoration:underline;">Exhibit&#160;99.3</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to </span>our Current Report on Form&#160;8-K filed with the SEC on April&#160;22,&#160;2021, there have been no material changes to the financial market risks described at December&#160;31,&#160;2020. We do not currently anticipate any other near-term changes in the nature of our financial market risk exposures or in management&#8217;s objectives and strategies with respect to managing such exposures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">ITEM 4. CONTROLS AND PROCEDURES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives of ensuring that information we are required to disclose in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer, or CEO, and chief financial officer, or CFO, as appropriate, to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. There is no assurance that our disclosure controls and procedures will operate effectively under all circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management, with the participation of our CEO and CFO, evaluated the effectiveness of our disclosure controls and procedures as of March&#160;31,&#160;2021. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rule&#160;13a-15(e) of the Exchange Act means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&#160;31,&#160;2021, our CEO and CFO have concluded that, as of March&#160;31,&#160;2021, our disclosure controls and procedures were effective at the reasonable assurance level.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no changes in our internal control over financial reporting&#160;(as defined in Rules 13a-15(f) and 15d-15(f) of the&#160;Exchange Act) during the fiscal quarter ended March&#160;31,&#160;2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. However, as a result of the Merger, our internal control over financial reporting may change. Our process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies, which may be identified during this process.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Inherent Limitations on Effectiveness of Controls</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions&#59; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II_OR_INFORMATION">PART II&#8212;OTHER INFORMATION</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">ITEM 1. LEGAL PROCEEDINGS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. We are aware of complaints that have been filed regarding the Merger, but we have not been served with any of such complaints. If we are served with any such complaints, we will assess at that time any contingencies for which we may need to reserve. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See <a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Commitments and Contingencies&#8212;Contingencies</span>, of the &#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; included in Part&#160;I, Item&#160;1. of this Quarterly Report for a discussion of legal matters.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">ITEM 1A. RISK FACTORS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, any of which may be relevant to decisions regarding an investment in or ownership of our stock. The occurrence of any of these risks could have a significant adverse effect on our reputation, business, financial condition, results of operations, growth and ability to accomplish our strategic objectives. We have organized the description of these risks into groupings in an effort to enhance readability, but many of the risks interrelate or could be grouped or ordered in other ways, so no special significance should be attributed to the groupings or order below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.05pt;"> </span>March&#160;9,&#160;2021,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>completed<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>merger<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.45pt;"> </span>Inc<span style="letter-spacing:0.05pt;">.</span>,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>ferred<span style="letter-spacing:-0.15pt;"> </span>to below<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>&#8220;Imm<span style="letter-spacing:0.05pt;">u</span>nityBio.&#8221;<span style="letter-spacing:-0.4pt;"> </span>After<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>he<span style="letter-spacing:-0.15pt;"> </span>completion<span style="letter-spacing:-0.4pt;"> </span>of this<span style="letter-spacing:-0.1pt;"> </span>merger,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>(formerly<span style="letter-spacing:-0.3pt;"> </span>known<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>NantK<span style="letter-spacing:-0.05pt;">w</span>est,<span style="letter-spacing:-0.45pt;"> </span>Inc.)<span style="letter-spacing:-0.1pt;"> </span>changed<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>name<span style="letter-spacing:0.05pt;"> </span>to ImmunityBio,&#160;Inc.,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>references<span style="letter-spacing:-0.4pt;"> </span>below<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>&#8220;the<span style="letter-spacing:-0.2pt;"> c</span>ompan<span style="letter-spacing:0.1pt;">y</span>,&#8221;<span style="letter-spacing:0.05pt;"> &#8220;the combined company,&#8221; </span>&#8220;we,&#8221;<span style="letter-spacing:0.05pt;"> &#8220;us,&#8221; </span>and &#8220;our&#8221;<span style="letter-spacing:-0.05pt;"> </span>refer<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> ImmunityBio, Inc. and its subsidiaries</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk<span style="letter-spacing:0.05pt;"> </span>Factor<span style="letter-spacing:-0.2pt;"> </span>Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>sks<span style="letter-spacing:-0.05pt;"> </span>Relat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to Our<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>inan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.15pt;"> </span>Condition<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>Capital<span style="letter-spacing:-0.3pt;"> </span>R<span style="letter-spacing:-0.05pt;">e</span>qui<span style="letter-spacing:-0.05pt;">r</span>em<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>ts</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">need</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nancing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fund</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">dev</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">lopment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comme</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">cialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">various</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">duct candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">if we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">financing,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">dev</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">lopment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Raising</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">addit</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">onal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">capital</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">dilution</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">stockholders,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">restrict</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operat</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ons</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">relinquish rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">debt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affect</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">flows</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.1pt;color:#000000;">l</span><span style="color:#000000;">exib</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ra</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ddit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">onal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">synergies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">benefits</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">expected</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">integration</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">zed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">xpe</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">fra</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">sinesses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">integrated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">succ</span><span style="letter-spacing:0.15pt;color:#000000;">e</span><span style="color:#000000;">ssfully,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">integration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">fficult,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">consuming</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">costly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ex</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ected. Operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">costs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">customer</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">loss</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disruption,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">difficult</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ionsh</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ps</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ploye</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">u</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">tom</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">, suppliers</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">vendors,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expected</span><span style="letter-spacing:-0.3pt;color:#000000;"> for the combined company</span><span style="color:#000000;">.</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Revenues</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">lower</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ed for the combined company.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">history</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operat</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">losses,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">expect</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to continue</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">incur</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">losses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">never</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">profitable.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">perating</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">h</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">story,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">biotechnology</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">ust</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">ich</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we operate,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">makes</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it diff</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cult</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">evaluate</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">busin</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ss</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">plan and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prospects.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s Related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.15pt;"> </span>Business and<span style="letter-spacing:-0.05pt;"> </span>I<span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;">u</span>stry<span style="letter-spacing:-0.05pt;"> </span>R<span style="letter-spacing:-0.05pt;">e</span>gulation</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in combination</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">exposes us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">risks.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">It may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">take</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">longer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cli</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">ical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">project,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to complete</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">them</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">al</span><span style="letter-spacing:-0.05pt;color:#000000;">l.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">higher</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">conventional</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">therapeutic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">chnologies</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">drug</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">il</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">demonst</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ate</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adequately</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sa</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">dates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">delay regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">mer</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">z</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Interim,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">initial,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">&#8220;top-line&#8221;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">preliminary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">announce</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">publi</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">c</span><span style="color:#000000;">hange</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">more patient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">become</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sub</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o audit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">veri</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">ication</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">procedures</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ould</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ult in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hang</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">final</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">experience</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">conducting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">lied</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rely</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to c</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">nduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">many</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials.</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">Any</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">relat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">according</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to Good</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">Practi</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;GCP&#8221;)</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regulations,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a timely</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">manner</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seek</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">btain</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">ulato</span><span style="letter-spacing:-0.1pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">val for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">initiated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">completed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expec</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or modify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cli</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">based</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">feedback</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">F</span><span style="color:#000000;">DA.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">Immuno-Oncology</span><span style="letter-spacing:-0.75pt;color:#000000;"> </span><span style="color:#000000;">Clinic,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Inc</span><span style="letter-spacing:0.15pt;color:#000000;">.</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a related</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">party,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in some</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">expose</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regul</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">tory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">risks.</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">If our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">site</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sufficiently</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">robust</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">there</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integrity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">sues, we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requ</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">red</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">repeat</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">required </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ontra</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ni</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">plans</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">delayed,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inc</span><span style="letter-spacing:-0.1pt;color:#000000;">u</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">enr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">lling</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">devel</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">pment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">receipt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ne</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">essary</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">marketing approvals</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delayed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">otherwise</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prod</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">undesirable</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">h</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">properties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">halt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">prev</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">heir regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">omm</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">pot</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nti</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or result</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consequences.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ndidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">complex,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duction,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">particularly</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resp</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o process</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">quali</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">control,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">scaling-up</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">capabili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">related</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third-party manufacturers</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">encounter</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficulties,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to provide</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> p</span><span style="color:#000000;">roducts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for patients,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delayed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stoppe</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to maintain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commerc</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ally</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">viable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">structure.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">maintaining</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approv</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">one</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">jurisdi</span><span style="letter-spacing:0.1pt;color:#000000;">c</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">does</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mean</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">suc</span><span style="letter-spacing:-0.15pt;color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ssful</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in obtaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">jurisdictions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">A variety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">risks</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">mar</span><span style="letter-spacing:-0.1pt;color:#000000;">k</span><span style="color:#000000;">eting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">rnationally</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">materially</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">adversely</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">affect</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">bus</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ness.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">never</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">zed</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">before,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">lack</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">exper</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ise,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">resources</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to successfully</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">commercia</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.1pt;color:#000000;">w</span><span style="color:#000000;">n</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">together</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">suitable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">collaborators.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks<span style="letter-spacing:-0.05pt;"> </span>Related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Government<span style="letter-spacing:-0.55pt;"> </span>Regulation</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ess</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">lengthy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">time-</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">onsumin</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">experience</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">signif</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ys</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">app</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">oval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Results</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">who</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ceives</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">compassionate</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">should</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">viewed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">representative</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">how</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">perform</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">well-controlled</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cannot</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to establish</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">utility</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">uncertain</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">never</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">realized.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">if we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">gulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">con</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">inue</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ongoing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">gulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">ob</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">igations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and continued</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">review,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in significant</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expense</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sub</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nalt</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we f</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">il</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o comply with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">requirements</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or experience</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">unanticipa</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">problems</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">GMP</span><span style="letter-spacing:-0.05pt;color:#000000;">-</span><span style="color:#000000;">in-a-Box</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a medical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">device,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">compliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">dical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">devices</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expensive, complex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">uncertain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">lead</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to enf</span><span style="letter-spacing:-0.1pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">aga</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nst</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consequences</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">our business.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s R<span style="letter-spacing:0.05pt;">e</span>lat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to I<span style="letter-spacing:-0.05pt;">n</span>te<span style="letter-spacing:-0.05pt;">l</span>le<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">P</span><span style="letter-spacing:0.05pt;">r</span>o<span style="letter-spacing:-0.05pt;">p</span>er<span style="letter-spacing:-0.05pt;">t</span>y</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unable</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to obtain,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">maintain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ect</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">enforce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.2pt;color:#000000;">a</span><span style="color:#000000;">tent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">propri</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">tary</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">dates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and technologies,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to compete</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">effectively</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">profitably.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">owned</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in-lice</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">sed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">appli</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">ations</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">issue</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">jurisdiction,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">pe</span><span style="color:#000000;">te eff</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ctively.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ection</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">is not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sufficie</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">broad,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">if we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">lose</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">protection,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">ab</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o pr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">vent our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comme</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">cializing</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">sim</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">lar</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">identical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rsely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">involved</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in lawsuits</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protect</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">enforce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">licenso</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">uld</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expensive,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">time-consuming</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">unsuccessful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Issued</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">techn</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">logy</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">found</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">invalid</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unenforceable</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">challenged</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in court</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">re </span><span style="color:#000000;">administrative</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">bodies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">States</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">abroad.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">potentially</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">conflict</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">others, and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ctu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">infringement,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">misa</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">iation</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">violation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">against</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our licensors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prevent</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">technologies.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">maintaining</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ection</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">depends</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">compliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">various</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ocedural,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">document</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">submission,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">fee</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">payment,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirements</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">imposed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agencies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">duced</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">eliminated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">non-compl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">e with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">ese</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quirements.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks<span style="letter-spacing:-0.05pt;"> </span>Related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.1pt;"> </span>Common Stock</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Dr.</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;Patrick </span><span style="color:#000000;">Soon-Shiong,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> E</span><span style="color:#000000;">xecutive</span><span style="letter-spacing:-0.35pt;color:#000000;"> C</span><span style="color:#000000;">hairman</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">principal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">stockholder,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">interests</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conflict wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rests.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Dr.</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;</span><span style="color:#000000;">Soon-Shiong,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">gh</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">his</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">voting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ontrol</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">company,</span><span style="letter-spacing:-0.4pt;color:#000000;"> has the ability </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">con</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">rol</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">actions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.1pt;color:#000000;">q</span><span style="color:#000000;">uire stockholder</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">T</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">common</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">stock</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">en</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">volatile,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inves</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ors</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">difficulty</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">shar</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">W</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">incurred</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">continue</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">incur</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a public</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">company</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">has</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be required</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">devote</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to compliance</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">initiatives</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">corporate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">governance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.1pt;color:#000000;">r</span><span style="color:#000000;">actices,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">maintaining</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:-0.05pt;color:#000000;">ec</span><span style="color:#000000;">tive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sys</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">em of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">porting.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Condition and Capital Requirements</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>ad<span style="letter-spacing:0.05pt;">d</span>iti<span style="letter-spacing:0.05pt;">o</span>nal<span style="letter-spacing:-0.3pt;"> </span>financing<span style="letter-spacing:-0.3pt;"> </span>to fund<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.05pt;">e</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>de<span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span>lop<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>and com<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.05pt;">r</span>cialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>pro<span style="letter-spacing:-0.05pt;">d</span>u<span style="letter-spacing:-0.05pt;">c</span>t candidat<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>, and<span style="letter-spacing:-0.05pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>financi<span style="letter-spacing:-0.1pt;">n</span>g,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>ple<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:-0.1pt;">e</span>lopment<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>commercia<span style="letter-spacing:-0.05pt;">l</span>ization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t ca<span style="letter-spacing:0.05pt;">n</span>didat<span style="letter-spacing:0.05pt;">e</span>s. Raising<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>capital<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>cau<span style="letter-spacing:-0.05pt;">s</span>e dilution<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>stock<span style="letter-spacing:-0.05pt;">h</span>olders,<span style="letter-spacing:-0.3pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>or require<span style="letter-spacing:0.05pt;"> </span>us to<span style="letter-spacing:-0.1pt;"> </span>relinquish<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>our technologies<span style="letter-spacing:-0.4pt;"> </span>or product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>consumed<span style="letter-spacing:-0.4pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>tantial<span style="letter-spacing:-0.2pt;"> </span>amounts<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>since<span style="letter-spacing:-0.25pt;"> </span>inception.<span style="letter-spacing:-0.35pt;"> </span>We have incurred net losses in each year since our inception and, as of March&#160;31, 2021, we had an accumulated deficit of $1.7&#160;billion. In<span style="letter-spacing:0.05pt;"> </span>ad<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>search<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>een<span style="letter-spacing:-0.15pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>expected<span style="letter-spacing:-0.3pt;"> </span>to in<span style="letter-spacing:0.05pt;">c</span>r<span style="letter-spacing:-0.05pt;">e</span>ase.<span style="letter-spacing:-0.25pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>sign<span style="letter-spacing:-0.05pt;">i</span>fic<span style="letter-spacing:-0.05pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>tion of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>funding<span style="letter-spacing:-0.25pt;"> </span>had<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>form<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>promissory<span style="letter-spacing:-0.05pt;"> </span>notes<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>presenting<span style="letter-spacing:-0.4pt;"> </span>$297.5&#160;million<span style="letter-spacing:-0.25pt;"> </span>in <span style="letter-spacing:-0.05pt;">i</span>ndebtedness, including interest thereon,<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> March&#160;31, 2021</span><span style="letter-spacing:-0.05pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>entities<span style="letter-spacing:-0.3pt;"> </span>affiliated with<span style="letter-spacing:-0.2pt;"> </span>Dr. Soon-Shiong with<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>maturity<span style="letter-spacing:-0.25pt;"> </span>date<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Se<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">t</span>ember&#160;<span style="letter-spacing:0.05pt;">3</span>0,&#160;2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, we<span style="letter-spacing:-0.45pt;"> held</span><span style="letter-spacing:-0.1pt;"> </span>cash,<span style="letter-spacing:-0.15pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>equiv<span style="letter-spacing:-0.05pt;">a</span>lents<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>etable<span style="letter-spacing:-0.35pt;"> </span>securities<span style="letter-spacing:-0.3pt;"> totaling </span>$84.3&#160;million.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to complete<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>in order<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>implement<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>plan,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>anticipate<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>spend<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>funds<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>available to us.<span style="letter-spacing:-0.05pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>changing<span style="letter-spacing:-0.35pt;"> </span>cir<span style="letter-spacing:-0.05pt;">c</span>umstances<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>spending<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gnif<span style="letter-spacing:-0.05pt;">i</span>can<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.4pt;"> </span>faster<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> </span>we curr<span style="letter-spacing:-0.05pt;">e</span>ntly<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;">t</span>ic<span style="letter-spacing:-0.05pt;">ip</span>ate,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>require additional<span style="letter-spacing:-0.3pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>furth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>funds<span style="letter-spacing:0.05pt;"> </span>sooner<span style="letter-spacing:-0.05pt;"> </span>if we choose to expand<span style="letter-spacing:-0.3pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>rapidly<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>presently<span style="letter-spacing:-0.35pt;"> </span>anticipate.<span style="letter-spacing:-0.35pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>fixed<span style="letter-spacing:-0.15pt;"> </span>expenses<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>rent<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>mitm<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span>uding those<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>collaborat<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subs<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>nt<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpec<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.3pt;"> </span>to <span style="letter-spacing:-0.05pt;">i</span>ncr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>se<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>futur<span style="letter-spacing:-0.05pt;">e</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>dditional<span style="letter-spacing:-0.3pt;"> </span>financing<span style="letter-spacing:-0.3pt;"> </span>to fund<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:-0.1pt;">u</span>re<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>erations,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>completing<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:0.1pt;">i</span>zation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>funding<span style="letter-spacing:-0.35pt;"> </span>requ<span style="letter-spacing:-0.1pt;">i</span>rements<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>including,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">progr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ming,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">os</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">luding</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">bil</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">im</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enro</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sub</span><span style="letter-spacing:-0.25pt;color:#000000;">j</span><span style="color:#000000;">ec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nufac</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ure Anktiva</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">treat</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">oing,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd po</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approvals</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regula</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ory</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">uthori</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">xe</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ute</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">als&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">manufact</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">red</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">consistent</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">European</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Medicines</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Agen</span><span style="letter-spacing:0.1pt;color:#000000;">c</span><span style="color:#000000;">y regulations&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">mount</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercialize,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">selling</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">prices</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availabi</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cover</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ge</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th commercializing</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pab</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">building,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">staffing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">validating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> facilities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Sta</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">es&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">erms</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pote</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">collaborations,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">contingent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;CVRs&#8221;),</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lestones,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">yalti</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">arrangements</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">established</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ash requirements</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fut</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">acquisitions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ime</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to respond</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">technological,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">regulatory,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">filing,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prosecuting,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">maintaining,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">defending</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enforcing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tial</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">acquis</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">tions,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">collaborations,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">licensing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">agreements</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">arrangements that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">establish.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>suffic<span style="letter-spacing:0.05pt;">i</span>ent<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reve<span style="letter-spacing:0.05pt;">n</span>ues,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>finance<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>uture<span style="letter-spacing:-0.2pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>needs<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>pu<span style="letter-spacing:0.05pt;">b</span>lic<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>private<span style="letter-spacing:-0.25pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>offerings,<span style="letter-spacing:-0.4pt;"> </span>license agreements,<span style="letter-spacing:-0.45pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>financings,<span style="letter-spacing:-0.4pt;"> </span>col<span style="letter-spacing:0.05pt;">l</span>abor<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.4pt;"> </span>str<span style="letter-spacing:-0.05pt;">a</span>teg<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.25pt;"> </span>al<span style="letter-spacing:-0.05pt;">l</span>ian<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dis<span style="letter-spacing:-0.1pt;">t</span>ribution<span style="letter-spacing:-0.35pt;"> </span>arrangements.<span style="letter-spacing:-0.5pt;"> W</span>e expect<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>issue additional<span style="letter-spacing:-0.3pt;"> </span>shares<span style="letter-spacing:-0.05pt;"> </span>in connection<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>raising<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ansactions.<span style="letter-spacing:-0.05pt;"> However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms, or at all, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, or the ATM. </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>committed<span style="letter-spacing:-0.35pt;"> </span>source<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>capital<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>to r<span style="letter-spacing:-0.05pt;">a</span>ise<span style="letter-spacing:-0.15pt;"> </span>add<span style="letter-spacing:-0.05pt;">i</span>tion<span style="letter-spacing:-0.05pt;">a</span>l capital<span style="letter-spacing:-0.2pt;"> </span>in sufficient<span style="letter-spacing:-0.3pt;"> </span>amounts<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>terms<span style="letter-spacing:-0.25pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>to us,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.2pt;"> </span>to del<span style="letter-spacing:-0.1pt;">a</span>y<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>reduce<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>scope<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>eliminate<span style="letter-spacing:-0.35pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>research or<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>programs<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>ef<span style="letter-spacing:-0.05pt;">f</span>orts.<span style="letter-spacing:-0.15pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>collaboration<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.1pt;">g</span>r<span style="letter-spacing:0.05pt;">e</span>ements<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:0.05pt;">a</span>ted<span style="letter-spacing:-0.35pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to meet<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.4pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>agr<span style="letter-spacing:0.05pt;">e</span>ements.<span style="letter-spacing:-0.4pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a result,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>acc<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>or private<span style="letter-spacing:-0.2pt;"> </span>capital<span style="letter-spacing:-0.2pt;"> </span>markets<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">w</span>henever<span style="letter-spacing:-0.25pt;"> </span>conditions<span style="letter-spacing:-0.4pt;"> </span>are favorable,<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>immediate<span style="letter-spacing:-0.45pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">p</span>i<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>t <span style="letter-spacing:-0.05pt;">th</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>m<span style="letter-spacing:0.05pt;">e</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>pital<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sale<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>conver<span style="letter-spacing:-0.05pt;">t</span>ible<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>securitie<span style="letter-spacing:-0.05pt;">s including through the ATM or other offerings</span>,<span style="letter-spacing:-0.3pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>diluted,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the terms<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>liquidation<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>preferences<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>your<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>stockholder.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>incurrence<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>indebtedness<span style="letter-spacing:-0.3pt;"> </span>would result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>fixed<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>strictive<span style="letter-spacing:-0.35pt;"> </span>covenants,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>limitations<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>debt, li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.35pt;"> </span>on our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span>qu<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>le<span style="letter-spacing:-0.05pt;">c</span>tu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.15pt;">r</span>operty<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>strictions<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>funds<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>strategic<span style="letter-spacing:-0.3pt;"> </span>partnerships<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd alliances<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>licensing<span style="letter-spacing:-0.35pt;"> </span>arrangements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parti<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y have<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>relinquish<span style="letter-spacing:-0.3pt;"> </span>valuable<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to our technologies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>to us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r cash<span style="letter-spacing:-0.05pt;"> </span>flows<span style="letter-spacing:-0.2pt;"> </span>and limit<span style="letter-spacing:-0.1pt;"> </span>our flexib<span style="letter-spacing:0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o raise addit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>apita<span style="letter-spacing:-0.05pt;">l</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a significant<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>growth.<span style="letter-spacing:-0.05pt;"> </span>As<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> March&#160;31, 2021</span>,<span style="letter-spacing:0.05pt;"> our in</span>debtedness<span style="letter-spacing:-0.4pt;"> </span>was $297.5&#160;mill<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.1pt;"> </span>consisting<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;">-</span>party<span style="letter-spacing:-0.15pt;"> </span>promissory<span style="letter-spacing:-0.4pt;"> </span>notes and interest thereon,<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ties<span style="letter-spacing:-0.25pt;"> </span>affiliated<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>ith<span style="letter-spacing:-0.1pt;"> </span>Dr.&#160;Soon-Shiong, w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>a <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>urity<span style="letter-spacing:-0.25pt;"> </span>date of<span style="letter-spacing:0.05pt;"> </span>September&#160;30,&#160;2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>important<span style="letter-spacing:-0.3pt;"> </span>consequences<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">require</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to dedicate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">portion</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">sh</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">equivalents</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">interest</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">incipal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">payments</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">d</span><span style="color:#000000;">ebt,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">reducing the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availability</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">equivalents</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">sh</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">flow</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to fund</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">capital</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">expenditures,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">working</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l, execution</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">strategy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">general</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">corporate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ncrease</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">borrowing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">even</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">debt</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to fund</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ncrease</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">vulnerability</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">general</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">economic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">industry</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">conditions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.1pt;color:#000000;">h</span><span style="color:#000000;">anges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in governm</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ntal</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">regulation</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">flexibility</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">planning</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or reacting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">industry,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">place</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">at a disadvantage compared</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to borrow</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">fund</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">, even</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">when</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">intain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">liquidity,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">ich</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">would</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">also</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">bi</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to further</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expand</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">business.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occurrence</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foregoing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facto</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perations</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to refinance<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>portion<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.2pt;"> </span>outstanding<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>it mat<span style="letter-spacing:-0.05pt;">u</span>res.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to refina<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>debt<span style="letter-spacing:-0.2pt;"> </span>or the<span style="letter-spacing:-0.05pt;"> </span>terms<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any refinanci<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">a</span>vorable<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>terms<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>debt.<span style="letter-spacing:-0.25pt;"> </span>F<span style="letter-spacing:-0.05pt;">u</span>rthermore,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>prevailing<span style="letter-spacing:-0.3pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest<span style="letter-spacing:-0.2pt;"> </span>rates<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>fact<span style="letter-spacing:-0.05pt;">o</span>rs<span style="letter-spacing:-0.25pt;"> </span>at the<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>refinancing result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>higher<span style="letter-spacing:-0.3pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>rates<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>refinancing,<span style="letter-spacing:-0.45pt;"> </span>then<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>expense<span style="letter-spacing:-0.3pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>refinanced<span style="letter-spacing:-0.4pt;"> </span>ind<span style="letter-spacing:-0.05pt;">e</span>btedness<span style="letter-spacing:-0.5pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>inc<span style="letter-spacing:0.05pt;">re</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>could materially<span style="letter-spacing:-0.3pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ffect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>flows<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ope<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.1pt;"> </span>synergies<span style="letter-spacing:0.05pt;"> </span>and benefits<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">xp</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">fro</span>m<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>gration<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reali<span style="letter-spacing:0.05pt;">z</span>ed<span style="letter-spacing:-0.3pt;"> </span>wit<span style="letter-spacing:0.05pt;">h</span>in<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xpe<span style="letter-spacing:0.05pt;">c</span>ted<span style="letter-spacing:-0.3pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>frame.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>compan<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.35pt;"> </span>now<span style="letter-spacing:-0.05pt;"> </span>renamed<span style="letter-spacing:-0.3pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.45pt;"> </span>Inc.<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>forme<span style="letter-spacing:-0.05pt;">r</span>ly<span style="letter-spacing:-0.25pt;"> </span>known<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>Nan<span style="letter-spacing:-0.05pt;">t</span>Kwest,<span style="letter-spacing:-0.15pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>realize<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>anticipated<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:0.05pt;">n</span>e<span style="letter-spacing:-0.05pt;">f</span>its<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>rger with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>depend,<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>a large<span style="letter-spacing:-0.25pt;"> </span>extent,<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to integrate<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>manner<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>fa<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>grow<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:0.05pt;"> </span>opportunities<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>achieves the<span style="letter-spacing:-0.15pt;"> </span>projected<span style="letter-spacing:-0.3pt;"> </span>synergies<span style="letter-spacing:-0.3pt;"> </span>identified<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mpany<span style="letter-spacing:-0.4pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affecting<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>rent<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>investments<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>grow<span style="letter-spacing:0.05pt;">t</span>h. <span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>f we are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ntegr<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">w</span>o co<span style="letter-spacing:-0.05pt;">m</span>pani<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>ssfu<span style="letter-spacing:-0.05pt;">l</span>ly,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>ticipated<span style="letter-spacing:-0.4pt;"> </span>benefits<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>merger,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xpected<span style="letter-spacing:-0.35pt;"> </span>synergies,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.05pt;"> </span>realized<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:-0.05pt;">u</span>lly<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at all<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>take<span style="letter-spacing:-0.2pt;"> </span>longer<span style="letter-spacing:-0.2pt;"> </span>to realize<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>expected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O<span style="letter-spacing:-0.05pt;">u</span>r b<span style="letter-spacing:-0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">s</span>es<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.05pt;">e</span>gra<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">u</span>c<span style="letter-spacing:-0.05pt;">c</span>essfu<span style="letter-spacing:-0.05pt;">l</span>ly,<span style="letter-spacing:-0.2pt;"> </span>or su<span style="letter-spacing:-0.05pt;">c</span>h integrat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>difficult,<span style="letter-spacing:-0.25pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>consuming<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cos<span style="letter-spacing:-0.1pt;">t</span>ly<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ed.<span style="letter-spacing:-0.35pt;"> </span>Operat<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g costs,<span style="letter-spacing:-0.05pt;"> </span>customer<span style="letter-spacing:-0.4pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>busin<span style="letter-spacing:0.15pt;">e</span>ss<span style="letter-spacing:0.05pt;"> </span>disruption,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>ffi<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>in <span style="letter-spacing:-0.05pt;">m</span>aintaining<span style="letter-spacing:-0.35pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>ationsh<span style="letter-spacing:-0.15pt;">i</span>ps<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>employe<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span>stom<span style="letter-spacing:0.05pt;">e</span>rs,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">s</span>uppliers<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>vendors, may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xp<span style="letter-spacing:0.05pt;">e</span>cted<span style="letter-spacing:-0.3pt;"> for the combined company</span>.<span style="letter-spacing:-0.1pt;"> </span>R<span style="letter-spacing:0.05pt;">ev</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">u</span>es<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>low<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>an<span style="letter-spacing:-0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.05pt;">e</span>d for the combined company.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>bina<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>of two<span style="letter-spacing:0.05pt;"> </span>busin<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>is <span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.1pt;">e</span>x,<span style="letter-spacing:-0.25pt;"> </span>costly<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>time-consuming<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>divert<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>managem<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.5pt;"> </span>attention<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ources<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mbining o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>businesses.<span style="letter-spacing:-0.05pt;"> </span>This<span style="letter-spacing:-0.2pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>dis<span style="letter-spacing:0.05pt;">r</span>upt<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>businesses.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>challenges<span style="letter-spacing:-0.35pt;"> </span>involved<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combining<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>two<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>to rea<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>ant<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">i</span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>nefi<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>merg<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ould<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>terruption<span style="letter-spacing:-0.4pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>mom<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>um<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n, the<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tiv<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>combined<span style="letter-spacing:-0.4pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of operations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>combined<span style="letter-spacing:-0.3pt;"> </span>comp<span style="letter-spacing:-0.05pt;">a</span>ny.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>overall<span style="letter-spacing:-0.25pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our <span style="letter-spacing:0.05pt;">b</span>usines<span style="letter-spacing:0.05pt;">s</span>es may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span>o<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in m<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>rial<span style="letter-spacing:-0.3pt;"> </span>un<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed problems,<span style="letter-spacing:-0.3pt;"> </span>expenses,<span style="letter-spacing:-0.35pt;"> </span>li<span style="letter-spacing:-0.1pt;">a</span>bilities,<span style="letter-spacing:-0.35pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>responses,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>customer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>relationships.<span style="letter-spacing:-0.5pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>difficulties<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>combining<span style="letter-spacing:-0.35pt;"> </span>the o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>include,<span style="letter-spacing:-0.25pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diversion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">matters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficu</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">gra</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">communications</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">syste</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dmin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ra</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ive</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">infrastruc</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ure</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">reporting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hallenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">conforming</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">standards,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">controls,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">procedu</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">accounting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">policies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cultures</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">compensation</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">struc</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ures between</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">two</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">integrating</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">attracting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">taining</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">personnel,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">talent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hallenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">retaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">existing,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">obtaining</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">supplie</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">achiev</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">anticipated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">savings,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">synergies,</span><span style="letter-spacing:-0.05pt;color:#000000;"> accretion targets, </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">opportunit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">financing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">plans</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">growth</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">prospects from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">combination&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">managing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nded</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">complex</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">onting</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">bil</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">unknown</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">liabili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cons</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quences</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">unforeseen</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">increased</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">nses</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ass</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ciated</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">merger.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>factors<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ontrol,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>them<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in lower<span style="letter-spacing:-0.2pt;"> </span>revenues,<span style="letter-spacing:-0.35pt;"> </span>higher<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>diversi<span style="letter-spacing:-0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>and energy,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>i<span style="letter-spacing:-0.05pt;">m</span>pact<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usiness,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>cond<span style="letter-spacing:-0.1pt;">i</span>tion<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>combined<span style="letter-spacing:-0.35pt;"> </span>company.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>integrated<span style="letter-spacing:-0.4pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sful<span style="letter-spacing:-0.05pt;">l</span>y,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>full<span style="letter-spacing:-0.15pt;"> </span>ben<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">g</span>er<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>real<span style="letter-spacing:-0.1pt;">i</span>zed,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nc<span style="letter-spacing:-0.05pt;">l</span>ud<span style="letter-spacing:-0.05pt;">i</span>ng,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">m</span>ong<span style="letter-spacing:-0.15pt;"> </span>others,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>synergies<span style="letter-spacing:-0.4pt;"> </span>or growth<span style="letter-spacing:0.05pt;"> </span>opportunities<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>expected.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.1pt;">e</span>nefits<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>achieved<span style="letter-spacing:-0.25pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>anticipated<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>frame<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all.<span style="letter-spacing:-0.1pt;"> </span>Furthe<span style="letter-spacing:0.05pt;">r</span>,<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>unanticipated costs<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>incurred<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>integration<span style="letter-spacing:-0.4pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>businesses.<span style="letter-spacing:0.05pt;"> </span>All<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>factors<span style="letter-spacing:-0.3pt;"> </span>cou<span style="letter-spacing:0.1pt;">l</span>d<span style="letter-spacing:-0.2pt;"> </span>negatively<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> company&#8217;s operations and/or the </span>price<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>company&#8217;s<span style="letter-spacing:-0.45pt;"> common stock</span>.<span style="letter-spacing:-0.35pt;"> </span>As a<span style="letter-spacing:-0.1pt;"> </span>result,<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>assured<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>businesses<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span>za<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>full ben<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpe<span style="letter-spacing:-0.05pt;">c</span>ted<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>rger<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>thin<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.35pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>fram<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span>al<span style="letter-spacing:-0.05pt;">l</span>.<span style="letter-spacing:-0.1pt;"> </span>A<span style="letter-spacing:-0.05pt;">c</span>cord<span style="letter-spacing:-0.05pt;">i</span>ngly,<span style="letter-spacing:-0.35pt;"> </span>hold<span style="letter-spacing:-0.05pt;">e</span>rs<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> combined </span>comp<span style="letter-spacing:-0.2pt;">a</span>ny&#8217;s<span style="letter-spacing:-0.3pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>experie<span style="letter-spacing:0.05pt;">n</span>ce<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>loss <span style="letter-spacing:0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lt<span style="letter-spacing:-0.05pt;"> </span>of a<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:0.05pt;">c</span>line<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>pri<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span>uch<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>sto<span style="letter-spacing:0.15pt;">c</span>k.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>a dec<span style="letter-spacing:-0.05pt;">l</span>ine<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> the combined company&#8217;s</span> com<span style="letter-spacing:-0.05pt;">m</span>on<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.1pt;">o</span>mpany&#8217;s<span style="letter-spacing:-0.4pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to issue <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">d</span>d<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cur<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obta<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>additio<span style="letter-spacing:0.05pt;">n</span>al<span style="letter-spacing:-0.4pt;"> </span>financing<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>future.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">history</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">operating</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">losses,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">expect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">continue</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">incur</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">loss</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s and may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">never</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">profitable.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>a bio<span style="letter-spacing:0.05pt;">p</span>harmaceutical<span style="letter-spacing:-0.65pt;"> </span>company,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>now<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>merger<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio<span style="letter-spacing:-0.5pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>been<span style="letter-spacing:-0.15pt;"> </span>completed,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a much<span style="letter-spacing:-0.25pt;"> </span>broader<span style="letter-spacing:-0.2pt;"> </span>portfolio<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>at various<span style="letter-spacing:-0.2pt;"> </span>stages<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>development.<span style="letter-spacing:-0.5pt;"> </span>None<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.15pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>sale<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>been sought,<span style="letter-spacing:-0.2pt;"> </span>althou<span style="letter-spacing:0.05pt;">g</span>h<span style="letter-spacing:-0.3pt;"> w</span>e<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.1pt;">g</span>reements<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">n</span>es,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>bioreactors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>related consumables<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>expenses as<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>seek to expand our business, including in connection with conducting research and development across multiple therapeutic areas, participating in clinical trial activities, continuing to acquire or in-license technologies, maintaining, protecting and expanding our intellectual property, seeking regulatory approvals and, upon successful receipt of FDA approval, commercializing our products. We will also incur costs as we hire additional personnel and increase our manufacturing capabilities, including the lease or purchase of a facility for the manufacturing of our product candidates for ongoing and future clinical trials and, upon potential receipt of FDA approval, for our initial commercialization activities. Moreover, we do not expect to have significant product sales or revenue for the next 12&#160;to 24&#160;months. These losses have had an<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>on our<span style="letter-spacing:-0.05pt;"> </span>stockholders&#8217;<span style="letter-spacing:-0.45pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>working<span style="letter-spacing:0.05pt;"> </span>cap<span style="letter-spacing:-0.1pt;">i</span>tal and, as these operating losses continue to increase significantly in the future due to such expenditures, will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Because of the numerous risks and uncertainties associated with our product development efforts, we are unable to predict when the<span style="letter-spacing:-0.15pt;"> c</span>ompany<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:0.1pt;">r</span>ofit<span style="letter-spacing:-0.05pt;">a</span>bl<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>l. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span>profitability<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>is de<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ndent<span style="letter-spacing:-0.3pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>obtaining<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approvals<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd su<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ssfully commercializing<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>alone<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>rties.<span style="letter-spacing:-0.3pt;"> </span>However,<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>profitable<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.1pt;"> o</span>r<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>successfully<span style="letter-spacing:-0.3pt;"> </span>developed<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>produced<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>thereafter<span style="letter-spacing:-0.3pt;"> </span>commercialized.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>operat<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.35pt;"> </span>history,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>ind<span style="letter-spacing:0.05pt;">u</span>stry in<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>op<span style="letter-spacing:0.05pt;">e</span>rate,<span style="letter-spacing:-0.3pt;"> </span>mak<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>it difficult<span style="letter-spacing:-0.35pt;"> </span>to evaluate<span style="letter-spacing:-0.25pt;"> </span>our bu<span style="letter-spacing:0.05pt;">s</span>iness<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perating<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.15pt;">i</span>story on<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>decision<span style="letter-spacing:-0.25pt;"> </span>to invest<span style="letter-spacing:-0.15pt;"> </span>in us<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>test<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pl<span style="letter-spacing:0.1pt;">a</span>ns<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>assumptions<span style="letter-spacing:-0.5pt;"> </span>in o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>plan.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>dependent<span style="letter-spacing:-0.4pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>implement<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>plan,<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usiness<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.2pt;"> </span>may be<span style="letter-spacing:-0.05pt;"> </span>modified<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>dir<span style="letter-spacing:-0.05pt;">e</span>ctors.<span style="letter-spacing:-0.3pt;"> </span>Investo<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.3pt;"> </span>therefore<span style="letter-spacing:-0.4pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>evaluate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>likelihood<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>success.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>problems,<span style="letter-spacing:-0.35pt;"> </span>exp<span style="letter-spacing:0.05pt;">e</span>nses,<span style="letter-spacing:-0.1pt;"> </span>difficulties,<span style="letter-spacing:-0.35pt;"> </span>compl<span style="letter-spacing:-0.05pt;">i</span>cations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>delays<span style="letter-spacing:-0.3pt;"> </span>normal<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:-0.35pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>pre-comme<span style="letter-spacing:-0.05pt;">r</span>cial<span style="letter-spacing:-0.55pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>any,<span style="letter-spacing:-0.4pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of which<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>beyond<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>control.<span style="letter-spacing:-0.25pt;"> </span>Accordingly,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>prospects<span style="letter-spacing:-0.4pt;"> </span>should<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>conside<span style="letter-spacing:-0.05pt;">r</span>ed<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>light<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>risks,<span style="letter-spacing:0.1pt;"> </span>expe<span style="letter-spacing:0.05pt;">n</span>ses<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>difficulties<span style="letter-spacing:-0.3pt;"> </span>frequently<span style="letter-spacing:-0.3pt;"> </span>encountered<span style="letter-spacing:-0.45pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>establishment<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:0.05pt;">u</span>siness<span style="letter-spacing:-0.05pt;"> </span>developing<span style="letter-spacing:-0.45pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>industry<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>characterized<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>entrants<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>intense<span style="letter-spacing:-0.2pt;"> </span>competition. Because<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>size<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>resources,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>poss<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to successfully<span style="letter-spacing:-0.5pt;"> </span>overcome<span style="letter-spacing:-0.35pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>uncer<span style="letter-spacing:-0.05pt;">t</span>ainties<span style="letter-spacing:-0.4pt;"> </span>frequently encountered<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>pre-commercial<span style="letter-spacing:-0.5pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>invo<span style="letter-spacing:-0.05pt;">l</span>ved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>rapidly<span style="letter-spacing:-0.3pt;"> </span>evolving<span style="letter-spacing:-0.25pt;"> </span>field<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>immunotherapy.<span style="letter-spacing:-0.55pt;"> </span>If<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>resea<span style="letter-spacing:-0.05pt;">r</span>ch<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>efforts<span style="letter-spacing:-0.25pt;"> </span>are successful,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">a</span>ssociated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>shift<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>new products based<span style="letter-spacing:-0.25pt;"> on innovative technologies</span>.<span style="letter-spacing:0.05pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>suc<span style="letter-spacing:0.1pt;">c</span>essful<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>oping<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>substantially<span style="letter-spacing:-0.45pt;"> </span>dependent<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>guarant<span style="letter-spacing:0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>ct can<span style="letter-spacing:0.05pt;">d</span>idates<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>ssfully complete<span style="letter-spacing:-0.3pt;"> </span>development,<span style="letter-spacing:-0.55pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>app<span style="letter-spacing:-0.1pt;">r</span>oval<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>success<span style="letter-spacing:0.05pt;">f</span>ully<span style="letter-spacing:-0.1pt;"> </span>commercialized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other than our proprietary GMP-in-a-Box bioreactors for which we have received nominal revenue to date, we<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oducts approved for commercial sale<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>for which<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>sought.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>invested<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>effo<span style="letter-spacing:-0.05pt;">r</span>ts<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> financial resources</span><span style="letter-spacing:-0.05pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>main<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>Anktiva,<span style="letter-spacing:-0.35pt;"> a</span>ldoxorubicin<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd human<span style="letter-spacing:-0.2pt;"> </span>adenovirus<span style="letter-spacing:-0.45pt;"> </span>serotype<span style="letter-spacing:-0.35pt;"> </span>5<span style="letter-spacing:0.05pt;"> </span>(&#8220;hAd5&#8221;)<span style="letter-spacing:-0.3pt;"> </span>vac<span style="letter-spacing:-0.05pt;">c</span>ine<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndid<span style="letter-spacing:-0.05pt;">a</span>tes, some<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>used<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combina<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>natural<span style="letter-spacing:-0.25pt;"> </span>killer<span style="letter-spacing:-0.25pt;"> </span>cells.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>invest<span style="letter-spacing:-0.15pt;"> </span>heavily<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">n</span>di<span style="letter-spacing:-0.05pt;">d</span>a<span style="letter-spacing:-0.05pt;">t</span>es<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>in our existing<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>any<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>pends e<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.05pt;">i</span>rely<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he successful<span style="letter-spacing:-0.4pt;"> </span>development,<span style="letter-spacing:-0.5pt;"> </span>regula<span style="letter-spacing:0.05pt;">t</span>ory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>each<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.25pt;"> </span>occur. Our ability to generate revenues<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>substantially<span style="letter-spacing:-0.4pt;"> </span>d<span style="letter-spacing:0.05pt;">e</span>pendent<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to dev<span style="letter-spacing:-0.1pt;">e</span>lop,<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approv<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>for, <span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">s</span>uc<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:0.05pt;">s</span>sful<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>m<span style="letter-spacing:-0.05pt;">e</span>rci<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>e,<span style="letter-spacing:-0.5pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>meaningful<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>venues<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>sale<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>never<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ble<span style="letter-spacing:-0.2pt;"> </span>to develop<span style="letter-spacing:-0.25pt;"> </span>or commercialize<span style="letter-spacing:-0.5pt;"> </span>a product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd non-clinical<span style="letter-spacing:-0.4pt;"> </span>de<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>lopment,<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approv<span style="letter-spacing:-0.05pt;">a</span>l,<span style="letter-spacing:-0.3pt;"> </span>commerc<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>arrangements, estab<span style="letter-spacing:-0.05pt;">l</span>ishment<span style="letter-spacing:-0.4pt;"> </span>of a<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.4pt;"> </span>o<span style="letter-spacing:-0.05pt;">r</span>ganization,<span style="letter-spacing:-0.35pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketing<span style="letter-spacing:-0.3pt;"> </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.3pt;"> </span>investm<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from product sales.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>assure<span style="letter-spacing:-0.05pt;"> </span>you<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>timelines<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>delayed<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>completed<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.25pt;"> </span>of reasons,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>negative<span style="letter-spacing:-0.25pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>pandemic.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>permitted<span style="letter-spacing:-0.35pt;"> </span>to market<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>promote<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> without receiving</span><span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>rom<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA or<span style="letter-spacing:-0.05pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>ign regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ny<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates or<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>appr<span style="letter-spacing:0.05pt;">o</span>v<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>llow<span style="letter-spacing:-0.2pt;"> </span>us to successfully<span style="letter-spacing:-0.5pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>compa<span style="letter-spacing:0.05pt;">r</span>able<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>gulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>conditions to allow<span style="letter-spacing:-0.25pt;"> </span>successful<span style="letter-spacing:-0.4pt;"> </span>commerciali<span style="letter-spacing:-0.05pt;">z</span>ation,<span style="letter-spacing:-0.7pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>then<span style="letter-spacing:-0.2pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>rom<span style="letter-spacing:-0.1pt;"> </span>those prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>tes<span style="letter-spacing:-0.1pt;"> </span>or els<span style="letter-spacing:0.05pt;">e</span>wh<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>fore<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>future,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all.<span style="letter-spacing:-0.15pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>signific<span style="letter-spacing:0.1pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in obtaining<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>and commercializing<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>mat<span style="letter-spacing:0.05pt;">e</span>rial<span style="letter-spacing:-0.35pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>previously<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">s</span>ubmitted<span style="letter-spacing:-0.25pt;"> </span>a Biologics<span style="letter-spacing:-0.4pt;"> </span>Licen<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.35pt;"> </span>Application<span style="letter-spacing:-0.4pt;"> </span>(&#8220;BLA&#8221;)<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>biologics<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a New<span style="letter-spacing:0.05pt;"> </span>Drug<span style="letter-spacing:-0.05pt;"> </span>Applicati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.3pt;"> </span>(&#8220;NDA&#8221;) for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>small<span style="letter-spacing:-0.2pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>pplication<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>compa<span style="letter-spacing:0.05pt;">r</span>able<span style="letter-spacing:-0.45pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>authorities,<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate,<span style="letter-spacing:-0.35pt;"> </span>and we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>curre<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>su<span style="letter-spacing:0.05pt;">c</span>cessful<span style="letter-spacing:-0.3pt;"> </span>in clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>regulatory approval.<span style="letter-spacing:-0.35pt;"> </span>Furthermore,<span style="letter-spacing:-0.45pt;"> </span>al<span style="letter-spacing:0.05pt;">t</span>hough<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>to submit<span style="letter-spacing:-0.2pt;"> </span>a B<span style="letter-spacing:-0.15pt;">L</span>A<span style="letter-spacing:-0.15pt;"> </span>and/or<span style="letter-spacing:-0.25pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>comparisons<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>established<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>erapies,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do n<span style="letter-spacing:0.05pt;">o</span>t expect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA to<span style="letter-spacing:-0.1pt;"> </span>base<span style="letter-spacing:-0.2pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>determination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>on such<span style="letter-spacing:-0.05pt;"> </span>comparisons,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA may<span style="letter-spacing:-0.1pt;"> </span>factor<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:0.05pt;">m</span>p<span style="letter-spacing:-0.05pt;">a</span>risons<span style="letter-spacing:-0.25pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span>its decision<span style="letter-spacing:-0.25pt;"> </span>whether<span style="letter-spacing:-0.35pt;"> </span>to approve<span style="letter-spacing:-0.35pt;"> </span>Ank<span style="letter-spacing:-0.05pt;">t</span>iva<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>consider<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>competing<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>alter<span style="letter-spacing:-0.2pt;"> </span>the tr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>nds<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>pe<span style="letter-spacing:-0.2pt;"> </span>con<span style="letter-spacing:-0.05pt;">c</span>urren<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">th</span>eir<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>BLA<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.25pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>filings,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:0.05pt;">e</span>ad<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>hang<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FD<span style="letter-spacing:0.05pt;">A</span>&#8217;s<span style="letter-spacing:-0.05pt;"> </span>review<span style="letter-spacing:-0.25pt;"> </span>requirements that<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>previously<span style="letter-spacing:-0.35pt;"> </span>communicated<span style="letter-spacing:-0.55pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>interpretation<span style="letter-spacing:-0.5pt;"> </span>thereof,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>for c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.3pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>design. Such<span style="letter-spacing:0.05pt;"> </span>changes<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>lay<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>cessitate<span style="letter-spacing:-0.4pt;"> </span>withdrawal<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our BLA<span style="letter-spacing:0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>filings.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>susceptible<span style="letter-spacing:-0.4pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>fai<span style="letter-spacing:-0.1pt;">l</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.1pt;"> </span>inherent<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>stage<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>development,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>appearance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>unexpected adverse<span style="letter-spacing:-0.3pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ac<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">i</span>eve<span style="letter-spacing:-0.2pt;"> </span>pri<span style="letter-spacing:0.05pt;">m</span>ary<span style="letter-spacing:-0.35pt;"> </span>endpoints<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>latory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if they are<span style="letter-spacing:-0.1pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>ssful<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">p</span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ved<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>abil<span style="letter-spacing:-0.1pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to generate<span style="letter-spacing:-0.3pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:0.1pt;">i</span>ll<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">price</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">uct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">competitively</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">leads</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">broad</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adoption&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">prepare</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a broad</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">network</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sites</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">administration</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">reate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">demand</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candid</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">tes</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">through</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tivities,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">arrangements</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">promote these</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">othe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">w</span><span style="color:#000000;">i</span><span style="letter-spacing:0.1pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">targeted</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">popul</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">tion(s)</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">neces</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">ary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">desirable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">successful</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">arketing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anufacture</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candid</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tes</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">through</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">contract</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">manufa</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">turing</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">organizations</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;CMOs&#8221;)</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">own,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">affiliates&#8217;,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">manufacturing f</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n suffi</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">qu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nti</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">cep</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">qu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">demand</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">at launch</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;">h</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">er&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">stablish</span><span style="font-weight:bold;font-style:italic;color:#000000;"> </span><span style="color:#000000;">and maintain agree</span><span style="letter-spacing:0.05pt;color:#000000;">m</span><span style="color:#000000;">ents</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">wholesalers,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">distributors,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">harmacies,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">group</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">purc</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">asing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">organizations</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">commercia</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ly reasonable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtain,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">maintain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">otect</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">enforce</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">pat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">exclusivity</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">duct candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">commercialize</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">any of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">receive</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ain</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">pli</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nce</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">app</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ble</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ws,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulations,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">guidance</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">speci</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">ic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ia</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">iz</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">luding</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ra</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">care professionals,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">advocacy</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">groups,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">communication</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ca</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">economic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">payors</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">formula</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">chieve</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">acceptance</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">medical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">community,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">thi</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">-</span><span style="color:#000000;">party</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">chieve</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">appropriate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">reimbursem</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">aintain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">distribution</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">logistics</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">network</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">capable</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">storage</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">within</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">specifications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">guidelines,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fu</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ther capable</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">delivery</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ffectively</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">compete</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">following</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">launch,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">assure</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">directed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dditional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">unexpected</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">risks</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">arise.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:-0.1pt;">o</span>mbination<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>apy<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>also depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>availability<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>er<span style="letter-spacing:0.05pt;">a</span>pi<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>with which<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>used.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>past<span style="letter-spacing:-0.2pt;"> </span>experienced,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>experience,<span style="letter-spacing:-0.35pt;"> </span>ch<span style="letter-spacing:0.05pt;">a</span>llenges<span style="letter-spacing:-0.4pt;"> </span>obtaining sufficient<span style="letter-spacing:-0.35pt;"> </span>quantities<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>b<span style="letter-spacing:-0.1pt;">a</span>cillus<span style="letter-spacing:-0.25pt;"> </span>Calmette-Gu&#233;rin<span style="letter-spacing:-0.55pt;"> </span>(&#8220;BCG&#8221;)<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>involving<span style="letter-spacing:-0.4pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>global<span style="letter-spacing:-0.15pt;"> </span>shor<span style="letter-spacing:0.1pt;">t</span>ages.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>no assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>source<span style="letter-spacing:-0.3pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>supplies<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>BCG<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>inical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a timely<span style="letter-spacing:-0.25pt;"> </span>fashion<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at <span style="letter-spacing:-0.1pt;">a</span>ll,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future,<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span>may be<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>supply-related<span style="letter-spacing:-0.45pt;"> </span>challenges<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.3pt;"> </span>e<span style="letter-spacing:0.05pt;">n</span>rollment<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>continued<span style="letter-spacing:-0.3pt;"> </span>prog<span style="letter-spacing:-0.05pt;">r</span>ess<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.3pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>information,<span style="letter-spacing:-0.45pt;"> </span>see <span style="letter-spacing:0.05pt;">&#8220;</span>&#8212;<span style="font-style:italic;">Our</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">clinical</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">trials</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">may</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">not</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">be</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">initiated</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">completed</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">when</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">we</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">expect,</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">and</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">we</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">may</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">be</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">required</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">to</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">conduct</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">additional</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">clinical</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">trials</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">modify</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">current or future</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">c</span><span style="font-style:italic;letter-spacing:-0.05pt;">l</span><span style="font-style:italic;">ini</span><span style="font-style:italic;letter-spacing:-0.05pt;">c</span><span style="font-style:italic;">al</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">trials</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">based on </span><span style="font-style:italic;letter-spacing:-0.05pt;">f</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">dback</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">we</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">c</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">ive</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;letter-spacing:-0.05pt;">f</span><span style="font-style:italic;letter-spacing:0.05pt;">r</span><span style="font-style:italic;">om the</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">FDA</span><span style="font-style:italic;letter-spacing:-0.05pt;">.</span><span style="font-style:italic;">&#8221;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.05pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.2pt;"> </span>our cash on hand in<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.05pt;"> </span>finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.15pt;"> </span>ins<span style="letter-spacing:-0.05pt;">t</span>rum<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>are sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o ris<span style="letter-spacing:-0.1pt;">k</span>s<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>adversely<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>busines<span style="letter-spacing:-0.1pt;">s</span>, r<span style="letter-spacing:-0.05pt;">e</span>sul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.05pt;"> </span>of op<span style="letter-spacing:-0.05pt;">e</span>rations,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>iquidi<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>and finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.35pt;"> </span>condi<span style="letter-spacing:-0.05pt;">t</span>ion.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>invest<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>in a variety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>financi<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>instruments,<span style="letter-spacing:-0.5pt;"> </span>principally<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mmercial<span style="letter-spacing:-0.4pt;"> </span>paper,<span style="letter-spacing:-0.2pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span>debt<span style="letter-spacing:-0.15pt;"> </span>securities<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">g</span>overnment<span style="letter-spacing:-0.35pt;"> </span>bonds.<span style="letter-spacing:-0.05pt;"> </span>All<span style="letter-spacing:-0.1pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span>dit,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">li</span>quidity,<span style="letter-spacing:-0.35pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.1pt;"> </span>ris<span style="letter-spacing:0.05pt;">k</span>. Such<span style="letter-spacing:0.05pt;"> </span>risks, in<span style="letter-spacing:0.05pt;">c</span>luding<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>severe<span style="letter-spacing:-0.35pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>distress<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>financial institutions<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>hold<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>cash,<span style="letter-spacing:-0.25pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>equiv<span style="letter-spacing:-0.05pt;">a</span>lents<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>investments,<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>liquid<span style="letter-spacing:-0.05pt;">i</span>ty,<span style="letter-spacing:-0.4pt;"> </span>impairment<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>investments,<span style="letter-spacing:-0.5pt;"> </span>realization<span style="letter-spacing:-0.35pt;"> </span>of substantial future<span style="letter-spacing:-0.2pt;"> </span>losses,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>complete<span style="letter-spacing:-0.35pt;"> </span>l<span style="letter-spacing:-0.05pt;">o</span>ss<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>investments<span style="letter-spacing:-0.45pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>long-term,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations, liquidity<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financi<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>condition.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:-0.15pt;"> </span>to manage<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our investments,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>investment<span style="letter-spacing:-0.35pt;"> </span>policy<span style="letter-spacing:-0.2pt;"> </span>that,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.25pt;"> </span>limits<span style="letter-spacing:-0.15pt;"> </span>the amount<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>invest<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>issue<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>single<span style="letter-spacing:-0.25pt;"> </span>issuer<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span>uires<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.1pt;"> </span>in high<span style="letter-spacing:-0.1pt;"> </span>credit<span style="letter-spacing:-0.15pt;"> </span>quali<span style="letter-spacing:-0.1pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>secur<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>preserve<span style="letter-spacing:-0.2pt;"> </span>liqu<span style="letter-spacing:-0.05pt;">i</span>d<span style="letter-spacing:-0.05pt;">i</span>ty.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s Related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.15pt;"> </span>Business and<span style="letter-spacing:-0.05pt;"> </span>I<span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;">u</span>stry</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idates<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>therapies,<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>exposes<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to additional<span style="letter-spacing:-0.4pt;"> </span>risks.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>combination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>therapies.<span style="letter-spacing:-0.3pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if any<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>to r<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">e</span>ive marketing<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>commercialized<span style="letter-spacing:-0.55pt;"> </span>for use<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>thera<span style="letter-spacing:-0.05pt;">p</span>ies,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>cont<span style="letter-spacing:-0.05pt;">i</span>nue<span style="letter-spacing:-0.25pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA or<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:-0.4pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>revoke<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:0.15pt;">r</span>apy<span style="letter-spacing:-0.3pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>in combination<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>or that<span style="letter-spacing:-0.1pt;"> </span>safety,<span style="letter-spacing:-0.25pt;"> </span>efficacy,<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>nufacturing<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>supply<span style="letter-spacing:-0.3pt;"> </span>issues<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>arise<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>therapies.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>rep<span style="letter-spacing:0.05pt;">l</span>aced<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>standard<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>care<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>indications<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>F<span style="letter-spacing:0.1pt;">D</span>A<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>foreign regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>onduct<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>occurrence<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>risks<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>if approved,<span style="letter-spacing:-0.3pt;"> </span>being<span style="letter-spacing:-0.25pt;"> </span>removed<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.4pt;"> </span>commercially.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>choose<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:0.1pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>in combination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>a<span style="letter-spacing:0.05pt;">p</span>ies<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>yet<span style="letter-spacing:-0.05pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to market<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>sell<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>in c<span style="letter-spacing:-0.05pt;">o</span>mb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>an u<span style="letter-spacing:0.05pt;">n</span>approved<span style="letter-spacing:-0.4pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.45pt;"> </span>indication<span style="letter-spacing:-0.3pt;"> </span>if that<span style="letter-spacing:-0.15pt;"> </span>unapproved<span style="letter-spacing:-0.45pt;"> </span>therapy<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>either<span style="letter-spacing:-0.25pt;"> </span>alone<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>unapproved<span style="letter-spacing:-0.4pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>ace<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>risks described<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>in development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>effects,<span style="letter-spacing:-0.25pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>la<span style="letter-spacing:-0.05pt;">c</span>k<span style="letter-spacing:-0.05pt;"> o</span>f<span style="letter-spacing:-0.05pt;"> </span>FDA approval.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>approve<span style="letter-spacing:-0.35pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">r</span>ugs<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>revoke<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>eir<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>safety,<span style="letter-spacing:-0.3pt;"> </span>efficacy,<span style="letter-spacing:-0.25pt;"> </span>quality,<span style="letter-spacing:-0.2pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>or supply<span style="letter-spacing:-0.3pt;"> </span>issues<span style="letter-spacing:0.05pt;"> </span>arise<span style="letter-spacing:-0.15pt;"> </span>with,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>choo<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>in combination<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>dev<span style="letter-spacing:-0.05pt;">e</span>lop,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of or<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>comb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>herapy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">It may<span style="letter-spacing:-0.1pt;"> </span>take<span style="letter-spacing:-0.1pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>complete<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>als<span style="letter-spacing:-0.05pt;"> t</span><span style="letter-spacing:0.05pt;">h</span>an we<span style="letter-spacing:-0.2pt;"> </span>project,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to complete<span style="letter-spacing:-0.35pt;"> </span>them<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>al<span style="letter-spacing:0.1pt;">l</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have<span style="letter-spacing:-0.1pt;"> </span>projected<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>date<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>commencement<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>continuation<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>co<span style="letter-spacing:0.05pt;">m</span>pletion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our o<span style="letter-spacing:0.05pt;">n</span>going<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>However,<span style="letter-spacing:-0.05pt;"> </span>a number of factors,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>heduling<span style="letter-spacing:-0.35pt;"> </span>conflicts<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>partici<span style="letter-spacing:0.1pt;">p</span>ating<span style="letter-spacing:-0.4pt;"> </span>clinicians<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>insti<span style="letter-spacing:-0.05pt;">t</span>utions,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd difficulties<span style="letter-spacing:-0.35pt;"> </span>in identi<span style="letter-spacing:-0.05pt;">f</span>ying<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.05pt;">n</span>roll<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>ti<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>eet<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>lig<span style="letter-spacing:-0.05pt;">i</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ri<span style="letter-spacing:-0.1pt;">t</span>eria,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>delays.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>clin<span style="letter-spacing:0.05pt;">i</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>rien<span style="letter-spacing:-0.05pt;">c</span>e delays<span style="letter-spacing:-0.3pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:0.05pt;">1</span>9<span style="letter-spacing:-0.05pt;"> </span>pand<span style="letter-spacing:-0.05pt;">e</span>mic&#59;<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>information,<span style="letter-spacing:-0.4pt;"> </span>see<span style="letter-spacing:-0.05pt;"> </span>&#8220;<span style="font-style:italic;">&#8212;Our business</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">could</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">be</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">adversely</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">a</span><span style="font-style:italic;letter-spacing:-0.05pt;">f</span><span style="font-style:italic;">fe</span><span style="font-style:italic;letter-spacing:-0.05pt;">c</span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">d</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">by</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">the</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">ff</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">cts</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">of h</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">al</span><span style="font-style:italic;letter-spacing:-0.05pt;">t</span><span style="font-style:italic;">h</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">ep</span><span style="font-style:italic;letter-spacing:-0.05pt;">i</span><span style="font-style:italic;">demi</span><span style="font-style:italic;letter-spacing:-0.05pt;">c</span><span style="font-style:italic;">s, p</span><span style="font-style:italic;letter-spacing:0.05pt;">a</span><span style="font-style:italic;">ndemics</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;letter-spacing:0.05pt;">o</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">contagious</span><span style="font-style:italic;letter-spacing:-0.45pt;"> </span><span style="font-style:italic;">diseases,</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">including</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:0.05pt;">h</span><span style="font-style:italic;">e</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">recent</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">pandemic</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">of</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:0.1pt;">h</span><span style="font-style:italic;">e</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">disease</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">caused</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">by</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">the</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">novel</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">coronavirus</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">SARS-CoV-2,</span><span style="font-style:italic;letter-spacing:-0.4pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">C</span><span style="font-style:italic;letter-spacing:-0.1pt;">O</span><span style="font-style:italic;">VID&#8209;19,</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">in</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">regions where</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">we</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">third</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">parties</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">on</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">which</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">we</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">rely</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">have</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">sig</span><span style="font-style:italic;letter-spacing:0.05pt;">n</span><span style="font-style:italic;">ificant</span><span style="font-style:italic;letter-spacing:-0.4pt;"> </span><span style="font-style:italic;">manufacturing</span><span style="font-style:italic;letter-spacing:-0.6pt;"> </span><span style="font-style:italic;">facilities,</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;letter-spacing:-0.05pt;">c</span><span style="font-style:italic;">oncentrations</span><span style="font-style:italic;letter-spacing:-0.5pt;"> </span><span style="font-style:italic;">of cli</span><span style="font-style:italic;letter-spacing:-0.1pt;">n</span><span style="font-style:italic;">ical</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">trial</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">sites</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">ot</span><span style="font-style:italic;letter-spacing:0.05pt;">h</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">business operations</span><span style="font-style:italic;letter-spacing:0.05pt;">.</span>&#8221; We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>commence<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>complete<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>pro<span style="letter-spacing:-0.1pt;">j</span>ected<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot conduct<span style="letter-spacing:-0.3pt;"> </span>them<span style="letter-spacing:-0.2pt;"> </span>suc<span style="letter-spacing:0.05pt;">ce</span>ssfully.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enro</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lm</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rie</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of re</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ons.</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ab</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enroll</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treat</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">duration</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affected</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multip</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">factors,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ry</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ults,</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hi</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ude efficacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fr</span><span style="letter-spacing:-0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.25pt;">P</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hase</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;II </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refle</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">analyses</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preliminary</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">P</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hase&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ials</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generally</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">positive,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessarily</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">representative</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interim</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cycled</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the appl</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ria</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">con</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inue,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigators</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prioritize</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patie</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progressed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forms</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">er</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient population,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bas</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">success</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perceived</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">succe</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initial</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">population.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patie</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progressed</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forms</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancer</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less responsive</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">treatment,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accordingly,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terim</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">show a decline</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in patient</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respon</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e rate</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessment</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue, investigato</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shift</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approach</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">population,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ultimately</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decline</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">both</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terim</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">final</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preliminary</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conversely,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in final</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follow</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a decline</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terim</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effic</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">progressed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forms</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancer</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cycled</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rep</span><span style="letter-spacing:-0.15pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">aced</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patients</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forms</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cancer.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigator</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">le</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bi</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">su</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">open-label</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">design</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adequately</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.2pt;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dled</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cause</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a decline</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dist</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">da</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preliminary results.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outcome</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stud</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to conduct</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">more</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follow-up</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">support</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">order</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidat</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biotechnology</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industries</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suffered sig</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ificant</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">setbacks</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in late-st</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ge</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">achieving</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">positive</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">res</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lts</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earlier</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development,</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cert</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hat</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tba</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ks.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>timely<span style="letter-spacing:-0.2pt;"> </span>completion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cli<span style="letter-spacing:-0.05pt;">n</span>ical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>accordance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>otocols<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>depend,<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">m</span>ong<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">e</span>nroll<span style="letter-spacing:-0.15pt;"> </span>a sufficient<span style="letter-spacing:-0.35pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>main<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>study<span style="letter-spacing:-0.15pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>conclusion,<span style="letter-spacing:-0.35pt;"> </span>incl<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.15pt;">d</span>ing<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>under the<span style="letter-spacing:-0.15pt;"> </span>constraints<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>pandemic.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.1pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompe<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:-0.15pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>therapeutic<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>eas<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>competition<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>reduce<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>types<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>pat<span style="letter-spacing:-0.1pt;">i</span>ents<span style="letter-spacing:-0.25pt;"> </span>av<span style="letter-spacing:0.05pt;">a</span>il<span style="letter-spacing:0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>us, because<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>opted<span style="letter-spacing:-0.2pt;"> </span>to enroll<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>instead<span style="letter-spacing:-0.25pt;"> </span>opt<span style="letter-spacing:-0.1pt;"> </span>to enroll<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>being<span style="letter-spacing:-0.25pt;"> </span>conducted<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors. Accordingly,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>guarantee<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>progress<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>planned<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>scheduled.<span style="letter-spacing:-0.35pt;"> </span>Delays<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>tient<span style="letter-spacing:-0.2pt;"> </span>enrollment<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ult<span style="letter-spacing:-0.05pt;"> </span>in increased<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>or may<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>outcome<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span><span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>prev<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>t<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>advance<span style="letter-spacing:-0.25pt;"> </span>the development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>institutions,<span style="letter-spacing:-0.45pt;"> </span>academic<span style="letter-spacing:-0.35pt;"> </span>instituti<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>contract<span style="letter-spacing:-0.3pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:-0.05pt;">r</span>ganiz<span style="letter-spacing:0.05pt;">a</span>tions<span style="letter-spacing:-0.45pt;"> </span>(&#8220;CROs&#8221;)<span style="letter-spacing:-0.05pt;"> </span>to conduct,<span style="letter-spacing:-0.35pt;"> </span>supervise<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>monitor<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>or all<span style="letter-spacing:0.05pt;"> </span>aspects<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.2pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>aspects<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> i</span>f we<span style="letter-spacing:0.05pt;"> </span>cond<span style="letter-spacing:0.05pt;">u</span>cted<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>em<span style="letter-spacing:-0.25pt;"> </span>entirely<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>own.<span style="letter-spacing:-0.05pt;"> </span>See<span style="letter-spacing:-0.2pt;"> </span>&#8220;<span style="letter-spacing:-0.1pt;">&#8212;</span><span style="font-style:italic;">We</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">have</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">limited</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">exp</span><span style="font-style:italic;letter-spacing:-0.1pt;">e</span><span style="font-style:italic;">rience</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">conducting</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">clinical</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">trials</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">and</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">have</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">relied</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">and</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">will</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">rely</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">on thi</span><span style="font-style:italic;letter-spacing:0.05pt;">r</span><span style="font-style:italic;">d</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">parties</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">and related</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">parties</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">to</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">conduct</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;letter-spacing:0.05pt;">m</span><span style="font-style:italic;">any</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">of</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">our</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">preclinical</span><span style="font-style:italic;letter-spacing:-0.4pt;"> </span><span style="font-style:italic;">studies</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">and</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">clinical</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">trials.</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">Any</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">failure</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">by a</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">third</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">party,</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">related</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">party,</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">or by</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">us</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">to</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">condu</span><span style="font-style:italic;letter-spacing:0.15pt;">c</span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">the</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">clinical trials</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">according</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">to Good</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">Clinical</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">Practice</span><span style="font-style:italic;letter-spacing:-0.35pt;"> </span><span style="font-style:italic;">(&#8220;GCP&#8221;)</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">regulations,</span><span style="font-style:italic;letter-spacing:-0.5pt;"> </span><span style="font-style:italic;">and</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">in</span><span style="font-style:italic;letter-spacing:-0.1pt;"> </span><span style="font-style:italic;">a</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">timely</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">manner</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">may</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">delay</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">prevent</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">our</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">ability</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">to seek</span><span style="font-style:italic;letter-spacing:-0.25pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">obtain</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">regulatory a</span><span style="font-style:italic;letter-spacing:0.05pt;">p</span><span style="font-style:italic;">proval</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">for</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span><span style="font-style:italic;">commercialize</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">our</span><span style="font-style:italic;letter-spacing:0.05pt;"> </span><span style="font-style:italic;">product</span><span style="font-style:italic;letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">candidate</span><span style="font-style:italic;letter-spacing:-0.1pt;">s</span>.&#8221;<span style="letter-spacing:-0.45pt;"> </span>If we<span style="letter-spacing:-0.05pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>men<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:-0.1pt;">n</span>ce<span style="letter-spacing:-0.3pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in,<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials, o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bu<span style="letter-spacing:-0.1pt;">s</span>iness as<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>pl<span style="letter-spacing:0.1pt;">a</span>nned<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>anticipate<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>CMOs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>partners<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>manufacture<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.15pt;"> </span>If th<span style="letter-spacing:-0.05pt;">e</span>y fail<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commence<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>complete,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>exper<span style="letter-spacing:-0.05pt;">i</span>ence<span style="letter-spacing:-0.4pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in,<span style="letter-spacing:-0.15pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:-0.1pt;">a</span>tes,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>cli<span style="letter-spacing:-0.05pt;">n</span>ical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">b</span>e delayed,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>will adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>our business<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.35pt;"> </span>planned.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>inical<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>al <span style="letter-spacing:-0.05pt;">c</span>osts may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>higher<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>an<span style="letter-spacing:-0.05pt;"> </span>for mo<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>tional<span style="letter-spacing:-0.35pt;"> </span>therapeutic<span style="letter-spacing:-0.4pt;"> </span>techno<span style="letter-spacing:0.05pt;">l</span>ogies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>inc<span style="letter-spacing:0.05pt;">l</span>ude,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>include,<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>based<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>erapy<span style="letter-spacing:-0.2pt;"> </span>technologies,<span style="letter-spacing:-0.5pt;"> </span>we expect<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ey<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>extensive<span style="letter-spacing:-0.3pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>developme<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>costs.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>to tr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>ti<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd to<span style="letter-spacing:-0.05pt;"> </span>tr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>t p<span style="letter-spacing:0.05pt;">o</span>tential<span style="letter-spacing:-0.15pt;"> </span>side<span style="letter-spacing:-0.1pt;"> </span>effects<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidat<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>significant.<span style="letter-spacing:-0.35pt;"> </span>Some<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>bill,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>btain<span style="letter-spacing:-0.1pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>from Medicare,<span style="letter-spacing:-0.3pt;"> </span>Medicaid,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>yors for<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>cos<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.1pt;"> </span>for pat<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.3pt;"> </span>enrol<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.3pt;"> </span>in our c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">an</span>d c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>sites<span style="letter-spacing:-0.1pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>of the United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>reimburse<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.15pt;">o</span>sts<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">y</span>pically<span style="letter-spacing:-0.35pt;"> </span>covered<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">S</span>ta<span style="letter-spacing:-0.05pt;">t</span>es,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>as a<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>su<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>those tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.1pt;"> </span>si<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o p<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>such costs. A<span style="letter-spacing:-0.05pt;">c</span>cord<span style="letter-spacing:-0.05pt;">i</span>ngly,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>signific<span style="letter-spacing:-0.1pt;">a</span>ntly<span style="letter-spacing:-0.5pt;"> </span>higher<span style="letter-spacing:-0.3pt;"> </span>per<span style="letter-spacing:-0.15pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:0.05pt;">o</span>se<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>conventional therapeutic technologies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">inical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fa</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">mons</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">adequately</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">safety</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and </span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fficacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cand</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">dates,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">prevent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lay</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regulatory a</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">proval</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">com</span><span style="letter-spacing:-0.1pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ercia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ization.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>manufa<span style="letter-spacing:-0.05pt;">c</span>turing<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be,<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">b</span>j<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ext<span style="letter-spacing:-0.05pt;">e</span>nsive<span style="letter-spacing:-0.35pt;"> </span>and rigorous<span style="letter-spacing:0.05pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regula<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>authorities<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>where<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>intend<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>test<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>et<span style="letter-spacing:-0.25pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates.<span style="letter-spacing:-0.4pt;"> </span>Before<span style="letter-spacing:-0.2pt;"> </span>obtaining<span style="letter-spacing:-0.3pt;"> </span>regulat<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>de<span style="letter-spacing:-0.1pt;">m</span>onstrate<span style="letter-spacing:-0.4pt;"> </span>through lengthy,<span style="letter-spacing:-0.35pt;"> </span>complex<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expensive<span style="letter-spacing:-0.3pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>safe<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>effective,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>safe,<span style="letter-spacing:-0.1pt;"> </span>pure<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>potent,<span style="letter-spacing:-0.2pt;"> </span>for use<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.2pt;"> </span>target<span style="letter-spacing:-0.25pt;"> </span>ind<span style="letter-spacing:0.15pt;">i</span>cation.<span style="letter-spacing:-0.4pt;"> </span>Because<span style="letter-spacing:-0.3pt;"> </span>most<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>regulation<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>biological<span style="letter-spacing:-0.3pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.3pt;"> </span>we <span style="letter-spacing:0.05pt;">w</span><span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>ed<span style="letter-spacing:-0.15pt;"> </span>to demonstrate<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>they<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>safe,<span style="letter-spacing:-0.2pt;"> </span>pure,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>potent<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in t<span style="letter-spacing:-0.05pt;">h</span>eir<span style="letter-spacing:-0.1pt;"> </span>target<span style="letter-spacing:-0.15pt;"> </span>ind<span style="letter-spacing:-0.1pt;">i</span>cations.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>small<span style="letter-spacing:-0.2pt;"> </span>molec<span style="letter-spacing:-0.05pt;">u</span>le<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.15pt;"> </span>to demonstrate<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>safe<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>effective<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.25pt;"> </span>target<span style="letter-spacing:-0.2pt;"> </span>indications.<span style="letter-spacing:-0.4pt;"> </span>Each<span style="letter-spacing:-0.15pt;"> </span>produ<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>monstrate<span style="letter-spacing:-0.45pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>vers<span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.1pt;"> </span>benefit<span style="letter-spacing:-0.25pt;"> </span>profile<span style="letter-spacing:-0.2pt;"> </span>in its<span style="letter-spacing:-0.1pt;"> </span>intended<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>population<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>for its<span style="letter-spacing:-0.15pt;"> </span>intended<span style="letter-spacing:-0.3pt;"> </span>use.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>risk/benefit<span style="letter-spacing:-0.4pt;"> </span>profile<span style="letter-spacing:-0.2pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>licensure<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span>depend<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>factors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>include<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.05pt;">s</span>how<span style="letter-spacing:0.05pt;"> </span>tumor<span style="letter-spacing:-0.15pt;"> </span>shrinkage,<span style="letter-spacing:-0.3pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>duration<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>response,<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>progression<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>disease,<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>improvement<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>survival.<span style="letter-spacing:-0.35pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sponse rates<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sufficient<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>unless we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>show an<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>equate<span style="letter-spacing:-0.35pt;"> </span>duration<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>response.<span style="letter-spacing:-0.05pt;"> </span>Regulatory<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>disagree<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>th our<span style="letter-spacing:-0.05pt;"> </span>chosen<span style="letter-spacing:-0.25pt;"> </span>endpoints<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>find<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our stu<span style="letter-spacing:0.05pt;">d</span>ies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>study<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">s</span>upport<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>approval.<span style="letter-spacing:-0.3pt;"> </span>Clinical<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>sting<span style="letter-spacing:-0.25pt;"> </span>is expensive<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>take<span style="letter-spacing:-0.2pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>complete,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>outcome<span style="letter-spacing:-0.3pt;"> </span>is inherently<span style="letter-spacing:-0.4pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>certain.<span style="letter-spacing:-0.2pt;"> </span>Failure<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:0.05pt;"> </span>occur<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.15pt;"> </span>during<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>proc<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>s.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lts<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>pr<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>lini<span style="letter-spacing:0.05pt;">c</span>al<span style="letter-spacing:-0.35pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>early<span style="letter-spacing:-0.2pt;"> </span>clini<span style="letter-spacing:-0.1pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>small<span style="letter-spacing:-0.15pt;"> </span>patient populations<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot be<span style="letter-spacing:-0.05pt;"> </span>predictive<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>resul<span style="letter-spacing:-0.15pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>later-stage<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>o<span style="letter-spacing:-0.05pt;">n</span>ce<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">p</span>p<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span>able<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>completed.<span style="letter-spacing:-0.35pt;"> </span>Additionally, early<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot produce<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>su<span style="letter-spacing:0.05pt;">p</span>po<span style="letter-spacing:-0.1pt;">r</span>t further<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>regulato<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.3pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>continued<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>P<span style="letter-spacing:-0.05pt;">r</span>eliminary,<span style="letter-spacing:-0.35pt;"> </span>single<span style="letter-spacing:-0.15pt;"> </span>coho<span style="letter-spacing:0.05pt;">r</span>t<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>top-line<span style="letter-spacing:-0.3pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>l<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>representative<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>final<span style="letter-spacing:-0.1pt;"> </span>study<span style="letter-spacing:-0.25pt;"> </span>results.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>in one<span style="letter-spacing:-0.05pt;"> </span>set<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patients<span style="letter-spacing:-0.35pt;"> </span>or l<span style="letter-spacing:0.05pt;">i</span>ne<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>predictive<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>those o<span style="letter-spacing:0.05pt;">b</span>tained<span style="letter-spacing:-0.15pt;"> </span>in another<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>var<span style="letter-spacing:-0.05pt;">i</span>ous<span style="letter-spacing:-0.2pt;"> </span>human<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>ported<span style="letter-spacing:-0.25pt;"> </span>in scientific<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>med<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.3pt;"> </span>literature<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>indicative<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>sults<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain in our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in later<span style="letter-spacing:-0.1pt;"> </span>stages<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to show the<span style="letter-spacing:-0.05pt;"> </span>desired<span style="letter-spacing:-0.3pt;"> </span>safety<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span>traits<span style="letter-spacing:-0.15pt;"> </span>despite<span style="letter-spacing:-0.25pt;"> </span>having<span style="letter-spacing:-0.3pt;"> </span>progressed through<span style="letter-spacing:-0.25pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>initial<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Preclinical<span style="letter-spacing:-0.4pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>reveal<span style="letter-spacing:-0.2pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.4pt;"> </span>cha<span style="letter-spacing:0.1pt;">r</span>a<span style="letter-spacing:-0.05pt;">c</span>ter<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">c</span>s,<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ncluding<span style="letter-spacing:-0.25pt;"> </span>safety concerns.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>typically<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>extreme<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>high<span style="letter-spacing:-0.15pt;"> </span>rate<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>attrition<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>proceeding<span style="letter-spacing:-0.4pt;"> </span>throu<span style="letter-spacing:0.05pt;">g</span>h<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tria<span style="letter-spacing:-0.1pt;">l</span>s.<span style="letter-spacing:-0.1pt;"> </span>Product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in later stages<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to show<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>des<span style="letter-spacing:-0.05pt;">i</span>red<span style="letter-spacing:-0.3pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>efficacy<span style="letter-spacing:-0.35pt;"> </span>profile<span style="letter-spacing:-0.2pt;"> </span>despite<span style="letter-spacing:-0.25pt;"> </span>having<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ogressed<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>preclinic<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>studi<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l trials.<span style="letter-spacing:-0.25pt;"> </span>Many<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.7pt;"> </span>industry<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>suffered<span style="letter-spacing:-0.25pt;"> </span>signi<span style="letter-spacing:-0.05pt;">f</span>icant<span style="letter-spacing:-0.4pt;"> </span>setbacks<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to l<span style="letter-spacing:0.05pt;">ac</span>k<span style="letter-spacing:-0.15pt;"> </span>of effic<span style="letter-spacing:0.05pt;">a</span>cy<span style="letter-spacing:-0.3pt;"> </span>or u<span style="letter-spacing:0.05pt;">n</span>acceptable<span style="letter-spacing:-0.35pt;"> </span>safety<span style="letter-spacing:-0.25pt;"> </span>issues,<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;">t</span>withstanding<span style="letter-spacing:-0.55pt;"> </span>promising<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>in earlier<span style="letter-spacing:-0.25pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>Most<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>begin<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>never<span style="letter-spacing:-0.25pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>by regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>f<span style="letter-spacing:-0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>om<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span><span style="letter-spacing:-0.05pt;">a</span>tion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.1pt;"> </span>inst<span style="letter-spacing:-0.05pt;">a</span>nc<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>signif<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>v<span style="letter-spacing:-0.05pt;">a</span>ri<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n saf<span style="letter-spacing:-0.05pt;">e</span>ty<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffic<span style="letter-spacing:-0.05pt;">a</span>cy<span style="letter-spacing:-0.3pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>betw<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>ffer<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.3pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>of the<span style="letter-spacing:-0.25pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>date<span style="letter-spacing:-0.3pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to n<span style="letter-spacing:0.05pt;">u</span>merous<span style="letter-spacing:-0.2pt;"> </span>factors,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in trial<span style="letter-spacing:-0.15pt;"> </span>procedures<span style="letter-spacing:-0.4pt;"> </span>set<span style="letter-spacing:-0.1pt;"> </span>forth<span style="letter-spacing:-0.15pt;"> </span>in pro<span style="letter-spacing:-0.05pt;">t</span>ocols,<span style="letter-spacing:-0.35pt;"> </span>differences<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>size<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>populations,<span style="letter-spacing:-0.5pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>in and adherence<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.1pt;"> </span>protocols<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rate<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>dropout<span style="letter-spacing:-0.25pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>partici<span style="letter-spacing:0.05pt;">p</span>ants.<span style="letter-spacing:-0.4pt;"> </span>Our current<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">u</span>ture<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>successful.<span style="letter-spacing:-0.35pt;"> </span>Moreove<span style="letter-spacing:-0.05pt;">r</span>,<span style="letter-spacing:-0.35pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a flaw<span style="letter-spacing:-0.1pt;"> </span>in a clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>cross-s<span style="letter-spacing:-0.15pt;">i</span>te<span style="letter-spacing:-0.1pt;"> </span>variation<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>properly<span style="letter-spacing:-0.25pt;"> </span>addressed,<span style="letter-spacing:-0.45pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>apparent<span style="letter-spacing:-0.25pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>the c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>is we<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>advan<span style="letter-spacing:-0.05pt;">c</span>ed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>un<span style="letter-spacing:-0.05pt;">t</span>il<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>ffer<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>si<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>va<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xamp<span style="letter-spacing:-0.05pt;">l</span>e,<span style="letter-spacing:-0.3pt;"> </span>our current<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.2pt;"> </span>are,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>our clinical trials<span style="letter-spacing:-0.15pt;"> </span>to be,<span style="letter-spacing:-0.05pt;"> </span>conducted<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>multiple<span style="letter-spacing:-0.35pt;"> </span>sites<span style="letter-spacing:-0.1pt;"> </span>in different<span style="letter-spacing:-0.25pt;"> </span>geograph<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>different<span style="letter-spacing:-0.3pt;"> </span>levels<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>experie<span style="letter-spacing:-0.05pt;">n</span>ce<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expertise<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>professionals,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>these<span style="letter-spacing:-0.05pt;"> </span>professionals<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span>mistakes<span style="letter-spacing:-0.25pt;"> </span>or in<span style="letter-spacing:-0.05pt;">t</span>roduce<span style="letter-spacing:-0.3pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>-sp<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">i</span>fic<span style="letter-spacing:-0.25pt;"> </span>var<span style="letter-spacing:-0.05pt;">i</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>disqualifying<span style="letter-spacing:-0.4pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>or impacting<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>abi<span style="letter-spacing:-0.1pt;">l</span>ity<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>in a study<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>data.<span style="letter-spacing:-0.1pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to test<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>with other<span style="letter-spacing:-0.25pt;"> </span>oncol<span style="letter-spacing:0.05pt;">o</span>gy<span style="letter-spacing:-0.3pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>design,<span style="letter-spacing:-0.25pt;"> </span>implementation<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>interpretat<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>cessary<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>than if<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>alone.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>suc<span style="letter-spacing:-0.05pt;">c</span>essfully<span style="letter-spacing:-0.5pt;"> </span>completed,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>guarantee<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nterpr<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>as we<span style="letter-spacing:0.05pt;"> </span>do,<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>submit<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>approval.<span style="letter-spacing:-0.4pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>not satisfactory<span style="letter-spacing:-0.4pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>application,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.2pt;"> </span>to expend<span style="letter-spacing:-0.2pt;"> significant resources</span>, which may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>to us,<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onduct<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span>upport<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span>otential<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>reported<span style="letter-spacing:-0.3pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>Anktiva.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>include ass<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">s</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.2pt;"> </span>of eff<span style="letter-spacing:-0.05pt;">i</span>ca<span style="letter-spacing:-0.05pt;">c</span>y,<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.45pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>cha<span style="letter-spacing:0.05pt;">n</span>ge<span style="letter-spacing:-0.2pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to sm<span style="letter-spacing:-0.1pt;">a</span>ll<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">a</span>mple<span style="letter-spacing:-0.15pt;"> </span>siz<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>ch<span style="letter-spacing:0.05pt;">a</span>nge<span style="letter-spacing:-0.25pt;"> </span>as p<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>ev<span style="letter-spacing:0.05pt;">a</span>luated<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>additional pat<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>led<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ia<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>hese<span style="letter-spacing:-0.1pt;"> </span>outco<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unfavorable,<span style="letter-spacing:-0.5pt;"> </span>deviate<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>earlier<span style="letter-spacing:-0.2pt;"> </span>reports,<span style="letter-spacing:-0.3pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>delay<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>regulatory approval<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>reported<span style="letter-spacing:-0.35pt;"> </span>preliminary<span style="letter-spacing:-0.35pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>esul<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hypothes</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bene</span><span style="letter-spacing:0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compared</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to alternative</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapies</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bas</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d on cross-tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comp</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risons</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of results</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">derived</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ad-to-he</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ia</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">da</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directly</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comparable</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due to differences</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in study</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protocols,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condit</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ons</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patient</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">populations.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cross-trial</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comparisons</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.1pt;">e</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iab</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predi</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tors</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the relative</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bene</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpared</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produ</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previously.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Int<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>m,<span style="letter-spacing:-0.3pt;"> </span>ini<span style="letter-spacing:-0.05pt;">t</span>ial,<span style="letter-spacing:-0.25pt;"> </span>&#8220;top-<span style="letter-spacing:-0.05pt;">l</span>in<span style="letter-spacing:-0.05pt;">e</span>&#8221;<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>ann<span style="letter-spacing:-0.05pt;">oun</span>ce<span style="letter-spacing:-0.1pt;"> </span>or p<span style="letter-spacing:-0.05pt;">u</span>blish<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>ime<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ay<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.1pt;">h</span>ange<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>patient d<span style="letter-spacing:0.05pt;">a</span>ta become<span style="letter-spacing:-0.25pt;"> </span>available<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.15pt;"> </span>to audit<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>verification<span style="letter-spacing:-0.45pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ocedures<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>mat<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">ch</span>anges<span style="letter-spacing:-0.1pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>final<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">d</span>ata.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<span style="letter-spacing:-0.25pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>time,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>publi<span style="letter-spacing:0.15pt;">c</span>ly<span style="letter-spacing:-0.35pt;"> </span>disclose<span style="letter-spacing:-0.25pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>top<span style="letter-spacing:-0.05pt;">-</span>line<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>studies<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>whi<span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>preliminary ana<span style="letter-spacing:-0.05pt;">l</span>ys<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hen-<span style="letter-spacing:-0.05pt;">a</span>vai<span style="letter-spacing:-0.05pt;">l</span>able<span style="letter-spacing:-0.45pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;">a</span>,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>lated<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.05pt;">i</span>ngs<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>conclusions<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span>llowing<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>comprehensive<span style="letter-spacing:-0.5pt;"> </span>review<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the data<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>particular<span style="letter-spacing:-0.35pt;"> </span>stu<span style="letter-spacing:0.05pt;">d</span>y<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>i<span style="letter-spacing:-0.05pt;">a</span>l.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>lso <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> m</span><span style="letter-spacing:0.05pt;">a</span>ke<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">u</span>mptions,<span style="letter-spacing:-0.3pt;"> </span>estimations,<span style="letter-spacing:-0.4pt;"> </span>calculations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onclusions<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>analyses<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>data,<span style="letter-spacing:-0.15pt;"> </span>and we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.15pt;">r</span>eceived<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>d the<span style="letter-spacing:-0.15pt;"> </span>opportunity<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>fully<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>carefully<span style="letter-spacing:-0.25pt;"> </span>eva<span style="letter-spacing:-0.1pt;">l</span>uate<span style="letter-spacing:-0.25pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>data.<span style="letter-spacing:-0.1pt;"> </span>As<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>top-line<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prelimi<span style="letter-spacing:-0.05pt;">n</span>ary<span style="letter-spacing:-0.4pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;"> </span>we r<span style="letter-spacing:-0.05pt;">e</span>port<span style="letter-spacing:-0.25pt;"> </span>may differ<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>same<span style="letter-spacing:-0.2pt;"> </span>studies,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>di<span style="letter-spacing:-0.05pt;">f</span>ferent<span style="letter-spacing:-0.25pt;"> </span>conclusions<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>con<span style="letter-spacing:-0.05pt;">s</span>iderations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sults,<span style="letter-spacing:-0.3pt;"> </span>once<span style="letter-spacing:-0.1pt;"> a</span>dditional<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>received<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>fully<span style="letter-spacing:-0.1pt;"> </span>evaluated.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">T</span>op-line<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.25pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.35pt;"> </span>to audit<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>verification<span style="letter-spacing:-0.35pt;"> </span>procedur<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ult<span style="letter-spacing:-0.05pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>final<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>being<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>ria<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.4pt;"> </span>different<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>prelimi<span style="letter-spacing:0.05pt;">n</span>ary<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>pre<span style="letter-spacing:-0.05pt;">v</span>iously<span style="letter-spacing:-0.45pt;"> </span>published.<span style="letter-spacing:-0.4pt;"> </span>As a resul<span style="letter-spacing:0.1pt;">t</span>,<span style="letter-spacing:-0.15pt;"> </span>top-line<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>should<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>viewed<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>caution<span style="letter-spacing:-0.2pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>fin<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>ble.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e,<span style="letter-spacing:-0.2pt;"> </span>we may<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>disc<span style="letter-spacing:-0.05pt;">l</span>ose<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nter<span style="letter-spacing:-0.05pt;">i</span>m<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ec<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>studi<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls.<span style="letter-spacing:-0.2pt;"> </span>Int<span style="letter-spacing:-0.05pt;">e</span>rim<span style="letter-spacing:-0.25pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.2pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y comp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>te<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o the<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">i</span>sk<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>or more<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.15pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>outcomes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>enrollment<span style="letter-spacing:-0.4pt;"> </span>continu<span style="letter-spacing:0.1pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>patient<span style="letter-spacing:-0.3pt;"> </span>data beco<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.3pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>b<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span>ien<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:-0.1pt;">i</span>nue<span style="letter-spacing:-0.35pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>treatments<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>dis<span style="letter-spacing:-0.05pt;">e</span>ase.<span style="letter-spacing:-0.25pt;"> </span>Adverse<span style="letter-spacing:-0.05pt;"> </span>differences<span style="letter-spacing:-0.4pt;"> </span>betw<span style="letter-spacing:-0.05pt;">e</span>en<span style="letter-spacing:-0.3pt;"> </span>pre<span style="letter-spacing:-0.05pt;">l</span>im<span style="letter-spacing:-0.05pt;">i</span>nary<span style="letter-spacing:-0.3pt;"> </span>or in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rim data<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>final<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.1pt;"> c</span>ould<span style="letter-spacing:-0.25pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ospects.<span style="letter-spacing:-0.35pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>disclosure<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interim<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>compe<span style="letter-spacing:0.05pt;">t</span>itors<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in v<span style="letter-spacing:0.05pt;">o</span>latility<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ice<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<span style="letter-spacing:-0.35pt;"> </span>others,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.2pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cept<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>agree<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>assumptions,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>im<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>culations,<span style="letter-spacing:-0.45pt;"> </span>conclusions<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>analyses<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may interpret<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>weigh<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>importance<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>differently,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>particular<span style="letter-spacing:-0.3pt;"> </span>program,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approvabili<span style="letter-spacing:-0.1pt;">t</span>y<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>particular<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd our<span style="letter-spacing:-0.05pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>in general.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>choose<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>publicly<span style="letter-spacing:-0.25pt;"> </span>dis<span style="letter-spacing:-0.1pt;">c</span>lose<span style="letter-spacing:-0.35pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>a particular study or<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.15pt;">a</span>l<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>based<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>what<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>typically<span style="letter-spacing:-0.25pt;"> </span>extensive<span style="letter-spacing:-0.3pt;"> </span>information,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>you<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>agree<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.05pt;">ha</span>t<span style="letter-spacing:-0.05pt;"> </span>we d<span style="letter-spacing:-0.05pt;">e</span>ter<span style="letter-spacing:-0.05pt;">m</span>ine<span style="letter-spacing:-0.35pt;"> </span>is <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>l or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>appropriate<span style="letter-spacing:-0.4pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>for<span style="letter-spacing:-0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lude<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">c</span>losure.<span style="letter-spacing:-0.3pt;"> </span>If the<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>m,<span style="letter-spacing:-0.35pt;"> </span>top-line<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>preliminary<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>report<span style="letter-spacing:-0.25pt;"> </span>differ<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>actual<span style="letter-spacing:-0.25pt;"> </span>results,<span style="letter-spacing:-0.2pt;"> </span>or if<span style="letter-spacing:0.05pt;"> </span>others,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities,<span style="letter-spacing:-0.45pt;"> </span>disagree<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>conclusions<span style="letter-spacing:-0.4pt;"> </span>reached,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>mercialize,<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>harmed,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, operating<span style="letter-spacing:-0.4pt;"> </span>results,<span style="letter-spacing:-0.2pt;"> </span>prospec<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We <span style="letter-spacing:-0.05pt;">h</span>ave<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mi<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>experi<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>co<span style="letter-spacing:-0.05pt;">n</span>du<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.05pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>relied<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>to co<span style="letter-spacing:-0.05pt;">n</span>duct<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.25pt;"> </span>stud<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>Any<span style="letter-spacing:-0.2pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>a third<span style="letter-spacing:-0.15pt;"> </span>part<span style="letter-spacing:-0.05pt;">y</span>,<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.1pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.1pt;"> </span>part<span style="letter-spacing:-0.05pt;">y</span>,<span style="letter-spacing:-0.2pt;"> </span>or by<span style="letter-spacing:-0.1pt;"> </span>us to <span style="letter-spacing:-0.05pt;">c</span>onduct<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> c</span>lini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>als<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ccording<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>Good<span style="letter-spacing:0.05pt;"> </span>Clinical Practice<span style="letter-spacing:-0.3pt;"> </span>(&#8220;GCP&#8221;) regulations,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>in a<span style="letter-spacing:-0.05pt;"> </span>timely<span style="letter-spacing:-0.15pt;"> </span>manner,<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or prevent<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ab<span style="letter-spacing:-0.05pt;">i</span>lity<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>or commercialization of our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>heavily<span style="letter-spacing:-0.25pt;"> </span>reliant<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.15pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>history<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cond<span style="letter-spacing:-0.05pt;">u</span>c<span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">tr</span>ials<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>have no<span style="letter-spacing:0.05pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a company<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>supporting<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>to gain<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approvals.<span style="letter-spacing:-0.4pt;"> </span>Securi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.3pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>requires<span style="letter-spacing:-0.25pt;"> </span>the submission<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>extensive<span style="letter-spacing:-0.35pt;"> </span>preclini<span style="letter-spacing:-0.1pt;">c</span>al<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>suppo<span style="letter-spacing:-0.05pt;">r</span>ting<span style="letter-spacing:-0.1pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>to <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>gulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>therapeutic<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ndic<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>est<span style="letter-spacing:-0.05pt;">a</span>blish<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidate&#8217;s<span style="letter-spacing:-0.35pt;"> </span>safety,<span style="letter-spacing:-0.2pt;"> </span>puri<span style="letter-spacing:-0.05pt;">t</span>y,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>potency,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>efficacy,<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>indicat<span style="letter-spacing:-0.1pt;">i</span>on.<span style="letter-spacing:-0.3pt;"> </span>Securing<span style="letter-spacing:-0.35pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requires<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>submission<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>information about<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>manufacturi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.55pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>inspection<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>manufactur<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.4pt;"> </span>facilities<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>linical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>sit<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>by,<span style="letter-spacing:0.05pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>authorities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Larg<span style="letter-spacing:-0.05pt;">e</span>-s<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>quire<span style="letter-spacing:-0.25pt;"> </span>signif<span style="letter-spacing:-0.1pt;">i</span>cant<span style="letter-spacing:-0.35pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>nagement<span style="letter-spacing:-0.4pt;"> </span>resources,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reliance<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>clini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>inves<span style="letter-spacing:-0.1pt;">t</span>igators,<span style="letter-spacing:-0.5pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs,<span style="letter-spacing:-0.05pt;"> </span>if used,<span style="letter-spacing:-0.05pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cons<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>tants.<span style="letter-spacing:-0.25pt;"> </span>Relying<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>investigato<span style="letter-spacing:-0.05pt;">r</span>s,<span style="letter-spacing:-0.4pt;"> </span>CROs<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>CMOs may<span style="letter-spacing:-0.1pt;"> </span>force<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>encounter<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>ch<span style="letter-spacing:-0.05pt;">a</span>ll<span style="letter-spacing:-0.05pt;">e</span>nges<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>are o<span style="letter-spacing:0.05pt;">u</span>tside<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>cont<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>l.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;">b</span>le<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>demonstrate<span style="letter-spacing:-0.4pt;"> </span>sufficient<span style="letter-spacing:-0.2pt;"> </span>comparability<span style="letter-spacing:-0.5pt;"> </span>between<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>manufactured<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>different<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">fa</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>llow<span style="letter-spacing:-0.2pt;"> </span>for inclusion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lts<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>treated<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>dif<span style="letter-spacing:-0.05pt;">f</span>erent<span style="letter-spacing:-0.25pt;"> </span>facilities,<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>registrations.<span style="letter-spacing:-0.5pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>u<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>CMO<span style="letter-spacing:0.05pt;">s</span>, they<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to manufacture<span style="letter-spacing:-0.4pt;"> </span>Anktiva<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:0.1pt;">w</span>ise<span style="letter-spacing:-0.3pt;"> </span>fulfill<span style="letter-spacing:-0.15pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>obligations<span style="letter-spacing:-0.45pt;"> </span>to us<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>cau<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interruptions<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>their b<span style="letter-spacing:0.05pt;">u</span>siness, including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>loss of<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>key<span style="letter-spacing:-0.1pt;"> </span>staff<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>interruptions<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>raw m<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.05pt;">r</span>ial<span style="letter-spacing:-0.25pt;"> </span>supply.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reliance</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">par</span><span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for dev</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lopm</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ivi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redu</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rol</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tiv</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">verth</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ss,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">responsible</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ensuring that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cordance</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protocol</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legal,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scientific</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standards,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reliance</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on CROs,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sites,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">does</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relieve</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ese</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">responsibilities.</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remain</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">responsible</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ensuring</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that each</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accordance</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">general</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investigat</span><span style="letter-spacing:-0.15pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onal</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plan</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protocols</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ensuring</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preclinical stu</span><span style="letter-spacing:0.05pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accordance</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Good</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Practice</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;GLP&#8221;)</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mparable</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCP</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducting,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recording,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">porting</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assure</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ported results</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dible</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ccur</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd th</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">righ</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">confidentiality</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pa</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ipan</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pro</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ec</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gula</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ory</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uthori</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nforce</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hese requirements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periodic</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspe</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tions</span><span style="letter-spacing:-0.35pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(inclu</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-approval</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ins</span><span style="letter-spacing:-0.1pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ections</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">once</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a BLA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is f</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">led</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA)</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trial</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sponsors,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical invest</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gators,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sit</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rtain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs. If w</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROs,</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nic</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tes,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">par</span><span style="letter-spacing:-0.15pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th applicable</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCP</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to enforcement</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gal</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tions,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lin</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">generated</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in our clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deemed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unreliable</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compa</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gulatory</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perform</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ad</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ni</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls. We</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assure</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inspe</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a given</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authority,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authority</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our cl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nic</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls comply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GCP</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">c</span>onducted<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>produced<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>curr<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.3pt;"> </span>Good Manufacturing<span style="letter-spacing:-0.5pt;"> </span>Prac<span style="letter-spacing:0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">c</span>es<span style="letter-spacing:-0.25pt;">&#160;</span>(<span style="letter-spacing:-0.05pt;">&#8220;</span>cGM<span style="letter-spacing:0.05pt;">P</span><span style="letter-spacing:-0.05pt;">&#8221;</span>) regulations.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:-0.2pt;"> </span>to comply<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CMOs&#8217;<span style="letter-spacing:0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>ilure<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>us to<span style="letter-spacing:-0.05pt;"> </span>rep<span style="letter-spacing:-0.05pt;">e</span>at<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span>als,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>would delay<span style="letter-spacing:-0.15pt;"> </span>the regulatory<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>process.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>qu<span style="letter-spacing:-0.05pt;">i</span>red<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>regist<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>post<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ults<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">ce</span>rt<span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ompl<span style="letter-spacing:0.05pt;">e</span>t<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>on a g<span style="letter-spacing:0.05pt;">o</span>vernment<span style="letter-spacing:0.05pt;"> </span>sponsored<span style="letter-spacing:-0.05pt;"> </span>database,<span style="letter-spacing:-0.3pt;"> </span>ClinicalTrials.gov,<span style="letter-spacing:-0.65pt;"> </span>wit<span style="letter-spacing:0.05pt;">h</span>in<span style="letter-spacing:-0.2pt;"> </span>specified<span style="letter-spacing:-0.25pt;"> </span>timeframes.<span style="letter-spacing:-0.45pt;"> </span>Failure<span style="letter-spacing:-0.2pt;"> </span>to do<span style="letter-spacing:-0.05pt;"> </span>so<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in enforcement<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;">c</span>tio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adverse pub<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span>ity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>to manufacture,<span style="letter-spacing:-0.45pt;"> </span>pac<span style="letter-spacing:-0.05pt;">k</span>age,<span style="letter-spacing:-0.25pt;"> </span>label<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>ship<span style="letter-spacing:-0.2pt;"> some of </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>clini<span style="letter-spacing:-0.15pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>conduc<span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.3pt;"> </span>Any performance<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">a</span>ilure on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>par<span style="letter-spacing:0.05pt;">t</span>ies<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commerc<span style="letter-spacing:0.05pt;">i</span>alization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product candidates,<span style="letter-spacing:-0.35pt;"> </span>if approved,<span style="letter-spacing:-0.3pt;"> </span>producing<span style="letter-spacing:-0.4pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>losses and<span style="letter-spacing:-0.1pt;"> </span>depriving<span style="letter-spacing:-0.4pt;"> </span>us of<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>revenues.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>report<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>finan<span style="letter-spacing:-0.15pt;">c</span>ial<span style="letter-spacing:-0.25pt;"> </span>interests<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>iga<span style="letter-spacing:-0.05pt;">t</span>ors<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.2pt;"> </span>relationships<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xc<span style="letter-spacing:0.05pt;">e</span>ed<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">e</span>rtain<span style="letter-spacing:-0.25pt;"> </span>fin<span style="letter-spacing:0.05pt;">a</span>nci<span style="letter-spacing:-0.05pt;">a</span>l thresholds<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>criteria.<span style="letter-spacing:-0.3pt;"> </span>Immuno-Oncology<span style="letter-spacing:-0.65pt;"> </span>Clinic,<span style="letter-spacing:-0.25pt;"> </span>Inc.<span style="letter-spacing:-0.1pt;">&#160;</span>(the<span style="letter-spacing:-0.1pt;"> </span>&#8220;<span style="letter-spacing:-0.05pt;">C</span>linic&#8221;)<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>conducted,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> is currently conducting,</span> and in the future may conduct clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>involving<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>tes.<span style="letter-spacing:-0.35pt;"> </span>Na<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>Works is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>colle<span style="letter-spacing:-0.05pt;">c</span>tion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>con<span style="letter-spacing:0.05pt;">t</span>rolled,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a majority<span style="letter-spacing:-0.35pt;"> </span>of which<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>owned,<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> our</span><span style="letter-spacing:-0.15pt;"> </span>Executive<span style="letter-spacing:-0.3pt;"> </span>Chairman,<span style="letter-spacing:-0.35pt;"> </span>Dr.&#160;Patrick Soon-Shion<span style="letter-spacing:0.05pt;">g</span>, and<span style="letter-spacing:-0.15pt;"> </span>provides<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>admin<span style="letter-spacing:0.05pt;">i</span>strative<span style="letter-spacing:-0.45pt;"> </span>servic<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>(and<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>loaned money)<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Clinic.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>ongoing<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>single<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>inv<span style="letter-spacing:-0.1pt;">e</span>stigational<span style="letter-spacing:-0.5pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>drug&#160;(&#8220;spIND&#8221;)<span style="letter-spacing:-0.05pt;"> </span>applications<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>the use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.25pt;"> a</span>ldoxorubicin<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates<span style="letter-spacing:-0.4pt;"> </span>enabled<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>adenovirus,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>Ad,<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>chnologies.<span style="letter-spacing:-0.5pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>comparable<span style="letter-spacing:-0.4pt;"> </span>fore<span style="letter-spacing:-0.05pt;">i</span>gn<span style="letter-spacing:-0.1pt;"> </span>regulatory authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>question<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.1pt;">e</span>grity<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.1pt;">l</span>inical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>conducted<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>inve<span style="letter-spacing:-0.05pt;">s</span>tigators<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>determined<span style="letter-spacing:-0.4pt;"> </span>to have<span style="letter-spacing:-0.1pt;"> </span>conflic<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our CROs, <span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hird<span style="letter-spacing:-0.05pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>rel<span style="letter-spacing:-0.05pt;">a</span>tionships<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>entities,<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors,<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> whom they </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>therapeutic<span style="letter-spacing:-0.35pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment<span style="letter-spacing:-0.4pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>position.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>third parties<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employ<span style="letter-spacing:0.05pt;">e</span>es,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>except<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>remedies<span style="letter-spacing:-0.2pt;"> </span>available<span style="letter-spacing:-0.25pt;"> </span>to us<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>agreements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>them,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>wheth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>devote sufficient<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>res<span style="letter-spacing:0.05pt;">o</span>u<span style="letter-spacing:-0.05pt;">r</span>ces<span style="letter-spacing:-0.15pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>ongoing<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>inical<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>preclinical<span style="letter-spacing:-0.35pt;"> </span>programs.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>car<span style="letter-spacing:0.05pt;">r</span>y<span style="letter-spacing:-0.1pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>duties, meet<span style="letter-spacing:-0.2pt;"> </span>expected<span style="letter-spacing:-0.25pt;"> </span>deadli<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>in accordance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>stated<span style="letter-spacing:-0.15pt;"> </span>protocols,<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>replaced<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if the<span style="letter-spacing:-0.1pt;"> </span>qual<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ccur<span style="letter-spacing:-0.05pt;">a</span>cy<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hey<span style="letter-spacing:-0.15pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>is compromised<span style="letter-spacing:-0.45pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>adhere<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>protocols,<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">g</span>ulatory<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>other reasons,<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to be<span style="letter-spacing:-0.2pt;"> </span>repeated,<span style="letter-spacing:-0.3pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>tended,<span style="letter-spacing:-0.4pt;"> </span>delayed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>terminated,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>layed<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n obtaining,<span style="letter-spacing:-0.4pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>eting approvals<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.15pt;">a</span>ndidates,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>delayed<span style="letter-spacing:-0.25pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>effor<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>to,<span style="letter-spacing:-0.15pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>to <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>actions.<span style="letter-spacing:-0.35pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a result,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>prospects<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>harmed,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>rease<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to g<span style="letter-spacing:-0.05pt;">e</span>nerate<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>del<span style="letter-spacing:-0.05pt;">a</span>yed.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>extent<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>successfully identify<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manage<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>performance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>ird-party<span style="letter-spacing:-0.45pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>providers<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>future,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>terially<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adverse<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>reliance<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>relat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>present<span style="letter-spacing:-0.3pt;"> </span>int<span style="letter-spacing:0.1pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>prope<span style="letter-spacing:-0.05pt;">r</span>ty-related<span style="letter-spacing:-0.55pt;"> </span>risks. For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">p</span>erly<span style="letter-spacing:-0.2pt;"> </span>obtain,<span style="letter-spacing:-0.25pt;"> </span>maintain, enforce<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">p</span>erty<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>propriet<span style="letter-spacing:-0.05pt;">a</span>ry<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a way<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>to expose<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to potential<span style="letter-spacing:-0.3pt;"> </span>litiga<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>operty-related<span style="letter-spacing:-0.5pt;"> </span>proceedings,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>proceedings<span style="letter-spacing:-0.5pt;"> </span>challen<span style="letter-spacing:0.05pt;">g</span>ing<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>scope,<span style="letter-spacing:-0.05pt;"> </span>ownership,<span style="letter-spacing:0.05pt;"> </span>validity<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.05pt;">n</span>force<span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our int<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.5pt;"> </span>property.<span style="letter-spacing:-0.35pt;"> </span>Collaborators<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>co-own<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>roperty<span style="letter-spacing:-0.3pt;"> </span>covering<span style="letter-spacing:-0.25pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.05pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaboration<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>them,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>in s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.15pt;"> </span>cases,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>exclusi<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.35pt;"> </span>right<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">l</span>ize<span style="letter-spacing:-0.55pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technology.<span style="letter-spacing:-0.35pt;"> </span>Col<span style="letter-spacing:0.05pt;">l</span>aborators<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>gain<span style="letter-spacing:-0.2pt;"> </span>ac<span style="letter-spacing:-0.05pt;">c</span>ess<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>form<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>ations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to c<span style="letter-spacing:0.05pt;">o</span>mmercialize<span style="letter-spacing:-0.55pt;"> </span>prop<span style="letter-spacing:-0.05pt;">r</span>ietary<span style="letter-spacing:-0.2pt;"> </span>technology.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>cooperation<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>to enfo<span style="letter-spacing:-0.05pt;">r</span>ce<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>defend<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>contri<span style="letter-spacing:0.05pt;">b</span>ute<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>arises<span style="letter-spacing:-0.25pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborations,<span style="letter-spacing:-0.55pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relations</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ps</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rd</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or re</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rmin</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nto</span><span style="letter-spacing:-0.05pt;"> a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rna</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ive</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ar</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ments</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on commercially</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rea</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onable</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Switching</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adding</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contrac</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involves</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requires</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manag</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">focus. In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tural</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transition</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">period</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">en</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new thi</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d p</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rty</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comm</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ork. As a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ult, delays</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occur,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compromise</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">desi</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">velopment</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">timelines.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dd</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our collaborators</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminates,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to technology</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intel</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coll</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">borator</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restri</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rm</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">na</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rely, which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continued</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">velopment</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utilizing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">colla</span><span style="letter-spacing:0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ator&#8217;s</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to stop</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">completely.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>relative<span style="letter-spacing:-0.25pt;"> </span>lack<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>experience<span style="letter-spacing:-0.35pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>contribute<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>planned<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>beginning<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>completing<span style="letter-spacing:-0.35pt;"> </span>on tim<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>l.<span style="letter-spacing:-0.1pt;"> </span>In addition,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>entered<span style="letter-spacing:-0.25pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>eements<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Clinic,<span style="letter-spacing:-0.3pt;"> </span>a related<span style="letter-spacing:-0.25pt;"> </span>party,<span style="letter-spacing:-0.15pt;"> </span>to co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>inue<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>oversee cer<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">L</span><span style="letter-spacing:0.05pt;">a</span>rge-s<span style="letter-spacing:-0.05pt;">c</span>ale<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reliance<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>CROs,<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>investigators<span style="letter-spacing:-0.45pt;"> </span>or consultants.<span style="letter-spacing:-0.45pt;"> </span>Consequently,<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>reliance<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>introduce<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>beyond<span style="letter-spacing:-0.3pt;"> </span>our control.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Clinic<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:0.05pt;">u</span>st communicate<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>coordinate<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>another<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>successful.<span style="letter-spacing:-0.15pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>our CROs, the<span style="letter-spacing:-0.1pt;"> </span>C<span style="letter-spacing:-0.05pt;">l</span>inic<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also have<span style="letter-spacing:-0.2pt;"> </span>relationships<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.1pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>entities,<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:-0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CROs,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Clinic<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.1pt;">a</span>rties<span style="letter-spacing:-0.25pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>our clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>perform<span style="letter-spacing:-0.35pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>duties<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>ob<span style="letter-spacing:-0.1pt;">l</span>igations,<span style="letter-spacing:-0.4pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>work stoppages,<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>adl<span style="letter-spacing:-0.05pt;">i</span>nes,<span style="letter-spacing:-0.2pt;"> </span>ter<span style="letter-spacing:-0.05pt;">m</span>in<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>gree<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>ed<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o be<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>pla<span style="letter-spacing:-0.05pt;">c</span>ed,<span style="letter-spacing:-0.35pt;"> </span>or if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>qua<span style="letter-spacing:-0.2pt;">l</span>ity<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>acy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hey<span style="letter-spacing:-0.1pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>compro<span style="letter-spacing:-0.05pt;">m</span>is<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.5pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to adhere to our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>protocols,<span style="letter-spacing:-0.4pt;"> </span>GCP<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>for any<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>reason,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>addition<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>or en<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r into new<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>rrang<span style="letter-spacing:-0.05pt;">e</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>al<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rn<span style="letter-spacing:-0.05pt;">a</span>tive<span style="letter-spacing:-0.4pt;"> </span>CROs, cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>invest<span style="letter-spacing:-0.05pt;">i</span>gato<span style="letter-spacing:-0.1pt;">r</span>s<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>enter<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>arr<span style="letter-spacing:-0.05pt;">a</span>ng<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.45pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;">e</span>rnat<span style="letter-spacing:-0.05pt;">i</span>ve CROs<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>commercially<span style="letter-spacing:-0.5pt;"> </span>reasonable<span style="letter-spacing:-0.4pt;"> </span>terms,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Clinic<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>intend<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>conducting<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.1pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>GC<span style="letter-spacing:0.05pt;">P</span>. GCP are regulations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>guidelines<span style="letter-spacing:-0.3pt;"> </span>enforced<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>gulatory<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.35pt;"> </span>around<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>world,<span style="letter-spacing:0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.1pt;">o</span>ugh<span style="letter-spacing:-0.15pt;"> </span>periodic<span style="letter-spacing:-0.3pt;"> </span>inspections,<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>in clinical<span style="letter-spacing:-0.2pt;"> </span>development.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we or<span style="letter-spacing:0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hird<span style="letter-spacing:-0.15pt;"> </span>part<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>il<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span>able<span style="letter-spacing:-0.35pt;"> </span>GCP<span style="letter-spacing:0.05pt;"> </span>regu<span style="letter-spacing:-0.05pt;">l</span>a<span style="letter-spacing:-0.1pt;">t</span>ions,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>gener<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">b</span>e deemed<span style="letter-spacing:-0.25pt;"> </span>unreliable<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>have to be<span style="letter-spacing:-0.05pt;"> </span>repeated,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>submiss<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>applicatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>delayed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al trials<span style="letter-spacing:-0.15pt;"> </span>before<span style="letter-spacing:-0.25pt;"> </span>approving<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ications.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>sub<span style="letter-spacing:-0.1pt;">j</span>ect<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>that,<span style="letter-spacing:-0.15pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>inspection,<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>determine<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>ils<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>omply<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>i<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">c</span>omply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>appl<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>GCP<span style="letter-spacing:-0.05pt;"> </span>regulati<span style="letter-spacing:0.05pt;">o</span>ns.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>our <span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ust<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onducted<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>material prod<span style="letter-spacing:0.05pt;">u</span>ced<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>GMP<span style="letter-spacing:0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>Good<span style="letter-spacing:-0.05pt;"> </span>Tissue<span style="letter-spacing:-0.3pt;"> </span>Practice<span style="letter-spacing:-0.35pt;"> </span>(&#8220;GTP&#8221;)<span style="letter-spacing:-0.25pt;"> </span>regulations,<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>enforced<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>o <span style="letter-spacing:-0.05pt;">c</span>omply<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>these regulations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to r<span style="letter-spacing:-0.05pt;">e</span>pe<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.2pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>wou<span style="letter-spacing:-0.05pt;">l</span>d delay<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>latory<span style="letter-spacing:-0.3pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>al<span style="letter-spacing:-0.25pt;"> </span>process.<span style="letter-spacing:-0.05pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>significantly imp<span style="letter-spacing:-0.05pt;">a</span>ct<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>f our CROs, the<span style="letter-spacing:-0.1pt;"> </span>C<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>,<span style="letter-spacing:-0.2pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>investigators<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>violate<span style="letter-spacing:-0.3pt;"> </span>federal<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>buse or<span style="letter-spacing:-0.05pt;"> </span>false<span style="letter-spacing:-0.1pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and regulations<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>privacy<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>security<span style="letter-spacing:-0.35pt;"> </span>laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;">t</span>ic<span style="letter-spacing:-0.05pt;">i</span>pate<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>part<span style="letter-spacing:-0.15pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>str<span style="letter-spacing:-0.1pt;">a</span>tegy<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>pursuing<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>wide<span style="letter-spacing:-0.15pt;"> </span>ran<span style="letter-spacing:0.05pt;">g</span>e<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>indicat<span style="letter-spacing:0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>potentially<span style="letter-spacing:-0.35pt;"> </span>addre<span style="letter-spacing:-0.1pt;">s</span>sed<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.1pt;"> i</span>nv<span style="letter-spacing:0.05pt;">o</span>lve<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>investigator-ini<span style="letter-spacing:-0.05pt;">t</span>ia<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls.<span style="letter-spacing:-0.2pt;"> </span>Wh<span style="letter-spacing:-0.05pt;">i</span>le<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ia<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.15pt;"> </span>gen<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>prov<span style="letter-spacing:-0.05pt;">i</span>de<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.1pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th v<span style="letter-spacing:-0.05pt;">a</span>lu<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.1pt;"> </span>inform<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>fu<span style="letter-spacing:-0.05pt;">t</span>ure<span style="letter-spacing:-0.1pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>ve<span style="letter-spacing:-0.15pt;">l</span>opment<span style="letter-spacing:-0.4pt;"> </span>strategy,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>generally<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>only<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>design<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Third-party<span style="letter-spacing:-0.35pt;"> </span>investigators<span style="letter-spacing:-0.4pt;"> </span>may design<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>involving<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>endpoints<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>dif<span style="letter-spacing:-0.05pt;">f</span>icult<span style="letter-spacing:-0.25pt;"> </span>to achieve<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in other<span style="letter-spacing:-0.35pt;"> </span>ways<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ncre<span style="letter-spacing:-0.05pt;">a</span>se<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of nega<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>par<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>design<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>own.<span style="letter-spacing:-0.05pt;"> </span>Negative<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.3pt;"> from</span><span style="letter-spacing:-0.1pt;"> </span>investigator-initiated<span style="letter-spacing:-0.7pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>reg<span style="letter-spacing:-0.05pt;">a</span>rdl<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.25pt;"> </span>of h<span style="letter-spacing:0.05pt;">o</span>w<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>was designed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>conducted,<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a m<span style="letter-spacing:-0.05pt;">a</span>terial<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> business</span><span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>perception<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> o</span>ur<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,<span style="letter-spacing:-0.35pt;"> </span>principal<span style="letter-spacing:-0.25pt;"> </span>investigators<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>serve<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>sci<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">f</span>ic<span style="letter-spacing:-0.35pt;"> </span>adv<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">o</span>rs<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>consultants<span style="letter-spacing:-0.35pt;"> </span>to us<span style="letter-spacing:0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>om<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>to t<span style="letter-spacing:-0.2pt;">i</span>me<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">e</span>i<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.25pt;"> </span>compen<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">a</span>tion in connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>services.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>add<span style="letter-spacing:0.05pt;">i</span>tion,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Clinic<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>con<span style="letter-spacing:0.05pt;">d</span>ucted, is currently conducting, and in the future may conduct,<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>invol<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>id<span style="letter-spacing:-0.05pt;">a</span>tes,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he Clinic<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>conduct,<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span>involving<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idate<span style="letter-spacing:-0.1pt;">s</span>.<span style="letter-spacing:-0.45pt;"> </span>NantWorks,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>controlled<span style="letter-spacing:-0.35pt;"> </span>by,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>majority<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>whi<span style="letter-spacing:0.1pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>by,<span style="letter-spacing:0.05pt;"> our</span> Executive<span style="letter-spacing:-0.3pt;"> </span>Chairman,<span style="letter-spacing:-0.3pt;"> </span>Dr.&#160;Soon&#8209;Shiong,<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.1pt;">r</span>ovides<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>administrative<span style="letter-spacing:-0.45pt;"> </span>services<span style="letter-spacing:-0.2pt;"> </span>(and<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>loaned<span style="letter-spacing:-0.3pt;"> </span>money)<span style="letter-spacing:-0.3pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>Cl<span style="letter-spacing:-0.05pt;">i</span>nic.<span style="letter-spacing:-0.2pt;"> </span>Under cer<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcu<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.05pt;">t</span>anc<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.45pt;"> </span>we m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>report<span style="letter-spacing:-0.2pt;"> </span>some<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>rel<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>onsh<span style="letter-spacing:-0.05pt;">i</span>ps<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA. The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>conclude<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a financ<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>relationship between<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Clinic<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d/or<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>principal<span style="letter-spacing:-0.3pt;"> </span>investigator<span style="letter-spacing:-0.4pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>created<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>conflict<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>herwise<span style="letter-spacing:-0.35pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nterpr<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>study.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may therefore<span style="letter-spacing:-0.35pt;"> </span>question<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>integrity<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>gen<span style="letter-spacing:-0.05pt;">e</span>rat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>site<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">t</span>he u<span style="letter-spacing:-0.05pt;">t</span>il<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:-0.1pt;">r</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;"> </span>its<span style="letter-spacing:0.05pt;">e</span>lf<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>j<span style="letter-spacing:0.05pt;">e</span>op<span style="letter-spacing:0.05pt;">a</span>rdi<span style="letter-spacing:0.05pt;">z</span>ed.<span style="letter-spacing:-0.45pt;"> </span>This could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>in approval,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>rejection,<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>pplications<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>ult<span style="letter-spacing:-0.05pt;">i</span>ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>ly<span style="letter-spacing:-0.35pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ad<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>den<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> regulatory approval </span>of<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">inical</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">init</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ated</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ompl</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">en we</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">xpect,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">conduct</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">addit</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">onal</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">als</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or modify</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">current or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">based</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">feedback</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">receive</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical<span style="letter-spacing:-0.25pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>is expen<span style="letter-spacing:-0.1pt;">s</span>ive,<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>consuming<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>uncertainty.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>guarantee<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>clini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>conducted as<span style="letter-spacing:0.05pt;"> </span>planned<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>completed<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>sc<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>dule,<span style="letter-spacing:-0.25pt;"> </span>if at<span style="letter-spacing:-0.1pt;"> </span>all,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> our</span><span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval. We previously ini<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>ted<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n p<span style="letter-spacing:-0.05pt;">a</span>ti<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.25pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> </span>bl<span style="letter-spacing:-0.05pt;">a</span>dder<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.15pt;">a</span>ncer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>indications,<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">om</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">t</span>im<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>col<span style="letter-spacing:-0.05pt;">l</span>abor<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to initiate<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>in new<span style="letter-spacing:-0.05pt;"> </span>indicat<span style="letter-spacing:-0.1pt;">i</span>ons,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>cohorts<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials.<span style="letter-spacing:-0.15pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>progress,<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.1pt;">s</span>sues may<span style="letter-spacing:-0.1pt;"> </span>arise<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>uld<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to suspend<span style="letter-spacing:0.05pt;"> </span>or terminate<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>clin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>or could<span style="letter-spacing:-0.25pt;"> </span>ca<span style="letter-spacing:0.05pt;">u</span>se<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>resul<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>cohort<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>differ<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>pri<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.15pt;"> </span>cohort.<span style="letter-spacing:-0.2pt;"> </span>For exa<span style="letter-spacing:-0.1pt;">m</span>ple,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">e</span>nce<span style="letter-spacing:-0.35pt;"> </span>slower th<span style="letter-spacing:-0.05pt;">a</span>n ant<span style="letter-spacing:-0.05pt;">i</span>cip<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>lm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">ia</span>ls,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>consequently<span style="letter-spacing:-0.4pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>lay<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>BLA<span style="letter-spacing:0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>filing<span style="letter-spacing:-0.1pt;"> </span>timelines<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>permit<span style="letter-spacing:-0.3pt;"> </span>comp<span style="letter-spacing:0.05pt;">e</span>titors<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obtain approvals<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>alter<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>BLA<span style="letter-spacing:-0.1pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>strategy.<span style="letter-spacing:-0.25pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">a</span>ilure<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>lini<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:0.05pt;">c</span>cur<span style="letter-spacing:-0.2pt;"> </span>at any<span style="letter-spacing:-0.15pt;"> </span>stage<span style="letter-spacing:-0.2pt;"> </span>of testing,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>future cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>successful.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Events<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>successful<span style="letter-spacing:-0.3pt;"> </span>or timely<span style="letter-spacing:-0.2pt;"> </span>initiation<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>compl<span style="letter-spacing:0.05pt;">e</span>tion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>developme<span style="letter-spacing:0.1pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product approval include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Institutional</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">Review</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Boards</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">(&#8220;IRBs&#8221;) may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">authorize</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our inv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">iga</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ence</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.15pt;color:#000000;">n</span><span style="color:#000000;">duct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;"> a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prosp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">te,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or a</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">end</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">oco</span><span style="letter-spacing:-0.15pt;color:#000000;">l</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">IRBs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">quire</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">modify</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">amend</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protocols&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in reaching</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a consensus</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">obta</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">gree</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">F</span><span style="letter-spacing:0.05pt;color:#000000;">D</span><span style="color:#000000;">A or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">om</span><span style="letter-spacing:-0.05pt;color:#000000;">p</span><span style="color:#000000;">arable</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> t</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">design or e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">igib</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enro</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">lm</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">disagree</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intended</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">indications,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">des</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gn</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ur</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">interpre</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ation</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">data from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">find</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate&#8217;s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">benefits do not outweigh</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">its</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">author</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">cc</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">pt</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ia</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in for</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cou</span><span style="letter-spacing:-0.1pt;color:#000000;">n</span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">allow</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cli</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">institution</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to support</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">investigational</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">drug (&#8220;IN</span><span style="letter-spacing:0.05pt;color:#000000;">D</span><span style="color:#000000;">&#8221;)</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we cannot</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">demonstrate</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">comparability</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the relevant</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">instit</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in its </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">lays</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in or fa</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lure</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">agre</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ptab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">ter</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">prosp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">CROs and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rms of which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">extensive</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">negotiation</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">vary</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">significantly</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">among</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">different</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">CROs and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">linical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mposition</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">temporary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">permanent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">hold,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">on the</span><span style="letter-spacing:-0.15pt;color:#000000;"> P</span><span style="color:#000000;">hase</span><span style="letter-spacing:0.05pt;color:#000000;">&#160;II</span><span style="color:#000000;">/III</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">hAd5</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19 vaccine</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pending</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">modific</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tions</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protocol</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">FDA&#8217;s review</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">informatio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">immunogenicity</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and safety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> P</span><span style="color:#000000;">hase&#160;I</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">portion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">study,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">temporary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">previously</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">experienc</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">2014&#160;clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">rel</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to aldoxorubicin&#59;</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">although</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">this</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">temporary</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inv</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">lved</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">single</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">death</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.1pt;color:#000000;">o</span><span style="color:#000000;">mpassionate</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patient,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">since</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">time,</span><span style="letter-spacing:-0.15pt;color:#000000;"> a</span><span style="color:#000000;">ldoxorubicin has</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">administered</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mul</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">iple</span><span style="letter-spacing:-0.25pt;color:#000000;"> P</span><span style="color:#000000;">hase&#160;II</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a Phase</span><span style="letter-spacing:-0.05pt;color:#000000;">&#160;III</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">linical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">no</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">rther</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">holds&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspensions</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">terminations</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">agencies,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">I</span><span style="color:#000000;">RBs, or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">various</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reasons, incl</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ding</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">noncompliance</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> regulatory requirements </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a finding</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">participants</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">being</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">exposed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to unacceptable</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">risks,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">undesirable</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ot</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">unexpected characteristics</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">findings</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">undesirable</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">used</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">biologically</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">mechanistically</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">si</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">il</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">r therapeutic or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rap</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">utic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ndid</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in adding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">investigators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">thdr</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sit</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ilure</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">CROs, cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ni</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dhere</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requ</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nts,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regulatory, contractual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ocol</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to perform</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in accordance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">GCP</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">requiremen</span><span style="letter-spacing:-0.2pt;color:#000000;">t</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">guidelines</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">occurrence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">can</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">idate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">viewed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">outweigh</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">its</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">benefits&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requireme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">guid</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nce</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">quire</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">amending</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">submitting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">n</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">w</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">protocols</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">auth</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and IRBs,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">programs,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">chan</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">review</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">times&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">here</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">qu</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">stions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disagreements</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">regarding</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">interpretations</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resul</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">emerge regarding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">plan</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">was</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">based,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">produ</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">being</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">greater</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">anticipate,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">insufficient</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">funds</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for a</span><span style="letter-spacing:-0.05pt;color:#000000;"> c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">substantial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">user</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">fees</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">requir</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA upon</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">filing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a BLA or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">NDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">linical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduci</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inconclusive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">results</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">provide</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">data</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">informati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">to support</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">each</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">necessa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">vel</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">statistical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">significance,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our deciding,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requiring</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">us,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to conduct</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">preclin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cal</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">studies,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">abandon</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">develo</span><span style="letter-spacing:-0.1pt;color:#000000;">p</span><span style="color:#000000;">ment</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nterruption</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">receiving,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">supplies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">drugs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or components</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">staffing shortages,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">production</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">slowdowns or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stoppages</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">disruptions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delivery</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">arly</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">results</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">negatively</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">affected</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">fficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">measures</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">overall response</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ponse</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">enrolled</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cohorts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">sted, and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">response</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">rate</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">duration</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">response</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">negat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">vely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">fected</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inclusion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">unconfirmed</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">res</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">onses</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pre</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">iminary results</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">report</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">sponses are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">later</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">confirmed&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to demonst</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">provides</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">vantage</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">standards</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">developme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">here</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">therapeutics</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;">t</span><span style="color:#000000;">atus</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">administering</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">combination</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approve</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subsequently</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">find</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">fau</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">proc</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">fac</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd fu</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ure</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">erc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">suppli</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">autho</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">take</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">longer</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">anticipate</span><span style="letter-spacing:-0.3pt;color:#000000;"> when </span><span style="color:#000000;">making</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">decision</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">transfer</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.85pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:1.6pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.8pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">CMOs</span><span style="letter-spacing:1.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.5pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:1.3pt;color:#000000;"> </span><span style="color:#000000;">larger-scale facilities</span><span style="letter-spacing:1.6pt;color:#000000;"> </span><span style="color:#000000;">operated</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.9pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.15pt;color:#000000;"> </span><span style="color:#000000;">CMO</span><span style="letter-spacing:1.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.8pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">delays</span><span style="letter-spacing:1.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">failure</span><span style="letter-spacing:1.5pt;color:#000000;"> </span><span style="color:#000000;">by our</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">CMOs</span><span style="letter-spacing:1.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.45pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.25pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:1.45pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:0.6pt;color:#000000;"> </span><span style="color:#000000;">necessary</span><span style="letter-spacing:1.75pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:1.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.95pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:0.65pt;color:#000000;"> </span><span style="color:#000000;">process&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">different</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">manufactur</span><span style="letter-spacing:0.15pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">within</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">cts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">diff</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">processes on the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ta</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">ported</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">report</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in manufacturing,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">testing,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">releasing,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">validatin</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">importing/exporting</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sta</span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">le</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">quantities</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ndidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clini</span><span style="letter-spacing:0.05pt;color:#000000;">ca</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">bili</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">foregoing,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of any</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">qua</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">issu</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s associ</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">contract manufacturer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">disruption</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">social</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">distancing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.1pt;color:#000000;">s</span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions imposed</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">governmental</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">agenc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">sites</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.05pt;color:#000000;"> C</span><span style="color:#000000;">OVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pandemic,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">include</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enroll</span><span style="letter-spacing:0.1pt;color:#000000;">m</span><span style="color:#000000;">ent d</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">lays</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ilur</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">follow</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protoco</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">s&#59;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in combinati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">mol</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">cular</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">ents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">comparative</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">age</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">ts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al </span><span style="letter-spacing:-0.05pt;color:#000000;">tr</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>conducting<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> P</span>hase<span style="letter-spacing:0.05pt;">&#160;II</span><span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>in combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>unresponsive<span style="letter-spacing:-0.4pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>non-muscle<span style="letter-spacing:-0.4pt;"> </span>invasive<span style="letter-spacing:-0.25pt;"> </span>bladder<span style="letter-spacing:-0.2pt;"> </span>cancer, (&#8220;NMIBC&#8221;)<span style="letter-spacing:0.05pt;"> </span>in both<span style="letter-spacing:-0.15pt;"> </span>carcinoma<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.1pt;">i</span>tu<span style="letter-spacing:-0.1pt;"> </span>(&#8220;CIS&#8221;)<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>papillary<span style="letter-spacing:-0.3pt;"> </span>forms.<span style="letter-spacing:-0.05pt;"> </span>Due<span style="letter-spacing:0.05pt;"> </span>to BCG<span style="letter-spacing:0.05pt;"> </span>shortages,<span style="letter-spacing:-0.4pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>were encountered<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>tient<span style="letter-spacing:-0.2pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>lm<span style="letter-spacing:-0.05pt;">e</span>nt.<span style="letter-spacing:-0.35pt;"> </span>As of December<span style="letter-spacing:-0.35pt;"> </span>2020,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>leted<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.35pt;"> </span>enrollment<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>BCG<span style="letter-spacing:-0.05pt;"> </span>unresponsive<span style="letter-spacing:-0.4pt;"> </span>C<span style="letter-spacing:-0.05pt;">I</span>S<span style="letter-spacing:-0.05pt;"> </span>cohort.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>en<span style="letter-spacing:-0.05pt;">r</span>olled<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>rec<span style="letter-spacing:-0.05pt;">e</span>iv<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>lower dos<span style="letter-spacing:-0.05pt;">a</span>ge<span style="letter-spacing:-0.05pt;"> </span>of BCG<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>herapy<span style="letter-spacing:-0.2pt;"> </span>before<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nroll<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>BCG shortages.<span style="letter-spacing:-0.3pt;"> </span>During<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>riod<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>shortages,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>enrolled<span style="letter-spacing:-0.25pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who have<span style="letter-spacing:-0.2pt;"> </span>received<span style="letter-spacing:-0.25pt;"> </span>a lower<span style="letter-spacing:-0.15pt;"> </span>dosage<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>BCG th<span style="letter-spacing:-0.05pt;">e</span>rapy<span style="letter-spacing:-0.25pt;"> </span>before<span style="letter-spacing:-0.25pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>lm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>in <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>global<span style="letter-spacing:-0.15pt;"> </span>shortage<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>BCG&#59;<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>ample,<span style="letter-spacing:-0.35pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>ti<span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">e</span>ived<span style="letter-spacing:-0.25pt;"> </span>the recommended<span style="letter-spacing:-0.45pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>doses,<span style="letter-spacing:-0.05pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>per<span style="letter-spacing:-0.05pt;"> </span>dose<span style="letter-spacing:-0.05pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span>one-third<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>recommended<span style="letter-spacing:-0.45pt;"> </span>stre<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">g</span>th.<span style="letter-spacing:-0.3pt;"> </span>All<span style="letter-spacing:-0.15pt;"> </span>patients,<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:0.05pt;">o</span>ut<span style="letter-spacing:-0.2pt;"> </span>exception,<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ceived<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>number of<span style="letter-spacing:0.05pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>doses<span style="letter-spacing:0.05pt;"> </span>consistent<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>F<span style="letter-spacing:-0.05pt;">D</span>A<span style="letter-spacing:0.05pt;"> </span>guidance,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:0.05pt;">r</span>oximately<span style="letter-spacing:-0.45pt;"> </span>90%<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>enrolled<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> tr</span>i<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s <span style="letter-spacing:-0.05pt;">o</span>f <span style="letter-spacing:-0.05pt;">D</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">mb</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>2020<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>received the<span style="letter-spacing:-0.15pt;"> </span>am<span style="letter-spacing:0.05pt;">o</span>unt<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>recommended<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>A<span style="letter-spacing:-0.05pt;">m</span>eri<span style="letter-spacing:-0.05pt;">c</span>an<span style="letter-spacing:-0.2pt;"> </span>Uro<span style="letter-spacing:-0.05pt;">l</span>ogic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>A<span style="letter-spacing:-0.05pt;">s</span>soci<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.15pt;"> </span>befo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nrol<span style="letter-spacing:-0.05pt;">l</span>ing<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>l.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>agreed<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>modification<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>study<span style="letter-spacing:-0.25pt;"> </span>design<span style="letter-spacing:-0.2pt;"> </span>to allow<span style="letter-spacing:-0.25pt;"> </span>enrollment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patients<span style="letter-spacing:-0.35pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>received<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> reduced</span><span style="letter-spacing:-0.35pt;"> </span>dose<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>first line<span style="letter-spacing:-0.1pt;"> </span>therapy.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>received<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>full<span style="letter-spacing:-0.15pt;"> </span>dose<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>BCG<span style="letter-spacing:-0.05pt;"> </span>+<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">A</span>nktiva<span style="letter-spacing:-0.15pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>trial&#59;<span style="letter-spacing:-0.1pt;"> </span>however,<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>considered<span style="letter-spacing:-0.35pt;"> </span>BCG u<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sponsive.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>disposition<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>assessment<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sults<span style="letter-spacing:-0.25pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>BCG<span style="letter-spacing:0.05pt;"> </span>un<span style="letter-spacing:-0.05pt;">r</span>esponsive<span style="letter-spacing:-0.35pt;"> </span>CIS NMIBC pat<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>det<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>by the<span style="letter-spacing:-0.1pt;"> </span>FDA dur<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>heir<span style="letter-spacing:-0.15pt;"> </span>rev<span style="letter-spacing:-0.05pt;">i</span>ew.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>consider<span style="letter-spacing:-0.15pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>ling<span style="letter-spacing:-0.3pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>fore<span style="letter-spacing:-0.3pt;"> </span>BLA<span style="letter-spacing:0.05pt;"> </span>submissio<span style="letter-spacing:0.05pt;">n</span>,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>labeling will reflect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>enrol<span style="letter-spacing:-0.15pt;">l</span>ed<span style="letter-spacing:-0.25pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>population<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>determined<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>d<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ing their<span style="letter-spacing:-0.2pt;"> </span>review.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preclinical</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acade</span><span style="letter-spacing:0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ic,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical,</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biotechnolo</span><span style="letter-spacing:0.05pt;">g</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">io</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cs</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nti</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combine</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborators.</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">llaborations</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to additional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bec</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contract</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiations,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to obtain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">multiple</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">par</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessity</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtaining</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for ther</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peut</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cs</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">used in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bina</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Th</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bin</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ther</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pi</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requ</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA regulatory</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o suc<span style="letter-spacing:-0.05pt;">c</span>essfu<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>te<span style="letter-spacing:-0.3pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addit<span style="letter-spacing:0.05pt;">i</span>onal<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>generate revenues.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>ke<span style="letter-spacing:-0.15pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>elect<span style="letter-spacing:-0.15pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>conduct<span style="letter-spacing:-0.35pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>trials to bridge<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>modified<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>earlier<span style="letter-spacing:-0.2pt;"> </span>versions.<span style="letter-spacing:0.05pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:-0.1pt;">t</span>ification<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not have<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>desired effect.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>acc<span style="letter-spacing:-0.1pt;">e</span>pt<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>versions<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>application,<span style="letter-spacing:-0.4pt;"> </span>delaying<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ials<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>programs<span style="letter-spacing:-0.4pt;"> </span>or nec<span style="letter-spacing:-0.05pt;">e</span>ssi<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>udi<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>unintended<span style="letter-spacing:-0.35pt;"> </span>con<span style="letter-spacing:0.05pt;">s</span>equences<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>necessitates<span style="letter-spacing:-0.4pt;"> </span>additional development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>work,<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>precl<span style="letter-spacing:-0.1pt;">i</span>nical<span style="letter-spacing:-0.45pt;"> </span>studies,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>refusal<span style="letter-spacing:-0.2pt;"> </span>to file<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>non-app<span style="letter-spacing:-0.05pt;">r</span>oval<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a BLA<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>NDA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>shorten<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>riods<span style="letter-spacing:-0.05pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protecti<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mpetitors<span style="letter-spacing:-0.4pt;"> </span>to bring products to market<span style="letter-spacing:-0.2pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do,<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> c</span>ould<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>rm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business and results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">o</span>ns.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>sub<span style="letter-spacing:-0.05pt;">s</span>tantial<span style="letter-spacing:-0.15pt;"> </span>discretion<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>approv<span style="letter-spacing:0.1pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>refuse<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>accept<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>dec<span style="letter-spacing:0.1pt;">i</span>de<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>are ins<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">f</span>ficient<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>quire<span style="letter-spacing:-0.3pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>preclini<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>studi<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>or o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>research.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>types<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>stu<span style="letter-spacing:0.05pt;">d</span>ies<span style="letter-spacing:-0.2pt;"> </span>and clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>v<span style="letter-spacing:0.05pt;">a</span>ry<span style="letter-spacing:-0.15pt;"> </span>depen<span style="letter-spacing:0.05pt;">d</span>ing<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.1pt;">a</span>ndidate,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>condition<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product candidate<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>designed<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>addre<span style="letter-spacing:0.1pt;">s</span>s<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>particular<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate.<span style="letter-spacing:-0.35pt;"> </span>Approval<span style="letter-spacing:-0.4pt;"> </span>policies,<span style="letter-spacing:-0.25pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>type<span style="letter-spacing:-0.1pt;"> </span>and amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>gain<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>du<span style="letter-spacing:-0.05pt;">r</span>ing<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>course<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate&#8217;s<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and may<span style="letter-spacing:-0.2pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span>among jurisdictions.<span style="letter-spacing:-0.5pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is possible<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>produ<span style="letter-spacing:0.1pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.1pt;"> </span>to develop<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>never<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">b</span>tain<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>appropriate<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approvals necessary<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>futu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commence<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>du<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.05pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ple<span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>obtaining,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>iling<span style="letter-spacing:-0.2pt;"> </span>to obtain,<span style="letter-spacing:-0.2pt;"> </span>required approvals<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate, which<span style="letter-spacing:-0.15pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">i</span>nancial<span style="letter-spacing:-0.3pt;"> </span>position<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adverse<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>price.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>Immuno-Oncology<span style="letter-spacing:-0.75pt;"> </span>Clinic,<span style="letter-spacing:-0.25pt;"> </span>I<span style="letter-spacing:-0.05pt;">n</span>c.,<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>party,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>expose<span style="letter-spacing:-0.25pt;"> </span>us to<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.25pt;"> </span>risks.<span style="letter-spacing:-0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>data for this<span style="letter-spacing:-0.1pt;"> </span>site<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>s not<span style="letter-spacing:-0.1pt;"> </span>suff<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">i</span>e<span style="letter-spacing:-0.05pt;">n</span>tly<span style="letter-spacing:-0.15pt;"> </span>rob<span style="letter-spacing:-0.05pt;">u</span>st<span style="letter-spacing:-0.1pt;"> </span>or if there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>integrity<span style="letter-spacing:-0.3pt;"> </span>iss<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.05pt;">s</span>, we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>quir<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>p<span style="letter-spacing:0.05pt;">e</span>at<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch st<span style="letter-spacing:0.05pt;">u</span>di<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>q<span style="letter-spacing:0.05pt;">u</span>i<span style="letter-spacing:0.05pt;">r</span>ed<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ontra<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>with other<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>sites,<span style="letter-spacing:-0.25pt;"> </span>and our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment<span style="letter-spacing:-0.45pt;"> </span>plans<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sig<span style="letter-spacing:-0.1pt;">n</span>ificantly<span style="letter-spacing:-0.25pt;"> </span>delayed,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>incur<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>cos<span style="letter-spacing:0.05pt;">t</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> P</span>hase&#160;I<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>II<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>haNK,<span style="letter-spacing:0.05pt;"> </span>PD-L1.t-haNK<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>t-haNK<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>ducted<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Immuno-Oncology<span style="letter-spacing:-0.3pt;"> </span>Clinic,<span style="letter-spacing:-0.25pt;"> </span>Inc.,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>is a<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.3pt;"> </span>party.<span style="letter-spacing:-0.15pt;"> </span>Relying<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a relat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>site<span style="letter-spacing:-0.1pt;"> </span>to develop<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>at<span style="letter-spacing:-0.15pt;"> </span>is used<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>basis<span style="letter-spacing:0.05pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>regulatory approval<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>expose<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to significant<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>risks.<span style="letter-spacing:0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>a study<span style="letter-spacing:-0.25pt;"> </span>u<span style="letter-spacing:0.05pt;">s</span>ed<span style="letter-spacing:-0.05pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>is condu<span style="letter-spacing:-0.1pt;">c</span>ted<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>site can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>rejected<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>integrity<span style="letter-spacing:-0.3pt;"> </span>issue<span style="letter-spacing:0.15pt;">s</span>,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> GCP&#160;</span>violations<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>site.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>integrity,<span style="letter-spacing:-0.4pt;"> </span>or regulatory<span style="letter-spacing:-0.35pt;"> </span>non-compliance<span style="letter-spacing:-0.6pt;"> </span>issues occur<span style="letter-spacing:-0.15pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>study,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval.<span style="letter-spacing:-0.4pt;"> </span>Furth<span style="letter-spacing:0.1pt;">e</span>rmore,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>site<span style="letter-spacing:-0.15pt;"> are</span> disrupted<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>site<span style="letter-spacing:-0.1pt;"> </span>experiences<span style="letter-spacing:-0.4pt;"> </span>disruptio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>in its<span style="letter-spacing:-0.05pt;"> </span>cli<span style="letter-spacing:-0.1pt;">n</span>ical<span style="letter-spacing:-0.2pt;"> </span>supplies<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>resources,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>potent<span style="letter-spacing:0.1pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>disruptions<span style="letter-spacing:-0.45pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19, then<span style="letter-spacing:0.8pt;"> </span>we<span style="letter-spacing:0.9pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>be<span style="letter-spacing:0.5pt;"> </span>required<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>suspend<span style="letter-spacing:1.8pt;"> </span>or<span style="letter-spacing:0.35pt;"> </span>terminate<span style="letter-spacing:2pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>study<span style="letter-spacing:1.35pt;"> </span>at<span style="letter-spacing:0.2pt;"> </span>this<span style="letter-spacing:0.6pt;"> </span>site,<span style="letter-spacing:1.1pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:1.2pt;"> </span>need<span style="letter-spacing:0.8pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>contract<span style="letter-spacing:1.45pt;"> </span>with<span style="letter-spacing:0.8pt;"> </span>other<span style="letter-spacing:1.25pt;"> </span>clinical<span style="letter-spacing:1.45pt;"> </span>sites<span style="letter-spacing:0.7pt;"> </span>for<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.75pt;"> </span>study,<span style="letter-spacing:0.85pt;"> </span>which<span style="letter-spacing:1.4pt;"> </span>will delay<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>clinical<span style="letter-spacing:1.45pt;"> </span>development and<span style="letter-spacing:0.55pt;"> </span>regulatory approval<span style="letter-spacing:1.5pt;"> </span>for<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.5pt;"> </span>product<span style="letter-spacing:1.65pt;"> </span>candidate.<span style="letter-spacing:2.05pt;"> </span>Failure<span style="letter-spacing:1.4pt;"> </span>of<span style="letter-spacing:0.3pt;"> </span>this<span style="letter-spacing:0.95pt;"> </span>site<span style="letter-spacing:0.75pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>comply<span style="letter-spacing:1.6pt;"> </span>with<span style="letter-spacing:0.6pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>regulations<span style="letter-spacing:0.25pt;"> </span>or<span style="letter-spacing:0.35pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>recruit<span style="letter-spacing:1.45pt;"> </span>a sufficient<span style="letter-spacing:1.6pt;"> </span>number<span style="letter-spacing:1.75pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>patients<span style="letter-spacing:1.3pt;"> </span>may<span style="letter-spacing:0.8pt;"> </span>require<span style="letter-spacing:1.7pt;"> </span>us<span style="letter-spacing:0.25pt;"> </span>to<span style="letter-spacing:0.8pt;"> </span>delay<span style="letter-spacing:0.85pt;"> </span>submission<span style="letter-spacing:0.25pt;"> </span>for<span style="letter-spacing:0.55pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:1.85pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>repeat<span style="letter-spacing:1.2pt;"> </span>clinical<span style="letter-spacing:1.45pt;"> </span>trials,<span style="letter-spacing:1.3pt;"> </span>which<span style="letter-spacing:1.15pt;"> </span>would<span style="letter-spacing:1.45pt;"> </span>delay<span style="letter-spacing:0.85pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>regulatory approval<span style="letter-spacing:1.85pt;"> </span>process.<span style="letter-spacing:1.4pt;"> </span>Moreover,<span style="letter-spacing:2.05pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>business<span style="letter-spacing:1.4pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>be<span style="letter-spacing:0.7pt;"> </span>implicated<span style="letter-spacing:2pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>site<span style="letter-spacing:0.75pt;"> </span>violates<span style="letter-spacing:1.4pt;"> </span>federal<span style="letter-spacing:1.55pt;"> </span>or<span style="letter-spacing:0.4pt;"> </span>state<span style="letter-spacing:1pt;"> </span>fraud<span style="letter-spacing:1.05pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>abuse<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.45pt;"> </span>false<span style="letter-spacing:1.2pt;"> </span>claims<span style="letter-spacing:1pt;"> </span>laws<span style="letter-spacing:0.9pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>regulations<span style="letter-spacing:2pt;"> </span>or healt<span style="letter-spacing:0.35pt;">h</span>care<span style="letter-spacing:1.7pt;"> </span>privacy<span style="letter-spacing:1.45pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>security<span style="letter-spacing:1.8pt;"> </span>laws.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.6pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>encounter<span style="letter-spacing:0.05pt;"> </span>difficulties<span style="letter-spacing:1.55pt;"> </span>enrolling<span style="letter-spacing:1.8pt;"> </span>patients<span style="letter-spacing:1.85pt;"> </span>in<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:1.05pt;"> </span>clinical<span style="letter-spacing:1pt;"> </span>trials,<span style="letter-spacing:1.6pt;"> </span>our<span style="letter-spacing:0.65pt;"> </span>clinical<span style="letter-spacing:1.7pt;"> </span>development<span style="letter-spacing:2pt;"> </span>activities<span style="letter-spacing:1.65pt;"> </span>and<span style="letter-spacing:1.2pt;"> </span>receipt<span style="letter-spacing:1.35pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>necessary<span style="letter-spacing:1.65pt;"> </span>marketing<span style="letter-spacing:1.9pt;"> </span>approvals could<span style="letter-spacing:0.8pt;"> </span>be<span style="letter-spacing:0.95pt;"> </span>delayed<span style="letter-spacing:1.4pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>otherwise<span style="letter-spacing:1.2pt;"> </span>adversely<span style="letter-spacing:1.8pt;"> </span>affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>timely<span style="letter-spacing:-0.2pt;"> </span>completion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>linical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>accordance<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>protocols<span style="letter-spacing:-0.3pt;"> </span>depends,<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">t</span>her<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>enr<span style="letter-spacing:0.05pt;">o</span>ll<span style="letter-spacing:-0.15pt;"> </span>a sufficient<span style="letter-spacing:-0.3pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of pat<span style="letter-spacing:-0.05pt;">i</span>ents,<span style="letter-spacing:-0.3pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ma<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span>un<span style="letter-spacing:-0.05pt;">t</span>il<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onclusion.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>difficulties<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>del<span style="letter-spacing:-0.1pt;">a</span>ys<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>enrollment<span style="letter-spacing:-0.4pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">c</span>linical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a va<span style="letter-spacing:-0.05pt;">r</span>iety<span style="letter-spacing:-0.2pt;"> </span>of reasons, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">size</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">nature</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ulation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">severity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">sease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">igib</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">rit</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ria</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">defined</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protocol&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">size</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">population</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">analysis</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">trial&#8217;s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">primary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">endpoints&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">proxim</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of pa</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ien</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ab</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ruit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">iga</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ppropria</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">comp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">xp</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to facilitate</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">enr</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">llment</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in clinical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">effective</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ess</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">recruiting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">publicity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">referral</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">actices</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">number</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">larger</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">ticipate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">enrollment</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hese</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">slower</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">antic</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">pate,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">potentially</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">affecting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">timelines</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enroll</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">studies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">sr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">present</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ir</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">el</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gibi</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">otherwise</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ply</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">he </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:-0.1pt;color:#000000;">o</span><span style="color:#000000;">toco</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">need</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to d</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ial,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">increase</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">needed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">enroll</span><span style="letter-spacing:-0.15pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">size</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">study</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clini</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">extend</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the study&#8217;s or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">trial&#8217;s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">duration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ompeting</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapeutics</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">involving</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">cell-ba</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">immunotherapy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">linicians&#8217;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">patients&#8217;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">percept</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ons</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">advantages</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">ndidate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">being</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">studied</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">n relation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ava</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lab</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">api</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nclud</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">drugs</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">treatments</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be approved for the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indications</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">investigating&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">lin</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nvestig</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tors</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nrol</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">who do not meet</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">enrollment</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">criteria,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">requiring</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">inclusion</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pati</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l </span><span style="letter-spacing:-0.05pt;color:#000000;">tr</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">l&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pproval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">indications for existing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapi</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">ap</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">general&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">con</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">en</span><span style="color:#000000;">ts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:0.05pt;color:#000000;">1</span><span style="color:#000000;">9</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">pandemic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">material</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">events,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">affect</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tria</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">slowing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">enrol</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ment</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">reducing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">number</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">eligible</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">risk</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ents</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">enrol</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ompl</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">turn</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">post-</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">rea</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">fo</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">low-up,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">follow</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">required study</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">procedures.</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">For</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">instance,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patients,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">cluding</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in any control</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">groups,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">withdraw from the clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not experiencing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">improvement</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">underlying</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">disease</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">ondition.</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">Withdrawal</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">fr</span><span style="letter-spacing:-0.05pt;color:#000000;">o</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">comprom</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he quality</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">data.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mpete<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>me<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>rap<span style="letter-spacing:-0.05pt;">e</span>utic<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>reas<span style="letter-spacing:-0.2pt;"> </span>as our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>competition<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:0.05pt;">i</span>ll<span style="letter-spacing:-0.1pt;"> </span>reduce<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>types<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>available<span style="letter-spacing:-0.25pt;"> </span>to u<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.05pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.1pt;">h</span>o<span style="letter-spacing:-0.05pt;"> </span>might<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>opted<span style="letter-spacing:-0.25pt;"> </span>to enroll<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>instead<span style="letter-spacing:-0.3pt;"> </span>opt<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enroll<span style="letter-spacing:-0.15pt;"> </span>in a<span style="letter-spacing:-0.1pt;"> </span>trial<span style="letter-spacing:-0.2pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>nducted<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors.<span style="letter-spacing:-0.4pt;"> </span>Bec<span style="letter-spacing:-0.1pt;">a</span>use<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>qua<span style="letter-spacing:0.05pt;">l</span>if<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">in</span>i<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>investigators is limited,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>sites<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>duce<span style="letter-spacing:-0.25pt;"> </span>the n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>at such<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>sites.<span style="letter-spacing:-0.15pt;"> </span>Moreover,<span style="letter-spacing:-0.45pt;"> </span>because<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candi<span style="letter-spacing:0.1pt;">d</span>ates<span style="letter-spacing:-0.45pt;"> </span>represent<span style="letter-spacing:-0.3pt;"> </span>a departure from<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>commonly<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">u</span>sed<span style="letter-spacing:-0.05pt;"> </span>methods<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>cancer<span style="letter-spacing:-0.4pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>viral<span style="letter-spacing:-0.2pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>treatm<span style="letter-spacing:-0.05pt;">e</span>nt,<span style="letter-spacing:-0.4pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>doctors<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>inclined<span style="letter-spacing:-0.25pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>conventional therapies,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>chemotherapy<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>immunotherapies,<span style="letter-spacing:-0.65pt;"> </span>rather<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>enroll<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>in <span style="letter-spacing:-0.05pt;">a</span>ny future<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendments<span style="letter-spacing:-0.45pt;"> </span>to our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>protocols<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;">f</span>fect<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nroll<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>in,<span style="letter-spacing:-0.1pt;"> </span>or results<span style="letter-spacing:-0.25pt;"> </span>of, our<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>i<span style="letter-spacing:-0.1pt;">a</span>ls,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>amendments<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>define<span style="letter-spacing:-0.25pt;"> </span>the patient<span style="letter-spacing:-0.25pt;"> </span>population<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>studied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we <span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">e</span>nroll<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>suff<span style="letter-spacing:-0.05pt;">i</span>ci<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>number<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.1pt;"> </span>our c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>de<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ys<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>ti<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nrol<span style="letter-spacing:-0.05pt;">l</span>ment<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>small<span style="letter-spacing:-0.15pt;"> </span>population<span style="letter-spacing:-0.2pt;"> </span>size<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in increased<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>af<span style="letter-spacing:-0.05pt;">f</span>ect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timing<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>outcome<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>completion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>ad<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>rsely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>advance<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cause</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">undesirable</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">side</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">effects</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ve</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">properties</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ould</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">halt</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cl</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">devel</span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pment,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pre</span><span style="letter-spacing:-0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ir regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">limit</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">eir</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pote</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tial</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">si</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ificant</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">negative</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consequences.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>reveal<span style="letter-spacing:-0.15pt;"> </span>a high<span style="letter-spacing:-0.1pt;"> a</span>nd unacceptable<span style="letter-spacing:-0.45pt;"> </span>severity<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ev<span style="letter-spacing:0.05pt;">a</span>len<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span>de<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ff<span style="letter-spacing:0.05pt;">e</span>cts,<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>events<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unexpect<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.35pt;"> </span>char<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rist<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>s. Undesirable<span style="letter-spacing:-0.4pt;"> </span>side<span style="letter-spacing:-0.1pt;"> </span>effects<span style="letter-spacing:-0.2pt;"> </span>caused<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.25pt;"> </span>us, IRBs, Drug Safety<span style="letter-spacing:-0.3pt;"> </span>Monitoring<span style="letter-spacing:-0.45pt;"> </span>Boards<span style="letter-spacing:0.05pt;"> </span>(&#8220;DSMBs&#8221;)<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>regu<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>tory<span style="letter-spacing:-0.35pt;"> </span>au<span style="letter-spacing:-0.05pt;">t</span>horit<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o int<span style="letter-spacing:-0.05pt;">e</span>rrupt,<span style="letter-spacing:-0.35pt;"> </span>de<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>lt<span style="letter-spacing:-0.15pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>restrictive<span style="letter-spacing:-0.35pt;"> </span>label<span style="letter-spacing:-0.2pt;"> </span>or t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>denial<span style="letter-spacing:-0.25pt;"> </span>of regulatory<span style="letter-spacing:-0.3pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>oval<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities.<span style="letter-spacing:-0.45pt;"> </span>Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to receive<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>approv<span style="letter-spacing:-0.05pt;">a</span>l,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>contingent<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>inclusion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>unfavorable information<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>labeling,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>limitations<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>indicated<span style="letter-spacing:-0.35pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>whi<span style="letter-spacing:-0.1pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>marketed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>distribu<span style="letter-spacing:-0.05pt;">t</span>ed,<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>bel<span style="letter-spacing:-0.15pt;"> </span>with sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.45pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>warnings,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>boxed<span style="letter-spacing:-0.15pt;"> </span>warnin<span style="letter-spacing:0.05pt;">g</span>s,<span style="letter-spacing:-0.25pt;"> </span>contraindicati<span style="letter-spacing:0.05pt;">o</span>ns,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>precautions,<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>lab<span style="letter-spacing:-0.1pt;">e</span>l<span style="letter-spacing:-0.2pt;"> </span>without<span style="letter-spacing:-0.25pt;"> </span>statements<span style="letter-spacing:-0.35pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>desirable<span style="letter-spacing:-0.25pt;"> </span>for successful commercialization,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.75pt;"> </span>requirements for<span style="letter-spacing:1pt;"> </span>costly<span style="letter-spacing:1.2pt;"> </span>post<span style="letter-spacing:0.9pt;"> </span>marketing<span style="letter-spacing:1.55pt;"> </span>testing<span style="letter-spacing:1.5pt;"> </span>and<span style="letter-spacing:0.9pt;"> </span>surveillance,<span style="letter-spacing:0.3pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>other<span style="letter-spacing:0.8pt;"> </span>requirements,<span style="letter-spacing:-0.15pt;"> </span>including<span style="letter-spacing:1.95pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>Risk<span style="letter-spacing:1.2pt;"> </span>Evaluation<span style="letter-spacing:1.9pt;"> </span>and Mitigation St<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tegy<span style="letter-spacing:-0.25pt;"> </span>(&#8220;REMS&#8221;)<span style="letter-spacing:-0.35pt;"> </span>to monitor<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.1pt;">r</span>oducts,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>in turn<span style="letter-spacing:-0.2pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.1pt;"> </span>commercializing<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>generating<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>venues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>sale of our current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>unacceptable<span style="letter-spacing:-0.45pt;"> </span>toxicities<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>effects<span style="letter-spacing:-0.3pt;"> </span>arise<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development of our product candidates,<span style="letter-spacing:-0.35pt;"> </span>we,<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>IRB,<span style="letter-spacing:-0.1pt;"> </span>DSMB or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.15pt;">c</span>omparable<span style="letter-spacing:-0.35pt;"> </span>foreign regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>us <span style="letter-spacing:-0.05pt;">t</span>o c<span style="letter-spacing:-0.05pt;">e</span>ase<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>ord<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>placed<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>hold,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>de<span style="letter-spacing:-0.1pt;">n</span>y<span style="letter-spacing:-0.1pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>targe<span style="letter-spacing:0.1pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>indications.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:-0.4pt;"> </span>foreign<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>d<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:0.05pt;">a</span>,<span style="letter-spacing:-0.15pt;"> </span>clini<span style="letter-spacing:0.05pt;">ca</span><span style="letter-spacing:-0.05pt;">l</span>,<span style="letter-spacing:-0.2pt;"> </span>or preclinical<span style="letter-spacing:-0.35pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>should<span style="letter-spacing:-0.25pt;"> </span>unacceptable<span style="letter-spacing:-0.4pt;"> </span>toxicities<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>ise.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.15pt;"> </span>to abandon<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of that product<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndid<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ce<span style="letter-spacing:-0.05pt;">r</span>ta<span style="letter-spacing:-0.05pt;">i</span>n uses<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>subpopulations<span style="letter-spacing:-0.5pt;"> </span>in which<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>undesirable<span style="letter-spacing:-0.35pt;"> </span>side<span style="letter-spacing:-0.1pt;"> </span>effects<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>characteristics are less<span style="letter-spacing:-0.05pt;"> </span>prevalent,<span style="letter-spacing:-0.35pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>severe<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>ac<span style="letter-spacing:-0.05pt;">c</span>ept<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>risk/b<span style="letter-spacing:-0.05pt;">e</span>nefit perspective.<span style="letter-spacing:-0.45pt;"> </span>Toxicities<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">s</span>sociated<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>produ<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:-0.1pt;">e</span>gatively<span style="letter-spacing:-0.35pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>our ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>cl<span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>using<span style="letter-spacing:-0.2pt;"> </span>tumor-infiltrating<span style="letter-spacing:-0.4pt;"> </span>lymphocyte<span style="letter-spacing:-0.4pt;">&#160;</span>(&#8220;TIL&#8221;)<span style="letter-spacing:-0.3pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>in lar<span style="letter-spacing:-0.05pt;">g</span>er<span style="letter-spacing:-0.15pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">p</span>opulations,<span style="letter-spacing:-0.45pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>in patients<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>yet<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:-0.15pt;">e</span>en<span style="letter-spacing:-0.2pt;"> </span>treated<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>have not yet<span style="letter-spacing:-0.05pt;"> </span>progressed<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>therapies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tr<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">a</span>tment-em<span style="letter-spacing:0.05pt;">e</span>rgent<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dv<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>ents<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>lso<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ff<span style="letter-spacing:0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>crui<span style="letter-spacing:-0.05pt;">t</span>ment<span style="letter-spacing:-0.4pt;"> </span>or the<span style="letter-spacing:-0.1pt;"> </span>ab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.15pt;"> </span>of enrol<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.3pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ec<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ple<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tr<span style="letter-spacing:-0.15pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>su<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n po<span style="letter-spacing:-0.05pt;">t</span>ent<span style="letter-spacing:-0.05pt;">i</span>al prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>liability<span style="letter-spacing:-0.3pt;"> </span>claims.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:0.1pt;">a</span>ve<span style="letter-spacing:-0.2pt;"> </span>observed<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include,<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>injection<span style="letter-spacing:-0.3pt;"> </span>site<span style="letter-spacing:-0.15pt;"> </span>pain<span style="letter-spacing:-0.1pt;"> </span>and reacti<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:-0.2pt;"> </span>fatigue,<span style="letter-spacing:-0.25pt;"> </span>nau<span style="letter-spacing:-0.05pt;">s</span>ea,<span style="letter-spacing:-0.15pt;"> </span>vomiting,<span style="letter-spacing:-0.3pt;"> </span>diarrhea,<span style="letter-spacing:-0.3pt;"> </span>muc<span style="letter-spacing:0.05pt;">o</span>sitis,<span style="letter-spacing:-0.4pt;"> </span>abdominal<span style="letter-spacing:-0.35pt;"> </span>pain,<span style="letter-spacing:-0.2pt;"> </span>anorexi<span style="letter-spacing:-0.05pt;">a</span>,<span style="letter-spacing:-0.25pt;"> </span>chills,<span style="letter-spacing:-0.15pt;"> </span>pyrexia,<span style="letter-spacing:-0.35pt;"> </span>arthr<span style="letter-spacing:-0.05pt;">a</span>lgia,<span style="letter-spacing:-0.35pt;"> </span>limb<span style="letter-spacing:-0.1pt;"> </span>edema,<span style="letter-spacing:-0.2pt;"> myelosuppression (neutropenia</span>,<span style="letter-spacing:0.05pt;"> </span>thromboc<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">t</span>openia,<span style="letter-spacing:-0.75pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ane<span style="letter-spacing:0.05pt;">m</span>ia)<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>hypoalbuminemia.<span style="letter-spacing:-0.6pt;"> </span>Combination<span style="letter-spacing:-0.4pt;"> </span>immunotherapy<span style="letter-spacing:-0.6pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>includes<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>frequent<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dverse<span style="letter-spacing:-0.3pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>adver<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.25pt;"> </span>events,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>esophagitis,<span style="letter-spacing:-0.45pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>omatitis,<span style="letter-spacing:-0.35pt;"> </span>epist<span style="letter-spacing:-0.1pt;">a</span>xis,<span style="letter-spacing:-0.4pt;"> </span>weight<span style="letter-spacing:-0.2pt;"> </span>loss, head<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.35pt;"> </span>alop<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">i</span>a, night<span style="letter-spacing:-0.2pt;"> </span>sweats,<span style="letter-spacing:-0.05pt;"> </span>peripheral<span style="letter-spacing:-0.3pt;"> </span>neuropa<span style="letter-spacing:0.05pt;">t</span>hy,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>death.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.2pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffects<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:0.05pt;">r</span>opriately<span style="letter-spacing:-0.45pt;"> </span>recognized<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>managed<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>treating medical<span style="letter-spacing:-0.3pt;"> </span>staff,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>toxicities<span style="letter-spacing:-0.3pt;"> </span>res<span style="letter-spacing:-0.05pt;">u</span>lting<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>norm<span style="letter-spacing:-0.05pt;">a</span>lly<span style="letter-spacing:-0.25pt;"> </span>encountered<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>general<span style="letter-spacing:-0.2pt;"> </span>patient<span style="letter-spacing:-0.15pt;"> </span>population<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>medical personnel.<span style="letter-spacing:0.05pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>occurrences<span style="letter-spacing:-0.5pt;"> </span>may<span style="letter-spacing:-0.15pt;"> materially </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, financial<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>ndition<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>os<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>cts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.1pt;"> </span>manufacture<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>is compl<span style="letter-spacing:-0.05pt;">e</span>x,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:0.05pt;">n</span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;"> </span>diffic<span style="letter-spacing:0.05pt;">u</span>lties<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>roduction,<span style="letter-spacing:-0.3pt;"> </span>part<span style="letter-spacing:-0.05pt;">i</span>cularly<span style="letter-spacing:-0.3pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>spe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pro<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:0.05pt;">s</span>s development,<span style="letter-spacing:-0.5pt;"> </span>quality<span style="letter-spacing:-0.2pt;"> </span>control,<span style="letter-spacing:-0.35pt;"> </span>or scaling-up<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.05pt;"> </span>capabilities.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>partie<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>thi<span style="letter-spacing:0.05pt;">r</span>d-party<span style="letter-spacing:-0.35pt;"> </span>manufacturers encoun<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.3pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span>h diff<span style="letter-spacing:-0.05pt;">i</span>cult<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>provide<span style="letter-spacing:-0.25pt;"> </span>supply<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>tients,<span style="letter-spacing:-0.2pt;"> </span>if approved,<span style="letter-spacing:-0.35pt;"> </span>could be<span style="letter-spacing:-0.05pt;"> </span>delayed<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>stopped,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to maintain<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>comme<span style="letter-spacing:-0.15pt;">r</span>cially<span style="letter-spacing:-0.45pt;"> </span>viable<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>structure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idates<span style="letter-spacing:-0.35pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>predominately<span style="letter-spacing:-0.45pt;"> </span>biologics,<span style="letter-spacing:-0.3pt;"> </span>v<span style="letter-spacing:-0.1pt;">e</span>ctors,<span style="letter-spacing:-0.25pt;"> </span>small<span style="letter-spacing:-0.25pt;"> </span>molecules<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>decentralize<span style="letter-spacing:0.05pt;">d</span>,<span style="letter-spacing:-0.5pt;"> </span>advanced<span style="letter-spacing:-0.35pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>ther<span style="letter-spacing:-0.05pt;">a</span>pies.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>manufacture of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>involves<span style="letter-spacing:-0.25pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>processes,<span style="letter-spacing:0.05pt;"> </span>es<span style="letter-spacing:-0.05pt;">p</span>ecially<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>biologics,<span style="letter-spacing:-0.3pt;"> </span>vecto<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>therapy<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>complex, highly<span style="letter-spacing:-0.25pt;"> </span>regulated<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to m<span style="letter-spacing:-0.05pt;">u</span>lt<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.3pt;"> </span>risks. As a r<span style="letter-spacing:-0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he <span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>xi<span style="letter-spacing:-0.05pt;">t</span>ies,<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">s</span>t to m<span style="letter-spacing:-0.05pt;">a</span>nuf<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">c</span>ture<span style="letter-spacing:-0.35pt;"> </span>biol<span style="letter-spacing:0.05pt;">o</span>gics,<span style="letter-spacing:-0.35pt;"> </span>vectors<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ll<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>rap<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>s gen<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.05pt;">l</span>y higher<span style="letter-spacing:-0.3pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>traditional<span style="letter-spacing:-0.3pt;"> </span>small<span style="letter-spacing:-0.2pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>che<span style="letter-spacing:-0.05pt;">m</span>ical<span style="letter-spacing:-0.3pt;"> </span>compounds,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>process is<span style="letter-spacing:-0.1pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>reliable<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd is<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>difficult<span style="letter-spacing:-0.25pt;"> </span>to rep<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duce.<span style="letter-spacing:-0.3pt;"> </span>Even minor<span style="letter-spacing:-0.05pt;"> </span>deviatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>mal<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>processes<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>reduced<span style="letter-spacing:-0.3pt;"> </span>production<span style="letter-spacing:-0.35pt;"> </span>yields,<span style="letter-spacing:-0.3pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>defects,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>supply disruptions.<span style="letter-spacing:-0.35pt;"> </span>If microbial,<span style="letter-spacing:-0.35pt;"> </span>viral,<span style="letter-spacing:-0.2pt;"> </span>environmental<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>contaminations<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>d<span style="letter-spacing:0.05pt;">i</span>scovered<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>facilities<span style="letter-spacing:-0.25pt;"> </span>in which<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>made,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>manufa<span style="letter-spacing:-0.05pt;">c</span>turing<span style="letter-spacing:-0.5pt;"> </span>fa<span style="letter-spacing:-0.05pt;">c</span>il<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>ed<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>closed<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>extended<span style="letter-spacing:-0.25pt;"> </span>period<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>investigate<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>rem<span style="letter-spacing:0.05pt;">e</span>dy<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>contamination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>manufact<span style="letter-spacing:-0.1pt;">u</span>red<span style="letter-spacing:-0.45pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>processes<span style="letter-spacing:0.05pt;"> </span>developed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>modified<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>institution collaborators<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>cli<span style="letter-spacing:-0.1pt;">n</span>i<span style="letter-spacing:0.05pt;">ca</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:0.05pt;">a</span>ls<span style="letter-spacing:-0.2pt;"> </span>or comm<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">c</span>i<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span><span style="letter-spacing:-0.05pt;">a</span>tion.<span style="letter-spacing:-0.6pt;"> </span>As a<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>ch<span style="letter-spacing:0.05pt;">a</span>ll<span style="letter-spacing:0.05pt;">e</span>ng<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>delays in our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>comme<span style="letter-spacing:0.05pt;">r</span>cialization<span style="letter-spacing:-0.6pt;"> </span>plans.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>redu<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>cost<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>goods<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">ro</span><span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>to levels<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>attractive<span style="letter-spacing:-0.3pt;"> </span>return<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>investme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>if and<span style="letter-spacing:-0.1pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>commercialized.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ma</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acture</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candi</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use CMOs.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ird-party</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">man</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">facture</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our prod</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oduct</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compete</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">access</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ma</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acturing</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ac</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">here</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a limited</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">urers</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operate</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cGMP</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ations</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">both</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capable</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our CMOs should</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cease</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in obtaining</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sufficient</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qua</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tities</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ini</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tr</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and, if approved,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supp</span><span style="letter-spacing:-0.1pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">renew</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements.</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.1pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ind</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tern</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve manuf</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tur</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regu</span><span style="letter-spacing:0.1pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new arrangement</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">less</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vorable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">than</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arr</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ngements</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">el</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transfer</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">necessary</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">processes</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> significant</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reliance<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>manufacturers<span style="letter-spacing:-0.35pt;"> </span>entails<span style="letter-spacing:-0.2pt;"> </span>exposure<span style="letter-spacing:-0.25pt;"> </span>to risks to which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>wou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>manufactured<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>ourselves, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nability</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">negotiate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">manu</span><span style="letter-spacing:0.05pt;color:#000000;">f</span><span style="color:#000000;">acturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">quality</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreements</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">parties</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">commercially</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">reaso</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">able</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">day-to-day</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">process</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a result</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">using</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">manufac</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">urers</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">all aspects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufact</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">vit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">over</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">protection</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ade</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">secrets,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">kno</span><span style="letter-spacing:-0.05pt;color:#000000;">w</span><span style="color:#000000;">-how</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">inf</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">rmation</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">misappropriation</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">advertent disclosure</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">being</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such a w</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to expose</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ermination</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">nonrenewal</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">agreements</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rties</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">manner</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">at a time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">costly</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">damag</span><span style="letter-spacing:0.1pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or result</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in delays</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disruptions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">operations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third-party</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">manufacturers</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">suppliers</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">caused</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">conditions</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">unrelated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or operations, including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">bankruptcy</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">manufacturer</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">supplier.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>manufacture<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cell<span style="letter-spacing:-0.1pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>quires<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>expertise<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>capital<span style="letter-spacing:-0.2pt;"> </span>investment,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>manufacturing techniques<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>controls.<span style="letter-spacing:-0.35pt;"> </span>Manufactur<span style="letter-spacing:-0.05pt;">e</span>rs<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cell<span style="letter-spacing:-0.1pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>often<span style="letter-spacing:-0.15pt;"> </span>encounter<span style="letter-spacing:-0.3pt;"> </span>difficulties<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduction,<span style="letter-spacing:-0.35pt;"> </span>particular<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">l</span>ing<span style="letter-spacing:-0.15pt;"> </span>up in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>l prod<span style="letter-spacing:0.05pt;">u</span>ction.<span style="letter-spacing:-0.2pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>problems<span style="letter-spacing:-0.3pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>dif<span style="letter-spacing:-0.05pt;">f</span>icu<span style="letter-spacing:-0.05pt;">l</span>ties<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>production<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>yields,<span style="letter-spacing:-0.2pt;"> </span>quality<span style="letter-spacing:-0.2pt;"> </span>control,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>stability<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span>roduct<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>quality assurance<span style="letter-spacing:-0.3pt;"> </span>testing,<span style="letter-spacing:-0.2pt;"> </span>shortages<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>qualified<span style="letter-spacing:-0.35pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compl<span style="letter-spacing:0.05pt;">i</span>ance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>strictly<span style="letter-spacing:-0.2pt;"> </span>enforced<span style="letter-spacing:-0.3pt;"> </span>fed<span style="letter-spacing:-0.1pt;">e</span>ral,<span style="letter-spacing:-0.25pt;"> </span>state,<span style="letter-spacing:-0.2pt;"> </span>local<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>re<span style="letter-spacing:0.05pt;">g</span>ulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>problems<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CMOs<span style="letter-spacing:0.05pt;"> </span>ex<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>rience<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>preparing<span style="letter-spacing:-0.4pt;"> </span>for c<span style="letter-spacing:0.05pt;">o</span>mmercial<span style="letter-spacing:-0.45pt;"> </span>scale<span style="letter-spacing:-0.2pt;"> </span>manufa<span style="letter-spacing:0.1pt;">c</span>turing<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a delay<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>impair<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to manufacture<span style="letter-spacing:-0.4pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>quan<span style="letter-spacing:-0.1pt;">t</span>ities<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>quanti<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.4pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cep<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ble cost,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>delay,<span style="letter-spacing:-0.25pt;"> </span>prevention,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>impairment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commerciali<span style="letter-spacing:-0.05pt;">z</span>ation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>andidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>could adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:-0.05pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>manufacturers<span style="letter-spacing:-0.45pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>del<span style="letter-spacing:0.05pt;">i</span>ver<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>quantities<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product candidates<span style="letter-spacing:-0.35pt;"> </span>on a<span style="letter-spacing:-0.05pt;"> </span>timely<span style="letter-spacing:-0.3pt;"> </span>basis and<span style="letter-spacing:-0.05pt;"> </span>at reasonable<span style="letter-spacing:-0.4pt;"> </span>costs,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.1pt;"> </span>likely<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>demand<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:0.05pt;">o</span>se<span style="letter-spacing:-0.05pt;"> </span>po<span style="letter-spacing:-0.05pt;">t</span>ent<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.35pt;"> </span>revenues.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>cilities<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>velop<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.15pt;"> </span>to FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regu<span style="letter-spacing:-0.15pt;">l</span>atory<span style="letter-spacing:-0.3pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>approval processes,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>CMOs<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to m<span style="letter-spacing:-0.05pt;">e</span>et<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ll<span style="letter-spacing:-0.1pt;"> </span>appl<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authority<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>quirements,<span style="letter-spacing:-0.4pt;"> </span>incl<span style="letter-spacing:0.05pt;">u</span>ding<span style="letter-spacing:-0.25pt;"> </span>cG<span style="letter-spacing:-0.05pt;">M</span>P,<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>ongoing basis.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>cGMP<span style="letter-spacing:-0.05pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>ments<span style="letter-spacing:-0.4pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>quality<span style="letter-spacing:-0.15pt;"> </span>control,<span style="letter-spacing:-0.25pt;"> </span>quality<span style="letter-spacing:-0.2pt;"> </span>ass<span style="letter-spacing:-0.05pt;">u</span>rance<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>maintenance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>records<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>documentation.<span style="letter-spacing:-0.5pt;"> </span>The<span style="letter-spacing:-0.1pt;"> F</span>DA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>enforce<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>facility<span style="letter-spacing:-0.2pt;"> </span>inspections.<span style="letter-spacing:-0.4pt;"> </span>Manufacturing<span style="letter-spacing:-0.5pt;"> </span>fac<span style="letter-spacing:0.05pt;">i</span>lities<span style="letter-spacing:-0.25pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>sub<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.2pt;"> </span>to pre-ap<span style="letter-spacing:-0.05pt;">p</span>roval<span style="letter-spacing:-0.4pt;"> </span>inspections<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the FDA<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>conducted<span style="letter-spacing:-0.35pt;"> </span>after<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>submit<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>eting<span style="letter-spacing:-0.25pt;"> </span>appli<span style="letter-spacing:-0.1pt;">c</span>ations,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>BLAs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">N</span>DAs,<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>Manufacturers<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>e<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o continuing<span style="letter-spacing:-0.35pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>regulato<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>inspections<span style="letter-spacing:-0.45pt;"> </span>following<span style="letter-spacing:-0.4pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.1pt;">v</span>al.<span style="letter-spacing:-0.15pt;"> </span>Further,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>CMOs must<span style="letter-spacing:-0.2pt;"> </span>supply<span style="letter-spacing:-0.2pt;"> </span>all nece<span style="letter-spacing:0.05pt;">s</span>sary<span style="letter-spacing:-0.25pt;"> </span>chemi<span style="letter-spacing:0.05pt;">s</span>try,<span style="letter-spacing:-0.45pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>quality<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>ntrol<span style="letter-spacing:-0.3pt;"> </span>documentation<span style="letter-spacing:-0.55pt;"> </span>in support<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a B<span style="letter-spacing:-0.1pt;">L</span>A<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>NDA on<span style="letter-spacing:-0.05pt;"> </span>a timely<span style="letter-spacing:-0.25pt;"> </span>basis.<span style="letter-spacing:-0.05pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>guarantee<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or our<span style="letter-spacing:-0.05pt;"> </span>CMOs<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o suc<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.05pt;">s</span>sfully<span style="letter-spacing:-0.35pt;"> </span>pass<span style="letter-spacing:-0.05pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>aspects<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a pre-approval<span style="letter-spacing:-0.4pt;"> </span>inspection<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>aut<span style="letter-spacing:-0.05pt;">h</span>or<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>progress<span style="letter-spacing:0.05pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>preclinic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>to marketing<span style="letter-spacing:-0.3pt;"> </span>app<span style="letter-spacing:-0.05pt;">r</span>oval<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>comme<span style="letter-spacing:-0.05pt;">r</span>cializa<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.75pt;"> </span>it is<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>various<span style="letter-spacing:-0.3pt;"> </span>aspects<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>program,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>manufactur<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.4pt;"> </span>methods<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>formulation,<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>altered<span style="letter-spacing:-0.3pt;"> </span>along<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>way<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>effort<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>optimize<span style="letter-spacing:-0.25pt;"> </span>yie<span style="letter-spacing:0.1pt;">l</span>d<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>manufacturing batch<span style="letter-spacing:-0.15pt;"> </span>size,<span style="letter-spacing:-0.1pt;"> </span>minimize<span style="letter-spacing:-0.3pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and achieve<span style="letter-spacing:-0.25pt;"> </span>consistent<span style="letter-spacing:-0.35pt;"> </span>quality<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ults.<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">S</span>uch<span style="letter-spacing:-0.1pt;"> </span>ch<span style="letter-spacing:0.05pt;">a</span>nges<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>rry<span style="letter-spacing:-0.1pt;"> </span>the risk<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">t</span>hese<span style="letter-spacing:-0.15pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>objectives. Any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>cause<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.35pt;"> </span>differen<span style="letter-spacing:0.05pt;">t</span>ly<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>planned<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>clinical trials<span style="letter-spacing:-0.15pt;"> </span>conducted<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>altered<span style="letter-spacing:-0.25pt;"> </span>materials.<span style="letter-spacing:-0.3pt;"> </span>This<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>lay<span style="letter-spacing:-0.2pt;"> </span>completion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>bridging<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>in<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.1pt;"> </span>or the<span style="letter-spacing:-0.1pt;"> </span>rep<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>cos<span style="letter-spacing:-0.1pt;">t</span>s,<span style="letter-spacing:-0.1pt;"> </span>delay<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>jeopardize<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">l</span>ize<span style="letter-spacing:-0.55pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.05pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>approv<span style="letter-spacing:0.1pt;">e</span>d,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs&#8217; manufacturing</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fac</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lities</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">com</span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">speci</span><span style="letter-spacing:-0.15pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ications,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cGMP, and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA, state,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory requirements.</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Poor</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">processes</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lead</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">introdu</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adventitious</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contaminants,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inadv</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rt</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.3pt;">changes in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">properties</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ndidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">detectable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in f</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">testing.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reliably</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">produce produ</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o spe</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ifi</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ions</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pt</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ordance</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;"> t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he str</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gu</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ory</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">equirements,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not o</span><span style="letter-spacing:0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tain</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approvals</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtain</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gulatory</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">roduct</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there is no</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assurance</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">either</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMOs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to manufacture</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approved</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">specificatio</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acceptable</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory authorities,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to produce</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in s</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fficient</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quantities</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meet</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">launch</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to me</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demand. Deviations</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufactur</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">further</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remedial</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ures</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costly</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time-consuming</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to implement</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">include</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">temporary</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rman</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uspe</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sion</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">clini</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tri</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">omm</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rcial</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mporary</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:0.1pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">closure</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a facility.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remedial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measures</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imposed</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whom</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contract</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materi</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lly</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">harm</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>CMOs,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>responsible<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>manufacture<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>approved,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>ca<span style="letter-spacing:-0.05pt;">n</span>didates.<span style="letter-spacing:-0.35pt;"> </span>A<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n regu<span style="letter-spacing:-0.05pt;">l</span>a<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>enfo<span style="letter-spacing:-0.05pt;">r</span>ce<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tions<span style="letter-spacing:-0.3pt;"> </span>aga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>manufacturers<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>u<span style="letter-spacing:0.05pt;">s</span>, inclu<span style="letter-spacing:0.05pt;">d</span>ing<span style="letter-spacing:-0.35pt;"> </span>fines<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>civil<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>criminal penalties,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>imprisonment,<span style="letter-spacing:-0.45pt;"> </span>suspension<span style="letter-spacing:-0.05pt;"> </span>or restrictions<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>production,<span style="letter-spacing:-0.45pt;"> </span>injunctions,<span style="letter-spacing:-0.35pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>denial<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> or supplements to </span>approved<span style="letter-spacing:-0.4pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>holds<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>termination<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>warning<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>untitled<span style="letter-spacing:-0.25pt;"> </span>letters,<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>authority<span style="letter-spacing:-0.25pt;"> </span>communications<span style="letter-spacing:-0.55pt;"> </span>warning<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>public about<span style="letter-spacing:-0.25pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>issues<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>biologic,<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>fusal<span style="letter-spacing:-0.2pt;"> </span>to permit<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>import<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>export<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>seizure,<span style="letter-spacing:-0.35pt;"> </span>detention,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>ecall,<span style="letter-spacing:-0.15pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>restrictions, suits<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.2pt;"> </span>civ<span style="letter-spacing:0.1pt;">i</span>l<span style="letter-spacing:-0.1pt;"> </span>False<span style="letter-spacing:-0.15pt;"> </span>Claims<span style="letter-spacing:-0.3pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>(&#8220;FCA&#8221;)<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:-0.4pt;"> </span>integrity<span style="letter-spacing:-0.3pt;"> </span>agr<span style="letter-spacing:0.05pt;">e</span>ements,<span style="letter-spacing:-0.45pt;"> </span>consent<span style="letter-spacing:-0.2pt;"> </span>decrees,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>withdrawal<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>challenges<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>completion<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>bridging<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>repetition<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>incr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>se clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>costs,<span style="letter-spacing:-0.05pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.35pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>efforts,<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>goods,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> material </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>on o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>cond<span style="letter-spacing:0.05pt;">i</span>tion,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cell-based<span style="letter-spacing:-0.35pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>b<span style="letter-spacing:-0.1pt;">i</span>ologics<span style="letter-spacing:-0.4pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>availability<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reagents,<span style="letter-spacing:-0.05pt;"> </span>specialized<span style="letter-spacing:-0.35pt;"> </span>equip<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>special<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>mat<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>als,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>hich<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be available<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.3pt;"> </span>on acceptable<span style="letter-spacing:-0.35pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>or at all.<span style="letter-spacing:-0.15pt;"> </span>For some<span style="letter-spacing:-0.2pt;"> </span>of t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>age<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">s</span>, eq<span style="letter-spacing:0.05pt;">ui</span>pment<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>materials,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>or may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.1pt;"> </span>on sole source<span style="letter-spacing:-0.05pt;"> </span>vendors<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>num<span style="letter-spacing:0.05pt;">b</span>er<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>vendors,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>uld<span style="letter-spacing:-0.25pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>manufacture<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>supply<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products,<span style="letter-spacing:-0.2pt;"> </span>if appro<span style="letter-spacing:-0.05pt;">v</span>ed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing our product candidates will require many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of our product candidates. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing. For some of these reagents, equipment and materials, we rely, and we may in the future rely, on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we<span style="letter-spacing:-0.05pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sca<span style="letter-spacing:0.1pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>manufactu<span style="letter-spacing:-0.05pt;">r</span>ing<span style="letter-spacing:-0.4pt;"> </span>process, we<span style="letter-spacing:0.05pt;"> </span>ex<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>supplies<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cer<span style="letter-spacing:0.1pt;">t</span>ain<span style="letter-spacing:-0.3pt;"> </span>materials<span style="letter-spacing:-0.3pt;"> </span>and equipment<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ocess.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to such<span style="letter-spacing:-0.05pt;"> </span>materials<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>me<span style="letter-spacing:-0.05pt;">r</span>ci<span style="letter-spacing:-0.05pt;">a</span>lly<span style="letter-spacing:-0.5pt;"> </span>re<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>on<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>terms,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>if we are<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to alter<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>in a commercially<span style="letter-spacing:-0.45pt;"> </span>viable<span style="letter-spacing:-0.15pt;"> </span>manner<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>avoid<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>materials<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>suitable<span style="letter-spacing:-0.3pt;"> </span>substitu<span style="letter-spacing:0.05pt;">t</span>e,<span style="letter-spacing:-0.4pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:-0.05pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to alter<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>so<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>quipm<span style="letter-spacing:-0.05pt;">e</span>nt,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>cha<span style="letter-spacing:-0.1pt;">n</span>ge<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>lead<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment<span style="letter-spacing:-0.45pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>commerci<span style="letter-spacing:-0.05pt;">a</span>lization<span style="letter-spacing:-0.6pt;"> </span>plans.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.3pt;"> </span>occurs<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.1pt;"> </span>a product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>is already<span style="letter-spacing:-0.2pt;"> </span>in clinical<span style="letter-spacing:-0.2pt;"> </span>testing,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>change<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to perform<span style="letter-spacing:-0.35pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>ex<span style="letter-spacing:-0.05pt;"> </span>vivo<span style="letter-spacing:-0.1pt;"> </span>comparability<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>to collect<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>undertaking<span style="letter-spacing:-0.45pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>van<span style="letter-spacing:0.05pt;">c</span>ed<span style="letter-spacing:-0.35pt;"> </span>clini<span style="letter-spacing:0.05pt;">ca</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We wi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">merc</span><span style="letter-spacing:-0.05pt;">ia</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lize</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidat</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our trials</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">ce</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ssf</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>programs<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>each<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>early<span style="letter-spacing:-0.15pt;"> </span>stage.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>demonstra<span style="letter-spacing:-0.1pt;">t</span>e<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates&#8217;<span style="letter-spacing:-0.4pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>ef<span style="letter-spacing:-0.05pt;">f</span>ic<span style="letter-spacing:-0.1pt;">a</span>cy<span style="letter-spacing:-0.35pt;"> </span>in humans<span style="letter-spacing:-0.25pt;"> </span>through ext<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.3pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>test<span style="letter-spacing:-0.05pt;">i</span>ng.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>experience<span style="letter-spacing:-0.35pt;"> </span>nu<span style="letter-spacing:-0.1pt;">m</span>erous<span style="letter-spacing:-0.1pt;"> </span>unforeseen<span style="letter-spacing:-0.45pt;"> </span>events<span style="letter-spacing:-0.3pt;"> </span>during,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a <span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">su</span><span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">f</span>, <span style="letter-spacing:0.05pt;">th</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.2pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prevent commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>includi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">fety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ffic</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">cy</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ults</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in various</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">human</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reported</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in scientific</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">medic</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">literature</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">indicat</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of res</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">lts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we obtain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">fter</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ewing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">test</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">res</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">lts,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">b</span><span style="color:#000000;">andon</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">projects</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">previously</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">believed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">promising&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulators</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sus</span><span style="letter-spacing:0.1pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ina</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">f </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he p</span><span style="letter-spacing:-0.15pt;color:#000000;">a</span><span style="color:#000000;">rticipating</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">subjects</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patients</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">exposed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to unacceptable</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">change</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">tech</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">ology</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">target</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ndicatio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">precluding</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">gulatory approval</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">limited</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">desired</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">include</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">undesirab</span><span style="letter-spacing:0.1pt;color:#000000;">l</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">side</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effects</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">chara</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">teristi</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that precl</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">de</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anufacturers</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the necessary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">standa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ds</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">production</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to supply</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">quantity&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">authorities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">find</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">design</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">does</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">meet</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirements.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>sting<span style="letter-spacing:-0.25pt;"> </span>is v<span style="letter-spacing:-0.05pt;">e</span>ry<span style="letter-spacing:-0.15pt;"> </span>expensive,<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>take<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>years<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>outcome<span style="letter-spacing:-0.35pt;"> </span>is uncertain.<span style="letter-spacing:-0.3pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>ke<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>much<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>12<span style="letter-spacing:-0.05pt;"> </span>months<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>learn<span style="letter-spacing:-0.25pt;"> </span>the results<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>om<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.2pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>Anktiva,<span style="letter-spacing:-0.25pt;"> a</span>ldoxorubicin,<span style="letter-spacing:-0.45pt;"> </span>Ad<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>yeast<span style="letter-spacing:-0.25pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>therapy.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>collected<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:0.05pt;">r</span>om<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.05pt;"> </span>sufficient<span style="letter-spacing:-0.3pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>F<span style="letter-spacing:0.05pt;">D</span>A<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>bladder<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ot<span style="letter-spacing:-0.05pt;">h</span>er<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>rapi<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>including o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>hAd5<span style="letter-spacing:0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>vaccine<span style="letter-spacing:-0.2pt;"> </span>candidate.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>cli<span style="letter-spacing:-0.05pt;">n</span>ical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>und<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>completed<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>ch<span style="letter-spacing:-0.05pt;">e</span>dule<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the FDA may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>approve<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>sale.<span style="letter-spacing:-0.1pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ad<span style="letter-spacing:-0.05pt;">e</span>quately<span style="letter-spacing:-0.45pt;"> </span>demonstrate<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>saf<span style="letter-spacing:0.05pt;">e</span>ty<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>development,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot receive<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>us from<span style="letter-spacing:-0.15pt;"> </span>generating revenues<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>achieving profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:-0.15pt;"> </span>if one of our<span style="letter-spacing:0.05pt;"> leading </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>A<span style="letter-spacing:0.05pt;">n</span>ktiva,<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>and commercialized,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>profitable.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>leading<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>tes,<span style="letter-spacing:-0.35pt;"> </span>Anktiva,<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>initi<span style="letter-spacing:-0.1pt;">a</span>lly<span style="letter-spacing:-0.35pt;"> </span>targeting<span style="letter-spacing:-0.25pt;"> </span>a small<span style="letter-spacing:-0.25pt;"> </span>population<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>tients<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>suffer<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>bladder<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ance<span style="letter-spacing:-0.05pt;">r</span>,<span style="letter-spacing:-0.2pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>and me<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>sta<span style="letter-spacing:-0.05pt;">t</span>ic<span style="letter-spacing:-0.35pt;"> </span>pan<span style="letter-spacing:-0.05pt;">c</span>re<span style="letter-spacing:-0.05pt;">a</span>tic<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;">c</span>er,<span style="letter-spacing:-0.25pt;"> </span>when us<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>comb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.05pt;">a</span>py.<span style="letter-spacing:-0.1pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA approves<span style="letter-spacing:-0.25pt;"> </span>this<span style="letter-spacing:-0.15pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>indication<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ven<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.3pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>share<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>it,<span style="letter-spacing:-0.05pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>target<span style="letter-spacing:-0.2pt;"> </span>population<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be small,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.25pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ofitability<span style="letter-spacing:-0.3pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>ning<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>indications.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>often<span style="letter-spacing:-0.25pt;"> </span>approves<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>therapies initially<span style="letter-spacing:-0.25pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>in patients<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>relapsed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>refractory<span style="letter-spacing:-0.3pt;"> </span>metastatic<span style="letter-spacing:-0.3pt;"> </span>disease,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mit<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>population.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:-0.45pt;"> </span>in connection<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>merger<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>assum<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>obligation<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>former<span style="letter-spacing:-0.2pt;"> </span>stockholde<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Al<span style="letter-spacing:-0.05pt;">t</span>or BioScience<span style="letter-spacing:-0.4pt;"> </span>Corporation<span style="letter-spacing:-0.45pt;"> </span>(succeeded<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>B<span style="letter-spacing:-0.05pt;">i</span>oScience<span style="letter-spacing:-0.4pt;"> </span>LLC)<span style="letter-spacing:-0.2pt;">&#160;</span>(&#8220;Altor&#8221;)<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>acquisit<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor.<span style="letter-spacing:-0.15pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.25pt;"> </span>payable<span style="letter-spacing:-0.3pt;"> </span>u<span style="letter-spacing:0.05pt;">p</span>on the<span style="letter-spacing:-0.1pt;"> </span>attainment<span style="letter-spacing:-0.35pt;"> </span>of certa<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>milestones<span style="letter-spacing:-0.1pt;"> </span>related<span style="letter-spacing:-0.3pt;"> </span>to Anktiva.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>former<span style="letter-spacing:-0.3pt;"> </span>Altor<span style="letter-spacing:-0.25pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>choose<span style="letter-spacing:-0.2pt;"> </span>to receive<span style="letter-spacing:-0.25pt;"> </span>these payments<span style="letter-spacing:-0.3pt;"> </span>either<span style="letter-spacing:-0.15pt;"> </span>in cas<span style="letter-spacing:0.05pt;">h</span>,<span style="letter-spacing:-0.1pt;"> </span>in an<span style="letter-spacing:-0.05pt;"> </span>equivalent<span style="letter-spacing:-0.5pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in a combination<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>at t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>payments<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>due, except<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>Dr.<span style="letter-spacing:-0.05pt;"> </span>S<span style="letter-spacing:0.05pt;">o</span>on-Shiong<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>party,<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor,<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>irrevocably<span style="letter-spacing:-0.45pt;"> </span>elected<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>pay<span style="letter-spacing:0.05pt;">m</span>ents<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>pe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.1pt;"> </span>of th<span style="letter-spacing:0.05pt;">e</span>ir CVRs<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>form<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:-0.3pt;"> </span>stock.<span style="letter-spacing:-0.15pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>CVR<span style="letter-spacing:-0.05pt;"> </span>payments<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>Dr.<span style="letter-spacing:0.05pt;">&#160;</span>Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.1pt;"> </span>aggregate<span style="letter-spacing:-0.35pt;"> </span>to approximately<span style="letter-spacing:-0.5pt;"> </span>$2<span style="letter-spacing:-0.05pt;">7</span><span style="letter-spacing:0.05pt;">9</span><span style="letter-spacing:-0.05pt;">.</span>5&#160;million.<span style="letter-spacing:-0.25pt;"> We</span><span style="letter-spacing:-0.3pt;"> </span>may,<span style="letter-spacing:-0.25pt;"> </span>however,<span style="letter-spacing:-0.3pt;"> </span>still<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>$164.2&#160;million<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>lating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regulatory milestone<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to $164.2&#160;million<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs relating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>milestone<span style="letter-spacing:-0.3pt;"> </span>should<span style="letter-spacing:-0.3pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>cho<span style="letter-spacing:0.05pt;">o</span>se<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>CVRs<span style="letter-spacing:0.05pt;"> </span>paid<span style="letter-spacing:-0.15pt;"> </span>in <span style="letter-spacing:-0.05pt;">c</span>ash instead<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>common stock.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to seek<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>sources<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>capital,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to a<span style="letter-spacing:0.05pt;">c</span>hieve<span style="letter-spacing:-0.25pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>or p<span style="letter-spacing:0.05pt;">o</span>sitive<span style="letter-spacing:-0.15pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span>flow.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>collaborate<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>governmen<span style="letter-spacing:0.05pt;">t</span>al,<span style="letter-spacing:-0.55pt;"> </span>academic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>tners,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>affili<span style="letter-spacing:-0.05pt;">a</span>tes,<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>improve<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>Anktiva, hAd5<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>in combinat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>imp<span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>other prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xpose<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>risks,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>we may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>realize<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>benefits<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>collaborations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborations</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outside</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">labo</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atories,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mplete</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">how</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conducted</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or reported</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">methods</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">used</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to manufacture</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anktiva</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidate,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whi</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">basis</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusions,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">projections</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cisions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to our current</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incorrect</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liable,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a negative</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">studies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imputed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proposed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cations,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if su</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imputation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">improper. Additionally,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third-par</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">naly</span><span style="letter-spacing:-0.05pt;">z</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ach</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">make</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predictions</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decisions</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompl</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ina</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cur</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unreliable.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further,<span style="letter-spacing:-0.35pt;"> </span>collaborations<span style="letter-spacing:-0.5pt;"> </span>involving<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>risks, w<span style="letter-spacing:0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>include<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>followin<span style="letter-spacing:0.05pt;">g</span>:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">related</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">affiliated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">companies,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">entitled</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to receive</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">exclusive</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">involving</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">signif</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">cant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">discretion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in deter</span><span style="letter-spacing:-0.1pt;color:#000000;">m</span><span style="color:#000000;">ining</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">resources</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">they</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">apply</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to a collaboration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pursue</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">devel</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">pment</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">elect</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ontinue</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">renew development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">commercialization</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">sed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ial</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">results,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">focus</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">due</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the acquisition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">prod</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">cts,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">availability</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">fundi</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">g</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">external</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">factors,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a business combination</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">resourc</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s or cr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">co</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">pe</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">pr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">orit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">es&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trials,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">provide</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">insufficient</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">nding</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clini</span><span style="letter-spacing:-0.15pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trial,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">stop</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trial,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">abandon</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">ca</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">didate, repeat</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trials</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">require</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">formulation</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">independe</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ly</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">develop,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">compete</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">rectly</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ind</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">rectly</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborator</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">distribution</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">one</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">commit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">resources</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to their</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ma</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">keting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">properly</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">intain,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">defend</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">enfo</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ce</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">operty</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">prope</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or proprietary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in a way</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">gives</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">se</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">tu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ea</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">en</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">tig</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ould</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">jeop</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rdi</span><span style="letter-spacing:-0.05pt;color:#000000;">z</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">inv</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">lid</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our in</span><span style="letter-spacing:-0.15pt;color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ual property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">mation</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expose</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">arise</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">between</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">a collaborator</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cause</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">termination</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">search,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">commerci</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">lization</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">costly</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">litigation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">arbitra</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">diverts</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">resources</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">(see</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">&#8220;</span><span style="color:#000000;">&#8212;</span><span style="font-style:italic;color:#000000;">If</span><span style="font-style:italic;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">conflicts arise</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">between</span><span style="font-style:italic;letter-spacing:-0.3pt;color:#000000;"> us</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">and</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> our</span><span style="font-style:italic;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">collaborators</span><span style="font-style:italic;letter-spacing:-0.55pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">or</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">strat</span><span style="font-style:italic;letter-spacing:0.1pt;color:#000000;">e</span><span style="font-style:italic;color:#000000;">gic</span><span style="font-style:italic;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">partners, these</span><span style="font-style:italic;letter-spacing:-0.15pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">parties</span><span style="font-style:italic;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">may</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">act</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">in</span><span style="font-style:italic;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">a</span><span style="font-style:italic;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">manner</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">adverse</span><span style="font-style:italic;letter-spacing:-0.35pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">to</span><span style="font-style:italic;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">us</span><span style="font-style:italic;letter-spacing:0.1pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">and could</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">limit</span><span style="font-style:italic;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">our</span><span style="font-style:italic;letter-spacing:0.05pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">ab</span><span style="font-style:italic;letter-spacing:-0.1pt;color:#000000;">i</span><span style="font-style:italic;color:#000000;">li</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">t</span><span style="font-style:italic;color:#000000;">y</span><span style="font-style:italic;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">t</span><span style="font-style:italic;color:#000000;">o </span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">i</span><span style="font-style:italic;letter-spacing:0.05pt;color:#000000;">m</span><span style="font-style:italic;color:#000000;">p</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">l</span><span style="font-style:italic;color:#000000;">ement</span><span style="font-style:italic;letter-spacing:-0.3pt;color:#000000;"> </span><span style="font-style:italic;color:#000000;">our strat</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">e</span><span style="font-style:italic;color:#000000;">gie</span><span style="font-style:italic;letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">.</span><span style="letter-spacing:-0.05pt;color:#000000;">&#8221;</span><span style="color:#000000;">)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborations</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">terminated</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">if</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ter</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ina</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ed,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">su</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ddit</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">onal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to pu</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">sue further</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">devel</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">pment</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or commercialization</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">app</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">icable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">f an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ag</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">eement</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">collaborator</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">terminates,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">intel</span><span style="letter-spacing:0.05pt;color:#000000;">l</span><span style="color:#000000;">ectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">licensed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.1pt;color:#000000;">o</span><span style="color:#000000;">llaborator</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">restricted</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">terminate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">entirely,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">whi</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">delay</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">continued</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">velopment</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">dates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">utilizing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">collabo</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ator&#8217;s technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellec</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">requi</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to stop</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">completely&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ollaborators</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">co-own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intelle</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">tual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">results</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">col</span><span style="letter-spacing:0.1pt;color:#000000;">l</span><span style="color:#000000;">aborating with</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">em,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">exclusive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">right</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to comm</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">rc</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ze</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">such int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ll</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">proper</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result,<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>enter<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>collaboration<span style="letter-spacing:-0.35pt;"> </span>agreements<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>str<span style="letter-spacing:0.05pt;">a</span>tegic<span style="letter-spacing:-0.25pt;"> </span>partnerships<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o re<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span>ze<span style="letter-spacing:-0.25pt;"> </span>the benefit<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>transactions<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>un<span style="letter-spacing:0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">cc</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>fully<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>m<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>company<span style="letter-spacing:-0.35pt;"> </span>culture,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>our timelines<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>versely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usiness. Add<span style="letter-spacing:0.05pt;">i</span>tionally,<span style="letter-spacing:-0.3pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.25pt;"> </span>in connection<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>coll<span style="letter-spacing:0.05pt;">a</span>boration<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>may li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">e</span>nter<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>w<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>co<span style="letter-spacing:-0.05pt;">l</span>labor<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.45pt;"> </span>agr<span style="letter-spacing:-0.15pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.4pt;"> </span>or stra<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>g<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.25pt;"> </span>partnerships<span style="letter-spacing:-0.5pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xperi<span style="letter-spacing:-0.05pt;">e</span>nce<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span>sues with existing<span style="letter-spacing:-0.35pt;"> </span>collaborations. We<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>that,<span style="letter-spacing:-0.15pt;"> </span>following<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>transa<span style="letter-spacing:-0.1pt;">c</span>tion<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>license,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>achieve<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>specific<span style="letter-spacing:-0.3pt;"> </span>net<span style="letter-spacing:-0.1pt;"> </span>inc<span style="letter-spacing:-0.05pt;">o</span>me<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">j</span>us<span style="letter-spacing:-0.05pt;">t</span>ifi<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>such transaction.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>delays<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>entering<span style="letter-spacing:-0.3pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>collaborations<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>strat<span style="letter-spacing:0.05pt;">e</span>gic<span style="letter-spacing:-0.25pt;"> </span>partnership<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>lated<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>the development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in certain<span style="letter-spacing:-0.2pt;"> </span>geograph<span style="letter-spacing:-0.1pt;">i</span>es<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>indications,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>prospects, financial<span style="letter-spacing:-0.25pt;"> </span>condition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">efforts</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to develop,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manufacture</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#8209;</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">19</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">therapeutics</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">personnel</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">who</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">require training,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may cause</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">some</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">employees</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">reallocate</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">me</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">from other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">duties</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in turn</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cause</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delays</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">supply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product candidates</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">trials.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.15pt;"> </span>planning<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19-related<span style="letter-spacing:-0.75pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>repurposed<span style="letter-spacing:-0.1pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>personnel<span style="letter-spacing:-0.35pt;"> </span>overseeing<span style="letter-spacing:-0.45pt;"> </span>q<span style="letter-spacing:0.05pt;">u</span>ality, clinical<span style="letter-spacing:-0.25pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>oncology<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 <span style="letter-spacing:0.05pt;">e</span>fforts and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>hire<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>aff<span style="letter-spacing:-0.15pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>efforts,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>expenses.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>focused<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">n</span>cology<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>infectious<span style="letter-spacing:-0.3pt;"> </span>disease drug<span style="letter-spacing:0.05pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or, if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>shifted<span style="letter-spacing:-0.3pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>COV<span style="letter-spacing:-0.1pt;">I</span>D<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>adequately<span style="letter-spacing:-0.35pt;"> </span>covered<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>em<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>oyees,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> if </span>new personnel<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to hire<span style="letter-spacing:-0.1pt;"> </span>to support<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>effor<span style="letter-spacing:-0.2pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>extensive<span style="letter-spacing:-0.3pt;"> </span>training,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.25pt;"> </span>oncology<span style="letter-spacing:-0.3pt;"> </span>ope<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tions<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>impacted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>conflicts<span style="letter-spacing:-0.25pt;"> </span>arise<span style="letter-spacing:-0.05pt;"> </span>betwe<span style="letter-spacing:-0.1pt;">e</span>n<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strat<span style="letter-spacing:-0.1pt;">e</span>gic<span style="letter-spacing:-0.35pt;"> </span>partners, these<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>act<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>manner<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.35pt;"> </span>to us and<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.1pt;"> </span>our ability to <span style="letter-spacing:-0.05pt;">i</span>mpl<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.35pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r s<span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>gi<span style="letter-spacing:-0.05pt;">e</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;">f</span>licts<span style="letter-spacing:-0.2pt;"> </span>arise<span style="letter-spacing:-0.1pt;"> </span>between<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span>or academic<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>tners<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>act<span style="letter-spacing:-0.1pt;"> </span>in a <span style="letter-spacing:-0.05pt;">m</span>anner<span style="letter-spacing:-0.2pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>to us<span style="letter-spacing:0.05pt;"> </span>and could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to implement<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>strategies.<span style="letter-spacing:-0.35pt;"> </span>Some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> e</span>xist<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>ad<span style="letter-spacing:-0.05pt;">e</span>mic<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>oll<span style="letter-spacing:-0.05pt;">a</span>bora<span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:-0.05pt;">n</span>ducting<span style="letter-spacing:-0.4pt;"> </span>multiple<span style="letter-spacing:-0.25pt;"> </span>product development<span style="letter-spacing:-0.4pt;"> </span>efforts.<span style="letter-spacing:-0.3pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>collaborato<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strategic<span style="letter-spacing:-0.3pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>develop, either alone or with others,<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oducts<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>comp<span style="letter-spacing:-0.05pt;">e</span>titive<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>collaborations.<span style="letter-spacing:-0.55pt;"> </span>Competing<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>either<span style="letter-spacing:-0.15pt;"> </span>dev<span style="letter-spacing:-0.1pt;">e</span>loped<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to which<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>rights,<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>withdrawal<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborator&#8217;s<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>partner&#8217;s<span style="letter-spacing:-0.35pt;"> </span>sup<span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>t for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>future.<span style="letter-spacing:-0.2pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>s<span style="letter-spacing:-0.15pt;">t</span>rategic<span style="letter-spacing:-0.3pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>could develop<span style="letter-spacing:-0.25pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>prec<span style="letter-spacing:-0.05pt;">l</span>ude<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>entering<span style="letter-spacing:-0.3pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>collaborations<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>competitors,<span style="letter-spacing:-0.4pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>timely<span style="letter-spacing:-0.2pt;"> </span>regula<span style="letter-spacing:0.05pt;">t</span>ory<span style="letter-spacing:-0.25pt;"> </span>approvals,<span style="letter-spacing:-0.3pt;"> </span>terminate the<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>gree<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>prem<span style="letter-spacing:-0.05pt;">a</span>tur<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.35pt;"> </span>or f<span style="letter-spacing:-0.05pt;">a</span>il<span style="letter-spacing:-0.15pt;"> </span>to devote<span style="letter-spacing:-0.2pt;"> </span>sufficient<span style="letter-spacing:-0.3pt;"> </span>resou<span style="letter-spacing:0.05pt;">r</span>ces<span style="letter-spacing:-0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mmercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.1pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>For example,<span style="letter-spacing:-0.3pt;"> </span>in May<span style="letter-spacing:-0.05pt;"> </span>2019,<span style="letter-spacing:-0.05pt;"> </span>Sorrento<span style="letter-spacing:-0.3pt;"> </span>Therapeutics,<span style="letter-spacing:-0.6pt;"> </span>Inc.<span style="letter-spacing:-0.1pt;"> </span>(&#8220;Sor<span style="letter-spacing:-0.05pt;">r</span>ento&#8221;)<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>jointly<span style="letter-spacing:-0.3pt;"> </span>established<span style="letter-spacing:-0.35pt;"> </span>a new<span style="letter-spacing:-0.05pt;"> </span>entity<span style="letter-spacing:-0.25pt;"> </span>called<span style="letter-spacing:-0.15pt;"> </span>Immunothe<span style="letter-spacing:0.05pt;">r</span>apy<span style="letter-spacing:-0.6pt;"> </span>NANTibody, LLC<span style="letter-spacing:-0.2pt;"> </span>(&#8220;NANTibody&#8221;)<span style="letter-spacing:-0.65pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a stand-alone<span style="letter-spacing:-0.4pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>company,<span style="letter-spacing:-0.35pt;"> </span>commenced<span style="letter-spacing:-0.45pt;"> </span>li<span style="letter-spacing:-0.05pt;">t</span>igation<span style="letter-spacing:-0.35pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>us and<span style="letter-spacing:-0.1pt;"> </span>certa<span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>officers<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>directors,<span style="letter-spacing:-0.15pt;"> </span>alleging<span style="letter-spacing:-0.35pt;"> </span>that <span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>improperly<span style="letter-spacing:-0.35pt;"> </span>caused<span style="letter-spacing:-0.2pt;"> </span>NANTibody<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>acquire<span style="letter-spacing:-0.25pt;"> </span>Ig<span style="letter-spacing:0.05pt;">D</span>raSol,<span style="letter-spacing:-0.25pt;"> </span>Inc.<span style="letter-spacing:-0.1pt;"> </span>(&#8220;Ig<span style="letter-spacing:0.05pt;">D</span>raSol&#8221;)<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in January&#160;2020<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">A</span>pril&#160;2020,<span style="letter-spacing:0.05pt;"> </span>Sorrento<span style="letter-spacing:-0.25pt;"> </span>sent<span style="letter-spacing:-0.1pt;"> </span>letters<span style="letter-spacing:-0.25pt;"> </span>purporting<span style="letter-spacing:-0.4pt;"> </span>to terminate<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense<span style="letter-spacing:-0.3pt;"> </span>agreement<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>excl<span style="letter-spacing:0.05pt;">u</span>sive<span style="letter-spacing:-0.25pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>agreement<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>NANTibody.<span style="letter-spacing:-0.05pt;"> </span>Additionally,<span style="letter-spacing:-0.5pt;"> </span>in July&#160;2020,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>ec<span style="letter-spacing:-0.05pt;">e</span>iv<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>a Request<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Arbitration<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>International<span style="letter-spacing:-0.4pt;"> </span>Chamber<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Commerce,<span style="letter-spacing:-0.35pt;"> </span>International<span style="letter-spacing:-0.35pt;"> </span>Court<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Arbitration,<span style="letter-spacing:-0.35pt;"> </span>served<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Shenzhen<span style="letter-spacing:-0.3pt;"> </span>B<span style="letter-spacing:-0.05pt;">e</span>ike<span style="letter-spacing:-0.2pt;"> </span>Biotechnology Co.<span style="letter-spacing:-0.1pt;"> </span>Ltd.<span style="letter-spacing:-0.1pt;"> </span>(&#8220;Beike&#8221;)<span style="letter-spacing:-0.35pt;"> </span>asserting<span style="letter-spacing:-0.25pt;"> </span>breach<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontract<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>subsidiary<span style="letter-spacing:-0.3pt;"> </span>Alt<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>&#8217;s<span style="letter-spacing:-0.2pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agreement<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>them.<span style="letter-spacing:-0.25pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>regarding<span style="letter-spacing:-0.4pt;"> </span>these dis<span style="letter-spacing:0.05pt;">p</span>u<span style="letter-spacing:-0.05pt;">t</span>es,<span style="letter-spacing:-0.15pt;"> </span>see<span style="letter-spacing:-0.1pt;"> </span><a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="letter-spacing:-0.1pt;text-decoration:underline;">Note&#160;8</span></a><span style="letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;letter-spacing:-0.1pt;">Commitments and Contingencie</span><span style="font-style:italic;">s&#8212;Contingencies</span><span style="letter-spacing:-0.1pt;">, of the </span>&#8220;Notes to Unaudited Condensed Combined Consolidated Financial Statements&#8221; that appear in Item&#160;1. &#8220;Financial Statements&#8221; of this Quarterly Report on Form&#160;10&#8209;Q.<span style="letter-spacing:-0.5pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>developments<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>efforts.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to use<span style="letter-spacing:0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.4pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>credits<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>offset<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">t</span>axable<span style="letter-spacing:-0.2pt;"> </span>income<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>rtain<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>im<span style="letter-spacing:-0.05pt;">i</span>tat<span style="letter-spacing:-0.05pt;">i</span>ons</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>general,<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>Sections<span style="letter-spacing:-0.35pt;">&#160;</span>382<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>383<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> Internal Revenue </span>Code,<span style="letter-spacing:-0.25pt;"> or Code, </span>a<span style="letter-spacing:-0.1pt;"> </span>corporation<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>undergoes<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>&#8220;ow<span style="letter-spacing:-0.1pt;">n</span>ership<span style="letter-spacing:-0.15pt;"> </span>change&#8221;<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to limitatio<span style="letter-spacing:-0.05pt;">n</span>s<span style="letter-spacing:-0.3pt;"> </span>on its<span style="letter-spacing:-0.05pt;"> a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">utilize its</span><span style="letter-spacing:0.05pt;"> </span>pre-change<span style="letter-spacing:-0.4pt;"> </span>net<span style="letter-spacing:-0.1pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>credits,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>NOLs<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span>dits,<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>offset<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>xab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.25pt;"> </span>inco<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>xes.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>pu<span style="letter-spacing:-0.05pt;">r</span>poses,<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>change generally<span style="letter-spacing:-0.35pt;"> </span>occurs<span style="letter-spacing:-0.3pt;"> </span>where<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>aggregate<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>ockholders<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>groups<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>stockho<span style="letter-spacing:-0.05pt;">l</span>ders<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>owns at least&#160;5%<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a corporation&#8217;s stock<span style="letter-spacing:-0.15pt;"> </span>increases<span style="letter-spacing:-0.3pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>50&#160;percentage<span style="letter-spacing:-0.35pt;"> </span>points<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">o</span>west<span style="letter-spacing:-0.1pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>percentage<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>spe<span style="letter-spacing:-0.05pt;">c</span>ifi<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>sting<span style="letter-spacing:-0.35pt;"> </span>period.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not conducted<span style="letter-spacing:-0.35pt;"> </span>a complete<span style="letter-spacing:-0.3pt;"> </span>study<span style="letter-spacing:-0.25pt;"> </span>to assess<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>occurred<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>multiple<span style="letter-spacing:-0.3pt;"> </span>chan<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>since<span style="letter-spacing:-0.25pt;"> </span>inception d<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>complexity<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>study.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xperienced<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>of control,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>defined<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Section&#160;382,<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:0.05pt;"> </span>since<span style="letter-spacing:-0.2pt;"> </span>inception<span style="letter-spacing:-0.3pt;"> </span>(inc<span style="letter-spacing:-0.05pt;">l</span>udi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>merger),<span style="letter-spacing:-0.35pt;"> </span>utilization<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>loss carryforwards<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>credit carryforwards<span style="letter-spacing:-0.55pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nnual<span style="letter-spacing:-0.2pt;"> </span>limitation<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>Section&#160;382. Any<span style="letter-spacing:0.05pt;"> </span>limitation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>expiration<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a portion<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>loss carryforwards<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>credit<span style="letter-spacing:-0.25pt;"> </span>carryforwards<span style="letter-spacing:-0.45pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>utilization.<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>credits<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>impaired<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>state law.<span style="letter-spacing:-0.15pt;"> </span>Acc<span style="letter-spacing:0.05pt;">o</span>rdingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to utilize<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.35pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>NOLs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>credits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raise</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ubstantial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ad</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nal</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funding</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to finance</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xperience</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">further</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chan</span><span style="letter-spacing:-0.05pt;">g</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">futur</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">some</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outside</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contr</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">L</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our abi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pre-change</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOLs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credits</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to offset</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potentially result</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">earn</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legislation</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commonly</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">referred</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax Cuts</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jobs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TCJA,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modified</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Co</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">virus Aid,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Relief,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onomic</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CARES</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Act,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOLs generated</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">periods</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beginning</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2017,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deduct</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">beginning</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to 80%</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">taxable</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">year,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xable</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">income</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hout</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regard</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOL</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deduction</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lf.</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TCJA </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">llo</span><span style="letter-spacing:0.05pt;">w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s p</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st-2017</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unused</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOLs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">car</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ied</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forward</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indefi</span><span style="letter-spacing:0.15pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">itely.</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rul</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">apply</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tax</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>law<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adv<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.25pt;"> </span>affe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:0.05pt;">u</span>sin<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.1pt;"> </span>and financial<span style="letter-spacing:-0.35pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>dition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>rules<span style="letter-spacing:-0.15pt;"> </span>dealing<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>U<span style="letter-spacing:-0.1pt;">.</span>S.<span style="letter-spacing:0.05pt;"> </span>federal,<span style="letter-spacing:-0.2pt;"> </span>sta<span style="letter-spacing:-0.1pt;">t</span>e,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>local<span style="letter-spacing:-0.15pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>taxation<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>constantly<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>review<span style="letter-spacing:-0.25pt;"> </span>by persons<span style="letter-spacing:-0.05pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:0.05pt;">e</span>gislative<span style="letter-spacing:-0.3pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>by the<span style="letter-spacing:-0.15pt;"> </span>IRS<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>Treasury<span style="letter-spacing:-0.25pt;"> </span>Department.<span style="letter-spacing:-0.4pt;"> </span>Changes<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>(which<span style="letter-spacing:-0.3pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>ret<span style="letter-spacing:-0.05pt;">r</span>oac<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.4pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">a</span>tion)<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our stockholders.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>recent<span style="letter-spacing:-0.15pt;"> </span>years,<span style="letter-spacing:-0.15pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>to continue<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>occur<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>future.<span style="letter-spacing:-0.2pt;"> </span>For <span style="letter-spacing:-0.05pt;">e</span>xamp<span style="letter-spacing:-0.05pt;">l</span>e,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he TCJA<span style="letter-spacing:-0.35pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>enacted<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>2017<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>reformed<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Code.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>TCJA,<span style="letter-spacing:0.05pt;"> </span>among<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>contained<span style="letter-spacing:-0.4pt;"> </span>signifi<span style="letter-spacing:-0.05pt;">c</span>ant<span style="letter-spacing:-0.4pt;"> </span>ch<span style="letter-spacing:-0.05pt;">a</span>nges<span style="letter-spacing:-0.05pt;"> t</span>o corporate<span style="letter-spacing:-0.4pt;"> </span>taxation,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>reduction<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>ate<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>x r<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>top<span style="letter-spacing:-0.1pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">i</span>nal<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>35%<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>flat<span style="letter-spacing:-0.05pt;"> </span>rate<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>21%,<span style="letter-spacing:0.05pt;"> </span>a limitation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>deduction for<span style="letter-spacing:0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>expense<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>30%<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>adjus<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>earnings<span style="letter-spacing:-0.35pt;"> </span>(except<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>small<span style="letter-spacing:-0.15pt;"> </span>businesses),<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>limitation<span style="letter-spacing:-0.3pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>deduction<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> n</span>et<span style="letter-spacing:-0.1pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>losses<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>80%<span style="letter-spacing:0.05pt;"> </span>of current<span style="letter-spacing:-0.2pt;"> </span>year<span style="letter-spacing:-0.2pt;"> </span>taxable<span style="letter-spacing:-0.2pt;"> </span>income<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>eli<span style="letter-spacing:0.1pt;">m</span>ination<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>net<span style="letter-spacing:-0.1pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>carrybacks<span style="letter-spacing:-0.4pt;"> </span>(though<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>net<span style="letter-spacing:-0.15pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>los<span style="letter-spacing:0.05pt;">s</span>es<span style="letter-spacing:-0.05pt;"> </span>generated<span style="letter-spacing:-0.35pt;"> </span>in <span style="letter-spacing:-0.05pt;">t</span>axable<span style="letter-spacing:-0.25pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>beginning after<span style="letter-spacing:-0.1pt;"> </span>December&#160;31,&#160;2017<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>carried<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.15pt;">w</span>ard<span style="letter-spacing:-0.15pt;"> </span>indefinitely),<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>modification<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>repeal<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>deductions<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">r</span>edits.<span style="letter-spacing:-0.3pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>on March&#160;2<span style="letter-spacing:0.05pt;">7</span>,&#160;2020,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Coronavirus<span style="letter-spacing:-0.5pt;"> </span>Aid,<span style="letter-spacing:-0.05pt;"> </span>Relief,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Economic<span style="letter-spacing:-0.3pt;"> </span>Security<span style="letter-spacing:-0.35pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>was enacted,<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ich,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>suspends<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>80%<span style="letter-spacing:-0.05pt;">&#160;l</span>imitation<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the deduction<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>losses<span style="letter-spacing:0.05pt;"> </span>in taxab<span style="letter-spacing:-0.1pt;">l</span>e<span style="letter-spacing:-0.25pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>beginning<span style="letter-spacing:-0.3pt;"> </span>before<span style="letter-spacing:-0.25pt;"> </span>January&#160;1,&#160;2021,<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>rmits<span style="letter-spacing:-0.2pt;"> </span>a 5-year<span style="letter-spacing:-0.2pt;"> </span>carryback<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.2pt;"> </span>losses<span style="letter-spacing:-0.05pt;"> </span>arising<span style="letter-spacing:-0.3pt;"> </span>in taxable<span style="letter-spacing:-0.25pt;"> </span>years<span style="letter-spacing:-0.25pt;"> </span>beginning<span style="letter-spacing:-0.3pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>December&#160;31,&#160;2017<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>January&#160;1,&#160;2021,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>gen<span style="letter-spacing:-0.1pt;">e</span>rally<span style="letter-spacing:-0.3pt;"> </span>caps<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>limitation<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>deduction<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>expense at<span style="letter-spacing:-0.1pt;"> </span>50%<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>adjusted<span style="letter-spacing:-0.25pt;"> </span>taxable<span style="letter-spacing:-0.25pt;"> </span>income<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>xable<span style="letter-spacing:-0.25pt;"> </span>years<span style="letter-spacing:-0.25pt;"> </span>beginning<span style="letter-spacing:-0.3pt;"> </span>in 2019<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>2020.<span style="letter-spacing:0.05pt;"> </span>It cannot<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>predicted<span style="letter-spacing:-0.3pt;"> </span>whether,<span style="letter-spacing:-0.25pt;"> </span>when,<span style="letter-spacing:0.05pt;"> </span>in what<span style="letter-spacing:-0.2pt;"> </span>form,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>what effective<span style="letter-spacing:-0.25pt;"> </span>dates,<span style="letter-spacing:-0.15pt;"> </span>new t<span style="letter-spacing:-0.15pt;">a</span>x laws<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>enacted,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulat<span style="letter-spacing:0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>rulings<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>enacted,<span style="letter-spacing:-0.25pt;"> </span>promu<span style="letter-spacing:-0.1pt;">l</span>gated<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>der<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r new tax<span style="letter-spacing:-0.1pt;"> </span>law<span style="letter-spacing:0.05pt;">s</span>, which could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>inc<span style="letter-spacing:-0.05pt;">r</span>ease<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> our</span><span style="letter-spacing:-0.55pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>x<span style="letter-spacing:-0.1pt;"> </span>liability<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>nner<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>whi<span style="letter-spacing:0.05pt;">c</span>h we<span style="letter-spacing:-0.3pt;"> </span>operate<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">i</span>nimize<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mitigate<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ny adverse<span style="letter-spacing:-0.3pt;"> </span>effects<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>in t<span style="letter-spacing:-0.05pt;">a</span>x <span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>w or in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rpre<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hereo<span style="letter-spacing:-0.05pt;">f</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>transfer<span style="letter-spacing:-0.05pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>poli<span style="letter-spacing:-0.05pt;">c</span>ies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>challenge<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>IRS or other<span style="letter-spacing:-0.25pt;"> </span>taxing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">u</span>thorities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>intercompany<span style="letter-spacing:-0.45pt;"> </span>relationships<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to complex<span style="letter-spacing:-0.25pt;"> </span>trans<span style="letter-spacing:-0.1pt;">f</span>er<span style="letter-spacing:-0.3pt;"> </span>pricing<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>administered<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.35pt;"> </span>in vario<span style="letter-spacing:-0.05pt;">u</span>s<span style="letter-spacing:-0.25pt;"> </span>juri<span style="letter-spacing:0.05pt;">s</span>di<span style="letter-spacing:0.05pt;">c</span>tions.<span style="letter-spacing:-0.15pt;"> </span>The relevant taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>disa<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>ee<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>deter<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>va<span style="letter-spacing:-0.05pt;">l</span>ue<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>se<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>sold<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquired<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expe<span style="letter-spacing:-0.05pt;">n</span>ses<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ttr<span style="letter-spacing:-0.05pt;">i</span>butab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>sp<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>if<span style="letter-spacing:-0.05pt;">i</span>c jurisdictions.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>disagreement<span style="letter-spacing:-0.5pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>occur,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>sustain<span style="letter-spacing:0.05pt;">e</span>d,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>pay<span style="letter-spacing:-0.2pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>taxes,<span style="letter-spacing:-0.15pt;"> </span>interest<span style="letter-spacing:-0.2pt;"> </span>and penalties,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one-time<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>charges,<span style="letter-spacing:-0.25pt;"> </span>high<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>rates,<span style="letter-spacing:-0.15pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>cash<span style="letter-spacing:-0.05pt;"> </span>flows,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>lower<span style="letter-spacing:-0.2pt;"> </span>overall<span style="letter-spacing:-0.25pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.4pt;"> </span>We bel<span style="letter-spacing:-0.05pt;">i</span>eve<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>fin<span style="letter-spacing:-0.05pt;">a</span>nc<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>em<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>fle<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>ad<span style="letter-spacing:-0.05pt;">e</span>quate<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">e</span>rves<span style="letter-spacing:-0.15pt;"> </span>to cover<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>contingency,<span style="letter-spacing:-0.45pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurances<span style="letter-spacing:-0.35pt;"> </span>in that<span style="letter-spacing:-0.2pt;"> </span>regard.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.3pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>examinations<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>returns by<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>IRS<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>domestic<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:0.05pt;"> </span>foreign<span style="letter-spacing:-0.05pt;"> </span>tax authorities.<span style="letter-spacing:-0.4pt;"> </span>An<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>out<span style="letter-spacing:0.05pt;">c</span>ome<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>audit<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>examination<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>IRS<span style="letter-spacing:0.05pt;"> </span>or other<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>authority<span style="letter-spacing:-0.35pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adver<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>on o<span style="letter-spacing:-0.05pt;">u</span>r op<span style="letter-spacing:-0.05pt;">e</span>rating<span style="letter-spacing:-0.25pt;"> </span>results and finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.35pt;"> </span>condit<span style="letter-spacing:-0.05pt;">i</span>on.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>regular<span style="letter-spacing:-0.25pt;"> </span>review<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>audit<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>IRS<span style="letter-spacing:0.05pt;"> a</span>nd<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>domestic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>tions.<span style="letter-spacing:-0.45pt;"> </span>As a<span style="letter-spacing:-0.05pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.2pt;"> </span>we may in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ce<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.25pt;"> </span>ass<span style="letter-spacing:-0.05pt;">e</span>ssm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.05pt;"> i</span>n <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.2pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>tax-related<span style="letter-spacing:-0.35pt;"> </span>assert<span style="letter-spacing:-0.05pt;">i</span>ons.<span style="letter-spacing:-0.3pt;"> </span>Taxing<span style="letter-spacing:-0.2pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>challenge<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>tax p<span style="letter-spacing:0.05pt;">o</span>sitions<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>methodologies<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>var<span style="letter-spacing:-0.1pt;">i</span>ous<span style="letter-spacing:-0.2pt;"> </span>matters,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>posit<span style="letter-spacing:0.1pt;">i</span>ons<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>garding<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>collection<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>taxes,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>termination<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>added<span style="letter-spacing:-0.25pt;"> </span>taxes<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>jurisdictions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>xes, which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpose us<span style="letter-spacing:-0.05pt;"> </span>to additional<span style="letter-spacing:-0.35pt;"> </span>taxes.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>regularly<span style="letter-spacing:-0.25pt;"> </span>assess<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>likelihood<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>outcomes<span style="letter-spacing:-0.3pt;"> </span>result<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>aminations<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>determine<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>equacy<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>provision<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>income<span style="letter-spacing:-0.2pt;"> </span>taxes.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.15pt;"> </span>assessments<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>require considerable<span style="letter-spacing:-0.4pt;"> </span>estimates<span style="letter-spacing:-0.3pt;"> </span>and judgments.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>calculation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our tax<span style="letter-spacing:-0.05pt;"> </span>liabilities<span style="letter-spacing:-0.35pt;"> </span>involv<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>dealing<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>uncertainties<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applic<span style="letter-spacing:0.05pt;">a</span>tion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>complex<span style="letter-spacing:-0.3pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>laws and<span style="letter-spacing:-0.1pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>in a variety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>jurisdictions.<span style="letter-spacing:-0.4pt;"> </span>There<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>positions<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.1pt;">e</span>thodologies<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>calculati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tax<span style="letter-spacing:-0.15pt;"> </span>liabilities<span style="letter-spacing:-0.35pt;"> </span>are accurate<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>outcomes<span style="letter-spacing:-0.3pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.05pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.05pt;"> </span>examinations<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>eff<span style="letter-spacing:-0.1pt;">e</span>ct<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We wi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subj</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ext</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">nsi</span><span style="letter-spacing:-0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ation,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">time</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consuming</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to unanticipated</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delays&#59;</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">obtain regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">some</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">still</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fficulties.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>processing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>nufacturing<span style="letter-spacing:-0.45pt;"> </span>activities<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to comprehensive<span style="letter-spacing:-0.55pt;"> </span>regulation<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Uni<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d States<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>by comparable<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>countries.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>aining<span style="letter-spacing:-0.3pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.4pt;"> </span>approvals,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>approvals,<span style="letter-spacing:-0.3pt;"> </span>is expensive<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>often<span style="letter-spacing:-0.15pt;"> </span>takes<span style="letter-spacing:-0.2pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>n<span style="letter-spacing:-0.05pt;"> </span>vary<span style="letter-spacing:-0.1pt;"> </span>substantially<span style="letter-spacing:-0.4pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>type,<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mplexity<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>novelty<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;">v</span>olved.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition, regulatory<span style="letter-spacing:-0.35pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>lack<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xperience<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>te<span style="letter-spacing:0.05pt;">c</span>hnologies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>lengthen<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>ncrease<span style="letter-spacing:-0.3pt;"> </span>our development<span style="letter-spacing:-0.4pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or prev<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.05pt;"> c</span>omm<span style="letter-spacing:-0.05pt;">e</span>rci<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>a<span style="letter-spacing:-0.05pt;">t</span>ion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No<span style="letter-spacing:-0.05pt;"> </span>fusion<span style="letter-spacing:0.05pt;"> </span>protein<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cell<span style="letter-spacing:-0.1pt;"> </span>thera<span style="letter-spacing:0.05pt;">p</span>y<span style="letter-spacing:-0.25pt;"> </span>using<span style="letter-spacing:-0.15pt;"> </span>Anktiva<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA. Consequently,<span style="letter-spacing:-0.55pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>precedent<span style="letter-spacing:-0.35pt;"> </span>for the<span style="letter-spacing:-0.05pt;"> </span>suc<span style="letter-spacing:0.05pt;">ce</span>ssful commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.1pt;">c</span>ts<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technolog<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>experience<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>pursuing<span style="letter-spacing:0.05pt;"> </span>appl<span style="letter-spacing:0.1pt;">i</span>cations<span style="letter-spacing:-0.4pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>to gain regulatory<span style="letter-spacing:-0.35pt;"> </span>approvals,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>impede<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>time<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>FDA approvals,<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>at all.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>yet<span style="letter-spacing:-0.05pt;"> </span>sought<span style="letter-spacing:-0.3pt;"> </span>FDA appro<span style="letter-spacing:0.05pt;">v</span>al<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>adaptive cell<span style="letter-spacing:-0.15pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>product.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commerciali<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>until<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>FDA approval,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>so<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ny delay<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>obtaining,<span style="letter-spacing:-0.35pt;"> </span>or inability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain,<span style="letter-spacing:-0.3pt;"> </span>FDA app<span style="letter-spacing:0.05pt;">r</span>oval<span style="letter-spacing:-0.25pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>violate<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span>uirements<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">a</span>ny<span style="letter-spacing:-0.1pt;"> </span>stage,<span style="letter-spacing:-0.15pt;"> </span>whether<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>obtained,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>face<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>numb<span style="letter-spacing:-0.15pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>regulatory consequences,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>refusal<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>approve<span style="letter-spacing:-0.25pt;"> </span>pending<span style="letter-spacing:-0.25pt;"> </span>application<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.5pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>suspension<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>revocation,<span style="letter-spacing:-0.35pt;"> </span>withdrawal<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an approval,<span style="letter-spacing:-0.35pt;"> </span>imposition<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>hold<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>warn<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>tt<span style="letter-spacing:-0.05pt;">e</span>rs,<span style="letter-spacing:-0.15pt;"> </span>unti<span style="letter-spacing:-0.05pt;">t</span>led<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>tt<span style="letter-spacing:-0.05pt;">e</span>rs,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>odifi<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.3pt;"> </span>of <span style="letter-spacing:-0.1pt;">p</span>romot<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.4pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>labeling, provision<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>corrective<span style="letter-spacing:-0.35pt;"> </span>information,<span style="letter-spacing:-0.4pt;"> </span>imposit<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>post-market<span style="letter-spacing:-0.45pt;"> </span>requiremen<span style="letter-spacing:0.05pt;">t</span>s,<span style="letter-spacing:-0.5pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>testing,<span style="letter-spacing:-0.2pt;"> </span>imposi<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>distribution<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other restrictions<span style="letter-spacing:-0.45pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>a REMS, product<span style="letter-spacing:-0.15pt;"> </span>recalls,<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>seizures<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>det<span style="letter-spacing:0.05pt;">e</span>ntions,<span style="letter-spacing:-0.45pt;"> </span>refusal<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>imports<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>exports,<span style="letter-spacing:-0.25pt;"> </span>total<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:0.05pt;">i</span>al<span style="letter-spacing:-0.3pt;"> </span>suspension<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>production or<span style="letter-spacing:0.05pt;"> </span>distribution,<span style="letter-spacing:-0.4pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>debarment,<span style="letter-spacing:-0.5pt;"> </span>injunctions,<span style="letter-spacing:-0.35pt;"> </span>fines,<span style="letter-spacing:-0.25pt;"> </span>consent<span style="letter-spacing:-0.3pt;"> </span>decrees,<span style="letter-spacing:-0.25pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>integrity<span style="letter-spacing:-0.3pt;"> </span>agreements,<span style="letter-spacing:-0.45pt;"> </span>debarment<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>receiving<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.35pt;"> </span>contracts, exclusion<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>in federal<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.2pt;"> </span>healt<span style="letter-spacing:0.05pt;">h</span>care<span style="letter-spacing:-0.4pt;"> </span>programs,<span style="letter-spacing:-0.4pt;"> </span>restituti<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:-0.3pt;"> </span>disgorgement,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>civ<span style="letter-spacing:-0.1pt;">i</span>l<span style="letter-spacing:-0.1pt;"> </span>or cr<span style="letter-spacing:-0.05pt;">i</span>min<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>pena<span style="letter-spacing:-0.05pt;">l</span>ti<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>fines<span style="letter-spacing:-0.15pt;"> </span>and imprisonment,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adverse<span style="letter-spacing:-0.35pt;"> </span>publicity,<span style="letter-spacing:-0.3pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>cons<span style="letter-spacing:0.05pt;">e</span>quences.<span style="letter-spacing:-0.45pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>labeling<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>or desirable<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>promotion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to undertake<span style="letter-spacing:-0.3pt;"> </span>post-m<span style="letter-spacing:-0.05pt;">a</span>rketing<span style="letter-spacing:-0.5pt;"> </span>trials.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>dition,<span style="letter-spacing:-0.35pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>identify side<span style="letter-spacing:-0.1pt;"> </span>effects<span style="letter-spacing:-0.2pt;"> </span>after<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>proble<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.35pt;"> </span>occur,<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>withdrawn,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>reformulation of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>projections<span style="letter-spacing:-0.35pt;"> </span>regarding<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>opportu<span style="letter-spacing:-0.1pt;">n</span>ities<span style="letter-spacing:-0.1pt;"> </span>for our product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>accurate,<span style="letter-spacing:-0.3pt;"> </span>and the<span style="letter-spacing:-0.05pt;"> </span>actual<span style="letter-spacing:-0.2pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>products, if a<span style="letter-spacing:0.05pt;">p</span>proved,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>small<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> w</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ima<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>verifia<span style="letter-spacing:-0.1pt;">b</span>le<span style="letter-spacing:-0.3pt;"> </span>internal<span style="letter-spacing:-0.3pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>size<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>nor<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>we o<span style="letter-spacing:0.05pt;">b</span>tained<span style="letter-spacing:-0.15pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>sur<span style="letter-spacing:-0.05pt;">v</span>eys<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>verify<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>size<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span>kets<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.15pt;">c</span>andidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>future prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates.<span style="letter-spacing:-0.45pt;"> </span>Since<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">u</span>rrent<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>represent<span style="letter-spacing:-0.4pt;"> </span>novel<span style="letter-spacing:-0.25pt;"> </span>approaches<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>reating<span style="letter-spacing:-0.25pt;"> </span>various conditions,<span style="letter-spacing:-0.4pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>difficult,<span style="letter-spacing:-0.3pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>eve<span style="letter-spacing:-0.1pt;">n</span>t,<span style="letter-spacing:-0.15pt;"> </span>to accurately<span style="letter-spacing:-0.35pt;"> </span>estimate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Ac<span style="letter-spacing:-0.1pt;">c</span>ordingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>spend sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>trying<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>uncertain<span style="letter-spacing:-0.3pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>market.<span style="letter-spacing:-0.2pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>projections<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of people<span style="letter-spacing:-0.2pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cancers<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>viral<span style="letter-spacing:-0.15pt;"> </span>dis<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>we are<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>rget<span style="letter-spacing:-0.05pt;">i</span>ng,<span style="letter-spacing:-0.25pt;"> </span>as we<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>as <span style="letter-spacing:-0.05pt;">t</span>he subset<span style="letter-spacing:-0.05pt;"> </span>of p<span style="letter-spacing:-0.05pt;">e</span>ople<span style="letter-spacing:-0.25pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">e</span>ases<span style="letter-spacing:-0.05pt;"> </span>who are<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>position<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>receive second-<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>third-line<span style="letter-spacing:-0.15pt;"> </span>therapy,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>to benefit<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>treatme<span style="letter-spacing:-0.15pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates,<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>beliefs<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>estimates. These<span style="letter-spacing:-0.25pt;"> </span>estimates<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>derived<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a v<span style="letter-spacing:0.05pt;">a</span>riety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>sources,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>lite<span style="letter-spacing:0.05pt;">r</span>ature,<span style="letter-spacing:-0.3pt;"> </span>surve<span style="letter-spacing:0.05pt;">y</span>s<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinics,<span style="letter-spacing:-0.25pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>foun<span style="letter-spacing:-0.05pt;">d</span>ations,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>mar<span style="letter-spacing:-0.05pt;">k</span>et<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">e</span>ar<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>by third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>prove<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>incorrec<span style="letter-spacing:0.05pt;">t</span>.<span style="letter-spacing:-0.3pt;"> </span>Further,<span style="letter-spacing:-0.25pt;"> </span>new studies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> a</span>pprovals<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>therapeutics<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he <span style="letter-spacing:-0.05pt;">e</span>sti<span style="letter-spacing:-0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>cidence<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prevalence<span style="letter-spacing:-0.35pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>diseases.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>number<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>turn<span style="letter-spacing:-0.1pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>lower<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>expected.<span style="letter-spacing:-0.3pt;"> </span>Add<span style="letter-spacing:-0.1pt;">i</span>tionally,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potentia<span style="letter-spacing:0.05pt;">l</span>ly<span style="letter-spacing:-0.35pt;"> </span>addressable<span style="letter-spacing:-0.4pt;"> </span>patie<span style="letter-spacing:-0.1pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>population<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>amenable<span style="letter-spacing:-0.3pt;"> </span>to treatment<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our tre<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">t</span>he r<span style="letter-spacing:-0.05pt;">e</span>i<span style="letter-spacing:-0.05pt;">m</span>burs<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.35pt;"> </span>of those<span style="letter-spacing:-0.2pt;"> </span>tre<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>by thi<span style="letter-spacing:-0.1pt;">r</span>d-party<span style="letter-spacing:-0.4pt;"> </span>payors.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>instance,<span style="letter-spacing:-0.3pt;"> </span>we exp<span style="letter-spacing:0.05pt;">ec</span>t<span style="letter-spacing:-0.25pt;"> </span>Anktiva<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>init<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>lly<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>arget<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>sm<span style="letter-spacing:-0.05pt;">a</span>ll<span style="letter-spacing:-0.2pt;"> </span>pat<span style="letter-spacing:-0.05pt;">i</span>ent p<span style="letter-spacing:0.05pt;">o</span>pulation<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>suffers from<span style="letter-spacing:-0.15pt;"> </span>bladder<span style="letter-spacing:-0.25pt;"> </span>cance<span style="letter-spacing:-0.05pt;">r</span>.<span style="letter-spacing:-0.25pt;"> </span>Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>share<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our product<span style="letter-spacing:-0.2pt;"> </span>candidat<span style="letter-spacing:-0.1pt;">e</span>s,<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">nt</span>i<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">rg</span><span style="letter-spacing:0.05pt;">e</span>t p<span style="letter-spacing:0.05pt;">o</span>pulations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">m</span>all,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.15pt;"> </span>achie<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>profitability<span style="letter-spacing:-0.45pt;"> </span>without<span style="letter-spacing:-0.2pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>f<span style="letter-spacing:-0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>indications.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">current</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">present,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">represent</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">novel</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approaches</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">treat</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of dis</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ase,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ere</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">many</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">un</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">certa</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gard</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">dev</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lop</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">market</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">acceptance,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">reimbursement</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">merc</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al p</span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tential</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human<span style="letter-spacing:-0.2pt;"> </span>immunotherapy<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>category<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>therapeutics.<span style="letter-spacing:-0.45pt;"> </span>B<span style="letter-spacing:-0.05pt;">e</span>cause<span style="letter-spacing:-0.3pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>relatively<span style="letter-spacing:-0.35pt;"> </span>new<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>expanding<span style="letter-spacing:-0.3pt;"> </span>area<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>novel<span style="letter-spacing:-0.25pt;"> </span>therapeutic int<span style="letter-spacing:-0.05pt;">e</span>rv<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>ny<span style="letter-spacing:-0.15pt;"> </span>un<span style="letter-spacing:0.05pt;">ce</span>rt<span style="letter-spacing:0.05pt;">a</span>inti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:0.05pt;">a</span>ted<span style="letter-spacing:-0.2pt;"> </span>to de<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>lopment,<span style="letter-spacing:-0.45pt;"> </span>marke<span style="letter-spacing:-0.15pt;">t</span>ing,<span style="letter-spacing:-0.35pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>me<span style="letter-spacing:-0.05pt;">r</span>ci<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>poten<span style="letter-spacing:-0.05pt;">t</span>ial<span style="letter-spacing:-0.3pt;"> </span>for <span style="letter-spacing:-0.05pt;">o</span>ur<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates. There<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>length<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>period,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>number<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>FDA will<span style="letter-spacing:-0.15pt;"> </span>requ<span style="letter-spacing:-0.05pt;">i</span>re<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> e</span>nrol<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.15pt;">t</span>he<span style="letter-spacing:-0.1pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>est<span style="letter-spacing:-0.05pt;">a</span>blish the<span style="letter-spacing:-0.1pt;"> </span>safety,<span style="letter-spacing:-0.25pt;"> </span>efficacy,<span style="letter-spacing:-0.3pt;"> </span>purity<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>potency<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>immunotherapy<span style="letter-spacing:-0.5pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ducts,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>g<span style="letter-spacing:0.05pt;">e</span>nerated<span style="letter-spacing:-0.3pt;"> </span>in these<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>accepta<span style="letter-spacing:-0.15pt;">b</span>le<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to support marketing<span style="letter-spacing:-0.35pt;"> </span>approval.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>ke<span style="letter-spacing:-0.2pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>usual<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>come<span style="letter-spacing:-0.15pt;"> </span>to a decision<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>BLA<span style="letter-spacing:-0.05pt;"> </span>and/<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.25pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>submit<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>det<span style="letter-spacing:-0.05pt;">e</span>rmine that<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>is not<span style="letter-spacing:-0.05pt;"> </span>en<span style="letter-spacing:0.05pt;">o</span>ugh<span style="letter-spacing:-0.2pt;"> </span>data,<span style="letter-spacing:-0.2pt;"> </span>information,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>exper<span style="letter-spacing:-0.05pt;">i</span>ence<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>decision.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we conduct<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>post-marketing<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>implement<span style="letter-spacing:-0.4pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>programs,<span style="letter-spacing:-0.4pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>REMS,<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>experience<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>roduct<span style="letter-spacing:-0.3pt;"> </span>candidates is obtained.<span style="letter-spacing:-0.3pt;"> </span>Finall<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.25pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>creased<span style="letter-spacing:-0.3pt;"> </span>usage,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:0.15pt;">n</span>tended<span style="letter-spacing:-0.25pt;"> </span>effect,<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">o</span>rk<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>combinati<span style="letter-spacing:0.05pt;">o</span>n therapies<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>unanticipated<span style="letter-spacing:-0.5pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>s,<span style="letter-spacing:-0.2pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>j<span style="letter-spacing:-0.05pt;">e</span>opard<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span>ing<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>continuing<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>find<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>manufacture<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:0.05pt;">i</span>fficult<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>anticipated,<span style="letter-spacing:-0.4pt;"> </span>resulting<span style="letter-spacing:-0.25pt;"> </span>in an<span style="letter-spacing:-0.15pt;"> </span>inability<span style="letter-spacing:-0.25pt;"> </span>to produce<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>sufficient amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.2pt;"> </span>or,<span style="letter-spacing:-0.05pt;"> </span>if approved,<span style="letter-spacing:-0.3pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>upply.<span style="letter-spacing:-0.3pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>complexity<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>novelty<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our manufacturing<span style="letter-spacing:-0.45pt;"> </span>process, there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">o</span>nly a limited<span style="letter-spacing:-0.25pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>manufactu<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>rs<span style="letter-spacing:-0.4pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>capability<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>ing<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Should<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> CMOs</span><span style="letter-spacing:-0.45pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">l</span>onger<span style="letter-spacing:-0.3pt;"> </span>produce<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>take<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:0.15pt;">i</span>me<span style="letter-spacing:-0.1pt;"> </span>to find<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>placement,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we <span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o f<span style="letter-spacing:-0.05pt;">i</span>nd a r<span style="letter-spacing:0.05pt;">e</span>pla<span style="letter-spacing:0.05pt;">c</span>em<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>approaches<span style="letter-spacing:-0.35pt;"> </span>offered<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>gain<span style="letter-spacing:-0.2pt;"> </span>broad<span style="letter-spacing:-0.25pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>among<span style="letter-spacing:-0.25pt;"> </span>docto<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>governmental agencies<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>insurers<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>willing<span style="letter-spacing:-0.2pt;"> </span>to provide<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.5pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> our </span>p<span style="letter-spacing:-0.05pt;">r</span>oposed<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.25pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span>ket<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>successfully<span style="letter-spacing:-0.4pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.25pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">d</span>o<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>yet<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>sufficient<span style="letter-spacing:-0.3pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>to <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">i</span>ably<span style="letter-spacing:-0.25pt;"> </span>est<span style="letter-spacing:-0.05pt;">i</span>ma<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>wh<span style="letter-spacing:-0.05pt;">a</span>t it<span style="letter-spacing:-0.05pt;"> will cost to </span>commercially<span style="letter-spacing:-0.45pt;"> </span>manu<span style="letter-spacing:-0.05pt;">f</span>acture<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>actual<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>manufacture<span style="letter-spacing:-0.45pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the commercial<span style="letter-spacing:-0.4pt;"> </span>viability<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.25pt;"> </span>products.<span style="letter-spacing:-0.3pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>goal<span style="letter-spacing:-0.2pt;"> </span>is to reduce<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>providing<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>therapies.<span style="letter-spacing:-0.4pt;"> </span>However, u<span style="letter-spacing:0.05pt;">n</span>less we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>reduce<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>amount,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>a commercial<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.4pt;"> </span>viable<span style="letter-spacing:-0.15pt;"> </span>product.<span style="letter-spacing:-0.35pt;"> </span>If we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>succes<span style="letter-spacing:-0.1pt;">s</span>fully<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>and commercialize<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>approach<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>suit<span style="letter-spacing:-0.1pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>economical<span style="letter-spacing:-0.35pt;"> </span>sources<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>materials<span style="letter-spacing:-0.3pt;"> </span>used<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>production<span style="letter-spacing:-0.35pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>products, we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>become<span style="letter-spacing:-0.25pt;"> </span>profitable,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adver<span style="letter-spacing:0.05pt;">s</span>ely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>on<span style="letter-spacing:-0.15pt;"> </span>stock.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.25pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her therapies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>pat<span style="letter-spacing:0.15pt;">i</span>ents<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>agents<span style="letter-spacing:-0.3pt;"> </span>provided<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of such<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>bina<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.05pt;">a</span>py may<span style="letter-spacing:-0.15pt;"> </span>inc<span style="letter-spacing:-0.05pt;">r</span>ease<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ov<span style="letter-spacing:-0.05pt;">e</span>rall<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ost<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>issues<span style="letter-spacing:-0.05pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>allocation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>reimbursements<span style="letter-spacing:-0.55pt;"> </span>between<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>thera<span style="letter-spacing:-0.1pt;">p</span>y<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>agents, all<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:0.1pt;">b</span>tain<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>combi<span style="letter-spacing:-0.1pt;">n</span>ation<span style="letter-spacing:-0.4pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hird-party<span style="letter-spacing:-0.35pt;"> </span>medical insu<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>rs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>law<span style="letter-spacing:-0.05pt;">s</span>uits<span style="letter-spacing:-0.35pt;"> </span>are brought<span style="letter-spacing:-0.05pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>u<span style="letter-spacing:0.1pt;">s</span>,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>incur<span style="letter-spacing:-0.05pt;"> </span>substanti<span style="letter-spacing:-0.1pt;">a</span>l liabilities<span style="letter-spacing:-0.3pt;"> </span>and may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>commer<span style="letter-spacing:0.05pt;">c</span>ialization<span style="letter-spacing:-0.75pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>inherent<span style="letter-spacing:-0.3pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>en<span style="letter-spacing:-0.15pt;"> </span>gre<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.25pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>f we commercialize<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>sued<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>perceived<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.25pt;"> </span>injury<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>otherwise u<span style="letter-spacing:0.05pt;">n</span>suitable<span style="letter-spacing:-0.25pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>tes<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:0.05pt;">n</span>g,<span style="letter-spacing:-0.15pt;"> </span>manufacturing,<span style="letter-spacing:-0.6pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>or sale.<span style="letter-spacing:-0.1pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>liability<span style="letter-spacing:-0.2pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>allegations<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>defects<span style="letter-spacing:-0.2pt;"> </span>in manufacturing,<span style="letter-spacing:-0.55pt;"> </span>defects<span style="letter-spacing:-0.25pt;"> </span>in design,<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>warn<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>dange<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.25pt;"> </span>inherent<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product,<span style="letter-spacing:-0.25pt;"> </span>negligence,<span style="letter-spacing:-0.4pt;"> </span>strict<span style="letter-spacing:-0.15pt;"> </span>lia<span style="letter-spacing:0.05pt;">b</span>ility<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>brea<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>warranties.<span style="letter-spacing:-0.45pt;"> </span>Claims<span style="letter-spacing:-0.3pt;"> </span>could also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>asse<span style="letter-spacing:-0.05pt;">r</span>ted<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>consumer<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:0.05pt;">t</span>ection<span style="letter-spacing:-0.3pt;"> </span>acts.<span style="letter-spacing:-0.2pt;"> </span>Large<span style="letter-spacing:-0.2pt;"> </span>judgements<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>awarded<span style="letter-spacing:-0.35pt;"> </span>in c<span style="letter-spacing:0.05pt;">l</span>ass<span style="letter-spacing:-0.05pt;"> </span>action<span style="letter-spacing:-0.15pt;"> </span>lawsuits<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>n ther<span style="letter-spacing:-0.05pt;">a</span>peu<span style="letter-spacing:-0.05pt;">t</span>ics<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>d u<span style="letter-spacing:0.05pt;">n</span>anticipated<span style="letter-spacing:-0.35pt;"> </span>side<span style="letter-spacing:-0.2pt;"> </span>effec<span style="letter-spacing:-0.05pt;">t</span>s.<span style="letter-spacing:-0.15pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>successfu<span style="letter-spacing:-0.1pt;">l</span>ly<span style="letter-spacing:-0.4pt;"> </span>defend<span style="letter-spacing:-0.3pt;"> </span>ourselves<span style="letter-spacing:-0.4pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>lia<span style="letter-spacing:-0.05pt;">b</span>ility<span style="letter-spacing:-0.35pt;"> </span>claims,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>incur<span style="letter-spacing:-0.15pt;"> </span>substant<span style="letter-spacing:0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>ab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required to limit<span style="letter-spacing:-0.15pt;"> </span>commercia<span style="letter-spacing:-0.1pt;">l</span>ization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.3pt;"> </span>defense<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">w</span>ould<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>management<span style="letter-spacing:-0.45pt;"> </span>resources.<span style="letter-spacing:-0.4pt;"> </span>Regardless of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>merits<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>eventual<span style="letter-spacing:-0.3pt;"> </span>ou<span style="letter-spacing:-0.05pt;">t</span>com<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>li<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.3pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>ims<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">demand</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">products,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">if approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">njury</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reputation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hdrawal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">part</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">pants</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or sit</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">poten</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ina</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ion</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of c</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ini</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sit</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">progr</span><span style="letter-spacing:-0.15pt;color:#000000;">a</span><span style="color:#000000;">ms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nitiation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">investigations</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">gulators,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approve</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">supplement</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">withdrawal</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">limit</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">osts</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">defend</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">diversion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">managemen</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">&#8217;s</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">resources&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substan</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">onet</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ry</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rds</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">par</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ic</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">pants</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">recalls,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hdrawals</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">labeling,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">promotional</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">restrictions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">oss of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">revenues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">negative</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">media</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">attention&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decrease</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">stock</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">overall</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">value</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">company&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">xhaustion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">available</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">insurance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">cap</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">tal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">resources&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">commerc</span><span style="letter-spacing:0.1pt;color:#000000;">i</span><span style="color:#000000;">alize</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">produ</span><span style="letter-spacing:-0.1pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>inability<span style="letter-spacing:-0.25pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>sufficient<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.1pt;">i</span>ability<span style="letter-spacing:-0.3pt;"> </span>insurance<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>cost<span style="letter-spacing:-0.05pt;"> </span>to protect<span style="letter-spacing:-0.2pt;"> </span>again<span style="letter-spacing:-0.1pt;">s</span>t<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>liab<span style="letter-spacing:-0.05pt;">i</span>lity<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>or inhibit<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop,<span style="letter-spacing:-0.25pt;"> </span>alone<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>llaborators.<span style="letter-spacing:-0.45pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>policies<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>various exclusions,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to product<span style="letter-spacing:-0.25pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>cove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>ge.<span style="letter-spacing:-0.3pt;"> </span>While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>obta<span style="letter-spacing:-0.1pt;">i</span>ned<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>ni<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>ls,<span style="letter-spacing:-0.2pt;"> </span>we may<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pay<span style="letter-spacing:-0.15pt;"> </span>am<span style="letter-spacing:0.05pt;">o</span>unts<span style="letter-spacing:-0.35pt;"> </span>awarded<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>court<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>negotiated<span style="letter-spacing:-0.3pt;"> </span>in a<span style="letter-spacing:-0.05pt;"> </span>set<span style="letter-spacing:-0.05pt;">t</span>l<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.2pt;"> </span>exceed<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:-0.35pt;"> </span>li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.35pt;"> </span>or th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>not covered<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>insurance,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain,<span style="letter-spacing:-0.25pt;"> </span>sufficient<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pital<span style="letter-spacing:-0.25pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>amounts.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>agreem<span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ny<span style="letter-spacing:-0.05pt;"> </span>future corporate<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>entitle<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>indem<span style="letter-spacing:0.1pt;">n</span>ifi<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.2pt;"> </span>losses, such<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ndemn<span style="letter-spacing:-0.05pt;">i</span>fi<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">v</span>ail<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>should<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>claim<span style="letter-spacing:-0.2pt;"> </span>arise.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Due to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>signif<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>ant<span style="letter-spacing:-0.4pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>so<span style="letter-spacing:-0.05pt;">u</span>rces<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>qu<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.1pt;"> </span>for <span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>dependi<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to access<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>apita<span style="letter-spacing:-0.05pt;">l</span>,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>must pri<span style="letter-spacing:0.05pt;">o</span>ritize<span style="letter-spacing:-0.4pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>d<span style="letter-spacing:0.1pt;">i</span>fferent<span style="letter-spacing:-0.25pt;"> </span>opportunit<span style="letter-spacing:-0.1pt;">i</span>es.<span style="letter-spacing:-0.4pt;"> </span>Moreover, we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>expend<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>resources on programs<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>yield<span style="letter-spacing:-0.15pt;"> </span>suc<span style="letter-spacing:-0.05pt;">c</span>essful<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.45pt;"> as opposed to</span><span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>profi<span style="letter-spacing:-0.15pt;">t</span>able<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>is a<span style="letter-spacing:-0.05pt;"> </span>greater<span style="letter-spacing:-0.3pt;"> </span>likelihood<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>sufficient<span style="letter-spacing:-0.4pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>pursue<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>or even<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>portion<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>opportunities<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>afforded<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Because<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>to fund<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operations,<span style="letter-spacing:-0.4pt;"> </span>our management must<span style="letter-spacing:-0.15pt;"> </span>make<span style="letter-spacing:-0.15pt;"> </span>signific<span style="letter-spacing:-0.1pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>prioritization<span style="letter-spacing:-0.45pt;"> </span>decisions<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">i</span>ndications<span style="letter-spacing:-0.35pt;"> </span>to pursue<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>how<span style="letter-spacing:-0.05pt;"> </span>much<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>allocate to each. Our m<span style="letter-spacing:-0.05pt;">a</span>nag<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.45pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>ev<span style="letter-spacing:-0.05pt;">a</span>lua<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ben<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>developing in-licensed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>jointly<span style="letter-spacing:-0.3pt;"> </span>owned tech<span style="letter-spacing:0.05pt;">n</span>ologies,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>some<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:0.05pt;">c</span>umstan<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:0.05pt;"> </span>contractually<span style="letter-spacing:-0.45pt;"> </span>obligated<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>purs<span style="letter-spacing:-0.05pt;">u</span>e,<span style="letter-spacing:-0.1pt;"> </span>relative<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:0.1pt;">e</span>loping<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span>ndications<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>programs. Our<span style="letter-spacing:0.05pt;"> </span>man<span style="letter-spacing:-0.1pt;">a</span>gement<span style="letter-spacing:-0.5pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>broad<span style="letter-spacing:-0.25pt;"> </span>discretion<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>suspend,<span style="letter-spacing:0.05pt;"> </span>scale<span style="letter-spacing:-0.2pt;"> </span>down,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>discontinue<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>developme<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to initia<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>programs<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>treat<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>diseases.<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>f<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>select<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commit resources<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>opportunities<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to successfully<span style="letter-spacing:-0.5pt;"> </span>develop,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>forego<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>pro<span style="letter-spacing:-0.1pt;">m</span>ising<span style="letter-spacing:-0.3pt;"> </span>opportunities,<span style="letter-spacing:-0.5pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.35pt;"> </span>condition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.15pt;"> </span>signifi<span style="letter-spacing:-0.05pt;">c</span>ant<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompe<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>biotech<span style="letter-spacing:0.05pt;">n</span>ology<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>pharmaceutical<span style="letter-spacing:-0.55pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.05pt;"> </span>non-prof<span style="letter-spacing:-0.05pt;">i</span>t ins<span style="letter-spacing:-0.05pt;">t</span>itut<span style="letter-spacing:-0.05pt;">i</span>ons.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>field<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>viral<span style="letter-spacing:-0.2pt;"> </span>infectious<span style="letter-spacing:-0.35pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>intense<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>acce<span style="letter-spacing:0.05pt;">n</span>tuated<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rapid<span style="letter-spacing:-0.15pt;"> </span>pace<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>tec<span style="letter-spacing:-0.1pt;">h</span>nological<span style="letter-spacing:-0.5pt;"> </span>development. Research<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>discoveries<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>breakthroughs<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>render<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>obsolete<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">v</span>en<span style="letter-spacing:-0.15pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>y<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>any revenues.<span style="letter-spacing:-0.3pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:-0.1pt;">r</span>oved<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>velopment<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>others<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are developing.<span style="letter-spacing:-0.4pt;"> </span>Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>substantially<span style="letter-spacing:-0.45pt;"> </span>gre<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>rch<span style="letter-spacing:-0.15pt;"> </span>and development<span style="letter-spacing:-0.4pt;"> </span>capabilities<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>approval,<span style="letter-spacing:-0.4pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span>u<span style="letter-spacing:-0.05pt;">f</span>acturing,<span style="letter-spacing:-0.4pt;"> </span>marketing,<span style="letter-spacing:-0.4pt;"> </span>f<span style="letter-spacing:0.05pt;">i</span>nancial<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>managerial<span style="letter-spacing:-0.4pt;"> </span>resourc<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do.<span style="letter-spacing:0.05pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">safe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">convenient</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">effective</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">immunothe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">pies</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapeutic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">less</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">expensive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">better</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">private</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reach</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">rapid</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">y,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reducing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">stablish</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">superior</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">positions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>focus<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>onco<span style="letter-spacing:-0.05pt;">l</span>ogical<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>infectious<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.1pt;">i</span>s<span style="letter-spacing:-0.05pt;">e</span>ase<span style="letter-spacing:-0.1pt;"> </span>indi<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>diff<span style="letter-spacing:-0.05pt;">i</span>cult<span style="letter-spacing:-0.4pt;"> </span>to treat<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>large<span style="letter-spacing:-0.25pt;"> </span>unmet<span style="letter-spacing:-0.15pt;"> </span>n<span style="letter-spacing:-0.1pt;">e</span>eds,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:-0.2pt;"> </span>our platforms<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>broadly<span style="letter-spacing:-0.2pt;"> </span>app<span style="letter-spacing:-0.05pt;">li</span>cab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>ac<span style="letter-spacing:-0.05pt;">r</span>oss<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ult<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.25pt;"> </span>tu<span style="letter-spacing:-0.05pt;">m</span>or<span style="letter-spacing:-0.1pt;"> </span>typ<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>infections.<span style="letter-spacing:-0.35pt;"> </span>Based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:0.05pt;">r</span>eadth<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>depth<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>platforms,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>our competitors<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>ran<span style="letter-spacing:0.05pt;">g</span>e<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>lar<span style="letter-spacing:-0.05pt;">g</span>e<span style="letter-spacing:-0.25pt;"> </span>pharmaceutical<span style="letter-spacing:-0.5pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>to e<span style="letter-spacing:-0.05pt;">m</span>erging<span style="letter-spacing:-0.3pt;"> </span>novel<span style="letter-spacing:-0.15pt;"> </span>biote<span style="letter-spacing:-0.1pt;">c</span>hnology<span style="letter-spacing:-0.55pt;"> </span>companies.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oncology</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perspective,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diff</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rent</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bas</span><span style="letter-spacing:-0.15pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modality.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NK</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lls</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modality,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pri</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ari</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompe</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th large</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">checkpoi</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inhibitors</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PLC,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AstraZeneca,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Squibb</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or BMS,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GlaxoSmithKline</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">plc,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GSK,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merck</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#38; Co.,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc.,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merck,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc.,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Roche</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holding</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AG,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or Roche.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pot</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nti</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xi</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for some</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">large</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to seek</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaboration</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combinat</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anktiva</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketed</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">checkpoint</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> inhibitors</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lso,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NK</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ell activation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modality,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compete</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">immunotherapy</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fusion</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otein</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpanies</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">veloping</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approaches</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">N</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ekt</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ther</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peuti</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Neoleukin</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov</span><span style="letter-spacing:0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rtis</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AG, R</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">che,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sanofi</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S.A., and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">context</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NMIBC,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FerGene,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc.,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Merck</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sesen</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bio,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inc.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>tumoricidal<span style="letter-spacing:-0.35pt;"> </span>macrophage<span style="letter-spacing:-0.45pt;"> </span>activation<span style="letter-spacing:-0.35pt;"> </span>modality,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>various<span style="letter-spacing:-0.25pt;"> </span>che<span style="letter-spacing:-0.05pt;">m</span>otherapeutic<span style="letter-spacing:-0.65pt;"> </span>agents,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>Abraxane,<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:0.05pt;">o</span>xorubicin<span style="letter-spacing:-0.3pt;"> </span>and paclitaxel/Taxol,<span style="letter-spacing:-0.6pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>antibody<span style="letter-spacing:-0.3pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>conjugate<span style="letter-spacing:-0.35pt;"> </span>produced<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>mmunomedics,<span style="letter-spacing:-0.5pt;"> </span>Inc.,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>Immunomedics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>T&#160;c<span style="letter-spacing:0.05pt;">e</span>ll<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>mory<span style="letter-spacing:-0.3pt;"> </span>moda<span style="letter-spacing:-0.05pt;">l</span>ity,<span style="letter-spacing:-0.35pt;"> </span>we a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>pete<span style="letter-spacing:-0.25pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> c</span><span style="letter-spacing:0.05pt;">e</span>ll<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.1pt;">a</span>py<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>chimeric<span style="letter-spacing:-0.3pt;"> </span>antigen<span style="letter-spacing:-0.25pt;"> </span>receptor<span style="letter-spacing:-0.3pt;"> </span>T&#160;cell,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>CAR-T<span style="letter-spacing:-0.1pt;">&#160;c</span>ell,<span style="letter-spacing:-0.1pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>including A<span style="letter-spacing:-0.05pt;">l</span>logene<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>herap<span style="letter-spacing:-0.05pt;">e</span>ut<span style="letter-spacing:-0.05pt;">i</span>cs<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">.</span>,<span style="letter-spacing:-0.1pt;"> </span>CRI<span style="letter-spacing:-0.05pt;">S</span><span style="letter-spacing:0.05pt;">P</span>R<span style="letter-spacing:-0.05pt;"> </span>Th<span style="letter-spacing:-0.05pt;">e</span>rapeu<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">c</span>s<span style="letter-spacing:-0.4pt;"> </span>AG, <span style="letter-spacing:-0.05pt;">F</span><span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>her<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:-0.1pt;">p</span>eut<span style="letter-spacing:-0.05pt;">i</span>cs,<span style="letter-spacing:-0.3pt;"> </span>Inc<span style="letter-spacing:-0.05pt;">.</span>,<span style="letter-spacing:-0.15pt;"> </span>Gilead Sciences,<span style="letter-spacing:-0.35pt;"> </span>Inc., or Gilead, I<span style="letter-spacing:-0.1pt;">n</span>tellia&#160;Therapeutics,<span style="letter-spacing:-0.45pt;"> </span>Inc.,<span style="letter-spacing:-0.2pt;"> </span>Iovance<span style="letter-spacing:-0.3pt;"> </span>Biotherapeutics,<span style="letter-spacing:-0.65pt;"> </span>Inc.<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Legend<span style="letter-spacing:-0.2pt;"> </span>Biotech<span style="letter-spacing:-0.25pt;"> </span>Corporation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>infectious<span style="letter-spacing:-0.4pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>per<span style="letter-spacing:0.15pt;">s</span>pective,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>compe<span style="letter-spacing:-0.1pt;">t</span>e<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>Abbott<span style="letter-spacing:-0.2pt;"> </span>Laboratories<span style="letter-spacing:-0.5pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>Abbott<span style="letter-spacing:-0.25pt;"> </span>Laborato<span style="letter-spacing:-0.05pt;">r</span>ies,<span style="letter-spacing:-0.55pt;"> </span>BMS,<span style="letter-spacing:0.05pt;"> </span>Gilead, and<span style="letter-spacing:-0.1pt;"> </span>GSK, in the<span style="letter-spacing:-0.05pt;"> </span>field<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>human<span style="letter-spacing:-0.3pt;"> </span>immunodeficiency<span style="letter-spacing:-0.65pt;"> </span>virus,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>HIV.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compe<span style="letter-spacing:-0.05pt;">t</span>itor<span style="letter-spacing:-0.4pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>ni<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>focused<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>rapy<span style="letter-spacing:-0.25pt;"> </span>curren<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.3pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>clude<span style="letter-spacing:-0.25pt;"> Altimmune, Inc., </span>AstraZeneca,<span style="letter-spacing:-0.1pt;"> </span>Athe<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>y<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.2pt;"> </span>Inc<span style="letter-spacing:-0.05pt;">.</span>/He<span style="letter-spacing:-0.05pt;">a</span>lios<span style="letter-spacing:-0.4pt;"> </span>K<span style="letter-spacing:-0.05pt;">.</span>K<span style="letter-spacing:-0.05pt;">.</span>, CanSioBio Biologics Inc., Capr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>or<span style="letter-spacing:-0.3pt;"> </span>Ther<span style="letter-spacing:-0.05pt;">a</span>peu<span style="letter-spacing:-0.05pt;">t</span>ics,<span style="letter-spacing:-0.35pt;"> </span>Inc<span style="letter-spacing:-0.05pt;">.</span>, CAR-T<span style="letter-spacing:0.05pt;"> </span>(Shanghai)<span style="letter-spacing:-0.35pt;"> </span>Biotechnology,<span style="letter-spacing:-0.5pt;"> </span>C<span style="letter-spacing:-0.05pt;">e</span>llavita<span style="letter-spacing:-0.25pt;"> </span>Pesquisa<span style="letter-spacing:-0.05pt;"> </span>Cient&#237;fica<span style="letter-spacing:-0.3pt;"> </span>L<span style="letter-spacing:-0.05pt;">t</span>da,<span style="letter-spacing:-0.15pt;"> </span>Cellenkos,<span style="letter-spacing:-0.35pt;"> </span>Inc.,<span style="letter-spacing:-0.1pt;"> </span>Cellular<span style="letter-spacing:-0.35pt;"> </span>Bio<span style="letter-spacing:0.1pt;">m</span>edicine<span style="letter-spacing:-0.45pt;"> </span>Group,<span style="letter-spacing:0.05pt;"> </span>Inc.,<span style="letter-spacing:-0.1pt;"> </span>Celularity,<span style="letter-spacing:-0.4pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>Sorrento Therapeutics,<span style="letter-spacing:-0.5pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>Chinese<span style="letter-spacing:-0.25pt;"> </span>Academy<span style="letter-spacing:-0.35pt;"> </span>of Sciences,<span style="letter-spacing:-0.4pt;"> </span>Chongqing<span style="letter-spacing:-0.35pt;"> </span>Sidemu<span style="letter-spacing:-0.3pt;"> </span>Biotechnology Technology/ImmunCyte Life Science,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>nc.,<span style="letter-spacing:-0.05pt;"> </span>Enli<span style="letter-spacing:-0.05pt;">ve</span>x<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>her<span style="letter-spacing:-0.05pt;">a</span>peut<span style="letter-spacing:-0.05pt;">i</span>cs Ltd,<span style="letter-spacing:-0.1pt;"> </span>Green<span style="letter-spacing:-0.15pt;"> </span>Cross<span style="letter-spacing:0.05pt;"> </span>LabCell<span style="letter-spacing:-0.25pt;"> </span>Co<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">p</span>.,<span style="letter-spacing:-0.05pt;"> </span>Hope<span style="letter-spacing:-0.05pt;"> </span>Biosciences,<span style="letter-spacing:-0.4pt;"> </span>Johnson<span style="letter-spacing:-0.05pt;"> </span>&#38;<span style="letter-spacing:-0.1pt;"> </span>Johnson,<span style="letter-spacing:0.05pt;"> Merck, </span>Me<span style="letter-spacing:-0.05pt;">s</span>oblast<span style="letter-spacing:-0.2pt;"> </span>Limited,<span style="letter-spacing:-0.25pt;"> </span>Moderna,<span style="letter-spacing:-0.4pt;"> </span>Inc.,<span style="letter-spacing:-0.1pt;"> </span>Novavax,<span style="letter-spacing:-0.05pt;"> </span>Inc.,<span style="letter-spacing:-0.2pt;"> </span>Orbsen<span style="letter-spacing:-0.05pt;"> </span>T<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>rapeu<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">c</span>s Limited,<span style="letter-spacing:-0.3pt;"> </span>Pfize<span style="letter-spacing:-0.05pt;">r</span>/BioNTech<span style="letter-spacing:-0.4pt;"> </span>SE,<span style="letter-spacing:-0.15pt;"> </span>Pluristem<span style="letter-spacing:-0.3pt;"> </span>Therapeutics,<span style="letter-spacing:-0.45pt;"> </span>Inc<span style="letter-spacing:0.05pt;">.</span>,<span style="letter-spacing:-0.1pt;"> </span>Rigshospitalet,<span style="letter-spacing:-0.5pt;"> </span>Tianhe<span style="letter-spacing:-0.2pt;"> </span>Stem<span style="letter-spacing:-0.15pt;"> </span>Cell<span style="letter-spacing:-0.15pt;"> </span>Biotechno<span style="letter-spacing:-0.1pt;">l</span>ogies<span style="letter-spacing:-0.6pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>University<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Minnesota/Fate Ther<span style="letter-spacing:-0.05pt;">a</span>peut<span style="letter-spacing:-0.05pt;">i</span>cs,<span style="letter-spacing:-0.35pt;"> </span>Inc<span style="letter-spacing:-0.05pt;">.</span>,<span style="letter-spacing:-0.15pt;"> Vaxart, Inc., </span>X<span style="letter-spacing:-0.05pt;">i</span>nji<span style="letter-spacing:-0.05pt;">a</span>ng<span style="letter-spacing:-0.1pt;"> </span>Med<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>Univ<span style="letter-spacing:-0.05pt;">e</span>rsity, and many other new competitors that are emerging frequently.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A large<span style="letter-spacing:-0.25pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>compa<span style="letter-spacing:-0.05pt;">n</span>ies,<span style="letter-spacing:-0.35pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>agenc<span style="letter-spacing:-0.1pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>academic<span style="letter-spacing:-0.3pt;"> </span>centers<span style="letter-spacing:-0.2pt;"> </span>around<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>world<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:0.05pt;">1</span>9<span style="letter-spacing:-0.05pt;"> </span>vaccines,<span style="letter-spacing:-0.35pt;"> </span>and many<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hese<span style="letter-spacing:-0.05pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n more<span style="letter-spacing:-0.25pt;"> </span>advanced<span style="letter-spacing:-0.3pt;"> </span>stages<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>started<span style="letter-spacing:-0.3pt;"> P</span>hase&#160;II<span style="letter-spacing:-0.05pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>III<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>or have already<span style="letter-spacing:-0.25pt;"> obtained</span><span style="letter-spacing:-0.2pt;"> </span>emergency<span style="letter-spacing:-0.35pt;"> </span>regulato<span style="letter-spacing:0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> the United States and internationally</span>.<span style="letter-spacing:-0.25pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if our<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>vaccine<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>arketing,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>value of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>op<span style="letter-spacing:0.05pt;">p</span>o<span style="letter-spacing:-0.05pt;">r</span>tunity<span style="letter-spacing:-0.25pt;"> will be</span><span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>impacted<span style="letter-spacing:-0.35pt;"> by</span><span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>vaccines<span style="letter-spacing:-0.35pt;"> that have obtained emergency regulatory approval, obtain full regulatory approval, </span>or<span style="letter-spacing:0.05pt;"> demonstrate</span><span style="letter-spacing:-0.15pt;"> better </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>sa<span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">e</span>ty<span style="letter-spacing:-0.1pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>our COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 vaccine<span style="letter-spacing:-0.2pt;"> </span>candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.1pt;"> </span>subst<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">a</span>lly<span style="letter-spacing:-0.25pt;"> </span>gre<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>search<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>cap<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>fin<span style="letter-spacing:-0.05pt;">a</span>nci<span style="letter-spacing:-0.05pt;">a</span>l, scientific,<span style="letter-spacing:-0.35pt;"> </span>regulatory,<span style="letter-spacing:-0.4pt;"> </span>manufacturing,<span style="letter-spacing:-0.55pt;"> </span>marketing,<span style="letter-spacing:-0.4pt;"> </span>sales,<span style="letter-spacing:-0.25pt;"> </span>human<span style="letter-spacing:-0.2pt;"> </span>resources,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do.<span style="letter-spacing:0.05pt;"> </span>Many<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>veral<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.05pt;">a</span>peut<span style="letter-spacing:-0.05pt;">i</span>c prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>already<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.25pt;"> </span>developed,<span style="letter-spacing:-0.35pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>successfully<span style="letter-spacing:-0.15pt;"> </span>commercialized,<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>obtaining<span style="letter-spacing:-0.3pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>their therapeutic<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>internationally.<span style="letter-spacing:-0.5pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mpetitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>produc<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>rapidly<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>we may obtain<span style="letter-spacing:-0.15pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>ou<span style="letter-spacing:-0.05pt;">r</span>s,<span style="letter-spacing:0.05pt;"> </span>whi<span style="letter-spacing:-0.1pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in competitors<span style="letter-spacing:-0.5pt;"> </span>establishing<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>strong<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.2pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to en<span style="letter-spacing:-0.15pt;">t</span>er<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rke<span style="letter-spacing:-0.05pt;">t</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Universities<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>priva<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>instit<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Europe<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>also potential<span style="letter-spacing:-0.25pt;"> </span>competitors.<span style="letter-spacing:-0.45pt;"> </span>While<span style="letter-spacing:-0.25pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>universities<span style="letter-spacing:-0.35pt;"> </span>and p<span style="letter-spacing:0.05pt;">u</span>blic<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>private<span style="letter-spacing:-0.25pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>institutions<span style="letter-spacing:-0.45pt;"> </span>primarily<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>educ<span style="letter-spacing:-0.05pt;">a</span>tional<span style="letter-spacing:-0.35pt;"> </span>objectives,<span style="letter-spacing:-0.35pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>technologies<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>lead<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>FDA approved<span style="letter-spacing:-0.35pt;"> </span>therapies<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>secure<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candi<span style="letter-spacing:-0.05pt;">d</span>ates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be licensed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>sold<span style="letter-spacing:-0.2pt;"> </span>to other<span style="letter-spacing:-0.2pt;"> </span>parties,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>Anktiva,<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a potential<span style="letter-spacing:-0.25pt;"> </span>therapy<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>bladder<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;">&#160;</span>(1)&#160;when<span style="letter-spacing:0.05pt;"> </span>used<span style="letter-spacing:-0.05pt;"> </span>in combin<span style="letter-spacing:-0.1pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>checkpoi<span style="letter-spacing:0.05pt;">n</span>t inhibitors,<span style="letter-spacing:-0.35pt;"> </span>lung<span style="letter-spacing:-0.1pt;"> </span>cancer,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>(2)&#160;when<span style="letter-spacing:0.05pt;"> </span>used<span style="letter-spacing:-0.05pt;"> </span>in combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> natural killer </span>cells,<span style="letter-spacing:-0.2pt;"> </span>metastatic<span style="letter-spacing:-0.3pt;"> </span>pancreatic<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ncer<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>triple<span style="letter-spacing:-0.2pt;"> </span>negative<span style="letter-spacing:-0.25pt;"> </span>brea<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>r,<span style="letter-spacing:-0.2pt;"> </span>or TNBC. Currently,<span style="letter-spacing:-0.35pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>developing<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">a</span>rious<span style="letter-spacing:-0.05pt;"> a</span>l<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rna<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>tre<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.35pt;"> </span>for bl<span style="letter-spacing:-0.05pt;">a</span>dd<span style="letter-spacing:-0.05pt;">e</span>r,<span style="letter-spacing:-0.2pt;"> </span>pancreatic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>breast<span style="letter-spacing:-0.25pt;"> </span>ca<span style="letter-spacing:-0.05pt;">n</span>cer,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>patients that<span style="letter-spacing:-0.1pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>progressed<span style="letter-spacing:0.05pt;"> </span>after<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.25pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>checkpoint<span style="letter-spacing:-0.4pt;"> </span>inhibitors<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>chemotherapy.<span style="letter-spacing:-0.55pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>ample,<span style="letter-spacing:-0.4pt;"> </span>Nektar<span style="letter-spacing:-0.2pt;"> </span>T<span style="letter-spacing:0.05pt;">h</span>erapeutics<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>cu<span style="letter-spacing:0.05pt;">r</span>rently<span style="letter-spacing:-0.35pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>an imm<span style="letter-spacing:0.05pt;">u</span>notherapy<span style="letter-spacing:-0.5pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>eatment<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>muscle-invasive<span style="letter-spacing:-0.65pt;"> </span>bladder<span style="letter-spacing:-0.2pt;"> </span>cancer<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">u</span>sing<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>IL-2<span style="letter-spacing:-0.2pt;"> </span>agonist<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>is in Pha<span style="letter-spacing:-0.1pt;">s</span>e&#160;III<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials.<span style="letter-spacing:-0.2pt;"> </span>Accordi<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">g</span>ly,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">A</span>nktiva<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>c<span style="letter-spacing:0.05pt;">e</span>s sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>competition<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>bladder,<span style="letter-spacing:-0.25pt;"> </span>lung,<span style="letter-spacing:-0.15pt;"> </span>pancreatic<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>brea<span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:-0.25pt;"> </span>cancer<span style="letter-spacing:-0.2pt;"> </span>treatment<span style="letter-spacing:-0.3pt;"> </span>space<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>multiple<span style="letter-spacing:-0.25pt;"> </span>companies.<span style="letter-spacing:-0.4pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>regulatory approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>avail<span style="letter-spacing:-0.05pt;">a</span>bility<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors&#8217;<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ould<span style="letter-spacing:-0.25pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>demand<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>charge<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our therapies.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>imple<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>plan<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>inhibited<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>price<span style="letter-spacing:-0.1pt;"> </span>competition<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the reluctance<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>to switch<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>methods<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:-0.3pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>physicians<span style="letter-spacing:-0.35pt;"> </span>switch<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>therap<span style="letter-spacing:0.05pt;">i</span>es,<span style="letter-spacing:-0.2pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>biologic prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>choose<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>reserve<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:0.1pt;">i</span>dates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in limited<span style="letter-spacing:-0.25pt;"> </span>circumstances.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:1.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:1.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:1.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceedings</span><span style="letter-spacing:2.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">respect</span><span style="letter-spacing:1.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.7pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scope</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership, validity</span><span style="letter-spacing:1.75pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</span><span style="letter-spacing:1.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceability</span><span style="letter-spacing:0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:1.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:1.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors'</span><span style="letter-spacing:0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products,</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</span><span style="letter-spacing:2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:1.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allege</span><span style="letter-spacing:1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.95pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:1.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringe,</span><span style="letter-spacing:1.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misappropriate </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise</span><span style="letter-spacing:1.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">violate</span><span style="letter-spacing:1.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their</span><span style="letter-spacing:1.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:1.8pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property. See </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-style:italic;">Risks</span><span style="font-style:italic;letter-spacing:1.1pt;"> </span><span style="font-style:italic;">Related</span><span style="font-style:italic;letter-spacing:1.35pt;"> </span><span style="font-style:italic;">to</span><span style="font-style:italic;letter-spacing:0.45pt;"> </span><span style="font-style:italic;">Intellectual</span><span style="font-style:italic;letter-spacing:2.05pt;"> </span><span style="font-style:italic;">Property.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mergers<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>acquisitions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pharmaceutical<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>indu<span style="letter-spacing:-0.05pt;">s</span>tries<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in even<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>entrat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>a smaller n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitors.<span style="letter-spacing:-0.45pt;"> </span>Early<span style="letter-spacing:-0.15pt;"> </span>stage<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>prove<span style="letter-spacing:-0.25pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mpetitors,<span style="letter-spacing:-0.45pt;"> </span>par<span style="letter-spacing:0.05pt;">t</span>icularly<span style="letter-spacing:-0.4pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>collaborat<span style="letter-spacing:0.05pt;">i</span>ve<span style="letter-spacing:-0.4pt;"> </span>arrangements<span style="letter-spacing:-0.5pt;"> </span>with large<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>established<span style="letter-spacing:-0.35pt;"> </span>compani<span style="letter-spacing:0.05pt;">e</span>s.<span style="letter-spacing:-0.35pt;"> </span>Th<span style="letter-spacing:0.05pt;">e</span>se<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:0.05pt;">e</span>te<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>us in<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:0.05pt;">c</span>ruiting<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>retaining<span style="letter-spacing:-0.3pt;"> </span>qualified<span style="letter-spacing:-0.25pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>management<span style="letter-spacing:-0.5pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>and establishing<span style="letter-spacing:-0.4pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.15pt;"> </span>sites<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>regist<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tion<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials,<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>acquiring<span style="letter-spacing:-0.3pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>complementary<span style="letter-spacing:-0.6pt;"> </span>to,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>for,<span style="letter-spacing:0.05pt;"> </span>our programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pu<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.2pt;"> </span>opinion<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.1pt;">c</span>rutiny<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>immunotherapy<span style="letter-spacing:-0.65pt;"> </span>app<span style="letter-spacing:0.05pt;">r</span>oaches<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>per<span style="letter-spacing:-0.05pt;">c</span>eption<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> us</span><span style="letter-spacing:-0.3pt;"> </span>and our product<span style="letter-spacing:-0.35pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ates,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may ad<span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span>rsely<span style="letter-spacing:-0.35pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>our abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>condu<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>latively<span style="letter-spacing:-0.3pt;"> </span>novel<span style="letter-spacing:-0.2pt;"> </span>technologies<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:0.05pt;">v</span>olving<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Anktiva,<span style="letter-spacing:-0.35pt;"> a</span>ldoxorubicin,<span style="letter-spacing:-0.45pt;"> </span>hAd5<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>yeast<span style="letter-spacing:-0.25pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>cell-based<span style="letter-spacing:-0.35pt;"> </span>therapies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>natural<span style="letter-spacing:-0.2pt;"> </span>killer cell<span style="letter-spacing:-0.15pt;"> </span>platform<span style="letter-spacing:-0.25pt;"> </span>utilizes<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>relatively<span style="letter-spacing:-0.35pt;"> </span>novel<span style="letter-spacing:-0.15pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>involv<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>genetic<span style="letter-spacing:-0.2pt;"> </span>modification<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>human<span style="letter-spacing:-0.35pt;"> </span>cells<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>util<span style="letter-spacing:-0.05pt;">i</span>zation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>modified<span style="letter-spacing:-0.25pt;"> </span>cells<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>other individuals.<span style="letter-spacing:-0.4pt;"> </span>Public<span style="letter-spacing:-0.2pt;"> </span>pe<span style="letter-spacing:-0.05pt;">r</span>ception<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>influ<span style="letter-spacing:-0.05pt;">e</span>nced<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>unsafe,<span style="letter-spacing:-0.25pt;"> </span>unethical<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>immo<span style="letter-spacing:-0.05pt;">r</span>al<span style="letter-spacing:-0.3pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>consequently,<span style="letter-spacing:-0.5pt;"> </span>our approach<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>gain<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>community.<span style="letter-spacing:-0.4pt;"> </span>Negative<span style="letter-spacing:-0.25pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>react<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cell-based<span style="letter-spacing:-0.3pt;"> </span>immunotherapy<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>general<span style="letter-spacing:-0.2pt;"> </span>could result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>regulation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>stricter<span style="letter-spacing:-0.2pt;"> </span>labeling<span style="letter-spacing:-0.25pt;"> </span>requirem<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>immunotherapy<span style="letter-spacing:-0.55pt;"> </span>products,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.05pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>and could<span style="letter-spacing:-0.25pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>decrease<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>demand<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop. Adverse<span style="letter-spacing:0.05pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>attitudes<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>our ability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enro<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l trials.<span style="letter-spacing:-0.2pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>depend<span style="letter-spacing:-0.25pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>specializing<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>dis<span style="letter-spacing:-0.1pt;">e</span>ases<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;">d</span>ida<span style="letter-spacing:-0.05pt;">t</span>es<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>rget<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">c</span>ribing, and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>willing<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.3pt;"> </span>treatments<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>lieu<span style="letter-spacing:-0.1pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addit<span style="letter-spacing:0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>ex<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ing<span style="letter-spacing:-0.15pt;"> </span>tre<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hey are<span style="letter-spacing:-0.1pt;"> </span>already<span style="letter-spacing:-0.2pt;"> </span>familiar<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>greater<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>available.<span style="letter-spacing:-0.35pt;"> </span>More<span style="letter-spacing:0.05pt;"> </span>restrictive<span style="letter-spacing:-0.35pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">n</span>ment<span style="letter-spacing:-0.35pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>lations<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>negative<span style="letter-spacing:-0.35pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>inion<span style="letter-spacing:-0.25pt;"> </span>could have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>del<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>impair<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>lopme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates or<span style="letter-spacing:0.05pt;"> </span>demand<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>develop.<span style="letter-spacing:-0.3pt;"> </span>Adverse<span style="letter-spacing:-0.05pt;"> </span>events<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>ultimately<span style="letter-spacing:-0.35pt;"> </span>attributable<span style="letter-spacing:-0.35pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the resulting<span style="letter-spacing:-0.25pt;"> </span>publicity<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>increas<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.35pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>regulation,<span style="letter-spacing:-0.35pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>pub<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.15pt;"> </span>perception,<span style="letter-spacing:-0.4pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>del<span style="letter-spacing:-0.1pt;">a</span>ys<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.25pt;"> </span>or approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>stricter<span style="letter-spacing:-0.2pt;"> </span>labeling<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>a decrease<span style="letter-spacing:-0.25pt;"> </span>in demand<span style="letter-spacing:-0.35pt;"> </span>for any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Development<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in combinati<span style="letter-spacing:-0.05pt;">o</span>n<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:0.05pt;"> </span>already<span style="letter-spacing:-0.3pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>product may<span style="letter-spacing:-0.1pt;"> </span>present<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>different<span style="letter-spacing:-0.25pt;"> </span>challenges than<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:0.15pt;">d</span>idate<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>single<span style="letter-spacing:-0.15pt;"> </span>agent.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.1pt;"> </span>along<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>natural<span style="letter-spacing:-0.2pt;"> </span>killer<span style="letter-spacing:-0.15pt;"> </span>cell<span style="letter-spacing:-0.1pt;"> </span>platfor<span style="letter-spacing:-0.05pt;">m</span>.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>studying<span style="letter-spacing:-0.25pt;"> </span>Anktiva<span style="letter-spacing:-0.25pt;"> </span>thera<span style="letter-spacing:0.05pt;">p</span>y<span style="letter-spacing:-0.25pt;"> </span>along<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>product candidates,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> a</span>ldoxorubicin<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>hAd5<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>in combination<span style="letter-spacing:-0.45pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.15pt;"> </span>another product may present<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>hal<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>nges.<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xamp<span style="letter-spacing:-0.05pt;">l</span>e,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>DA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:0.05pt;">q</span>uire<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>x<span style="letter-spacing:-0.25pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>designs<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ev<span style="letter-spacing:-0.05pt;">a</span>lua<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>contribution<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>each prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>observed<span style="letter-spacing:-0.2pt;"> </span>effects.<span style="letter-spacing:-0.3pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>show<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>pos<span style="letter-spacing:-0.05pt;">i</span>tive<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>su<span style="letter-spacing:-0.05pt;">l</span>ts<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.05pt;">t</span>ribut<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>already<span style="letter-spacing:-0.25pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>product.<span style="letter-spacing:-0.35pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>fol<span style="letter-spacing:0.05pt;">l</span>owing<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>approval,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>used<span style="letter-spacing:-0.05pt;"> </span>in conjunction<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>cross labeled<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>combined<span style="letter-spacing:-0.3pt;"> </span>use.<span style="letter-spacing:0.05pt;"> </span>To<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>at<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do not<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>already<span style="letter-spacing:-0.2pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>ed<span style="letter-spacing:-0.15pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>this<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>work<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:0.1pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>another<span style="letter-spacing:-0.2pt;"> </span>company<span style="letter-spacing:-0.35pt;"> </span>to satisfy<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>requirement.<span style="letter-spacing:-0.4pt;"> </span>Moreov<span style="letter-spacing:-0.1pt;">e</span>r,<span style="letter-spacing:-0.35pt;"> </span>developments<span style="letter-spacing:-0.45pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>already<span style="letter-spacing:-0.25pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.05pt;">m</span>pact<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>for <span style="letter-spacing:-0.05pt;">t</span>he <span style="letter-spacing:-0.05pt;">c</span>omb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>prospects<span style="letter-spacing:-0.3pt;"> </span>should<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval.<span style="letter-spacing:-0.3pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>developments<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.3pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>produc<span style="letter-spacing:-0.1pt;">t</span>&#8217;s<span style="letter-spacing:-0.3pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> of efficacy </span>profile,<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;">v</span>ailability<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approv<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>product,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>anges<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>standard<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>care.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A Fast<span style="letter-spacing:-0.1pt;"> </span>Track<span style="letter-spacing:-0.15pt;"> </span>designation,<span style="letter-spacing:-0.5pt;"> </span>Breakthrough<span style="letter-spacing:-0.2pt;"> </span>Therapy<span style="letter-spacing:-0.25pt;"> </span>designation<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>designation<span style="letter-spacing:-0.4pt;"> </span>to facilitate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>lead<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>faster<span style="letter-spacing:0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>aster<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>review<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>process,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>likelihood<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>ca<span style="letter-spacing:-0.05pt;">n</span>didat<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">i</span>ve marketing<span style="letter-spacing:-0.45pt;"> </span>approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>received,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.1pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:-0.1pt;">u</span>ture,<span style="letter-spacing:-0.1pt;"> </span>Fast<span style="letter-spacing:-0.2pt;"> </span>Track<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>Breakthrough<span style="letter-spacing:-0.55pt;"> </span>Therapy<span style="letter-spacing:-0.25pt;"> </span>designation<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;">di</span>dat<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.3pt;"> </span>Rec<span style="letter-spacing:-0.05pt;">e</span>ipt<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a designation<span style="letter-spacing:-0.35pt;"> </span>to facilitate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>date<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>is within<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>discretion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>Accordi<span style="letter-spacing:0.05pt;">n</span>gly,<span style="letter-spacing:-0.5pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">n</span>e<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product cand<span style="letter-spacing:-0.05pt;">i</span>dat<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>cr<span style="letter-spacing:-0.05pt;">i</span>te<span style="letter-spacing:-0.05pt;">r</span>ia<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">i</span>gnat<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>disagree.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>event,<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>receipt<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a desig<span style="letter-spacing:0.05pt;">n</span>ation<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>faster<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>process, review<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>compa<span style="letter-spacing:-0.05pt;">r</span>ed<span style="letter-spacing:-0.3pt;"> </span>to product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>considered<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>conventional<span style="letter-spacing:-0.5pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>procedures and<span style="letter-spacing:-0.1pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>ass<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e ultimate<span style="letter-spacing:-0.25pt;"> </span>mar<span style="letter-spacing:-0.05pt;">k</span>eting<span style="letter-spacing:-0.4pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA. In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>later<span style="letter-spacing:-0.1pt;"> </span>decide<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:-0.2pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>the designation<span style="letter-spacing:-0.35pt;"> </span>conditions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">As</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a condition</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">approval,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">FDA m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">q</span><span style="letter-spacing:0.1pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ire</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">implement</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">var</span><span style="letter-spacing:0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ous</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">post-marketing</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">conduct</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">post-marketi</span><span style="letter-spacing:0.1pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">studies,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">any of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">substantial</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">investment</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">time,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">effort,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">money,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">im</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">omm</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rcial</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">prospects.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>biologic<span style="letter-spacing:-0.35pt;"> </span>licens<span style="letter-spacing:0.05pt;">i</span>ng,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>is authorized<span style="letter-spacing:-0.4pt;"> </span>to <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>quire<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">s</span>ponsors of<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>BLAs<span style="letter-spacing:0.05pt;"> </span>implement<span style="letter-spacing:-0.35pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>post-m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.4pt;"> </span>requirements, including<span style="letter-spacing:-0.3pt;"> </span>REMS<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> P</span>hase&#160;IV trials.<span style="letter-spacing:-0.15pt;"> </span>For e<span style="letter-spacing:0.05pt;">x</span>ample,<span style="letter-spacing:-0.3pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.25pt;"> </span>Novartis&#8217;<span style="letter-spacing:-0.4pt;"> </span>Kymriah<span style="letter-spacing:-0.25pt;"> </span>in August&#160;2017,<span style="letter-spacing:0.05pt;"> </span>a CAR-T&#160;cell<span style="letter-spacing:-0.2pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>eatment of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to 25&#160;years<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>age<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>B<span style="letter-spacing:-0.05pt;">-</span>cell<span style="letter-spacing:-0.15pt;"> </span>precursor<span style="letter-spacing:-0.4pt;"> </span>acute<span style="letter-spacing:-0.35pt;"> </span>lymphoblastic<span style="letter-spacing:-0.45pt;"> </span>leukemia<span style="letter-spacing:-0.3pt;">&#160;</span>(&#8220;ALL&#8221;)<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>refractory<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in second<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.2pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>pse,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>FDA required<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>post-marketing<span style="letter-spacing:-0.5pt;"> </span>commitments,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>a Phase&#160;IV<span style="letter-spacing:-0.05pt;"> </span>trial,<span style="letter-spacing:-0.1pt;"> </span>revalidation<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">e</span>st<span style="letter-spacing:-0.1pt;"> </span>method,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">R</span>EMS<span style="letter-spacing:-0.05pt;"> </span>program<span style="letter-spacing:-0.25pt;"> </span>that included,<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>certification<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>hospitals<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>cli<span style="letter-spacing:-0.05pt;">n</span>ics<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>dis<span style="letter-spacing:0.05pt;">p</span>ense<span style="letter-spacing:-0.25pt;"> </span>Kym<span style="letter-spacing:-0.05pt;">r</span>iah,<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>certification<span style="letter-spacing:-0.4pt;"> </span>includes<span style="letter-spacing:-0.3pt;"> </span>a n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>implementation<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>Kymriah<span style="letter-spacing:-0.25pt;"> </span>training<span style="letter-spacing:-0.25pt;"> </span>program<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mited<span style="letter-spacing:-0.25pt;"> </span>distribution<span style="letter-spacing:-0.4pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">t</span>ifi<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>hospit<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd <span style="letter-spacing:-0.05pt;">t</span>heir<span style="letter-spacing:-0.1pt;"> </span>associ<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d clinics.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>pproval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>determine<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>burdensome<span style="letter-spacing:-0.35pt;"> </span>post-ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>al requirements<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>necessary to ensure<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">n</span>didates<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.25pt;"> </span>safe,<span style="letter-spacing:-0.1pt;"> </span>pure<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>potent.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to e<span style="letter-spacing:-0.1pt;">s</span>tablish<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>implement<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>post-approval requirements,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>ill likely<span style="letter-spacing:-0.15pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to invest<span style="letter-spacing:-0.25pt;"> </span>a signif<span style="letter-spacing:-0.05pt;">i</span>cant<span style="letter-spacing:-0.45pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>time,<span style="letter-spacing:-0.15pt;"> </span>effort<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>mon<span style="letter-spacing:0.1pt;">e</span>y.<span style="letter-spacing:-0.15pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>post-approv<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mit<span style="letter-spacing:-0.15pt;"> </span>the commercial<span style="letter-spacing:-0.4pt;"> </span>prospects<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to establish<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">e</span>ffective<span style="letter-spacing:-0.3pt;"> </span>marketing<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>capabilities<span style="letter-spacing:-0.35pt;"> </span>or enter<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>agreements<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>and sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candida<span style="letter-spacing:-0.05pt;">t</span>es,<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>approved,<span style="letter-spacing:-0.35pt;"> </span>and as a<span style="letter-spacing:-0.05pt;"> </span>result,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>revenues.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a comme<span style="letter-spacing:-0.05pt;">r</span>cial<span style="letter-spacing:-0.4pt;"> </span>infrastructure<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>marketing,<span style="letter-spacing:-0.35pt;"> </span>sale<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>dis<span style="letter-spacing:-0.15pt;">t</span>ribution<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>products.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>approved,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>must<span style="letter-spacing:-0.2pt;"> </span>build<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>rketing,<span style="letter-spacing:-0.35pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>distribution<span style="letter-spacing:-0.35pt;"> </span>capabilities<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> a</span>rrange<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.35pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>rvic<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>, whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ime<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>req<span style="letter-spacing:0.05pt;">u</span>ire<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>f<span style="letter-spacing:-0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>ncial<span style="letter-spacing:-0.25pt;"> </span>expenditures<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.4pt;"> </span>in doing<span style="letter-spacing:-0.15pt;"> </span>so.<span style="letter-spacing:-0.05pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>re<span style="letter-spacing:-0.15pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>involved<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>establishing<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>and sales<span style="letter-spacing:-0.15pt;"> </span>capabilities.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>recruiting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>tra<span style="letter-spacing:-0.1pt;">i</span>ning<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.2pt;"> </span>force<span style="letter-spacing:-0.25pt;"> </span>is expensive<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>time-cons<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">m</span>ing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> any product </span>launch.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">u</span>nch<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we recruit<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>sales<span style="letter-spacing:-0.2pt;"> </span>force<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>establish<span style="letter-spacing:-0.35pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>capab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>delayed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>occur<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>reason,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>incurred<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>expenses<span style="letter-spacing:-0.3pt;"> </span>prematurely<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>unnecessarily.<span style="letter-spacing:-0.5pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>effor<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>costly,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>investment<span style="letter-spacing:-0.4pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>lost<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>retain<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>reposi<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>sales<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>rsonnel.<span style="letter-spacing:-0.4pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">e</span>ffe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.3pt;"> </span>est<span style="letter-spacing:-0.05pt;">a</span>blish a sales<span style="letter-spacing:-0.15pt;"> </span>force<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>a marketing<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;"> </span>infr<span style="letter-spacing:0.05pt;">a</span>structure,<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur s<span style="letter-spacing:0.05pt;">a</span>les force<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.4pt;"> </span>teams<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot be<span style="letter-spacing:-0.1pt;"> </span>successful<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mmercializing<span style="letter-spacing:-0.6pt;"> </span>our current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>To<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>extent<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>to comm<span style="letter-spacing:-0.1pt;">e</span>rcialize<span style="letter-spacing:-0.5pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval,<span style="letter-spacing:-0.35pt;"> </span>we would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>ef<span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>ts<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>liable<span style="letter-spacing:-0.2pt;"> </span>if they<span style="letter-spacing:-0.2pt;"> </span>fai<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>gal<span style="letter-spacing:-0.15pt;"> </span>or re<span style="letter-spacing:-0.05pt;">g</span>ulatory<span style="letter-spacing:-0.35pt;"> </span>requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>little<span style="letter-spacing:-0.15pt;"> </span>to no prior<span style="letter-spacing:-0.2pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>ma<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>eting,<span style="letter-spacing:-0.4pt;"> </span>sale,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>distribution<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.6pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>risks<span style="letter-spacing:0.05pt;"> </span>involved in the<span style="letter-spacing:-0.15pt;"> </span>building<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>managing<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a commercial<span style="letter-spacing:-0.5pt;"> </span>infra<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>ru<span style="letter-spacing:0.05pt;">c</span>ture.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:0.05pt;">a</span>bli<span style="letter-spacing:0.1pt;">s</span>hment<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>m<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">pab</span>il<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span>uding<span style="letter-spacing:-0.3pt;"> </span>a comprehensive healthcare<span style="letter-spacing:-0.35pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>progra<span style="letter-spacing:-0.05pt;">m</span>,<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>expensive<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>consuming<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ould<span style="letter-spacing:-0.25pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>launch,<span style="letter-spacing:-0.3pt;"> </span>and we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>successf<span style="letter-spacing:-0.05pt;">u</span>lly<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:-0.05pt;">e</span>lop<span style="letter-spacing:-0.3pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>p<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty.<span style="letter-spacing:-0.4pt;"> </span>W<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>to compete<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>pharmace<span style="letter-spacing:-0.1pt;">u</span>tical<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>biotechnology companies<span style="letter-spacing:-0.4pt;"> </span>to recruit,<span style="letter-spacing:-0.25pt;"> </span>hire,<span style="letter-spacing:-0.15pt;"> </span>train,<span style="letter-spacing:-0.2pt;"> </span>manage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>retain<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>affairs,<span style="letter-spacing:-0.15pt;"> </span>marketing,<span style="letter-spacing:-0.35pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commer<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.45pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>personnel.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span>vent<span style="letter-spacing:-0.1pt;"> </span>we <span style="letter-spacing:0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to develop<span style="letter-spacing:-0.25pt;"> </span>a commercial<span style="letter-spacing:-0.4pt;"> </span>infras<span style="letter-spacing:0.05pt;">t</span>ructure,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:0.05pt;">u</span>re<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>would l<span style="letter-spacing:-0.05pt;">i</span>mit<span style="letter-spacing:-0.15pt;"> </span>our abi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.25pt;"> </span>to generate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>revenues.<span style="letter-spacing:-0.3pt;"> </span>Facto<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>inhibit<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>to commercialize<span style="letter-spacing:-0.6pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">g</span>enerate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>revenues inc<span style="letter-spacing:-0.05pt;">l</span>ude:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">f t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="color:#000000;">19 pandemic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">continues</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reocc</span><span style="letter-spacing:0.1pt;color:#000000;">u</span><span style="color:#000000;">rs</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">it may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">negatively</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to establish</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">operations,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">educa</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and interact</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">pro</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">essionals,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">successfully</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">laun</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">h</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">timely</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">access</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">persuade</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">adequ</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">numbers</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">physicians</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prescribe</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">rrent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to effectively</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">oversee</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">geogr</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">phically</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">dispersed</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">team&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">time</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">itial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">ongoing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">training</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">k</span><span style="color:#000000;">eting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">pe</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">onnel</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">compliance matters</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">monitoring</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">n inability</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">secure</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">adequate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">private</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">plans&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">indications</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imitations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">warnings,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">distribution</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">restrictio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">conta</span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ned</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">products&#8217;</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ny distribution</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">strictions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">imposed</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">agr</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">part</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">mandatory</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">REMS</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">voluntary</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">risk management</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">plan&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">iability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or marketing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">personnel</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">who</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">fail</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">comply</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">applicable</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">gulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">lack</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">complementary</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">offered</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">personnel,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">put</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">etitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">disadvantage</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">relative</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">o companies</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">extensive</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">lines&#59;</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unforeseen</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">costs</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">expenses</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">sociated</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">creating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">independent</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">organization</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">engaging</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">contract</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s organization.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>our product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>achieve<span style="letter-spacing:-0.25pt;"> </span>b<span style="letter-spacing:0.05pt;">r</span>oad<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>acceptance,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>rev<span style="letter-spacing:0.1pt;">e</span>nues<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>from their<span style="letter-spacing:-0.2pt;"> </span>sales<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>limit<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>commercialized<span style="letter-spacing:-0.55pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>indication.<span style="letter-spacing:-0.2pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>appropri<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>regulatory authorities<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>sale,<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>gain<span style="letter-spacing:-0.15pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>among<span style="letter-spacing:-0.25pt;"> </span>physicians,<span style="letter-spacing:-0.4pt;"> </span>patients,<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ird-party<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>in <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.15pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>community.<span style="letter-spacing:-0.4pt;"> </span>If any<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>gain<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.4pt;"> </span>level<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>acceptance,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>generate<span style="letter-spacing:-0.3pt;"> </span>significant prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>bec<span style="letter-spacing:0.05pt;">o</span>me<span style="letter-spacing:-0.35pt;"> </span>pro<span style="letter-spacing:0.1pt;">f</span>itable.<span style="letter-spacing:-0.2pt;"> </span>Market<span style="letter-spacing:-0.3pt;"> </span>acceptance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>medic<span style="letter-spacing:0.1pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>community,<span style="letter-spacing:-0.45pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>will depend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:0.05pt;">o</span>me<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>yond our<span style="letter-spacing:-0.05pt;"> </span>control.<span style="letter-spacing:-0.35pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>physicians<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>often<span style="letter-spacing:-0.2pt;"> </span>reluctant<span style="letter-spacing:-0.3pt;"> </span>to switch<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;">i</span>r<span style="letter-spacing:-0.2pt;"> </span>patients,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patients may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>relu<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">a</span>nt<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o swit<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>fro<span style="letter-spacing:-0.05pt;">m</span>,<span style="letter-spacing:-0.15pt;"> </span>exist<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>rap<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ven<span style="letter-spacing:-0.1pt;"> </span>wh<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>w<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>poten<span style="letter-spacing:-0.05pt;">t</span>ia<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.4pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span>f<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;"> t</span>re<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nter<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rke<span style="letter-spacing:-0.05pt;">t</span>. Efforts<span style="letter-spacing:-0.2pt;"> </span>to educate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>community<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>benefits<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>signific<span style="letter-spacing:0.05pt;">a</span>nt<span style="letter-spacing:-0.4pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>may n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>.<span style="letter-spacing:-0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>is approved<span style="letter-spacing:-0.4pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>level<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>acceptance,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>generate sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>become<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>ofitable.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>degree<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>acceptance<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>d<span style="letter-spacing:-0.1pt;">e</span>pend<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of factors,<span style="letter-spacing:-0.2pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">continued</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prevalence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">severity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adverse</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">associated</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">indications</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approv</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">claims</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prod</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">cts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">imitations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">warnings</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">contained</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product&#8217;s</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">FDA-approv</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">labeling,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">po</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ential</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">limitations</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">warnings</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ducts that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">more</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">strictive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">standard</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">care</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">tar</span><span style="letter-spacing:0.05pt;color:#000000;">g</span><span style="color:#000000;">eted</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">indications</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ch</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">relative</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diffic</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">lty</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">adminis</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ration</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ost</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">treatment</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">versus</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">economic</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd clinical</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">benefit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in relation</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to a</span><span style="letter-spacing:-0.1pt;color:#000000;">l</span><span style="color:#000000;">ternative</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">treatments</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availability</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">adequ</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">coverage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">parties,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">insurance</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">companies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">payors,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by government</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">healthcare</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">programs,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">Medicare</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">Medicai</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">extent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strength</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">distribution</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">safety,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">efficacy</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">advantages</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">over,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">v</span><span style="color:#000000;">ai</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">bi</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ity</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of, a</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">nat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">tre</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tm</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">lr</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ady</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">used</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hat</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">later</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be approved</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intended</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">distribution</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">restricti</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ns</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">imposed</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">FDA with</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">respect</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">produ</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">to which</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">agree</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">part</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a mandatory REMS</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">voluntary</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">risk</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">management plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">timing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">market</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">introduction</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">well</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">offer</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">cand</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">dates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">sale</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">at</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">prices&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">willingness</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">target</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">population</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">try</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">therapies</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ph</span><span style="letter-spacing:0.1pt;color:#000000;">y</span><span style="color:#000000;">sicians</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">prescribe</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">these</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">extent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strength</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:0.05pt;color:#000000;">-</span><span style="color:#000000;">party</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">manufacturer</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and supplier</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">support&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">produ</span><span style="letter-spacing:0.15pt;color:#000000;">c</span><span style="color:#000000;">ts</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">same</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">dverse</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">publicity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">about</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">favora</span><span style="letter-spacing:-0.05pt;color:#000000;">b</span><span style="color:#000000;">le</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">publicity</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">about</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">p</span><span style="color:#000000;">etitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">liability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">claims.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>efforts<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>educate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>medic<span style="letter-spacing:0.1pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>community<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>pa<span style="letter-spacing:0.05pt;">y</span>o<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.15pt;"> </span>as to the<span style="letter-spacing:-0.1pt;"> </span>benefits<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gnificant<span style="letter-spacing:-0.35pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>and may<span style="letter-spacing:-0.2pt;"> </span>never<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>successful.<span style="letter-spacing:-0.45pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>med<span style="letter-spacing:0.1pt;">i</span>cal<span style="letter-spacing:-0.35pt;"> </span>community<span style="letter-spacing:-0.4pt;"> </span>accepts<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>safe<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>indications, p<span style="letter-spacing:0.05pt;">h</span>ysicians<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>immediately<span style="letter-spacing:-0.4pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>receptive<span style="letter-spacing:-0.3pt;"> </span>to such<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>slow to adopt<span style="letter-spacing:-0.25pt;"> </span>them<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>accept<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>re<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the approved<span style="letter-spacing:-0.35pt;"> </span>indications.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>fut<span style="letter-spacing:-0.05pt;">u</span>re<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:-0.05pt;">r</span>oved<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">d</span>equate<span style="letter-spacing:-0.3pt;"> </span>level<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>accepta<span style="letter-spacing:-0.05pt;">n</span>ce<span style="letter-spacing:-0.45pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>physicians, patients,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payors, we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>meaningful<span style="letter-spacing:-0.35pt;"> </span>revenues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidat<span style="letter-spacing:-0.15pt;">e</span>s,<span style="letter-spacing:-0.3pt;"> </span>in which<span style="letter-spacing:-0.15pt;"> </span>case<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> n</span>ot expect<span style="letter-spacing:-0.25pt;"> </span>to become profitable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mpetition<span style="letter-spacing:-0.45pt;"> </span>sooner<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>anticipated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>enactment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Biologics<span style="letter-spacing:-0.4pt;"> </span>Price<span style="letter-spacing:-0.25pt;"> </span>Competition<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Innovation<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>2009<span style="letter-spacing:0.05pt;"> </span>(&#8220;BPCIA&#8221;)<span style="letter-spacing:0.05pt;"> </span>created<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>abbre<span style="letter-spacing:0.05pt;">v</span>iated<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>thway<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">p</span>proval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>biosimilar and<span style="letter-spacing:-0.1pt;"> </span>inte<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">c</span>hangeable<span style="letter-spacing:-0.5pt;"> </span>biological<span style="letter-spacing:-0.3pt;"> </span>products.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>abbreviated<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>pathway<span style="letter-spacing:-0.3pt;"> </span>establi<span style="letter-spacing:-0.05pt;">s</span>hes<span style="letter-spacing:-0.3pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>authority<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approve<span style="letter-spacing:-0.25pt;"> </span>biosimilar biologics,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>possible<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>signation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>biosimilar<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>&#8220;in<span style="letter-spacing:0.05pt;">t</span>erchangeable&#8221;<span style="letter-spacing:-0.65pt;"> </span>based<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:-0.1pt;"> </span>sim<span style="letter-spacing:-0.1pt;">i</span>lar<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.35pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>n <span style="letter-spacing:-0.05pt;">e</span>xisting<span style="letter-spacing:-0.25pt;"> </span>brand<span style="letter-spacing:-0.25pt;"> </span>product.<span style="letter-spacing:-0.25pt;"> </span>Under<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>BPCIA, the<span style="letter-spacing:-0.15pt;"> </span>FDA cannot<span style="letter-spacing:-0.3pt;"> </span>make<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">a</span>pplication<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a biosimilar<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>12<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:-0.15pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>original<span style="letter-spacing:-0.25pt;"> </span>branded<span style="letter-spacing:-0.35pt;"> </span>product was approved under a BLA.<span style="letter-spacing:0.05pt;"> </span>Certain<span style="letter-spacing:-0.2pt;"> </span>changes,<span style="letter-spacing:-0.25pt;"> </span>ho<span style="letter-spacing:-0.05pt;">w</span>ever,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>supplements<span style="letter-spacing:-0.4pt;"> </span>to an<span style="letter-spacing:-0.05pt;"> </span>app<span style="letter-spacing:-0.1pt;">r</span>oved<span style="letter-spacing:-0.3pt;"> </span>BLA,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>subsequent applications<span style="letter-spacing:-0.5pt;"> </span>fil<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>spons<span style="letter-spacing:0.05pt;">o</span>r,<span style="letter-spacing:-0.05pt;"> </span>manufacturer, li<span style="letter-spacing:-0.05pt;">c</span>ensor,<span style="letter-spacing:-0.1pt;"> </span>pred<span style="letter-spacing:-0.05pt;">e</span>cessor<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>entity<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>qualify<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>12-year<span style="letter-spacing:-0.2pt;"> </span>exclusivity<span style="letter-spacing:-0.4pt;"> </span>period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>BPCIA&#8217;s<span style="letter-spacing:-0.05pt;"> </span>12-year<span style="letter-spacing:-0.3pt;"> </span>period<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>exclusivity.<span style="letter-spacing:-0.35pt;"> </span>Howev<span style="letter-spacing:0.05pt;">e</span>r,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t consider<span style="letter-spacing:-0.35pt;"> </span>our <span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>od<span style="letter-spacing:0.05pt;">u</span>ct candidates<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reference<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">o</span>ten<span style="letter-spacing:-0.1pt;">t</span>ially<span style="letter-spacing:-0.35pt;"> </span>creating<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>opport<span style="letter-spacing:0.05pt;">u</span>nity<span style="letter-spacing:-0.45pt;"> </span>f<span style="letter-spacing:0.05pt;">o</span>r bi<span style="letter-spacing:0.05pt;">o</span>similar<span style="letter-spacing:-0.3pt;"> </span>competition<span style="letter-spacing:-0.4pt;"> </span>sooner<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;"> a</span>nti<span style="letter-spacing:-0.05pt;">c</span>ipa<span style="letter-spacing:-0.05pt;">t</span>ed. Additionally,<span style="letter-spacing:-0.45pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>pe<span style="letter-spacing:-0.05pt;">r</span>iod<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span>ock<span style="letter-spacing:-0.2pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>pursu<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>via<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>tradit<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.4pt;"> </span>BLA,<span style="letter-spacing:0.05pt;"> </span>rather<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>via the<span style="letter-spacing:-0.15pt;"> </span>abbreviated<span style="letter-spacing:-0.4pt;"> </span>pathway.<span style="letter-spacing:-0.3pt;"> </span>Changes<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>period<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>legis<span style="letter-spacing:0.05pt;">l</span>ation<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>en<span style="letter-spacing:-0.1pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>to reduce<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>exclusivity.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>a period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>BPCIA<span style="letter-spacing:-0.05pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>product,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>subse<span style="letter-spacing:0.05pt;">q</span>ue<span style="letter-spacing:0.1pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>include<span style="letter-spacing:-0.25pt;"> </span>a modification<span style="letter-spacing:-0.45pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>structure<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>impacts<span style="letter-spacing:-0.3pt;"> </span>safety,<span style="letter-spacing:-0.3pt;"> </span>purity,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>potency,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dditional<span style="letter-spacing:-0.35pt;"> </span>periods<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>exclusivity<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>those prod<span style="letter-spacing:0.05pt;">u</span>cts.<span style="letter-spacing:-0.05pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>to which<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>biosimilar,<span style="letter-spacing:-0.35pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>approv<span style="letter-spacing:0.05pt;">e</span>d,<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>substituted<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ny one<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>refere<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in a way<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is similar<span style="letter-spacing:-0.2pt;"> </span>to traditional<span style="letter-spacing:-0.3pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>substitution<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>non-biological<span style="letter-spacing:-0.45pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>is not<span style="letter-spacing:-0.05pt;"> </span>y<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;"> </span>clear,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>dep<span style="letter-spacing:-0.1pt;">e</span>nd<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>marke<span style="letter-spacing:0.05pt;">t</span>place<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>factors that<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>still<span style="letter-spacing:-0.15pt;"> </span>developing.<span style="letter-spacing:-0.45pt;"> </span>Medicare<span style="letter-spacing:-0.4pt;"> </span>Part<span style="letter-spacing:-0.2pt;"> </span>B encourages<span style="letter-spacing:-0.45pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>biosimilars<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>paying<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>provider<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sa<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.2pt;"> </span>perc<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">a</span>ge<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>f<span style="letter-spacing:-0.05pt;">e</span>rence<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>average sale<span style="letter-spacing:-0.2pt;"> </span>price<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a mark-up,<span style="letter-spacing:-0.4pt;"> </span>regardless<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>whi<span style="letter-spacing:0.1pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>is reimbursed.<span style="letter-spacing:-0.45pt;"> </span>It is<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> w</span>ill give<span style="letter-spacing:-0.1pt;"> </span>rei<span style="letter-spacing:-0.05pt;">m</span>bursement<span style="letter-spacing:-0.5pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span>feren<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>biosim<span style="letter-spacing:-0.05pt;">i</span>lars<span style="letter-spacing:-0.35pt;"> </span>even o<span style="letter-spacing:0.05pt;">v</span>er<span style="letter-spacing:-0.05pt;"> </span>reference<span style="letter-spacing:-0.3pt;"> </span>biologics<span style="letter-spacing:-0.35pt;"> </span>abs<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">i</span>na<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interchangeability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For<span style="letter-spacing:0.95pt;"> </span>our<span style="letter-spacing:0.5pt;"> </span>small<span style="letter-spacing:1.25pt;"> </span>molecular<span style="letter-spacing:1.9pt;"> </span>product<span style="letter-spacing:1.65pt;"> </span>candidates,<span style="letter-spacing:1.85pt;"> </span>if<span style="letter-spacing:0.25pt;"> </span>qualified,<span style="letter-spacing:1.75pt;"> </span>the<span style="letter-spacing:0.4pt;"> </span>regulatory exclusivity<span style="letter-spacing:1.9pt;"> </span>period<span style="letter-spacing:1.7pt;"> </span>is less<span style="letter-spacing:0.6pt;"> </span>than<span style="letter-spacing:0.95pt;"> </span>for<span style="letter-spacing:1pt;"> </span>our<span style="letter-spacing:0.55pt;"> </span>biologic<span style="letter-spacing:1.9pt;"> </span>product<span style="letter-spacing:1.15pt;"> </span>candidates. The<span style="letter-spacing:0.55pt;"> </span>Federal Food,<span style="letter-spacing:1.35pt;"> </span>Drug,<span style="letter-spacing:1.4pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>Cosmetic<span style="letter-spacing:1.7pt;"> </span>Act<span style="letter-spacing:0.65pt;">&#160;</span>(&#8220;FDCA&#8221;) provides<span style="letter-spacing:1.6pt;"> </span>a<span style="letter-spacing:0.15pt;"> </span>five-year<span style="letter-spacing:1.75pt;"> </span>period<span style="letter-spacing:1.25pt;"> </span>of<span style="letter-spacing:0.35pt;"> </span>non-patent<span style="letter-spacing:1.75pt;"> </span>marketing<span style="letter-spacing:2.05pt;"> </span>exclusivity<span style="letter-spacing:1.8pt;"> </span>within<span style="letter-spacing:1.2pt;"> </span>the<span style="letter-spacing:0.7pt;"> </span>United<span style="letter-spacing:1.45pt;"> </span>States<span style="letter-spacing:1pt;"> </span>to<span style="letter-spacing:0.65pt;"> </span>the<span style="letter-spacing:0.85pt;"> </span>first<span style="letter-spacing:0.65pt;"> </span>applicant to<span style="letter-spacing:0.8pt;"> </span>gain<span style="letter-spacing:0.75pt;"> </span>approval<span style="letter-spacing:1.9pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>an<span style="letter-spacing:0.25pt;"> </span>NDA<span style="letter-spacing:0.9pt;"> </span>for<span style="letter-spacing:1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:1.05pt;"> </span>chemical<span style="letter-spacing:1.9pt;"> </span>entity.<span style="letter-spacing:1.15pt;"> </span>A<span style="letter-spacing:0.55pt;"> </span>drug<span style="letter-spacing:1.1pt;"> </span>is<span style="letter-spacing:0.75pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:1pt;"> </span>chemical<span style="letter-spacing:1.55pt;"> </span>entity<span style="letter-spacing:1.05pt;"> </span>if the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>previously<span style="letter-spacing:-0.45pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>containing<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>active<span style="letter-spacing:-0.2pt;"> </span>moiety,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>is the<span style="letter-spacing:-0.15pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ion<span style="letter-spacing:-0.15pt;"> </span>respons<span style="letter-spacing:-0.05pt;">i</span>ble<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>action<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>substance.<span style="letter-spacing:-0.3pt;"> </span>During the<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>clusivity<span style="letter-spacing:-0.35pt;"> </span>period,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cept<span style="letter-spacing:-0.25pt;"> </span>for rev<span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>n abbr<span style="letter-spacing:-0.05pt;">e</span>vi<span style="letter-spacing:-0.1pt;">a</span>ted<span style="letter-spacing:-0.4pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a 505(b)(2)<span style="letter-spacing:-0.05pt;">&#160;</span>NDA submitted<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>another<span style="letter-spacing:-0.25pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>version<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>where<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>applica<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>does<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a legal<span style="letter-spacing:-0.15pt;"> </span>right<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>refe<span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ll<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">th</span>e<span style="letter-spacing:-0.05pt;"> da</span>ta required<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>approval.<span style="letter-spacing:-0.4pt;"> </span>However,<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>submitted<span style="letter-spacing:-0.3pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>four<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:-0.15pt;"> </span>if it <span style="letter-spacing:-0.15pt;">c</span>ontains<span style="letter-spacing:-0.25pt;"> </span>a certification<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>inva<span style="letter-spacing:-0.1pt;">l</span>idity<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>non-infringement. The<span style="letter-spacing:-0.2pt;"> </span>FDCA<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>provides<span style="letter-spacing:-0.25pt;"> </span>three<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>mar<span style="letter-spacing:-0.1pt;">k</span>eting<span style="letter-spacing:-0.4pt;"> </span>exclu<span style="letter-spacing:0.05pt;">s</span>ivity<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>an NDA, 505(b<span style="letter-spacing:-0.05pt;">)</span>(2)<span style="letter-spacing:0.05pt;">&#160;</span>N<span style="letter-spacing:0.05pt;">D</span>A<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>supplement<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>exi<span style="letter-spacing:0.05pt;">s</span>ting<span style="letter-spacing:-0.3pt;"> </span>NDA if<span style="letter-spacing:-0.1pt;"> </span>new c<span style="letter-spacing:0.15pt;">l</span><span style="letter-spacing:-0.05pt;">in</span>i<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">al </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>bioav<span style="letter-spacing:0.05pt;">a</span>ilability<span style="letter-spacing:-0.5pt;"> </span>studies,<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">c</span>onducted<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>sponsored<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>appli<span style="letter-spacing:-0.05pt;">c</span>ant<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>deemed<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> e</span>ss<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>he approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicatio<span style="letter-spacing:0.05pt;">n</span>,<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>w<span style="letter-spacing:-0.15pt;"> </span>indications,<span style="letter-spacing:-0.35pt;"> </span>dosages<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strengths<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>drug.<span style="letter-spacing:0.05pt;"> </span>As su<span style="letter-spacing:0.05pt;">c</span>h, we m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>ce<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:0.05pt;">e</span>tition<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>gene<span style="letter-spacing:-0.05pt;">r</span>ic versions<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>small<span style="letter-spacing:-0.2pt;"> </span>molecule<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>negative<span style="letter-spacing:0.05pt;">l</span>y<span style="letter-spacing:-0.3pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>long-term<span style="letter-spacing:-0.3pt;"> </span>busi<span style="letter-spacing:-0.05pt;">n</span>ess<span style="letter-spacing:-0.2pt;"> </span>prospects<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>opportunities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y proposed<span style="letter-spacing:0.05pt;"> </span>branded<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>names,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">a</span>ilure<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>associated<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>adversely affect<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r <span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any name<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>intend<span style="letter-spacing:-0.15pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>regardless<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>secured<span style="letter-spacing:-0.2pt;"> </span>a formal<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ademark<span style="letter-spacing:-0.35pt;"> </span>registration<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>Patent<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Trademark<span style="letter-spacing:-0.4pt;"> </span>Office<span style="letter-spacing:-0.2pt;">&#160;</span>(&#8220;USPTO&#8221;).<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>typically<span style="letter-spacing:-0.35pt;"> </span>conducts<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>prop<span style="letter-spacing:0.05pt;">o</span>sed<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>names,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>aluation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>pote<span style="letter-spacing:-0.1pt;">n</span>tial<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>confusion<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>names.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>object<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a product<span style="letter-spacing:-0.3pt;"> </span>n<span style="letter-spacing:0.1pt;">a</span>me<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>it beli<span style="letter-spacing:-0.05pt;">e</span>v<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>appropriately<span style="letter-spacing:-0.5pt;"> </span>implies<span style="letter-spacing:-0.2pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>contributes<span style="letter-spacing:-0.35pt;"> </span>to an<span style="letter-spacing:-0.15pt;"> </span>overstatement<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> e</span>fficacy.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>objects<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proposed<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>names,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>adopt<span style="letter-spacing:-0.15pt;"> </span>alternative<span style="letter-spacing:-0.4pt;"> </span>names<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>adopt<span style="letter-spacing:-0.25pt;"> </span>alternative<span style="letter-spacing:-0.35pt;"> </span>names,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>lose<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>benefit<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>tradema<span style="letter-spacing:-0.05pt;">r</span>k<span style="letter-spacing:0.05pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>date<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>expend<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>dditional<span style="letter-spacing:-0.35pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>effort<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o iden<span style="letter-spacing:-0.05pt;">t</span>ify<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>sui<span style="letter-spacing:-0.05pt;">t</span>ab<span style="letter-spacing:-0.05pt;">l</span>e prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>name<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>trademark<span style="letter-spacing:-0.35pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>infringe<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.1pt;">w</span>ise<span style="letter-spacing:-0.3pt;"> </span>violate<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>ri<span style="letter-spacing:0.05pt;">g</span>hts<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>ac<span style="letter-spacing:-0.05pt;">c</span>ep<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ble to the<span style="letter-spacing:-0.1pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>build<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.2pt;"> </span>brand<span style="letter-spacing:-0.25pt;"> </span>identity<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a new<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>name<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a timely<span style="letter-spacing:-0.25pt;"> </span>manner<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at all,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.05pt;">o</span>uld<span style="letter-spacing:-0.1pt;"> </span>li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>to commercialize<span style="letter-spacing:-0.5pt;"> </span>our product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pendent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">informa</span><span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">olog</span><span style="letter-spacing:-0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fras</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ructure</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">data.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.1pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">omputer</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.1pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ems,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">used</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CROs, C</span><span style="letter-spacing:0.05pt;">M</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Os, </span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">contractors</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consultants,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or suffer s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rity</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">b</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ea</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dependent<span style="letter-spacing:-0.3pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>inform<span style="letter-spacing:-0.1pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>systems,<span style="letter-spacing:-0.35pt;"> </span>infrastruc<span style="letter-spacing:0.05pt;">t</span>ure<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>data.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ordinary<span style="letter-spacing:-0.2pt;"> </span>course<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>directly<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>indirectly col<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ore<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>transm<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">i</span>tive<span style="letter-spacing:-0.25pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property,<span style="letter-spacing:-0.3pt;"> </span>confidential<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nforma<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.4pt;"> </span>pre<span style="letter-spacing:-0.1pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>dat<span style="letter-spacing:-0.05pt;">a</span>,<span style="letter-spacing:-0.15pt;"> </span>proprie<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ry<span style="letter-spacing:-0.3pt;"> </span>bus<span style="letter-spacing:-0.05pt;">i</span>ness information,<span style="letter-spacing:-0.4pt;"> </span>personal<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>personally<span style="letter-spacing:-0.4pt;"> </span>identifiable<span style="letter-spacing:-0.35pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ec<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>centers<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our networks,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span>T<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.2pt;"> </span>secure<span style="letter-spacing:-0.2pt;"> </span>processing,<span style="letter-spacing:-0.45pt;"> </span>ma<span style="letter-spacing:-0.05pt;">i</span>nten<span style="letter-spacing:-0.05pt;">a</span>nce<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd tr<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.05pt;">m</span>iss<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of this<span style="letter-spacing:-0.15pt;"> </span>inform<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>is <span style="letter-spacing:-0.05pt;">c</span>rit<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.45pt;"> </span>The multitude<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>complexity<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>computer<span style="letter-spacing:-0.35pt;"> </span>systems<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CROs, CMOs, clinical<span style="letter-spacing:-0.2pt;"> </span>sites<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ractors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>consultan<span style="letter-spacing:0.05pt;">t</span>s<span style="letter-spacing:-0.35pt;"> </span>make<span style="letter-spacing:-0.25pt;"> </span>them inherently<span style="letter-spacing:-0.35pt;"> </span>vulnerable<span style="letter-spacing:-0.35pt;"> </span>to service<span style="letter-spacing:-0.25pt;"> </span>interruption<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>destruction,<span style="letter-spacing:-0.35pt;"> </span>mal<span style="letter-spacing:-0.1pt;">i</span>cious<span style="letter-spacing:-0.3pt;"> </span>intrusion<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>ndom<span style="letter-spacing:-0.3pt;"> </span>attack.<span style="letter-spacing:-0.25pt;"> </span>Data<span style="letter-spacing:-0.1pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>security<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">b</span>reaches<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties, employees,<span style="letter-spacing:-0.35pt;"> </span>contractors<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>others<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>pose<span style="letter-spacing:0.05pt;"> </span>a risk<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>sensiti<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.25pt;"> </span>data,<span style="letter-spacing:-0.1pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property,<span style="letter-spacing:-0.4pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:-0.3pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our employees,<span style="letter-spacing:-0.35pt;"> </span>patients,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>partn<span style="letter-spacing:-0.05pt;">e</span>rs<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>exposed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>unaut<span style="letter-spacing:0.05pt;">h</span>o<span style="letter-spacing:-0.05pt;">r</span>ized<span style="letter-spacing:-0.3pt;"> </span>persons<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>public.<span style="letter-spacing:-0.2pt;"> </span>Despite<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>implement<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>security measures,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>computer<span style="letter-spacing:-0.35pt;"> </span>systems<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our CROs,<span style="letter-spacing:-0.05pt;"> </span>C<span style="letter-spacing:-0.05pt;">M</span>Os, c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontractors<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>consultants<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>vulnerable<span style="letter-spacing:-0.35pt;"> </span>to failure<span style="letter-spacing:-0.2pt;"> </span>or damage<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>computer<span style="letter-spacing:-0.3pt;"> </span>viruses<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>mal<span style="letter-spacing:-0.05pt;">w</span>are,<span style="letter-spacing:-0.4pt;"> </span>employee<span style="letter-spacing:-0.3pt;"> </span>error,<span style="letter-spacing:-0.15pt;"> </span>unauthorized<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>authori<span style="letter-spacing:0.05pt;">z</span>ed<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">c</span>c<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.15pt;"> </span>or oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>cybe<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>ecurity<span style="letter-spacing:-0.4pt;"> </span>attacks,<span style="letter-spacing:-0.2pt;"> </span>natural<span style="letter-spacing:-0.25pt;"> </span>disasters, terrorism,<span style="letter-spacing:-0.35pt;"> </span>war,<span style="letter-spacing:-0.05pt;"> </span>fire<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>telecommunication<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>electrical<span style="letter-spacing:-0.35pt;"> </span>failures.<span style="letter-spacing:-0.25pt;"> </span>Cyberattacks<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>increasing<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>equency,<span style="letter-spacing:-0.35pt;"> </span>sophistica<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>intensity.<span style="letter-spacing:-0.3pt;"> </span>The techniques<span style="letter-spacing:-0.4pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>cyber<span style="letter-spacing:-0.25pt;"> </span>crimina<span style="letter-spacing:0.05pt;">l</span>s<span style="letter-spacing:-0.25pt;"> </span>change<span style="letter-spacing:-0.2pt;"> </span>frequently,<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>recognized<span style="letter-spacing:-0.45pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>launched<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>originate<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>wide<span style="letter-spacing:-0.2pt;"> </span>variety<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>sources,<span style="letter-spacing:0.05pt;"> </span>including o<span style="letter-spacing:0.05pt;">u</span>tside<span style="letter-spacing:-0.2pt;"> </span>groups<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>external<span style="letter-spacing:-0.25pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oviders,<span style="letter-spacing:-0.3pt;"> </span>organized<span style="letter-spacing:-0.35pt;"> </span>crime<span style="letter-spacing:-0.2pt;"> </span>aff<span style="letter-spacing:-0.1pt;">i</span>liates,<span style="letter-spacing:-0.3pt;"> </span>terrorist<span style="letter-spacing:-0.35pt;"> </span>organizations<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ho<span style="letter-spacing:0.05pt;">s</span>tile<span style="letter-spacing:-0.05pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span>nments<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>gen<span style="letter-spacing:0.05pt;">c</span>ie<span style="letter-spacing:0.05pt;">s</span>. Cy<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>rattacks<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>deployment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>rmful<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>lwar<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>deni<span style="letter-spacing:-0.05pt;">a</span>l-of-serv<span style="letter-spacing:-0.05pt;">i</span>ce,<span style="letter-spacing:-0.45pt;"> </span>soc<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>engineering<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>means<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>ervice<span style="letter-spacing:-0.2pt;"> </span>reliability<span style="letter-spacing:-0.3pt;"> </span>and thre<span style="letter-spacing:-0.05pt;">a</span>ten<span style="letter-spacing:-0.3pt;"> </span>da<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.15pt;"> </span>confid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span>ty,<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>gri<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd av<span style="letter-spacing:-0.05pt;">a</span>i<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity.<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>hile<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>shared<span style="letter-spacing:-0.2pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>partner,<span style="letter-spacing:-0.15pt;"> </span>NantWorks,<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>invested,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>continue<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>invest,<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>protection<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.3pt;"> </span>technolo<span style="letter-spacing:0.05pt;">g</span>y<span style="letter-spacing:-0.4pt;"> </span>infrastruc<span style="letter-spacing:-0.05pt;">t</span>ure,<span style="letter-spacing:-0.45pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assurance<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> our </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>forts of<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.1pt;"> </span>partners, vendors,<span style="letter-spacing:-0.05pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs,<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>sites<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>ntractors<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>sultants<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>inte<span style="letter-spacing:-0.05pt;">r</span>ruptions,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>identify<span style="letter-spacing:-0.25pt;"> </span>brea<span style="letter-spacing:-0.1pt;">c</span>hes<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>their systems,<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ffect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and/or<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of cr<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>nsi<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.25pt;"> </span>infor<span style="letter-spacing:-0.05pt;">m</span>a<span style="letter-spacing:-0.05pt;">t</span>io<span style="letter-spacing:-0.05pt;">n</span>,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in financial,<span style="letter-spacing:-0.35pt;"> </span>legal,<span style="letter-spacing:-0.15pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>reputational<span style="letter-spacing:-0.4pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>to us.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addit<span style="letter-spacing:-0.15pt;">i</span>on,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>insurance<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>suf<span style="letter-spacing:-0.05pt;">f</span>icient<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>type<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.15pt;">m</span>ount<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cover<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>claims rel<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cur<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">r</span>ea<span style="letter-spacing:-0.05pt;">c</span>hes,<span style="letter-spacing:-0.1pt;"> </span>cyb<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">a</span>ttacks<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>breaches.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>event<span style="letter-spacing:-0.15pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.25pt;"> </span>interruptions<span style="letter-spacing:-0.5pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>it could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a dis<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">u</span>ption<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>develop<span style="letter-spacing:-0.1pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>progra<span style="letter-spacing:-0.05pt;">m</span>s.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">F</span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xa<span style="letter-spacing:-0.05pt;">m</span>p<span style="letter-spacing:-0.05pt;">l</span>e, the<span style="letter-spacing:-0.15pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>completed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ongoing<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.3pt;"> </span>trials<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>delays<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>efforts and<span style="letter-spacing:-0.1pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>to r<span style="letter-spacing:-0.1pt;">e</span>cover<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>produce<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>data,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>limit<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to effec<span style="letter-spacing:-0.15pt;">t</span>ively<span style="letter-spacing:-0.35pt;"> </span>execute<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>recall,<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>required.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>the extent<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>disruption<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>breach<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>damage<span style="letter-spacing:-0.4pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>applications,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inappropriate<span style="letter-spacing:-0.45pt;"> </span>disclosure<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>personal, confid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>propri<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">a</span>ry<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nforma<span style="letter-spacing:-0.05pt;">t</span>ion,<span style="letter-spacing:-0.4pt;"> </span>we could<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>ur<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>abi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>od<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>dela<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">e</span>d.<span style="letter-spacing:-0.3pt;"> </span>Any such<span style="letter-spacing:-0.05pt;"> </span>event could<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proceedings,<span style="letter-spacing:-0.4pt;"> </span>liability<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>otect<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>personal<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>si<span style="letter-spacing:0.05pt;">g</span>nificant<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>penalties, and<span style="letter-spacing:-0.1pt;"> </span>damage<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>reputation<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>confidence<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trials,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> c</span>linical<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O<span style="letter-spacing:-0.05pt;">u</span>r b<span style="letter-spacing:-0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> c</span>ou<span style="letter-spacing:-0.05pt;">l</span>d be adversely affected by t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of <span style="letter-spacing:-0.05pt;">h</span>ea<span style="letter-spacing:-0.05pt;">l</span>th<span style="letter-spacing:-0.2pt;"> </span>ep<span style="letter-spacing:-0.05pt;">i</span>de<span style="letter-spacing:-0.05pt;">m</span>i<span style="letter-spacing:-0.1pt;">c</span>s,<span style="letter-spacing:-0.35pt;"> </span>pandemics<span style="letter-spacing:-0.35pt;"> </span>or contagious diseases, including the r<span style="letter-spacing:-0.1pt;">e</span>cent<span style="letter-spacing:-0.15pt;"> </span>pandemic<span style="letter-spacing:-0.3pt;"> </span>of the disease caused<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>novel<span style="letter-spacing:-0.1pt;"> </span>coronav<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.05pt;">u</span>s SARS-CoV-2<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>COVID&#8209;19,<span style="letter-spacing:-0.05pt;"> including its currently known and unknown variants, </span>in regio<span style="letter-spacing:0.1pt;">n</span>s<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>h<span style="letter-spacing:-0.05pt;">e</span>re<span style="letter-spacing:-0.05pt;"> w</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>r <span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.05pt;"> </span>signif<span style="letter-spacing:-0.05pt;">i</span>cant man<span style="letter-spacing:-0.05pt;">u</span>fa<span style="letter-spacing:-0.05pt;">c</span>tu<span style="letter-spacing:-0.05pt;">r</span>i<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.2pt;"> </span>faci<span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.25pt;"> </span>co<span style="letter-spacing:-0.05pt;">n</span>c<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.15pt;"> </span>of <span style="letter-spacing:-0.05pt;">c</span>lini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>r<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>operations.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outbreaks of epidemic, pandemic or contagious diseases, such as the COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 pandemic, may significantly disrupt our operations and adversely affect our business, financial condition and results of operations. In March&#160;2020, the World Health Organization&#160;(&#8220;W<span style="letter-spacing:-0.05pt;">H</span>O&#8221;)<span style="letter-spacing:-0.15pt;"> </span>declared the outbreak of the COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 pandemic as the novel coronavirus continues to spread throughout the world. The spread of this pandemic has caused significant volatility and uncertainty in the U.S. and international markets and has resulted in increased risks to our operations. The<span style="letter-spacing:-0.2pt;"> </span>COVI<span style="letter-spacing:0.05pt;">D</span><span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:0.05pt;"> </span>pandemic, including currently known and unknown variants of COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19,<span style="letter-spacing:-0.35pt;"> </span>could materially<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>headquarters<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>facilities,<span style="letter-spacing:-0.35pt;"> </span>whi<span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>subje<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>to state<span style="letter-spacing:-0.1pt;"> </span>executive<span style="letter-spacing:-0.35pt;"> </span>orders and<span style="letter-spacing:-0.1pt;"> </span>shelter-in-place<span style="letter-spacing:-0.5pt;"> </span>orders,<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">a</span>t our c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>sit<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>business or<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>manufacturers,<span style="letter-spacing:-0.55pt;"> </span>CR<span style="letter-spacing:0.05pt;">O</span>s, CM<span style="letter-spacing:0.05pt;">O</span>s, <span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span>inic<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>sit<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>whom<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>condu<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orders</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iss</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">local</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gove</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nments</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elsewhere,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">states</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">emergency</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cl</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">red</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">te and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">local</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">level</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in most</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">juris</span><span style="letter-spacing:-0.15pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ictions</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">throughout</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sta</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es.</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shelter-in-place</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gov</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rnment</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orders,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perception</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orde</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shutdowns</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrictions</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conduct</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">occur,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandem</span><span style="letter-spacing:0.15pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infectious diseases</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personnel</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at third-party</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturing</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">faciliti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">countries,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ava</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bil</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or cost</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materials,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whi</span><span style="letter-spacing:-0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disrupt</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">supply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chain.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monitoring</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">includi</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;color:#000000;">Financial</span><span style="color:#000000;">: We anticipate that the pandemic could have an adverse financial impact in the short-term and potentially beyond. As a result of slower patient enrollment, we may not be able to complete our clinical trials as planned or in a timely manner. We expect to continue spending on research and development during the ye</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">r-ended December</span><span style="letter-spacing:-0.35pt;color:#000000;">&#160;</span><span style="color:#000000;">31,&#160;2021 and beyond, and we could also have unexpected expenses related to the pandemic. The short-term continued expenses, as well as the overall uncertainty and disruption caused by the pandemic, will likely cause a delay in our ability to commercialize a product and adversely impact our financial results.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Supply Chain</span><span style="font-size:10pt;color:#000000;">: An extended duration of this pandemic could result in significant disruptions in our respective supply chains and distribution channels in the future. For example, quarantines, shelter-in-place and similar government orders, travel restrictions and health impacts of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic, could impact the availability or productivity of personnel at third-party laboratory supply manufacturers, distributors, freight carriers and other necessary components of our supply chain. In addition, there may be unfavorable changes in the availability or cost of raw materials, intermediates and other materials necessary for production, which may result in disruptions in our supply chain and adversely affect our ability to have</span><span style="font-size:10pt;letter-spacing:-0.1pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">manufactured certain product candidates for clinical supply.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Clinical Trials</span><span style="font-size:10pt;color:#000000;">: This pandemic may adversely affect certain of our clinical trials, including our ability to initiate and complete our clinical trials within the anticipated timelines. Due to site and participant availability during the pandemic, new subject enrollment is expected to slow,</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;"> a</span><span style="font-size:10pt;color:#000000;">t</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">l</span><span style="font-size:10pt;letter-spacing:-0.05pt;color:#000000;">e</span><span style="font-size:10pt;color:#000000;">ast in the short-term, for most of our clinical trials. For ongoing trials, we have seen an increasing number of clinical trial sites imposing restrictions on patient visits to limit risks of possible COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 exposure, and we may experience issues with participant compliance with clinical trial protocols as a result of quarantines, travel restrictions and interruptions to healthcare services. The current pressures on medical systems and the prioritization of healthcare resources toward the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic have also resulted in interruptions in data collection and submissions for certain clinical trials and delayed starts for certain planned studies. As a result, our anticipated filing and marketing timelines may be adversely impacted.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Overall Economic and Capital</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Markets</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.25pt;color:#000000;"> </span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Environmen</span><span style="text-decoration:underline;font-size:10pt;letter-spacing:-0.05pt;color:#000000;">t</span><span style="font-size:10pt;color:#000000;">: The impact of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic could result in a prolonged recession or depression in the United</span><span style="font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">States or globally that could harm the banking system, limit demand for all products and services and cause other seen and unforeseen events and circumstances, all of which could negatively impact us. The continued spread of COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 has led to and could continue to lead to severe disruption and volatility in the United</span><span style="font-size:10pt;letter-spacing:-0.2pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">States and global capital markets, which could result in a decline in stock price, increase our cost of capital and adversely affect our ability to access the capital markets in the future. In addition, trading prices on the public stock market have been highly volatile as a result of the COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19 pandemic.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="text-decoration:underline;font-size:10pt;color:#000000;">Regulatory Reviews</span><span style="font-size:10pt;color:#000000;">: The operations of the FDA or other regulatory agencies may be adversely affected. In response to COVID</span><span style="Background-color:#FFFFFF;font-size:10pt;">&#8209;</span><span style="font-size:10pt;color:#000000;">19, federal, state and local governments are issuing new rules, regulations, orders and advisories on a regular basis. These government actions can impact us, our members and our suppliers. There is also the possibility that we may experience delays with obtaining approvals for our IND applications,</span><span style="font-size:10pt;letter-spacing:-0.45pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">BLA</span><span style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">s</span><span style="font-size:10pt;color:#000000;">, and/or</span><span style="font-size:10pt;letter-spacing:-0.25pt;color:#000000;"> </span><span style="font-size:10pt;color:#000000;">NDA</span><span style="font-size:10pt;letter-spacing:0.05pt;color:#000000;">s</span><span style="font-size:10pt;color:#000000;">.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>formed,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>future form<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>seek,<span style="letter-spacing:-0.15pt;"> </span>strategic<span style="letter-spacing:-0.2pt;"> </span>alliances<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>enter<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.4pt;"> </span>licensing<span style="letter-spacing:-0.4pt;"> </span>arrangements<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>future,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may not<span style="letter-spacing:-0.1pt;"> </span>real<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">e</span>fits<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>alliances<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.05pt;">n</span>s<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>ar<span style="letter-spacing:-0.05pt;">r</span>a<span style="letter-spacing:-0.05pt;">n</span>gem<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>formed,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>m<span style="letter-spacing:-0.05pt;"> </span>or seek,<span style="letter-spacing:-0.15pt;"> </span>str<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>gic<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>li<span style="letter-spacing:-0.05pt;">a</span>nces,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>rea<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span>joint<span style="letter-spacing:-0.15pt;"> </span>v<span style="letter-spacing:-0.05pt;">e</span>ntures<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.05pt;">a</span>bo<span style="letter-spacing:-0.05pt;">r</span>at<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nter<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.25pt;"> </span>additio<span style="letter-spacing:0.05pt;">n</span>al<span style="letter-spacing:-0.4pt;"> </span>licensing arrangements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>relat<span style="letter-spacing:0.1pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>complement<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>augment<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>dev<span style="letter-spacing:-0.05pt;">e</span>lopm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>iz<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.65pt;"> </span>effor<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>develop.<span style="letter-spacing:-0.3pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>entered<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>agreement<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.1pt;">h</span>er<span style="letter-spacing:-0.05pt;">e</span>by<span style="letter-spacing:-0.05pt;"> </span>Vir<span style="letter-spacing:-0.05pt;">a</span>cta granted<span style="letter-spacing:-0.2pt;"> </span>to us<span style="letter-spacing:0.05pt;"> </span>exclusive<span style="letter-spacing:-0.3pt;"> </span>world-wide<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Viracta&#8217;s<span style="letter-spacing:-0.35pt;"> </span>Phase&#160;II<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>VRx-3996,<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>plat<span style="letter-spacing:0.05pt;">f</span>orm<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>NK<span style="letter-spacing:-0.05pt;"> </span>cell therapies. However, <span style="letter-spacing:-0.05pt;">i</span>f Vir<span style="letter-spacing:-0.05pt;">a</span>cta<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>i<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.15pt;"> </span>suffic<span style="letter-spacing:-0.05pt;">i</span>ent<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pit<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>te<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>heir<span style="letter-spacing:-0.1pt;"> </span>pivo<span style="letter-spacing:-0.05pt;">t</span>al<span style="letter-spacing:-0.25pt;"> P</span>hase&#160;II<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>,<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rial<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>s u<span style="letter-spacing:-0.15pt;">n</span><span style="letter-spacing:0.05pt;">s</span>uc<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:0.05pt;">s</span>sful,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>our future<span style="letter-spacing:-0.1pt;"> </span>clini<span style="letter-spacing:0.05pt;">c</span>al trial<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>NK<span style="letter-spacing:-0.05pt;"> </span>cell<span style="letter-spacing:-0.15pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>in combination<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>VRx-3996<span style="letter-spacing:0.05pt;"> </span>fails,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Vi<span style="letter-spacing:-0.05pt;">r</span>acta<span style="letter-spacing:-0.15pt;"> </span>license<span style="letter-spacing:-0.3pt;"> </span>would be<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>ver<span style="letter-spacing:-0.05pt;">s</span>ely<span style="letter-spacing:-0.2pt;"> </span>affected.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relationships</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to incur</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-recurring</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">charg</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">near</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">long-term</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenditur</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">curi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that dilute</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholders</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">disrupt</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">face</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signif</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cant</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competition</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seeki</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appropriate</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tegic partners</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">negotiation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">time-consuming</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complex.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suc</span><span style="letter-spacing:0.15pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">essful</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to estab</span><span style="letter-spacing:0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ish</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">strategic partnership</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alternative</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candi</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">because</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deemed</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at too</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">early</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stage</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or collaborative</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ef</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ort</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">view</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">having</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requisite</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">po</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ential</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demonstrate</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ffic</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cy.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we license</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquire</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">busine</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ses,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alize</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefit</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ansactions</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suc</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">essfully</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gra</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">them</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">culture.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">strategic</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">transaction</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or l</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cense,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">chieve</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or sp</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">net</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ome</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">j</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ifi</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such transa</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any del</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ys</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">en</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ring</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rat</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gic</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partnership</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">related</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialization</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ndidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in certain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">geographies</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">indications,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rm</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our b</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">siness</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospects,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O<span style="letter-spacing:-0.05pt;">u</span>r ma<span style="letter-spacing:-0.05pt;">nu</span>facturi<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.3pt;"> </span>fac<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>gat<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.4pt;"> </span>impacted<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ongoing COVID-19<span style="letter-spacing:-0.25pt;"> </span>pa<span style="letter-spacing:0.05pt;">n</span>demic.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:-0.2pt;">19</span><span style="letter-spacing:-0.4pt;"> </span>pandemic,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>taken<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.2pt;"> </span>response,<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>disrupt<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>internal<span style="letter-spacing:-0.25pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>heightening<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>a sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.45pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>workforce<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>suffer<span style="letter-spacing:-0.2pt;"> </span>illness<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>othe<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">w</span>ise<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>permitted<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to work,<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees work<span style="letter-spacing:-0.05pt;"> </span>remotely,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>heightened<span style="letter-spacing:-0.35pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>risks,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>relat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cybersecurity<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:0.1pt;">e</span>rnal<span style="letter-spacing:-0.2pt;"> </span>controls.<span style="letter-spacing:-0.25pt;"> </span>Additionally<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.4pt;"> </span>pandemic has impacted,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>conti<span style="letter-spacing:0.05pt;">n</span>ue<span style="letter-spacing:-0.3pt;"> </span>to impact,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>office<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>manufa<span style="letter-spacing:-0.05pt;">c</span>turing<span style="letter-spacing:-0.5pt;"> </span>lo<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:0.05pt;">e</span>ll as<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>analytica<span style="letter-spacing:-0.05pt;">l</span>,<span style="letter-spacing:-0.35pt;"> </span>process developme<span style="letter-spacing:0.05pt;">n</span>t,<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd tr<span style="letter-spacing:-0.05pt;">a</span>nsit<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.05pt;">a</span>l resea<span style="letter-spacing:-0.05pt;">r</span>ch<span style="letter-spacing:-0.25pt;"> </span>teams,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>effects<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>facility<span style="letter-spacing:-0.3pt;"> </span>closures,<span style="letter-spacing:-0.25pt;"> </span>reductions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span>pe<span style="letter-spacing:0.15pt;">r</span>ating<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">h</span>ours<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>social<span style="letter-spacing:-0.15pt;"> </span>distancing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>fforts.<span style="letter-spacing:-0.1pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>a small<span style="letter-spacing:-0.15pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>working<span style="letter-spacing:0.05pt;"> </span>clusters<span style="letter-spacing:-0.3pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>manufacturing,<span style="letter-spacing:-0.5pt;"> </span>analytical,<span style="letter-spacing:-0.3pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>development,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>translational<span style="letter-spacing:-0.45pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">e</span>ar<span style="letter-spacing:0.05pt;">c</span>h,<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d p<span style="letter-spacing:0.05pt;">o</span>sitive<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19,<span style="letter-spacing:-0.05pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to temporarily<span style="letter-spacing:-0.4pt;"> </span>close<span style="letter-spacing:-0.15pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>offic<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>fa<span style="letter-spacing:-0.05pt;">c</span>il<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>mpora<span style="letter-spacing:-0.05pt;">r</span>ily<span style="letter-spacing:-0.4pt;"> </span>suspend<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:-0.15pt;"> </span>to con<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>deep<span style="letter-spacing:-0.15pt;"> </span>cle<span style="letter-spacing:-0.1pt;">a</span>n<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>facilities<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to ensure<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees.<span style="letter-spacing:-0.4pt;"> </span>Additionall<span style="letter-spacing:-0.05pt;">y</span>,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>predi<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>wh<span style="letter-spacing:-0.05pt;">e</span>th<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ondit<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>concerns<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>or whether<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>frequent<span style="letter-spacing:-0.25pt;"> </span>disruptions<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n the<span style="letter-spacing:-0.1pt;"> </span>fu<span style="letter-spacing:-0.05pt;">t</span>ure,<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lud<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>complete<span style="letter-spacing:-0.35pt;"> </span>closure<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or more<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>facilities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>fai<span style="letter-spacing:-0.05pt;">l</span>ure<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>sta<span style="letter-spacing:-0.05pt;">t</span>e,<span style="letter-spacing:-0.2pt;"> </span>nation<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>and/or<span style="letter-spacing:-0.05pt;"> </span>international<span style="letter-spacing:-0.45pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:0.1pt;">r</span>otection<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>regulatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>lead<span style="letter-spacing:-0.1pt;"> </span>to government<span style="letter-spacing:-0.5pt;"> </span>enfo<span style="letter-spacing:0.05pt;">r</span>c<span style="letter-spacing:0.05pt;">e</span>ment<span style="letter-spacing:-0.3pt;"> </span>actions and<span style="letter-spacing:-0.05pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>penalties<span style="letter-spacing:-0.35pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span>sely<span style="letter-spacing:-0.4pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>results.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>legislative<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regu<span style="letter-spacing:-0.05pt;">l</span>a<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>tiv<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.05pt;"> th</span>e<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>levels<span style="letter-spacing:-0.2pt;"> </span>addressing<span style="letter-spacing:-0.45pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>concerns,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>some state<span style="letter-spacing:-0.1pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>apply<span style="letter-spacing:-0.25pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>broadly<span style="letter-spacing:-0.2pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Health<span style="letter-spacing:-0.2pt;"> </span>Insuran<span style="letter-spacing:-0.1pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>Portability<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>Accountability<span style="letter-spacing:-0.5pt;"> </span>Act<span style="letter-spacing:-0.2pt;">&#160;</span>(&#8220;HIPAA<span style="letter-spacing:-0.05pt;">&#8221;</span>)<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:-0.05pt;">g</span>ulations.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example, California<span style="letter-spacing:-0.35pt;"> </span>recently<span style="letter-spacing:-0.25pt;"> </span>enacted<span style="letter-spacing:-0.3pt;"> </span>legislation&#8212;the<span style="letter-spacing:-0.5pt;"> </span>Cali<span style="letter-spacing:-0.05pt;">f</span>ornia<span style="letter-spacing:-0.4pt;"> </span>Consumer<span style="letter-spacing:-0.4pt;"> </span>Privacy<span style="letter-spacing:-0.3pt;"> </span>Act<span style="letter-spacing:-0.2pt;">&#160;</span>(&#8220;CCPA&#8221;)&#8212;which<span style="letter-spacing:-0.15pt;"> </span>went<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>January&#160;1,&#160;2020.<span style="letter-spacing:-0.05pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>CCPA,<span style="letter-spacing:-0.05pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>creates<span style="letter-spacing:-0.3pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>secur<span style="letter-spacing:0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>obligations<span style="letter-spacing:-0.4pt;"> </span>for covered<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>and provides<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to California<span style="letter-spacing:-0.35pt;"> </span>con<span style="letter-spacing:-0.05pt;">s</span>umers,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to opt<span style="letter-spacing:-0.05pt;"> </span>out<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>disclosures<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>informatio<span style="letter-spacing:-0.1pt;">n</span>.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>CCPA<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>provides<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>vil<span style="letter-spacing:-0.15pt;"> </span>pen<span style="letter-spacing:-0.05pt;">a</span>lt<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>priv<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>right<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>action<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>statuto<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.3pt;"> </span>damages<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>br<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">c</span>hes,<span style="letter-spacing:-0.1pt;"> </span>ther<span style="letter-spacing:-0.05pt;">e</span>by<span style="letter-spacing:-0.15pt;"> </span>po<span style="letter-spacing:-0.05pt;">t</span>ent<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ncre<span style="letter-spacing:-0.05pt;">a</span>sing<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">i</span>sks<span style="letter-spacing:-0.1pt;"> </span>asso<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">t</span>ed with<span style="letter-spacing:-0.1pt;"> </span>a data<span style="letter-spacing:-0.2pt;"> </span>breach.<span style="letter-spacing:-0.2pt;"> </span>Although<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>law<span style="letter-spacing:-0.1pt;"> </span>includ<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>exceptions,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.35pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>collected<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>clinic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>spec<span style="letter-spacing:-0.05pt;">i</span>fi<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the law,<span style="letter-spacing:-0.2pt;"> </span>it may<span style="letter-spacing:-0.1pt;"> </span>regulate<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>proce<span style="letter-spacing:-0.1pt;">s</span>sing<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>personal<span style="letter-spacing:-0.35pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>depending<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>context.<span style="letter-spacing:-0.25pt;"> </span>Additionally, a new privacy law, the California Privacy Rights Act&#160;(&#8220;CPRA&#8221;), was approved by California voters in November&#160;2020. The CPRA significantly modified the CCPA, which may require us to modify our practices and policies and may further increase our compliance costs and potential liability. To the extent these state laws as well as other federal and state privacy laws, including new laws and changes in existing laws, apply to our business and operations, our compliance costs and potential liability with respect to personal information we collect could expose us to great liability and increase compliance costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>various<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>jurisdictions<span style="letter-spacing:-0.5pt;"> </span>rel<span style="letter-spacing:0.15pt;">a</span>ting<span style="letter-spacing:-0.2pt;"> </span>to privacy<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>security.<span style="letter-spacing:-0.3pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>European<span style="letter-spacing:-0.35pt;"> </span>Uni<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:0.05pt;">&#160;</span>(&#8220;<span style="letter-spacing:-0.05pt;">E</span>U&#8221;)<span style="letter-spacing:-0.2pt;"> member states and other </span>foreign<span style="letter-spacing:-0.3pt;"> </span>jurisdictions,<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>Switzerland,<span style="letter-spacing:-0.5pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>ado<span style="letter-spacing:0.05pt;">p</span>ted<span style="letter-spacing:-0.3pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>gulations<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>impose<span style="letter-spacing:-0.2pt;"> </span>signific<span style="letter-spacing:-0.05pt;">a</span>nt<span style="letter-spacing:-0.35pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>nce<span style="letter-spacing:-0.4pt;"> </span>o<span style="letter-spacing:0.05pt;">b</span>ligations<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>us. Moreover,<span style="letter-spacing:-0.45pt;"> </span>the EU<span style="letter-spacing:-0.05pt;"> </span>Data<span style="letter-spacing:-0.1pt;"> </span>Protection<span style="letter-spacing:-0.3pt;"> </span>Directive,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>formerly<span style="letter-spacing:-0.35pt;"> </span>governed<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>coll<span style="letter-spacing:-0.05pt;">e</span>ction,<span style="letter-spacing:-0.45pt;"> </span>process<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>personal<span style="letter-spacing:-0.25pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>EU,<span style="letter-spacing:-0.05pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>replaced<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.15pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>EU<span style="letter-spacing:0.05pt;"> </span>General<span style="letter-spacing:-0.3pt;"> </span>Data<span style="letter-spacing:-0.1pt;"> </span>Protection<span style="letter-spacing:-0.4pt;"> </span>Regulation<span style="letter-spacing:-0.35pt;">&#160;</span><span style="letter-spacing:-0.05pt;">(</span><span style="letter-spacing:0.05pt;">&#8220;</span>GDPR&#8221;)<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>May&#160;2018.<span style="letter-spacing:0.05pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>GDPR, which<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>wid<span style="letter-spacing:-0.05pt;">e</span>-ranging<span style="letter-spacing:-0.55pt;"> </span>in scope<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>applies<span style="letter-spacing:0.05pt;"> </span>extraterritorially,<span style="letter-spacing:-0.55pt;"> </span>imposes<span style="letter-spacing:-0.25pt;"> </span>sev<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>consent<span style="letter-spacing:-0.2pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>individuals<span style="letter-spacing:-0.4pt;"> </span>to whom<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>personal<span style="letter-spacing:-0.35pt;"> </span>d<span style="letter-spacing:0.05pt;">a</span>ta<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>la<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>infor<span style="letter-spacing:-0.05pt;">m</span>a<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>individuals,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>security<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>personal<span style="letter-spacing:-0.25pt;"> </span>data,<span style="letter-spacing:-0.1pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>breach<span style="letter-spacing:-0.3pt;"> </span>n<span style="letter-spacing:0.1pt;">o</span>tification,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>adopti<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.3pt;"> </span>of appropriate<span style="letter-spacing:-0.4pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>g<span style="letter-spacing:0.05pt;">o</span>vernance,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:0.05pt;"> </span>policies,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>ocedures,<span style="letter-spacing:-0.3pt;"> </span>training<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>audits,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ird-party<span style="letter-spacing:-0.35pt;"> </span>processors in<span style="letter-spacing:-0.05pt;"> </span>connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>processing<span style="letter-spacing:-0.35pt;"> </span>of personal<span style="letter-spacing:-0.3pt;"> </span>data.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>GDPR<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>imposes<span style="letter-spacing:0.05pt;"> </span>strict<span style="letter-spacing:-0.25pt;"> </span>rules<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>transfer<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>personal<span style="letter-spacing:-0.35pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>EU, including<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States,<span style="letter-spacing:-0.25pt;"> </span>provides<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>authority<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>imposes<span style="letter-spacing:-0.25pt;"> </span>large<span style="letter-spacing:-0.15pt;"> </span>pe<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>lties<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>noncompliance,<span style="letter-spacing:-0.55pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>for fines<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>up to<span style="letter-spacing:-0.15pt;"> </span>&#8364;20&#160;million<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>4% of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ann<span style="letter-spacing:0.05pt;">u</span>al<span style="letter-spacing:-0.3pt;"> </span>global<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>venues<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the n<span style="letter-spacing:0.05pt;">o</span>ncompliant<span style="letter-spacing:-0.35pt;"> </span>entity,<span style="letter-spacing:-0.3pt;"> </span>whichever<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>greater.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>GDPR<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>apply<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>only<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>transactions,<span style="letter-spacing:-0.45pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>to transfers<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>information between<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>subsidiarie<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>employee<span style="letter-spacing:-0.35pt;"> </span>infor<span style="letter-spacing:-0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">i</span>on.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complying</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">numerous,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">complex</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">changing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulations</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expensi</span><span style="letter-spacing:0.05pt;">v</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">difficult,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ilure</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">omply</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pri</span><span style="letter-spacing:0.05pt;">v</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acy</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data security</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incident</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involving</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misapp</span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opriation,</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unauthorized</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">processing,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or disclosure</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sensitive</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or confid</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nti</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsumer</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">personal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">formation,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CROs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associates</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">another</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could adversely</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business, financial</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sults</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">but</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">im</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to:</span><span style="letter-spacing:-0.1pt;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inv</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iga</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.1pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#59;</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fines</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">penalties&#59; compensatory,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">special,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">punitive</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages&#59;</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigati</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n&#59;</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orders</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regarding</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pri</span><span style="letter-spacing:-0.05pt;">v</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">secur</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pra</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es&#59;</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requireme</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we provide</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">notices,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">monitoring</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rvices</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">credit</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restorat</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relevant</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">services</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to impacted</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dividu</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls&#59;</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licenses</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business&#59;</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">repu</span><span style="letter-spacing:0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ational</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damage&#59;</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">injunctive</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rel</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ef.</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imp</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">em</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nta</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCPA and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GDPR</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has incr</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our responsibility</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in r</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lation</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to personal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">process,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in clinical</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quired</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to put</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">place</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ddition</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l m</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hanisms</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nsure</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompli</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CCPA, </span><span style="letter-spacing:0.05pt;">G</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DPR</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gulations,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vert</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nagement&#8217;s</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">attention</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">doing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bu</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iness.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulation</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">leg</span><span style="letter-spacing:0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">slative</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regar</span><span style="letter-spacing:0.05pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">privacy</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">security</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(together</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicable industry</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standards)</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inc</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ease</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business. In</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regard,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expect</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proposed</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws, regulations</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">andards</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">relating</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to privacy</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EU</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdiction</span><span style="letter-spacing:0.1pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imp</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such future</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ws,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ions</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">standards</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>assure<span style="letter-spacing:0.05pt;"> </span>you<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>CROs<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>service<span style="letter-spacing:-0.2pt;"> </span>providers<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>customers&#8217;,<span style="letter-spacing:-0.4pt;"> </span>suppliers&#8217;,<span style="letter-spacing:-0.35pt;"> </span>tr<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:-0.1pt;"> </span>patients&#8217;<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>employees&#8217; personally<span style="letter-spacing:-0.3pt;"> </span>identifiable<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>sensitive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>confide<span style="letter-spacing:-0.05pt;">n</span>tial<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>in relation<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>responsible<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>breach<span style="letter-spacing:-0.2pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>o<span style="letter-spacing:0.05pt;">b</span>ligations<span style="letter-spacing:0.05pt;"> </span>imposed<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">w</span>ill not<span style="letter-spacing:-0.05pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.15pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>breache<span style="letter-spacing:-0.15pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a corresponding<span style="letter-spacing:-0.45pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:0.05pt;">u</span>tti<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>breach<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>obligations<span style="letter-spacing:-0.45pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>privacy<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.1pt;">e</span>gulatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>in turn<span style="letter-spacing:-0.2pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>ely<span style="letter-spacing:-0.25pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bus<span style="letter-spacing:0.05pt;">i</span>ness,<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:0.05pt;"> </span>condition.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>assure<span style="letter-spacing:0.05pt;"> </span>you<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>contractual<span style="letter-spacing:-0.4pt;"> </span>measures<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd our own<span style="letter-spacing:-0.05pt;"> </span>privacy<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>security-related<span style="letter-spacing:-0.45pt;"> </span>safeguards<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>otect<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risks associ<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hird-par<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.35pt;"> </span>processing,<span style="letter-spacing:-0.45pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>storage<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.05pt;">m</span>iss<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of su<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nforma<span style="letter-spacing:-0.1pt;">t</span>ion.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> our</span><span style="letter-spacing:-0.15pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>heavily<span style="letter-spacing:-0.25pt;"> </span>dependent<span style="letter-spacing:-0.4pt;"> </span>on our<span style="letter-spacing:-0.05pt;"> </span>senior<span style="letter-spacing:-0.05pt;"> </span>management,<span style="letter-spacing:-0.5pt;"> </span>particularly<span style="letter-spacing:-0.4pt;"> </span>Dr.<span style="letter-spacing:-0.05pt;"> </span>Soon-Shiong,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> E</span>xecutive<span style="letter-spacing:-0.3pt;"> C</span>hairman,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>member<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our senior<span style="letter-spacing:-0.05pt;"> </span>manageme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">a</span>m<span style="letter-spacing:-0.2pt;"> </span>in <span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">fu</span>t<span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ven<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>temporary,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>harm<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r busines<span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>lose<span style="letter-spacing:-0.2pt;"> </span>members<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>senior<span style="letter-spacing:-0.1pt;"> </span>manageme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>short<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>extended<span style="letter-spacing:-0.3pt;"> </span>time,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to find<span style="letter-spacing:-0.1pt;"> </span>appropriate<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>placemen<span style="letter-spacing:-0.15pt;">t</span>s<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>m<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.2pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s, and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affec<span style="letter-spacing:-0.05pt;">t</span>ed.<span style="letter-spacing:-0.25pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>existing<span style="letter-spacing:-0.35pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>extent<span style="letter-spacing:-0.2pt;"> </span>upon the<span style="letter-spacing:-0.1pt;"> </span>performance and<span style="letter-spacing:-0.1pt;"> </span>active<span style="letter-spacing:-0.2pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>key<span style="letter-spacing:-0.1pt;"> </span>individuals,<span style="letter-spacing:-0.35pt;"> </span>particularly<span style="letter-spacing:-0.45pt;"> </span>Dr.&#160;Soon-Shiong,<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>Executive<span style="letter-spacing:-0.3pt;"> </span>Chairman.<span style="letter-spacing:-0.4pt;"> </span>Although<span style="letter-spacing:-0.3pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:-0.1pt;"> </span>focuses<span style="letter-spacing:-0.05pt;"> </span>heavily on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>matters<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>highly<span style="letter-spacing:-0.2pt;"> </span>active<span style="letter-spacing:-0.15pt;"> </span>in our<span style="letter-spacing:-0.15pt;"> </span>management,<span style="letter-spacing:-0.45pt;"> </span>he<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:-0.15pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>devote<span style="letter-spacing:-0.25pt;"> </span>a si<span style="letter-spacing:0.05pt;">g</span>nificant<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>his<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>to a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>different<span style="letter-spacing:-0.35pt;"> </span>endeavors<span style="letter-spacing:-0.3pt;"> </span>and companies,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>NantHealth,<span style="letter-spacing:-0.45pt;">&#160;</span>Inc.,<span style="letter-spacing:-0.1pt;"> </span>Nan<span style="letter-spacing:-0.05pt;">t</span>Media<span style="letter-spacing:-0.35pt;"> </span>Holdings,<span style="letter-spacing:-0.35pt;"> </span>LLC<span style="letter-spacing:-0.1pt;"> </span>(which<span style="letter-spacing:-0.2pt;"> </span>operates<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>Los<span style="letter-spacing:-0.05pt;"> </span>Angeles<span style="letter-spacing:-0.35pt;"> </span>Times<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>San<span style="letter-spacing:0.05pt;"> </span>Diego<span style="letter-spacing:-0.15pt;"> </span>Union-Tribune)<span style="letter-spacing:-0.55pt;"> </span>and NantWorks,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a collection<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>multiple<span style="letter-spacing:-0.3pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>space.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:0.05pt;">i</span>sks related<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>dependence<span style="letter-spacing:-0.35pt;"> </span>upon Dr.&#160;Soon-Shiong<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>particularly<span style="letter-spacing:-0.35pt;"> </span>acute<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">i</span>ven<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>percentage,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>commerc<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>relationships<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>entities<span style="letter-spacing:-0.2pt;"> </span>aff<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>hi<span style="letter-spacing:-0.05pt;">m</span>,<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">i</span>s role<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>company<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>pub<span style="letter-spacing:0.05pt;">l</span>ic<span style="letter-spacing:-0.25pt;"> </span>reputati<span style="letter-spacing:0.05pt;">o</span>n.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dependent<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>funding<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>Dr.<span style="letter-spacing:0.05pt;">&#160;</span>Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>aff<span style="letter-spacing:-0.05pt;">i</span>liates,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not be<span style="letter-spacing:-0.05pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>when<span style="letter-spacing:0.05pt;"> </span>needed<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>he<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>obligation<span style="letter-spacing:-0.35pt;"> </span>to p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>vide.<span style="letter-spacing:-0.1pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>lose<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>short<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>extended time,<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>reason,<span style="letter-spacing:-0.3pt;"> </span>including,<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>contraction<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to find<span style="letter-spacing:-0.2pt;"> </span>appropriate<span style="letter-spacing:-0.35pt;"> </span>replace<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.5pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.25pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competition<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>qualified<span style="letter-spacing:-0.3pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>pharmaceuticals<span style="letter-spacing:-0.6pt;"> </span>industry<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>intense<span style="letter-spacing:-0.2pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">i</span>ndividuals<span style="letter-spacing:-0.45pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>possess the skills<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>experience<span style="letter-spacing:-0.35pt;"> </span>required.<span style="letter-spacing:-0.35pt;"> </span>To<span style="letter-spacing:-0.05pt;"> </span>induce<span style="letter-spacing:-0.2pt;"> </span>valuable<span style="letter-spacing:-0.25pt;"> </span>emp<span style="letter-spacing:-0.1pt;">l</span>oyees<span style="letter-spacing:-0.45pt;"> </span>to remain<span style="letter-spacing:-0.2pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>company,<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>addition<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>salary<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>incentives,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>provided, and<span style="letter-spacing:-0.1pt;"> </span>plan<span style="letter-spacing:-0.2pt;"> </span>to contin<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:-0.3pt;"> </span>providing,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>quity<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>ntive<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:0.05pt;">w</span>ards that<span style="letter-spacing:-0.1pt;"> </span>v<span style="letter-spacing:0.05pt;">e</span>st<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ver<span style="letter-spacing:-0.05pt;"> </span>tim<span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>equity<span style="letter-spacing:-0.25pt;"> </span>incentive<span style="letter-spacing:-0.3pt;"> </span>awards that<span style="letter-spacing:-0.15pt;"> </span>vest<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>may be<span style="letter-spacing:0.05pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>affected<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>movements<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>beyond<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>control,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>insufficient<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>counteract<span style="letter-spacing:-0.3pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>luc<span style="letter-spacing:-0.05pt;">r</span>ative offers<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>companies.<span style="letter-spacing:-0.45pt;"> </span>Despite<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ffor<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ret<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>valu<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">m</span>ploye<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.35pt;"> </span>me<span style="letter-spacing:-0.05pt;">m</span>be<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>manageme<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.5pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>vel<span style="letter-spacing:0.05pt;">o</span>pment<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ea<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y ter<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>mploy<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>short<span style="letter-spacing:-0.05pt;"> </span>notice.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.1pt;"> </span>sign<span style="letter-spacing:-0.05pt;">i</span>ficant<span style="letter-spacing:-0.4pt;"> </span>competition<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>employee<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.45pt;"> </span>particularly<span style="letter-spacing:-0.35pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>per<span style="letter-spacing:-0.05pt;">s</span>onnel,<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>other biopharmaceutical<span style="letter-spacing:-0.6pt;"> </span>companies,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>include<span style="letter-spacing:-0.3pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>publicly<span style="letter-spacing:-0.25pt;"> </span>traded<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>privately<span style="letter-spacing:-0.25pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>companies,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>hire<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:-0.1pt;">e</span>w<span style="letter-spacing:-0.15pt;"> </span>em<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>oyees<span style="letter-spacing:-0.4pt;"> </span>quickly enough<span style="letter-spacing:-0.2pt;"> </span>to meet<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>nee<span style="letter-spacing:0.05pt;">d</span>s.<span style="letter-spacing:-0.15pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>employment<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>key<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>hired<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>&#8220;<span style="letter-spacing:-0.05pt;">a</span>t-wi<span style="letter-spacing:-0.05pt;">l</span>l&#8221;<span style="letter-spacing:-0.3pt;"> </span>basis, which<span style="letter-spacing:-0.15pt;"> </span>means<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>leave<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employment<span style="letter-spacing:-0.45pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>time,<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>notice.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>maintain<span style="letter-spacing:-0.3pt;"> </span>&#8220;key<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.1pt;">m</span><span style="letter-spacing:-0.05pt;">an</span>&#8221;<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">s</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">c</span>e <span style="letter-spacing:-0.05pt;">p</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> l</span>i<span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e individuals<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>lives<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employees.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">a</span>ttr<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>re<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.25pt;"> </span>quality<span style="letter-spacing:-0.3pt;"> </span>personnel<span style="letter-spacing:-0.3pt;"> </span>on ac<span style="letter-spacing:-0.05pt;">c</span>ep<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>ble<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rms,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>l,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business a<span style="letter-spacing:0.15pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>operating<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>suffer.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to grow</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">size</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">capabili</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">organization,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">experie</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ce</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">difficulties</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">managing</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">growth.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dependent<span style="letter-spacing:-0.4pt;"> </span>u<span style="letter-spacing:0.05pt;">p</span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>rv<span style="letter-spacing:-0.05pt;">i</span>ces<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our exe<span style="letter-spacing:-0.05pt;">c</span>ut<span style="letter-spacing:-0.05pt;">i</span>ves<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd our<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.45pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>en<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">a</span>g<span style="letter-spacing:0.1pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:0.05pt;">m</span>en<span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>loss<span style="letter-spacing:-0.1pt;"> </span>of the services<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>executive<span style="letter-spacing:-0.35pt;"> </span>officers<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>nior<span style="letter-spacing:-0.2pt;"> </span>research<span style="letter-spacing:-0.3pt;"> </span>personnel<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>programs<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>search<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd development<span style="letter-spacing:-0.45pt;"> </span>efforts. In<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>accordance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> p</span><span style="letter-spacing:-0.05pt;">l</span>an,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to hire<span style="letter-spacing:-0.1pt;"> a</span>dditional<span style="letter-spacing:-0.3pt;"> </span>qualified<span style="letter-spacing:-0.25pt;"> </span>personnel,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>areas<span style="letter-spacing:-0.25pt;"> </span>of resea<span style="letter-spacing:-0.05pt;">r</span>ch,<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>nufa<span style="letter-spacing:-0.05pt;">c</span>turing,<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>lin<span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>nagement,<span style="letter-spacing:-0.5pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>affairs,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>marketing.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>continuing<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>cruit<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>hire<span style="letter-spacing:-0.15pt;"> </span>the necessary<span style="letter-spacing:-0.3pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>near<span style="letter-spacing:-0.2pt;"> </span>term.<span style="letter-spacing:-0.25pt;"> </span>However,<span style="letter-spacing:-0.05pt;"> </span>competition<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>quali<span style="letter-spacing:-0.05pt;">f</span>ied<span style="letter-spacing:-0.35pt;"> </span>em<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>oyees<span style="letter-spacing:-0.45pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>ani<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the biotechnology<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ndustry is<span style="letter-spacing:-0.1pt;"> </span>intense,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>assur<span style="letter-spacing:0.05pt;">a</span>nce<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>given<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>att<span style="letter-spacing:-0.1pt;">r</span>act,<span style="letter-spacing:-0.2pt;"> </span>hire,<span style="letter-spacing:-0.1pt;"> </span>retain<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>motivate<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>highly skilled<span style="letter-spacing:-0.2pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>need.<span style="letter-spacing:-0.15pt;"> </span>Future<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>impose<span style="letter-spacing:-0.35pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>added<span style="letter-spacing:-0.25pt;"> </span>responsibilities<span style="letter-spacing:-0.55pt;"> </span>on members<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>management,<span style="letter-spacing:-0.45pt;"> </span>includi<span style="letter-spacing:0.05pt;">n</span>g:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">dentifying,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">recruiting,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">integrating,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">mai</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">otiv</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anaging</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">internal</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">efforts</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">effectively,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">clinical</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">FDA rev</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ew</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">process</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">wh</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">e complying</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contractual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contractors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">mproving</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operational,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">management</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">controls,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">procedures.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>performance<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>depend,<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part,<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o effectively<span style="letter-spacing:-0.4pt;"> </span>manage<span style="letter-spacing:-0.3pt;"> </span>any future<span style="letter-spacing:-0.2pt;"> </span>growth,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>divert<span style="letter-spacing:-0.15pt;"> </span>a disproportionate<span style="letter-spacing:-0.55pt;"> </span>amount<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>atte<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>away<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>day-to-day<span style="letter-spacing:-0.35pt;"> </span>activit<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n ord<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>to devote<span style="letter-spacing:-0.2pt;"> </span>a substan<span style="letter-spacing:0.05pt;">t</span>ial<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>manag<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>rely,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foreseeable<span style="letter-spacing:-0.35pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>we exp<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>y,<span style="letter-spacing:-0.1pt;"> </span>in substan<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>part<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>organizations,<span style="letter-spacing:-0.55pt;"> </span>advisors<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onsultants<span style="letter-spacing:-0.4pt;"> </span>to provide<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>services.<span style="letter-spacing:-0.25pt;"> </span>There<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">s</span>surance<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>indep<span style="letter-spacing:0.1pt;">e</span>ndent<span style="letter-spacing:-0.5pt;"> </span>organizations,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dvisors and<span style="letter-spacing:-0.2pt;"> </span>consult<span style="letter-spacing:0.05pt;">a</span>nts<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e ava<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.15pt;"> </span>when<span style="letter-spacing:0.05pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.1pt;">d</span>ed,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">q</span>ualified<span style="letter-spacing:-0.25pt;"> </span>replacemen<span style="letter-spacing:-0.05pt;">t</span>s.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ef<span style="letter-spacing:0.05pt;">f</span>ectively<span style="letter-spacing:-0.35pt;"> </span>manage<span style="letter-spacing:-0.25pt;"> </span>our o<span style="letter-spacing:0.05pt;">u</span>tsourced<span style="letter-spacing:-0.3pt;"> </span>activities<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if the<span style="letter-spacing:-0.25pt;"> </span>quality,<span style="letter-spacing:-0.25pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>accuracy<span style="letter-spacing:-0.25pt;"> </span>of the<span style="letter-spacing:-0.15pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>nsultants<span style="letter-spacing:-0.4pt;"> </span>is compromised<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>reason,<span style="letter-spacing:-0.25pt;"> </span>our cl<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>extended,<span style="letter-spacing:-0.3pt;"> </span>delayed,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>terminated,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>regulato<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.15pt;"> </span>advance<span style="letter-spacing:-0.3pt;"> </span>our b<span style="letter-spacing:0.05pt;">u</span>siness.<span style="letter-spacing:0.05pt;"> </span>There<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>we wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> a</span>ble<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>nage<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xist<span style="letter-spacing:-0.15pt;">i</span>ng<span style="letter-spacing:-0.1pt;"> </span>consultants<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>oth<span style="letter-spacing:-0.1pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>competent<span style="letter-spacing:-0.3pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>contra<span style="letter-spacing:-0.05pt;">c</span>tors<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>consultants on<span style="letter-spacing:0.05pt;"> </span>economically<span style="letter-spacing:-0.45pt;"> </span>reasonab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.4pt;"> </span>terms,<span style="letter-spacing:-0.15pt;"> </span>if at<span style="letter-spacing:-0.05pt;"> </span>all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to effectively<span style="letter-spacing:-0.4pt;"> </span>expand<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>organization<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>hiring<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>expanding<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>groups<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>consultants<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>contractors,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">cc</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sfully<span style="letter-spacing:-0.2pt;"> </span>implem<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">a</span>sks necessary<span style="letter-spacing:-0.4pt;"> </span>to further<span style="letter-spacing:-0.3pt;"> </span>develop<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and,<span style="letter-spacing:-0.2pt;"> </span>accordi<span style="letter-spacing:0.05pt;">n</span>gl<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>achieve our<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:-0.05pt;">e</span>arch,<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>ve<span style="letter-spacing:-0.05pt;">l</span>opmen<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>om<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>iz<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.65pt;"> </span>goals<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a timely<span style="letter-spacing:-0.2pt;"> </span>b<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">i</span>s,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> a</span>ll.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>engage<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:0.05pt;"> </span>acquis<span style="letter-spacing:0.1pt;">i</span>tions<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>strate<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.35pt;"> </span>partne<span style="letter-spacing:0.05pt;">r</span>ships,<span style="letter-spacing:-0.05pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.25pt;"> </span>our capital<span style="letter-spacing:-0.25pt;"> </span>requirements,<span style="letter-spacing:-0.5pt;"> </span>dilute<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>stockhol<span style="letter-spacing:-0.05pt;">de</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">u</span>s <span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">u</span>r debt<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>assume<span style="letter-spacing:0.05pt;"> </span>contingent<span style="letter-spacing:-0.35pt;"> </span>liabilities,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>us to<span style="letter-spacing:-0.1pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>risk<span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>evaluate<span style="letter-spacing:-0.3pt;"> </span>various<span style="letter-spacing:-0.3pt;"> </span>acqui<span style="letter-spacing:0.05pt;">s</span>itions<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>strategic<span style="letter-spacing:-0.25pt;"> </span>par<span style="letter-spacing:0.05pt;">t</span>nerships,<span style="letter-spacing:-0.1pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>acqu<span style="letter-spacing:-0.05pt;">i</span>ring<span style="letter-spacing:-0.3pt;"> </span>complementary<span style="letter-spacing:-0.55pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>inte<span style="letter-spacing:-0.05pt;">l</span>lectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights, technologies,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.1pt;">e</span>s.<span style="letter-spacing:-0.05pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>or strategic<span style="letter-spacing:-0.3pt;"> </span>partnership<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>ent<span style="letter-spacing:-0.1pt;">a</span>il<span style="letter-spacing:-0.15pt;"> </span>numerous<span style="letter-spacing:-0.4pt;"> </span>risks,<span style="letter-spacing:-0.05pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ncreased</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expenses</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">cash</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">assumption</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">indebtedness</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or c</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ntingent</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">iab</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">issuance</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">equity</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">securities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ssimilati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">operation</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">acquired</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">compa</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">oduct,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">fficulties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">associ</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">with integrating</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">diversion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">managem</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">nt&#8217;s</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">attention</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">programs</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd initiatives</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">in pursuing</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">strategic</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">rger</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or acquisition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">retention</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">employees,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">loss</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">k</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">personnel,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">uncert</span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">inties</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">mai</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">tain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">key</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">relationship</span><span style="letter-spacing:-0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ks </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd un</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">er</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ies</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">asso</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ia</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">w</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">th</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ty</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">transaction,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">inc</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">uding</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">prospects</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">products or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to generate</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">acquired</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and/or</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sufficient</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to meet</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">objectives</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">undertaking</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">t</span><span style="color:#000000;">he acquisition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">even</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to offset the associated</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">acquisition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">maintenance</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">costs.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">size</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nat</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">strategic</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquisitions,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquire</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">busine</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ses</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raise</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ddit</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onal</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pit</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to o</span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">erate</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manage</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">businesses</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limited</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">experience.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mak</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">larger</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquisitions</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raise</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fund</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the acquisition</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expo</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">associated</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">capital</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">raising</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquiring</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ere</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fter</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">larger</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">busin</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so increase</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">management,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">burdens.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">undertake</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquisitions,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">di</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">utive</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">curiti</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s,</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ssume or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incur</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">debt</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ligations,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">incur</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">large</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one-</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ime</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expenses</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquire</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">int</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ngible</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assets</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">res</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lt</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in significant</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ort</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">za</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expense. Moreover,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to locate</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suitable</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">acquisition</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">opportunities</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inability</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impair</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grow</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ob</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ss</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o technology</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">important</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">development</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.1pt;"> </span>orphan<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>status or<span style="letter-spacing:-0.05pt;"> B</span>reakthrough<span style="letter-spacing:-0.05pt;"> T</span>herapy<span style="letter-spacing:-0.25pt;"> </span>designation<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>either<span style="letter-spacing:-0.25pt;"> </span>is granted,<span style="letter-spacing:-0.25pt;"> </span>we may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>maintain<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>b<span style="letter-spacing:0.05pt;">e</span>nefits<span style="letter-spacing:-0.35pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> B</span>reakthrough T<span style="letter-spacing:0.05pt;">h</span>erapy<span style="letter-spacing:-0.25pt;"> </span>designation<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>orphan<span style="letter-spacing:0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>status,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>market<span style="letter-spacing:-0.35pt;"> </span>exc<span style="letter-spacing:-0.05pt;">l</span>u<span style="letter-spacing:-0.05pt;">s</span>i<span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">t</span>y.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Orphan<span style="letter-spacing:0.05pt;"> </span>Drug<span style="letter-spacing:0.05pt;"> </span>Act,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>grant<span style="letter-spacing:-0.25pt;"> </span>orphan<span style="letter-spacing:-0.3pt;"> </span>designation<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a drug<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>biologic<span style="letter-spacing:-0.25pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>to treat<span style="letter-spacing:-0.1pt;"> </span>a ra<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.1pt;"> </span>disease<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cond<span style="letter-spacing:-0.05pt;">i</span>tion<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>there is no<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>easonable<span style="letter-spacing:-0.35pt;"> </span>expectation<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>cost<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>developi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>making<span style="letter-spacing:-0.2pt;"> </span>ava<span style="letter-spacing:-0.1pt;">i</span>lable<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>a drug<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>biologic<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.1pt;">c</span>ondition<span style="letter-spacing:-0.3pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>recovered from<span style="letter-spacing:-0.15pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>biologic.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>a product<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>orphan<span style="letter-spacing:-0.2pt;"> </span>drug<span style="letter-spacing:-0.05pt;"> </span>designation<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>ubsequently<span style="letter-spacing:-0.4pt;"> </span>receives<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>first<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>for the disease for which<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>such designation,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>is entitled<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>orphan<span style="letter-spacing:-0.2pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>exclusivity,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>means<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">p</span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ve<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>other applications,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>full<span style="letter-spacing:-0.15pt;"> </span>BLA<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.25pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>biologic<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>indication<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>seven<span style="letter-spacing:-0.25pt;"> </span>y<span style="letter-spacing:0.05pt;">e</span>ar<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.1pt;"> </span>ex<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>pt<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>lim<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcumst<span style="letter-spacing:-0.05pt;">a</span>nc<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.45pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>as a showing<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">s</span>uperiority<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>orphan<span style="letter-spacing:-0.3pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>exclusivi<span style="letter-spacing:0.15pt;">t</span>y. In<span style="letter-spacing:-0.05pt;"> </span>2012,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA est<span style="letter-spacing:0.1pt;">a</span>blished<span style="letter-spacing:-0.35pt;"> </span>a Breakthrough<span style="letter-spacing:-0.55pt;"> </span>The<span style="letter-spacing:0.05pt;">r</span>apy<span style="letter-spacing:-0.35pt;"> d</span>esignation,<span style="letter-spacing:-0.45pt;"> </span>which is intended<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>expedite<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>treat<span style="letter-spacing:-0.1pt;"> </span>serious<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>life-threatening<span style="letter-spacing:-0.5pt;"> </span>conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.1pt;"> </span>orphan<span style="letter-spacing:-0.2pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>status<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates,<span style="letter-spacing:-0.45pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>lo<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>seek<span style="letter-spacing:-0.1pt;"> </span>approval for<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>indication<span style="letter-spacing:-0.35pt;"> </span>broader<span style="letter-spacing:-0.3pt;"> </span>than<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>orphan<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.1pt;">e</span>signated<span style="letter-spacing:-0.35pt;"> </span>indicat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>lost<span style="letter-spacing:-0.15pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>requ<span style="letter-spacing:-0.05pt;">e</span>st<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:-0.1pt;">o</span>r designation<span style="letter-spacing:-0.4pt;"> </span>was materially<span style="letter-spacing:-0.3pt;"> </span>defective<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>assure suffi<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>qu<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>needs<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rare<span style="letter-spacing:-0.2pt;"> </span>disease<span style="letter-spacing:-0.2pt;"> </span>or condition.<span style="letter-spacing:-0.3pt;"> </span>In addition,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> B</span>reakthrough<span style="letter-spacing:-0.45pt;"> T</span>herapy<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:0.1pt;">e</span>signati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">n</span>e or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>there<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.4pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>we wi<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.15pt;"> </span>rec<span style="letter-spacing:-0.05pt;">e</span>ive such<span style="letter-spacing:0.05pt;"> </span>designation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:-0.05pt;">e</span>come<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span>olv<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n securit<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.15pt;">i</span>gation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>stockholder<span style="letter-spacing:-0.4pt;"> </span>derivative<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>gation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n conn<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.05pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>merger<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>Im<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">u</span>ni<span style="letter-spacing:-0.15pt;">t</span>yBio,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>could divert<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>attention<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">n</span>agement<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>harm<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bus<span style="letter-spacing:-0.1pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.05pt;"> </span>and i<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:0.05pt;">u</span>rance<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ov<span style="letter-spacing:0.05pt;">e</span>rage<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">u</span>ffi<span style="letter-spacing:-0.05pt;">c</span>ie<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>cov<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>ated<span style="letter-spacing:-0.25pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and damages.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities<span style="letter-spacing:-0.35pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>stockho<span style="letter-spacing:-0.05pt;">l</span>der<span style="letter-spacing:-0.45pt;"> </span>derivative<span style="letter-spacing:-0.3pt;"> </span>litigation<span style="letter-spacing:-0.2pt;"> </span>frequently<span style="letter-spacing:-0.3pt;"> </span>follows<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>annou<span style="letter-spacing:0.05pt;">n</span>cement<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>rans<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">c</span>tions,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>as the<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>e of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>division<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>announcement<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>bu<span style="letter-spacing:-0.1pt;">s</span>iness<span style="letter-spacing:0.05pt;"> </span>combination<span style="letter-spacing:-0.45pt;"> </span>transaction.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>in c<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">n</span>nection<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>merger with<span style="letter-spacing:-0.1pt;"> </span>ImmunityBio,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>become<span style="letter-spacing:-0.35pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in this<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>future.<span style="letter-spacing:-0.2pt;"> </span>Litigation<span style="letter-spacing:-0.3pt;"> </span>often<span style="letter-spacing:-0.2pt;"> </span>is expensive<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>dive<span style="letter-spacing:-0.05pt;">rt</span>s<span style="letter-spacing:-0.2pt;"> </span>management&#8217;s<span style="letter-spacing:-0.5pt;"> </span>attention and<span style="letter-spacing:-0.1pt;"> </span>reso<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ces,<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>combined<span style="letter-spacing:-0.35pt;"> </span>company.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>pect<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>ties<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:0.05pt;">e</span>rfo<span style="letter-spacing:0.05pt;">r</span>m<span style="letter-spacing:-0.15pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ssential<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">v</span>i<span style="letter-spacing:0.05pt;">c</span>es<span style="letter-spacing:-0.05pt;"> </span>for any<span style="letter-spacing:0.2pt;"> </span>products<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>commerci<span style="letter-spacing:-0.05pt;">al</span>i<span style="letter-spacing:-0.05pt;">z</span><span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.45pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">u</span>d<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">c</span>es<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>lat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to distribution,<span style="letter-spacing:-0.5pt;"> </span>gove<span style="letter-spacing:0.05pt;">r</span>nme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.45pt;"> </span>pri<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>porti<span style="letter-spacing:0.05pt;">n</span>g,<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span>stom<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">v</span>i<span style="letter-spacing:0.05pt;">c</span>e,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">cc</span>ounts<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.15pt;">e</span>ivable<span style="letter-spacing:-0.25pt;"> </span>management,<span style="letter-spacing:-0.45pt;"> </span>cash coll<span style="letter-spacing:-0.05pt;">e</span>ction<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.25pt;"> </span>event<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">re</span>por<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">n</span>g.<span style="letter-spacing:-0.2pt;"> </span>If t<span style="letter-spacing:-0.05pt;">h</span>ese third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>expected<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>req<span style="letter-spacing:-0.1pt;">u</span>ire<span style="letter-spacing:-0.05pt;">m</span>ents,<span style="letter-spacing:-0.35pt;"> </span>our abil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>ize<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;">n</span>t or f<span style="letter-spacing:-0.05pt;">u</span>ture product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gn<span style="letter-spacing:-0.05pt;">i</span>ficant<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.45pt;"> </span>impa<span style="letter-spacing:-0.05pt;">c</span>ted<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o regulatory<span style="letter-spacing:-0.4pt;"> </span>san<span style="letter-spacing:-0.05pt;">c</span>tions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>retain<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>service<span style="letter-spacing:-0.25pt;"> </span>prov<span style="letter-spacing:0.05pt;">i</span>ders<span style="letter-spacing:-0.25pt;"> </span>to perform<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>variety<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>functions<span style="letter-spacing:-0.3pt;"> </span>rel<span style="letter-spacing:-0.15pt;">a</span>ted<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>sale<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>current<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>futu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>key aspects<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>out<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>direct<span style="letter-spacing:-0.15pt;"> </span>control.<span style="letter-spacing:-0.25pt;"> </span>T<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.2pt;"> </span>service<span style="letter-spacing:-0.25pt;"> </span>providers<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>provide<span style="letter-spacing:-0.25pt;"> </span>key<span style="letter-spacing:-0.2pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>distribution,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ustomer<span style="letter-spacing:-0.4pt;"> </span>service,<span style="letter-spacing:-0.35pt;"> </span>accounts receivable<span style="letter-spacing:-0.35pt;"> </span>management,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>oll<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ion.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we r<span style="letter-spacing:-0.05pt;">e</span>ta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>servi<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.25pt;"> </span>provider,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>substanti<span style="letter-spacing:-0.05pt;">a</span>lly<span style="letter-spacing:-0.45pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.05pt;"> </span>on it<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>providers<span style="letter-spacing:-0.3pt;"> </span>that perform<span style="letter-spacing:-0.35pt;"> </span>services<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>entrusting<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inventories<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.1pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>handling.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>thi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">-</span>party<span style="letter-spacing:-0.3pt;"> </span>ser<span style="letter-spacing:-0.05pt;">v</span>i<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.1pt;"> </span>providers<span style="letter-spacing:-0.35pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ply w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>regulations,<span style="letter-spacing:-0.4pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>et<span style="letter-spacing:-0.15pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>ad<span style="letter-spacing:-0.05pt;">l</span>ines<span style="letter-spacing:-0.25pt;"> </span>or otherwise<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>carry<span style="letter-spacing:-0.15pt;"> </span>out<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>ir<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontr<span style="letter-spacing:-0.05pt;">a</span>ctu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>duti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>encounter<span style="letter-spacing:-0.4pt;"> </span>physical<span style="letter-spacing:-0.35pt;"> </span>or natural<span style="letter-spacing:-0.25pt;"> </span>damage<span style="letter-spacing:-0.3pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>aciliti<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>deliver<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>demand<span style="letter-spacing:-0.35pt;"> </span>wou<span style="letter-spacing:0.05pt;">l</span>d<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>significantly<span style="letter-spacing:-0.45pt;"> </span>impaired<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to regulatory<span style="letter-spacing:-0.35pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>action.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>engage<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ird<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>perform<span style="letter-spacing:-0.25pt;"> </span>various<span style="letter-spacing:-0.25pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>el<span style="letter-spacing:-0.05pt;">a</span>ting<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>reporting,<span style="letter-spacing:-0.4pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>database management,<span style="letter-spacing:-0.45pt;"> </span>fulfillment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>requ<span style="letter-spacing:0.05pt;">e</span>sts<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>regarding<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>relat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>services.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>qual<span style="letter-spacing:0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>accuracy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>data m<span style="letter-spacing:0.05pt;">a</span>int<span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.4pt;"> </span>by the<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>rvi<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.15pt;"> </span>providers<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>insufficient,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>rwise<span style="letter-spacing:-0.15pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>requiremen<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.45pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">a</span>dverse<span style="letter-spacing:-0.1pt;"> </span>event reporting,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>sanctions.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Add</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lly,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ra</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">par</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculate</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pricing</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mandated</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">various</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fails</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to timely</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adj</span><span style="letter-spacing:-0.1pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">required</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">errs</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">calculating</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pric</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ansac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ta</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our financial records,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impact</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scount</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rebate</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">liability,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">po</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tially</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to regula</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ory</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sanctions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FCA</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lawsuits.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>maintaining<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idates<span style="letter-spacing:-0.25pt;"> </span>in one<span style="letter-spacing:-0.05pt;"> </span>jurisdiction<span style="letter-spacing:-0.45pt;"> </span>does<span style="letter-spacing:0.05pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t mean<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>successful<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>obtaining regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>jurisdictions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>ed<span style="letter-spacing:-0.35pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>separate marketing<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>numerous<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>vary<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>quirements.<span style="letter-spacing:-0.4pt;"> </span>Obtaining<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>maintaining<span style="letter-spacing:-0.45pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>jurisdiction<span style="letter-spacing:-0.4pt;"> </span>does<span style="letter-spacing:0.05pt;"> n</span>ot guarantee<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>or ma<span style="letter-spacing:-0.05pt;">i</span>nt<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">j</span>urisdiction,<span style="letter-spacing:-0.45pt;"> </span>while<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">o</span>btaining<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>jurisdiction<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a negative<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>others.<span style="letter-spacing:-0.25pt;"> </span>Approval<span style="letter-spacing:-0.35pt;"> </span>policies<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>va<span style="letter-spacing:-0.05pt;">r</span>y<span style="letter-spacing:-0.15pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>jurisdictions.<span style="letter-spacing:-0.45pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>e<span style="letter-spacing:-0.05pt;">v</span>en<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>grants<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>comparable<span style="letter-spacing:-0.35pt;"> </span>regulatory authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>forei<span style="letter-spacing:0.05pt;">g</span>n<span style="letter-spacing:-0.25pt;"> </span>jurisdictions<span style="letter-spacing:-0.45pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>approve<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>manufacturing,<span style="letter-spacing:-0.5pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">t</span>hose countries.<span style="letter-spacing:-0.35pt;"> </span>Approval procedures<span style="letter-spacing:-0.45pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>jurisdict<span style="letter-spacing:0.1pt;">i</span>ons<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>inv<span style="letter-spacing:0.05pt;">o</span>lve<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>administ<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>tive<span style="letter-spacing:-0.55pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>view<span style="letter-spacing:-0.3pt;"> </span>periods<span style="letter-spacing:-0.3pt;"> </span>different<span style="letter-spacing:-0.25pt;"> </span>from,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>han,<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the United<span style="letter-spacing:-0.3pt;"> </span>States,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>preclinical<span style="letter-spacing:-0.4pt;"> </span>studies<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>linical<span style="letter-spacing:-0.2pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>nducted<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>jurisdiction<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>accepted<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>regulatory authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>jurisdict<span style="letter-spacing:-0.05pt;">i</span>ons.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>jurisdictions<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>S<span style="letter-spacing:-0.1pt;">t</span>ates,<span style="letter-spacing:-0.25pt;"> </span>a product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.4pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> r</span>eimbursement<span style="letter-spacing:-0.5pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>it can be<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>sale<span style="letter-spacing:-0.2pt;"> </span>in that<span style="letter-spacing:-0.1pt;"> </span>jurisdiction.<span style="letter-spacing:-0.55pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>cases,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>intend<span style="letter-spacing:-0.25pt;"> </span>to charge<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>is also<span style="letter-spacing:-0.25pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>approval.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>or o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>file<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>latory<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">p</span>p<span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>al<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in international<span style="letter-spacing:-0.45pt;"> </span>jurisdicti<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>btain<span style="letter-spacing:-0.2pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>from regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">S</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>n a<span style="letter-spacing:-0.05pt;"> t</span>im<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">b</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">s</span>i<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>if <span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">l.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>submit<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketing<span style="letter-spacing:-0.35pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>in o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.15pt;"> </span>countries.<span style="letter-spacing:-0.3pt;"> </span>Regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>j<span style="letter-spacing:-0.05pt;">u</span>risdictions<span style="letter-spacing:-0.45pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>St<span style="letter-spacing:0.05pt;">a</span>tes<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidat<span style="letter-spacing:0.1pt;">es</span><span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>must<span style="letter-spacing:-0.2pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>jurisdictions.<span style="letter-spacing:-0.4pt;"> </span>O<span style="letter-spacing:0.05pt;">b</span>taining<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>and compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.25pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>delays,<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:0.05pt;">i</span>fficulties<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> prevent the </span>introduction<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in cer<span style="letter-spacing:-0.1pt;">t</span>ain<span style="letter-spacing:-0.25pt;"> </span>countries.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>fail<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>in internat<span style="letter-spacing:-0.05pt;">i</span>onal<span style="letter-spacing:-0.5pt;"> </span>markets<span style="letter-spacing:-0.3pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>receive applicable<span style="letter-spacing:-0.35pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approvals,<span style="letter-spacing:-0.4pt;"> </span>our target<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>duced<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>full<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our <span style="letter-spacing:-0.1pt;">p</span>roduct<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">A<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">v</span>ariety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span>ks associat<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>ma<span style="letter-spacing:0.05pt;">r</span>keti<span style="letter-spacing:0.1pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>internationally<span style="letter-spacing:-0.55pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>busi<span style="letter-spacing:-0.1pt;">n</span><span style="letter-spacing:0.05pt;">e</span>ss.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>plan<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>accordingly,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to additional<span style="letter-spacing:-0.3pt;"> </span>risks related<span style="letter-spacing:-0.3pt;"> </span>to operating<span style="letter-spacing:-0.35pt;"> </span>in foreign<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>approvals,<span style="letter-spacing:-0.4pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulato</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">requirem</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">in foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">countries&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unexpected</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tariffs,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">rriers,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and exchange</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">controls</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">conomic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">weakness,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">inflation,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">political</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">instability</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">in particular</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">fore</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">gn</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">economies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">markets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ompliance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">with</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">tax,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">employment,</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">immigration</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">labor</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">laws</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">employees</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">living</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">traveling</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">taxes,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">wi</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">hholding</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">payroll</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">taxes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">currency</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">fluctuations,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">could</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ult</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">in in</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">re</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">op</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">expenses</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">reduced</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">revenues,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">oth</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">incident</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to doing</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">business</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in an</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">count</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">y&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">sta</span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="color:#000000;">fing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">managing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">operations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">workforce</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">uncertainty</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">countries</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">labor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">unrest</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is more</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">common</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">than</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">United</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">States&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">differing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">payor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">reimbursement</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">regimes,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">governm</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">ntal</span><span style="letter-spacing:-0.55pt;color:#000000;"> </span><span style="color:#000000;">payors</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patient</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">self-pay</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">systems,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">controls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">liability</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">Foreign</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">C</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">rrupt</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">Practices</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">Act</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">1977,</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FCP</span><span style="letter-spacing:-0.05pt;color:#000000;">A</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">comparable</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">foreign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hallenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">enforcing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">contrac</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">ual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">especially</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">ign</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">countries</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">do</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">resp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">protect </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nte</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tu</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">op</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rty</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">me</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ex</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">Un</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d </span><span style="letter-spacing:-0.05pt;color:#000000;">S</span><span style="color:#000000;">ta</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">es&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">production</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">tages</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">events</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">affecting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">raw</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">mat</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rial</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">supply</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufact</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">ring</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">capabilities</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">abroad&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">public</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">epidemics</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">global</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">economy,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">coronavirus</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">pandemic</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">currently</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">hav</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">an</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">impact</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">throughout</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">the world&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">business</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">interruptions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">geo-po</span><span style="letter-spacing:-0.1pt;color:#000000;">l</span><span style="color:#000000;">itical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">actions,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">war</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">terrorism.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>risks <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>soc<span style="letter-spacing:-0.05pt;">i</span>at<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> i</span>nter<span style="letter-spacing:-0.05pt;">n</span>ational<span style="letter-spacing:-0.4pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>material<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>adv<span style="letter-spacing:-0.05pt;">e</span>rsely<span style="letter-spacing:-0.35pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.15pt;">i</span>n<span style="letter-spacing:-0.2pt;"> </span>profitable<span style="letter-spacing:-0.3pt;"> </span>operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have <span style="letter-spacing:-0.05pt;">n</span>ev<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>m<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span><span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ate<span style="letter-spacing:-0.4pt;"> </span>before,<span style="letter-spacing:-0.2pt;"> </span>and we<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>ay<span style="letter-spacing:-0.05pt;"> l</span>ack<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>cessary<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpertis<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>personnel<span style="letter-spacing:-0.05pt;"> </span>and <span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>so<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ssf<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">ly </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>products on our own or<span style="letter-spacing:0.05pt;"> </span>together<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">u</span>itable<span style="letter-spacing:-0.2pt;"> </span>collaborators.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>never<span style="letter-spacing:-0.25pt;"> </span>commercialized<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>currently<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>therapeutic<span style="letter-spacing:-0.35pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;">c</span>e,<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>distribution<span style="letter-spacing:-0.4pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pabi<span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.3pt;"> </span>To<span style="letter-spacing:-0.1pt;"> </span>ach<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>ve commercial<span style="letter-spacing:-0.4pt;"> </span>success<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense<span style="letter-spacing:-0.25pt;"> </span>to others,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>rely<span style="letter-spacing:-0.15pt;"> </span>on the<span style="letter-spacing:-0.15pt;"> </span>assistance<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>guidance<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.05pt;"> </span>collaborators.<span style="letter-spacing:-0.5pt;"> </span>For prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>retain<span style="letter-spacing:-0.15pt;"> </span>comm<span style="letter-spacing:-0.1pt;">e</span>rcialization<span style="letter-spacing:-0.65pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>sales,<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>sup<span style="letter-spacing:0.05pt;">p</span>ly organization<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>outsource<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">c</span>tivities<span style="letter-spacing:-0.35pt;"> </span>to a third<span style="letter-spacing:-0.1pt;"> </span>party.<span style="letter-spacing:-0.15pt;"> </span>Factors<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>andidates,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>approved,<span style="letter-spacing:-0.4pt;"> </span>on o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>recruiting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>retaining<span style="letter-spacing:-0.3pt;"> </span>ad<span style="letter-spacing:-0.05pt;">e</span>quate<span style="letter-spacing:-0.25pt;"> </span>numbers<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.3pt;"> </span>sales<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>mar<span style="letter-spacing:-0.05pt;">k</span>eting<span style="letter-spacing:-0.4pt;"> </span>personnel,<span style="letter-spacing:-0.4pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>oping<span style="letter-spacing:-0.45pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>educational<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing programs<span style="letter-spacing:-0.3pt;"> </span>to increase<span style="letter-spacing:-0.25pt;"> </span>public<span style="letter-spacing:-0.15pt;"> </span>acc<span style="letter-spacing:-0.15pt;">e</span>ptance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>ensuring<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>compan<span style="letter-spacing:0.05pt;">y</span>,<span style="letter-spacing:-0.35pt;"> </span>empl<span style="letter-spacing:-0.05pt;">o</span>yees<span style="letter-spacing:-0.45pt;"> and third parties </span>under<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>althcare<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>unforeseen<span style="letter-spacing:-0.45pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>creating<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.2pt;"> </span>independent<span style="letter-spacing:-0.4pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>organization. Developing<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.25pt;"> </span>organization<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>expensive<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>time-consuming<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>launch<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.1pt;">a</span>ndidates<span style="letter-spacing:-0.4pt;"> </span>upon approval.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to build<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>market<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>organization.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>build<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>distribution and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>capabilities<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>suitable<span style="letter-spacing:-0.25pt;"> </span>partners<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>we may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>genera<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.25pt;"> </span>revenues<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>them<span style="letter-spacing:-0.15pt;"> </span>or be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>reach<span style="letter-spacing:-0.2pt;"> </span>or sustain<span style="letter-spacing:-0.2pt;"> </span>profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s R<span style="letter-spacing:0.05pt;">e</span>lat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to Government<span style="letter-spacing:-0.25pt;"> </span>Regulation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span>roval<span style="letter-spacing:-0.15pt;"> </span>process<span style="letter-spacing:-0.05pt;"> </span>is len<span style="letter-spacing:-0.05pt;">g</span>thy<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>time-consuming,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> m</span>ay<span style="letter-spacing:-0.1pt;"> </span>exp<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>e<span style="letter-spacing:-0.05pt;">n</span>ce<span style="letter-spacing:-0.3pt;"> </span>sig<span style="letter-spacing:-0.05pt;">n</span>ifi<span style="letter-spacing:-0.05pt;">c</span>ant<span style="letter-spacing:-0.25pt;"> </span>de<span style="letter-spacing:-0.05pt;">l</span>ays<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>cl<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>al<span style="letter-spacing:-0.2pt;"> </span>de<span style="letter-spacing:-0.1pt;">v</span>elopment<span style="letter-spacing:-0.45pt;"> </span>and regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>previously<span style="letter-spacing:-0.35pt;"> </span>sub<span style="letter-spacing:-0.1pt;">m</span>itted<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>BLA<span style="letter-spacing:-0.05pt;"> </span>or NDA to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">F</span>DA, or<span style="letter-spacing:0.1pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>filings<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>compa<span style="letter-spacing:-0.1pt;">r</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.4pt;"> </span>fore<span style="letter-spacing:-0.05pt;">i</span>gn<span style="letter-spacing:-0.15pt;"> </span>au<span style="letter-spacing:-0.05pt;">t</span>horit<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.3pt;"> </span>BLAs <span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>N<span style="letter-spacing:0.05pt;">D</span>As mu<span style="letter-spacing:0.05pt;">s</span>t include<span style="letter-spacing:-0.2pt;"> </span>extensive<span style="letter-spacing:-0.35pt;"> </span>preclini<span style="letter-spacing:-0.1pt;">c</span>al<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.1pt;">a</span>ta<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>supporting<span style="letter-spacing:-0.35pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>establish<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate&#8217;s<span style="letter-spacing:-0.35pt;"> </span>safety<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>efficacy<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>NDAs, or<span style="letter-spacing:-0.05pt;"> </span>safety, p<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ity<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>potency<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>BLAs,<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>des<span style="letter-spacing:0.1pt;">i</span>red<span style="letter-spacing:-0.2pt;"> </span>indication.<span style="letter-spacing:-0.35pt;"> </span>Additionally,<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:0.05pt;">o</span>pulation<span style="letter-spacing:-0.25pt;"> </span>is defined<span style="letter-spacing:-0.3pt;"> </span>per<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>discussion<span style="letter-spacing:-0.35pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h the<span style="letter-spacing:-0.1pt;"> </span>FDA as patients who<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>progressed<span style="letter-spacing:-0.05pt;"> </span>following<span style="letter-spacing:-0.35pt;"> </span>initial<span style="letter-spacing:-0.15pt;"> </span>systemic<span style="letter-spacing:-0.3pt;"> </span>therapy<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>recurrent<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">e</span>t<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">t</span>at<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.35pt;"> </span>disease,<span style="letter-spacing:-0.3pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>clude<span style="letter-spacing:-0.15pt;"> </span>many<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>advan<span style="letter-spacing:-0.05pt;">c</span>ed<span style="letter-spacing:-0.35pt;"> </span>pat<span style="letter-spacing:-0.05pt;">i</span>en<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>enrolled to date.<span style="letter-spacing:-0.1pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>bel<span style="letter-spacing:-0.15pt;">i</span>efs<span style="letter-spacing:-0.1pt;"> </span>regarding<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">i</span>stration<span style="letter-spacing:-0.35pt;"> </span>pathway<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>A<span style="letter-spacing:0.05pt;">n</span>ktiva<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>interpretat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>communications with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>date<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>to address<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>communic<span style="letter-spacing:-0.1pt;">a</span>tions,<span style="letter-spacing:-0.6pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>orre<span style="letter-spacing:-0.05pt;">c</span>t.<span style="letter-spacing:-0.25pt;"> </span>Fu<span style="letter-spacing:-0.05pt;">r</span>ther,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nroll<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>ria<span style="letter-spacing:-0.05pt;">l</span>s<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>further adjusted<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>feedback<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>agency<span style="letter-spacing:-0.2pt;"> </span>inp<span style="letter-spacing:0.05pt;">u</span>t.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>revised<span style="letter-spacing:-0.2pt;"> </span>protocol<span style="letter-spacing:-0.25pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>defines<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>population<span style="letter-spacing:-0.35pt;"> </span>to include<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>advanced<span style="letter-spacing:-0.35pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>study,<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.35pt;"> </span>reported<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>date,<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>anges<span style="letter-spacing:-0.35pt;"> </span>to implement<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>n independent<span style="letter-spacing:-0.45pt;"> </span>review committee<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>assay<span style="letter-spacing:0.05pt;"> </span>validat<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>implementation,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>within<span style="letter-spacing:-0.3pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>study<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>supportive<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>pproval,<span style="letter-spacing:-0.3pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.35pt;"> </span>anticipated<span style="letter-spacing:-0.35pt;"> </span>timeline<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>opment<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>approval ent<span style="letter-spacing:-0.05pt;">i</span>rely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>delays,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.35pt;"> </span>ar<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>ed<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">i</span>ncr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span>se<span style="letter-spacing:-0.2pt;"> </span>enrol<span style="letter-spacing:-0.05pt;">l</span>m<span style="letter-spacing:-0.05pt;">e</span>nt,<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>t<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>planned<span style="letter-spacing:-0.3pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ials<span style="letter-spacing:-0.25pt;"> </span>for a va<span style="letter-spacing:-0.05pt;">r</span>iety<span style="letter-spacing:-0.2pt;"> </span>of reasons,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>delays<span style="letter-spacing:-0.25pt;"> </span>related<span style="letter-spacing:-0.2pt;"> </span>to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">availability</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">financial</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">resourc</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">com</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">ence</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nd </span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ompl</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">te</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">anned</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reaching agreement on acceptable contra</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining approval at each clinical trial site</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">by an</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">IRB</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or cen</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ral</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">IRB&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruiting suitable patients to participate in a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ving patients complete a trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial sites deviating from trial protocol or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adding </span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">w clinical trial sites&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">anufacturing sufficient quantities of qual</span><span style="letter-spacing:0.1pt;color:#000000;">i</span><span style="color:#000000;">fied</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">materials</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">cGMP</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">appl</span><span style="letter-spacing:0.05pt;color:#000000;">y</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">them</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">on a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subje</span><span style="letter-spacing:0.1pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">basis for use in clinical trials&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">imely</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">implementing</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">validating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">changes</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">quality</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">control</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">processes</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">methods</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">needed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">address</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA feedback.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>encounter<span style="letter-spacing:-0.3pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>physicians<span style="letter-spacing:-0.4pt;"> </span>encounter unresolved<span style="letter-spacing:-0.4pt;"> </span>e<span style="letter-spacing:-0.05pt;">t</span>hical<span style="letter-spacing:-0.25pt;"> </span>issues<span style="letter-spacing:-0.05pt;"> </span>associated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>enrolling<span style="letter-spacing:-0.3pt;"> </span>patients<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trials<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>lieu<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>prescrib<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>eatments<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:-0.05pt;">s</span>tablished<span style="letter-spacing:-0.3pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>profil<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.15pt;"> </span>Furth<span style="letter-spacing:-0.05pt;">e</span>r,<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>trial<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted by the FDA<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>authorities,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>recommended<span style="letter-spacing:-0.45pt;"> </span>for suspension<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>termination by DSMBs due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>g<span style="letter-spacing:0.05pt;">o</span>vernmental<span style="letter-spacing:0.05pt;"> </span>regula<span style="letter-spacing:-0.1pt;">t</span>ions<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>administrative<span style="letter-spacing:-0.45pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:0.1pt;">a</span>ck<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>funding<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>trial.<span style="letter-spacing:-0.1pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>experience<span style="letter-spacing:-0.4pt;"> </span>termination<span style="letter-spacing:-0.4pt;"> </span>of,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>delays<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>completion<span style="letter-spacing:0.05pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>trial<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:-0.1pt;">s</span>pects<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>h<span style="letter-spacing:-0.1pt;">a</span>rmed,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>generate<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:0.05pt;"> </span>revenues<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Results for any patient who receives compassionate use access to our product candidates should not be viewed as representative of how the product candidate will perform in a well-controlled clinical trial, and cannot be used to establish safety or efficacy for regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We often receive requests for compassionate use access to our investigational drugs by patients that do not meet the entry criteria for enrollment into our clinical tri<span style="letter-spacing:-0.05pt;">a</span>ls. Generally, patients requesting compassionate use have no other treatment alternatives for life threatening conditions. We<span style="letter-spacing:-0.1pt;"> </span>evaluate each compassionate use request on an individual basis, and in some cases grant access to our investigational product<span style="letter-spacing:-0.3pt;"> </span>candidates outside of our sponsored clinical trials<span style="letter-spacing:-0.15pt;"> </span>if a physician certifies that the patient receiving treatment is critically ill and does not meet the entry criteria for one of our open clinical trials. Individual patient results from compassionate use access may not be used to support submission of a regulatory application, may<span style="letter-spacing:-0.2pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t support approval of a product candidate<span style="letter-spacing:-0.25pt;"> </span>and should not be considered to be indicative of results from any on-going or future well-controlled clinical trial. Before we can seek regulatory approval for any of our product candidates, we must demonstrate in well-controlled clinical trials statistically significant evidence that the product candidate is both safe and effective for the indication we are seeking approval. The results of our compassionate use program may not be used to establish safety or efficacy or regulatory approval.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The clinical and commercial utility of our product<span style="letter-spacing:-0.35pt;"> </span>candidates are uncertain and may never be realized.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:0.05pt;">d</span>idates are in the early stages of development. We currently have ongoing clinical trials to evaluate our<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>spective<span style="letter-spacing:-0.3pt;"> </span>product cand<span style="letter-spacing:-0.05pt;">i</span>dat<span style="letter-spacing:-0.05pt;">e</span>s. Success in early clinical trials does not ensure that large-scale clinical trials will be successful, nor does it predict final results. In addition, we will not be able to treat patients if we cannot manufacture a sufficient quantity of Anktiva<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>therapies that meet our minimum specifications. In addition, Anktiva<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of our other product candidates<span style="letter-spacing:-0.35pt;"> </span>have only been tested in a small number of patients. Results from these clinical trials may not necessarily be indicative of the safety and tolerability or efficacy of our product<span style="letter-spacing:-0.2pt;"> </span>candidates as we expand into larger clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not ultimately be able to provide the FDA with substantial clinical evidence to support a claim of safety, purity and potency sufficient to enable the FDA to approve our product candidate for any indication. This may be because later clinical trials fail to reproduce favorable data obtained in earlier clinical trials, because the FDA disagrees with how we interpret the data from these clinical trials or because the FDA does not accept these therapeutic effects as valid endpoints in pivotal clinical trials necessary for market approval. We will also need to demonstrate that our product candidates are safe. We do not have data on possible harmful long-term effects of our product candidates and do not expect to have this data in the near future. As a result, our ability to generate clinical safety and effectiveness data sufficient to support submission of a marketing application or commercialization of our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates is uncertain and is subject to significant risk.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">recei</span><span style="letter-spacing:-0.15pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">proval</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">andida</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">es,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ue</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to ongoing</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">obl</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gations</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">continued </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">latory</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">iew,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">sult</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">significant</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">expense</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">sub</span><span style="letter-spacing:-0.05pt;">j</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o p</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">na</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">fail</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">comp</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">w</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ith</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">regula</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ory requirements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">experience </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">unanticipated</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">problems</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>surveillance<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>monitor<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>efficacy<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">n</span>didate. The<span style="letter-spacing:-0.2pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>a REMS<span style="letter-spacing:0.05pt;"> </span>to app<span style="letter-spacing:-0.1pt;">r</span>ove<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>entail<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a medication<span style="letter-spacing:-0.35pt;"> </span>guide,<span style="letter-spacing:-0.15pt;"> </span>phy<span style="letter-spacing:-0.05pt;">s</span>i<span style="letter-spacing:-0.05pt;">c</span>ian<span style="letter-spacing:-0.2pt;"> </span>communication plans<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>addit<span style="letter-spacing:-0.15pt;">i</span>onal<span style="letter-spacing:-0.35pt;"> </span>elements<span style="letter-spacing:-0.25pt;"> </span>to ensure<span style="letter-spacing:-0.2pt;"> </span>safe<span style="letter-spacing:-0.1pt;"> </span>use,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as restricted<span style="letter-spacing:-0.35pt;"> </span>distribution<span style="letter-spacing:-0.35pt;"> </span>methods,<span style="letter-spacing:-0.3pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>regist<span style="letter-spacing:-0.05pt;">r</span>ies<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>minimization<span style="letter-spacing:-0.5pt;"> </span>tools.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>post-approv<span style="letter-spacing:0.1pt;">a</span>l<span style="letter-spacing:-0.45pt;"> P</span>hase&#160;IV<span style="letter-spacing:-0.05pt;"> </span>trials.<span style="letter-spacing:-0.15pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">F</span>DA and<span style="letter-spacing:-0.15pt;"> </span>comp<span style="letter-spacing:0.05pt;">a</span>rable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.25pt;"> </span>authorities<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>continue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>closely<span style="letter-spacing:-0.2pt;"> </span>monitor<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>safety<span style="letter-spacing:0.05pt;"> </span>profile<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>after<span style="letter-spacing:-0.15pt;"> </span>approval.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>or comparable<span style="letter-spacing:-0.35pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>b<span style="letter-spacing:0.05pt;">e</span>come<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.05pt;">w</span>are<span style="letter-spacing:-0.1pt;"> </span>of new safety<span style="letter-spacing:-0.2pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>after approval of any<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ey<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>withdraw<span style="letter-spacing:-0.35pt;"> </span>approval,<span style="letter-spacing:-0.35pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>lab<span style="letter-spacing:-0.05pt;">e</span>ling<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>es<span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">a</span>blishm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>of a<span style="letter-spacing:-0.05pt;"> </span>REMS or<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>strategy,<span style="letter-spacing:-0.25pt;"> </span>impo<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.45pt;"> </span>restrictions<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a product&#8217;s<span style="letter-spacing:-0.3pt;"> </span>indicated<span style="letter-spacing:-0.35pt;"> </span>uses or<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>rketing,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>impose<span style="letter-spacing:-0.2pt;"> </span>ongoing<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>for pot<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>lly<span style="letter-spacing:-0.35pt;"> </span>cost<span style="letter-spacing:-0.05pt;">l</span>y p<span style="letter-spacing:0.05pt;">o</span>st<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">a</span>pproval<span style="letter-spacing:-0.25pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>post<span style="letter-spacing:0.05pt;">-</span>market<span style="letter-spacing:-0.25pt;"> </span>surveillance.<span style="letter-spacing:-0.45pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>restric<span style="letter-spacing:0.05pt;">t</span>ions<span style="letter-spacing:-0.45pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>limit<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:0.1pt;">a</span>les<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we,<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>contractors,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>collab<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>ators<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>responsible<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>compliance,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>requirem<span style="letter-spacing:-0.1pt;">e</span>nts<span style="letter-spacing:-0.4pt;"> </span>related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>product design,<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;">t</span>ing, clinical trials and preclinical studies approval,<span style="letter-spacing:-0.3pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>processes<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>quality,<span style="letter-spacing:-0.25pt;"> </span>lab<span style="letter-spacing:-0.05pt;">e</span>ling,<span style="letter-spacing:-0.35pt;"> </span>packaging,<span style="letter-spacing:-0.35pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>stribution,<span style="letter-spacing:-0.45pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>event<span style="letter-spacing:-0.2pt;"> </span>and deviation<span style="letter-spacing:-0.35pt;"> </span>reporting,<span style="letter-spacing:-0.35pt;"> </span>storage,<span style="letter-spacing:-0.25pt;"> </span>advertising,<span style="letter-spacing:-0.35pt;"> </span>marketing,<span style="letter-spacing:-0.4pt;"> </span>promotion,<span style="letter-spacing:-0.35pt;"> </span>sale,<span style="letter-spacing:-0.15pt;"> </span>imp<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>t,<span style="letter-spacing:-0.25pt;"> </span>export,<span style="letter-spacing:-0.25pt;"> </span>sub<span style="letter-spacing:-0.1pt;">m</span>issions<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>safety<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>post-ma<span style="letter-spacing:0.05pt;">r</span>keting<span style="letter-spacing:-0.5pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and reports<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>deviation<span style="letter-spacing:-0.35pt;"> </span>reports,<span style="letter-spacing:-0.2pt;"> </span>registration,<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>listing,<span style="letter-spacing:-0.3pt;"> </span>annual<span style="letter-spacing:-0.2pt;"> </span>user<span style="letter-spacing:-0.05pt;"> </span>fees,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reco<span style="letter-spacing:0.05pt;">r</span>dkeeping<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidat<span style="letter-spacing:0.1pt;">e</span>s.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r collaborators,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ract<span style="letter-spacing:-0.25pt;"> </span>manufacturers,<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.05pt;"> s</span>ubject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>periodic<span style="letter-spacing:-0.35pt;"> </span>unannounced<span style="letter-spacing:-0.55pt;"> </span>ins<span style="letter-spacing:0.05pt;">p</span>ections<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>to monitor<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ensure compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requ<span style="letter-spacing:0.1pt;">i</span>rements.<span style="letter-spacing:-0.45pt;"> </span>Application<span style="letter-spacing:-0.4pt;"> </span>holders<span style="letter-spacing:-0.15pt;"> </span>must<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.3pt;"> </span>notify<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA,<span style="letter-spacing:0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>depending<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>nature<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.1pt;">h</span>ange,<span style="letter-spacing:-0.25pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>FDA pre-approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>changes.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.05pt;">i</span>ance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>post-approval<span style="letter-spacing:-0.5pt;"> </span>regulat<span style="letter-spacing:-0.1pt;">i</span>ons<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a negative<span style="letter-spacing:-0.35pt;"> </span>effe<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operating results<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Later<span style="letter-spacing:-0.2pt;"> </span>discovery<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>previously<span style="letter-spacing:-0.4pt;"> </span>unknown<span style="letter-spacing:-0.05pt;"> </span>problems<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>events<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>unanticipated<span style="letter-spacing:-0.45pt;"> </span>severity<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>frequency,<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>is less<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.3pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>previously<span style="letter-spacing:-0.3pt;"> </span>tho<span style="letter-spacing:0.05pt;">u</span>ght,<span style="letter-spacing:-0.35pt;"> </span>problems<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-pa<span style="letter-spacing:-0.05pt;">r</span>ty<span style="letter-spacing:-0.3pt;"> </span>manu<span style="letter-spacing:-0.05pt;">f</span>acturers<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>processes,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>fa<span style="letter-spacing:-0.05pt;">i</span>lure<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in,<span style="letter-spacing:-0.05pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">marketing,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">distribution,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">manufacturing</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duct</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">withdrawal</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">f</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">market,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or voluntary</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">mandatory</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">labeling</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">produ</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">warnings,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">ch</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">black</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">box</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">warnings, contraindications,</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">pre</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">autions,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">restrictions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">indication</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">odifications</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">omotional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">p</span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">hanges</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">o</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">uct</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">labeling</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">way</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">is administered&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">iability</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">harm</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">used</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">o p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subjects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">restitution,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">disgorg</span><span style="letter-spacing:-0.1pt;color:#000000;">e</span><span style="color:#000000;">m</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">warning</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">tt</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rs,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">un</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">letters,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">holds</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">ter</span><span style="letter-spacing:-0.05pt;color:#000000;">mi</span><span style="color:#000000;">nat</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ni</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">al</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tr</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">h</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">FDA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approve</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">pending</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">appli</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ations</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">supplements</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">approved</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">filed</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">suspension</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">revoc</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tion</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of license</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">seizure</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">detention,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.1pt;color:#000000;"> </span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to permit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">import</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">export</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">njunctions</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">imposition</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">civil</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">cri</span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">na</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ti</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">imprisonment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">F</span><span style="color:#000000;">DA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">debarment,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">debarme</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">government</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">contr</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">cts,</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">orders</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">und</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">existing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">cont</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">acts,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">excl</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="color:#000000;">sion</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">fed</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ral healthcare</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">programs,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">consent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">decrees,</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">corporate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">integrity</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">authority</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">issuance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">al</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rts,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">D</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ar</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">H</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">thc</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">re</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">Prov</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">der</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rs,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">press</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">leases,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">communications</span><span style="letter-spacing:-0.6pt;color:#000000;"> </span><span style="color:#000000;">con</span><span style="letter-spacing:0.05pt;color:#000000;">t</span><span style="color:#000000;">aining warnings</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">i</span><span style="letter-spacing:-0.05pt;color:#000000;">n</span><span style="color:#000000;">formation</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">about</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">biologic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reputational</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">harm&#59;</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">becoming</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">less</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">competitive.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>events<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effects<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>op<span style="letter-spacing:-0.05pt;">e</span>rations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>business and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ice<span style="letter-spacing:-0.05pt;"> </span>and could<span style="letter-spacing:-0.2pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>harm<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busi<span style="letter-spacing:-0.05pt;">n</span>ess,<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condit<span style="letter-spacing:0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operat<span style="letter-spacing:-0.05pt;">i</span>ons,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>spects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA&#8217;s and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authorities&#8217;</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">policies</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">change,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">add</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tional</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">g</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overnment</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gulations</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enacted</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cou</span><span style="letter-spacing:0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">limit</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or delay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">likelihood,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nature</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulati</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arise</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from future</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gisla</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or ad</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inistr</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ther</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unit</span><span style="letter-spacing:-0.15pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">S</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tes</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ab</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we a</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">slow or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">un</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ble</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adapt</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o ch</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in existing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adoption</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">new</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">requirements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or policies,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">le</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to maintain</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compl</span><span style="letter-spacing:-0.1pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ance,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lose</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketi</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obtained,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">atory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enfor</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">achieve</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sustain</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">profitability.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>GMP-in-a-Box<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>regulated<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>com<span style="letter-spacing:0.05pt;">p</span>liance<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.25pt;"> </span>is expensive,<span style="letter-spacing:-0.55pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>and uncertain,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>failure<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>com<span style="letter-spacing:0.1pt;">p</span>ly<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>lead<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.1pt;">t</span>her<span style="letter-spacing:-0.05pt;"> </span>negative<span style="letter-spacing:-0.25pt;"> </span>consequen<span style="letter-spacing:0.1pt;">c</span>es for our busine<span style="letter-spacing:-0.05pt;">s</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd si<span style="letter-spacing:-0.05pt;">m</span>il<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>genc<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gula<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>med<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>devices.<span style="letter-spacing:-0.3pt;"> </span>Complying<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>costly,<span style="letter-spacing:-0.3pt;"> </span>time-consuming,<span style="letter-spacing:-0.6pt;"> </span>complex<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">u</span>ncertain.<span style="letter-spacing:-0.2pt;"> </span>For instance,<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.05pt;">f</span>ore<span style="letter-spacing:-0.15pt;"> </span>a new<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>intended<span style="letter-spacing:-0.25pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.35pt;"> </span>dev<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">ce</span>,<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>rketed<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;"> </span>State<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mpany<span style="letter-spacing:-0.4pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>irst submit and<span style="letter-spacing:-0.1pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>510(k)<span style="letter-spacing:0.05pt;"> </span>clearance<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pre-marketing<span style="letter-spacing:-0.45pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>F<span style="letter-spacing:-0.05pt;">D</span>A,<span style="letter-spacing:-0.05pt;"> </span>unless<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>exe<span style="letter-spacing:-0.05pt;">m</span>ption<span style="letter-spacing:-0.4pt;"> </span>applies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA<span style="letter-spacing:0.05pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>wide-ranging<span style="letter-spacing:-0.5pt;"> </span>and include,<span style="letter-spacing:-0.3pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>things,<span style="letter-spacing:-0.3pt;"> </span>oversight<span style="letter-spacing:-0.4pt;"> </span>of:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">design,</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">development,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">manufacture</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">(including</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">su</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">plie</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">s)</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">aboratory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">preclinical</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.15pt;color:#000000;">t</span><span style="color:#000000;">udi</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">cl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">nic</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">tri</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">safety</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">effectiveness&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">labeling&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">storage</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">shipping&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">kee</span><span style="letter-spacing:0.05pt;color:#000000;">p</span><span style="color:#000000;">ing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">pre-market</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">m</span><span style="color:#000000;">arketing,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">adverti</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">ing</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">promotion&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">sales</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and distribution&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">changes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">recalls&#59;</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">post-market</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">surveillance</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">porting</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">deaths</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">serious</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">injuries</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">malfunctions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>regulated<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>gen<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.25pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>rols<span style="letter-spacing:-0.1pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lud<span style="letter-spacing:-0.05pt;">e:</span><span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gistr<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FDA&#59; list<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">e</span>rc<span style="letter-spacing:-0.05pt;">i</span>ally<span style="letter-spacing:-0.4pt;"> </span>distributed prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA&#59; complying<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>cGMP<span style="letter-spacing:-0.1pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>Quality<span style="letter-spacing:-0.2pt;"> </span>Systems<span style="letter-spacing:-0.35pt;"> </span>Regulations&#59;<span style="letter-spacing:-0.4pt;"> </span>filing<span style="letter-spacing:-0.25pt;"> </span>reports<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>keeping<span style="letter-spacing:-0.25pt;"> </span>recor<span style="letter-spacing:0.05pt;">d</span>s<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>tive<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o certain<span style="letter-spacing:-0.2pt;"> </span>types<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>devices<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>repo<span style="letter-spacing:-0.1pt;">r</span>ting<span style="letter-spacing:-0.3pt;"> </span>regulation&#59;<span style="letter-spacing:-0.35pt;"> </span>assuring<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>device<span style="letter-spacing:-0.2pt;"> </span>la<span style="letter-spacing:-0.05pt;">b</span>eling<span style="letter-spacing:-0.3pt;"> </span>complies<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>device labeling<span style="letter-spacing:-0.3pt;"> </span>requirements&#59;<span style="letter-spacing:-0.5pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:0.1pt;">e</span>rtain<span style="letter-spacing:-0.25pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>field<span style="letter-spacing:-0.1pt;"> </span>removals<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>corrections<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA&#59;<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>pre-market<span style="letter-spacing:-0.35pt;"> </span>notification<span style="letter-spacing:-0.3pt;"> </span>510(k)<span style="letter-spacing:-0.05pt;"> </span>clearance<span style="letter-spacing:-0.3pt;"> </span>for devices<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>marketing.<span style="letter-spacing:-0.4pt;"> </span>Some<span style="letter-spacing:-0.15pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span>known as<span style="letter-spacing:0.05pt;"> </span>510(k)-exempt<span style="letter-spacing:-0.5pt;"> </span>d<span style="letter-spacing:0.05pt;">e</span>vices<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketed<span style="letter-spacing:-0.3pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>marketing-clearance<span style="letter-spacing:-0.75pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">p</span>proval<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the FDA.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>general<span style="letter-spacing:-0.2pt;"> </span>controls,<span style="letter-spacing:-0.3pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>Class&#160;II<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>devices<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o spe<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.1pt;"> </span>controls,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>adherence<span style="letter-spacing:-0.3pt;"> </span>to a particular<span style="letter-spacing:-0.35pt;"> </span>guidance d<span style="letter-spacing:0.05pt;">o</span>cument<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>performa<span style="letter-spacing:-0.1pt;">n</span>ce<span style="letter-spacing:-0.4pt;"> </span>standard.<span style="letter-spacing:-0.35pt;"> </span>Instead<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>obtaining<span style="letter-spacing:-0.35pt;"> </span>510(k)<span style="letter-spacing:0.05pt;"> </span>cle<span style="letter-spacing:-0.1pt;">a</span>rance,<span style="letter-spacing:-0.3pt;"> </span>most<span style="letter-spacing:-0.2pt;"> </span>Class&#160;<span style="letter-spacing:-0.05pt;">I</span>II<span style="letter-spacing:0.05pt;"> </span>devices<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subje<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>pre-m<span style="letter-spacing:-0.05pt;">a</span>rket approval,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>PMA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>refuse<span style="letter-spacing:-0.25pt;"> </span>to clear<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>approve<span style="letter-spacing:-0.3pt;"> </span>pre-market<span style="letter-spacing:-0.4pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>develop.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>action<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other comparable<span style="letter-spacing:-0.35pt;"> </span>non-U.S.<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adver<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">i</span>nancial<span style="letter-spacing:-0.25pt;"> </span>condit<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.4pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>failure to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.45pt;"> </span>action<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>clude<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the following<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tions:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">un</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">it</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">ed</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ters,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">warn</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ng</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">tt</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rs,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">fines,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.05pt;color:#000000;">j</span><span style="color:#000000;">unctions,</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">consent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">dec</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ees</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">civil</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">un</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">nti</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ip</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ted</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">exp</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nditur</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">address</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">defend</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">actions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">ustomer</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">notificatio</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">repair,</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">replacement</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">refunds&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recall,</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">detention</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">seizure</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">restrictions</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">partial</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">suspension</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">total</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sh</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">down</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">duction&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusing</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">delaying</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">requests</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">510(k)</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clearance</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">PMA</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">new</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">modified</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">operating</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ri</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">tions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">510(k)</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">clearances</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">PMA approvals</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">h</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ve</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">already</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">granted&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">grant</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">export</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">approval</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">products&#59;</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">riminal</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">prosecution.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>events<span style="letter-spacing:-0.2pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to occur,<span style="letter-spacing:-0.25pt;"> </span>it<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>res<span style="letter-spacing:-0.05pt;">u</span>lts<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operatio<span style="letter-spacing:0.05pt;">n</span>s.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>neces<span style="letter-spacing:-0.05pt;">s</span>ary<span style="letter-spacing:-0.3pt;"> </span>clearances<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approvals<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>un<span style="letter-spacing:0.05pt;">d</span>uly<span style="letter-spacing:-0.05pt;"> </span>delayed<span style="letter-spacing:-0.25pt;"> </span>in doing<span style="letter-spacing:-0.3pt;"> </span>so,<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>develop,<span style="letter-spacing:-0.25pt;"> </span>which could<span style="letter-spacing:-0.25pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>Further<span style="letter-spacing:-0.05pt;">m</span>ore,<span style="letter-spacing:-0.4pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>anted<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>clearances<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approvals<span style="letter-spacing:-0.35pt;"> </span>for any<span style="letter-spacing:-0.15pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>device<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.1pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>include sig<span style="letter-spacing:0.05pt;">n</span>ificant<span style="letter-spacing:-0.4pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> i</span>ndicated<span style="letter-spacing:-0.3pt;"> </span>uses for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>limit<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.1pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>product.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>regula<span style="letter-spacing:0.05pt;">t</span>es<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>verti<span style="letter-spacing:0.05pt;">s</span>ing<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d promotion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>devices<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ensure<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>ims<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>consist<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gu<span style="letter-spacing:-0.05pt;">l</span>atory<span style="letter-spacing:-0.3pt;"> </span>clearances<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approvals,<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>adequate<span style="letter-spacing:-0.35pt;"> </span>and reasonable<span style="letter-spacing:-0.4pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>to substantiate<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ai<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>promotional<span style="letter-spacing:-0.45pt;"> </span>labeling<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adv<span style="letter-spacing:-0.05pt;">e</span>rtising<span style="letter-spacing:-0.4pt;"> </span>is n<span style="letter-spacing:-0.05pt;">e</span>i<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>alse<span style="letter-spacing:-0.15pt;"> </span>nor<span style="letter-spacing:0.05pt;"> </span>misleading<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>respect.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA determines<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>adv<span style="letter-spacing:0.05pt;">e</span>rtising<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>misleading,<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>subst<span style="letter-spacing:-0.05pt;">a</span>ntiated<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>permi<span style="letter-spacing:-0.05pt;">s</span>sible,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enforc<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nt actions,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>warning<span style="letter-spacing:-0.25pt;"> </span>letters,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to r<span style="letter-spacing:-0.05pt;">e</span>vise<span style="letter-spacing:-0.25pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>cor<span style="letter-spacing:-0.05pt;">r</span>ections<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>rest<span style="letter-spacing:0.05pt;">i</span>tutions.<span style="letter-spacing:-0.4pt;"> </span>Any medical device<span style="letter-spacing:1.1pt;"> </span>products<span style="letter-spacing:1.75pt;"> </span>we<span style="letter-spacing:0.7pt;"> </span>develop<span style="letter-spacing:1.7pt;"> </span>will<span style="letter-spacing:0.8pt;"> </span>be<span style="letter-spacing:0.15pt;"> </span>subject<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>extensive<span style="letter-spacing:1.7pt;"> </span>regulation<span style="letter-spacing:1.8pt;"> </span>by<span style="letter-spacing:0.4pt;"> </span>the<span style="letter-spacing:0.65pt;"> </span>FDA<span style="letter-spacing:1.2pt;"> </span>and<span style="letter-spacing:0.55pt;"> </span>non-U.S.<span style="letter-spacing:0.4pt;"> </span>regulatory<span style="letter-spacing:0.05pt;"> </span>agencies.<span style="letter-spacing:1.95pt;"> </span>Further,<span style="letter-spacing:1.65pt;"> </span>all<span style="letter-spacing:0.45pt;"> </span>of<span style="letter-spacing:0.55pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>potential<span style="letter-spacing:1.7pt;"> </span>medical device<span style="letter-spacing:1.1pt;"> </span>products<span style="letter-spacing:1.9pt;"> </span>and<span style="letter-spacing:0.5pt;"> </span>material<span style="letter-spacing:1.6pt;"> </span>modifications will<span style="letter-spacing:0.8pt;"> </span>be<span style="letter-spacing:0.55pt;"> </span>subject<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:0.75pt;"> </span>extensive<span style="letter-spacing:1.4pt;"> </span>regulation and<span style="letter-spacing:1pt;"> </span>clearance<span style="letter-spacing:1.5pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>approval from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>non-U.S.<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>agencies<span style="letter-spacing:-0.35pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to commercial<span style="letter-spacing:-0.4pt;"> </span>sale<span style="letter-spacing:-0.1pt;"> a</span>nd<span style="letter-spacing:-0.1pt;"> </span>distribution<span style="letter-spacing:-0.4pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as after<span style="letter-spacing:-0.2pt;"> </span>clearance<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>approva<span style="letter-spacing:0.1pt;">l</span>.<span style="letter-spacing:-0.3pt;"> </span>Fai<span style="letter-spacing:-0.05pt;">l</span>ure<span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>with applicable<span style="letter-spacing:-0.35pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>quirements<span style="letter-spacing:-0.5pt;"> </span>regarding,<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>promoting,<span style="letter-spacing:-0.35pt;"> </span>manufacturing,<span style="letter-spacing:-0.55pt;"> </span>or labeling<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>medical<span style="letter-spacing:-0.4pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>subject<span style="letter-spacing:-0.1pt;"> </span>us to a variety<span style="letter-spacing:-0.2pt;"> </span>of administrative<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>judicial<span style="letter-spacing:-0.2pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>sanctions,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>F<span style="letter-spacing:0.05pt;">o</span>rm&#160;483<span style="letter-spacing:0.05pt;"> </span>observations,<span style="letter-spacing:-0.45pt;"> </span>warning<span style="letter-spacing:-0.25pt;"> </span>lette<span style="letter-spacing:-0.05pt;">r</span>s,<span style="letter-spacing:-0.25pt;"> </span>untitled<span style="letter-spacing:-0.2pt;"> </span>lett<span style="letter-spacing:-0.05pt;">e</span>rs,<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>re<span style="letter-spacing:-0.05pt;">c</span>alls,<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>seiz<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>es,<span style="letter-spacing:-0.25pt;"> </span>total or<span style="letter-spacing:0.05pt;"> </span>partial<span style="letter-spacing:-0.2pt;"> </span>suspension<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>production<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dist<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:-0.1pt;">i</span>bution,<span style="letter-spacing:-0.4pt;"> </span>injunctions,<span style="letter-spacing:-0.4pt;"> </span>fines,<span style="letter-spacing:-0.25pt;"> </span>civil<span style="letter-spacing:-0.1pt;"> </span>penalties<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>criminal<span style="letter-spacing:-0.3pt;"> </span>prosecution.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.1pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>me<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span>cal<span style="letter-spacing:-0.3pt;"> device products cause </span>or<span style="letter-spacing:0.05pt;"> </span>contribute<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ath<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>serious i<span style="letter-spacing:0.05pt;">n</span>jury<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>malfunction<span style="letter-spacing:-0.45pt;"> </span>in certain<span style="letter-spacing:-0.25pt;"> </span>ways,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.2pt;"> </span>report<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>applica<span style="letter-spacing:0.1pt;">b</span>le<span style="letter-spacing:-0.3pt;"> </span>medical<span style="letter-spacing:-0.3pt;"> </span>device<span style="letter-spacing:-0.25pt;"> </span>reporting regulations,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in voluntary<span style="letter-spacing:-0.35pt;"> </span>corr<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tions<span style="letter-spacing:-0.25pt;"> </span>or ag<span style="letter-spacing:-0.05pt;">e</span>ncy<span style="letter-spacing:-0.2pt;"> </span>enfor<span style="letter-spacing:-0.05pt;">c</span>em<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>export<span style="letter-spacing:-0.25pt;"> </span>and import<span style="letter-spacing:-0.2pt;"> </span>controls<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>impair<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>in international<span style="letter-spacing:-0.45pt;"> </span>markets<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">du</span>e to <span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g requirements<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;"> </span>to liability<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>are <span style="letter-spacing:0.05pt;">n</span>ot in<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omplian<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>laws.<span style="letter-spacing:-0.25pt;"> </span>Compliance<span style="letter-spacing:-0.45pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.1pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>legal<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.1pt;">m</span>ents<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mit<span style="letter-spacing:-0.15pt;"> </span>our ab<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">e</span>te<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;">e</span>ign<span style="letter-spacing:-0.15pt;"> </span>marke<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>and s<span style="letter-spacing:-0.05pt;">u</span>b<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.15pt;"> </span>us to<span style="letter-spacing:-0.05pt;"> </span>liab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> v</span>io<span style="letter-spacing:-0.05pt;">l</span>ate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;">m</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>export<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>import<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.&#160;Export<span style="letter-spacing:-0.2pt;"> </span>Administration<span style="letter-spacing:-0.6pt;"> </span>Regulations,<span style="letter-spacing:-0.4pt;"> </span>U.S.&#160;Cust<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.35pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>v<span style="letter-spacing:0.05pt;">a</span>rious<span style="letter-spacing:-0.15pt;"> </span>economic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.1pt;">a</span>nctions<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>administered<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>U.S.&#160;Treasury<span style="letter-spacing:-0.35pt;"> </span>Department&#8217;s<span style="letter-spacing:-0.55pt;"> </span>Office<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Foreign<span style="letter-spacing:-0.35pt;"> </span>Assets Co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>rols.<span style="letter-spacing:-0.2pt;"> </span>Exports<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and solutions<span style="letter-spacing:-0.25pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations.<span style="letter-spacing:-0.35pt;"> </span>If we f<span style="letter-spacing:-0.05pt;">a</span>il<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regu<span style="letter-spacing:-0.1pt;">l</span>ations,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>civil<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>criminal<span style="letter-spacing:-0.25pt;"> </span>penalties,<span style="letter-spacing:-0.35pt;"> </span>including the<span style="letter-spacing:-0.1pt;"> </span>possible<span style="letter-spacing:-0.3pt;"> </span>loss of<span style="letter-spacing:0.05pt;"> </span>export<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>import<span style="letter-spacing:-0.25pt;"> </span>privi<span style="letter-spacing:-0.15pt;">l</span>eges&#59;<span style="letter-spacing:-0.45pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.05pt;">m</span>posed<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>responsible<span style="letter-spacing:-0.4pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>managers&#59;<span style="letter-spacing:-0.3pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">e</span>x<span style="letter-spacing:0.05pt;">tre</span><span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he incarceration<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>responsible<span style="letter-spacing:-0.4pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidat<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>export<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>import<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>cr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>ys<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the introduction,<span style="letter-spacing:-0.4pt;"> </span>provision,<span style="letter-spacing:-0.4pt;"> </span>or sale<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>international<span style="letter-spacing:-0.4pt;"> </span>markets,<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>using<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>or,<span style="letter-spacing:0.05pt;"> </span>in some<span style="letter-spacing:-0.25pt;"> </span>cases,<span style="letter-spacing:-0.15pt;"> </span>preve<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>export<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>import<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>governments<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>persons altogether.<span style="letter-spacing:-0.4pt;"> </span>Any<span style="letter-spacing:-0.05pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>export,<span style="letter-spacing:-0.3pt;"> </span>provide,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>sell<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.15pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>solutions<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, financial condition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are subject</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and for</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ign</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">anti-corruption</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">anti-money</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aundering </span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">aws with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">sp</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">erations</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">non-compl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">such laws</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">can subj</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">riminal</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">/</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">civil</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">liabi</span><span style="letter-spacing:0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FCPA,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U<span style="letter-spacing:0.1pt;">.</span>S.<span style="letter-spacing:-0.05pt;"> </span>domestic<span style="letter-spacing:-0.35pt;"> </span>bribery<span style="letter-spacing:-0.2pt;"> </span>sta<span style="letter-spacing:0.05pt;">t</span>ute<span style="letter-spacing:-0.2pt;"> </span>contained<span style="letter-spacing:-0.35pt;"> </span>in 18&#160;U.S.C.&#160;&#167;201,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:0.05pt;">&#160;</span>T<span style="letter-spacing:-0.05pt;">r</span>avel<span style="letter-spacing:-0.2pt;"> </span>Act,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>USA<span style="letter-spacing:0.05pt;">&#160;</span>PATRIOT<span style="letter-spacing:-0.05pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>possibly other<span style="letter-spacing:-0.2pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>nation<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>anti-bribery<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>anti-money<span style="letter-spacing:-0.35pt;"> </span>laund<span style="letter-spacing:-0.05pt;">e</span>ring<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>in which<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:0.1pt;">c</span>tivities.<span style="letter-spacing:-0.35pt;"> </span>Anti-corruption<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>interpreted broadly<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prohibit<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>e<span style="letter-spacing:0.05pt;">m</span>ployees,<span style="letter-spacing:-0.35pt;"> </span>agents,<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">e</span>di<span style="letter-spacing:-0.05pt;">a</span>ries,<span style="letter-spacing:-0.5pt;"> </span>jo<span style="letter-spacing:-0.05pt;">i</span>nt<span style="letter-spacing:-0.1pt;"> </span>ventu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.2pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>collaborato<span style="letter-spacing:0.05pt;">r</span>s<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>authorizing, promising,<span style="letter-spacing:-0.35pt;"> </span>offering<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>providing,<span style="letter-spacing:-0.4pt;"> </span>directly<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>indirectly,<span style="letter-spacing:-0.35pt;"> </span>improper<span style="letter-spacing:-0.3pt;"> </span>payments<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>benefits<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>recipients<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:-0.3pt;"> </span>sector.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>use CROs abroad<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ials.<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>engage<span style="letter-spacing:-0.3pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>intermediaries<span style="letter-spacing:-0.45pt;"> </span>to sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>solu<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span>abroad<span style="letter-spacing:-0.3pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>enter<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>commercialization<span style="letter-spacing:-0.65pt;"> </span>phase<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>nec<span style="letter-spacing:0.05pt;">e</span>ssary<span style="letter-spacing:-0.2pt;"> </span>permits,<span style="letter-spacing:-0.35pt;"> </span>licenses,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approvals.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>third-party intermediaries<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>direct<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">i</span>rect<span style="letter-spacing:-0.3pt;"> </span>interactions<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>fficials<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state-owned<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>ffi<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>ted<span style="letter-spacing:-0.3pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>n be<span style="letter-spacing:-0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>ld<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.2pt;"> </span>for the<span style="letter-spacing:-0.1pt;"> </span>corrupt<span style="letter-spacing:-0.25pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>i<span style="letter-spacing:-0.05pt;">l</span>leg<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ivi<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>intermediarie<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.4pt;"> </span>representatives,<span style="letter-spacing:-0.6pt;"> </span>contractors,<span style="letter-spacing:-0.4pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>and agents,<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>explicitly<span style="letter-spacing:-0.3pt;"> </span>authori<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>actual<span style="letter-spacing:-0.15pt;"> </span>knowledge<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> have </span>adopted<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>anti-corruption<span style="letter-spacing:-0.5pt;"> </span>policy<span style="letter-spacing:-0.2pt;">, which </span>mandates<span style="letter-spacing:-0.35pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FCPA<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>anti<span style="letter-spacing:-0.05pt;">-</span>corruption<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>throughout<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>world.<span style="letter-spacing:-0.05pt;"> </span>However,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>no assurance<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-par<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.05pt;">e</span>di<span style="letter-spacing:-0.05pt;">a</span>ries<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> t</span>his<span style="letter-spacing:-0.05pt;"> </span>po<span style="letter-spacing:-0.1pt;">l</span>icy<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>anti-corruption<span style="letter-spacing:-0.5pt;"> </span>laws.<span style="letter-spacing:0.05pt;"> </span>Non-compl<span style="letter-spacing:-0.05pt;">i</span>ance<span style="letter-spacing:-0.6pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> a</span>nti-corruption<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>anti-money<span style="letter-spacing:-0.35pt;"> </span>laundering<span style="letter-spacing:-0.4pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>us to<span style="letter-spacing:-0.1pt;"> </span>whistleblower<span style="letter-spacing:-0.45pt;"> </span>compl<span style="letter-spacing:0.1pt;">a</span>ints,<span style="letter-spacing:-0.35pt;"> </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>sanctions,<span style="letter-spacing:-0.4pt;"> </span>settlements,<span style="letter-spacing:-0.45pt;"> </span>prosecution,<span style="letter-spacing:-0.4pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>investigations,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>en<span style="letter-spacing:-0.05pt;">f</span>orcement<span style="letter-spacing:-0.4pt;"> </span>actions.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>launched,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>governm<span style="letter-spacing:0.05pt;">e</span>ntal<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>sanctions<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>imposed,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>prevail<span style="letter-spacing:-0.2pt;"> </span>in any p<span style="letter-spacing:0.05pt;">o</span>ssible<span style="letter-spacing:-0.15pt;"> </span>civil<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>criminal<span style="letter-spacing:-0.35pt;"> </span>liti<span style="letter-spacing:0.1pt;">g</span>ation,<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>mat<span style="letter-spacing:0.05pt;">e</span>rially<span style="letter-spacing:-0.3pt;"> </span>harmed.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>res<span style="letter-spacing:0.05pt;">p</span>onding<span style="letter-spacing:-0.2pt;"> </span>to any ac<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>lik<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>sign<span style="letter-spacing:-0.05pt;">i</span>ficant<span style="letter-spacing:-0.35pt;"> </span>diversion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>manag<span style="letter-spacing:-0.1pt;">e</span>me<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>&#8217;s<span style="letter-spacing:-0.4pt;"> </span>attention<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>resources<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>defense<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and other<span style="letter-spacing:-0.25pt;"> </span>professional<span style="letter-spacing:-0.4pt;"> </span>fees.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>certa<span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>cases,<span style="letter-spacing:-0.2pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">u</span>tho<span style="letter-spacing:0.05pt;">r</span>ities<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to appoint<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>inde<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ndent<span style="letter-spacing:-0.4pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>monitor,<span style="letter-spacing:-0.2pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in added<span style="letter-spacing:-0.25pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>administrative<span style="letter-spacing:-0.5pt;"> </span>burdens.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span>iron<span style="letter-spacing:-0.05pt;">m</span>ental,<span style="letter-spacing:-0.4pt;"> </span>he<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>th,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>g<span style="letter-spacing:0.05pt;">u</span>lations,<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:0.05pt;">c</span>luding<span style="letter-spacing:-0.15pt;"> </span>reg<span style="letter-spacing:0.05pt;">u</span>lations<span style="letter-spacing:-0.25pt;"> </span>go<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:0.05pt;">r</span>ning<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>han<span style="letter-spacing:0.05pt;">d</span>ling,<span style="letter-spacing:-0.1pt;"> </span>storage<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>disposal of<span style="letter-spacing:0.05pt;"> </span>hazardous<span style="letter-spacing:-0.05pt;"> </span>materials,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>fines<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>na<span style="letter-spacing:-0.05pt;">l</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inc<span style="letter-spacing:-0.1pt;">u</span>r<span style="letter-spacing:-0.15pt;"> </span>co<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span>s that<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>harm our busi<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subje<span style="letter-spacing:-0.1pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>to numerous<span style="letter-spacing:-0.3pt;"> </span>environmental,<span style="letter-spacing:-0.65pt;"> </span>health<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>safety<span style="letter-spacing:-0.15pt;"> </span>laws and<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>those<span style="letter-spacing:-0.05pt;"> </span>governing<span style="letter-spacing:-0.3pt;"> </span>laboratory<span style="letter-spacing:-0.3pt;"> </span>pro<span style="letter-spacing:-0.05pt;">c</span>edures<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the handling,<span style="letter-spacing:-0.4pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>storage,<span style="letter-spacing:-0.25pt;"> </span>treatme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>disposal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.3pt;"> </span>mat<span style="letter-spacing:-0.1pt;">e</span>rials<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>wastes.<span style="letter-spacing:0.05pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>involve<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.3pt;"> </span>mat<span style="letter-spacing:-0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls,<span style="letter-spacing:-0.3pt;"> </span>inc<span style="letter-spacing:-0.05pt;">l</span>uding chemicals,<span style="letter-spacing:-0.4pt;"> </span>biol<span style="letter-spacing:0.05pt;">o</span>gical<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>terials<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>infectious<span style="letter-spacing:-0.3pt;"> </span>agents.<span style="letter-spacing:-0.2pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oduce<span style="letter-spacing:-0.15pt;"> </span>hazardous<span style="letter-spacing:-0.4pt;"> </span>waste<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oducts.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>generally<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.1pt;">c</span>ontract<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third parties<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>disposal<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">i</span>als<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>w<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;">t</span>es.<span style="letter-spacing:-0.05pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.1pt;">e</span>li<span style="letter-spacing:-0.05pt;">m</span>in<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risk of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.4pt;"> </span>or in<span style="letter-spacing:-0.05pt;">j</span>ury<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:-0.1pt;">r</span>om<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>rials.<span style="letter-spacing:-0.3pt;"> </span>In the event<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>contami<span style="letter-spacing:0.05pt;">n</span>ation<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>injury<span style="letter-spacing:-0.15pt;"> </span>resulting<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us of<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.3pt;"> </span>materials,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>liable<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>resulting<span style="letter-spacing:-0.3pt;"> </span>damages,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>any liability<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>exceed<span style="letter-spacing:-0.25pt;"> </span>our resources.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>incur<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.1pt;">i</span>gnifi<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">a</span>nt<span style="letter-spacing:-0.4pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>asso<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">a</span>ted<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>vil<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">r</span>iminal<span style="letter-spacing:-0.3pt;"> </span>fines<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>penalt<span style="letter-spacing:-0.05pt;">ie</span>s<span style="letter-spacing:-0.3pt;"> </span>for fai<span style="letter-spacing:-0.05pt;">l</span>ure<span style="letter-spacing:-0.25pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>omply<span style="letter-spacing:-0.2pt;"> </span>with such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>maintain<span style="letter-spacing:-0.3pt;"> </span>wo<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">k</span>ers&#8217;<span style="letter-spacing:0.05pt;"> </span>compensat<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.35pt;"> </span>insu<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>nce<span style="letter-spacing:-0.1pt;"> </span>to cover<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>expenses,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>incur<span style="letter-spacing:-0.25pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>to injuries<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>resulting from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.3pt;"> </span>materia<span style="letter-spacing:-0.05pt;">l</span>s,<span style="letter-spacing:-0.25pt;"> </span>this<span style="letter-spacing:-0.1pt;"> </span>insurance<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>provide<span style="letter-spacing:-0.35pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>liabilities.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.25pt;"> </span>maintain<span style="letter-spacing:-0.25pt;"> </span>insurance<span style="letter-spacing:-0.3pt;"> </span>for environmental<span style="letter-spacing:-0.5pt;"> </span>liability<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>toxic<span style="letter-spacing:-0.2pt;"> </span>tort<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>ass<span style="letter-spacing:-0.1pt;">e</span>rted<span style="letter-spacing:-0.15pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>storage<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>disposal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>bio<span style="letter-spacing:-0.05pt;">l</span>ogical<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.4pt;"> </span>ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>incur<span style="letter-spacing:-0.3pt;"> </span>subst<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>osts in<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>wi<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> </span>cur<span style="letter-spacing:-0.05pt;">r</span>ent<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>environmental,<span style="letter-spacing:-0.5pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>al<span style="letter-spacing:-0.05pt;">t</span>h,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>fety<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ws <span style="letter-spacing:-0.05pt;">a</span>nd regulations.<span style="letter-spacing:-0.4pt;"> </span>These current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regu<span style="letter-spacing:0.05pt;">l</span>ations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>impair<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>research,<span style="letter-spacing:-0.35pt;"> </span>development,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>production<span style="letter-spacing:-0.4pt;"> </span>efforts.<span style="letter-spacing:-0.3pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd regulations<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>substanti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>penalties<span style="letter-spacing:-0.3pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>sancti<span style="letter-spacing:0.05pt;">o</span>ns.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">thir</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">-</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:0.05pt;">a</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:0.2pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manufacturers that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">engage</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">hazardous</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">biological</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">materials</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">manner</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">causes</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">injury</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">violates a</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">plicable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">law,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">liable</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">for damages.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>involve<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>rolled<span style="letter-spacing:-0.3pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span>otentially<span style="letter-spacing:-0.25pt;"> </span>hazardous<span style="letter-spacing:-0.4pt;"> </span>substan<span style="letter-spacing:0.05pt;">c</span>es,<span style="letter-spacing:-0.3pt;"> </span>incl<span style="letter-spacing:0.05pt;">u</span>ding<span style="letter-spacing:-0.3pt;"> </span>chemical<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>biological<span style="letter-spacing:-0.35pt;"> </span>mate<span style="letter-spacing:-0.05pt;">r</span>ials,<span style="letter-spacing:-0.3pt;"> </span>by us<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>manufacturers<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.15pt;"> </span>manufact<span style="letter-spacing:-0.05pt;">u</span>rers<span style="letter-spacing:-0.45pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>eng<span style="letter-spacing:0.05pt;">a</span>ge<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span>ubje<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>to federal,<span style="letter-spacing:-0.2pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>local<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.1pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>gov<span style="letter-spacing:-0.1pt;">e</span>rning<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>manufacture,<span style="letter-spacing:-0.45pt;"> </span>stora<span style="letter-spacing:-0.05pt;">g</span>e,<span style="letter-spacing:-0.35pt;"> </span>handling<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>disposal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>haza<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">d</span>ous materials.<span style="letter-spacing:-0.35pt;"> </span>Although<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>pro<span style="letter-spacing:0.05pt;">c</span>edures<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>using,<span style="letter-spacing:-0.25pt;"> </span>storing<span style="letter-spacing:-0.2pt;"> </span>and disposing<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>materials<span style="letter-spacing:-0.3pt;"> </span>comply<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>legally<span style="letter-spacing:-0.2pt;"> </span>pre<span style="letter-spacing:0.1pt;">s</span>cribed<span style="letter-spacing:-0.25pt;"> </span>standards,<span style="letter-spacing:-0.3pt;"> </span>we cannot<span style="letter-spacing:-0.2pt;"> </span>completely<span style="letter-spacing:-0.35pt;"> </span>elimi<span style="letter-spacing:-0.1pt;">n</span>ate<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>contamination<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>jury<span style="letter-spacing:-0.25pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>medic<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.3pt;"> </span>materia<span style="letter-spacing:-0.05pt;">l</span>s.<span style="letter-spacing:-0.3pt;"> </span>As a result<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>contamination<span style="letter-spacing:-0.5pt;"> </span>or injury,<span style="letter-spacing:-0.25pt;"> </span>we m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>ur<span style="letter-spacing:-0.05pt;"> l</span>iab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>or loc<span style="letter-spacing:-0.05pt;">a</span>l,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ity,<span style="letter-spacing:-0.15pt;"> </span>st<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">e</span>der<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>author<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> c</span>urta<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>use of th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>ls<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rru<span style="letter-spacing:-0.2pt;">p</span>t<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>the event<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>accident,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>held<span style="letter-spacing:-0.2pt;"> </span>l<span style="letter-spacing:0.15pt;">i</span>able<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>damages<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>penalized<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>fines,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>iab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>exceed<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>resources.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>any ins<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>nce<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>liabilities<span style="letter-spacing:-0.3pt;"> </span>arising<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>om<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>hazardous<span style="letter-spacing:-0.4pt;"> </span>mate<span style="letter-spacing:-0.05pt;">r</span>ials.<span style="letter-spacing:-0.25pt;"> </span>Compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>environme<span style="letter-spacing:0.05pt;">n</span>tal<span style="letter-spacing:-0.5pt;"> </span>laws<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>is e<span style="letter-spacing:0.05pt;">x</span>pensive,<span style="letter-spacing:-0.35pt;"> </span>and current<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>environmental<span style="letter-spacing:-0.45pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>research,<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>production<span style="letter-spacing:-0.35pt;"> </span>efforts,<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>harm<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>prospects, financial<span style="letter-spacing:-0.25pt;"> </span>condition<span style="letter-spacing:-0.3pt;"> </span>or results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in<span style="letter-spacing:-0.1pt;"> </span>funding for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA, the<span style="letter-spacing:-0.05pt;"> </span>SEC and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>agen<span style="letter-spacing:0.05pt;">c</span>i<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>d hind<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>eir<span style="letter-spacing:-0.15pt;"> </span>abili<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>to hire<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>retain<span style="letter-spacing:-0.25pt;"> </span>key<span style="letter-spacing:-0.1pt;"> </span>leader<span style="letter-spacing:0.05pt;">s</span>hip<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other personnel,<span style="letter-spacing:0.05pt;"> </span>preve<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>services<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.05pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>developed<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commerc<span style="letter-spacing:-0.05pt;">i</span>alized<span style="letter-spacing:-0.6pt;"> </span>in a t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.2pt;"> </span>manner<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>otherwise<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">p</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ose<span style="letter-spacing:-0.05pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span>from performing<span style="letter-spacing:-0.35pt;"> </span>normal<span style="letter-spacing:-0.2pt;"> </span>functions<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>operation<span style="letter-spacing:-0.4pt;"> </span>of our b<span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">y</span>,<span style="letter-spacing:-0.05pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">u</span>ld<span style="letter-spacing:-0.1pt;"> </span>negatively<span style="letter-spacing:-0.35pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r busines<span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>to review<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approve<span style="letter-spacing:-0.35pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>affected<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a v<span style="letter-spacing:-0.05pt;">a</span>riety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>cluding<span style="letter-spacing:-0.35pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>budget<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>funding<span style="letter-spacing:-0.3pt;"> </span>levels, ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>hire<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>retain<span style="letter-spacing:-0.2pt;"> </span>key<span style="letter-spacing:-0.05pt;"> </span>personnel<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>accept<span style="letter-spacing:-0.2pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>u<span style="letter-spacing:-0.05pt;">s</span>er fees<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>statutory,<span style="letter-spacing:-0.3pt;"> </span>regulato<span style="letter-spacing:-0.1pt;">r</span>y,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>policy<span style="letter-spacing:-0.15pt;"> </span>changes. Average<span style="letter-spacing:-0.3pt;"> </span>rev<span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>m<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>the agency<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>fluctuated<span style="letter-spacing:-0.3pt;"> </span>in recent<span style="letter-spacing:-0.15pt;"> </span>years<span style="letter-spacing:-0.15pt;"> </span>as a<span style="letter-spacing:-0.05pt;"> </span>result.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>funding<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA,<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>Securities<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>E<span style="letter-spacing:0.05pt;">x</span>change<span style="letter-spacing:-0.3pt;"> </span>Co<span style="letter-spacing:-0.05pt;">m</span>mission,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>SEC, and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ich<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>rely<span style="letter-spacing:-0.2pt;"> </span>is <span style="letter-spacing:-0.05pt;">i</span>nherently<span style="letter-spacing:-0.35pt;"> </span>fluid<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>unpredictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Disruptions<span style="letter-spacing:-0.35pt;"> </span>at the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>genc<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> </span>slow the<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>drugs<span style="letter-spacing:-0.05pt;"> </span>to be<span style="letter-spacing:-0.1pt;"> </span>reviewed<span style="letter-spacing:-0.3pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>nec<span style="letter-spacing:-0.1pt;">e</span>ssary<span style="letter-spacing:-0.2pt;"> </span>government agencies,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:-0.05pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>last<span style="letter-spacing:-0.1pt;"> </span>several<span style="letter-spacing:-0.25pt;"> </span>years,<span style="letter-spacing:-0.15pt;"> </span>incl<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.1pt;">d</span>ing<span style="letter-spacing:-0.25pt;"> </span>beginning<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>December&#160;22,&#160;2018,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>U.S. g<span style="letter-spacing:0.05pt;">o</span>vernment<span style="letter-spacing:-0.3pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>shut<span style="letter-spacing:-0.2pt;"> </span>d<span style="letter-spacing:0.05pt;">o</span>wn<span style="letter-spacing:-0.05pt;"> </span>several<span style="letter-spacing:-0.2pt;"> </span>times<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>agencies,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>SEC,<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>had<span style="letter-spacing:-0.1pt;"> </span>to furlough<span style="letter-spacing:-0.35pt;"> </span>crit<span style="letter-spacing:-0.1pt;">i</span>c<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>F<span style="letter-spacing:0.05pt;">D</span>A, SEC<span style="letter-spacing:-0.15pt;"> </span>and other<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>employ<span style="letter-spacing:0.05pt;">e</span>es<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>stop<span style="letter-spacing:-0.1pt;"> </span>critical<span style="letter-spacing:-0.2pt;"> </span>activities.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>respo<span style="letter-spacing:0.05pt;">n</span>se<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19<span style="letter-spacing:-0.05pt;"> </span>pand<span style="letter-spacing:-0.05pt;">e</span>mic,<span style="letter-spacing:-0.4pt;"> in 2020, </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> had</span><span style="letter-spacing:-0.3pt;"> </span>announced<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>will contin<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:-0.3pt;"> </span>to p<span style="letter-spacing:0.05pt;">o</span>stpone<span style="letter-spacing:-0.2pt;"> </span>domestic<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:-0.1pt;">o</span>reign<span style="letter-spacing:-0.25pt;"> </span>routine<span style="letter-spacing:-0.2pt;"> </span>surveillance<span style="letter-spacing:-0.45pt;"> </span>inspections<span style="letter-spacing:-0.45pt;"> </span>due<span style="letter-spacing:-0.1pt;"> </span>to COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19.<span style="letter-spacing:0.05pt;"> According to FDA&#8217;s 2021 guidance on manufacturing, supply chain, and drug and biological product inspections during COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="letter-spacing:0.05pt;">19 public health emergency, FDA indicated that it intends to continue using other tools and approaches where possible for pre-approval inspections, and that it will continue to conduct &#8220;mission-critical&#8221; inspections on a case-by-case basis, or, where possible to do so safely, resume prioritized domestic inspections, such as pre-approval and surveillance inspections. </span>If a prolonged<span style="letter-spacing:-0.4pt;"> </span>government<span style="letter-spacing:-0.35pt;"> </span>shutdown occurs, or if the government experiences a protracted backlog of inspections and regulatory review,<span style="letter-spacing:-0.2pt;"> </span>it could<span style="letter-spacing:-0.15pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>abi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>me<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>view<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">c</span>ess our<span style="letter-spacing:-0.05pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>submissions, which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adverse effect<span style="letter-spacing:-0.15pt;"> </span>on our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:-0.05pt;"> </span>F<span style="letter-spacing:-0.1pt;">u</span>rther,<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>shutdo<span style="letter-spacing:-0.1pt;">w</span>ns<span style="letter-spacing:0.05pt;">, delays, or prioritization policies </span>could<span style="letter-spacing:-0.15pt;"> </span>potentially<span style="letter-spacing:-0.35pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our ability<span style="letter-spacing:-0.2pt;"> </span>to access<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>markets<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>necessary<span style="letter-spacing:0.05pt;"> </span>capital<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to properly<span style="letter-spacing:-0.35pt;"> </span>ca<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">i</span>talize<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>cont<span style="letter-spacing:-0.05pt;">i</span>nue<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>f<span style="letter-spacing:-0.05pt;">e</span>deral<span style="letter-spacing:-0.25pt;"> </span>and s<span style="letter-spacing:-0.1pt;">t</span>ate<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>and promotional<span style="letter-spacing:-0.45pt;"> </span>laws,<span style="letter-spacing:-0.2pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:0.05pt;"> </span>and ab<span style="letter-spacing:-0.05pt;">u</span>se<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>privacy<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>security<span style="letter-spacing:-0.25pt;"> </span>laws, we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>face<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>penalties<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.1pt;">u</span>r busines<span style="letter-spacing:0.05pt;">s</span>, fi<span style="letter-spacing:0.05pt;">n</span>an<span style="letter-spacing:0.05pt;">c</span>ial<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">c</span>onditio<span style="letter-spacing:0.05pt;">n</span>,<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sults of operations,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.1pt;"> </span>affe<span style="letter-spacing:0.05pt;">c</span>ted.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>company,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">j</span>ect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>sta<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.2pt;"> </span>Anti<span style="letter-spacing:-0.05pt;">-</span>Kickback<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.1pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tut<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>AKS, <span style="letter-spacing:-0.05pt;">t</span>he FCA, the civil monetary pen<span style="letter-spacing:-0.05pt;">a</span>lt<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.2pt;"> </span>st<span style="letter-spacing:-0.05pt;">a</span>tut<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Medicaid<span style="letter-spacing:-0.3pt;"> </span>Drug Rebate<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>atute<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>requirements,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.2pt;"> </span>Physician<span style="letter-spacing:-0.4pt;"> </span>Payment Sunshine<span style="letter-spacing:-0.3pt;"> </span>Act,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Veter<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.25pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>1992,<span style="letter-spacing:-0.05pt;"> </span>HIP<span style="letter-spacing:0.05pt;">A</span>A<span style="letter-spacing:-0.05pt;">&#160;</span>(as<span style="letter-spacing:0.05pt;"> </span>amended<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">b</span>y<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Inf<span style="letter-spacing:0.05pt;">o</span>rmation<span style="letter-spacing:-0.3pt;"> </span>Technology<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Economics<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>C<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.3pt;"> </span>He<span style="letter-spacing:-0.05pt;">a</span>lth Act),<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>FCPA, the<span style="letter-spacing:-0.1pt;"> </span>Patient<span style="letter-spacing:-0.2pt;"> </span>Pro<span style="letter-spacing:0.1pt;">t</span>ection<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Affordable<span style="letter-spacing:-0.45pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>Act<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;">&#160;</span>2010<span style="letter-spacing:-0.05pt;">&#160;</span>(as<span style="letter-spacing:-0.05pt;"> </span>amended<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Health<span style="letter-spacing:-0.3pt;"> </span>Care<span style="letter-spacing:-0.1pt;"> </span>and Education<span style="letter-spacing:-0.35pt;"> </span>Reconcilia<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.45pt;"> </span>Act),<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the ACA,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>laws. Even<span style="letter-spacing:-0.25pt;"> </span>though<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>make<span style="letter-spacing:-0.15pt;"> </span>referrals<span style="letter-spacing:-0.3pt;"> </span>of healthcare<span style="letter-spacing:-0.35pt;"> </span>services<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>bill<span style="letter-spacing:-0.1pt;"> </span>directly<span style="letter-spacing:-0.3pt;"> </span>to M<span style="letter-spacing:0.05pt;">e</span>dicare,<span style="letter-spacing:-0.2pt;"> </span>Medicaid,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third-party payors,<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>fe<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sta<span style="letter-spacing:0.05pt;">t</span>e<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>pertaining<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patients&#8217;<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:-0.15pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our b<span style="letter-spacing:0.05pt;">u</span>siness.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>icable<span style="letter-spacing:-0.35pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abuse<span style="letter-spacing:-0.15pt;"> </span>enforc<span style="letter-spacing:0.05pt;">e</span>ment<span style="letter-spacing:-0.5pt;"> </span>by both<span style="letter-spacing:-0.15pt;"> </span>the federal<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>states<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laws</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">g</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ulations</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">q</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uire</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.15pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lculation</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compl</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">x</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pricing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">information</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">presc</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iption</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drugs,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliance</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to invest</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in sig</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ificant</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resources</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.3pt;">to</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a price</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infrastructure,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depend</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compute</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">report</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug </span><span style="letter-spacing:-0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ricing.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pricing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reported</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Centers</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Med</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">caid</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Services,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CMS, must</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certified.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non</span><span style="letter-spacing:-0.1pt;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliant</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activiti</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expose</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FCA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if t</span><span style="letter-spacing:-0.05pt;">he</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">re</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in o</span><span style="letter-spacing:0.05pt;">v</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ercharging agencies,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">underpaying</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rebates</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to age</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cies,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">causing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agencies</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overpay</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>violation<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>fed<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.4pt;"> </span>law,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">n</span>mental<span style="letter-spacing:-0.45pt;"> </span>regulations<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>apply<span style="letter-spacing:-0.25pt;"> </span>to us,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>penalties,<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.4pt;"> </span>civ<span style="letter-spacing:-0.05pt;">i</span>l,<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">r</span>im<span style="letter-spacing:-0.05pt;">i</span>nal,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">a</span>dministrative<span style="letter-spacing:-0.45pt;"> </span>pen<span style="letter-spacing:0.05pt;">a</span>lties,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">a</span>mag<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>fin<span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.15pt;"> </span>d<span style="letter-spacing:0.05pt;">i</span>sgorgement,<span style="letter-spacing:-0.55pt;"> </span>debarment<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>contracts, refusal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>orders<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>existing<span style="letter-spacing:-0.3pt;"> </span>contracts,<span style="letter-spacing:-0.4pt;"> </span>exclusion<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.15pt;"> </span>hea<span style="letter-spacing:0.05pt;">l</span>th<span style="letter-spacing:-0.15pt;"> </span>care<span style="letter-spacing:-0.2pt;"> </span>programs,<span style="letter-spacing:-0.3pt;"> </span>corpor<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ntegr<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>agre<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd the<span style="letter-spacing:-0.05pt;"> </span>curtailment<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>restructuring<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>op<span style="letter-spacing:0.05pt;">e</span>rations,<span style="letter-spacing:-0.45pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>materially<span style="letter-spacing:-0.35pt;"> </span>adv<span style="letter-spacing:-0.05pt;">e</span>rsely<span style="letter-spacing:-0.4pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to operate<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>financial results.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>physicians<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">v</span>iders<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>entities<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>whom<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>to do<span style="letter-spacing:-0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>is found<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>to be<span style="letter-spacing:0.65pt;"> </span>in<span style="letter-spacing:0.55pt;"> </span>compliance<span style="letter-spacing:1.65pt;"> </span>with<span style="letter-spacing:1.2pt;"> </span>applicable<span style="letter-spacing:2pt;"> </span>laws,<span style="letter-spacing:0.65pt;"> </span>they<span style="letter-spacing:1.15pt;"> </span>may<span style="letter-spacing:0.85pt;"> </span>be<span style="letter-spacing:0.55pt;"> </span>subject<span style="letter-spacing:1.4pt;"> </span>to<span style="letter-spacing:0.4pt;"> </span>criminal,<span style="letter-spacing:1.75pt;"> </span>civil,<span style="letter-spacing:0.95pt;"> </span>or<span style="letter-spacing:0.5pt;"> </span>administrative<span style="letter-spacing:0.4pt;"> </span>sanctions,<span style="letter-spacing:2pt;"> </span>including<span style="letter-spacing:1.55pt;"> </span>but<span style="letter-spacing:1pt;"> </span>not<span style="letter-spacing:0.8pt;"> </span>limited<span style="letter-spacing:1.2pt;"> </span>to,<span style="letter-spacing:0.6pt;"> </span>exclusions<span style="letter-spacing:1.9pt;"> </span>from participation in<span style="letter-spacing:0.6pt;"> </span>government<span style="letter-spacing:2.05pt;"> </span>healt<span style="letter-spacing:0.35pt;">h</span>care<span style="letter-spacing:1.8pt;"> </span>programs,<span style="letter-spacing:1.55pt;"> </span>which<span style="letter-spacing:1.25pt;"> </span>could<span style="letter-spacing:1.1pt;"> </span>also<span style="letter-spacing:0.5pt;"> </span>materially<span style="letter-spacing:0.05pt;"> </span>affect<span style="letter-spacing:1.05pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.7pt;"> </span>particular,<span style="letter-spacing:1.7pt;"> </span>if<span style="letter-spacing:0.45pt;"> </span>we<span style="letter-spacing:0.65pt;"> </span>are<span style="letter-spacing:0.7pt;"> </span>found<span style="letter-spacing:0.6pt;"> </span>to<span style="letter-spacing:0.3pt;"> </span>have<span style="letter-spacing:1.25pt;"> </span>impermissibly<span style="letter-spacing:0.2pt;"> </span>promoted<span style="letter-spacing:1.75pt;"> </span>any<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.45pt;"> </span>our<span style="letter-spacing:0.95pt;"> </span>product<span style="letter-spacing:1.65pt;"> </span>candidates,<span style="letter-spacing:1.7pt;"> </span>we<span style="letter-spacing:0.5pt;"> </span>may<span style="letter-spacing:0.9pt;"> </span>become<span style="letter-spacing:1.4pt;"> </span>subject<span style="letter-spacing:1.8pt;"> </span>to<span style="letter-spacing:0.25pt;"> </span>significant<span style="letter-spacing:0.2pt;"> </span>liability<span style="letter-spacing:1.5pt;"> </span>and government fines.<span style="letter-spacing:1.25pt;"> </span>We,<span style="letter-spacing:0.85pt;"> </span>and<span style="letter-spacing:0.65pt;"> </span>any<span style="letter-spacing:0.7pt;"> </span>of<span style="letter-spacing:0.8pt;"> </span>our<span style="letter-spacing:0.6pt;"> </span>collaborators,<span style="letter-spacing:2.1pt;"> </span>must<span style="letter-spacing:1.1pt;"> </span>comply<span style="letter-spacing:1.2pt;"> </span>with<span style="letter-spacing:1.05pt;"> </span>requirements<span style="letter-spacing:0.25pt;"> </span>concerning<span style="letter-spacing:1.85pt;"> </span>advertising<span style="letter-spacing:1.9pt;"> </span>and promotion<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval.<span style="letter-spacing:-0.35pt;"> </span>Pro<span style="letter-spacing:0.05pt;">m</span>otional<span style="letter-spacing:-0.45pt;"> </span>communications<span style="letter-spacing:-0.6pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.05pt;">a</span>peut<span style="letter-spacing:-0.05pt;">i</span>cs are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to a variety<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>restrictions<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>continuing<span style="letter-spacing:-0.4pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA,<span style="letter-spacing:-0.05pt;"> </span>Department<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Justice,<span style="letter-spacing:-0.2pt;"> </span>Department<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Health<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Human Services&#8217;<span style="letter-spacing:-0.4pt;"> </span>Office<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Inspector<span style="letter-spacing:-0.3pt;"> </span>General,<span style="letter-spacing:-0.25pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>attorneys<span style="letter-spacing:-0.4pt;"> </span>general,<span style="letter-spacing:-0.3pt;"> </span>members<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Congress,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>public.<span style="letter-spacing:-0.25pt;"> </span>When<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>comparable<span style="letter-spacing:-0.45pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory authorities<span style="letter-spacing:-0.4pt;"> </span>issue<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regulato<span style="letter-spacing:0.05pt;">r</span>y<span style="letter-spacing:-0.25pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">t</span>hose<span style="letter-spacing:-0.05pt;"> </span>specific<span style="letter-spacing:-0.3pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>dications<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>product is approved.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>desired<span style="letter-spacing:-0.2pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>indications<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> m</span>arket<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>promote<span style="letter-spacing:-0.25pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>indic<span style="letter-spacing:0.05pt;">a</span>tions<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>uses,<span style="letter-spacing:-0.05pt;"> </span>refe<span style="letter-spacing:-0.05pt;">r</span>red<span style="letter-spacing:-0.2pt;"> </span>to as off-label<span style="letter-spacing:-0.3pt;"> </span>uses,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busin<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affected.<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>e<span style="letter-spacing:-0.1pt;"> </span>further<span style="letter-spacing:-0.25pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to sufficiently<span style="letter-spacing:-0.4pt;"> </span>substantiate<span style="letter-spacing:-0.4pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>aims<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>make<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.1pt;">r</span>oduct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>comparing<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>companies&#8217; prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>must<span style="letter-spacing:-0.15pt;"> </span>abide<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;">&#8217;</span>s<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.2pt;">t</span>rict<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.55pt;"> </span>regarding<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>content<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>omotion<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>advertising.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While<span style="letter-spacing:-0.25pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>oose<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>prescribe<span style="letter-spacing:-0.4pt;"> </span>produ<span style="letter-spacing:0.1pt;">c</span>ts<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>described<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>product&#8217;s<span style="letter-spacing:-0.35pt;"> </span>labeling<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">d</span>iffer<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>tested<span style="letter-spacing:-0.15pt;"> </span>in clinical trials<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>authorities,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>prohibited<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rketing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>promoting<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>indications<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>are n<span style="letter-spacing:0.05pt;">o</span>t specifically<span style="letter-spacing:-0.4pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>FDA.<span style="letter-spacing:-0.05pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>off-label<span style="letter-spacing:-0.3pt;"> </span>uses<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>across<span style="letter-spacing:-0.05pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>specialties<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>onstitute<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>appropriate<span style="letter-spacing:-0.4pt;"> </span>tr<span style="letter-spacing:0.05pt;">ea</span><span style="letter-spacing:-0.05pt;">t</span>m<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">o</span>me pat<span style="letter-spacing:-0.05pt;">i</span>ents<span style="letter-spacing:-0.35pt;"> </span>in v<span style="letter-spacing:-0.05pt;">a</span>ri<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcu<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.05pt;">t</span>anc<span style="letter-spacing:-0.1pt;">e</span>s.<span style="letter-spacing:-0.4pt;"> </span>Regulatory<span style="letter-spacing:-0.35pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>generally<span style="letter-spacing:-0.45pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>regulate<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>behavi<span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>physicians<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>their choice<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>treatment<span style="letter-spacing:-0.3pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>practice<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>medicine.<span style="letter-spacing:-0.3pt;"> </span>Regulatory<span style="letter-spacing:-0.35pt;"> </span>au<span style="letter-spacing:-0.05pt;">t</span>horities<span style="letter-spacing:-0.45pt;"> </span>do,<span style="letter-spacing:-0.05pt;"> </span>however,<span style="letter-spacing:-0.3pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>communications<span style="letter-spacing:-0.6pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>biopharmace<span style="letter-spacing:-0.05pt;">u</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.05pt;">co</span>mp<span style="letter-spacing:0.05pt;">a</span>n<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s concerning<span style="letter-spacing:-0.4pt;"> </span>off-label<span style="letter-spacing:-0.3pt;"> </span>use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>FDA and<span style="letter-spacing:-0.1pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>agencies<span style="letter-spacing:-0.35pt;"> </span>actively<span style="letter-spacing:-0.25pt;"> </span>enforce<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>garding<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>rticularly<span style="letter-spacing:-0.4pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>prohibiting<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>of off-label<span style="letter-spacing:-0.35pt;"> </span>uses,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>a company<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>found<span style="letter-spacing:0.05pt;"> </span>to ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>imprope<span style="letter-spacing:-0.05pt;">r</span>ly<span style="letter-spacing:-0.3pt;"> </span>promoted<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>produ<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>gnificant<span style="letter-spacing:-0.4pt;"> </span>sanctions.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>fe<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>has lev<span style="letter-spacing:-0.05pt;">i</span>ed<span style="letter-spacing:-0.2pt;"> </span>large<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ivil<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd cr<span style="letter-spacing:-0.05pt;">i</span>min<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>fines<span style="letter-spacing:-0.2pt;"> </span>aga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompan<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>for a<span style="letter-spacing:-0.05pt;">l</span>leged<span style="letter-spacing:-0.2pt;"> </span>improper<span style="letter-spacing:-0.35pt;"> </span>promotion<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.1pt;"> </span>en<span style="letter-spacing:-0.05pt;">j</span>oined<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>ver<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>comp<span style="letter-spacing:-0.05pt;">a</span>nies<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>engaging<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>off-label promotio<span style="letter-spacing:0.05pt;">n</span>.<span style="letter-spacing:-0.4pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:0.05pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>requested<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>enter<span style="letter-spacing:-0.25pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>consent<span style="letter-spacing:-0.2pt;"> </span>decrees<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>permanent<span style="letter-spacing:-0.35pt;"> </span>injunctions<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>specified<span style="letter-spacing:-0.3pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span>conduct is changed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>curtailed.<span style="letter-spacing:-0.35pt;"> </span>Thus,<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>promote<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>indicat<span style="letter-spacing:0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>uses<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>they<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>approved.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">States,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">engaging</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imp</span><span style="letter-spacing:0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rmissible</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promotion</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">follow</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">off-label</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uses</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subje</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">false</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ai</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deral</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutes,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inc</span><span style="letter-spacing:0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uding</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fraud</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">abuse</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consumer</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">laws,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lead to civil and criminal penalties </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fines,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governmental</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">authori</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restrict</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manner</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whi</span><span style="letter-spacing:0.1pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promote</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">distr</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bute</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">therapeutic</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">example,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">corporate</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">integrity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sus</span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ension</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusion</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rom participation</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fede</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ate</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thc</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">debarment</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gove</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.1pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntracts</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refusal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">orders</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">under</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">existing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contracts.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">false</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st</span><span style="letter-spacing:0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tut</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lude</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">F</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CA,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">allows</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to bring</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a l</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wsuit</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biopharmaceut</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cal</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">behalf</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fe</span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ral</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alleging</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">submission</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">false</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or fraudulent claims</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">causing</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to pre</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">false</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fraudulent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yment</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a federal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">program</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medic</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicaid.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vernment</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decides</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to intervene</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd pr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">va</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ls</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wsu</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individual</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceeds</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fines</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">settl</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">me</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">funds. If the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vernment</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">declines</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inte</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">v</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ene,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">individ</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">al</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pursue</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">case</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alone.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.15pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FCA lawsuits</span><span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ga</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nst</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nufacture</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drugs</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd biologics</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">volume</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breadt</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ading</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ver</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substan</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ivil</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd criminal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">settlements,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">up</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to $3.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">billi</span><span style="letter-spacing:-0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pertaining</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rta</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practices</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promoting</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">off</span><span style="letter-spacing:-0.05pt;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">label</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ses.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FCA</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lawsuits</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:0.05pt;">x</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pose</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">manufacturers</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fol</span><span style="letter-spacing:0.1pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ow-on</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payo</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fraudulent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">practices.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This growth in litigation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increased</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a biopharmaceutical</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">company</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lse</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claim</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">action,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pay</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tt</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">em</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fines</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">itu</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rim</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nal</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vil</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pen</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lt</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">omply</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">burdensome</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reporting</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">compliance</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligations,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exc</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uded</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">M</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">M</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ca</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ot</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hea</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thcare</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our future</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">oll</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bora</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law</span><span style="letter-spacing:-0.05pt;">f</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ully</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">promote</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our approved</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if any,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">become</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ubject</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adve</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bu</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iness,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resul</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perations</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>program<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>mitigate<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>investigation<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>pro<span style="letter-spacing:0.05pt;">s</span>ecution<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>violations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> t</span>he<span style="letter-spacing:-0.15pt;"> </span>risks cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>entirely eliminated.<span style="letter-spacing:-0.35pt;"> </span>Moreo<span style="letter-spacing:0.05pt;">v</span>er,<span style="letter-spacing:-0.15pt;"> </span>achieving<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>sustaining<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.05pt;">i</span>an<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>feder<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>fraud<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>prove<span style="letter-spacing:-0.25pt;"> </span>costly. Any action<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.05pt;"> </span>for violation<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>succ<span style="letter-spacing:-0.1pt;">e</span>ssfully<span style="letter-spacing:-0.5pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>it,<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to incur<span style="letter-spacing:-0.15pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>expenses<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>div<span style="letter-spacing:0.05pt;">e</span>rt<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>gement&#8217;s<span style="letter-spacing:-0.55pt;"> </span>attention<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>oper<span style="letter-spacing:0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>reimbursement may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unavai<span style="letter-spacing:-0.1pt;">l</span>able<span style="letter-spacing:-0.5pt;"> </span>in certain<span style="letter-spacing:-0.2pt;"> </span>market<span style="letter-spacing:-0.3pt;"> </span>segments<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>ma<span style="letter-spacing:0.05pt;">k</span>e<span style="letter-spacing:-0.15pt;"> </span>it difficult<span style="letter-spacing:-0.25pt;"> </span>for us to sell<span style="letter-spacing:-0.1pt;"> </span>our product<span style="letter-spacing:-0.4pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>pro<span style="letter-spacing:-0.05pt;">f</span>itably.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>both<span style="letter-spacing:-0.2pt;"> </span>domestic<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>forei<span style="letter-spacing:0.05pt;">g</span>n<span style="letter-spacing:-0.25pt;"> </span>markets,<span style="letter-spacing:-0.25pt;"> </span>sales<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>tes,<span style="letter-spacing:-0.35pt;"> </span>if approved,<span style="letter-spacing:-0.3pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>availability<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>reimbursement from<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>payors.<span style="letter-spacing:0.05pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>include<span style="letter-spacing:-0.2pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>programs<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>Medicare<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>M<span style="letter-spacing:-0.05pt;">e</span>dicaid,<span style="letter-spacing:-0.2pt;"> </span>managed<span style="letter-spacing:-0.25pt;"> </span>care<span style="letter-spacing:-0.15pt;"> </span>providers,<span style="letter-spacing:-0.35pt;"> </span>private health<span style="letter-spacing:-0.2pt;"> </span>insu<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>rs and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>org<span style="letter-spacing:-0.05pt;">a</span>nizations.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>because<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>represent<span style="letter-spacing:-0.35pt;"> </span>n<span style="letter-spacing:-0.05pt;">e</span>w<span style="letter-spacing:-0.1pt;"> </span>approaches<span style="letter-spacing:-0.35pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>treatment<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>cancer,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot accurately<span style="letter-spacing:-0.35pt;"> </span>estimate<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>venues<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients<span style="letter-spacing:-0.25pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>provided<span style="letter-spacing:-0.35pt;"> </span>medical<span style="letter-spacing:-0.35pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>conditions<span style="letter-spacing:-0.35pt;"> </span>g<span style="letter-spacing:-0.1pt;">e</span>nerally<span style="letter-spacing:-0.35pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payo<span style="letter-spacing:-0.05pt;">r</span>s<span style="letter-spacing:-0.2pt;"> </span>to reimburse<span style="letter-spacing:-0.3pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>costs <span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>so<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th the<span style="letter-spacing:-0.05pt;">i</span>r<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ea<span style="letter-spacing:-0.05pt;">t</span>men<span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.35pt;"> </span>Ob<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">i</span>ning<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>overage<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adequate<span style="letter-spacing:-0.35pt;"> </span>rei<span style="letter-spacing:0.1pt;">m</span>bursement<span style="letter-spacing:-0.55pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>g<span style="letter-spacing:0.05pt;">o</span>vernmental<span style="letter-spacing:-0.4pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>programs,<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>Medicare<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>Med<span style="letter-spacing:-0.05pt;">i</span>caid,<span style="letter-spacing:-0.35pt;"> </span>and commercial<span style="letter-spacing:-0.4pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>critical<span style="letter-spacing:-0.2pt;"> </span>to new<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>acceptance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.05pt;">-</span>party<span style="letter-spacing:-0.35pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>decide<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>treatments<span style="letter-spacing:-0.45pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>cover<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reimbursemen<span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.5pt;"> </span>Coverage<span style="letter-spacing:-0.4pt;"> </span>decisions may<span style="letter-spacing:-0.2pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>economic<span style="letter-spacing:-0.35pt;"> </span>standards<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>disf<span style="letter-spacing:-0.05pt;">a</span>vor<span style="letter-spacing:-0.15pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>drug<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>est<span style="letter-spacing:-0.05pt;">a</span>blished<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>lower<span style="letter-spacing:-0.25pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>therapeutic<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>tern<span style="letter-spacing:-0.05pt;">a</span>tiv<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.4pt;"> </span>are alr<span style="letter-spacing:-0.05pt;">e</span>ady<span style="letter-spacing:-0.25pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">s</span>ubsequently<span style="letter-spacing:-0.5pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>available.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>rei<span style="letter-spacing:0.05pt;">m</span>bursement<span style="letter-spacing:-0.55pt;"> </span>is not<span style="letter-spacing:-0.15pt;"> </span>available,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> l</span>im<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>vels,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> candidates may be </span>competitively<span style="letter-spacing:-0.45pt;"> </span>disadvantaged,<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>we,<span style="letter-spacing:0.05pt;"> </span>or our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>llaborators,<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to s<span style="letter-spacing:-0.05pt;">u</span>ccessfully<span style="letter-spacing:-0.4pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.15pt;"> </span>if <span style="letter-spacing:-0.05pt;">c</span>over<span style="letter-spacing:-0.05pt;">a</span>ge<span style="letter-spacing:-0.3pt;"> </span>is provided,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>amount<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>high<span style="letter-spacing:-0.2pt;"> </span>enough<span style="letter-spacing:-0.3pt;"> </span>to allow<span style="letter-spacing:-0.25pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>to establish<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>maintain<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rket<span style="letter-spacing:-0.25pt;"> </span>share<span style="letter-spacing:-0.15pt;"> </span>sufficient<span style="letter-spacing:-0.05pt;"> </span>to realize<span style="letter-spacing:-0.2pt;"> </span>a sufficient<span style="letter-spacing:-0.3pt;"> </span>return<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>investments.<span style="letter-spacing:-0.4pt;"> </span>Alternatively,<span style="letter-spacing:-0.55pt;"> </span>securing<span style="letter-spacing:-0.25pt;"> </span>favorable<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>imbursement<span style="letter-spacing:-0.6pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>y<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>quire<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to compromise<span style="letter-spacing:-0.45pt;"> </span>pricing<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>realizing<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>margin<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>cost.<span style="letter-spacing:-0.2pt;"> </span>Reimbursement<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payor<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>depend<span style="letter-spacing:-0.2pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>num<span style="letter-spacing:-0.05pt;">b</span>er<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>factors,<span style="letter-spacing:-0.3pt;"> </span>including,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:0.05pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>to,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>yor&#8217;s<span style="letter-spacing:-0.05pt;"> </span>determination<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a product<span style="letter-spacing:-0.2pt;"> </span>is:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">benefit</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">its</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">health</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">plan&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">saf</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">,</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">eff</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">ive</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">med</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">lly</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">ne</span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">s</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ry&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">ppropriate</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">specific</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">patient&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">c</span><span style="color:#000000;">os</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">-eff</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">ct</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ve&#59;</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">neither</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">experimental</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">nor investigati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">nal.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining<span style="letter-spacing:-0.3pt;"> </span>co<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>rage<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of a product<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a government<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payor<span style="letter-spacing:-0.25pt;"> </span>is a time<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">c</span>onsuming<span style="letter-spacing:-0.65pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>costly<span style="letter-spacing:-0.25pt;"> </span>process that could<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to provide<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>payor<span style="letter-spacing:-0.25pt;"> </span>supporting<span style="letter-spacing:-0.35pt;"> </span>scientific,<span style="letter-spacing:-0.35pt;"> </span>clinical<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>cost-effectiveness<span style="letter-spacing:-0.65pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if we o<span style="letter-spacing:0.05pt;">b</span>tain<span style="letter-spacing:0.05pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>given<span style="letter-spacing:-0.2pt;"> </span>product,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>res<span style="letter-spacing:-0.05pt;">u</span>lting<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>imbursement<span style="letter-spacing:-0.45pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>yment<span style="letter-spacing:-0.25pt;"> </span>rates<span style="letter-spacing:-0.2pt;"> </span>might<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>achieve<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>sust<span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.05pt;"> </span>profit<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:0.05pt;"> </span>co-payments<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>patients<span style="letter-spacing:-0.25pt;"> </span>find<span style="letter-spacing:-0.2pt;"> </span>unacceptably<span style="letter-spacing:-0.45pt;"> </span>high.<span style="letter-spacing:-0.15pt;"> </span>Moreover,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>factors<span style="letter-spacing:-0.2pt;"> </span>noted<span style="letter-spacing:-0.25pt;"> </span>above<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>continued<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foc<span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.2pt;"> </span>of <span style="letter-spacing:0.1pt;">p</span>olicy<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulatory debate<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>has,<span style="letter-spacing:0.05pt;"> </span>thus<span style="letter-spacing:-0.2pt;"> </span>far, shown<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>movement<span style="letter-spacing:-0.4pt;"> </span>towards<span style="letter-spacing:0.05pt;"> </span>permanent<span style="letter-spacing:-0.4pt;"> </span>policy<span style="letter-spacing:-0.15pt;"> </span>chang<span style="letter-spacing:-0.05pt;">e</span>s&#59;<span style="letter-spacing:-0.3pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.1pt;"> </span>tr<span style="letter-spacing:-0.05pt;">e</span>nd<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>lik<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">c</span>ontinu<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>or less<span style="letter-spacing:0.05pt;"> </span>favorable<span style="letter-spacing:-0.3pt;"> </span>impacts<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>pricing.<span style="letter-spacing:-0.3pt;"> </span>Patients<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>unlikely<span style="letter-spacing:-0.35pt;"> </span>to use<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>uct<span style="letter-spacing:-0.15pt;"> </span>cand<span style="letter-spacing:0.05pt;">i</span>dates<span style="letter-spacing:-0.35pt;"> </span>unless<span style="letter-spacing:-0.05pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>provided,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reimbu<span style="letter-spacing:-0.05pt;">r</span>se<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.55pt;"> </span>is <span style="letter-spacing:-0.05pt;">a</span>dequ<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.25pt;"> </span>to cover<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>portion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States,<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>uniform<span style="letter-spacing:-0.35pt;"> </span>policy<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.6pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>exists<span style="letter-spacing:-0.15pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>thi<span style="letter-spacing:-0.1pt;">r</span>d-party<span style="letter-spacing:-0.35pt;"> </span>payors.<span style="letter-spacing:0.05pt;"> </span>Therefore,<span style="letter-spacing:-0.4pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>and reimbursement<span style="letter-spacing:-0.5pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>differ<span style="letter-spacing:-0.15pt;"> </span>significantly<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>payor<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>payor.<span style="letter-spacing:-0.2pt;"> </span>As<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>determination<span style="letter-spacing:-0.45pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>often<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>time-consuming<span style="letter-spacing:-0.55pt;"> </span>and costly<span style="letter-spacing:-0.25pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>provide<span style="letter-spacing:-0.2pt;"> </span>scientific<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>support<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>to each<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>yor<span style="letter-spacing:-0.15pt;"> </span>separately,<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>no assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>coverage<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ade<span style="letter-spacing:0.05pt;">q</span>uate<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prices<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>id<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a drug<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>pending<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>class<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>trade.<span style="letter-spacing:-0.15pt;"> </span>Prices<span style="letter-spacing:-0.15pt;"> </span>charged<span style="letter-spacing:-0.25pt;"> </span>to government<span style="letter-spacing:-0.4pt;"> </span>c<span style="letter-spacing:-0.1pt;">u</span>stomers<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to price<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>on<span style="letter-spacing:-0.05pt;">t</span>rols,<span style="letter-spacing:-0.15pt;"> </span>inc<span style="letter-spacing:-0.05pt;">l</span>uding<span style="letter-spacing:-0.35pt;"> </span>ceilings, and<span style="letter-spacing:-0.1pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>institutions<span style="letter-spacing:-0.35pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>discounts<span style="letter-spacing:-0.4pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>rough group<span style="letter-spacing:-0.05pt;"> </span>purchasing<span style="letter-spacing:-0.35pt;"> </span>organizations.<span style="letter-spacing:-0.45pt;"> </span>Net<span style="letter-spacing:-0.1pt;"> </span>prices<span style="letter-spacing:-0.1pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>drugs<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>further<span style="letter-spacing:-0.3pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">b</span>y<span style="letter-spacing:-0.05pt;"> </span>man<span style="letter-spacing:0.05pt;">d</span>atory<span style="letter-spacing:-0.45pt;"> </span>discounts<span style="letter-spacing:-0.4pt;"> </span>or rebates<span style="letter-spacing:-0.2pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>government<span style="letter-spacing:-0.4pt;"> </span>hea<span style="letter-spacing:-0.1pt;">l</span>thcare<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>demanded<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>payors.<span style="letter-spacing:0.1pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is also<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>uncom<span style="letter-spacing:-0.05pt;">m</span>on<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>conditio<span style="letter-spacing:-0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>warrant multiple<span style="letter-spacing:-0.25pt;"> </span>disc<span style="letter-spacing:0.05pt;">o</span>unts<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>fferent<span style="letter-spacing:-0.35pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>unit,<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>purcha<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.3pt;"> </span>discounts<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>institution<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>care<span style="letter-spacing:-0.15pt;"> </span>providers<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>reb<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>he<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">l</span>th<span style="letter-spacing:-0.15pt;"> </span>pl<span style="letter-spacing:0.05pt;">a</span>ns<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:0.05pt;">a</span>t pay<span style="letter-spacing:-0.15pt;"> </span>them,<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>reduces<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>net<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">l</span>iz<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>origin<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>le.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>programs<span style="letter-spacing:-0.3pt;"> </span>impo<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.3pt;"> </span>penalties<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>manufacturers<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>drugs<span style="letter-spacing:-0.05pt;"> </span>marketed<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>NDA<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>BLA,<span style="letter-spacing:0.05pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>form<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>mandatory<span style="letter-spacing:-0.5pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>rebates and/or<span style="letter-spacing:-0.3pt;"> </span>discounts<span style="letter-spacing:-0.4pt;"> </span>if commercial<span style="letter-spacing:-0.4pt;"> </span>prices<span style="letter-spacing:-0.15pt;"> </span>increase<span style="letter-spacing:-0.25pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>rate<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Consumer<span style="letter-spacing:-0.4pt;"> </span>P<span style="letter-spacing:0.05pt;">r</span>ice<span style="letter-spacing:-0.05pt;"> </span>Index-U<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">a</span>n,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>rebates<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.2pt;"> </span>discou<span style="letter-spacing:0.05pt;">n</span>ts,<span style="letter-spacing:-0.35pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be substantial,<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o r<span style="letter-spacing:-0.05pt;">a</span>ise<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>om<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>es.<span style="letter-spacing:-0.15pt;"> </span>Regu<span style="letter-spacing:-0.05pt;">l</span>atory<span style="letter-spacing:-0.4pt;"> </span>au<span style="letter-spacing:-0.1pt;">t</span>horities<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>attempted<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>limiting coverage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>particular<span style="letter-spacing:-0.35pt;"> </span>medicat<span style="letter-spacing:-0.1pt;">i</span>ons,<span style="letter-spacing:-0.3pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>affect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>profitably.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>v<span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>y,<span style="letter-spacing:-0.1pt;"> </span>as cost-effecti<span style="letter-spacing:0.05pt;">v</span>e,<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>cover<span style="letter-spacing:0.05pt;">a</span>ge<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.1pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>our customers,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sufficient<span style="letter-spacing:-0.3pt;"> </span>to allow<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>products,<span style="letter-spacing:-0.25pt;"> </span>if any,<span style="letter-spacing:-0.1pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>marketed<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>competit<span style="letter-spacing:-0.1pt;">i</span>ve<span style="letter-spacing:-0.4pt;"> </span>basis.<span style="letter-spacing:0.05pt;"> </span>Cost<span style="letter-spacing:-0.2pt;"> </span>control initiatives<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our collaborators,<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>decrease,<span style="letter-spacing:-0.2pt;"> </span>discount,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>rebate<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>portion<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ice<span style="letter-spacing:-0.05pt;"> </span>we,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>they,<span style="letter-spacing:-0.25pt;"> </span>might<span style="letter-spacing:-0.2pt;"> </span>establish<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>which could result in lower than<span style="letter-spacing:-0.1pt;"> </span>anticipated<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oduct<span style="letter-spacing:-0.25pt;"> </span>revenues.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>realized<span style="letter-spacing:-0.3pt;"> </span>prices<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>any,<span style="letter-spacing:-0.1pt;"> </span>decrease<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other third-party<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>yors do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>provide<span style="letter-spacing:-0.3pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>coverage<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>reimbursement,<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>ospects<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>revenues<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd profitability<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>suffer.<span style="letter-spacing:0.05pt;"> </span>Moreover,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>recent<span style="letter-spacing:-0.25pt;"> </span>and o<span style="letter-spacing:0.05pt;">n</span>going<span style="letter-spacing:-0.15pt;"> </span>series<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>congressional<span style="letter-spacing:-0.55pt;"> </span>hearings<span style="letter-spacing:-0.35pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to drug<span style="letter-spacing:-0.05pt;"> </span>pricing<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>presented<span style="letter-spacing:-0.3pt;"> </span>heigh<span style="letter-spacing:-0.05pt;">t</span>ened<span style="letter-spacing:-0.45pt;"> </span>attention<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.6pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>nd<span style="letter-spacing:0.05pt;">u</span>st<span style="letter-spacing:-0.05pt;">r</span>y, creating<span style="letter-spacing:-0.3pt;"> </span>the po<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>ial<span style="letter-spacing:-0.3pt;"> </span>for poli<span style="letter-spacing:-0.05pt;">t</span>ic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sure,<span style="letter-spacing:-0.1pt;"> </span>whi<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>resulting<span style="letter-spacing:-0.3pt;"> </span>legisla<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>policy<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.15pt;"> </span>un<span style="letter-spacing:-0.05pt;">c</span>ert<span style="letter-spacing:-0.05pt;">a</span>inty.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming<span style="letter-spacing:-0.05pt;"> </span>cove<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span>ge<span style="letter-spacing:-0.35pt;"> </span>is approved,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>resulting<span style="letter-spacing:-0.25pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>rat<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>n<span style="letter-spacing:0.05pt;">o</span>t be<span style="letter-spacing:-0.1pt;"> </span>adequate.<span style="letter-spacing:-0.3pt;"> </span>If payors<span style="letter-spacing:0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>candidates to maximum payment<span style="letter-spacing:-0.3pt;"> </span>amounts<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impose<span style="letter-spacing:-0.35pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>difficult<span style="letter-spacing:-0.25pt;"> </span>to obtain<span style="letter-spacing:-0.3pt;"> </span>reimbursement,<span style="letter-spacing:-0.55pt;"> </span>providers<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>choose<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>therapies<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>less expensive<span style="letter-spacing:-0.3pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>compared<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>payors<span style="letter-spacing:-0.05pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>h<span style="letter-spacing:-0.15pt;">i</span>gh c<span style="letter-spacing:0.05pt;">o</span>payments,<span style="letter-spacing:-0.5pt;"> </span>benefic<span style="letter-spacing:-0.05pt;">i</span>aries<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>decline<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>rescriptions<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>seek alternative<span style="letter-spacing:-0.35pt;"> </span>therapies.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to conduct<span style="letter-spacing:-0.25pt;"> </span>post-marketing<span style="letter-spacing:-0.5pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>in order<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>de<span style="letter-spacing:-0.05pt;">m</span>onstrate<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost-effectiveness<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>fut<span style="letter-spacing:-0.05pt;">u</span>re<span style="letter-spacing:-0.15pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>to the satisfacti<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>hospitals<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>target<span style="letter-spacing:-0.2pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>third-party<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>yors.<span style="letter-spacing:-0.15pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>studies<span style="letter-spacing:-0.2pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to commit<span style="letter-spacing:-0.25pt;"> </span>a s<span style="letter-spacing:-0.1pt;">i</span>gnificant<span style="letter-spacing:-0.45pt;"> </span>amou<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.25pt;"> </span>of management<span style="letter-spacing:-0.45pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>res<span style="letter-spacing:0.05pt;">o</span>u<span style="letter-spacing:-0.05pt;">r</span>ces.<span style="letter-spacing:-0.15pt;"> </span>Our future<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>od<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>ultimately<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>consid<span style="letter-spacing:-0.05pt;">e</span>red<span style="letter-spacing:-0.2pt;"> </span>cost-<span style="letter-spacing:-0.05pt;">e</span>ffec<span style="letter-spacing:-0.05pt;">t</span>iv<span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.35pt;"> </span>Ad<span style="letter-spacing:-0.05pt;">e</span>quate<span style="letter-spacing:-0.05pt;"> </span>third-party coverage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>reimbursement<span style="letter-spacing:-0.5pt;"> </span>might<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.25pt;"> </span>us to<span style="letter-spacing:-0.05pt;"> </span>ma<span style="letter-spacing:-0.05pt;">i</span>nta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>pr<span style="letter-spacing:-0.05pt;">i</span>ce<span style="letter-spacing:-0.2pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>vels<span style="letter-spacing:-0.2pt;"> </span>suff<span style="letter-spacing:-0.05pt;">i</span>ci<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>to r<span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">l</span>ize<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>n <span style="letter-spacing:-0.05pt;">a</span>ppropria<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.4pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>tu<span style="letter-spacing:-0.05pt;">r</span>n<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>investment<span style="letter-spacing:-0.4pt;"> </span>in prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors,<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>domestic<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>eign,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>comme<span style="letter-spacing:-0.05pt;">r</span>cial,<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>developing<span style="letter-spacing:-0.35pt;"> </span>increasingly<span style="letter-spacing:-0.5pt;"> </span>sophisticated<span style="letter-spacing:-0.4pt;"> </span>meth<span style="letter-spacing:-0.05pt;">o</span>ds<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>controlling healthcare<span style="letter-spacing:-0.35pt;"> </span>costs.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>third-party<span style="letter-spacing:-0.45pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>requiring<span style="letter-spacing:-0.3pt;"> </span>higher<span style="letter-spacing:-0.3pt;"> </span>levels<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>evidence<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>benefits<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>clinical o<span style="letter-spacing:0.05pt;">u</span>tcomes<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>challenging<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>prices<span style="letter-spacing:-0.15pt;"> </span>charged.<span style="letter-spacing:-0.35pt;"> </span>We,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators,<span style="letter-spacing:-0.5pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>nnot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sure<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>they,<span style="letter-spacing:-0.15pt;"> </span>commercia<span style="letter-spacing:-0.05pt;">l</span>ize<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd,<span style="letter-spacing:-0.05pt;"> </span>if <span style="letter-spacing:-0.05pt;">a</span>va<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e,<span style="letter-spacing:-0.3pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>re<span style="letter-spacing:-0.05pt;">i</span>mburs<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.4pt;"> </span>rates<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>adequate.<span style="letter-spacing:-0.3pt;"> </span>Further,<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.15pt;"> </span>net<span style="letter-spacing:-0.05pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>for drug<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to additional<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ductions<span style="letter-spacing:-0.4pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.05pt;"> </span>presently<span style="letter-spacing:-0.4pt;"> </span>restrict<span style="letter-spacing:-0.25pt;"> </span>imports<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>drugs<span style="letter-spacing:-0.05pt;"> </span>fr<span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.1pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>where<span style="letter-spacing:-0.15pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>may be<span style="letter-spacing:-0.05pt;"> </span>sold<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>low<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>es<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>han<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Un<span style="letter-spacing:-0.05pt;">ite</span>d Sta<span style="letter-spacing:-0.05pt;">t</span>es.<span style="letter-spacing:-0.15pt;"> </span>An in<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.25pt;"> </span>to pro<span style="letter-spacing:-0.05pt;">m</span>ptly<span style="letter-spacing:-0.35pt;"> </span>obt<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>coverage<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>adequate<span style="letter-spacing:-0.3pt;"> </span>payment<span style="letter-spacing:-0.35pt;"> </span>rates<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>bo<span style="letter-spacing:0.05pt;">t</span>h<span style="letter-spacing:-0.15pt;"> </span>government-funded and<span style="letter-spacing:-0.1pt;"> </span>private<span style="letter-spacing:-0.2pt;"> </span>payors<span style="letter-spacing:0.05pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.3pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>effe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>operating results,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>raise<span style="letter-spacing:-0.15pt;"> </span>capit<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.3pt;"> </span>needed<span style="letter-spacing:-0.2pt;"> </span>to commercialize<span style="letter-spacing:-0.55pt;"> </span>products,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>overall<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">been,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">likely</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to be,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">legislative</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proposals</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ate</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">levels</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">directed</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">broadening</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">availability of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">containing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lowering</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">predict</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiatives</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopted</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continuing</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">government,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">insurance</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">companies,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">managed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">care</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">organizations</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yors</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rvices</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to contain</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.1pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduce</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of hea</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">thc</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re and</span><span style="letter-spacing:-0.05pt;">/</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.1pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pose</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">price</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">controls</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">demand</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates,</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">if we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">obtain</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">regulatory</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">set</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">price</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">b</span><span style="letter-spacing:0.1pt;color:#000000;">e</span><span style="color:#000000;">lieve</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">is </span><span style="letter-spacing:-0.05pt;color:#000000;">f</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">ir</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ability</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">generate</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">revenues</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">achieve</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">profitability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">level</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">taxes</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">required</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">to pay&#59;</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">ava</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">lab</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">li</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">of c</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">pit</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any<span style="letter-spacing:-0.05pt;"> </span>reduction<span style="letter-spacing:-0.35pt;"> </span>in <span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>imbursement<span style="letter-spacing:-0.45pt;"> </span>fr<span style="letter-spacing:-0.05pt;">o</span>m Medicare<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>gove<span style="letter-spacing:-0.05pt;">r</span>nment<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.1pt;"> </span>in a similar<span style="letter-spacing:-0.2pt;"> </span>reduct<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>in payments<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.1pt;">r</span>ivate<span style="letter-spacing:-0.15pt;"> </span>payors,<span style="letter-spacing:-0.05pt;"> </span>which may<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.35pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>pro<span style="letter-spacing:-0.05pt;">f</span>itabil<span style="letter-spacing:-0.05pt;">i</span>ty.<span style="letter-spacing:-0.35pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>particular<span style="letter-spacing:-0.35pt;"> </span>challenge<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>arises<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>fact<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>prima<span style="letter-spacing:-0.05pt;">r</span>ily<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an inpatient<span style="letter-spacing:-0.25pt;"> </span>setting.<span style="letter-spacing:-0.2pt;"> </span>Inpatient<span style="letter-spacing:-0.3pt;"> </span>rei<span style="letter-spacing:-0.05pt;">m</span>bursement<span style="letter-spacing:-0.5pt;"> </span>generally<span style="letter-spacing:-0.4pt;"> </span>relies<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>ringent<span style="letter-spacing:-0.3pt;"> </span>packaging<span style="letter-spacing:-0.35pt;"> </span>rules<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">e</span>an<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>no s<span style="letter-spacing:0.05pt;">e</span>par<span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.15pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates.<span style="letter-spacing:-0.35pt;"> </span>Additionally,<span style="letter-spacing:-0.45pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>ta<span style="letter-spacing:-0.15pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o set<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he p<span style="letter-spacing:-0.05pt;">a</span>ym<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>npat<span style="letter-spacing:-0.05pt;">i</span>ent<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;">d</span>missions<span style="letter-spacing:-0.45pt;"> </span>is usually<span style="letter-spacing:-0.3pt;"> </span>several<span style="letter-spacing:-0.2pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>old<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot take<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>account<span style="letter-spacing:-0.25pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>of the<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>therapy<span style="letter-spacing:-0.2pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>administration<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>special<span style="letter-spacing:-0.25pt;"> </span>rules<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>created<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>for imm<span style="letter-spacing:0.05pt;">u</span>notherapy<span style="letter-spacing:-0.5pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>eatments<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>hosp<span style="letter-spacing:-0.05pt;">i</span>tals<span style="letter-spacing:-0.3pt;"> </span>might<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>receive<span style="letter-spacing:-0.25pt;"> </span>enough<span style="letter-spacing:-0.25pt;"> </span>rei<span style="letter-spacing:-0.1pt;">m</span>bursement<span style="letter-spacing:-0.5pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>over<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>treatment,<span style="letter-spacing:-0.35pt;"> </span>which will<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>negative<span style="letter-spacing:-0.25pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:0.05pt;">i</span>r<span style="letter-spacing:-0.2pt;"> </span>adoption<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>legislati<span style="letter-spacing:-0.05pt;">o</span>n,<span style="letter-spacing:-0.4pt;"> </span>regulatory<span style="letter-spacing:-0.45pt;"> </span>propo<span style="letter-spacing:0.05pt;">s</span>als,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>payor initiatives<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>increase<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>compl<span style="letter-spacing:-0.15pt;">i</span>ance,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>adversely affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>our product<span style="letter-spacing:-0.35pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>obta<span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>a<span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:0.05pt;"> </span>raise<span style="letter-spacing:-0.05pt;"> </span>capital.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>j<span style="letter-spacing:0.05pt;">u</span>risdictions,<span style="letter-spacing:-0.4pt;"> </span>there<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>been<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of legislative<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regula<span style="letter-spacing:-0.05pt;">t</span>ory<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>propos<span style="letter-spacing:-0.05pt;">e</span>d c<span style="letter-spacing:0.05pt;">h</span>anges<span style="letter-spacing:-0.3pt;"> </span>regarding<span style="letter-spacing:-0.35pt;"> </span>the healthcare<span style="letter-spacing:-0.35pt;"> </span>system<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>event<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>delay<span style="letter-spacing:-0.15pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates,<span style="letter-spacing:-0.45pt;"> </span>restrict<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulate<span style="letter-spacing:-0.3pt;"> </span>post-approval<span style="letter-spacing:-0.45pt;"> </span>activities,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>our ability,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our c<span style="letter-spacing:0.1pt;">o</span>llaborators,<span style="letter-spacing:-0.45pt;"> </span>to profitably<span style="letter-spacing:-0.35pt;"> </span>sell<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>urrent<span style="letter-spacing:-0.2pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ws,<span style="letter-spacing:-0.05pt;"> </span>as w<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;"> </span>as other<span style="letter-spacing:-0.25pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>reform<span style="letter-spacing:-0.2pt;"> </span>measures<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>adopted<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:0.05pt;">u</span>ture,<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in more<span style="letter-spacing:-0.25pt;"> </span>rigorous<span style="letter-spacing:0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>rage<span style="letter-spacing:-0.25pt;"> </span>criteria<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>downward<span style="letter-spacing:-0.05pt;"> </span>press<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>price<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collabora<span style="letter-spacing:0.1pt;">t</span>ors,<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>receive<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>approved<span style="letter-spacing:-0.3pt;"> </span>products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since<span style="letter-spacing:-0.2pt;"> </span>enactment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ACA<span style="letter-spacing:-0.05pt;"> </span>in 2010,<span style="letter-spacing:0.05pt;"> </span>in both<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>ce<span style="letter-spacing:-0.05pt;">r</span>tain<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>jurisdictions,<span style="letter-spacing:-0.5pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>a number<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>gislative<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulatory changes<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>health<span style="letter-spacing:-0.2pt;"> </span>care<span style="letter-spacing:-0.15pt;"> </span>sys<span style="letter-spacing:0.1pt;">t</span>em<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to sell<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>profitably.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>August&#160;2011,<span style="letter-spacing:-0.05pt;"> </span>the Budget<span style="letter-spacing:-0.2pt;"> </span>Control<span style="letter-spacing:-0.2pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>of 2<span style="letter-spacing:0.05pt;">0</span>11,<span style="letter-spacing:0.05pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>created<span style="letter-spacing:-0.25pt;"> </span>measures<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>spending<span style="letter-spacing:-0.35pt;"> </span>reductions<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Congress.<span style="letter-spacing:0.05pt;"> </span>A<span style="letter-spacing:-0.05pt;"> </span>Joint<span style="letter-spacing:-0.15pt;"> </span>Select<span style="letter-spacing:-0.15pt;"> </span>Committee<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>Deficit<span style="letter-spacing:-0.2pt;"> </span>Reduction,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">sk</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">w</span><span style="letter-spacing:-0.05pt;">i</span>th recommending<span style="letter-spacing:-0.5pt;"> </span>a targeted<span style="letter-spacing:-0.35pt;"> </span>defi<span style="letter-spacing:0.05pt;">c</span>it<span style="letter-spacing:-0.3pt;"> </span>reducti<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>including<span style="letter-spacing:-0.3pt;"> implementation of </span>aggregate<span style="letter-spacing:-0.3pt;"> </span>reductions<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Medicare<span style="letter-spacing:-0.25pt;"> </span>payments<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>providers up<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>2%<span style="letter-spacing:0.05pt;"> </span>per<span style="letter-spacing:-0.05pt;"> </span>fiscal<span style="letter-spacing:-0.15pt;"> </span>year,<span style="letter-spacing:-0.25pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>went<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>April&#160;1,&#160;2013<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> will</span><span style="letter-spacing:-0.1pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>in effect<span style="letter-spacing:-0.25pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>2030, with the exception of a temporary suspension implemented under various COVID<span style="Background-color:#FFFFFF;">&#8209;</span>19 relief legislation from May 1, 2020 through the end of 2021,<span style="letter-spacing:0.05pt;"> </span>un<span style="letter-spacing:-0.05pt;">l</span>ess<span style="letter-spacing:-0.05pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>Congressional<span style="letter-spacing:-0.45pt;"> </span>action<span style="letter-spacing:-0.15pt;"> </span>is taken. In<span style="letter-spacing:0.05pt;"> </span>J<span style="letter-spacing:-0.05pt;">a</span>nuary&#160;2013,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>American<span style="letter-spacing:-0.3pt;"> </span>Taxpayer<span style="letter-spacing:-0.25pt;"> </span>Relief<span style="letter-spacing:-0.25pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>2012,<span style="letter-spacing:-0.05pt;"> </span>or ATRA,<span style="letter-spacing:0.05pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.4pt;"> </span>which,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>reduced<span style="letter-spacing:-0.35pt;"> </span>Medicare<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:0.1pt;">a</span>yments<span style="letter-spacing:-0.4pt;"> </span>to several<span style="letter-spacing:-0.2pt;"> </span>provi<span style="letter-spacing:0.05pt;">d</span><span style="letter-spacing:-0.05pt;">e</span>rs,<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>primary<span style="letter-spacing:-0.25pt;"> </span>foc<span style="letter-spacing:0.05pt;">u</span>s<span style="letter-spacing:-0.2pt;"> </span>on the<span style="letter-spacing:-0.1pt;"> </span>hospit<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span>outpatient<span style="letter-spacing:-0.35pt;"> </span>setting and<span style="letter-spacing:-0.1pt;"> </span>ancillary<span style="letter-spacing:-0.25pt;"> </span>services,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>hospitals,<span style="letter-spacing:-0.4pt;"> </span>imaging<span style="letter-spacing:-0.3pt;"> </span>centers<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>can<span style="letter-spacing:-0.05pt;">c</span>er<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>re<span style="letter-spacing:-0.05pt;">a</span>tm<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>cen<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rs,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>inc<span style="letter-spacing:-0.05pt;">r</span>eased<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>st<span style="letter-spacing:-0.05pt;">a</span>tute<span style="letter-spacing:-0.2pt;"> </span>of li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">at</span>ions<span style="letter-spacing:-0.45pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the government<span style="letter-spacing:0.05pt;"> </span>to recover<span style="letter-spacing:-0.2pt;"> </span>ove<span style="letter-spacing:-0.05pt;">r</span>payments<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>providers<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>three<span style="letter-spacing:-0.15pt;"> </span>to five&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, various portions of the ACA have been subject to judicial and constitutional challenges. In particular, on D<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">e</span>mber&#160;14,&#160;2018, the<span style="letter-spacing:-0.05pt;"> </span>U.S. District<span style="letter-spacing:-0.2pt;"> </span>Court<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>N<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>thern<span style="letter-spacing:-0.2pt;"> </span>District<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Texas<span style="letter-spacing:-0.15pt;"> </span>struck<span style="letter-spacing:-0.15pt;"> </span>down<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>ACA, deemi<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.2pt;"> </span>it unconstitutional<span style="letter-spacing:-0.55pt;"> </span>giv<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>Congress<span style="letter-spacing:0.05pt;"> </span>repealed<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>individual<span style="letter-spacing:-0.3pt;"> </span>mandate in 2017&#59;<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>July&#160;9,&#160;2019,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>Court<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Appeals<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Fifth<span style="letter-spacing:-0.2pt;"> </span>Circuit<span style="letter-spacing:-0.3pt;"> </span>heard<span style="letter-spacing:-0.15pt;"> </span>arguments<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>appeal<span style="letter-spacing:-0.2pt;"> </span>in this<span style="letter-spacing:-0.1pt;"> </span>matter.<span style="letter-spacing:-0.25pt;"> </span>On<span style="letter-spacing:0.05pt;"> </span>December&#160;18,&#160;2019,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Fifth Circuit<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">u</span>led<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>ACA&#8217;s<span style="letter-spacing:0.05pt;"> </span>individual<span style="letter-spacing:-0.3pt;"> </span>mand<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>is unconstitutional<span style="letter-spacing:-0.55pt;"> </span>gi<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">T</span><span style="letter-spacing:0.05pt;">a</span>x<span style="letter-spacing:-0.05pt;"> </span>A<span style="letter-spacing:-0.05pt;">c</span>t <span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">i</span>min<span style="letter-spacing:-0.05pt;">a</span>ted<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">a</span>x p<span style="letter-spacing:-0.05pt;">e</span>nal<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>soc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>individual mandate.<span style="letter-spacing:-0.3pt;"> </span>In concluding<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>individual<span style="letter-spacing:-0.3pt;"> </span>mand<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>is unconstitutional,<span style="letter-spacing:-0.6pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ques<span style="letter-spacing:0.1pt;">t</span>ion<span style="letter-spacing:-0.25pt;"> </span>remains<span style="letter-spacing:-0.3pt;"> </span>whether,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>how<span style="letter-spacing:0.05pt;"> </span>much<span style="letter-spacing:-0.2pt;"> </span>of,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>rest<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ACA<span style="letter-spacing:-0.05pt;"> i</span>s severable<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>that constitutional<span style="letter-spacing:-0.45pt;"> </span>defect.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>Fifth<span style="letter-spacing:-0.15pt;"> </span>C<span style="letter-spacing:-0.05pt;">i</span>rcuit<span style="letter-spacing:-0.2pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>manded<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>case<span style="letter-spacing:-0.1pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>Dis<span style="letter-spacing:-0.05pt;">t</span>rict<span style="letter-spacing:-0.3pt;"> </span>Court<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Northern<span style="letter-spacing:-0.25pt;"> </span>District<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Tex<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>further<span style="letter-spacing:-0.3pt;"> </span>analyze<span style="letter-spacing:-0.25pt;"> </span>whether the<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>provisions<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ACA<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>severable<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>currently<span style="letter-spacing:-0.4pt;"> </span>exist<span style="letter-spacing:-0.15pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>law.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">The Supreme Court of the United States held oral arguments on the Fifth Circuit Court case in November 2020 and is expected to issue a decision later in 2021. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, on January 28, 2021, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through May 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, among other directives. It is unclear how this Supreme Court decision, future litigation, and healthcare measures promulgated by the Biden administration will impact the ACA, our business, financial condition and results of operations. </span>We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontinue<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ev<span style="letter-spacing:-0.05pt;">a</span>lua<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>ACA<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>possible<span style="letter-spacing:-0.25pt;"> </span>repeal and<span style="letter-spacing:-0.1pt;"> </span>replacement<span style="letter-spacing:-0.4pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>Complying<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>legislat<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>reversing<span style="letter-spacing:-0.35pt;"> </span>changes<span style="letter-spacing:-0.3pt;"> </span>imp<span style="letter-spacing:-0.05pt;">l</span>emented<span style="letter-spacing:-0.4pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ACA could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>time-intensive<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>expensive,<span style="letter-spacing:-0.4pt;"> </span>resulting<span style="letter-spacing:-0.25pt;"> </span>in a<span style="letter-spacing:-0.1pt;"> </span>mater<span style="letter-spacing:-0.1pt;">i</span>al<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">federal</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">state</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthca</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reform</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measures</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adopted</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in more</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">igorous</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">crit</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ria,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d regulatory</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">burdens</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operating</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreased</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenues</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bioph</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rmaceutical</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreased</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eturns</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our development</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efforts,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">downward</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pressure</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pri</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we re</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ive</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for any</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pproved</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">drug.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduction</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in rei</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bursement</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from Medicare</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">governm</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">programs</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduction</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pay</span><span style="letter-spacing:0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">private</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payors.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">implem</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntation</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">st containment</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">measures</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">her</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">healthcare</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reforms</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">being</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gene</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">te</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rev</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nues,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tt</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prof</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bil</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ommercialize</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our prod</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ct</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>proposals<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>expand<span style="letter-spacing:-0.3pt;"> </span>post-approval<span style="letter-spacing:-0.55pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>restrict<span style="letter-spacing:-0.3pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span>les<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promotional<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ctivities<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>drugs.<span style="letter-spacing:0.05pt;"> </span>We cannot<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>sure<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>add<span style="letter-spacing:-0.05pt;">i</span>tional<span style="letter-spacing:-0.35pt;"> </span>legislati<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>enacted,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>regulations,<span style="letter-spacing:-0.35pt;"> </span>guid<span style="letter-spacing:0.05pt;">a</span>nce,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>interpretations<span style="letter-spacing:-0.55pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>changed,<span style="letter-spacing:-0.3pt;"> </span>or what<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">h</span>anges<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>rketing<span style="letter-spacing:-0.35pt;"> </span>approvals<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>any,<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>increased<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:0.05pt;">c</span>rutiny<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Congress<span style="letter-spacing:-0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>FDA&#8217;s<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>process<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>si<span style="letter-spacing:0.05pt;">g</span>nificantly<span style="letter-spacing:-0.4pt;"> </span>delay<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>prevent<span style="letter-spacing:-0.2pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval,<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>ll as<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>stringent<span style="letter-spacing:-0.25pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>labeling<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>post-marketing<span style="letter-spacing:-0.35pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>been<span style="letter-spacing:-0.2pt;"> increasing legislative efforts and enforcement interest in the United States with respect to drug pricing practices, including Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives, some of which resulted in lawsuits against the HHS challenging various aspects of the rules. In January 2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and agency heads to review new or pending rules of the prior administration. The impact of these lawsuits as well as legislative, executive, and administrative actions of the Biden administration on us and the pharmaceutical industry as a whole remains unclear. </span>At<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>sta<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.1pt;"> </span>level,<span style="letter-spacing:-0.25pt;"> </span>legislatures<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>increasingly<span style="letter-spacing:-0.4pt;"> </span>passed<span style="letter-spacing:-0.05pt;"> </span>legislation<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>implemented<span style="letter-spacing:-0.45pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>designed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>control p<span style="letter-spacing:0.05pt;">h</span>armaceutical<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>biological<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>pricing,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patient<span style="letter-spacing:-0.2pt;"> </span>reimbursem<span style="letter-spacing:0.1pt;">e</span>nt<span style="letter-spacing:-0.6pt;"> </span>constraints,<span style="letter-spacing:-0.35pt;"> </span>dis<span style="letter-spacing:0.05pt;">c</span>ounts,<span style="letter-spacing:-0.3pt;"> </span>restrictions<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>and marketing<span style="letter-spacing:-0.4pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>discl<span style="letter-spacing:0.05pt;">o</span>sure<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>transparency<span style="letter-spacing:-0.4pt;"> </span>measures,<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:0.05pt;">d</span>,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>cases,<span style="letter-spacing:-0.25pt;"> </span>designed<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>encou<span style="letter-spacing:0.05pt;">r</span>age<span style="letter-spacing:-0.3pt;"> </span>importation<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>bulk<span style="letter-spacing:-0.1pt;"> </span>purc<span style="letter-spacing:0.05pt;">h</span>asing<span style="font-weight:bold;font-style:italic;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>predict<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>course<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>federal<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>state<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span>g<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">l</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Uni<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>directed<span style="letter-spacing:-0.25pt;"> </span>at broaden<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>availability<span style="letter-spacing:-0.35pt;"> </span>of healthcare<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>containing<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>lowering<span style="letter-spacing:-0.35pt;"> </span>the cost of<span style="letter-spacing:0.05pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>a<span style="letter-spacing:-0.05pt;">l</span>thc<span style="letter-spacing:-0.05pt;">a</span>re.<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">T</span>he<span style="letter-spacing:-0.05pt;"> </span>ACA and<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>further<span style="letter-spacing:-0.2pt;"> </span>changes<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>law<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>framewo<span style="letter-spacing:-0.1pt;">r</span>k<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>reduce<span style="letter-spacing:-0.2pt;"> </span>our revenues<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">d</span>verse<span style="letter-spacing:-0.3pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>con<span style="letter-spacing:0.05pt;">d</span>ition<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>f<span style="letter-spacing:0.05pt;"> </span>operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Go<span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>tside<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">t</span>ates<span style="letter-spacing:-0.25pt;"> </span>tend<span style="letter-spacing:-0.05pt;"> t</span>o <span style="letter-spacing:-0.05pt;">i</span>mpose<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>r<span style="letter-spacing:-0.05pt;">i</span>ct<span style="letter-spacing:-0.2pt;"> </span>pri<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.1pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>trols,<span style="letter-spacing:-0.15pt;"> </span>whi<span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ad<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:0.05pt;">r</span>s<span style="letter-spacing:0.05pt;">e</span>ly<span style="letter-spacing:-0.2pt;"> </span>aff<span style="letter-spacing:0.05pt;">e</span>ct<span style="letter-spacing:-0.15pt;"> </span>our r<span style="letter-spacing:0.05pt;">e</span>v<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:0.05pt;">u</span>e<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:0.05pt;">y</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>international<span style="letter-spacing:-0.4pt;"> </span>markets,<span style="letter-spacing:-0.35pt;"> </span>reimbu<span style="letter-spacing:-0.05pt;">r</span>sement<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>health<span style="letter-spacing:-0.15pt;"> </span>care<span style="letter-spacing:-0.25pt;"> </span>pa<span style="letter-spacing:0.05pt;">y</span><span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.25pt;"> </span>systems<span style="letter-spacing:-0.35pt;"> </span>vary<span style="letter-spacing:-0.2pt;"> </span>significantly<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>country,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ns<span style="letter-spacing:-0.05pt;">t</span>itu<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>ceilings <span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;"> </span>specific<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>therapies.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>rticularly<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>EU,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>prescript<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.3pt;"> </span>pharmaceuticals<span style="letter-spacing:-0.6pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>contr<span style="letter-spacing:-0.05pt;">o</span>l.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>pricing<span style="letter-spacing:-0.25pt;"> </span>negotiations<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span>considerable<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>aft<span style="letter-spacing:-0.15pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">e</span>ipt<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>rk<span style="letter-spacing:-0.05pt;">e</span>ting approval<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>product.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>coverage<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reimbursement<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pricing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>in s<span style="letter-spacing:-0.05pt;">o</span>me<span style="letter-spacing:-0.05pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to conduct<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ini<span style="letter-spacing:-0.05pt;">c</span>al<span style="letter-spacing:-0.25pt;"> </span>tr<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t compares<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost-effectiveness<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidate<span style="letter-spacing:-0.35pt;"> </span>to other<span style="letter-spacing:-0.2pt;"> </span>avail<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>therapies.<span style="letter-spacing:-0.35pt;"> </span>There<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>prod<span style="letter-spacing:-0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be considered<span style="letter-spacing:-0.35pt;"> </span>cost-effective<span style="letter-spacing:-0.5pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>payors,<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.25pt;"> </span>level<span style="letter-spacing:-0.15pt;"> </span>of reimbursement<span style="letter-spacing:-0.5pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>lable,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>third-<span style="letter-spacing:-0.05pt;">p</span>arty<span style="letter-spacing:-0.35pt;"> </span>payors&#8217;<span style="letter-spacing:0.05pt;"> </span>reimbursement p<span style="letter-spacing:0.05pt;">o</span>licies<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to sell<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>pro<span style="letter-spacing:-0.05pt;">f</span>itably.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>imbu<span style="letter-spacing:0.05pt;">r</span>sement<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>cand<span style="letter-spacing:-0.1pt;">i</span>dates<span style="letter-spacing:-0.4pt;"> </span>is unavailable<span style="letter-spacing:-0.4pt;"> </span>or limited in scope or amount,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>pricing<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>set<span style="letter-spacing:-0.15pt;"> </span>at unsatis<span style="letter-spacing:-0.05pt;">f</span>actory<span style="letter-spacing:-0.45pt;"> </span>l<span style="letter-spacing:0.05pt;">e</span>vels,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business <span style="letter-spacing:0.05pt;">c</span>ould<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>harmed,<span style="letter-spacing:-0.25pt;"> </span>possibly<span style="letter-spacing:-0.25pt;"> </span>materially.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">employees,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">independent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">contractors,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">consultants,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">commercial</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">partners</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">vendors</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">engage</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">misconduct</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">improper</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ac</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">es, in</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">luding</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">non</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">omp</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ian</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">gu</span><span style="letter-spacing:-0.05pt;">la</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">tory</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">standards</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.1pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">requirements.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>exposed<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>employee<span style="letter-spacing:-0.35pt;"> </span>fraud<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>illegal<span style="letter-spacing:-0.15pt;"> </span>activity<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employee<span style="letter-spacing:0.1pt;">s</span>,<span style="letter-spacing:-0.35pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>contractors,<span style="letter-spacing:-0.25pt;"> </span>consultants,<span style="letter-spacing:-0.45pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>partners<span style="letter-spacing:-0.25pt;"> </span>and vendors.<span style="letter-spacing:-0.05pt;"> </span>Misconduct<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>inc<span style="letter-spacing:-0.05pt;">l</span>ude<span style="letter-spacing:-0.3pt;"> </span>intentional,<span style="letter-spacing:-0.4pt;"> </span>reckless<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>negli<span style="letter-spacing:0.1pt;">g</span>ent<span style="letter-spacing:-0.35pt;"> </span>conduct<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>fails<span style="letter-spacing:-0.2pt;"> </span>to:<span style="letter-spacing:-0.1pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>laws of the<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">F</span>DA and other similar<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span>bodies,<span style="letter-spacing:-0.2pt;"> </span>provide<span style="letter-spacing:-0.3pt;"> </span>true,<span style="letter-spacing:-0.1pt;"> </span>complete<span style="letter-spacing:-0.3pt;"> </span>and accurate<span style="letter-spacing:-0.25pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>egulatory<span style="letter-spacing:-0.3pt;"> </span>bodies,<span style="letter-spacing:-0.3pt;"> </span>comply with<span style="letter-spacing:-0.1pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>standards<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>established,<span style="letter-spacing:-0.4pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>h<span style="letter-spacing:-0.05pt;">e</span>alt<span style="letter-spacing:0.05pt;">h</span>care<span style="letter-spacing:-0.3pt;"> </span>fraud<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>abuse<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">e</span>d <span style="letter-spacing:-0.05pt;">S</span>ta<span style="letter-spacing:-0.05pt;">t</span>es<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd si<span style="letter-spacing:-0.05pt;">m</span>il<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span>audulent misconduct<span style="letter-spacing:-0.35pt;"> </span>laws,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>report<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.1pt;">i</span>nancial<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">f</span>ormation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.2pt;"> </span>accu<span style="letter-spacing:0.1pt;">r</span>ately<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to disclose<span style="letter-spacing:-0.3pt;"> </span>unauthorized<span style="letter-spacing:-0.55pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>f<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>begin<span style="letter-spacing:-0.15pt;"> </span>comm<span style="letter-spacing:-0.05pt;">e</span>rcializing<span style="letter-spacing:-0.6pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States, our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.35pt;"> </span>exposure<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>aws will<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>re<span style="letter-spacing:-0.05pt;">a</span>se sig<span style="letter-spacing:0.05pt;">n</span>ificantly,<span style="letter-spacing:-0.45pt;"> </span>and o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>likely<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>increase.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>impact,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>things,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.2pt;"> </span>activities<span style="letter-spacing:-0.3pt;"> </span>with principal<span style="letter-spacing:-0.3pt;"> </span>investigators<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>patients,<span style="letter-spacing:-0.25pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>proposed<span style="letter-spacing:0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>sales,<span style="letter-spacing:-0.25pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd education<span style="letter-spacing:-0.3pt;"> </span>programs.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>particular,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>sales and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>items<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>services,<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>rangements<span style="letter-spacing:-0.5pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>industry,<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">extensive laws designed to prevent </span>fraud,<span style="letter-spacing:-0.25pt;"> </span>kickb<span style="letter-spacing:0.05pt;">a</span>cks,<span style="letter-spacing:-0.3pt;"> </span>self-dealing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>abusive<span style="letter-spacing:-0.1pt;"> </span>pra<span style="letter-spacing:-0.05pt;">c</span>ti<span style="letter-spacing:-0.05pt;">c</span>es.<span style="letter-spacing:-0.25pt;"> </span>Th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>restrict<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prohibit<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>wide<span style="letter-spacing:-0.15pt;"> </span>range<span style="letter-spacing:-0.15pt;"> </span>of pricing, discounting,<span style="letter-spacing:-0.45pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>eting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>promotion,<span style="letter-spacing:-0.4pt;"> </span>structuring<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commission(s),<span style="letter-spacing:-0.5pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>customer<span style="letter-spacing:-0.25pt;"> </span>incentive<span style="letter-spacing:-0.35pt;"> </span>programs<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>bu<span style="letter-spacing:-0.1pt;">s</span>iness<span style="letter-spacing:0.05pt;"> </span>arrangements generally.<span style="letter-spacing:-0.3pt;"> </span>Activities<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to these<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>involve<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>improper<span style="letter-spacing:-0.35pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>obta<span style="letter-spacing:0.05pt;">i</span>ned<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>course<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patient<span style="letter-spacing:-0.25pt;"> </span>rec<span style="letter-spacing:0.05pt;">r</span>uit<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">i</span>nic<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>tri<span style="letter-spacing:-0.05pt;">a</span>ls.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>always<span style="letter-spacing:-0.3pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>to identify<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd deter<span style="letter-spacing:-0.2pt;"> </span>misconduct<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>imp<span style="letter-spacing:-0.05pt;">r</span>oper<span style="letter-spacing:-0.3pt;"> </span>activities<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>employ<span style="letter-spacing:-0.1pt;">e</span>es<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>engage<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business o<span style="letter-spacing:0.05pt;">p</span>erations,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>independent<span style="letter-spacing:-0.5pt;"> </span>contractors,<span style="letter-spacing:-0.4pt;"> </span>consultants,<span style="letter-spacing:-0.45pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>principal<span style="letter-spacing:-0.35pt;"> </span>investigators,<span style="letter-spacing:-0.55pt;"> </span>CROs,<span style="letter-spacing:0.05pt;"> </span>suppliers<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>vendors, and<span style="letter-spacing:-0.1pt;"> </span>the precautions<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>take<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>detect<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prevent<span style="letter-spacing:-0.3pt;"> </span>inappropriate<span style="letter-spacing:-0.45pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.1pt;">e</span>ffective<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cont<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>lli<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span>unknown<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>unmanaged<span style="letter-spacing:-0.4pt;"> </span>risks or<span style="letter-spacing:0.05pt;"> </span>losses<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in protecting<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>investigations<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>lawsuits<span style="letter-spacing:-0.35pt;"> </span>stemming<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>a failure<span style="letter-spacing:-0.25pt;"> </span>to comply<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>or regulations. Efforts<span style="letter-spacing:-0.25pt;"> </span>to ensure<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>arrangements<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>involve<span style="letter-spacing:-0.25pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>sts.<span style="letter-spacing:-0.15pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is possible<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>governmental<span style="letter-spacing:-0.45pt;"> </span>and enforcement<span style="letter-spacing:-0.4pt;"> </span>authorities<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>con<span style="letter-spacing:-0.1pt;">c</span>lude<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employee<span style="letter-spacing:-0.05pt;">s</span>&#8217;,<span style="letter-spacing:-0.35pt;"> </span>consultants&#8217;,<span style="letter-spacing:-0.4pt;"> </span>coll<span style="letter-spacing:-0.05pt;">a</span>borators&#8217;,<span style="letter-spacing:-0.45pt;"> </span>contractors&#8217;,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>vendors&#8217;<span style="letter-spacing:0.05pt;"> </span>bus<span style="letter-spacing:-0.05pt;">i</span>ness<span style="letter-spacing:-0.1pt;"> </span>practices<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not comply<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>statutes,<span style="letter-spacing:-0.35pt;"> </span>regulations<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>case<span style="letter-spacing:-0.2pt;"> </span>law<span style="letter-spacing:-0.1pt;"> </span>interpret<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>able<span style="letter-spacing:-0.35pt;"> </span>fr<span style="letter-spacing:-0.05pt;">a</span>ud<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abuse<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>healthcare<span style="letter-spacing:-0.3pt;"> </span>laws<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>regulations.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>any such<span style="letter-spacing:0.05pt;"> </span>actions<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>instituted<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> a</span>nd we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>successful<span style="letter-spacing:-0.3pt;"> </span>in defending<span style="letter-spacing:-0.4pt;"> </span>oursel<span style="letter-spacing:-0.15pt;">v</span>es<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>asserting<span style="letter-spacing:-0.35pt;"> </span>our rights,<span style="letter-spacing:-0.3pt;"> </span>those<span style="letter-spacing:-0.15pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a si<span style="letter-spacing:0.05pt;">g</span>nificant impact<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>imposit<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of civil,<span style="letter-spacing:-0.15pt;"> </span>criminal<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>administrative<span style="letter-spacing:-0.5pt;"> </span>penalties,<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.05pt;">a</span>mages,<span style="letter-spacing:-0.3pt;"> </span>disgorgement,<span style="letter-spacing:-0.3pt;"> </span>monetary<span style="letter-spacing:-0.3pt;"> </span>fines,<span style="letter-spacing:-0.15pt;"> </span>possible exclusion<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>participation<span style="letter-spacing:-0.4pt;"> </span>in Medicare,<span style="letter-spacing:-0.25pt;"> </span>Medicaid<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>fed<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>programs,<span style="letter-spacing:-0.3pt;"> </span>contr<span style="letter-spacing:0.05pt;">a</span>ctual<span style="letter-spacing:-0.35pt;"> </span>damages,<span style="letter-spacing:-0.35pt;"> </span>reputational<span style="letter-spacing:-0.45pt;"> </span>ha<span style="letter-spacing:-0.05pt;">r</span>m,<span style="letter-spacing:-0.15pt;"> </span>diminished<span style="letter-spacing:-0.35pt;"> </span>profits and<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>earnings,<span style="letter-spacing:-0.4pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>agreeme<span style="letter-spacing:0.05pt;">n</span>ts,<span style="letter-spacing:-0.5pt;"> </span>withdrawal<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>approvals,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.05pt;">u</span>rtailme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our oper<span style="letter-spacing:0.05pt;">a</span>tions,<span style="letter-spacing:-0.35pt;"> </span>among<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>ngs,<span style="letter-spacing:-0.1pt;"> </span>any of which could adversely affect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to oper<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations.<span style="letter-spacing:-0.2pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commer<span style="letter-spacing:0.05pt;">c</span>ialization<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>likely<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>equivalents<span style="letter-spacing:-0.4pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>healthcare<span style="letter-spacing:-0.35pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>mention<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.3pt;"> </span>above,<span style="letter-spacing:-0.2pt;"> </span>among<span style="letter-spacing:-0.2pt;"> </span>other foreign<span style="letter-spacing:-0.25pt;"> </span>laws.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">R<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;">k</span>s R<span style="letter-spacing:0.05pt;">e</span>lat<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>to I<span style="letter-spacing:-0.05pt;">n</span>te<span style="letter-spacing:-0.05pt;">l</span>le<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">P</span><span style="letter-spacing:0.05pt;">r</span>o<span style="letter-spacing:-0.05pt;">p</span>er<span style="letter-spacing:-0.05pt;">t</span>y</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to obtain,<span style="letter-spacing:-0.3pt;"> </span>mai<span style="letter-spacing:0.05pt;">n</span>tain,<span style="letter-spacing:-0.3pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>enfor<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>rights for<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.35pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ates<span style="letter-spacing:-0.35pt;"> </span>and technologies, we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffectively<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>oper<span style="letter-spacing:0.05pt;">a</span>te profitably.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>dependent<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:0.05pt;">a</span>rge<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>rt<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>obtaining,<span style="letter-spacing:-0.3pt;"> </span>maint<span style="letter-spacing:0.05pt;">a</span>ining,<span style="letter-spacing:-0.45pt;"> </span>protecting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>enforcing<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.05pt;">i</span>ghts<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Uni<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.2pt;"> </span>St<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>countries<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>avoid<span style="letter-spacing:-0.2pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>fringing<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>proprietary rights<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>rs.<span style="letter-spacing:-0.15pt;"> </span>Certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intel<span style="letter-spacing:0.05pt;">l</span>ectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>entities,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pr<span style="letter-spacing:-0.05pt;">e</span>paration<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>prosecution<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patents and<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applic<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.4pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>performed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>control.<span style="letter-spacing:-0.3pt;"> </span>Furthermore,<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>law<span style="letter-spacing:-0.2pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>sco<span style="letter-spacing:-0.05pt;">p</span>e<span style="letter-spacing:-0.05pt;"> o</span>f<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">a</span>i<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>field<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>oper<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.3pt;"> </span>is still<span style="letter-spacing:-0.15pt;"> </span>evolving<span style="letter-spacing:-0.25pt;"> </span>and,<span style="letter-spacing:-0.2pt;"> </span>consequently,<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>posi<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>industry<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>st<span style="letter-spacing:-0.05pt;">r</span>ong<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>well-established<span style="letter-spacing:-0.4pt;"> </span>fields.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>positions<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.45pt;"> </span>compani<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>highly<span style="letter-spacing:-0.25pt;"> </span>uncertain<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>involve<span style="letter-spacing:-0.2pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>fact<span style="letter-spacing:-0.05pt;">u</span>al<span style="letter-spacing:-0.3pt;"> </span>questions<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>important<span style="letter-spacing:-0.35pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>principles<span style="letter-spacing:0.05pt;"> </span>remain<span style="letter-spacing:-0.25pt;"> </span>unresolved.<span style="letter-spacing:-0.45pt;"> </span>No<span style="letter-spacing:-0.05pt;"> </span>consistent<span style="letter-spacing:-0.2pt;"> </span>policy<span style="letter-spacing:-0.2pt;"> </span>regarding<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>breadth<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>allowed<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span>ents<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>emerged<span style="letter-spacing:-0.25pt;"> </span>to date.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issuance</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conclusive</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to its</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validity</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or enfor</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bil</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ty</span><span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is unc</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rt</span><span style="letter-spacing:-0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">how</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">much</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an</span><span style="letter-spacing:0.1pt;">y</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our patents,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">including</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if they</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenged</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">court</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">proceedings,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re-examinations</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">positions,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brought</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United St</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ign</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">jurisdi</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tions</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ha</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nge</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validity</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a patent.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenge</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validity</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforceability</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tent</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fter</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.05pt;">issuance. It is possible </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompe</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">itor</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suc</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">essfu</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cha</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nge</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenge</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">li</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ir</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cov</span><span style="letter-spacing:-0.05pt;">er</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">age.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cost</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of litigation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to uphold</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">validity</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to prevent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringement</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subst</span><span style="letter-spacing:0.1pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntial.</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">outcome</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is a</span><span style="letter-spacing:0.1pt;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">verse</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to us, t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ird</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">use</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patented</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invention</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wi</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hout</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payment</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to us.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">possible</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competi</span><span style="letter-spacing:-0.15pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">infringe</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">avoid</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the patented</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">design</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">innovation.</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stop</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ese</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">need</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to file</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uit.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lawsuits</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exp</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nsive</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consume time</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resou</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ces,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">suc</span><span style="letter-spacing:-0.15pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">essful</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stopping</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">violation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">there</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sk that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">court</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decide that</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">valid</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stop</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inventions.</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.15pt;">l</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">so</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risk tha</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the validity</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upheld,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">urt</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">refuse</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stop</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">grounds</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activities</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.1pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vered</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not infringe,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>ties<span style="letter-spacing:-0.25pt;"> </span>file<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tents<span style="letter-spacing:-0.2pt;"> </span>claiming<span style="letter-spacing:-0.3pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>used<span style="letter-spacing:0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>claimed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensor(s)<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>patent application,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>requ<span style="letter-spacing:-0.05pt;">i</span>red<span style="letter-spacing:-0.3pt;"> </span>to p<span style="letter-spacing:-0.05pt;">a</span>rti<span style="letter-spacing:-0.05pt;">c</span>ip<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rference<span style="letter-spacing:-0.4pt;"> </span>proceedings<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>Patent<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd <span style="letter-spacing:-0.05pt;">T</span>rade<span style="letter-spacing:-0.05pt;">m</span>ark<span style="letter-spacing:-0.35pt;"> </span>Off<span style="letter-spacing:-0.05pt;">i</span>ce<span style="letter-spacing:-0.1pt;">&#160;</span>(<span style="letter-spacing:-0.05pt;">&#8220;</span>U<span style="letter-spacing:-0.05pt;">S</span>P<span style="letter-spacing:-0.05pt;">T</span>O&#8221;)<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o d<span style="letter-spacing:-0.05pt;">e</span>ter<span style="letter-spacing:-0.05pt;">m</span>ine<span style="letter-spacing:-0.4pt;"> </span>priority<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>invention<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>or patent<span style="letter-spacing:-0.15pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>at<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>sub<span style="letter-spacing:-0.05pt;">j</span>e<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">i</span>rs<span style="letter-spacing:-0.05pt;">t</span>-to-<span style="letter-spacing:-0.05pt;">i</span>nvent<span style="letter-spacing:-0.4pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>w<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>t<span style="letter-spacing:-0.05pt;">e</span>d <span style="letter-spacing:-0.05pt;">S</span>ta<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.1pt;">s</span>,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>participate<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>proceed<span style="letter-spacing:0.05pt;">i</span>ngs<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO <span style="letter-spacing:-0.05pt;">f</span>or<span style="letter-spacing:0.05pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>paten<span style="letter-spacing:0.1pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">p</span>plications<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> f</span>irst-inve<span style="letter-spacing:-0.1pt;">n</span>tor-to-f<span style="letter-spacing:-0.05pt;">i</span>le<span style="letter-spacing:-0.7pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>w<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">S</span>tate<span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.1pt;"> </span>We may<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>qu<span style="letter-spacing:-0.05pt;">i</span>red<span style="letter-spacing:-0.3pt;"> </span>to p<span style="letter-spacing:-0.05pt;">a</span>rti<span style="letter-spacing:-0.05pt;">c</span>ip<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nterference<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oceedings<span style="letter-spacing:-0.3pt;"> </span>inv<span style="letter-spacing:0.05pt;">o</span>lving<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>pend<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>applications.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cease<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>prevailing<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ird<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a result<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>unfavorable<span style="letter-spacing:-0.4pt;"> </span>out<span style="letter-spacing:-0.1pt;">c</span>ome<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rfer<span style="letter-spacing:-0.05pt;">e</span>nce<span style="letter-spacing:-0.45pt;"> </span>proceeding<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>proceeding.<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>prevailing<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>rty<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>case<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>offer<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">e</span>rc<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>cc<span style="letter-spacing:-0.05pt;">e</span>pt<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.15pt;"> </span>or at<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>l.<span style="letter-spacing:-0.1pt;"> </span>Ev<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>f we were<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>license,<span style="letter-spacing:-0.25pt;"> </span>it could<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">b</span>e<span style="letter-spacing:-0.05pt;"> </span>non-exclusive,<span style="letter-spacing:-0.55pt;"> </span>thereby<span style="letter-spacing:-0.3pt;"> </span>giving<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">o</span>mpetitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.3pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:0.05pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>to us,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.35pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>ke<span style="letter-spacing:-0.2pt;"> </span>subst<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ensing<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>royalty<span style="letter-spacing:-0.2pt;"> </span>payments.<span style="letter-spacing:-0.3pt;"> </span>Any of<span style="letter-spacing:-0.05pt;"> </span>the foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our b<span style="letter-spacing:0.05pt;">u</span>siness, financi<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:0.05pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>op<span style="letter-spacing:0.05pt;">e</span>rations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>any of<span style="letter-spacing:-0.05pt;"> </span>our owned<span style="letter-spacing:-0.25pt;"> </span>or in-lice<span style="letter-spacing:0.15pt;">n</span>sed<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not issue<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>in any<span style="letter-spacing:-0.05pt;"> </span>jurisdi<span style="letter-spacing:-0.05pt;">c</span>tion,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>fec<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">v</span>el<span style="letter-spacing:-0.05pt;">y</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes<span style="letter-spacing:-0.25pt;"> </span>in either<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>laws<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;">i</span>r<span style="letter-spacing:-0.1pt;"> </span>interpretation<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ountries<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>diminish<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>protect our inventions, obtain, m<span style="letter-spacing:0.05pt;">a</span>int<span style="letter-spacing:0.05pt;">a</span>in,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">e</span>nfor<span style="letter-spacing:0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>int<span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.25pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and,<span style="letter-spacing:-0.2pt;"> </span>more<span style="letter-spacing:-0.2pt;"> </span>generally,<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>v<span style="letter-spacing:-0.05pt;">a</span>lue<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>narrow<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>scope of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>lice<span style="letter-spacing:0.05pt;">n</span>sed<span style="letter-spacing:-0.2pt;"> </span>paten<span style="letter-spacing:-0.1pt;">t</span>s.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>ith<span style="letter-spacing:-0.2pt;"> </span>respe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>to bo<span style="letter-spacing:-0.05pt;">t</span>h<span style="letter-spacing:-0.05pt;"> i</span>n-li<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.05pt;">n</span>sed<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property,<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:0.05pt;">n</span>ot<span style="letter-spacing:-0.2pt;"> </span>predict<span style="letter-spacing:-0.2pt;"> </span>whether<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications we<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>currently<span style="letter-spacing:-0.25pt;"> </span>pursuing will<span style="letter-spacing:-0.15pt;"> </span>issue<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>particular<span style="letter-spacing:-0.3pt;"> </span>j<span style="letter-spacing:-0.05pt;">u</span>risdiction<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>ssued<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>provide sufficient<span style="letter-spacing:-0.35pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>ties.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>prosecution<span style="letter-spacing:-0.35pt;"> </span>process is expensive,<span style="letter-spacing:-0.45pt;"> </span>time-consuming,<span style="letter-spacing:-0.6pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>complex,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>fil<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.1pt;"> </span>pros<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>u<span style="letter-spacing:-0.05pt;">t</span>e,<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>int<span style="letter-spacing:-0.05pt;">a</span>in,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nforc<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.25pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>desir<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.35pt;"> </span>at<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>reasonable<span style="letter-spacing:-0.4pt;"> </span>cost<span style="letter-spacing:-0.15pt;"> </span>or in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">i</span>m<span style="letter-spacing:0.05pt;">e</span>ly<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>nn<span style="letter-spacing:0.05pt;">e</span>r.<span style="letter-spacing:-0.25pt;"> </span>It<span style="letter-spacing:-0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:0.05pt;"> </span>possible<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>fa<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;"> t</span>o id<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>fy<span style="letter-spacing:-0.2pt;"> </span>patentable<span style="letter-spacing:-0.3pt;"> </span>aspects<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>output<span style="letter-spacing:-0.2pt;"> </span>in time<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protection.<span style="letter-spacing:-0.35pt;"> </span>Althou<span style="letter-spacing:0.05pt;">g</span>h<span style="letter-spacing:-0.35pt;"> </span>we enter<span style="letter-spacing:0.05pt;"> </span>into<span style="letter-spacing:0.05pt;"> </span>nondisclosure<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.45pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to confidential<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patentable<span style="letter-spacing:-0.35pt;"> </span>aspects<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:0.05pt;"> </span>research<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:0.05pt;"> </span>outp<span style="letter-spacing:0.05pt;">u</span>t,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>emplo<span style="letter-spacing:0.05pt;">y</span>ees,<span style="letter-spacing:-0.45pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>collaborato<span style="letter-spacing:0.05pt;">r</span>s,<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>scientific<span style="letter-spacing:-0.3pt;"> </span>collabo<span style="letter-spacing:-0.1pt;">r</span>ators,<span style="letter-spacing:-0.45pt;"> </span>CROs,<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ontract<span style="letter-spacing:-0.3pt;"> </span>manufactu<span style="letter-spacing:0.05pt;">r</span>ers,<span style="letter-spacing:-0.45pt;"> </span>consultants,<span style="letter-spacing:-0.45pt;"> </span>advisors,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ese<span style="letter-spacing:-0.1pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>bre<span style="letter-spacing:-0.05pt;">a</span>ch<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>em<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>disclose<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>output<span style="letter-spacing:-0.3pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>a patent<span style="letter-spacing:-0.15pt;"> </span>application<span style="letter-spacing:-0.35pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>filed,<span style="letter-spacing:-0.15pt;"> </span>thereby<span style="letter-spacing:-0.3pt;"> </span>jeopardizing<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protection.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>maintain<span style="letter-spacing:-0.25pt;"> </span>valid<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>enforceable<span style="letter-spacing:-0.4pt;"> </span>pate<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.2pt;"> </span>depends<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>whether<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>differences<span style="letter-spacing:-0.45pt;"> </span>bet<span style="letter-spacing:0.1pt;">w</span>een<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inventions<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>art<span style="letter-spacing:-0.15pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>patentable<span style="letter-spacing:-0.3pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>t.<span style="letter-spacing:-0.15pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>publications<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>discoveries<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">e</span>ntif<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.25pt;"> </span>li<span style="letter-spacing:-0.05pt;">t</span>era<span style="letter-spacing:-0.05pt;">t</span>ure oft<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.1pt;">a</span>g behind<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>actual<span style="letter-spacing:-0.15pt;"> </span>discoveries,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>at<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>jurisdicti<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>typically<span style="letter-spacing:-0.35pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:0.05pt;">u</span>blished<span style="letter-spacing:-0.3pt;"> </span>until<span style="letter-spacing:-0.1pt;"> </span>18&#160;months<span style="letter-spacing:0.05pt;"> </span>after<span style="letter-spacing:-0.1pt;"> </span>filing,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span>cases<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>all.<span style="letter-spacing:-0.15pt;"> </span>Therefore,<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">e</span>re<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.1pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>claimed<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>wned<span style="letter-spacing:-0.1pt;"> </span>or licensed<span style="letter-spacing:-0.35pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>pending<span style="letter-spacing:-0.25pt;"> </span>pat<span style="letter-spacing:0.1pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>applications,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>to file<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>inventions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the<span style="letter-spacing:-0.1pt;"> </span>scope<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any pate<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>sufficiently<span style="letter-spacing:-0.35pt;"> </span>broad,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>lose<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protection,<span style="letter-spacing:-0.35pt;"> </span>our abili<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o pre<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.1pt;"> </span>our <span style="letter-spacing:0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">to</span><span style="letter-spacing:0.05pt;">r</span>s<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">o</span>m<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>o<span style="letter-spacing:-0.05pt;">m</span>m<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">z</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span>mi<span style="letter-spacing:-0.05pt;">la</span>r<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>r id<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:0.05pt;">c</span>al<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">ec</span><span style="letter-spacing:-0.05pt;">hn</span>ology<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>would<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>position<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>pharmaceutical<span style="letter-spacing:-0.55pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>generally<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>highly<span style="letter-spacing:-0.25pt;"> </span>uncertain,<span style="letter-spacing:-0.35pt;"> </span>involves<span style="letter-spacing:-0.25pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>factual<span style="letter-spacing:-0.2pt;"> </span>questions,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>has been<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>subje<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span>uch<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>ga<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n r<span style="letter-spacing:-0.05pt;">e</span>cent<span style="letter-spacing:-0.2pt;"> </span>y<span style="letter-spacing:-0.05pt;">e</span>ars.<span style="letter-spacing:-0.1pt;"> </span>As a<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:-0.1pt;">u</span>lt,<span style="letter-spacing:-0.05pt;"> t</span>he<span style="letter-spacing:-0.05pt;"> </span>issu<span style="letter-spacing:-0.05pt;">a</span>nce,<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>ope,<span style="letter-spacing:-0.2pt;"> </span>va<span style="letter-spacing:-0.05pt;">l</span>idi<span style="letter-spacing:-0.05pt;">t</span>y,<span style="letter-spacing:-0.25pt;"> </span>enfor<span style="letter-spacing:-0.05pt;">c</span>eab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.5pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>are highly<span style="letter-spacing:-0.25pt;"> </span>uncertain.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>p<span style="letter-spacing:-0.05pt;">e</span>nding<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>appli<span style="letter-spacing:0.1pt;">c</span>ations<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lt<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.3pt;"> </span>hAd5, aldoxorubicin<span style="letter-spacing:-0.05pt;"> or other </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>chnologies<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>effective<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.3pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>commerc<span style="letter-spacing:0.05pt;">i</span>alizing<span style="letter-spacing:-0.55pt;"> </span>competit<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.45pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>product candidates.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">coverage</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claimed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applicati</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">significantly</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issued,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">scope</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reinterpreted</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">after issu</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nce.</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">E</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ven</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pat</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appl</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ca</span><span style="letter-spacing:-0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ions</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">currently</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">future</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">issue</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a form</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with any</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">meaningful</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protection,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prevent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competit</span><span style="letter-spacing:0.1pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rs</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rties</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpeting</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">th us,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otherwise</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pet</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tive</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dvant</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ge. Any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:0.05pt;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">challenged,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">na</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ro</span><span style="letter-spacing:0.05pt;">w</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumvented,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">invalidated</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties.</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consequently,</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">know </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">whether</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anktiva</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hAd5</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.05pt;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.05pt;">other</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protectable</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">remain</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">protected</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">valid</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforc</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s.</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our competitors</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to circumvent</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by developing</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">similar</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">alterna</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ive</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">roducts</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in a</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">non-infringing manner</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">business,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">results</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operations</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">growth</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospects.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>issuance<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>is not<span style="letter-spacing:-0.15pt;"> </span>conclusive<span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>to its<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>nto<span style="letter-spacing:0.05pt;">r</span>ship,<span style="letter-spacing:-0.4pt;"> </span>scope,<span style="letter-spacing:-0.3pt;"> </span>validity,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>enforceability,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tents<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> c</span>hallenged<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>courts<span style="letter-spacing:-0.25pt;"> </span>or patent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">f</span>fices<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>abroad.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licens<span style="letter-spacing:0.1pt;">o</span>rs<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a third-p<span style="letter-spacing:-0.05pt;">a</span>rty<span style="letter-spacing:-0.35pt;"> </span>preissuance<span style="letter-spacing:-0.35pt;"> </span>submission<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>rior<span style="letter-spacing:-0.1pt;"> </span>art<span style="letter-spacing:-0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>USPTO,<span style="letter-spacing:0.05pt;"> </span>or become<span style="letter-spacing:-0.3pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>opposition,<span style="letter-spacing:-0.35pt;"> </span>derivation,<span style="letter-spacing:-0.35pt;"> </span>revoc<span style="letter-spacing:-0.05pt;">a</span>tion,<span style="letter-spacing:-0.35pt;"> </span>reexaminat<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.4pt;"> </span>post-grant<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">int</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">pa</span><span style="font-style:italic;letter-spacing:0.05pt;">r</span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;">s</span><span style="font-style:italic;letter-spacing:-0.05pt;"> </span>review,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>interference<span style="letter-spacing:-0.45pt;"> </span>pro<span style="letter-spacing:0.05pt;">c</span>eedings<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>similar proceedings<span style="letter-spacing:-0.4pt;"> </span>challenging<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>licensed<span style="letter-spacing:-0.35pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights.<span style="letter-spacing:-0.3pt;"> </span>An<span style="letter-spacing:0.05pt;"> </span>ad<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">e</span>rse<span style="letter-spacing:-0.2pt;"> </span>determination<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>submission,<span style="letter-spacing:-0.4pt;"> </span>proceeding<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>litigation could reduce the scope of,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>invalidate<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>render<span style="letter-spacing:-0.2pt;"> </span>unenforceable,<span style="letter-spacing:-0.55pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.4pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>rights,<span style="letter-spacing:-0.3pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.05pt;"> par</span>t<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>o<span style="letter-spacing:-0.05pt;">m</span>m<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">a</span>lize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.25pt;"> </span>hAd5 or other prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>techno<span style="letter-spacing:0.1pt;">l</span>ogies<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.3pt;"> </span>directly<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.25pt;"> </span>us,<span style="letter-spacing:-0.05pt;"> </span>without<span style="letter-spacing:-0.25pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>to us,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inability<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>ma<span style="letter-spacing:0.05pt;">n</span>uf<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span>ure<span style="letter-spacing:-0.35pt;"> </span>or co<span style="letter-spacing:-0.05pt;">m</span>mer<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>e prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>infringing<span style="letter-spacing:-0.3pt;"> </span>third-party<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>rights.<span style="letter-spacing:-0.2pt;"> </span>Moreover,<span style="letter-spacing:-0.45pt;"> </span>we, or<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ne of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors,<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>participate<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>inter<span style="letter-spacing:0.1pt;">f</span>erence<span style="letter-spacing:-0.4pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>declared by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>determine<span style="letter-spacing:-0.3pt;"> </span>priority<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> i</span>nvention<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>post-grant<span style="letter-spacing:-0.4pt;"> </span>challenge<span style="letter-spacing:-0.35pt;"> </span>proceed<span style="letter-spacing:0.1pt;">i</span>ngs,<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>oppositions<span style="letter-spacing:-0.45pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a fo<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>ign<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>office,<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>challenge<span style="letter-spacing:-0.3pt;"> </span>our or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensor&#8217;s<span style="letter-spacing:-0.4pt;"> </span>priority<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>invention<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>features<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patentabi<span style="letter-spacing:-0.05pt;">l</span>ity<span style="letter-spacing:-0.5pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications.<span style="letter-spacing:-0.45pt;"> </span>Such challenges<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights,<span style="letter-spacing:-0.1pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>exclusivity,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in patent<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:-0.15pt;">l</span>aims<span style="letter-spacing:-0.2pt;"> </span>being<span style="letter-spacing:-0.15pt;"> </span>narrowed,<span style="letter-spacing:-0.4pt;"> </span>invalidated,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>unenforceable,<span style="letter-spacing:-0.5pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to stop<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>usi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>commercializing<span style="letter-spacing:-0.6pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>identical<span style="letter-spacing:-0.3pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>products,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>dura<span style="letter-spacing:-0.15pt;">t</span>ion<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>protection<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.3pt;"> </span>hAd5<span style="letter-spacing:0.05pt;"> or other </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span><span style="letter-spacing:0.05pt;">n</span>didates<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>te<span style="letter-spacing:-0.05pt;">c</span>hnologies.<span style="letter-spacing:-0.45pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> s</span>ubstantial<span style="letter-spacing:-0.35pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>req<span style="letter-spacing:-0.05pt;">u</span>ire<span style="letter-spacing:-0.2pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>time from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>scientists<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>management,<span style="letter-spacing:-0.45pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he <span style="letter-spacing:-0.05pt;">e</span>ven<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.2pt;"> </span>out<span style="letter-spacing:-0.05pt;">c</span>ome<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>vorab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o u<span style="letter-spacing:-0.1pt;">s</span>.<span style="letter-spacing:-0.05pt;"> </span>If we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>unsuccessf<span style="letter-spacing:-0.05pt;">u</span>l<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>proceeding or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>priority<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>inventorship<span style="letter-spacing:-0.5pt;"> </span>dispute,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>maintain<span style="letter-spacing:-0.3pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such interference<span style="letter-spacing:-0.45pt;"> </span>proceedings<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>priority<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>invento<span style="letter-spacing:-0.05pt;">r</span>ship<span style="letter-spacing:-0.5pt;"> </span>disputes.<span style="letter-spacing:-0.25pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>available<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>commercially<span style="letter-spacing:-0.45pt;"> </span>reasonable<span style="letter-spacing:-0.35pt;"> </span>terms<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at all,<span style="letter-spacing:-0.05pt;"> </span>or may be<span style="letter-spacing:-0.15pt;"> </span>non-exclusive.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>maintain<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>licenses,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>n<span style="letter-spacing:0.05pt;">e</span>ed<span style="letter-spacing:-0.1pt;"> </span>to cease<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>dev<span style="letter-spacing:-0.05pt;">e</span>lopment,<span style="letter-spacing:-0.45pt;"> </span>manufacture,<span style="letter-spacing:-0.5pt;"> </span>and commercialization<span style="letter-spacing:-0.65pt;"> </span>of one<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>develo<span style="letter-spacing:0.05pt;">p</span>.<span style="letter-spacing:-0.3pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>loss<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>exc<span style="letter-spacing:-0.15pt;">l</span>usivity<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>narrowing<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>own<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>patent claims<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to stop<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>using<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>comme<span style="letter-spacing:0.05pt;">r</span>cializing<span style="letter-spacing:-0.55pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>identical<span style="letter-spacing:-0.3pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>given<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>development,<span style="letter-spacing:-0.45pt;"> </span>testing,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>regulatory<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>view<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>new<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>atents<span style="letter-spacing:-0.25pt;"> </span>protecting<span style="letter-spacing:-0.3pt;"> </span>such prod<span style="letter-spacing:0.05pt;">u</span>ct<span style="letter-spacing:-0.1pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xpire<span style="letter-spacing:-0.15pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>shortly<span style="letter-spacing:-0.2pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>commercia<span style="letter-spacing:-0.15pt;">l</span>ized.<span style="letter-spacing:-0.6pt;"> </span>As<span style="letter-spacing:-0.05pt;"> </span>a result,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not provide<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>sufficient<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>exclude<span style="letter-spacing:-0.3pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.05pt;"> </span>commercializing<span style="letter-spacing:-0.6pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>oducts<span style="letter-spacing:-0.3pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>identical<span style="letter-spacing:-0.25pt;"> </span>to ours.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>in-licensed<span style="letter-spacing:-0.4pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>appli<span style="letter-spacing:0.05pt;">c</span>ations<span style="letter-spacing:-0.5pt;"> </span>are,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>be,<span style="letter-spacing:-0.05pt;"> </span>co-owned<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.15pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our licensors<span style="letter-spacing:-0.35pt;"> </span>co-own<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>at<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.3pt;"> </span>we in-l<span style="letter-spacing:-0.05pt;">i</span>cense<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.05pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>whom<span style="letter-spacing:0.05pt;"> </span>we do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a direct<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">r</span>elationship.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>exclusive rights<span style="letter-spacing:-0.15pt;"> </span>to certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tent<span style="letter-spacing:-0.15pt;"> </span>applications<span style="letter-spacing:-0.5pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>de<span style="letter-spacing:0.05pt;">p</span>endent,<span style="letter-spacing:-0.4pt;"> </span>in part,<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>inter-insti<span style="letter-spacing:-0.1pt;">t</span>utional<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">g</span>r<span style="letter-spacing:0.05pt;">e</span>ements<span style="letter-spacing:-0.35pt;"> </span>b<span style="letter-spacing:0.05pt;">e</span>t<span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>joint owners<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applications,<span style="letter-spacing:-0.45pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>to our l<span style="letter-spacing:-0.05pt;">i</span>cense<span style="letter-spacing:-0.25pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>ex<span style="letter-spacing:-0.05pt;">c</span>lusive<span style="letter-spacing:-0.3pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>rol<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>grant<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>co-ow<span style="letter-spacing:-0.05pt;">n</span>ers&#8217;<span style="letter-spacing:-0.05pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>we are<span style="letter-spacing:-0.15pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>unable<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cure<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.05pt;"> e</span>xc<span style="letter-spacing:-0.05pt;">l</span>us<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.25pt;"> </span>rights,<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>co-owners<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.3pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to other<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>mpetitors,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competit<span style="letter-spacing:-0.05pt;">o</span>rs<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>competing<span style="letter-spacing:-0.4pt;"> </span>prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>technology.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>cooperation<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>co-<span style="letter-spacing:0.1pt;">o</span>wners<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.15pt;"> </span>to enforce<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>cooperat<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>vided<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">e</span>titive<span style="letter-spacing:-0.4pt;"> </span>positi<span style="letter-spacing:0.05pt;">o</span>n, b<span style="letter-spacing:0.05pt;">u</span>siness, financial<span style="letter-spacing:-0.25pt;"> </span>conditions,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">olv</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">n lawsu</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">prote</span><span style="letter-spacing:-0.15pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">enforce</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or other</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">o</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">lectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our licensors,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">expensive,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">-consum</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ng</span><span style="letter-spacing:-0.55pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">ce</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ssf</span><span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.1pt;">t</span>ies<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>infringe,<span style="letter-spacing:-0.3pt;"> </span>misappropriate<span style="letter-spacing:-0.55pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>v<span style="letter-spacing:-0.05pt;">i</span>olate<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.15pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>proper<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>lic<span style="letter-spacing:-0.15pt;">e</span>nsors<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in i<span style="letter-spacing:0.05pt;">n</span>ventorship,<span style="letter-spacing:-0.4pt;"> </span>priority<span style="letter-spacing:-0.3pt;"> </span>or validity disputes.<span style="letter-spacing:-0.25pt;"> </span>To<span style="letter-spacing:-0.15pt;"> </span>counter<span style="letter-spacing:-0.3pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>fringement<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>una<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">t</span>horized<span style="letter-spacing:-0.45pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>file<span style="letter-spacing:-0.05pt;"> </span>infringement<span style="letter-spacing:-0.4pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>expensive<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>time-consuming.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>infrin<span style="letter-spacing:0.05pt;">g</span>ement<span style="letter-spacing:-0.45pt;"> </span>proceeding,<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>court<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>decide<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:0.05pt;">a</span>tents<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>valid<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>is u<span style="letter-spacing:0.05pt;">n</span>enforceable<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>refuse to stop<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>chnology<span style="letter-spacing:-0.35pt;"> </span>at issue<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>grounds<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>cover<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>in ques<span style="letter-spacing:0.05pt;">t</span>ion.<span style="letter-spacing:-0.4pt;"> </span>An<span style="letter-spacing:-0.05pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>defense<span style="letter-spacing:-0.2pt;"> </span>proceeding<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>put<span style="letter-spacing:-0.05pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>ur<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">w</span>ed<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>paten<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>at risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>being<span style="letter-spacing:-0.2pt;"> </span>invalidated,<span style="letter-spacing:-0.4pt;"> </span>held<span style="letter-spacing:-0.1pt;"> </span>unen<span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>ceable,<span style="letter-spacing:-0.4pt;"> </span>or interpreted<span style="letter-spacing:-0.35pt;"> </span>narrowly,<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>put<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applica<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.5pt;"> </span>at risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>iss<span style="letter-spacing:-0.05pt;">u</span>ing.<span style="letter-spacing:-0.2pt;"> </span>Defense<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>cl<span style="letter-spacing:0.05pt;">a</span>im<span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:-0.25pt;"> </span>reg<span style="letter-spacing:0.05pt;">a</span>rdl<span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:-0.3pt;"> </span>of th<span style="letter-spacing:0.05pt;">ei</span>r<span style="letter-spacing:-0.2pt;"> </span>merit,<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>involve subst<span style="letter-spacing:-0.05pt;">a</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>li<span style="letter-spacing:-0.05pt;">t</span>iga<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>xpense<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>diver<span style="letter-spacing:-0.05pt;">s</span>ion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>employee<span style="letter-spacing:-0.3pt;"> </span>resources<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business.<span style="letter-spacing:0.05pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>beca<span style="letter-spacing:-0.05pt;">u</span>se<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>substantial amount<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>discovery<span style="letter-spacing:-0.35pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>in connection<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>proper<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.2pt;"> </span>litigation,<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>risk that<span style="letter-spacing:-0.2pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>confidential<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be compromised<span style="letter-spacing:-0.45pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>disclosure<span style="letter-spacing:-0.3pt;"> </span>dur<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.1pt;"> </span>this<span style="letter-spacing:-0.2pt;"> </span>type<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>litigation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even<span style="letter-spacing:-0.2pt;"> </span>if<span style="letter-spacing:-0.05pt;"> </span>resolv<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>f<span style="letter-spacing:-0.05pt;">a</span>vor,<span style="letter-spacing:-0.05pt;"> </span>li<span style="letter-spacing:-0.05pt;">t</span>ig<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>proceed<span style="letter-spacing:-0.05pt;">i</span>ngs<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.25pt;"> </span>to intellectual<span style="letter-spacing:-0.4pt;"> </span>prop<span style="letter-spacing:-0.05pt;">e</span>rty<span style="letter-spacing:-0.35pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>cause<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to <span style="letter-spacing:-0.05pt;">i</span>ncur<span style="letter-spacing:-0.25pt;"> </span>significant<span style="letter-spacing:-0.35pt;"> </span>expenses<span style="letter-spacing:-0.25pt;"> </span>and could<span style="letter-spacing:-0.2pt;"> </span>distract<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>personnel<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>norm<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>responsibilities.<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addit<span style="letter-spacing:-0.1pt;">i</span>on,<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>public<span style="letter-spacing:-0.25pt;"> </span>announcements<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>resul<span style="letter-spacing:-0.1pt;">t</span>s<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>hearings,<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:0.05pt;">o</span>tions,<span style="letter-spacing:-0.35pt;"> </span>or other<span style="letter-spacing:-0.25pt;"> </span>interim<span style="letter-spacing:-0.2pt;"> </span>proceedings<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dev<span style="letter-spacing:0.05pt;">e</span>lop<span style="letter-spacing:-0.05pt;">m</span>ents,<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd if<span style="letter-spacing:-0.05pt;"> </span>secur<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.05pt;">a</span>lysts<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>investors<span style="letter-spacing:-0.3pt;"> </span>per<span style="letter-spacing:-0.05pt;">c</span>eive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hese<span style="letter-spacing:-0.05pt;"> </span>results<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>negative,<span style="letter-spacing:-0.3pt;"> </span>it c<span style="letter-spacing:-0.05pt;">o</span>uld<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>adverse eff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.2pt;"> </span>on the<span style="letter-spacing:-0.1pt;"> </span>pri<span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.2pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock.<span style="letter-spacing:-0.15pt;"> </span>Such<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>uld<span style="letter-spacing:-0.15pt;"> </span>substan<span style="letter-spacing:-0.1pt;">t</span>ially<span style="letter-spacing:-0.45pt;"> </span>increase<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>operating<span style="letter-spacing:-0.3pt;"> </span>los<span style="letter-spacing:-0.1pt;">s</span>es<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>reduce<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>resources<span style="letter-spacing:-0.05pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">e</span>ve<span style="letter-spacing:-0.05pt;">l</span>op<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;">i</span>vit<span style="letter-spacing:-0.05pt;">i</span>es<span style="letter-spacing:-0.25pt;"> </span>or any<span style="letter-spacing:-0.15pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;">e</span>s,<span style="letter-spacing:-0.05pt;"> </span>marketing,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>distribution<span style="letter-spacing:-0.4pt;"> </span>ac<span style="letter-spacing:-0.1pt;">t</span>ivities.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">f</span>icient<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>conduct<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>proce<span style="letter-spacing:0.05pt;">e</span>dings<span style="letter-spacing:-0.5pt;"> </span>adequately.<span style="letter-spacing:-0.35pt;"> </span>Some<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>sustain<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>costs<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or proceedings<span style="letter-spacing:-0.4pt;"> </span>more<span style="letter-spacing:-0.05pt;"> </span>effectively<span style="letter-spacing:-0.4pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>b<span style="letter-spacing:0.1pt;">e</span>cause<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>finan<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.3pt;"> </span>resources<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>more<span style="letter-spacing:-0.15pt;"> </span>mature<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>developed<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>portfoli<span style="letter-spacing:0.05pt;">o</span>s. Un<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>rt<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>sult<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>continuation<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.15pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.05pt;">d</span>verse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to comp<span style="letter-spacing:-0.05pt;">e</span>te<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>rke<span style="letter-spacing:-0.05pt;">t</span>p<span style="letter-spacing:-0.05pt;">l</span>a<span style="letter-spacing:-0.05pt;">c</span>e.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;letter-spacing:0.05pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Issued<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.15pt;"> </span>covering<span style="letter-spacing:-0.2pt;"> </span>our t<span style="letter-spacing:-0.05pt;">e</span>chnology<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:-0.05pt;"> </span>invalid<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>e<span style="letter-spacing:-0.05pt;">n</span>for<span style="letter-spacing:-0.05pt;">c</span>eab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.2pt;"> </span>if <span style="letter-spacing:-0.05pt;">c</span>ha<span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.05pt;">e</span>ng<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>in <span style="letter-spacing:-0.05pt;">c</span>ourt<span style="letter-spacing:-0.05pt;"> </span>or before administrative<span style="letter-spacing:-0.45pt;"> </span>bodies<span style="letter-spacing:-0.3pt;"> </span>in the<span style="letter-spacing:-0.2pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>abroad.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.3pt;"> </span>initiate<span style="letter-spacing:-0.2pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>proceedings<span style="letter-spacing:-0.5pt;"> </span>against<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>to enforce<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>covering<span style="letter-spacing:-0.25pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or <span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">t</span>her technologies,<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>defendant<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>counterclaim<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>invalid<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;">/</span>or<span style="letter-spacing:-0.2pt;"> </span>unenforceable<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>infringe<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:-0.2pt;"> </span>paten<span style="letter-spacing:0.05pt;">t</span>s.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>in the United<span style="letter-spacing:-0.3pt;"> </span>States,<span style="letter-spacing:-0.3pt;"> </span>defendant<span style="letter-spacing:-0.35pt;"> </span>counte<span style="letter-spacing:0.05pt;">r</span>claims<span style="letter-spacing:-0.5pt;"> </span>alleging<span style="letter-spacing:-0.25pt;"> </span>invalidity<span style="letter-spacing:-0.35pt;"> </span>and/or<span style="letter-spacing:-0.25pt;"> </span>unenforceability<span style="letter-spacing:-0.55pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>commonplace,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>numerous<span style="letter-spacing:-0.3pt;"> </span>gro<span style="letter-spacing:-0.05pt;">u</span>nds<span style="letter-spacing:0.05pt;"> </span>upon<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>third party<span style="letter-spacing:-0.2pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>assert<span style="letter-spacing:-0.15pt;"> </span>invalidity<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unenforceability<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a pate<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.25pt;"> </span>Groun<span style="letter-spacing:0.05pt;">d</span>s<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>a validity<span style="letter-spacing:-0.2pt;"> </span>challenge<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>alleged<span style="letter-spacing:-0.25pt;"> </span>failure<span style="letter-spacing:-0.35pt;"> </span>to meet<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>several statutory<span style="letter-spacing:-0.25pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>lack<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>novelty,<span style="letter-spacing:-0.25pt;"> </span>obviousness,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>non-enablemen<span style="letter-spacing:-0.05pt;">t</span>.<span style="letter-spacing:-0.65pt;"> </span>Grounds<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>unenforceability<span style="letter-spacing:-0.6pt;"> </span>assertion<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>allegation<span style="letter-spacing:-0.3pt;"> </span>that someone<span style="letter-spacing:-0.35pt;"> </span>connected<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>prosecution<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>withheld<span style="letter-spacing:-0.25pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>USPTO<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">t</span>her<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.35pt;"> </span>body,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>made<span style="letter-spacing:-0.2pt;"> </span>a misleading statement,<span style="letter-spacing:-0.35pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>prosecution.<span style="letter-spacing:-0.45pt;"> </span>T<span style="letter-spacing:0.05pt;">h</span>ird<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>raise<span style="letter-spacing:-0.1pt;"> </span>similar<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;">f</span>ore<span style="letter-spacing:-0.15pt;"> </span>administrative<span style="letter-spacing:-0.55pt;"> </span>bodies<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>or abro<span style="letter-spacing:-0.05pt;">a</span>d,<span style="letter-spacing:-0.2pt;"> </span>ev<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he cont<span style="letter-spacing:-0.05pt;">e</span>xt<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>tig<span style="letter-spacing:-0.05pt;">a</span>tion.<span style="letter-spacing:-0.35pt;"> </span>Such m<span style="letter-spacing:-0.05pt;">e</span>chan<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.4pt;"> </span>include<span style="letter-spacing:-0.25pt;"> </span>re-examination,<span style="letter-spacing:-0.5pt;"> </span>post<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.2pt;"> </span>review,<span style="letter-spacing:-0.3pt;"> </span><span style="font-style:italic;">int</span><span style="font-style:italic;letter-spacing:-0.05pt;">e</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.15pt;"> </span><span style="font-style:italic;">par</span><span style="font-style:italic;letter-spacing:-0.05pt;">t</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;">s</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span>review,<span style="letter-spacing:-0.2pt;"> </span>interference<span style="letter-spacing:-0.45pt;"> </span>proce<span style="letter-spacing:-0.1pt;">e</span>dings,<span style="letter-spacing:-0.5pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>proceedings, and<span style="letter-spacing:-0.1pt;"> </span>equivalent<span style="letter-spacing:-0.3pt;"> </span>procee<span style="letter-spacing:-0.05pt;">d</span>ings<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>jurisdictions<span style="letter-spacing:-0.4pt;"> </span>(e.g.,<span style="letter-spacing:-0.15pt;"> </span>opposition<span style="letter-spacing:-0.4pt;"> </span>proceedings).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.2pt;"> </span>cost<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>litigati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>proceeding<span style="letter-spacing:-0.45pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights,<span style="letter-spacing:-0.3pt;"> </span>even<span style="letter-spacing:-0.1pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>resolved<span style="letter-spacing:-0.25pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>favor,<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>substantial.<span style="letter-spacing:-0.4pt;"> </span>Some<span style="letter-spacing:-0.15pt;"> </span>of o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>better<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;">b</span>le<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o sus<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>os<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such li<span style="letter-spacing:-0.05pt;">t</span>ig<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.1pt;"> </span>ot<span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>proceeding<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">e</span>cause<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ey<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>su<span style="letter-spacing:0.05pt;">b</span>stantially<span style="letter-spacing:-0.2pt;"> </span>greater<span style="letter-spacing:-0.2pt;"> </span>resources.<span style="letter-spacing:-0.4pt;"> </span>Such proceedings<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>revocati<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>cancellation<span style="letter-spacing:-0.4pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>amendment<span style="letter-spacing:-0.4pt;"> </span>to,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>a way<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:-0.2pt;"> </span>cover<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or technologies. The<span style="letter-spacing:-0.2pt;"> </span>outcome<span style="letter-spacing:-0.3pt;"> </span>following<span style="letter-spacing:-0.35pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>assertions<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>invalidity<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>unenforceability<span style="letter-spacing:-0.55pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>unpredi<span style="letter-spacing:0.1pt;">c</span>table.<span style="letter-spacing:-0.45pt;"> </span>With<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">v</span>alidity<span style="letter-spacing:-0.2pt;"> </span>question,<span style="letter-spacing:-0.4pt;"> </span>for example,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>there<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>invalidating<span style="letter-spacing:-0.4pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>art,<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensor,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensor&#8217;s<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>counsel<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patent exa<span style="letter-spacing:-0.05pt;">m</span>iner<span style="letter-spacing:-0.35pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>unaw<span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.3pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>prosecution.<span style="letter-spacing:-0.4pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>a third<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>prevail<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>a legal<span style="letter-spacing:-0.15pt;"> </span>ass<span style="letter-spacing:0.05pt;">e</span>rtion<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>invalidity<span style="letter-spacing:-0.35pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>unenforceability,<span style="letter-spacing:-0.65pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>lose<span style="letter-spacing:-0.2pt;"> </span>at least<span style="letter-spacing:-0.15pt;"> </span>part,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>perha<span style="letter-spacing:-0.05pt;">p</span>s<span style="letter-spacing:-0.3pt;"> </span>all,<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>protection on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>candidates.<span style="letter-spacing:-0.45pt;"> </span>Such<span style="letter-spacing:0.05pt;"> </span>a loss of patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>uld<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>impact<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>co<span style="letter-spacing:-0.05pt;">n</span>dition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">T</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">se</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r t</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">no</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ogy</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pote</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ly</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">confli</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">rights of</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">others,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">third-party</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">property in</span><span style="letter-spacing:-0.05pt;">f</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ingement,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">misappropriat</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">other</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">violation</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">licensors</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">collaborators</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">prevent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">delay</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">deve</span><span style="letter-spacing:0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">opment</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and com</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ercia</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ization</span><span style="letter-spacing:-0.65pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">product</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">technologies.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our com<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ial<span style="letter-spacing:-0.4pt;"> </span>suc<span style="letter-spacing:-0.05pt;">c</span>ess<span style="letter-spacing:-0.1pt;"> </span>dep<span style="letter-spacing:-0.05pt;">e</span>nds<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>ou<span style="letter-spacing:-0.05pt;">r</span>,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>lice<span style="letter-spacing:0.05pt;">n</span>sors&#8217;<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>collaborators&#8217;<span style="letter-spacing:-0.45pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to avoid<span style="letter-spacing:-0.25pt;"> </span>infringing,<span style="letter-spacing:-0.45pt;"> </span>misappropriating<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>otherwise<span style="letter-spacing:-0.35pt;"> </span>violating the<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>intellectu<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.45pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties.<span style="letter-spacing:-0.25pt;"> </span>There<span style="letter-spacing:-0.2pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>amount<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>complex<span style="letter-spacing:-0.25pt;"> </span>litiga<span style="letter-spacing:0.05pt;">t</span>ion<span style="letter-spacing:-0.25pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutic<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:-0.7pt;"> </span>industry.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:0.05pt;"> </span>potential<span style="letter-spacing:-0.3pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or other<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>have,<span style="letter-spacing:-0.2pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or acquire<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>they<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>assert<span style="letter-spacing:-0.25pt;"> </span>again<span style="letter-spacing:-0.05pt;">s</span>t<span style="letter-spacing:-0.3pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>they<span style="letter-spacing:-0.2pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>so,<span style="letter-spacing:0.05pt;"> </span>then<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>alter<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates,<span style="letter-spacing:-0.35pt;"> </span>pay<span style="letter-spacing:-0.1pt;"> </span>lic<span style="letter-spacing:-0.1pt;">e</span>nsing<span style="letter-spacing:-0.25pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>or cease<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>comme<span style="letter-spacing:-0.05pt;">r</span>cialization<span style="letter-spacing:-0.65pt;"> </span>activiti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to the<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates conflict<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>others,<span style="letter-spacing:-0.25pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>parti<span style="letter-spacing:-0.1pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>bring<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>act<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.1pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>licensees,<span style="letter-spacing:-0.35pt;"> </span>suppliers<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>customers,<span style="letter-spacing:-0.45pt;"> </span>claim<span style="letter-spacing:0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>damages<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>seeking<span style="letter-spacing:-0.2pt;"> </span>to enjoin<span style="letter-spacing:-0.25pt;"> </span>manufacturing,<span style="letter-spacing:-0.55pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>affected<span style="letter-spacing:-0.25pt;"> </span>products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>conducted<span style="letter-spacing:-0.3pt;"> </span>fr<span style="letter-spacing:-0.05pt;">e</span>edom<span style="letter-spacing:-0.05pt;">-</span>to-operate,<span style="letter-spacing:-0.65pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>FTO,<span style="letter-spacing:0.05pt;"> </span>analyses<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>landscape<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>lead<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candi<span style="letter-spacing:0.05pt;">d</span>ates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>continue<span style="letter-spacing:-0.25pt;"> </span>to u<span style="letter-spacing:0.05pt;">n</span>dertake<span style="letter-spacing:-0.25pt;"> </span>FTO<span style="letter-spacing:-0.05pt;"> </span>analyses<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.6pt;"> </span>processes,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidate,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>contemplated<span style="letter-spacing:-0.5pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>processes<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>pr<span style="letter-spacing:-0.05pt;">o</span>ducts,<span style="letter-spacing:-0.15pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>patent applications<span style="letter-spacing:-0.4pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span>ublish<span style="letter-spacing:-0.15pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>18&#160;months,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applicat<span style="letter-spacing:-0.05pt;">i</span>ons<span style="letter-spacing:-0.35pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>change<span style="letter-spacing:-0.3pt;"> </span>ov<span style="letter-spacing:0.1pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e,<span style="letter-spacing:-0.2pt;"> </span>no F<span style="letter-spacing:-0.05pt;">T</span>O<span style="letter-spacing:-0.1pt;"> </span>analysis<span style="letter-spacing:-0.25pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>considered<span style="letter-spacing:0.05pt;"> </span>exhaustive.<span style="letter-spacing:-0.4pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>aware<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.3pt;"> </span>already<span style="letter-spacing:-0.25pt;"> </span>been<span style="letter-spacing:-0.1pt;"> </span>issued<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>competitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:-0.05pt;">i</span>ght<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">s</span>sert<span style="letter-spacing:-0.1pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>infringed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>rent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.1pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>It<span style="letter-spacing:-0.05pt;"> </span>is also<span style="letter-spacing:-0.2pt;"> </span>possible<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:-0.05pt;"> </span>to have<span style="letter-spacing:-0.2pt;"> </span>infringed<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>aware,<span style="letter-spacing:-0.3pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.3pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>relevant<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies.<span style="letter-spacing:-0.5pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>take<span style="letter-spacing:-0.1pt;"> </span>many<span style="letter-spacing:0.05pt;"> </span>years<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">s</span>su<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>re<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>curr<span style="letter-spacing:0.05pt;">e</span>ntly<span style="letter-spacing:-0.25pt;"> </span>pending<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>a<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.4pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.05pt;">a</span>ter<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n issued <span style="letter-spacing:-0.1pt;">p</span>atents<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>f<span style="letter-spacing:-0.05pt;">r</span>inge.<span style="letter-spacing:-0.2pt;"> </span>Furthermore,<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>intellectu<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>remains<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>evolving<span style="letter-spacing:-0.25pt;"> </span>area<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>many risks<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>uncertainties.<span style="letter-spacing:-0.45pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>such,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to ensure<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>market<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>without<span style="letter-spacing:-0.3pt;"> </span>conflict<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property-related<span style="letter-spacing:-0.65pt;"> </span>leg<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.15pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.2pt;"> </span>aga<span style="letter-spacing:-0.05pt;">i</span>nst<span style="letter-spacing:-0.25pt;"> </span>us <span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>sful,<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>pot<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.2pt;"> </span>for <span style="letter-spacing:-0.05pt;">d</span>amages<span style="letter-spacing:-0.25pt;"> </span>(including<span style="letter-spacing:-0.35pt;"> </span>treble<span style="letter-spacing:-0.25pt;"> </span>damages<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>attorneys&#8217;<span style="letter-spacing:-0.4pt;"> </span>fees<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>willful<span style="letter-spacing:-0.3pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>fringement),<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>enjoined<span style="letter-spacing:-0.3pt;"> </span>from,<span style="letter-spacing:-0.15pt;"> </span>or required<span style="letter-spacing:-0.25pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>continue,<span style="letter-spacing:-0.3pt;"> </span>manufacturing,<span style="letter-spacing:-0.5pt;"> </span>promoting<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>affected<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.1pt;">d</span>ucts.<span style="letter-spacing:-0.2pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">n</span>ot prevail<span style="letter-spacing:-0.2pt;"> </span>in any<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;">c</span>tion<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>required<span style="letter-spacing:-0.3pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>applicable<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span>ctu<span style="letter-spacing:-0.05pt;">a</span>l proper<span style="letter-spacing:-0.05pt;">t</span>y m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>available<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>acceptable<span style="letter-spacing:-0.35pt;"> </span>terms<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>at<span style="letter-spacing:-0.05pt;"> a</span>ll.<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.15pt;"> </span>if we were<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>obta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.15pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>non-exclusive,<span style="letter-spacing:-0.6pt;"> </span>thereby<span style="letter-spacing:-0.3pt;"> </span>giving<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>ird<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>it could<span style="letter-spacing:-0.25pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to make<span style="letter-spacing:-0.35pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>royalty<span style="letter-spacing:0.05pt;"> </span>payments.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>cou<span style="letter-spacing:0.1pt;">l</span>d<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to redesign<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>infringing<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>ducts,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>impossible<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>require<span style="letter-spacing:-0.3pt;"> </span>substantial<span style="letter-spacing:-0.35pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>monetary<span style="letter-spacing:-0.35pt;"> </span>expenditure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Defense<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">f</span>ringement<span style="letter-spacing:-0.4pt;"> </span>claims,<span style="letter-spacing:-0.2pt;"> </span>regardless<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>merit,<span style="letter-spacing:-0.15pt;"> </span>wou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.05pt;"> </span>involve<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>litigation<span style="letter-spacing:-0.25pt;"> </span>expense<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>substan<span style="letter-spacing:0.05pt;">t</span>ial<span style="letter-spacing:-0.4pt;"> </span>diversion<span style="letter-spacing:-0.3pt;"> </span>of management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employee<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">s</span>ources<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, and<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.1pt;">m</span>pact<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>reputation.<span style="letter-spacing:-0.35pt;"> </span>Some<span style="letter-spacing:-0.25pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>su<span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">c</span>osts of<span style="letter-spacing:0.05pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>administrative<span style="letter-spacing:-0.55pt;"> </span>proceedings<span style="letter-spacing:-0.5pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>effectively<span style="letter-spacing:-0.35pt;"> </span>than<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>greater<span style="letter-spacing:-0.3pt;"> </span>fin<span style="letter-spacing:0.05pt;">a</span>ncial<span style="letter-spacing:-0.3pt;"> </span>resources.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>here<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>public announcements<span style="letter-spacing:-0.55pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>hearings,<span style="letter-spacing:-0.35pt;"> </span>m<span style="letter-spacing:-0.05pt;">o</span>tions,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>interim<span style="letter-spacing:-0.25pt;"> </span>proceedings<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>dev<span style="letter-spacing:-0.1pt;">e</span>lopments,<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>if securities<span style="letter-spacing:-0.35pt;"> </span>analysts<span style="letter-spacing:-0.3pt;"> </span>or investors<span style="letter-spacing:-0.3pt;"> </span>per<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>i<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e results<span style="letter-spacing:-0.2pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>negative,<span style="letter-spacing:-0.3pt;"> </span>it<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.25pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>price<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ock.<span style="letter-spacing:-0.25pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>occurrence<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.15pt;"> </span>foregoing<span style="letter-spacing:-0.4pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>bu<span style="letter-spacing:-0.05pt;">s</span>iness,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>resul<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span>perations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obtaining<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>maintaining<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>prote<span style="letter-spacing:-0.1pt;">c</span>tion<span style="letter-spacing:-0.35pt;"> </span>depends<span style="letter-spacing:0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>compliance<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:0.05pt;"> </span>procedural,<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;">c</span>ument<span style="letter-spacing:-0.4pt;"> </span>submission,<span style="letter-spacing:-0.05pt;"> </span>fee<span style="letter-spacing:-0.05pt;"> </span>paymen<span style="letter-spacing:0.05pt;">t</span>,<span style="letter-spacing:-0.25pt;"> </span>and other requirements<span style="letter-spacing:-0.45pt;"> </span>imposed<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.15pt;"> </span>govern<span style="letter-spacing:0.05pt;">m</span>ent<span style="letter-spacing:-0.5pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>agencies,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>red<span style="letter-spacing:-0.05pt;">u</span>ced<span style="letter-spacing:-0.05pt;"> </span>or eliminated<span style="letter-spacing:-0.35pt;"> </span>for non-compliance<span style="letter-spacing:-0.65pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>se <span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">qu</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span><span style="letter-spacing:0.05pt;">t</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic<span style="letter-spacing:-0.25pt;"> </span>maintenance<span style="letter-spacing:-0.45pt;"> </span>fees,<span style="letter-spacing:-0.1pt;"> </span>renewal<span style="letter-spacing:-0.25pt;"> </span>fees,<span style="letter-spacing:-0.2pt;"> </span>annuity<span style="letter-spacing:-0.2pt;"> </span>fees,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>various<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>fees<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>pat<span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>due<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>id<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">t</span>he USPTO and<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>in several<span style="letter-spacing:-0.25pt;"> </span>stages<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>lifetime<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>patent.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>USPTO<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>various<span style="letter-spacing:-0.25pt;"> </span>fore<span style="letter-spacing:0.05pt;">i</span>gn<span style="letter-spacing:-0.2pt;"> </span>governmental<span style="letter-spacing:-0.5pt;"> </span>pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>agen<span style="letter-spacing:-0.05pt;">c</span>i<span style="letter-spacing:-0.05pt;">e</span>s require<span style="letter-spacing:-0.2pt;"> </span>compliance<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>sever<span style="letter-spacing:-0.1pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>procedural,<span style="letter-spacing:-0.4pt;"> </span>documentary,<span style="letter-spacing:-0.5pt;"> </span>fee<span style="letter-spacing:-0.1pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>similar<span style="letter-spacing:-0.25pt;"> </span>provisions<span style="letter-spacing:-0.4pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>ocess.<span style="letter-spacing:-0.05pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>certain circumstances,<span style="letter-spacing:-0.55pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>rely<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>to pay<span style="letter-spacing:-0.2pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>fees<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>take<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>ne<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ss<span style="letter-spacing:0.05pt;">a</span>ry<span style="letter-spacing:-0.2pt;"> </span>ac<span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o co<span style="letter-spacing:-0.05pt;">m</span>ply<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th <span style="letter-spacing:-0.05pt;">t</span>hese<span style="letter-spacing:-0.05pt;"> </span>requi<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts.<span style="letter-spacing:-0.45pt;"> </span>Wh<span style="letter-spacing:-0.05pt;">i</span>le<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>inadvertent<span style="letter-spacing:-0.35pt;"> </span>lapse can<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.2pt;"> </span>cases<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>cured<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>payment<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a late<span style="letter-spacing:-0.15pt;"> </span>f<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;"> </span>or by<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>me<span style="letter-spacing:-0.05pt;">a</span>ns<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>cord<span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">c</span>e<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>app<span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.3pt;"> </span>rul<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.15pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>s<span style="letter-spacing:-0.05pt;">i</span>tua<span style="letter-spacing:-0.15pt;">t</span>ions<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>which n<span style="letter-spacing:0.05pt;">o</span>ncompliance<span style="letter-spacing:-0.45pt;"> </span>can<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in ab<span style="letter-spacing:-0.05pt;">a</span>ndonment<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>lapse<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applica<span style="letter-spacing:-0.1pt;">t</span>ion,<span style="letter-spacing:-0.35pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>in partial<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>complete<span style="letter-spacing:-0.3pt;"> </span>loss<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>relevant jurisdiction.<span style="letter-spacing:-0.4pt;"> </span>Noncompliance<span style="letter-spacing:-0.5pt;"> </span>e<span style="letter-spacing:0.05pt;">v</span>ents<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.1pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in abandonment<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>lapse<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>applica<span style="letter-spacing:-0.1pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>inclu<span style="letter-spacing:0.05pt;">d</span>e,<span style="letter-spacing:-0.35pt;"> </span>but<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.2pt;"> </span>to,<span style="letter-spacing:-0.1pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to respond<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>official<span style="letter-spacing:-0.2pt;"> </span>actions<span style="letter-spacing:-0.3pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>prescribed<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.2pt;"> </span>limits,<span style="letter-spacing:-0.2pt;"> </span>non-payment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>fees<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>failure<span style="letter-spacing:-0.25pt;"> </span>to properly<span style="letter-spacing:-0.25pt;"> </span>legalize<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>submit<span style="letter-spacing:-0.25pt;"> </span>formal<span style="letter-spacing:-0.3pt;"> </span>documents.<span style="letter-spacing:-0.4pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>an event,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>might<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to e<span style="letter-spacing:0.05pt;">n</span>ter<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>market<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>similar<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>identical<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a mat<span style="letter-spacing:-0.05pt;">e</span>rial<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>dverse<span style="letter-spacing:-0.1pt;"> </span>imp<span style="letter-spacing:-0.05pt;">a</span>ct on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.35pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">United</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">States</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">law</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">diminish</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">value</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of patents</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">in general,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">i</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pairing</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ability</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">protect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>case<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">m</span>munotherapy<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>biopharmaceutical<span style="letter-spacing:-0.65pt;"> </span>companies,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>success<span style="letter-spacing:-0.05pt;"> </span>is dependent<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>intellec<span style="letter-spacing:-0.1pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>property,<span style="letter-spacing:-0.35pt;"> </span>particularly<span style="letter-spacing:-0.4pt;"> </span>patents. Obtaining<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>enforcing<span style="letter-spacing:-0.4pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>b<span style="letter-spacing:-0.05pt;">i</span>opharmaceutical<span style="letter-spacing:-0.6pt;"> </span>industry<span style="letter-spacing:-0.35pt;"> </span>invol<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.3pt;"> </span>both<span style="letter-spacing:-0.1pt;"> </span>technological<span style="letter-spacing:-0.55pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>complexity,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>is ther<span style="letter-spacing:-0.05pt;">e</span>fore<span style="letter-spacing:-0.25pt;"> </span>costly,<span style="letter-spacing:-0.25pt;"> </span>time-consuming<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>inherently<span style="letter-spacing:-0.35pt;"> </span>uncertain.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.15pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>cen<span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.25pt;"> </span>ena<span style="letter-spacing:-0.1pt;">c</span>ted<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>is currently<span style="letter-spacing:-0.3pt;"> </span>implementing<span style="letter-spacing:-0.5pt;"> </span>wide-ranging<span style="letter-spacing:-0.45pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>reform legislation.<span style="letter-spacing:-0.4pt;"> </span>Assuming<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>requir<span style="letter-spacing:-0.05pt;">e</span>m<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.4pt;"> </span>for pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">a</span>bil<span style="letter-spacing:-0.05pt;">i</span>ty<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:-0.05pt;">e</span>t,<span style="letter-spacing:-0.15pt;"> </span>prior<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>M<span style="letter-spacing:-0.05pt;">a</span>rch&#160;2013, <span style="letter-spacing:-0.05pt;">i</span>n <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">t</span>at<span style="letter-spacing:-0.05pt;">e</span>s,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first <span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>invent<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>claimed<span style="letter-spacing:-0.3pt;"> </span>invention<span style="letter-spacing:0.05pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>entitled<span style="letter-spacing:-0.2pt;"> </span>to t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>nt,<span style="letter-spacing:-0.25pt;"> </span>while<span style="letter-spacing:-0.2pt;"> </span>outside<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>Un<span style="letter-spacing:-0.05pt;">i</span>ted<span style="letter-spacing:-0.1pt;"> </span>S<span style="letter-spacing:-0.05pt;">t</span>a<span style="letter-spacing:-0.05pt;">t</span>es,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>file<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>tent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>at<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.05pt;">i</span>tl<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:-0.15pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>patent.<span style="letter-spacing:-0.25pt;"> </span>After<span style="letter-spacing:-0.2pt;"> </span>March&#160;2013, u<span style="letter-spacing:0.05pt;">n</span>der<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Leahy-Smith<span style="letter-spacing:-0.4pt;"> </span>America<span style="letter-spacing:-0.25pt;"> </span>Inv<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.2pt;"> </span>Act,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>America<span style="letter-spacing:-0.25pt;"> </span>Invents<span style="letter-spacing:-0.2pt;"> </span>Act,<span style="letter-spacing:-0.2pt;"> </span>enacted<span style="letter-spacing:-0.2pt;"> </span>in September&#160;2011,<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>transitioned<span style="letter-spacing:-0.35pt;"> </span>to a<span style="letter-spacing:-0.1pt;"> </span>first-to-file<span style="letter-spacing:-0.4pt;"> </span>system<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:0.05pt;"> </span>which,<span style="letter-spacing:-0.3pt;"> </span>assuming<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>requir<span style="letter-spacing:-0.1pt;">e</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>ntab<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>re<span style="letter-spacing:-0.05pt;"> m</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.2pt;"> </span>inventor<span style="letter-spacing:-0.25pt;"> </span>to file<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>w<span style="letter-spacing:-0.1pt;">i</span>ll<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span>it<span style="letter-spacing:-0.05pt;">l</span>ed<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>on an<span style="letter-spacing:0.05pt;"> </span>invention<span style="letter-spacing:-0.3pt;"> </span>regardless<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>whether<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>to invent<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>claimed<span style="letter-spacing:-0.35pt;"> </span>inve<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ion.<span style="letter-spacing:-0.3pt;"> </span>A<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>files<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.25pt;"> </span>application<span style="letter-spacing:-0.4pt;"> </span>in the<span style="letter-spacing:-0.15pt;"> </span>USPTO after<span style="letter-spacing:-0.1pt;"> </span>March&#160;2013,<span style="letter-spacing:0.05pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>before<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;">r</span>efore<span style="letter-spacing:-0.35pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>awarded<span style="letter-spacing:-0.25pt;"> </span>a patent<span style="letter-spacing:-0.15pt;"> </span>covering<span style="letter-spacing:-0.3pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>invention<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>ours even<span style="letter-spacing:-0.2pt;"> </span>if we<span style="letter-spacing:0.05pt;"> </span>had<span style="letter-spacing:-0.2pt;"> </span>made<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>inve<span style="letter-spacing:-0.05pt;">n</span>tion<span style="letter-spacing:-0.35pt;"> </span>before<span style="letter-spacing:-0.2pt;"> </span>it was<span style="letter-spacing:-0.05pt;"> </span>made by<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.2pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">g</span>nizant<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>invention<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>of a<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>application.<span style="letter-spacing:-0.35pt;"> </span>Since<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>appli<span style="letter-spacing:0.05pt;">ca</span><span style="letter-spacing:-0.05pt;">t</span>ions<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>most<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>a<span style="letter-spacing:0.05pt;">r</span>e<span style="letter-spacing:-0.05pt;"> </span>con<span style="letter-spacing:-0.05pt;">f</span>idential<span style="letter-spacing:-0.4pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>after<span style="letter-spacing:-0.2pt;"> </span>filing<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>until<span style="letter-spacing:-0.2pt;"> </span>issuance,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>cert<span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors were the<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>either<span style="letter-spacing:-0.2pt;"> </span>file<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>ap<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">l</span>ication<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>lated<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.1pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>invent<span style="letter-spacing:-0.2pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>c<span style="letter-spacing:-0.1pt;">l</span>aimed<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>or o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>licensor&#8217;s<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>applications.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>Ame<span style="letter-spacing:-0.05pt;">r</span>ica<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">I</span>nvents<span style="letter-spacing:-0.2pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.2pt;"> </span>includes<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>n<span style="letter-spacing:0.05pt;">u</span>mber<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>significant<span style="letter-spacing:-0.4pt;"> </span>changes<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>affect<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>way patent applications<span style="letter-spacing:-0.4pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>pro<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.05pt;">c</span>ut<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>so<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> a</span>ffect<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>litig<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">i</span>on.<span style="letter-spacing:-0.25pt;"> </span>These<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;">c</span>lude<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">l</span>lowing<span style="letter-spacing:-0.3pt;"> </span>thi<span style="letter-spacing:-0.05pt;">r</span>d-party<span style="letter-spacing:-0.45pt;"> </span>submission<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>ior<span style="letter-spacing:-0.05pt;"> </span>art<span style="letter-spacing:-0.15pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>USPTO during patent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>osecution<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>proced<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>es<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>attack<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>validity<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a p<span style="letter-spacing:-0.1pt;">a</span>tent<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>USPTO-administered<span style="letter-spacing:-0.75pt;"> </span>post<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">g</span><span style="letter-spacing:-0.05pt;">r</span>ant<span style="letter-spacing:-0.1pt;"> </span>proceedings,<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>ncluding<span style="letter-spacing:-0.4pt;"> </span>post-grant review,<span style="letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">int</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span><span style="font-style:italic;">r</span><span style="font-style:italic;letter-spacing:-0.2pt;"> </span><span style="font-style:italic;">pa</span><span style="font-style:italic;letter-spacing:0.05pt;">r</span><span style="font-style:italic;">t</span><span style="font-style:italic;letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.05pt;"> </span>review,<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>derivation<span style="letter-spacing:-0.3pt;"> </span>proceedings.<span style="letter-spacing:-0.5pt;"> </span>There<span style="letter-spacing:0.05pt;">f</span>ore,<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>America<span style="letter-spacing:-0.35pt;"> </span>Invents<span style="letter-spacing:-0.3pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>imp<span style="letter-spacing:-0.05pt;">l</span>ementation<span style="letter-spacing:-0.5pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>uncertainties<span style="letter-spacing:-0.4pt;"> </span>and costs<span style="letter-spacing:0.05pt;"> </span>surrounding<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>prosecution<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.4pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>appli<span style="letter-spacing:0.05pt;">c</span>ations<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>enforcement<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>defense<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>issued patents,<span style="letter-spacing:-0.35pt;"> </span>all<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.1pt;">c</span>ould<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.4pt;"> </span>res<span style="letter-spacing:0.1pt;">u</span>lts<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>prosp<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span>ts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally,<span style="letter-spacing:-0.45pt;"> </span>recent<span style="letter-spacing:-0.15pt;"> </span>U<span style="letter-spacing:-0.05pt;">.</span>S.<span style="letter-spacing:0.05pt;"> </span>Supreme<span style="letter-spacing:-0.25pt;"> </span>Court<span style="letter-spacing:-0.15pt;"> </span>rulings<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>narr<span style="letter-spacing:-0.1pt;">o</span>wed<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>scope<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>pro<span style="letter-spacing:-0.05pt;">t</span>ec<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>ava<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>cer<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">a</span>in<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.05pt;">i</span>rcu<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.05pt;">t</span>anc<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>weak<span style="letter-spacing:-0.05pt;">e</span>ned<span style="letter-spacing:-0.3pt;"> </span>the rights<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>owners<span style="letter-spacing:0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cer<span style="letter-spacing:0.1pt;">t</span>ain<span style="letter-spacing:-0.2pt;"> </span>situations.<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">I</span>n<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>creasing<span style="letter-spacing:-0.35pt;"> </span>uncertainty<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>regard<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to obtain<span style="letter-spacing:-0.25pt;"> </span>pate<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>futur<span style="letter-spacing:0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>this comb<span style="letter-spacing:-0.05pt;">i</span>nat<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>of even<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>cre<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>unc<span style="letter-spacing:-0.05pt;">e</span>rt<span style="letter-spacing:-0.05pt;">a</span>inty<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>respe<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.05pt;"> t</span>o the<span style="letter-spacing:-0.15pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>once<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:0.05pt;">t</span>ained. Depending<span style="letter-spacing:-0.45pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>decisio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Congress,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>federal courts,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO,<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>regulations<span style="letter-spacing:-0.35pt;"> </span>governing<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>change<span style="letter-spacing:-0.25pt;"> </span>in unpredictable<span style="letter-spacing:-0.5pt;"> </span>ways<span style="letter-spacing:-0.05pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>weaken<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>abi<span style="letter-spacing:0.05pt;">l</span>ity<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>new patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>enforce<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>exist<span style="letter-spacing:0.15pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">i</span>ght<span style="letter-spacing:-0.15pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>fut<span style="letter-spacing:-0.05pt;">u</span>re.<span style="letter-spacing:-0.25pt;"> </span>While<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>believe<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>ow<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>d or licensed<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>found<span style="letter-spacing:-0.05pt;"> </span>invalid<span style="letter-spacing:-0.25pt;"> </span>based<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.2pt;"> </span>predict<span style="letter-spacing:-0.2pt;"> </span>how<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>decisions<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>Congress,<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>federal<span style="letter-spacing:-0.25pt;"> </span>c<span style="letter-spacing:-0.1pt;">o</span>urts<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>USPTO<span style="letter-spacing:-0.05pt;"> </span>may impact<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>comme<span style="letter-spacing:0.05pt;">r</span>cialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>cand<span style="letter-spacing:-0.05pt;">i</span>dates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>b<span style="letter-spacing:-0.05pt;">j</span>ec<span style="letter-spacing:-0.05pt;">t</span>,<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>part,<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">m</span>s<span style="letter-spacing:-0.15pt;"> </span>and condit<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:-0.1pt;">o</span>ns<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>es granted<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>others.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>rely<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>to cer<span style="letter-spacing:-0.15pt;">t</span>ain<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.45pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>important<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.35pt;"> </span>to the<span style="letter-spacing:-0.15pt;"> </span>developme<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:-0.4pt;"> </span>of aldoxorubicin<span style="letter-spacing:-0.5pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>enabled<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>yeast,<span style="letter-spacing:-0.15pt;"> </span>inclu<span style="letter-spacing:0.05pt;">d</span>ing<span style="letter-spacing:-0.3pt;"> T</span>armogen,<span style="letter-spacing:-0.45pt;"> </span>technologies.<span style="letter-spacing:-0.55pt;"> </span>For<span style="letter-spacing:-0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>July&#160;2017,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>entered<span style="letter-spacing:-0.25pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.2pt;">a</span>n<span style="letter-spacing:-0.05pt;"> </span>exc<span style="letter-spacing:-0.05pt;">l</span>us<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.3pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense agreement<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>CytRx<span style="letter-spacing:-0.2pt;"> </span>Corporation,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>CytRx,<span style="letter-spacing:-0.3pt;"> </span>pursuant<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> we</span><span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>c<span style="letter-spacing:0.05pt;">e</span>ived<span style="letter-spacing:-0.25pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>ex<span style="letter-spacing:0.05pt;">c</span>lusive<span style="letter-spacing:-0.3pt;"> </span>li<span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:0.05pt;">e</span>rtain<span style="letter-spacing:-0.25pt;"> </span>of CytRx&#8217;s<span style="letter-spacing:-0.25pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">u</span>al<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to aldoxorubicin.<span style="letter-spacing:-0.45pt;"> I</span>n January&#160;2020<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>e<span style="letter-spacing:-0.1pt;">n</span>tered<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>exclusive<span style="letter-spacing:-0.3pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>agreement<span style="letter-spacing:-0.3pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th GlobeImmune,<span style="letter-spacing:-0.55pt;"> </span>Inc.,<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>GlobeImmune,<span style="letter-spacing:-0.55pt;"> </span>pursuant<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.2pt;"> </span>we obtained<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>n <span style="letter-spacing:-0.05pt;">e</span>xc<span style="letter-spacing:-0.05pt;">l</span>us<span style="letter-spacing:-0.05pt;">i</span>ve<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>GlobeImmune&#8217;s<span style="letter-spacing:-0.55pt;"> </span>intel<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.4pt;"> </span>prop<span style="letter-spacing:-0.05pt;">e</span>rty<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">a</span>ting<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;">i</span>r<span style="letter-spacing:-0.1pt;"> T</span>armogen<span style="letter-spacing:-0.3pt;"> </span>platform<span style="letter-spacing:-0.25pt;"> </span>to c<span style="letter-spacing:0.05pt;">o</span>mplem<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.45pt;"> </span>yeast technology.<span style="letter-spacing:-0.4pt;"> I</span>n<span style="letter-spacing:-0.1pt;"> </span>August&#160;2020,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>entered<span style="letter-spacing:-0.2pt;"> </span>into<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agreement<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>ios<span style="letter-spacing:-0.05pt;">B</span>io<span style="letter-spacing:-0.2pt;"> </span>Ltd.,<span style="letter-spacing:-0.1pt;"> </span>formerly<span style="letter-spacing:-0.25pt;"> </span>named<span style="letter-spacing:-0.3pt;"> </span>Stabilitech<span style="letter-spacing:-0.4pt;"> </span>Bi<span style="letter-spacing:0.05pt;">o</span>pharma<span style="letter-spacing:-0.4pt;"> </span>Ltd.,<span style="letter-spacing:-0.15pt;"> </span>or iosBio,<span style="letter-spacing:-0.3pt;"> </span>pursuant<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>iosBio<span style="letter-spacing:-0.2pt;"> </span>granted<span style="letter-spacing:-0.25pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>exclusive<span style="letter-spacing:-0.3pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>rt<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.15pt;"> </span>of iosBio&#8217;s<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nt<span style="letter-spacing:-0.1pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>SARS-CoV-2 and successor<span style="letter-spacing:0.05pt;"> </span>vaccine<span style="letter-spacing:-0.25pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>(and,<span style="letter-spacing:-0.2pt;"> </span>in connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>license,<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>granted<span style="letter-spacing:-0.25pt;"> </span>iosBio<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>non-exclusive<span style="letter-spacing:-0.5pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to its<span style="letter-spacing:-0.05pt;"> </span>adenovirus<span style="letter-spacing:-0.35pt;"> </span>constructs<span style="letter-spacing:-0.4pt;"> </span>for the<span style="letter-spacing:-0.1pt;"> </span>prevention<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>treatment<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">h</span>ingles<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>infec<span style="letter-spacing:-0.1pt;">t</span>ious<span style="letter-spacing:-0.3pt;"> </span>disease<span style="letter-spacing:-0.3pt;"> </span>ta<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">g</span>ets<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.05pt;"> </span>mutua<span style="letter-spacing:-0.15pt;">l</span>ly<span style="letter-spacing:-0.25pt;"> </span>agreed<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>in good<span style="letter-spacing:-0.05pt;"> </span>fai<span style="letter-spacing:-0.05pt;">t</span>h).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License<span style="letter-spacing:-0.3pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>prov<span style="letter-spacing:-0.1pt;">i</span>de<span style="letter-spacing:-0.2pt;"> </span>exclusive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span>ights<span style="letter-spacing:-0.15pt;"> </span>to use<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>tellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>in all<span style="letter-spacing:-0.1pt;"> </span>releva<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.25pt;"> </span>fiel<span style="letter-spacing:0.05pt;">d</span>s<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>in all territories<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>wish<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>dev<span style="letter-spacing:0.15pt;">e</span>lop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>commercialize<span style="letter-spacing:-0.5pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>produ<span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> f</span>uture.<span style="letter-spacing:-0.1pt;"> </span>As<span style="letter-spacing:0.05pt;"> </span>a result,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to prevent<span style="letter-spacing:-0.2pt;"> </span>competitors<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>developi<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commercializing<span style="letter-spacing:-0.55pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">l</span>so utilizes<span style="letter-spacing:-0.25pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have in-l<span style="letter-spacing:-0.05pt;">i</span>cens<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">u</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ch</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">do</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ot have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preparation,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filing,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecution</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintenance, and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforcement,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defense</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appli</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ations</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">covering</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technology</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we l</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cense</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from third</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties.</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cer</span><span style="letter-spacing:0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ain</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in-licensed</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out</span><span style="letter-spacing:-0.05pt;">-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">controlled</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensors</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensees will</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prepa</span><span style="letter-spacing:-0.05pt;">r</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">filed,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecuted,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">maintained,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">enforced,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="letter-spacing:0.05pt;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defended</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a manner</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">con</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">istent</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">best</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">interests</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:0.1pt;">b</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">usiness.</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensors</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or li</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ns</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">il</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pros</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ut</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">int</span><span style="letter-spacing:0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in,</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nforce,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lose</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rig</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">those</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">application</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduced</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminated,</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercialize</span><span style="letter-spacing:-0.55pt;"> </span><span style="letter-spacing:-0.05pt;">A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nktiva</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our product</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subject</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rights could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">affec</span><span style="letter-spacing:0.1pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to prevent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competitors</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">making,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">using</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lling</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">competing</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products.</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">I</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">even</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">where we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">right</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecution</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we have</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensed</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">third</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">still</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adversely affected</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prejudiced</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">actions</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inact</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ns</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensees,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licensors</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">counsel</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">took</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">place</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prior</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">date</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assumed control</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">over</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prosecution.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore,<span style="letter-spacing:-0.45pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>in-li<span style="letter-spacing:0.05pt;">c</span>ensed<span style="letter-spacing:-0.35pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">j</span>ect<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>a reservation<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>one<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our in-licensed<span style="letter-spacing:-0.4pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>was<span style="letter-spacing:-0.05pt;"> </span>funded<span style="letter-spacing:-0.3pt;"> </span>in part<span style="letter-spacing:-0.2pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>U.S.&#160;government.<span style="letter-spacing:-0.5pt;"> </span>As a<span style="letter-spacing:-0.05pt;"> </span>res<span style="letter-spacing:0.05pt;">u</span>lt,<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:0.05pt;">&#160;</span>government<span style="letter-spacing:-0.4pt;"> </span>m<span style="letter-spacing:-0.1pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">rig</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">s</span>u<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>t<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">l</span>l<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>tu<span style="letter-spacing:-0.05pt;">al </span>property.<span style="letter-spacing:-0.3pt;"> </span>When<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>oped<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;"> </span>government<span style="letter-spacing:-0.5pt;"> </span><span style="letter-spacing:0.05pt;">f</span>unding,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>gover<span style="letter-spacing:0.1pt;">n</span>ment<span style="letter-spacing:-0.5pt;"> </span>generally<span style="letter-spacing:-0.3pt;"> </span>obtains<span style="letter-spacing:-0.3pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>resulting patents,<span style="letter-spacing:-0.3pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>a non-exclusive<span style="letter-spacing:-0.45pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>au<span style="letter-spacing:-0.05pt;">t</span>horizing<span style="letter-spacing:-0.45pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>gover<span style="letter-spacing:0.05pt;">n</span>ment<span style="letter-spacing:-0.5pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>invention<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>others<span style="letter-spacing:-0.2pt;"> </span>use the<span style="letter-spacing:-0.1pt;"> </span>invention<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>behalf.<span style="letter-spacing:-0.2pt;"> </span>The U.S.<span style="letter-spacing:0.05pt;">&#160;</span>government&#8217;s<span style="letter-spacing:-0.5pt;"> </span>righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>permit<span style="letter-spacing:-0.25pt;"> </span>it to<span style="letter-spacing:-0.05pt;"> </span>disclose<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>funded<span style="letter-spacing:-0.2pt;"> </span>inventions<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>to third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>to exercise<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.1pt;">m</span>arch-in<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use<span style="letter-spacing:-0.05pt;"> </span>or allow<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>to use<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>licensed<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span>was<span style="letter-spacing:0.05pt;"> </span>developed<span style="letter-spacing:-0.3pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>U.S.&#160;government<span style="letter-spacing:-0.4pt;"> </span>funding.<span style="letter-spacing:-0.35pt;"> </span>The<span style="letter-spacing:-0.2pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>government<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>ex<span style="letter-spacing:-0.05pt;">e</span>rcise<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:-0.05pt;">t</span>s march-in<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>if it determines<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>action<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>we fail<span style="letter-spacing:-0.1pt;"> </span>to achieve<span style="letter-spacing:-0.25pt;"> </span>practical<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>pplication<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>government-funded<span style="letter-spacing:-0.65pt;"> </span>technology,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>because ac<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.2pt;"> </span>is ne<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>ssary<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">a</span>ll<span style="letter-spacing:-0.05pt;">e</span>vi<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.3pt;"> </span>he<span style="letter-spacing:-0.05pt;">a</span>lth<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>saf<span style="letter-spacing:-0.05pt;">e</span>ty<span style="letter-spacing:-0.2pt;"> </span>ne<span style="letter-spacing:-0.05pt;">e</span>ds,<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o m<span style="letter-spacing:-0.2pt;">e</span>et<span style="letter-spacing:-0.15pt;"> </span>requirements<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>fed<span style="letter-spacing:-0.05pt;">e</span>ral<span style="letter-spacing:-0.2pt;"> </span>regulations,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>give<span style="letter-spacing:-0.1pt;"> </span>preference<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>U.S.&#160;industry.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>our rights<span style="letter-spacing:-0.15pt;"> </span>in such<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>requirements<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>manufact<span style="letter-spacing:0.05pt;">u</span>re<span style="letter-spacing:-0.4pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>embodying<span style="letter-spacing:-0.4pt;"> </span>s<span style="letter-spacing:0.05pt;">u</span>ch<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Unit<span style="letter-spacing:-0.1pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>Stat<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>in c<span style="letter-spacing:0.05pt;">e</span>rt<span style="letter-spacing:0.05pt;">a</span>in circumstances<span style="letter-spacing:-0.45pt;"> </span>if this<span style="letter-spacing:-0.1pt;"> </span>requir<span style="letter-spacing:-0.05pt;">e</span>ment<span style="letter-spacing:-0.5pt;"> </span>is not<span style="letter-spacing:-0.05pt;"> </span>waived.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>exercise<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>U.S.<span style="letter-spacing:-0.05pt;">&#160;</span>government<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>its<span style="letter-spacing:-0.05pt;"> </span>reserved<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>could have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.15pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>positi<span style="letter-spacing:0.05pt;">o</span>n,<span style="letter-spacing:-0.3pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>cond<span style="letter-spacing:-0.1pt;">i</span>tion,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prosp<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">s</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>fail<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>obl<span style="letter-spacing:-0.05pt;">i</span>gations<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>n t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>em<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>u<span style="letter-spacing:-0.05pt;">n</span>der<span style="letter-spacing:-0.05pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>r<span style="letter-spacing:-0.05pt;">i</span>ghts<span style="letter-spacing:-0.1pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.25pt;"> </span>or otherwise experience<span style="letter-spacing:-0.4pt;"> </span>disruptions<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>lat<span style="letter-spacing:-0.05pt;">i</span>o<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:0.05pt;">h</span>ips<span style="letter-spacing:-0.2pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r lic<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:0.05pt;">s</span>ors,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">l</span>d lo<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>at<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>important<span style="letter-spacing:-0.3pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">u</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">s</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>en<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span>o<span style="letter-spacing:-0.05pt;"> l</span>ic<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>gre<span style="letter-spacing:-0.05pt;">e</span>men<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>need<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>lice<span style="letter-spacing:0.05pt;">n</span>ses<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>others<span style="letter-spacing:-0.25pt;"> </span>to advance<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>research<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>allow commercialization<span style="letter-spacing:-0.65pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:0.05pt;">a</span>ndidates.<span style="letter-spacing:-0.35pt;"> </span>It<span style="letter-spacing:-0.1pt;"> </span>is possible<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:0.05pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>licen<span style="letter-spacing:0.05pt;">s</span>es<span style="letter-spacing:-0.15pt;"> </span>at a reasonable<span style="letter-spacing:-0.45pt;"> </span>cost<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>reasonable terms,<span style="letter-spacing:-0.15pt;"> </span>if at all.<span style="letter-spacing:-0.1pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>event,<span style="letter-spacing:-0.2pt;"> </span>we may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> r</span><span style="letter-spacing:0.05pt;">e</span>quired<span style="letter-spacing:-0.2pt;"> </span>to expend<span style="letter-spacing:-0.2pt;"> </span>sign<span style="letter-spacing:-0.1pt;">i</span>ficant<span style="letter-spacing:-0.4pt;"> </span>time<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>resources<span style="letter-spacing:-0.4pt;"> </span>to redesign<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>candidates,<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the methods<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>manufacturing<span style="letter-spacing:-0.45pt;"> </span>them<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>deve<span style="letter-spacing:0.05pt;">l</span>op<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>replace<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.45pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>feasible<span style="letter-spacing:-0.4pt;"> </span>on a<span style="letter-spacing:-0.05pt;"> </span>technical<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>commercial<span style="letter-spacing:-0.4pt;"> </span>basis. If<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>so,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>com<span style="letter-spacing:0.05pt;">m</span>ercialize<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>cted<span style="letter-spacing:-0.25pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>continue<span style="letter-spacing:-0.35pt;"> </span>to utilize<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>existing<span style="letter-spacing:-0.25pt;"> </span>technology, which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>harm<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business, financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.35pt;"> </span>significan<span style="letter-spacing:-0.05pt;">t</span>ly.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>provide<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>assurances<span style="letter-spacing:-0.35pt;"> </span>that third-party<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">a</span>tents<span style="letter-spacing:-0.15pt;"> </span>do<span style="letter-spacing:-0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>exist<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>might<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>enforced<span style="letter-spacing:-0.3pt;"> </span>aga<span style="letter-spacing:0.05pt;">i</span>nst<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>manufacturing<span style="letter-spacing:-0.5pt;"> </span>methods,<span style="letter-spacing:-0.3pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span>duct<span style="letter-spacing:-0.2pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span>tes,<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>methods or<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.35pt;"> </span>resulting<span style="letter-spacing:-0.35pt;"> </span>in either<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>injunct<span style="letter-spacing:-0.05pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>prohibiting<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>man<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">f</span>acture<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>fut<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>sales,<span style="letter-spacing:-0.25pt;"> </span>or,<span style="letter-spacing:-0.05pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>respect<span style="letter-spacing:-0.25pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>sale<span style="letter-spacing:-0.05pt;">s</span>,<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>obligation<span style="letter-spacing:-0.35pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>part<span style="letter-spacing:-0.1pt;"> </span>to pay<span style="letter-spacing:-0.1pt;"> </span>royalties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>forms<span style="letter-spacing:0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>to third<span style="letter-spacing:-0.1pt;"> </span>parti<span style="letter-spacing:-0.1pt;">e</span>s,<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>significant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>each<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>agreements,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>agreements,<span style="letter-spacing:-0.45pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>im<span style="letter-spacing:0.05pt;">p</span>ose<span style="letter-spacing:-0.1pt;"> </span>various<span style="letter-spacing:-0.3pt;"> </span>development,<span style="letter-spacing:-0.45pt;"> </span>diligence,<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.1pt;">c</span>ommercialization,<span style="letter-spacing:-0.65pt;"> </span>and other<span style="letter-spacing:-0.25pt;"> </span>obligatio<span style="letter-spacing:0.05pt;">n</span>s<span style="letter-spacing:-0.4pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>us.<span style="letter-spacing:-0.05pt;"> </span>Certain<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.1pt;">e</span>quire<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>meet<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.45pt;"> </span>ti<span style="letter-spacing:-0.1pt;">m</span>el<span style="letter-spacing:-0.05pt;">i</span>nes,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">e</span>xerc<span style="letter-spacing:-0.05pt;">i</span>se<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omm<span style="letter-spacing:-0.05pt;">er</span>cially<span style="letter-spacing:-0.35pt;"> </span>reasonable efforts to develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>commercialize<span style="letter-spacing:-0.55pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.1pt;">s</span>,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>maintain<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>licenses.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>spite<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>f<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>efforts,<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>mig<span style="letter-spacing:0.05pt;">h</span>t<span style="letter-spacing:-0.2pt;"> </span>conclude<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have ma<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.05pt;">l</span>y<span style="letter-spacing:-0.25pt;"> </span>bre<span style="letter-spacing:-0.05pt;">a</span>ch<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>our oblig<span style="letter-spacing:-0.05pt;">a</span>tions<span style="letter-spacing:-0.45pt;"> </span>und<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span>ag<span style="letter-spacing:-0.05pt;">r</span>ee<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>might<span style="letter-spacing:-0.2pt;"> </span>ther<span style="letter-spacing:0.05pt;">e</span>fore<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:0.05pt;">a</span>te<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>lic<span style="letter-spacing:0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>gr<span style="letter-spacing:0.05pt;">e</span>ements,<span style="letter-spacing:-0.35pt;"> </span>th<span style="letter-spacing:0.05pt;">e</span>reby<span style="letter-spacing:-0.15pt;"> </span>removing or limiting our ability to develop<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>com<span style="letter-spacing:-0.1pt;">m</span>ercialize<span style="letter-spacing:-0.5pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>chnology<span style="letter-spacing:-0.35pt;"> </span>covered<span style="letter-spacing:-0.3pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>ements.<span style="letter-spacing:-0.45pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>in-licenses<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rmin<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>d,<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>the u<span style="letter-spacing:0.05pt;">n</span>derlying<span style="letter-spacing:-0.25pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>to provide<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.2pt;">e</span>nded<span style="letter-spacing:-0.35pt;"> </span>exclusivity,<span style="letter-spacing:-0.35pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.25pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>freedom<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>seek<span style="letter-spacing:-0.15pt;"> </span>regulatory<span style="letter-spacing:-0.35pt;"> </span>approval<span style="letter-spacing:-0.3pt;"> </span>of, and to market,<span style="letter-spacing:-0.25pt;"> </span>products<span style="letter-spacing:-0.3pt;"> </span>identical<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>ours and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>cease<span style="letter-spacing:-0.2pt;"> </span>our development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commerciali<span style="letter-spacing:-0.05pt;">z</span>ation<span style="letter-spacing:-0.6pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>of Anktiva.<span style="letter-spacing:-0.25pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>adver<span style="letter-spacing:-0.1pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>comp<span style="letter-spacing:0.05pt;">e</span>titive<span style="letter-spacing:-0.4pt;"> </span>position,<span style="letter-spacing:-0.3pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>conditions,<span style="letter-spacing:-0.4pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover,<span style="letter-spacing:-0.35pt;"> </span>disputes<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>arise<span style="letter-spacing:-0.15pt;"> </span>regar<span style="letter-spacing:-0.05pt;">d</span>ing<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>a licensing<span style="letter-spacing:-0.25pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>ement,<span style="letter-spacing:-0.35pt;"> </span>including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">scope</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">granted</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">un</span><span style="letter-spacing:0.05pt;color:#000000;">d</span><span style="color:#000000;">er the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;">g</span><span style="color:#000000;">r</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">em</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nt</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">o</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">her</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">int</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">rpre</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">on-re</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.65pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="color:#000000;">sues&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">extent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to which</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:0.05pt;color:#000000;">r</span><span style="color:#000000;">ocesses</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">infringe</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">on</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">licensor</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">is not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">subject</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">censing agr</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">em</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">nt&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">sublicensing</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborative</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">relationships&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">obligations</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">under</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">agreement</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">what</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">activ</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ties</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">satisfy</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">those</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">diligence</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">obligations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inventorship</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">ownership</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">inventions</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">know-how</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">resulting</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">joint</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">eati</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">n</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or use of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellect</span><span style="letter-spacing:0.05pt;color:#000000;">u</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">by our licensors</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">us</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:0.05pt;color:#000000;">a</span><span style="color:#000000;">nd</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">tners&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">priority</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">invent</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">on</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patented</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technology.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>agreements<span style="letter-spacing:-0.35pt;"> </span>und<span style="letter-spacing:-0.15pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>curre<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span>ly<span style="letter-spacing:-0.35pt;"> </span>license<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>technology<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>complex,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>certain<span style="letter-spacing:-0.3pt;"> </span>provisions in such agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>susc<span style="letter-spacing:-0.05pt;">e</span>ptib<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.15pt;"> </span>to <span style="letter-spacing:-0.05pt;">m</span>ult<span style="letter-spacing:-0.05pt;">i</span>ple<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rpr<span style="letter-spacing:-0.05pt;">e</span>ta<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:-0.1pt;">i</span>ons.<span style="letter-spacing:-0.45pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>resolution<span style="letter-spacing:-0.3pt;"> </span>of any<span style="letter-spacing:-0.15pt;"> </span>contract<span style="letter-spacing:-0.35pt;"> </span>interpretation<span style="letter-spacing:-0.5pt;"> </span>disagreement<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>arise<span style="letter-spacing:-0.2pt;"> </span>could narrow what<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>believe<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>scope<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>relevant<span style="letter-spacing:-0.25pt;"> </span>i<span style="letter-spacing:-0.05pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technology,<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>increase<span style="letter-spacing:-0.35pt;"> </span>what<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">b</span>elieve<span style="letter-spacing:-0.15pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>financial or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.1pt;">h</span>e<span style="letter-spacing:-0.05pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>agreement,<span style="letter-spacing:-0.35pt;"> </span>either<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.3pt;"> </span>eff<span style="letter-spacing:-0.05pt;">e</span>ct<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects.<span style="letter-spacing:-0.35pt;"> </span>Moreover,<span style="letter-spacing:-0.45pt;"> </span>if disputes<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.1pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>censed<span style="letter-spacing:-0.25pt;"> </span>prevent<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>impair<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> a</span>b<span style="letter-spacing:-0.05pt;">i</span>li<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>int<span style="letter-spacing:-0.05pt;">a</span>in<span style="letter-spacing:-0.3pt;"> </span>our current<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>ic<span style="letter-spacing:-0.05pt;">e</span>ns<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>arrangements<span style="letter-spacing:-0.5pt;"> </span>on com<span style="letter-spacing:-0.05pt;">m</span>erc<span style="letter-spacing:-0.05pt;">i</span>a<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">c</span><span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>pt<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">e</span>rms,<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to successfully<span style="letter-spacing:-0.4pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>commerci<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.05pt;">z</span>e<span style="letter-spacing:-0.55pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>odu<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndida<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>s,<span style="letter-spacing:-0.35pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span>ch<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adve<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busi<span style="letter-spacing:-0.05pt;">n</span>ess,<span style="letter-spacing:-0.25pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>conditions,<span style="letter-spacing:-0.4pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have<span style="letter-spacing:-0.15pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>mi<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;">e</span>ign<span style="letter-spacing:-0.05pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>proper<span style="letter-spacing:-0.05pt;">t</span>y rights<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.3pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.05pt;"> </span>rights t<span style="letter-spacing:0.05pt;">h</span>roug<span style="letter-spacing:0.05pt;">h</span>out<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>world.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>int<span style="letter-spacing:-0.1pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.25pt;"> </span>States.<span style="letter-spacing:-0.25pt;"> </span>Filing,<span style="letter-spacing:-0.25pt;"> </span>prosecuting<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>def<span style="letter-spacing:-0.05pt;">e</span>nding<span style="letter-spacing:-0.3pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates<span style="letter-spacing:-0.35pt;"> </span>in all<span style="letter-spacing:-0.15pt;"> </span>countries throughout<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>world<span style="letter-spacing:0.05pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>prohibitively<span style="letter-spacing:-0.4pt;"> </span>expensive,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>in some<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>outside<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">S</span>t<span style="letter-spacing:-0.05pt;">a</span>tes<span style="letter-spacing:-0.15pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ss extensive<span style="letter-spacing:-0.35pt;"> </span>than<span style="letter-spacing:-0.15pt;"> </span>those<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Uni<span style="letter-spacing:0.05pt;">t</span>ed<span style="letter-spacing:-0.2pt;"> </span>States.<span style="letter-spacing:-0.25pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.35pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>llectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">a</span>me<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>xt<span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">a</span>s feder<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">t</span>ate<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>ws<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>St<span style="letter-spacing:-0.05pt;">a</span>te<span style="letter-spacing:-0.1pt;">s</span>.<span style="letter-spacing:-0.2pt;"> </span>Consequently,<span style="letter-spacing:-0.45pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to p<span style="letter-spacing:0.05pt;">r</span>event<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span>acticing<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>inv<span style="letter-spacing:0.05pt;">e</span>ntions<span style="letter-spacing:-0.35pt;"> </span>in all<span style="letter-spacing:-0.15pt;"> </span>countries o<span style="letter-spacing:0.05pt;">u</span>tside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>selling<span style="letter-spacing:-0.2pt;"> </span>or importing<span style="letter-spacing:-0.3pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>made<span style="letter-spacing:-0.25pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>inventions<span style="letter-spacing:-0.35pt;"> </span>in and<span style="letter-spacing:-0.1pt;"> </span>into<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>United<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.25pt;"> </span>or other jurisdictions. Competitors may<span style="letter-spacing:-0.2pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>technologies<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>jurisdictions<span style="letter-spacing:-0.45pt;"> </span>where<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>obtained<span style="letter-spacing:-0.3pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>products<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>further,<span style="letter-spacing:-0.3pt;"> may export </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>in<span style="letter-spacing:-0.05pt;">f</span>ringing<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>to territories<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>ere<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protection,<span style="letter-spacing:-0.4pt;"> </span>but<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>strong<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>that<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">i</span>n<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>Unit<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.05pt;"> </span>Stat<span style="letter-spacing:0.05pt;">e</span>s.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:0.05pt;">s</span>e prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candid<span style="letter-spacing:0.05pt;">a</span>tes<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>effective<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>suff<span style="letter-spacing:-0.05pt;">i</span>ci<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>to pr<span style="letter-spacing:-0.05pt;">e</span>vent<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span>m from<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">e</span>ting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>companies<span style="letter-spacing:-0.35pt;"> </span>ha<span style="letter-spacing:0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>encountered<span style="letter-spacing:-0.5pt;"> </span>significant<span style="letter-spacing:-0.3pt;"> </span>problems<span style="letter-spacing:-0.3pt;"> </span>in protecting<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>defending<span style="letter-spacing:-0.3pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>in foreign<span style="letter-spacing:-0.3pt;"> </span>juris<span style="letter-spacing:-0.05pt;">d</span>ictions.<span style="letter-spacing:-0.5pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.2pt;"> </span>systems<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>particularly<span style="letter-spacing:-0.35pt;"> </span>certain<span style="letter-spacing:-0.25pt;"> </span>developing<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ount<span style="letter-spacing:-0.05pt;">r</span>ies,<span style="letter-spacing:-0.3pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>favor<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>enforcement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.05pt;"> </span>protection,<span style="letter-spacing:-0.4pt;"> </span>parti<span style="letter-spacing:0.1pt;">c</span>ularly<span style="letter-spacing:-0.4pt;"> </span>those<span style="letter-spacing:-0.25pt;"> </span>relating<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>biopharma<span style="letter-spacing:-0.05pt;">c</span>eutical<span style="letter-spacing:-0.65pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>o<span style="letter-spacing:0.05pt;">d</span>ucts,<span style="letter-spacing:-0.15pt;"> </span>whi<span style="letter-spacing:-0.05pt;">c</span>h<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>make<span style="letter-spacing:-0.2pt;"> </span>it<span style="letter-spacing:-0.05pt;"> </span>diffic<span style="letter-spacing:-0.05pt;">u</span>lt<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>stop<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>infringement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>competing<span style="letter-spacing:-0.35pt;"> </span>products<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>vio<span style="letter-spacing:-0.05pt;">l</span>ation<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.1pt;"> </span>generally.<span style="letter-spacing:-0.35pt;"> </span>Proceedings<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>enforce<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">i</span>n foreign<span style="letter-spacing:-0.2pt;"> </span>jurisdictions could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>divert<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>attention<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>aspects<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>put<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.15pt;"> </span>at<span style="letter-spacing:-0.1pt;"> </span>risk<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>being<span style="letter-spacing:-0.25pt;"> </span>invalidated or<span style="letter-spacing:0.05pt;"> </span>interpreted<span style="letter-spacing:-0.4pt;"> </span>narrowly<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>appli<span style="letter-spacing:-0.15pt;">c</span>ations<span style="letter-spacing:-0.5pt;"> </span>at risk<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>issuing<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>provoke<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>to assert<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>ag<span style="letter-spacing:-0.1pt;">a</span>inst<span style="letter-spacing:-0.3pt;"> </span>us.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>prevail in <span style="letter-spacing:-0.05pt;">a</span>ny <span style="letter-spacing:-0.05pt;">l</span><span style="letter-spacing:0.05pt;">a</span>wsu<span style="letter-spacing:-0.05pt;">i</span>ts<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.1pt;"> </span>we <span style="letter-spacing:-0.05pt;">i</span>nit<span style="letter-spacing:-0.05pt;">i</span>at<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>damages<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>medies<span style="letter-spacing:-0.3pt;"> </span>awa<span style="letter-spacing:-0.05pt;">r</span>ded,<span style="letter-spacing:-0.4pt;"> </span>if any,<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">o</span>m<span style="letter-spacing:-0.05pt;">m</span>er<span style="letter-spacing:-0.05pt;">c</span>ia<span style="letter-spacing:-0.05pt;">l</span>ly<span style="letter-spacing:-0.5pt;"> </span>me<span style="letter-spacing:-0.05pt;">a</span>ningful.<span style="letter-spacing:-0.4pt;"> </span>A<span style="letter-spacing:-0.05pt;">c</span>cordingly,<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>e<span style="letter-spacing:-0.05pt;">f</span>forts to enforce<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>around<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>world<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>inadequate<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>a significant<span style="letter-spacing:-0.35pt;"> </span>commercial<span style="letter-spacing:-0.45pt;"> </span>advantage<span style="letter-spacing:-0.3pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>develop<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many<span style="letter-spacing:0.05pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>compulsory<span style="letter-spacing:-0.4pt;"> </span>licensing<span style="letter-spacing:-0.25pt;"> </span>laws<span style="letter-spacing:-0.05pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>owner<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>compelled<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.05pt;"> </span>licenses<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>parties.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">I</span>n<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>many countries<span style="letter-spacing:-0.3pt;"> </span>limit<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>enforceabili<span style="letter-spacing:-0.15pt;">t</span>y<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>government<span style="letter-spacing:-0.45pt;"> </span>agencies<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>gov<span style="letter-spacing:0.05pt;">e</span>rnment<span style="letter-spacing:-0.45pt;"> </span>contractors.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>countries,<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>owner<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have li<span style="letter-spacing:-0.05pt;">m</span>it<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:0.05pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>med<span style="letter-spacing:-0.05pt;">i</span>es,<span style="letter-spacing:-0.25pt;"> </span>wh<span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>diminish<span style="letter-spacing:-0.35pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>value<span style="letter-spacing:-0.25pt;"> </span>of such<span style="letter-spacing:-0.05pt;"> </span>patent.<span style="letter-spacing:-0.2pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>forced<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>c<span style="letter-spacing:-0.05pt;">e</span>nse<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.05pt;"> </span>pa<span style="letter-spacing:-0.05pt;">r</span>ti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th respect<span style="letter-spacing:-0.2pt;"> </span>to any<span style="letter-spacing:-0.1pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>relevant<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>competi<span style="letter-spacing:-0.1pt;">t</span>ive<span style="letter-spacing:-0.4pt;"> </span>position<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>impaired,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>conditi<span style="letter-spacing:-0.1pt;">o</span>n,<span style="letter-spacing:-0.25pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and prospects<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dversely<span style="letter-spacing:-0.3pt;"> </span>affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to claims<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>our employees,<span style="letter-spacing:-0.35pt;"> </span>consultants or i<span style="letter-spacing:-0.05pt;">n</span>depende<span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.3pt;"> </span>co<span style="letter-spacing:-0.05pt;">n</span>trac<span style="letter-spacing:-0.05pt;">t</span>ors<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">h</span>ave<span style="letter-spacing:-0.1pt;"> </span>wro<span style="letter-spacing:-0.05pt;">n</span>gfully<span style="letter-spacing:-0.25pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>disclosed<span style="letter-spacing:-0.3pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:0.05pt;">e</span>cr<span style="letter-spacing:0.05pt;">e</span>ts<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r confident<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span>forma<span style="letter-spacing:-0.05pt;">t</span>ion<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parti<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>claims<span style="letter-spacing:-0.3pt;"> </span>asserti<span style="letter-spacing:0.05pt;">n</span>g<span style="letter-spacing:-0.05pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>what<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.15pt;"> </span>regard<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>own<span style="letter-spacing:-0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">e</span>ived<span style="letter-spacing:-0.3pt;"> </span>conf<span style="letter-spacing:-0.05pt;">i</span>dent<span style="letter-spacing:-0.05pt;">i</span>al<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>their<span style="letter-spacing:-0.1pt;"> </span>employees<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>con<span style="letter-spacing:-0.05pt;">t</span>ractors.<span style="letter-spacing:-0.45pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>plan<span style="letter-spacing:-0.15pt;"> </span>to employ<span style="letter-spacing:-0.25pt;"> </span>and contract<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>individuals<span style="letter-spacing:-0.3pt;"> </span>who<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>previously<span style="letter-spacing:-0.35pt;"> </span>e<span style="letter-spacing:0.05pt;">m</span>ployed<span style="letter-spacing:-0.3pt;"> </span>at other<span style="letter-spacing:-0.25pt;"> </span>biotechnology<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pharmaceutical<span style="letter-spacing:-0.6pt;"> </span>companies.<span style="letter-spacing:-0.35pt;"> </span>We<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to <span style="letter-spacing:-0.05pt;">c</span>la<span style="letter-spacing:-0.05pt;">i</span>ms<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>or o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.4pt;"> </span>consultants<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>ind<span style="letter-spacing:0.05pt;">e</span>pendent<span style="letter-spacing:-0.4pt;"> </span>contractors<span style="letter-spacing:-0.35pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>inadver<span style="letter-spacing:-0.05pt;">t</span>ently<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>otherwise<span style="letter-spacing:-0.3pt;"> </span>used<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>disclosed<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">t</span>her<span style="letter-spacing:-0.25pt;"> </span>confidential information<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>emp<span style="letter-spacing:-0.05pt;">l</span>oyees&#8217;<span style="letter-spacing:-0.4pt;"> </span>former<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">m</span>ployers.<span style="letter-spacing:-0.35pt;"> </span>Litigation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>to defend<span style="letter-spacing:-0.25pt;"> </span>against<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>pursue<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>ai<span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">s</span>.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">E</span>ven<span style="letter-spacing:-0.15pt;"> </span>if we are<span style="letter-spacing:-0.1pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>ssful<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>resolv<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>l<span style="letter-spacing:-0.05pt;">a</span>ims,<span style="letter-spacing:-0.25pt;"> </span>l<span style="letter-spacing:-0.05pt;">i</span>tig<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.3pt;"> </span>cou<span style="letter-spacing:-0.05pt;">l</span>d<span style="letter-spacing:-0.15pt;"> </span>result<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:0.05pt;">a</span>nti<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ost<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>distraction<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>management<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>employees.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition,</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">while</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is our poli</span><span style="letter-spacing:-0.15pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to require</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">empl</span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yees,</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:-0.05pt;">c</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsultants</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">independ</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contractors</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">involved</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conception</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or development</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prop</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rty</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to execute</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assigning</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intell</span><span style="letter-spacing:-0.2pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ctual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unsuccessful</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">executing</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an agreement</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">each</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">party</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">who,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fact,</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conceives</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develops</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">regard</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">own.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assignment</span><span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.15pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intellectual</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property rights</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">self-executing,</span><span style="letter-spacing:-0.6pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> a</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gn</span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agr</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents</span><span style="letter-spacing:-0.45pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bre</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ched,</span><span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd we</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">forced</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to bring</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">claims</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.1pt;">h</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ird</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties,</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">defend claims</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">they</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bring</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determine</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ownership</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wh</span><span style="letter-spacing:-0.05pt;">a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we r</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">gard</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our int</span><span style="letter-spacing:-0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll</span><span style="letter-spacing:-0.1pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ctual</span><span style="letter-spacing:-0.4pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">property.</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</span><span style="letter-spacing:-0.05pt;"> f</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">going</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a material</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adve</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</span><span style="letter-spacing:0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bu</span><span style="letter-spacing:-0.05pt;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iness,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition,</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resul</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">perations,</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospects.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>li<span style="letter-spacing:-0.05pt;">c</span>ense<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquire<span style="letter-spacing:-0.25pt;"> </span>new<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.05pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>tellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">e</span>chnology<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>i<span style="letter-spacing:0.05pt;">r</span>d<span style="letter-spacing:-0.2pt;"> </span>pa<span style="letter-spacing:0.05pt;">r</span>ti<span style="letter-spacing:0.05pt;">e</span>s.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An<span style="letter-spacing:-0.05pt;"> </span>element<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>s<span style="letter-spacing:0.05pt;">t</span>rategy<span style="letter-spacing:-0.3pt;"> </span>is to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>intel<span style="letter-spacing:-0.1pt;">l</span>ectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.25pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>echnologies<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">f</span>filiates.<span style="letter-spacing:-0.3pt;"> </span>Other parties,<span style="letter-spacing:-0.25pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates,<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.1pt;">a</span>tents<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>filed<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.1pt;">i</span>kely<span style="letter-spacing:-0.25pt;"> </span>filing<span style="letter-spacing:-0.15pt;"> </span>pat<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span>applications<span style="letter-spacing:-0.45pt;"> </span>potentially<span style="letter-spacing:-0.35pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>to our b<span style="letter-spacing:0.05pt;">u</span>siness.<span style="letter-spacing:0.05pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>order<span style="letter-spacing:-0.25pt;"> </span>to avoid<span style="letter-spacing:-0.25pt;"> </span>infringing<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.25pt;"> </span>patents,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>it<span style="letter-spacing:-0.1pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>prud<span style="letter-spacing:0.1pt;">e</span>nt<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>licenses<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>patents<span style="letter-spacing:-0.25pt;"> </span>f<span style="letter-spacing:0.05pt;">r</span>om<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>parties.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span>addition, w<span style="letter-spacing:-0.05pt;">i</span>th r<span style="letter-spacing:-0.05pt;">e</span>sp<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>nts<span style="letter-spacing:-0.3pt;"> </span>we <span style="letter-spacing:-0.05pt;">c</span>o-own<span style="letter-spacing:-0.05pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>parties, including<span style="letter-spacing:-0.65pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>affiliates, we<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>require<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">c</span><span style="letter-spacing:0.05pt;">e</span>nses<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>co-owners&#8217;<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">in</span>terest<span style="letter-spacing:-0.15pt;"> </span>to such<span style="letter-spacing:-0.05pt;"> </span>patents. The<span style="letter-spacing:-0.15pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.5pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>competitive<span style="letter-spacing:-0.4pt;"> </span>area,<span style="letter-spacing:-0.1pt;"> </span>and other<span style="letter-spacing:-0.2pt;"> </span>mo<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.15pt;"> </span>established<span style="letter-spacing:-0.35pt;"> </span>companies<span style="letter-spacing:-0.45pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>pursue<span style="letter-spacing:0.05pt;"> </span>strategies<span style="letter-spacing:-0.3pt;"> </span>to license or<span style="letter-spacing:0.05pt;"> </span>acquire<span style="letter-spacing:-0.2pt;"> </span>third-party<span style="letter-spacing:-0.35pt;"> </span>intellect<span style="letter-spacing:-0.1pt;">u</span>al<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>consider<span style="letter-spacing:-0.25pt;"> </span>attract<span style="letter-spacing:-0.1pt;">i</span>ve<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>necessary.<span style="letter-spacing:-0.3pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>established<span style="letter-spacing:-0.4pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>a competitive advantage<span style="letter-spacing:-0.35pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>us due<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o <span style="letter-spacing:-0.05pt;">t</span>heir<span style="letter-spacing:-0.1pt;"> </span>siz<span style="letter-spacing:-0.05pt;">e</span>,<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>pit<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">es</span>ources<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>greater<span style="letter-spacing:-0.25pt;"> </span>clinical<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>commercial<span style="letter-spacing:-0.05pt;">i</span>z<span style="letter-spacing:-0.05pt;">a</span>tion<span style="letter-spacing:-0.65pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>p<span style="letter-spacing:-0.05pt;">a</span>bi<span style="letter-spacing:-0.05pt;">l</span>it<span style="letter-spacing:-0.05pt;">i</span>es.<span style="letter-spacing:-0.35pt;"> </span>In addition,<span style="letter-spacing:-0.3pt;"> </span>companies<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>perceive<span style="letter-spacing:-0.3pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>a competitor<span style="letter-spacing:-0.35pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>unwilling<span style="letter-spacing:-0.45pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>assign<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>license<span style="letter-spacing:-0.3pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>to us.<span style="letter-spacing:0.05pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>also<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>license<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>acquire<span style="letter-spacing:-0.3pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party<span style="letter-spacing:-0.15pt;"> </span>intelle<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>on terms that<span style="letter-spacing:-0.1pt;"> </span>would<span style="letter-spacing:-0.05pt;"> </span>allow<span style="letter-spacing:-0.15pt;"> </span>us<span style="letter-spacing:0.05pt;"> </span>to make<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>approp<span style="letter-spacing:-0.05pt;">r</span>iate<span style="letter-spacing:-0.35pt;"> </span>return<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>inv<span style="letter-spacing:-0.1pt;">e</span>stment<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>at all.<span style="letter-spacing:-0.15pt;"> </span>No<span style="letter-spacing:-0.05pt;"> </span>assurance<span style="letter-spacing:-0.3pt;"> </span>can<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>given<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>succ<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:0.05pt;">s</span>ful<span style="letter-spacing:-0.2pt;"> in licensing any additional </span>rights<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>ird<span style="letter-spacing:-0.2pt;"> </span>parties<span style="letter-spacing:-0.25pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>af<span style="letter-spacing:0.05pt;">f</span>iliates.<span style="letter-spacing:-0.35pt;"> </span>Our<span style="letter-spacing:-0.05pt;"> </span>inability<span style="letter-spacing:-0.25pt;"> </span>to l<span style="letter-spacing:-0.05pt;">i</span>cense<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>techno<span style="letter-spacing:-0.05pt;">l</span>ogies<span style="letter-spacing:-0.5pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>identified, or<span style="letter-spacing:0.05pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>we <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> i</span>n <span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>future<span style="letter-spacing:-0.2pt;"> </span>id<span style="letter-spacing:-0.05pt;">e</span>ntify,<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.15pt;">c</span>ould<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span>dverse<span style="letter-spacing:-0.2pt;"> </span>impact<span style="letter-spacing:-0.3pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>ability<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:0.1pt;">o</span>mplete<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>to develop<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>c<span style="letter-spacing:-0.05pt;">a</span>ndidates.<span style="letter-spacing:-0.4pt;"> </span>Even<span style="letter-spacing:-0.15pt;"> </span>if we<span style="letter-spacing:-0.05pt;"> </span>were<span style="letter-spacing:-0.2pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to obtain<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>lice<span style="letter-spacing:-0.05pt;">n</span>se,<span style="letter-spacing:-0.15pt;"> </span>it could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>non-exclu<span style="letter-spacing:0.05pt;">s</span>ive,<span style="letter-spacing:-0.5pt;"> </span>thereby<span style="letter-spacing:-0.25pt;"> </span>giving<span style="letter-spacing:-0.25pt;"> </span>our competitors<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third parties<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>technologies<span style="letter-spacing:-0.45pt;"> </span>licensed<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>it could<span style="letter-spacing:-0.15pt;"> </span>require<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to make<span style="letter-spacing:-0.2pt;"> </span>substantial<span style="letter-spacing:-0.45pt;"> </span>licensing<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>royalty<span style="letter-spacing:-0.2pt;"> </span>payments.<span style="letter-spacing:-0.3pt;"> </span>Failure<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:0.05pt;"> </span>necessary<span style="letter-spacing:-0.4pt;"> </span>rights<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>licenses<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>detriment<span style="letter-spacing:-0.1pt;">a</span>lly<span style="letter-spacing:-0.45pt;"> </span>af<span style="letter-spacing:-0.05pt;">f</span>ect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>planned<span style="letter-spacing:-0.25pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>current<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.25pt;"> </span>additional<span style="letter-spacing:-0.3pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>increase<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>cost,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>extend<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timelines<span style="letter-spacing:-0.3pt;"> </span>associated<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>development,<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>products,<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>to abandon<span style="letter-spacing:-0.3pt;"> </span>development<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>relevant program<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidate.<span style="letter-spacing:-0.3pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">e</span>ffect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>co<span style="letter-spacing:0.05pt;">n</span>dition,<span style="letter-spacing:-0.3pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of o<span style="letter-spacing:0.05pt;">p</span>erations<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we<span style="letter-spacing:-0.1pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>ob<span style="letter-spacing:-0.05pt;">t</span>ain<span style="letter-spacing:-0.15pt;"> </span>pa<span style="letter-spacing:-0.05pt;">t</span>ent<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>rm<span style="letter-spacing:-0.15pt;"> </span>ext<span style="letter-spacing:-0.05pt;">e</span>nsion<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.05pt;"> </span>data<span style="letter-spacing:-0.1pt;"> </span>exclusivity<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.05pt;"> </span>product ca<span style="letter-spacing:0.05pt;">n</span>didat<span style="letter-spacing:0.05pt;">e</span>s<span style="letter-spacing:-0.25pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>d<span style="letter-spacing:0.05pt;">e</span>v<span style="letter-spacing:0.05pt;">e</span>lop,<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">m</span>at<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">r</span><span style="letter-spacing:-0.05pt;">i</span>ally<span style="letter-spacing:-0.3pt;"> </span>harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending<span style="letter-spacing:-0.45pt;"> </span>upon<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>timing,<span style="letter-spacing:-0.25pt;"> </span>duration<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>specifi<span style="letter-spacing:-0.05pt;">c</span>s<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>FDA<span style="letter-spacing:-0.05pt;"> </span>marketing<span style="letter-spacing:-0.3pt;"> </span>approval<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>we may<span style="letter-spacing:-0.15pt;"> </span>develop,<span style="letter-spacing:-0.3pt;"> </span>one<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:0.05pt;"> </span>more<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our owned<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>in-licensed<span style="letter-spacing:-0.35pt;"> </span>U.S. patents<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>eligible<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>limited<span style="letter-spacing:-0.25pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>under<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.25pt;"> </span>D<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">u</span>g<span style="letter-spacing:-0.05pt;"> </span>Price<span style="letter-spacing:-0.15pt;"> </span>Competition<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>Patent<span style="letter-spacing:-0.15pt;"> </span>Term<span style="letter-spacing:-0.2pt;"> </span>Restoration<span style="letter-spacing:-0.35pt;"> </span>Act of&#160;1984,<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>Hatch-Wa<span style="letter-spacing:0.05pt;">x</span><span style="letter-spacing:-0.05pt;">m</span>an<span style="letter-spacing:-0.55pt;"> </span>Act.<span style="letter-spacing:-0.2pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>Hatch-Waxman<span style="letter-spacing:-0.5pt;"> </span>Act<span style="letter-spacing:-0.1pt;"> </span>permits<span style="letter-spacing:-0.2pt;"> </span>a<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>term<span style="letter-spacing:-0.2pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>up<span style="letter-spacing:0.05pt;"> </span>to five&#160;years<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>te<span style="letter-spacing:-0.05pt;">r</span>m<span style="letter-spacing:-0.1pt;"> </span>lost d<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span>ing the<span style="letter-spacing:-0.15pt;"> </span>FDA reg<span style="letter-spacing:0.05pt;">u</span>latory<span style="letter-spacing:-0.3pt;"> </span>review<span style="letter-spacing:-0.2pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">c</span>ess.<span style="letter-spacing:-0.15pt;"> </span>A<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>cannot<span style="letter-spacing:-0.3pt;"> </span>extend<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.35pt;"> </span>term<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>beyond<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>total<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">o</span>f<span style="letter-spacing:0.05pt;"> </span>14&#160;years<span style="letter-spacing:-0.2pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>date<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>product<span style="letter-spacing:-0.25pt;"> </span>approval,<span style="letter-spacing:-0.3pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>patent<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>extended<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>only<span style="letter-spacing:-0.15pt;"> </span>tho<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.15pt;"> </span>claims<span style="letter-spacing:-0.2pt;"> </span>covering<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>approved<span style="letter-spacing:-0.35pt;"> </span>drug,<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>method<span style="letter-spacing:-0.2pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>using<span style="letter-spacing:-0.15pt;"> </span>it,<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>a method<span style="letter-spacing:-0.25pt;"> </span>for manufacturing<span style="letter-spacing:-0.45pt;"> </span>it may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>extended.<span style="letter-spacing:-0.3pt;"> </span>Similar<span style="letter-spacing:-0.25pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>tensions<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>compensation<span style="letter-spacing:-0.45pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>lost<span style="letter-spacing:-0.1pt;"> </span>during<span style="letter-spacing:-0.2pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>gulatory<span style="letter-spacing:-0.3pt;"> </span>re<span style="letter-spacing:0.05pt;">v</span><span style="letter-spacing:-0.05pt;">i</span>ew<span style="letter-spacing:-0.15pt;"> </span>processes are<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.05pt;"> a</span>va<span style="letter-spacing:-0.05pt;">i</span>lab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.3pt;"> </span>in certain<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>countries<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>territories,<span style="letter-spacing:-0.35pt;"> </span>such<span style="letter-spacing:0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>Europe<span style="letter-spacing:-0.25pt;"> </span>under<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>Supplementary<span style="letter-spacing:-0.5pt;"> </span>Patent<span style="letter-spacing:-0.2pt;"> </span>Certificate.<span style="letter-spacing:-0.4pt;"> </span>Howev<span style="letter-spacing:0.05pt;">e</span>r,<span style="letter-spacing:0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">g</span>ranted<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>in the<span style="letter-spacing:-0.05pt;"> </span>United<span style="letter-spacing:-0.2pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>and/or<span style="letter-spacing:-0.3pt;"> </span>foreign<span style="letter-spacing:-0.3pt;"> </span>countries<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>territories<span style="letter-spacing:-0.35pt;"> </span>because<span style="letter-spacing:-0.3pt;"> </span>of,<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>example,<span style="letter-spacing:-0.35pt;"> </span>failing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>exercise<span style="letter-spacing:-0.25pt;"> </span>due<span style="letter-spacing:-0.2pt;"> </span>diligence<span style="letter-spacing:-0.35pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span>testing<span style="letter-spacing:-0.2pt;"> </span>phase<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>regulatory review<span style="letter-spacing:-0.3pt;"> </span>process,<span style="letter-spacing:0.05pt;"> </span>failing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>apply<span style="letter-spacing:-0.15pt;"> </span>within<span style="letter-spacing:-0.2pt;"> </span>applicable<span style="letter-spacing:-0.3pt;"> </span>d<span style="letter-spacing:-0.1pt;">e</span>adlines,<span style="letter-spacing:-0.35pt;"> </span>failing<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>apply<span style="letter-spacing:-0.2pt;"> </span>prior<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.1pt;">e</span>xpiration<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>relevant<span style="letter-spacing:-0.3pt;"> </span>patents,<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>otherwise<span style="letter-spacing:-0.15pt;"> </span>fa<span style="letter-spacing:-0.05pt;">i</span>ling<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">a</span>tisfy applicable<span style="letter-spacing:-0.35pt;"> </span>requirements.<span style="letter-spacing:-0.5pt;"> </span>Mor<span style="letter-spacing:-0.05pt;">e</span>over,<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ppli<span style="letter-spacing:-0.05pt;">c</span>ab<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>ti<span style="letter-spacing:-0.05pt;">m</span>e<span style="letter-spacing:-0.15pt;"> </span>period<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>scope<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>protect<span style="letter-spacing:-0.1pt;">i</span>on<span style="letter-spacing:-0.2pt;"> </span>afforded<span style="letter-spacing:-0.35pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>than<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.1pt;"> </span>request.<span style="letter-spacing:-0.25pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>unable to obtain<span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>extension<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>term<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>extension<span style="letter-spacing:-0.3pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>shorter<span style="letter-spacing:-0.25pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>an<span style="letter-spacing:-0.2pt;"> </span>what<span style="letter-spacing:-0.2pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>request,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.2pt;"> </span>approval<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>competing prod<span style="letter-spacing:0.05pt;">u</span>cts<span style="letter-spacing:-0.05pt;"> </span>following<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>patent<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:0.05pt;">x</span>piration,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>busine<span style="letter-spacing:0.05pt;">s</span>s,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operations<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:-0.05pt;"> </span>prospects<span style="letter-spacing:-0.4pt;"> </span>co<span style="letter-spacing:0.05pt;">u</span>ld<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:0.05pt;">e</span>ri<span style="letter-spacing:0.05pt;">a</span>lly<span style="letter-spacing:-0.35pt;"> </span>harm<span style="letter-spacing:0.05pt;">e</span>d.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to claims<span style="letter-spacing:-0.3pt;"> </span>challenging<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>inv<span style="letter-spacing:-0.05pt;">e</span>n<span style="letter-spacing:-0.05pt;">t</span>orship<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">n</span>d<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>ll<span style="letter-spacing:-0.05pt;">e</span>c<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.4pt;"> </span>propert<span style="letter-spacing:-0.05pt;">y</span>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>mer<span style="letter-spacing:-0.2pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>collaborators<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">t</span>her<span style="letter-spacing:-0.2pt;"> </span>third<span style="letter-spacing:-0.15pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.2pt;"> </span>h<span style="letter-spacing:-0.05pt;">a</span>ve<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.05pt;">e</span>rest<span style="letter-spacing:-0.25pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in-licensed patents,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets,<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>inventor<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>co-inv<span style="letter-spacing:-0.15pt;">e</span>ntor.<span style="letter-spacing:-0.25pt;"> </span>For example,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors<span style="letter-spacing:-0.25pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>ha<span style="letter-spacing:-0.05pt;">v</span>e<span style="letter-spacing:-0.15pt;"> </span>inventorship<span style="letter-spacing:-0.4pt;"> </span>disputes<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:-0.05pt;">r</span>ise from<span style="letter-spacing:-0.15pt;"> </span>conflicting<span style="letter-spacing:-0.35pt;"> </span>obligations<span style="letter-spacing:-0.4pt;"> </span>of emplo<span style="letter-spacing:0.05pt;">y</span>ees,<span style="letter-spacing:-0.45pt;"> </span>consult<span style="letter-spacing:0.05pt;">a</span>nts<span style="letter-spacing:-0.45pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>others<span style="letter-spacing:-0.15pt;"> </span>who<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>involved<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>developing<span style="letter-spacing:-0.4pt;"> our </span>Anktiva<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.3pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>technologies. Litigation<span style="letter-spacing:-0.3pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>necessary<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>defend<span style="letter-spacing:-0.2pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>c<span style="letter-spacing:0.05pt;">l</span>aims<span style="letter-spacing:-0.2pt;"> </span>challenging<span style="letter-spacing:-0.35pt;"> </span>inventorship<span style="letter-spacing:-0.5pt;"> </span>or our<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>licensors&#8217;<span style="letter-spacing:-0.3pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>owned<span style="letter-spacing:0.05pt;"> </span>or in-licensed<span style="letter-spacing:-0.4pt;"> </span>patents,<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>licensors<span style="letter-spacing:-0.35pt;"> </span>fail<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>defending<span style="letter-spacing:-0.35pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>addition<span style="letter-spacing:-0.25pt;"> </span>to p<span style="letter-spacing:-0.05pt;">a</span>ying<span style="letter-spacing:-0.2pt;"> </span>monetary dam<span style="letter-spacing:-0.05pt;">a</span>ges,<span style="letter-spacing:-0.2pt;"> </span>we <span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.1pt;"> </span>lose<span style="letter-spacing:-0.1pt;"> </span>v<span style="letter-spacing:-0.05pt;">a</span>lu<span style="letter-spacing:-0.05pt;">a</span>ble<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>ec<span style="letter-spacing:-0.05pt;">t</span>ual<span style="letter-spacing:-0.5pt;"> </span>prope<span style="letter-spacing:-0.05pt;">r</span>ty<span style="letter-spacing:-0.2pt;"> </span>rights,<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>exclusive<span style="letter-spacing:-0.35pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>of,<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>right<span style="letter-spacing:-0.1pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>use,<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>l<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">c</span>tual<span style="letter-spacing:-0.4pt;"> </span>prop<span style="letter-spacing:-0.1pt;">e</span>rty<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>important<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>our Anktiva<span style="letter-spacing:-0.35pt;"> </span>product<span style="letter-spacing:-0.2pt;"> </span>candidates<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>technologies.<span style="letter-spacing:-0.45pt;"> </span>Even<span style="letter-spacing:-0.25pt;"> </span>if<span style="letter-spacing:-0.1pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>successful<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>defending<span style="letter-spacing:-0.3pt;"> </span>against<span style="letter-spacing:-0.3pt;"> </span>such<span style="letter-spacing:0.05pt;"> </span>claims,<span style="letter-spacing:-0.25pt;"> </span>litigation<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sult<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>sub<span style="letter-spacing:0.05pt;">s</span>t<span style="letter-spacing:0.05pt;">a</span>nti<span style="letter-spacing:0.05pt;">a</span>l<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>osts and<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>a distraction<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employees.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.25pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">e</span>ffect<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">b</span>usin<span style="letter-spacing:0.05pt;">e</span>ss,<span style="letter-spacing:-0.1pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition, results<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>operati<span style="letter-spacing:0.05pt;">o</span>ns<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">we</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">are</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">unable</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to protect</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">confidentiality</span><span style="letter-spacing:-0.5pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r t</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ade</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">s</span><span style="letter-spacing:0.05pt;">e</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ets,</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">o</span><span style="letter-spacing:0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">r business and</span><span style="letter-spacing:0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pe</span><span style="letter-spacing:-0.05pt;">t</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">it</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ve</span><span style="letter-spacing:-0.35pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">pos</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">i</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">on</span><span style="letter-spacing:-0.2pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">wou</span><span style="letter-spacing:-0.05pt;">l</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">d</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">be</span><span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ar</span><span style="letter-spacing:-0.05pt;">m</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ed.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In<span style="letter-spacing:0.05pt;"> </span>addition<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>seeking<span style="letter-spacing:-0.2pt;"> </span>patents<span style="letter-spacing:-0.3pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>Anktiva,<span style="letter-spacing:-0.35pt;"> hAd5</span><span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>yeast<span style="letter-spacing:-0.15pt;"> </span>te<span style="letter-spacing:-0.05pt;">c</span>hn<span style="letter-spacing:0.05pt;">o</span>logies<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>p<span style="letter-spacing:0.05pt;">r</span>oduct<span style="letter-spacing:-0.15pt;"> </span>candidates<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span>technologies,<span style="letter-spacing:-0.5pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>lso<span style="letter-spacing:-0.1pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>ly<span style="letter-spacing:-0.1pt;"> </span>on tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.15pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>cr<span style="letter-spacing:-0.05pt;">e</span>ts and<span style="letter-spacing:-0.1pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>agreements<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">r</span>otect<span style="letter-spacing:-0.15pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>unpatented<span style="letter-spacing:-0.35pt;"> </span>know-how,<span style="letter-spacing:-0.05pt;"> </span>technology,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>to mainta<span style="letter-spacing:-0.1pt;">i</span>n<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>omp<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">t</span>ive p<span style="letter-spacing:0.05pt;">o</span>sition.<span style="letter-spacing:-0.15pt;"> </span>Trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>know-how<span style="letter-spacing:-0.05pt;"> </span>can<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>difficult<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect.<span style="letter-spacing:-0.25pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>expect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>know-how<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>over<span style="letter-spacing:-0.15pt;"> </span>time<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>dis<span style="letter-spacing:-0.05pt;">s</span>e<span style="letter-spacing:-0.05pt;">m</span>ina<span style="letter-spacing:-0.05pt;">t</span>ed<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>thin<span style="letter-spacing:-0.15pt;"> </span>the industry<span style="letter-spacing:-0.25pt;"> </span>through<span style="letter-spacing:-0.25pt;"> </span>independent<span style="letter-spacing:-0.4pt;"> </span>deve<span style="letter-spacing:-0.05pt;">l</span>opment,<span style="letter-spacing:-0.5pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>publication<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>journ<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.25pt;"> </span>articles<span style="letter-spacing:-0.2pt;"> </span>des<span style="letter-spacing:-0.1pt;">c</span>ribing<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>methodology,<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>movement<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">p</span>ersonnel<span style="letter-spacing:-0.3pt;"> </span>from academic<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>industry<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:0.05pt;">c</span>ientific<span style="letter-spacing:-0.2pt;"> </span>positions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.15pt;"> </span>seek<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>these<span style="letter-spacing:-0.15pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">a</span>nd other<span style="letter-spacing:-0.15pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>technology,<span style="letter-spacing:-0.4pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>part,<span style="letter-spacing:-0.1pt;"> </span>by entering<span style="letter-spacing:-0.3pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>nondisclosure<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>confidentia<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">t</span>y<span style="letter-spacing:-0.5pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.45pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>parties<span style="letter-spacing:0.05pt;"> </span>who have<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to them,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.05pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees,<span style="letter-spacing:-0.35pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>collaborators,<span style="letter-spacing:-0.45pt;"> </span>outs<span style="letter-spacing:-0.05pt;">i</span>de<span style="letter-spacing:-0.25pt;"> </span>s<span style="letter-spacing:-0.05pt;">c</span>ien<span style="letter-spacing:-0.05pt;">t</span>ific<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>oll<span style="letter-spacing:-0.05pt;">a</span>borators,<span style="letter-spacing:-0.3pt;"> </span>CROs,<span style="letter-spacing:-0.05pt;"> </span>CMOs,<span style="letter-spacing:-0.5pt;"> </span>consultants, advisors,<span style="letter-spacing:-0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>rd<span style="letter-spacing:-0.05pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">e</span>s.<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">W</span>e<span style="letter-spacing:-0.1pt;"> </span>also<span style="letter-spacing:-0.15pt;"> </span>ent<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>nto<span style="letter-spacing:-0.05pt;"> c</span>onfid<span style="letter-spacing:-0.05pt;">e</span>nti<span style="letter-spacing:-0.05pt;">a</span>li<span style="letter-spacing:-0.1pt;">t</span>y<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>invention<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>pat<span style="letter-spacing:-0.1pt;">e</span>nt<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span><span style="letter-spacing:0.05pt;">s</span>sign<span style="letter-spacing:-0.05pt;">m</span>ent<span style="letter-spacing:-0.35pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>consultants<span style="letter-spacing:-0.35pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>well<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">r</span>ain<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>employees<span style="letter-spacing:-0.45pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>to bring<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>use<span style="letter-spacing:0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>information<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.1pt;">e</span>chnology<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.2pt;"> </span>former<span style="letter-spacing:-0.2pt;"> </span>employers<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>in their<span style="letter-spacing:-0.15pt;"> </span>w<span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">r</span>k,<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>remind<span style="letter-spacing:-0.2pt;"> </span>former<span style="letter-spacing:0.05pt;"> </span>empl<span style="letter-spacing:0.05pt;">o</span>yees<span style="letter-spacing:-0.35pt;"> </span>when they<span style="letter-spacing:-0.1pt;"> </span>leave<span style="letter-spacing:-0.15pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>eir<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.45pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>confidentiality<span style="letter-spacing:-0.45pt;"> </span>obli<span style="letter-spacing:-0.05pt;">g</span>ations.<span style="letter-spacing:-0.45pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>cannot<span style="letter-spacing:-0.25pt;"> </span>guarantee<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">e</span>nt<span style="letter-spacing:0.05pt;">e</span>red<span style="letter-spacing:-0.15pt;"> </span>into<span style="letter-spacing:-0.1pt;"> </span>su<span style="letter-spacing:0.05pt;">c</span>h agreements<span style="letter-spacing:-0.35pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>party<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>had<span style="letter-spacing:-0.2pt;"> </span>access<span style="letter-spacing:-0.2pt;"> </span>to our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>secrets<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.1pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>technology<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>processes.<span style="letter-spacing:0.05pt;"> </span>Despite<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>efforts,<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of these<span style="letter-spacing:-0.2pt;"> </span>par<span style="letter-spacing:-0.05pt;">t</span>ies<span style="letter-spacing:-0.3pt;"> </span>may bre<span style="letter-spacing:-0.05pt;">a</span>ch<span style="letter-spacing:-0.25pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>em<span style="letter-spacing:-0.05pt;">e</span>nts<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.1pt;">a</span>nd disclose<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.35pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>formation,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.35pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets,<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be able<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>obtain<span style="letter-spacing:-0.15pt;"> </span>adequate<span style="letter-spacing:-0.35pt;"> </span>rem<span style="letter-spacing:-0.05pt;">e</span>dies<span style="letter-spacing:-0.35pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>such bre<span style="letter-spacing:-0.05pt;">a</span>ches.<span style="letter-spacing:-0.3pt;"> </span>Enfor<span style="letter-spacing:-0.05pt;">c</span>ing<span style="letter-spacing:-0.35pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>im<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>a p<span style="letter-spacing:-0.05pt;">a</span>rty<span style="letter-spacing:-0.2pt;"> </span>il<span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.05pt;">g</span>ally<span style="letter-spacing:-0.35pt;"> </span>disclosed<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>misappropriated<span style="letter-spacing:-0.5pt;"> </span>a<span style="letter-spacing:-0.05pt;"> t</span>rade<span style="letter-spacing:-0.15pt;"> </span>secr<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.05pt;"> </span>d<span style="letter-spacing:-0.05pt;">i</span>fficu<span style="letter-spacing:-0.05pt;">l</span>t,<span style="letter-spacing:-0.35pt;"> </span>expensive,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>time-consuming,<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>outcome<span style="letter-spacing:0.05pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>unpredictable.<span style="letter-spacing:-0.3pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.25pt;"> </span>some<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.1pt;">c</span>ourts inside<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>outside<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Uni<span style="letter-spacing:-0.1pt;">t</span>ed<span style="letter-spacing:-0.3pt;"> </span>States<span style="letter-spacing:-0.15pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:0.05pt;"> </span>willing<span style="letter-spacing:-0.3pt;"> </span>or u<span style="letter-spacing:0.05pt;">n</span>willing<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>protect<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets.<span style="letter-spacing:-0.3pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>secrets<span style="letter-spacing:-0.2pt;"> </span>w<span style="letter-spacing:0.05pt;">e</span>re to be<span style="letter-spacing:-0.15pt;"> </span>lawfully<span style="letter-spacing:-0.35pt;"> </span>obtained<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">o</span>r<span style="letter-spacing:-0.05pt;"> </span>independently<span style="letter-spacing:-0.5pt;"> </span>developed<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a c<span style="letter-spacing:0.05pt;">o</span>mpetitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>third party,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>rig<span style="letter-spacing:0.05pt;">h</span>t<span style="letter-spacing:-0.1pt;"> </span>to prevent<span style="letter-spacing:-0.3pt;"> </span>them<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>using<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>technology<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>information<span style="letter-spacing:-0.35pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>compete<span style="letter-spacing:-0.25pt;"> </span>with<span style="letter-spacing:-0.1pt;"> </span>us.<span style="letter-spacing:-0.05pt;"> </span>If<span style="letter-spacing:0.05pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ade<span style="letter-spacing:-0.25pt;"> </span>secr<span style="letter-spacing:-0.05pt;">e</span>ts<span style="letter-spacing:-0.15pt;"> </span>were<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>o be disclosed<span style="letter-spacing:-0.4pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>independently<span style="letter-spacing:-0.5pt;"> </span>developed<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>a competitor<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>third<span style="letter-spacing:-0.2pt;"> </span>party,<span style="letter-spacing:-0.25pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>com<span style="letter-spacing:-0.05pt;">p</span>etitive<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">p</span>osition<span style="letter-spacing:-0.25pt;"> </span>would<span style="letter-spacing:0.05pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>materially<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If<span style="letter-spacing:-0.05pt;"> </span>our trademarks<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.25pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>are<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>ad<span style="letter-spacing:0.05pt;">e</span>quately<span style="letter-spacing:-0.35pt;"> </span>protected,<span style="letter-spacing:-0.35pt;"> </span>t<span style="letter-spacing:-0.05pt;">h</span>en<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:-0.1pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.1pt;"> </span>to build<span style="letter-spacing:-0.2pt;"> </span>name<span style="letter-spacing:-0.2pt;"> </span>recognition<span style="letter-spacing:-0.4pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>marke<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>and o<span style="letter-spacing:0.05pt;">u</span>r busi<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our<span style="letter-spacing:-0.05pt;"> </span>registered<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>unregistered<span style="letter-spacing:-0.4pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ade<span style="letter-spacing:-0.25pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>challenged,<span style="letter-spacing:-0.4pt;"> </span>infringed,<span style="letter-spacing:-0.4pt;"> </span>circumvented<span style="letter-spacing:-0.5pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>dec<span style="letter-spacing:-0.05pt;">l</span>ared<span style="letter-spacing:-0.3pt;"> </span>generic<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>det<span style="letter-spacing:-0.05pt;">e</span>rmined<span style="letter-spacing:-0.35pt;"> </span>to be<span style="letter-spacing:-0.15pt;"> </span>infringing on<span style="letter-spacing:0.05pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>marks.<span style="letter-spacing:-0.3pt;"> </span>We<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>able<span style="letter-spacing:-0.2pt;"> </span>to pro<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.2pt;"> </span>our righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>dem<span style="letter-spacing:-0.05pt;">a</span>rks<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>nd<span style="letter-spacing:-0.05pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.25pt;"> </span>names,<span style="letter-spacing:-0.2pt;"> </span>which<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>need<span style="letter-spacing:-0.1pt;"> </span>to build<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:-0.25pt;"> </span>reco<span style="letter-spacing:-0.1pt;">g</span>nition<span style="letter-spacing:-0.35pt;"> </span>among p<span style="letter-spacing:0.05pt;">o</span>tential<span style="letter-spacing:-0.15pt;"> </span>partners<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>customers<span style="letter-spacing:-0.3pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>markets<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>interest.<span style="letter-spacing:-0.25pt;"> </span>At<span style="letter-spacing:-0.05pt;"> </span>times,<span style="letter-spacing:-0.15pt;"> </span>competitors<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.2pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ird<span style="letter-spacing:-0.15pt;"> </span>parties<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span>adopt<span style="letter-spacing:-0.2pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>names<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>de<span style="letter-spacing:-0.05pt;">m</span>arks<span style="letter-spacing:-0.15pt;"> </span>sim<span style="letter-spacing:-0.05pt;">i</span>l<span style="letter-spacing:-0.05pt;">a</span>r<span style="letter-spacing:-0.15pt;"> </span>to o<span style="letter-spacing:0.05pt;">u</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">s</span>,<span style="letter-spacing:0.05pt;"> </span>t<span style="letter-spacing:0.05pt;">h</span>ereby<span style="letter-spacing:-0.3pt;"> </span>im<span style="letter-spacing:0.05pt;">p</span><span style="letter-spacing:-0.05pt;">e</span>ding<span style="letter-spacing:-0.4pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>ability<span style="letter-spacing:-0.2pt;"> </span>to build<span style="letter-spacing:-0.25pt;"> </span>brand<span style="letter-spacing:-0.15pt;"> </span>identity<span style="letter-spacing:-0.25pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>possibly<span style="letter-spacing:-0.35pt;"> </span>leading<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>mar<span style="letter-spacing:0.05pt;">k</span>et<span style="letter-spacing:-0.3pt;"> </span>confusion.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:-0.05pt;"> </span>addition,<span style="letter-spacing:-0.3pt;"> </span>there<span style="letter-spacing:-0.2pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>name<span style="letter-spacing:-0.25pt;"> </span>or tradema<span style="letter-spacing:-0.05pt;">r</span>k<span style="letter-spacing:-0.25pt;"> </span>infringement<span style="letter-spacing:-0.45pt;"> </span>claims<span style="letter-spacing:-0.25pt;"> </span>brought<span style="letter-spacing:-0.25pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>owners of<span style="letter-spacing:-0.05pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>registered<span style="letter-spacing:-0.3pt;"> </span>t<span style="letter-spacing:-0.05pt;">r</span>ademarks<span style="letter-spacing:-0.35pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>incorporate<span style="letter-spacing:-0.4pt;"> </span>variations<span style="letter-spacing:-0.35pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>registered<span style="letter-spacing:-0.3pt;"> </span>or u<span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>gistered<span style="letter-spacing:-0.3pt;"> </span>trademarks<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>trade<span style="letter-spacing:-0.2pt;"> </span>names.<span style="letter-spacing:-0.25pt;"> </span>Over<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>long<span style="letter-spacing:-0.1pt;"> </span>term,<span style="letter-spacing:-0.25pt;"> </span>if we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>unable<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>e<span style="letter-spacing:-0.1pt;">s</span>tablish<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">a</span>me<span style="letter-spacing:-0.1pt;"> </span>recognition<span style="letter-spacing:-0.35pt;"> </span>based<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>tradem<span style="letter-spacing:-0.05pt;">a</span>rks<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>names, th<span style="letter-spacing:0.05pt;">e</span>n<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:0.05pt;">a</span>y<span style="letter-spacing:-0.15pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>able<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span><span style="letter-spacing:0.05pt;">c</span>om<span style="letter-spacing:0.05pt;">p</span>ete<span style="letter-spacing:-0.25pt;"> </span>eff<span style="letter-spacing:0.05pt;">e</span>ctively<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>adversely<span style="letter-spacing:-0.4pt;"> </span>aff<span style="letter-spacing:-0.05pt;">e</span>cted.<span style="letter-spacing:-0.35pt;"> </span>Our efforts<span style="letter-spacing:-0.2pt;"> </span>to enforce<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>proprietary<span style="letter-spacing:-0.4pt;"> </span>rights related<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>trademarks,<span style="letter-spacing:-0.35pt;"> </span>trade<span style="letter-spacing:-0.15pt;"> </span>sec<span style="letter-spacing:0.1pt;">r</span>ets,<span style="letter-spacing:-0.2pt;"> </span>domain<span style="letter-spacing:-0.25pt;"> </span>names,<span style="letter-spacing:-0.2pt;"> </span>copyrights<span style="letter-spacing:-0.45pt;"> </span>or other<span style="letter-spacing:-0.15pt;"> </span>intellectual<span style="letter-spacing:-0.4pt;"> </span>property<span style="letter-spacing:-0.3pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>ineffective<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>resu<span style="letter-spacing:-0.05pt;">l</span>t<span style="letter-spacing:-0.05pt;"> </span>in substan<span style="letter-spacing:-0.05pt;">t</span>i<span style="letter-spacing:-0.05pt;">a</span>l<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>os<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.1pt;"> </span>and diversion<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>resources<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>adversely<span style="letter-spacing:-0.3pt;"> </span>affect<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business, financial<span style="letter-spacing:-0.25pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>r<span style="letter-spacing:0.05pt;">e</span>sults<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.35pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospect<span style="letter-spacing:-0.1pt;">s</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual<span style="letter-spacing:-0.4pt;"> </span>pr<span style="letter-spacing:0.05pt;">o</span>perty<span style="letter-spacing:-0.2pt;"> </span>rights<span style="letter-spacing:-0.05pt;"> </span>do<span style="letter-spacing:0.05pt;"> </span>not<span style="letter-spacing:-0.15pt;"> </span>necessarily<span style="letter-spacing:-0.4pt;"> </span>address all<span style="letter-spacing:-0.05pt;"> </span>potential<span style="letter-spacing:-0.25pt;"> </span>threats.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The<span style="letter-spacing:-0.15pt;"> </span>degree<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>future<span style="letter-spacing:-0.15pt;"> </span>protection<span style="letter-spacing:-0.35pt;"> </span>afforded<span style="letter-spacing:-0.35pt;"> </span>by<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>is<span style="letter-spacing:-0.1pt;"> </span>uncertain<span style="letter-spacing:-0.3pt;"> </span>because<span style="letter-spacing:-0.25pt;"> </span>intellectual<span style="letter-spacing:-0.35pt;"> </span>property<span style="letter-spacing:-0.35pt;"> </span>rights<span style="letter-spacing:-0.2pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>limitations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not adequately<span style="letter-spacing:-0.35pt;"> </span>protect<span style="letter-spacing:-0.2pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>business<span style="letter-spacing:0.05pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>permit<span style="letter-spacing:-0.2pt;"> </span>us<span style="letter-spacing:-0.05pt;"> </span>to<span style="letter-spacing:-0.05pt;"> m</span><span style="letter-spacing:0.05pt;">a</span><span style="letter-spacing:-0.05pt;">i</span>nta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>our comp<span style="letter-spacing:-0.05pt;">e</span>ti<span style="letter-spacing:-0.05pt;">t</span>ive<span style="letter-spacing:-0.45pt;"> </span>advantage.<span style="letter-spacing:-0.4pt;"> </span>For<span style="letter-spacing:0.05pt;"> </span>example:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">able</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="letter-spacing:0.05pt;color:#000000;">o</span><span style="color:#000000;">ducts</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">t</span><span style="letter-spacing:-0.05pt;color:#000000;">h</span><span style="color:#000000;">at</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">to our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">product</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">candidates</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">or utilize</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">technology</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">but</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the claims</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">own&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">make</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">inven</span><span style="letter-spacing:-0.1pt;color:#000000;">t</span><span style="color:#000000;">ions</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">covered</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">i</span><span style="color:#000000;">ssued patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">or pending</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">appl</span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">cation</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">license</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">own</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">now</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">in the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we, or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">licensors</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">collaborators,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">might</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">been</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">first</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.1pt;color:#000000;">a</span><span style="color:#000000;">pplications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">covering</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">c</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="color:#000000;">rtain</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or their</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">inventions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">others</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">independently</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">deve</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">op</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">similar</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">alternati</span><span style="letter-spacing:-0.05pt;color:#000000;">v</span><span style="color:#000000;">e</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">duplicate</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">any</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">of our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">without</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">infringing</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">ow</span><span style="letter-spacing:0.05pt;color:#000000;">n</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d or </span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">i</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="letter-spacing:-0.05pt;color:#000000;">en</span><span style="letter-spacing:0.05pt;color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">in</span><span style="color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">l</span><span style="color:#000000;">l</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="letter-spacing:0.05pt;color:#000000;">c</span><span style="color:#000000;">tual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">t is</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">possible</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">current</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">future</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">pending</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">owned</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">licensed</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">patent</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">applications</span><span style="letter-spacing:-0.45pt;color:#000000;"> </span><span style="color:#000000;">will</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">le</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">d</span><span style="letter-spacing:-0.05pt;color:#000000;"> t</span><span style="color:#000000;">o issued pat</span><span style="letter-spacing:-0.05pt;color:#000000;">e</span><span style="color:#000000;">nts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">i</span><span style="color:#000000;">ssued</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">hold</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ights</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">be</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">held</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">invalid</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">unenforceable,</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">including</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">as</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">result</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">legal</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">challenges</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">by</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> c</span><span style="color:#000000;">ompetitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or other</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">parties&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">competitors</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">other</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:-0.05pt;color:#000000;">r</span><span style="color:#000000;">ties</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.05pt;color:#000000;">i</span><span style="color:#000000;">ght</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">conduct</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">research</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">development</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">in countries</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">where</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">we</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">do not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">have</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">pa</span><span style="letter-spacing:0.1pt;color:#000000;">t</span><span style="color:#000000;">ent</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">rights and</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">then</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">use</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">the</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">information</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">learned</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">from</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">s</span><span style="letter-spacing:-0.05pt;color:#000000;">u</span><span style="color:#000000;">ch</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">activities</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">competitive</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">products</span><span style="letter-spacing:-0.35pt;color:#000000;"> </span><span style="color:#000000;">for</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">sale</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">major</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">commercial</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">mark</span><span style="letter-spacing:0.05pt;color:#000000;">e</span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="letter-spacing:0.05pt;color:#000000;">s&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">develop</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">additional</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">proprietary</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">technologies</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">that</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">are</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patenta</span><span style="letter-spacing:0.05pt;color:#000000;">b</span><span style="color:#000000;">le&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="letter-spacing:-0.05pt;color:#000000;">t</span><span style="color:#000000;">he</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">patents</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">of</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">others</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">m</span><span style="letter-spacing:0.1pt;color:#000000;">a</span><span style="color:#000000;">y</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">harm</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">our</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">business&#59;</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">choose</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">not</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">a patent</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">in order</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">to</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">maintain</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">certain</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">trade</span><span style="letter-spacing:-0.25pt;color:#000000;"> </span><span style="color:#000000;">secrets</span><span style="letter-spacing:-0.2pt;color:#000000;"> </span><span style="color:#000000;">or</span><span style="letter-spacing:0.05pt;color:#000000;"> </span><span style="color:#000000;">know-how,</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">and</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">third</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">party</span><span style="letter-spacing:-0.15pt;color:#000000;"> </span><span style="color:#000000;">may</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">subsequently</span><span style="letter-spacing:-0.5pt;color:#000000;"> </span><span style="color:#000000;">file</span><span style="letter-spacing:-0.1pt;color:#000000;"> </span><span style="color:#000000;">a</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">p</span><span style="letter-spacing:-0.05pt;color:#000000;">a</span><span style="color:#000000;">tent covering</span><span style="letter-spacing:-0.3pt;color:#000000;"> </span><span style="color:#000000;">such</span><span style="letter-spacing:-0.05pt;color:#000000;"> </span><span style="color:#000000;">intellectual</span><span style="letter-spacing:-0.4pt;color:#000000;"> </span><span style="color:#000000;">property.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Should<span style="letter-spacing:-0.3pt;"> </span>any<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>these<span style="letter-spacing:-0.2pt;"> </span>events<span style="letter-spacing:-0.25pt;"> </span>occur,<span style="letter-spacing:-0.2pt;"> </span>they<span style="letter-spacing:-0.1pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.2pt;"> </span>a material<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>ef<span style="letter-spacing:-0.05pt;">f</span>ect<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>condition,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.25pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>growth prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">O<span style="letter-spacing:-0.05pt;">n</span>e<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> our</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">s</span>s<span style="letter-spacing:-0.05pt;">u</span>ed<span style="letter-spacing:-0.1pt;"> </span>U<span style="letter-spacing:-0.05pt;">.</span>S. pa<span style="letter-spacing:-0.05pt;">t</span>e<span style="letter-spacing:-0.05pt;">n</span>ts<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.05pt;"> </span>subject<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;"> </span>claim<span style="letter-spacing:-0.15pt;"> </span>chall<span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">ng</span>i<span style="letter-spacing:-0.05pt;">n</span>g<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">h</span>e<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">i</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">v</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.05pt;">n</span>t<span style="letter-spacing:-0.05pt;">or</span><span style="letter-spacing:0.05pt;">s</span><span style="letter-spacing:-0.05pt;">h</span>ip.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.05pt;"> </span>September<span style="letter-spacing:-0.4pt;">&#160;</span>10,<span style="letter-spacing:-0.05pt;"> </span>2020,<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>legal<span style="letter-spacing:-0.15pt;"> </span>complaint<span style="letter-spacing:-0.3pt;"> </span>was<span style="letter-spacing:0.1pt;"> </span>filed<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>California<span style="letter-spacing:-0.3pt;"> </span>court<span style="letter-spacing:-0.25pt;"> </span>where<span style="letter-spacing:-0.25pt;"> </span>Institute<span style="letter-spacing:-0.25pt;"> </span>for<span style="letter-spacing:-0.05pt;"> </span>Cancer<span style="letter-spacing:-0.3pt;"> </span>Research<span style="letter-spacing:-0.4pt;">&#160;</span>(d/b/a<span style="letter-spacing:-0.15pt;">&#160;</span>Fox<span style="letter-spacing:0.05pt;"> </span>Chase<span style="letter-spacing:-0.15pt;"> </span>Cancer<span style="letter-spacing:-0.2pt;"> </span>Center)<span style="letter-spacing:-0.3pt;"> </span>argued that<span style="letter-spacing:-0.1pt;"> </span>it has a<span style="letter-spacing:-0.05pt;"> </span>co-ownership<span style="letter-spacing:-0.5pt;"> </span>i<span style="letter-spacing:-0.1pt;">n</span>terest<span style="letter-spacing:-0.25pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>Patent<span style="letter-spacing:-0.15pt;"> </span>No.&#160;10,456,420<span style="letter-spacing:0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">n</span>d<span style="letter-spacing:-0.15pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>underlying<span style="letter-spacing:-0.35pt;"> </span>U.S.<span style="letter-spacing:0.05pt;"> </span>Patent<span style="letter-spacing:-0.25pt;"> </span>Application<span style="letter-spacing:-0.4pt;"> </span>No.&#160;15/529,<span style="letter-spacing:0.05pt;">8</span>48,<span style="letter-spacing:-0.25pt;"> </span>as well<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>c<span style="letter-spacing:-0.05pt;">e</span>rta<span style="letter-spacing:-0.05pt;">i</span>n<span style="letter-spacing:-0.15pt;"> </span>r<span style="letter-spacing:-0.05pt;">e</span>la<span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">e</span>d patent<span style="letter-spacing:-0.2pt;"> </span>applications<span style="letter-spacing:-0.4pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>issued p<span style="letter-spacing:-0.05pt;">a</span>ten<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.2pt;"> </span>th<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.15pt;"> </span>inc<span style="letter-spacing:-0.05pt;">l</span>ude<span style="letter-spacing:-0.25pt;"> </span>cl<span style="letter-spacing:-0.05pt;">a</span>im<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.2pt;"> </span>subj<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>tt<span style="letter-spacing:-0.05pt;">e</span>r<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ll<span style="letter-spacing:-0.05pt;">e</span>gedly<span style="letter-spacing:-0.35pt;"> </span>invented<span style="letter-spacing:-0.25pt;"> </span>by one<span style="letter-spacing:-0.15pt;"> </span>of the<span style="letter-spacing:-0.05pt;"> </span>claimant&#8217;s<span style="letter-spacing:-0.4pt;"> </span>employee<span style="letter-spacing:0.1pt;">s</span>.<span style="letter-spacing:-0.35pt;"> </span>On<span style="letter-spacing:-0.05pt;"> </span>September&#160;30,&#160;2020, we<span style="letter-spacing:-0.15pt;"> </span>fil<span style="letter-spacing:0.05pt;">e</span>d<span style="letter-spacing:-0.15pt;"> </span>motion<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>court<span style="letter-spacing:-0.2pt;"> </span>asking<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.05pt;">c</span>ompl<span style="letter-spacing:-0.05pt;">a</span>int<span style="letter-spacing:-0.3pt;"> </span>be<span style="letter-spacing:-0.2pt;"> </span>dismissed.<span style="letter-spacing:-0.35pt;"> We </span>dis<span style="letter-spacing:0.05pt;">a</span>gr<span style="letter-spacing:-0.05pt;">e</span><span style="letter-spacing:0.05pt;">e</span><span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>hat<span style="letter-spacing:-0.1pt;"> </span>th<span style="letter-spacing:-0.05pt;">i</span>s<span style="letter-spacing:-0.1pt;"> </span>c<span style="letter-spacing:-0.05pt;">l</span>aim<span style="letter-spacing:-0.2pt;"> </span>for co-owner<span style="letter-spacing:-0.1pt;">s</span>hip<span style="letter-spacing:-0.15pt;"> </span>has<span style="letter-spacing:0.05pt;"> </span>merit<span style="letter-spacing:-0.15pt;"> </span>and intends<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>vigorously<span style="letter-spacing:-0.35pt;"> </span>defend<span style="letter-spacing:-0.25pt;"> our</span><span style="letter-spacing:-0.05pt;"> </span>posi<span style="letter-spacing:-0.05pt;">t</span>ion.<span style="letter-spacing:-0.2pt;"> </span>All<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>he<span style="letter-spacing:-0.05pt;"> </span>exist<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.15pt;"> </span>n<span style="letter-spacing:-0.05pt;">a</span>m<span style="letter-spacing:-0.05pt;">e</span>d<span style="letter-spacing:-0.25pt;"> </span>inventors<span style="letter-spacing:-0.3pt;"> </span>have<span style="letter-spacing:-0.1pt;"> </span>assigned<span style="letter-spacing:-0.25pt;"> </span>their<span style="letter-spacing:-0.15pt;"> </span>righ<span style="letter-spacing:-0.05pt;">t</span>s<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>this<span style="letter-spacing:-0.15pt;"> </span>p<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">e</span>nt<span style="letter-spacing:-0.2pt;"> </span>to us. We will continue<span style="letter-spacing:-0.25pt;"> </span>to have<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.05pt;">u</span>ndivided<span style="letter-spacing:-0.3pt;"> </span>interest<span style="letter-spacing:-0.25pt;"> </span>in the<span style="letter-spacing:-0.1pt;"> entire</span><span style="letter-spacing:-0.2pt;"> </span>patent<span style="letter-spacing:-0.2pt;"> </span>even<span style="letter-spacing:-0.2pt;"> </span>if claimant<span style="letter-spacing:-0.3pt;"> </span>succeeds<span style="letter-spacing:-0.25pt;"> </span>in this<span style="letter-spacing:-0.1pt;"> </span>suit.<span style="letter-spacing:-0.15pt;"> However, l</span>it<span style="letter-spacing:-0.05pt;">i</span>gat<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>his<span style="letter-spacing:-0.05pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">t</span>er could<span style="letter-spacing:-0.25pt;"> </span>result<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>substantial<span style="letter-spacing:-0.4pt;"> </span>costs<span style="letter-spacing:0.05pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>a distraction<span style="letter-spacing:-0.35pt;"> </span>to management<span style="letter-spacing:-0.45pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.25pt;"> </span>employees.<span style="letter-spacing:-0.35pt;"> </span>Any<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>foregoing<span style="letter-spacing:-0.3pt;"> </span>could<span style="letter-spacing:-0.15pt;"> </span>have<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>ma<span style="letter-spacing:-0.05pt;">t</span>erial<span style="letter-spacing:-0.3pt;"> </span>adverse<span style="letter-spacing:-0.2pt;"> </span>effect<span style="letter-spacing:-0.15pt;"> </span>on o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>business,<span style="letter-spacing:-0.05pt;"> </span>financial<span style="letter-spacing:-0.25pt;"> </span>cond<span style="letter-spacing:0.05pt;">i</span>tion,<span style="letter-spacing:-0.35pt;"> </span>results<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>operations<span style="letter-spacing:-0.4pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>growth<span style="letter-spacing:0.05pt;"> </span>prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks<span style="letter-spacing:-0.05pt;"> </span>Related<span style="letter-spacing:-0.25pt;"> </span>to<span style="letter-spacing:-0.05pt;"> </span>Our<span style="letter-spacing:-0.1pt;"> </span>Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr. Soon-Shiong,<span style="letter-spacing:0.05pt;"> </span>o<span style="letter-spacing:-0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> E</span>xecutive<span style="letter-spacing:-0.35pt;"> C</span>hairman and our principal stockholder, h<span style="letter-spacing:0.05pt;">a</span>s signifi<span style="letter-spacing:0.05pt;">c</span>ant interests<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>oth<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:0.05pt;">c</span>ompanies<span style="letter-spacing:-0.35pt;"> </span>w<span style="letter-spacing:0.05pt;">h</span>i<span style="letter-spacing:0.05pt;">c</span>h<span style="letter-spacing:-0.05pt;"> </span>may<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:0.1pt;">c</span>onfli<span style="letter-spacing:-0.05pt;">c</span>t<span style="letter-spacing:-0.25pt;"> </span>w<span style="letter-spacing:-0.05pt;">i</span>th<span style="letter-spacing:-0.1pt;"> </span>our i<span style="letter-spacing:0.05pt;">n</span>t<span style="letter-spacing:0.05pt;">e</span>r<span style="letter-spacing:0.05pt;">e</span>sts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive<span style="letter-spacing:-0.35pt;"> C</span>hairma<span style="letter-spacing:0.05pt;">n</span>, Dr. Soon-Shiong, is the founder of NantWorks,<span style="letter-spacing:-0.45pt;"> </span>L<span style="letter-spacing:0.1pt;">L</span>C<span style="letter-spacing:-0.2pt;">&#160;</span>(&#8220;NantWorks&#8221;). The various NantWorks companies are currently exploring opportunities in the immunotherapy,<span style="letter-spacing:-0.55pt;"> </span>oncology, infectious disease and inflammatory disease fields. In particular, we have agreements with a number of related parties that provide services, technology and equipment for use in their efforts to develop their product pipelines. Dr. Soon-Shiong holds a controlling interest, either directly or indirectly, in these entities. Consequently, Dr. Soon-Shiong&#8217;s interests may not be aligned with our other stockholders and he may from time to time be incentivized to take certain actions that benefit his other interests and that our other stockholders do not view as being in their interest as investors in our company. In addition, other companies affiliated with Dr. Soon-Shiong may compete with us for business opportunities or, in the future, develop products that are competitive with ours (including products in other therapeutic fields which we may target in the future). Moreover, even if they do not directly relate to us, actions taken by Dr. Soon-Shiong and the companies with which he is involved could impact us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also pursuing supply arrangements for various investigational agents controlled by affiliates to be used in their clinical trials. If Dr. Soon-Shiong w<span style="letter-spacing:-0.05pt;">e</span>re to cease his affiliation with us or NantWorks, these entities may be unwilling to continue these relationships with us on commercially reasonable terms, or at all, and as a result may impede our ability to control the supply chain for our combination therapies. These collaboration agreements do not typically specify how sales will be apportioned between the parties upon successful commercialization of the product. As a result, we cannot guarantee that we will receive a percentage of the revenues that is at least proportional to the costs that we will incur in commercializing the product candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We<span style="letter-spacing:-0.1pt;"> </span>have entered into sh<span style="letter-spacing:-0.05pt;">a</span>red<span style="letter-spacing:-0.05pt;"> </span>s<span style="letter-spacing:-0.05pt;">e</span>rvic<span style="letter-spacing:-0.05pt;">e</span>s<span style="letter-spacing:-0.2pt;"> </span>agr<span style="letter-spacing:-0.05pt;">e</span>e<span style="letter-spacing:-0.05pt;">m</span>ents with NantWorks, pursuant to which NantWorks and its affiliates provide corporate, general and administrative and other support services to us. If Dr. Soon-Shiong was to cease his affiliation with us or with NantWorks, we may be unable to establish or maintain this relationship with NantWorks on a commercially reasonable basis, if at all. As a result, we could experience a lack of business continuity due to loss of historical and institutional knowledge and a lack of familiarity of new employees and/or new service providers with business processes, operating requirements, policies and procedures, and we may incur additional costs as new employees and/or service providers gain necessary experience. In addition, the loss of the services of NantWorks might significantly delay or prevent the development of our product<span style="letter-spacing:-0.3pt;"> </span>ca<span style="letter-spacing:0.05pt;">n</span>didates or achievement of other business objectives by diverting management&#8217;s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dr.</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Soon-Shiong,</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">through</span><span style="letter-spacing:0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">his</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">voti</span><span style="letter-spacing:-0.05pt;">n</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">g</span><span style="letter-spacing:-0.15pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">co</span><span style="letter-spacing:0.05pt;">n</span><span style="letter-spacing:-0.05pt;">t</span><span style="letter-spacing:0.05pt;">r</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ol</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">of</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">t</span><span style="letter-spacing:-0.05pt;">h</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">e</span><span style="letter-spacing:-0.05pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">compan</span><span style="letter-spacing:0.05pt;">y</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">,</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.15pt;">has the ability</span><span style="letter-spacing:-0.25pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">to</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">control</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">actions</span><span style="letter-spacing:-0.3pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">req</span><span style="letter-spacing:-0.05pt;">u</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ire</span><span style="letter-spacing:-0.1pt;"> </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stockholder a</span><span style="letter-spacing:0.05pt;">p</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">proval.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr.<span style="letter-spacing:0.05pt;"> </span>Soon-Shiong,<span style="letter-spacing:-0.05pt;"> </span>through<span style="letter-spacing:-0.35pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>direct<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>indi<span style="letter-spacing:0.05pt;">r</span>ect<span style="letter-spacing:-0.2pt;"> </span>ownership<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>company&#8217;s<span style="letter-spacing:-0.5pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock,<span style="letter-spacing:-0.25pt;"> has</span><span style="letter-spacing:-0.1pt;"> </span>voting<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>company.<span style="letter-spacing:-0.4pt;"> As of</span><span style="letter-spacing:-0.3pt;"> March&#160;31, 2021</span>,<span style="letter-spacing:-0.25pt;"> </span>Dr.&#160;So<span style="letter-spacing:0.05pt;">o</span>n<span style="letter-spacing:-0.05pt;">-</span><span style="letter-spacing:0.05pt;">S</span>hiong<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.2pt;"> </span>certain<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>his<span style="letter-spacing:-0.05pt;"> </span>af<span style="letter-spacing:0.05pt;">f</span>iliates<span style="letter-spacing:-0.25pt;"> </span>beneficially<span style="letter-spacing:-0.4pt;"> </span>own<span style="letter-spacing:0.05pt;"> </span>approximately&#160;81.8%<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company&#8217;s<span style="letter-spacing:-0.35pt;"> </span>common<span style="letter-spacing:-0.3pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>outstanding.<span style="letter-spacing:-0.45pt;"> </span><span style="letter-spacing:0.05pt;">A</span>dditionally,<span style="letter-spacing:-0.35pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>affilia<span style="letter-spacing:-0.1pt;">t</span>e<span style="letter-spacing:-0.25pt;"> </span>of Dr.&#160;Soon-Shiong holds<span style="letter-spacing:-0.15pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>warrant<span style="letter-spacing:-0.2pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>pur<span style="letter-spacing:0.05pt;">c</span>ha<span style="letter-spacing:0.05pt;">s</span>e<span style="letter-spacing:-0.2pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>additional<span style="letter-spacing:0.05pt;"> </span>1,638,000&#160;shares<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> the</span><span style="letter-spacing:-0.35pt;"> </span>comp<span style="letter-spacing:0.05pt;">a</span>ny&#8217;s<span style="letter-spacing:-0.2pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.25pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.1pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>exercisable<span style="letter-spacing:-0.35pt;"> </span>if certain<span style="letter-spacing:-0.25pt;"> </span>perfor<span style="letter-spacing:-0.1pt;">m</span>ance<span style="letter-spacing:-0.4pt;"> </span>conditions<span style="letter-spacing:-0.4pt;"> </span>are<span style="letter-spacing:-0.1pt;"> </span>satisfie<span style="letter-spacing:0.05pt;">d</span>.<span style="letter-spacing:-0.3pt;"> </span>Dr. Soon-Shiong and his related party also <span style="letter-spacing:0.05pt;">h</span>old<span style="letter-spacing:-0.15pt;"> approximately $279.5&#160;million in the aggregate of </span>contingent<span style="letter-spacing:-0.45pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>rights<span style="letter-spacing:-0.15pt;"> </span>(&#8220;C<span style="letter-spacing:0.1pt;">V</span>Rs&#8221;)<span style="letter-spacing:-0.05pt;"> </span>iss<span style="letter-spacing:0.05pt;">u</span>ed<span style="letter-spacing:-0.05pt;"> </span>to the<span style="letter-spacing:-0.05pt;"> </span>fo<span style="letter-spacing:-0.05pt;">r</span>mer<span style="letter-spacing:-0.2pt;"> </span>s<span style="letter-spacing:-0.1pt;">t</span>ockholders<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>BioScience<span style="letter-spacing:-0.45pt;"> </span>Corporation<span style="letter-spacing:-0.45pt;"> </span>(succeeded<span style="letter-spacing:-0.4pt;"> </span>by<span style="letter-spacing:0.05pt;"> </span>Altor<span style="letter-spacing:-0.15pt;"> </span>BioScience<span style="letter-spacing:-0.4pt;"> </span>LLC)<span style="letter-spacing:-0.25pt;"> </span>(&#8220;Altor<span style="letter-spacing:0.05pt;">&#8221;</span>)<span style="letter-spacing:-0.35pt;"> </span>in connection<span style="letter-spacing:-0.4pt;"> </span>with<span style="letter-spacing:-0.2pt;"> NantCell</span>&#8217;s<span style="letter-spacing:-0.6pt;"> </span>acquisition<span style="letter-spacing:-0.4pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>Altor.<span style="letter-spacing:-0.25pt;"> I</span>f the<span style="letter-spacing:-0.15pt;"> </span>u<span style="letter-spacing:0.05pt;">n</span>derlying<span style="letter-spacing:-0.25pt;"> </span>conditions<span style="letter-spacing:-0.05pt;"> </span>for<span style="letter-spacing:0.05pt;"> </span>payment<span style="letter-spacing:-0.25pt;"> </span>are<span style="letter-spacing:-0.05pt;"> </span>met,<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>CVRs<span style="letter-spacing:-0.05pt;"> </span>become<span style="letter-spacing:-0.3pt;"> </span>paya<span style="letter-spacing:0.05pt;">b</span><span style="letter-spacing:-0.05pt;">l</span>e<span style="letter-spacing:-0.35pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>cash<span style="letter-spacing:-0.2pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>shares<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company&#8217;s</span><span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>any<span style="letter-spacing:-0.2pt;"> </span>combination<span style="letter-spacing:-0.4pt;"> </span>as the<span style="letter-spacing:-0.05pt;"> </span>holder<span style="letter-spacing:-0.2pt;"> </span>elects. Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> and his related party </span>have<span style="letter-spacing:-0.05pt;"> irrevocably agreed</span><span style="letter-spacing:-0.25pt;"> </span>to receive<span style="letter-spacing:-0.2pt;"> </span>shares<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company&#8217;s</span><span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> in satisfaction</span><span style="letter-spacing:-0.05pt;"> </span>of their<span style="letter-spacing:-0.1pt;"> </span>CVRs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Soon-Shiong is<span style="letter-spacing:-0.05pt;"> </span>in a position<span style="letter-spacing:-0.25pt;"> </span>to con<span style="letter-spacing:-0.1pt;">t</span>rol<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>outcome<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>corporate<span style="letter-spacing:-0.3pt;"> </span>actions<span style="letter-spacing:-0.2pt;"> </span>that<span style="letter-spacing:-0.25pt;"> </span>require,<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>accomplished<span style="letter-spacing:-0.45pt;"> </span>by,<span style="letter-spacing:0.05pt;"> </span>sto<span style="letter-spacing:-0.05pt;">c</span>kholder<span style="letter-spacing:-0.45pt;"> </span>approval, including<span style="letter-spacing:-0.3pt;"> </span>amending<span style="letter-spacing:-0.3pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>bylaws<span style="letter-spacing:0.05pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company,<span style="letter-spacing:-0.4pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>elect<span style="letter-spacing:0.05pt;">i</span>on<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>removal<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>directors<span style="letter-spacing:-0.3pt;"> </span>and<span style="letter-spacing:-0.25pt;"> </span>transactions<span style="letter-spacing:-0.5pt;"> </span>involving<span style="letter-spacing:-0.3pt;"> </span>a change<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>control.<span style="letter-spacing:-0.25pt;"> </span>Dr.&#160;Soon-Shiong&#8217;s<span style="letter-spacing:-0.05pt;"> controlling</span><span style="letter-spacing:-0.45pt;"> </span>ownership<span style="letter-spacing:0.05pt;"> </span>could<span style="letter-spacing:-0.2pt;"> </span>limit<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:0.05pt;">b</span>ility<span style="letter-spacing:-0.2pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.25pt;"> </span>stockholders<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.05pt;"> </span>company<span style="letter-spacing:-0.3pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>influence<span style="letter-spacing:-0.3pt;"> </span>corporate<span style="letter-spacing:-0.35pt;"> </span><span style="letter-spacing:-0.05pt;">m</span><span style="letter-spacing:0.05pt;">a</span>t<span style="letter-spacing:-0.05pt;">t</span>ers,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the interests<span style="letter-spacing:-0.25pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>not<span style="letter-spacing:-0.05pt;"> </span>coincide<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>company&#8217;s<span style="letter-spacing:-0.35pt;"> </span>interests<span style="letter-spacing:-0.3pt;"> </span>or<span style="letter-spacing:0.05pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>int<span style="letter-spacing:-0.1pt;">e</span>rests<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>its<span style="letter-spacing:-0.15pt;"> </span>remaining<span style="letter-spacing:-0.3pt;"> </span>stockholders.<span style="letter-spacing:-0.35pt;"> </span>In<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>ddit<span style="letter-spacing:-0.05pt;">i</span>on,<span style="letter-spacing:-0.2pt;"> </span>ent<span style="letter-spacing:-0.05pt;">i</span>ti<span style="letter-spacing:-0.05pt;">e</span>s affiliated<span style="letter-spacing:-0.3pt;"> </span>with<span style="letter-spacing:-0.2pt;"> </span>Dr.&#160;Soon-Shiong<span style="letter-spacing:0.05pt;"> </span>hold<span style="letter-spacing:-0.1pt;"> </span>p<span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">o</span><span style="letter-spacing:-0.05pt;">m</span>issory<span style="letter-spacing:-0.1pt;"> </span>representing<span style="letter-spacing:-0.4pt;"> </span>$297.5<span style="letter-spacing:-0.05pt;">&#160;</span>million<span style="letter-spacing:-0.2pt;"> </span>in<span style="letter-spacing:-0.05pt;"> </span>indebtedness, including interest thereon,<span style="letter-spacing:-0.5pt;"> </span>of<span style="letter-spacing:0.05pt;"> the company</span><span style="letter-spacing:-0.45pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>of<span style="letter-spacing:0.05pt;"> March&#160;31, 2021</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, pursuant to the Nominating Agreement between us and Cambridge Equities, LP, or Cambridge, an entity that Dr.&#160;Soon-Shiong controls, Cambridge has the ability to designate one director to be nominated for election to our board of directors for as long as Cambridge continues to hold at least 20% of the issued and outstanding shares of our common stock. Dr. Soon-Shiong was selected by Cambridge to hold this board seat. Dr. Soon-Shiong and his affiliates will therefore have significant influence over management and significant control over matters requiring stockholder approval, including the annual election of directors and significant corporate transactions, such as a merger or other sale of our company or its assets, for the foreseeable future. This control will limit stockholders&#8217; ability to influence corporate matters and, as a result, we may take actions that our stockholders do not view as beneficial. As a result, the market price of our common stock could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market price of our common stock has been and may continue to be volatile, and investors may have difficulty selling their shares.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our common stock is listed on The Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not active. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into strategic partnerships or acquire companies or products by using our shares of common stock as consideration.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock market in general and the market for biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the commencement, enrollment or results of the planned clinical trials of our product candidates or any future clinical trials we may conduct, or changes in the development status of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse results or delays in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in laws or regulations applicable to our products, including but not limited to clinical trial requirements for approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure to commercialize our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions or departures of key scientific or management personnel&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unanticipated serious safety concerns related to the use of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to effectively manage our growth&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in our quarterly operating results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our liquidity position and the amount and nature of any debt we may incur&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements that our revenue or income are below or that costs or losses are greater than analysts&#8217; expectations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">publication of research reports about us or our industry, or immunotherapy in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the market valuations of similar companies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of large blocks of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in stock market prices and volumes&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">significant lawsuits, including patent or stockholder litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the perception of our clinical trial results by retail investors, which investors may be subject to the influence of information provided by third party investor websites and independent authors distributing information on the internet&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic slowdowns&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">coordinated actions by independent third-party actors to affect the price of certain stocks, coordinated via the Internet and otherwise&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other factors described in this &#8220;</span><span style="font-style:italic;color:#000000;">Risk Factors</span><span style="color:#000000;">&#8221; section.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results or financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plan, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market perceives that our stockholders intend to sell substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly. In addition, our Executive<span style="letter-spacing:-0.3pt;"> </span>Chairman, Dr.&#160;Soon-Shiong, and his affiliates cur<span style="letter-spacing:-0.05pt;">r</span>ently<span style="letter-spacing:-0.25pt;"> </span>beneficially own approximately&#160;81.8% of our outstanding shares of common stock. Sales of stock by Dr.&#160;Soon-Shiong and his affiliates could have an adverse effect on the trading price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain holders of our common stock are entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as defined in Rule&#160;144 under the Securities Act. Any sales of securities by these stockholders could have an adverse effect on the market price of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we expect that additional capital may be needed in the future to continue our planned operations, including conducting clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating as a public company. To raise capital, we may sell common stock, including as part of the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies&#160;LLC, or the ATM, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, including through the ATM, convertible securities or other equity securities, investors may be materially diluted and new investors could gain rights, preferences and privileges senior to the holders of our common<span style="letter-spacing:-0.25pt;"> </span>stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to compliance initiatives and corporate governance practices, including maintaining an effective system of internal control over financial reporting.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company listed in the U.S., and increasingly after we no longer qual<span style="letter-spacing:-0.05pt;">i</span>fy<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>&#8220;smaller<span style="letter-spacing:-0.25pt;"> </span>reporting company,&#8221; we have incurred and will continue to incur significant additional legal, accounting and other expenses as a result of operating as a public company. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including Sarbanes-Oxley and regulations implemented by the SEC and Nasdaq, may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to create a larger finance function with additional personnel to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us, and our business may be harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company in the U.S., we may<span style="letter-spacing:-0.2pt;"> </span>be required, pursuant to Section&#160;404 of Sarbanes-Oxley, or Section&#160;404, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting. The controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. In<span style="letter-spacing:0.05pt;"> </span>addition,<span style="letter-spacing:-0.35pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>are<span style="letter-spacing:-0.15pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to disclose<span style="letter-spacing:-0.25pt;"> </span>any<span style="letter-spacing:-0.1pt;"> </span>material<span style="letter-spacing:-0.25pt;"> </span>weakn<span style="letter-spacing:-0.05pt;">e</span>sses<span style="letter-spacing:-0.25pt;"> </span>identified<span style="letter-spacing:-0.3pt;"> </span>by our management<span style="letter-spacing:-0.45pt;"> </span>in our<span style="letter-spacing:-0.05pt;"> </span>internal<span style="letter-spacing:-0.2pt;"> </span>control<span style="letter-spacing:-0.25pt;"> </span>over<span style="letter-spacing:-0.2pt;"> </span>financial<span style="letter-spacing:-0.3pt;"> </span>reporting,<span style="letter-spacing:-0.35pt;"> </span>and,<span style="letter-spacing:-0.1pt;"> </span>when<span style="letter-spacing:-0.05pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>no<span style="letter-spacing:-0.05pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a &#8220;<span style="letter-spacing:0.05pt;">s</span>maller<span style="letter-spacing:-0.25pt;"> </span>reporting<span style="letter-spacing:-0.3pt;"> </span>company,&#8221;<span style="letter-spacing:-0.4pt;"> </span><span style="letter-spacing:0.05pt;">w</span>e will<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.05pt;"> </span>required<span style="letter-spacing:-0.25pt;"> </span>to provide<span style="letter-spacing:-0.3pt;"> </span>a<span style="letter-spacing:-0.1pt;"> </span>statement<span style="letter-spacing:-0.3pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>independent<span style="letter-spacing:-0.45pt;"> </span>registered<span style="letter-spacing:-0.3pt;"> </span>public<span style="letter-spacing:-0.2pt;"> </span>accounting<span style="letter-spacing:-0.4pt;"> </span>firm<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.05pt;"> </span>issued<span style="letter-spacing:0.05pt;"> </span>an<span style="letter-spacing:-0.05pt;"> </span>opinion<span style="letter-spacing:-0.2pt;"> </span>on<span style="letter-spacing:-0.05pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>internal<span style="letter-spacing:-0.25pt;"> </span>control<span style="letter-spacing:-0.2pt;"> </span>over<span style="letter-spacing:-0.1pt;"> f</span>inancial<span style="letter-spacing:-0.3pt;"> </span>reporting.<span style="letter-spacing:-0.35pt;"> </span>To date,<span style="letter-spacing:-0.15pt;"> </span>we<span style="letter-spacing:0.05pt;"> </span>have not engaged our independent registered public accounting firm to perform an audit of, and give an opinion on, our internal control over financial reporting. There can be no assurance that we will not discover deficiencies or a material weakness in our internal control over financial reporting or that our auditor will agree with management&#8217;s assessment of our internal control over financial reporting if or when our auditor conducts such audit and delivers an opinion.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business our controls and procedures may become inadequate because of changes in conditions or the degree of compliance with these policies or procedures may deteriorate and material weaknesses in our internal control over financial reporting may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, can provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no absolute assurance that all control issues have been or will be detected. If we are unable, or are perceived as unable, to produce reliable financial reports due to internal control deficiencies, investors could lose confidence in our reported financial information and operating results, which could result in a negative market reaction.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To fully comply with Section 404, we will need to retain additional employees to supplement our current finance staff, and we may not be able to do so in a timely manner, or at all. In addition, in the process of evaluating our internal control over financial reporting, we expect that certain of our internal control practices will need to be updated to comply with the requirements of Section&#160;404 and the regulations promulgated thereunder, and we may not be able to do so on a timely basis, or at all. In the event that we are not able to demonstrate compliance with Section&#160;404 in a timely manner, or are unable to produce timely or accurate financial statements, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or Nasdaq, and investors may lose confidence in our operating results and the price of our common stock could decline. Furthermore, if we are unable to certify that our internal control over financial reporting is effective and in compliance with Section&#160;404, we may be subject to sanctions or investigations by regulatory authorities, such as the SEC or stock exchanges, and investors could lose confidence in the accuracy and completeness of our financial reports, which could hurt our business, the price of our common stock and our ability to access the capital markets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating as a public company makes it more expensive for us to obtain directors&#8217; and officers&#8217; liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors, or as members of senior management.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a restatement</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> of our financial statements were to occur</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, our </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">stock</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">holders&#8217;</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> confidence in the </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">c</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ompany&#8217;s financial reporting in the future</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> may be affected</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, which could in turn have a material adverse effect on our business and stock price.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements, and we could be required to restate our financial results. In addition, if we are unable to successfully remediate any future material weaknesses in our internal controls or if we are unable to produce accurate and timely financial statements, our stock price may be adversely affected, and we may be unable to maintain compliance with applicable stock exchange listing requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have not paid cash dividends in the past and do not expect to pay dividends in the future. Any return on investment may be limited to the value of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting us at such time as the board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if our stock price appreciates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we are relying on the exemptions from corporate governance requirements as a result of being a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards, you do not have the same protections afforded to stockholders of companies that are subject to such requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive<span style="letter-spacing:-0.35pt;"> </span>Chairman, Dr.&#160;Patrick Soon-Shiong, and entities affiliated with him, control a majority of our common stock. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq listing standards. Under these rules, a company of which more than 50% of the voting power is held by an individual, a group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain Nasdaq corporate governance requirements, including&#160;(1)&#160;the requirement that a majority of the board of directors consist of independent directors, and (2)&#160;the requirement that we have a nominating and corporate governance committee that is composed entirely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Accordingly, you do not have the same protections afforded to stockholders of companies that are subject to all of the Nasdaq corporate governance requirements. However, our board of directors is currently comprised of a majority of independent directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to smaller reporting companies could make our common stock less attractive to investors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>no<span style="letter-spacing:0.05pt;"> </span>longer<span style="letter-spacing:-0.3pt;"> </span>qualify<span style="letter-spacing:-0.2pt;"> </span>as<span style="letter-spacing:-0.05pt;"> </span>an<span style="letter-spacing:-0.15pt;"> </span>emerging<span style="letter-spacing:-0.35pt;"> </span>g<span style="letter-spacing:0.05pt;">r</span>owth<span style="letter-spacing:0.05pt;"> </span>company,<span style="letter-spacing:-0.3pt;"> </span>we<span style="letter-spacing:-0.05pt;"> </span>qualify<span style="letter-spacing:-0.3pt;"> </span>as<span style="letter-spacing:0.05pt;"> </span>a &#8220;smaller<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">r</span><span style="letter-spacing:0.05pt;">e</span>porting<span style="letter-spacing:-0.25pt;"> </span>company&#8221;<span style="letter-spacing:-0.3pt;"> </span>during<span style="letter-spacing:-0.3pt;"> </span>fiscal<span style="letter-spacing:-0.2pt;"> </span>year<span style="letter-spacing:-0.2pt;">&#160;</span>2021,<span style="letter-spacing:-0.05pt;"> </span>which<span style="letter-spacing:-0.25pt;"> </span>allows<span style="letter-spacing:-0.3pt;"> </span>us to take<span style="letter-spacing:-0.1pt;"> </span>advantage<span style="letter-spacing:-0.3pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>many<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>same<span style="letter-spacing:-0.15pt;"> </span>e<span style="letter-spacing:-0.05pt;">x</span>emptions<span style="letter-spacing:-0.35pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>disclosu<span style="letter-spacing:-0.05pt;">r</span>e<span style="letter-spacing:-0.3pt;"> </span>requirements,<span style="letter-spacing:-0.45pt;"> </span>including<span style="letter-spacing:-0.3pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>dis<span style="letter-spacing:0.05pt;">c</span>losure<span style="letter-spacing:-0.3pt;"> </span>obligations<span style="letter-spacing:-0.35pt;"> </span>regard<span style="letter-spacing:-0.05pt;">i</span>ng<span style="letter-spacing:-0.3pt;"> </span>executive compensation<span style="letter-spacing:-0.5pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:0.05pt;"> </span>periodic<span style="letter-spacing:-0.25pt;"> </span>reports<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>proxy<span style="letter-spacing:-0.05pt;"> </span>statements.<span style="letter-spacing:-0.35pt;"> </span>These<span style="letter-spacing:-0.25pt;"> </span>exemptions<span style="letter-spacing:-0.45pt;"> </span>include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s discussion and analysis of financial condition and results of operations&#8221; disclosure&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reduced disclosure obligations regarding executive compensation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors<span style="letter-spacing:0.05pt;"> </span>may<span style="letter-spacing:-0.1pt;"> </span>find<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>less<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:0.05pt;">t</span><span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result<span style="letter-spacing:-0.05pt;"> </span>of our<span style="letter-spacing:-0.05pt;"> </span>re<span style="letter-spacing:-0.05pt;">l</span>i<span style="letter-spacing:-0.05pt;">a</span>nce<span style="letter-spacing:-0.25pt;"> </span>on<span style="letter-spacing:0.05pt;"> </span><span style="letter-spacing:-0.05pt;">th</span>ese<span style="letter-spacing:-0.2pt;"> </span>exemptio<span style="letter-spacing:0.05pt;">n</span>s.<span style="letter-spacing:-0.35pt;"> </span>If<span style="letter-spacing:-0.05pt;"> </span>some<span style="letter-spacing:-0.25pt;"> </span>investors<span style="letter-spacing:-0.25pt;"> </span><span style="letter-spacing:-0.05pt;">f</span>ind our<span style="letter-spacing:0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>less at<span style="letter-spacing:-0.05pt;">t</span>ra<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.3pt;"> </span><span style="letter-spacing:-0.05pt;">a</span>s<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>result,<span style="letter-spacing:-0.2pt;"> </span><span style="letter-spacing:-0.05pt;">t</span>here<span style="letter-spacing:-0.15pt;"> </span>m<span style="letter-spacing:-0.05pt;">a</span>y<span style="letter-spacing:-0.05pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>a<span style="letter-spacing:-0.05pt;"> </span>l<span style="letter-spacing:-0.05pt;">e</span>ss<span style="letter-spacing:-0.05pt;"> </span>a<span style="letter-spacing:-0.05pt;">c</span>tive<span style="letter-spacing:-0.2pt;"> </span>tr<span style="letter-spacing:-0.05pt;">a</span>ding<span style="letter-spacing:-0.2pt;"> </span>mark<span style="letter-spacing:-0.05pt;">e</span>t<span style="letter-spacing:-0.35pt;"> </span>for our<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.25pt;"> </span>stock<span style="letter-spacing:-0.2pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>m<span style="letter-spacing:0.1pt;">a</span>rket<span style="letter-spacing:-0.2pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.05pt;"> </span>o<span style="letter-spacing:0.05pt;">u</span>r<span style="letter-spacing:-0.05pt;"> </span>common<span style="letter-spacing:-0.35pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>may<span style="letter-spacing:-0.2pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>reduced<span style="letter-spacing:-0.25pt;"> </span>or<span style="letter-spacing:-0.05pt;"> </span>more v<span style="letter-spacing:0.05pt;">o</span>l<span style="letter-spacing:0.05pt;">a</span>til<span style="letter-spacing:-0.05pt;">e</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to additional income tax liabilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a U.S.-based company subject to tax in the U.S. and certain<span style="letter-spacing:-0.2pt;"> </span>foreign<span style="letter-spacing:-0.2pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>jurisdictions. Significant judgment is required in determining our global provision for income taxes, deferred tax assets or liabilities, and in evaluating our tax positions on a worldwide basis. While we believe our tax positions are consistent with the tax laws in the jurisdictions in which we conduct our business, it is possible that these positions may be overturned by jurisdictional tax authorities, which may have a significant impact on our global provision for income taxes.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business may be materially affected by changes to fiscal and tax policies. Negative or unexpected tax consequences could adversely affect our results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our domestic and international business operations, and our business and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017, or TCJA, which was approved by Congress on December&#160;20,&#160;2017 significantly changed the U.S. Internal Revenue Code. Such changes include a reduction in the corporate tax rate and limitations on certain corporate deductions and credits, among other changes. We have generally accounted for such changes in accordance with our understanding of the TCJA and guidance available as of the date of this filing as described in more detail in our financial statements. The CARES Act, which was signed into law on March&#160;27,&#160;2020, further modified the TCJA and we will continue to monitor and assess the impact of the federal legislation on our business and the extent to which various states conform to the newly enacted federal tax law. In addition, adverse changes in the financial outlook of our operations or further changes in tax laws or regulations could lead to changes in our valuation allowances against deferred tax assets on our consolidated balance sheets, which could materially affect our results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts&#8217; cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are not subject to the provisions of Section&#160;203 of the Delaware General Corporation Law, which could negatively affect your investment.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We elected in our amended and restated certificate of incorporation to not be subject to the provisions of Section&#160;203 of the Delaware General Corporation Law. In general, Section&#160;203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder. An &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or, in certain cases, within three years prior, did own) 15% or more of the corporation&#8217;s voting stock. Our decision not to be subject to Section&#160;203 will allow, for example, our Executive<span style="letter-spacing:-0.35pt;"> C</span>hairman (who, with members of his immediate family and entities affiliated with him, currently beneficially own, in the aggregate, approximately&#160;81.8% of our common stock as of March&#160;31, 2021) to transfer shares in excess of 15% of our voting stock to a third-party free of the restrictions imposed by Section&#160;203. This may make us more vulnerable to takeovers that are completed without the approval of our board of directors and/or without giving us the ability to prohibit or delay such takeovers as effectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders. These provisions include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a requirement that special meetings of stockholders be called only by the board of directors, the president or the chief executive officer&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance notice requirements for stockholder proposals and nominations for election to our board of directors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(a)&#160;Recent Sales of Unregistered Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">(b)&#160;Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">ITEM 3. DEFAULTS UPON SENIOR SECURITIES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">ITEM 4. MINE SAFETY DISCLOSURES.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_5_OR_INFORMATION">ITEM 5. OTHER INFORMATION.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;8&#8209;K/Item&#160;5.02&#160;Departure of Directors or Certain Officers&#59; Election of Directors&#59; Appointment of Certain Officers&#59; Compensatory Arrangements of Certain Officers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;&#160;Richard Adcock, our Chief Executive Officer, President and member of our Board of Directors, had previously received an award of restricted stock units, or RSUs, in NantCell&#160;(formerly known as ImmunityBio, Inc., a private company). On March&#160;9,&#160;2021, in connection with the closing of the Merger, these RSUs in NantCell were assumed by the Company and converted (using the Exchange Ratio of 0.8190) into RSUs, on the same terms and conditions immediately prior to the Merger, to purchase 172,420&#160;shares of the Company&#8217;s common stock. The RSUs subject to Mr.&#160;Adcock&#8217;s award shall vest as follows:&#160;five&#160;percent (5%) will vest on September&#160;9,&#160;2021&#59; five&#160;percent&#160;(5%) will vest on the earlier of&#160;(A)&#160;December&#160;31,&#160;2022 and (B)&#160;the 60th&#160;day following approval by the FDA of a biologics license application or equivalent application for approval of Anktiva for use in the treatment of non-muscle invasive bladder cancer&#59; twenty&#160;percent&#160;(20%) will vest on December&#160;31,&#160;2023&#59; twenty&#160;percent&#160;(20%) will vest on December&#160;31,&#160;2024&#59; twenty&#160;percent&#160;(20%) will vest on December&#160;31,&#160;2025&#59; and the remaining thirty&#160;percent&#160;(30%) will vest on December&#160;31,&#160;2026.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;&#160;On May&#160;12,&#160;2021, the Compensation Committee of the Company&#8217;s Board of Directors approved the payment of cash bonuses to the Company&#8217;s named executive officers for the 2020&#160;fiscal year in the following amounts:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Richard Adcock, Chief Executive Officer and President of the Company&#160;(served as Chief Executive Officer during 2020 from hire date of October&#160;26,&#160;2020), 100%&#160;of target bonus, prorated from date of hire, equivalent to $67,808&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">David Sachs, Chief Financial Officer of the Company&#160;(served as Chief Financial Officer of privately held NantCell during 2020), 100%&#160;of target bonus, equivalent to $193,500&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Barry Simon, M.D., Chief Corporate Affairs Officer of the Company&#160;(served as President and Chief Administrative Officer during 2020), 75%&#160;of target bonus, equivalent to $152,786&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Sonja Nelson, Senior Vice President, Finance of the Company&#160;(served as Chief Financial Officer during 2020), 100%&#160;of target bonus, equivalent to $147,000</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As previously disclosed, Dr.&#160;Patrick Soon-Shiong is no longer compensated as an executive of the Company and therefore did not receive a cash bonus for 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The bonus payments are consistent with the previously disclosed terms of the employment agreements or offer letters of each executive offer listed above, and the cash bonus awards were based on the Compensation Committee&#8217;s consideration of achievement of operational and financial goals plus a discretionary component.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS">ITEM 6. EXHIBITS.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed below are incorporated by reference or are filed with this Quarterly Report, in each case as indicated therein (numbered in accordance with Item&#160;601 of Regulation&#160;S&#8209;K).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:7.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="bottom" style="width:92.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;2.1</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312520323766/d21044dex21.htm"><span style="text-decoration:underline;">Agreement and Plan of Merger, dated as of December&#160;21,&#160;2020, by and among ImmunityBio, Inc. (f/k/a NantKwest, Inc.), NantCell, Inc. (f/k/a ImmunityBio, Inc.) and Nectarine Merger Sub, Inc. (filed as Exhibit&#160;2.1 to the company&#8217;s Current Report on Form&#160;8-K filed with the SEC on December&#160;22,&#160;2020).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:23.05pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521075243/d307217dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of ImmunityBio, Inc. (f/k/a NantKwest, Inc.) dated March&#160;9,&#160;2021 (filed as Exhibit&#160;3.1 to the company&#8217;s Form&#160;8-K filed with the SEC on March&#160;10,&#160;2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2#&#94;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1326110/000119312521011616/d28678dex1031.htm"><span style="text-decoration:underline;">Offer Letter, dated August&#160;3,&#160;2020, by and among ImmunityBio,&#160;Inc. and David Sachs (filed as Exhibit&#160;10.31 to the company&#8217;s Registration Statement on Form&#160;S-4 (Reg. No.&#160;333-252232) filed with the SEC on January&#160;19,&#160;2021).</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;99.2</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Combined Consolidated Financial Statements of ImmunityBio, Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell, Inc.) (filed as Exhibit&#160;99.2 to the company&#8217;s Current Report on Form&#160;8-K/A filed with the SEC on April&#160;22,&#160;2021).</span></a></p></td>
</tr>
<tr style="height:4.3pt;">
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex311_109.htm"><span style="text-decoration:underline;"> Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Executive Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2*</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex312_108.htm"><span style="text-decoration:underline;"> Rule 13a-14(a) / 15(d)-14(a) Certification of Principal Financial Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1**</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex321_107.htm"><span style="text-decoration:underline;"> Section 1350 Certification of Chief Executive Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.2**</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ibrx-ex322_106.htm"><span style="text-decoration:underline;"> Section 1350 Certification of Chief Financial Officer.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Labels Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:56.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:7.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="9" valign="top" style="width:92.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of ImmunityBio,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been redacted in compliance with Regulation S-K Item&#160;601(a)(6).</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#TABLE_CONTENTS"><span style="text-decoration:underline;">Table of Contents</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">IMMUNITYBIO, INC.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 14, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 14, 2021</p></td>
<td valign="top" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom" style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ibrx-ex311_109.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ibrx-ex311_109.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE <font style="color:#000000;">SARBANES-OXLEY</font> ACT OF 2002</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Adcock, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of ImmunityBio, Inc.&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;May 14, 2021</p></td>
<td valign="bottom"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Adcock</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Principal Executive Officer</font>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ibrx-ex312_108.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ibrx-ex312_108.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE <font style="color:#000000;">SARBANES-OXLEY</font> ACT OF 2002</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;margin-left:5%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David C. Sachs, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of ImmunityBio, Inc.&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#894;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#894; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Calibri;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;font-family:Times New Roman;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:55%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk69215249"></a>Date:&nbsp;&nbsp;May 14, 2021</p></td>
<td valign="bottom"  style="width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C. Sachs</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:55%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:0.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:41%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Principal Financial and Accounting Officer</font>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ibrx-ex321_107.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ibrx-ex321_107.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. &#167; 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE <font style="color:#000000;">SARBANES-OXLEY</font> ACT OF 2002</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:5.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard Adcock, the chief executive officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), certify for the purposes of 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.13%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">the Quarterly Report of the Company on Form 10-Q for the quarter ended March 31, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.13%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 14, 2021</p></td>
<td valign="top"  style="width:2.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.68%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Adcock</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Adcock</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p></td>
</tr>
<tr>
<td valign="top"  style="width:49.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:45.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<font style="font-style:italic;">Principal Executive Officer</font>)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ibrx-ex322_106.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ibrx-ex322_106.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO 18 U.S.C. &#167; 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE <font style="color:#000000;">SARBANES-OXLEY</font> ACT OF 2002</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:5.06%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, David C. Sachs, the chief financial officer of ImmunityBio, Inc. (the &#8220;Company&#8221;), certify for the purposes of 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.13%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">i.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">the Quarterly Report of the Company on Form 10-Q for the quarter ended March&#160;31, 2021 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#894; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.13%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">ii.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:11pt;color:#000000;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk69216287"></a>Date: May 14, 2021</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ David C. Sachs</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">David C. Sachs</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:11pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ibrx-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4036434+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:ibrx="http://www.immunitybio.com/20210331" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.immunitybio.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.immunitybio.com/20210331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ibrx-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets" id="Role_StatementCondensedCombinedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Combined Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Combined Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100030 - Statement - Condensed Combined Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited" id="Role_StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited">
        <link:definition>100040 - Statement - Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited" id="Role_StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited">
        <link:definition>100050 - Statement - Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Combined Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails" id="Role_DisclosureFinancialStatementDetails">
        <link:definition>100090 - Disclosure - Financial Statement Details</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics" id="Role_DisclosureEquityInvestmentInViractaTherapeutics">
        <link:definition>100100 - Disclosure - Equity Investment in Viracta Therapeutics</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100110 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100120 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100130 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements" id="Role_DisclosureRelatedPartyAgreements">
        <link:definition>100150 - Disclosure - Related Party Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit" id="Role_DisclosureStockholdersDeficit">
        <link:definition>100160 - Disclosure - Stockholders&#8217; Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables" id="Role_DisclosureDescriptionOfBusinessTables">
        <link:definition>100210 - Disclosure - Description of Business (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100220 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables" id="Role_DisclosureFinancialStatementDetailsTables">
        <link:definition>100230 - Disclosure - Financial Statement Details (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100240 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100250 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100260 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables" id="Role_DisclosureRelatedPartyAgreementsTables">
        <link:definition>100270 - Disclosure - Related Party Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100280 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" id="Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Description of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" id="Role_DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail">
        <link:definition>100300 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
        <link:definition>100320 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" id="Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
        <link:definition>100330 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" id="Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
        <link:definition>100340 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail" id="Role_DisclosureFinancialStatementDetailsAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Financial Statement Details - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" id="Role_DisclosureFinancialStatementDetailsOtherAssetsDetail">
        <link:definition>100360 - Disclosure - Financial Statement Details - Other Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail" id="Role_DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail">
        <link:definition>100370 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail" id="Role_DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail">
        <link:definition>100380 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail" id="Role_DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Equity Investment in Viracta Therapeutics - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" id="Role_DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail">
        <link:definition>100400 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" id="Role_DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
        <link:definition>100420 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail">
        <link:definition>100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail">
        <link:definition>100450 - Disclosure - Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail" id="Role_DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail">
        <link:definition>100480 - Disclosure - Commitment and Contingencies - Summary of Information Regarding Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail" id="Role_DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail">
        <link:definition>100490 - Disclosure - Commitment and Contingencies - Components of Lease Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail" id="Role_DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail">
        <link:definition>100500 - Disclosure - Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" id="Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
        <link:definition>100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2" id="Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2">
        <link:definition>100520 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail" id="Role_DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail">
        <link:definition>100530 - Disclosure - Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" id="Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Related Party Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" id="Role_DisclosureStockholdersDeficitAdditionalInformationDetail">
        <link:definition>100550 - Disclosure - Stockholders&apos; Deficit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
        <link:definition>100570 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" id="Role_DisclosureStockBasedCompensationStockOptionActivityDetail">
        <link:definition>100580 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption" id="Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption">
        <link:definition>100590 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail" id="Role_DisclosureStockBasedCompensationRsusActivityDetail">
        <link:definition>100600 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100620 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_ConvertibleNoteReceivableNonCurrent" name="ConvertibleNoteReceivableNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" name="NonCashInterestIncomeExpenseFromOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" name="OperatingLeaseRightOfUseAssetNonCashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_FinancialStatementDetailsAbstract" name="FinancialStatementDetailsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ViractaTherapeuticsIncMember" name="ViractaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_MarketableDebtAndEquitySecuritiesMember" name="MarketableDebtAndEquitySecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ATMSalesAgreementWithJefferiesLLCMember" name="ATMSalesAgreementWithJefferiesLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantCellIncMember" name="NantCellIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" name="ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantKwestMember" name="NantKwestMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_MergerExchangeRatio" name="MergerExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" name="OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ibrx_OwnershipPercentageByKeyExecutives" name="OwnershipPercentageByKeyExecutives" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_NantKwestIncMember" name="NantKwestIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AccountingPoliciesLineItems" name="AccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AccountingPoliciesTable" name="AccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AtTheMarketOfferingProgramMember" name="AtTheMarketOfferingProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" name="AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_OutstandingStockOptionsMember" name="OutstandingStockOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" name="NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" name="PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidServices" name="PrepaidServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidLicenseFees" name="PrepaidLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_InsurancePremiumFinancingAsset" name="InsurancePremiumFinancingAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_EquipmentDepositsCurrent" name="EquipmentDepositsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidEquipmentMaintenance" name="PrepaidEquipmentMaintenance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidSuppliesWithRelatedParty" name="PrepaidSuppliesWithRelatedParty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" name="PrepaidSoftwareLicenseFeesInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" name="PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_AccruedDissentingShares" name="AccruedDissentingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedPreclinicalAndClinicalTrialCosts" name="AccruedPreclinicalAndClinicalTrialCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedResearchAndDevelopmentCosts" name="AccruedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedLaboratoryEquipmentAndSupplies" name="AccruedLaboratoryEquipmentAndSupplies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedCapitalExpenditures" name="AccruedCapitalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" name="TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_InterestAndInvestmentIncomeNetMember" name="InterestAndInvestmentIncomeNetMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SunesisPharmaceuticalsIncMember" name="SunesisPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_PurchaseOfConvertibleNoteUponConversion" name="PurchaseOfConvertibleNoteUponConversion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" name="CashEquivalentsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_CurrentAssetsMember" name="CurrentAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NoncurrentAssetsMember" name="NoncurrentAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" name="AvailableForSaleSecuritiesDebtSecuritiesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" name="AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_AnnualPaymentForSupportOfResearchActivities" name="AnnualPaymentForSupportOfResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedReimbursableCostsPayable" name="AccruedReimbursableCostsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_LicensingAgreementAbstract" name="LicensingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_LicensingAgreementLineItems" name="LicensingAgreementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_LicensingAgreementTable" name="LicensingAgreementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ClinicalTrialActivitiesMember" name="ClinicalTrialActivitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_IosbioLtdExclusiveLicenseAgreementMember" name="IosbioLtdExclusiveLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_CooperativeResearchAndDevelopmentAgreementMember" name="CooperativeResearchAndDevelopmentAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_EtubicsCorporationMember" name="EtubicsCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" name="MinimumAnnualPaymentsForSupportOfResearchActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" name="EstimatedUnpaidResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PayableOutstanding" name="PayableOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_PercentageOfWhollyOwnedSubsidiary" name="PercentageOfWhollyOwnedSubsidiary" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ibrx_ChangeInContingentConsideration" name="ChangeInContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_FairValueOfContingentConsiderationObligation" name="FairValueOfContingentConsiderationObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_VivaBioCellMember" name="VivaBioCellMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AltorBioScienceCorporationMember" name="AltorBioScienceCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ContingentValueRightsPayableAtDecember312022Member" name="ContingentValueRightsPayableAtDecember312022Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" name="ContingentValueRightsPayableBeforeDecember312026Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_DrSoonShiongAndPelatedPartyMember" name="DrSoonShiongAndPelatedPartyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AltorBioScienceLLCMember" name="AltorBioScienceLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ContingentValueRightsPayable" name="ContingentValueRightsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" name="MinimumNetSalesMilestoneContingentValueRightsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AccruedPaymentForDissentingShares" name="AccruedPaymentForDissentingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" name="OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_NantBioIncMember" name="NantBioIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantOmicsLLCMember" name="NantOmicsLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_VariousMember" name="VariousMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantWorksMember" name="NantWorksMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_DuleyRoadMember" name="DuleyRoadMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ImmunoOncologyClinicMember" name="ImmunoOncologyClinicMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantPharmaMember" name="NantPharmaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantCapitalMember" name="NantCapitalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantMobileMember" name="NantMobileMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NCSCMember" name="NCSCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantWorksLimitedLiabilityCompanyMember" name="NantWorksLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SharedServicesAgreementMember" name="SharedServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ReimbursementsMember" name="ReimbursementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_AmendmentToExtendLeaseTermMember" name="AmendmentToExtendLeaseTermMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ImmunoOncologyClinicIncMember" name="ImmunoOncologyClinicIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantBioScienceMember" name="NantBioScienceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NantCancerStemCellLLCMember" name="NantCancerStemCellLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SorrentoMember" name="SorrentoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_BioreactorMember" name="BioreactorMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_EmployeeBonusesPaymentMember" name="EmployeeBonusesPaymentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_VendorCostsPaymentsMember" name="VendorCostsPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_DougStLLCMember" name="DougStLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ElSegundoCaliforniaMember" name="ElSegundoCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_DuleyRoadLLCMember" name="DuleyRoadLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" name="SevenYearTermCommencingInSeptemberTwentyNineteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" name="SevenYearTermCommencingInJulyTwentyNineteenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SixZeroFiveNashLLCMember" name="SixZeroFiveNashLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_DemandPromissoryNoteMember" name="DemandPromissoryNoteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_RelatedPartyNotesPayableMember" name="RelatedPartyNotesPayableMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_PromissoryNoteMember" name="PromissoryNoteMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NumberOfSquareFootOfFacilityLeased" name="NumberOfSquareFootOfFacilityLeased" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ibrx_BaseMonthlyRent" name="BaseMonthlyRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_AnnualPercentageIncreasesToBaseRent" name="AnnualPercentageIncreasesToBaseRent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_LeaseAgreementExtendedPeriod" name="LeaseAgreementExtendedPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_NumberOfOfficers" name="NumberOfOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ibrx_InitialTermOfAgreement" name="InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_RelatedPartyInstallmentPayment" name="RelatedPartyInstallmentPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_RelatedPartyTransactionConditionalPayment" name="RelatedPartyTransactionConditionalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_NewAgreementTerminationNoticePeriod" name="NewAgreementTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_PrepaidBalance" name="PrepaidBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_RelatedPartyTransactionInitialTermOfAgreement" name="RelatedPartyTransactionInitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" name="ResearchAndDevelopmentExpenseRatablePaymentPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_PrepaymentOfFundingAmount" name="PrepaymentOfFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" name="PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_RelatedPartyAgreementRenewalTerm" name="RelatedPartyAgreementRenewalTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_PeriodOfExtendedLeaseTerm" name="PeriodOfExtendedLeaseTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" name="AnnualPercentageIncreasesToMonthlyFixedCharge" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_OptionsToExtendNumberOfTerms" name="OptionsToExtendNumberOfTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_LeaseholdImprovementPayables" name="LeaseholdImprovementPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_LeaseRelatedPayables" name="LeaseRelatedPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AmountOfAdvanceReceivedOnNote" name="AmountOfAdvanceReceivedOnNote" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" name="AmountOfAdvanceReceivedOnNoteOutstanding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_NantCellTwoThousandAndFifteenPlanMember" name="NantCellTwoThousandAndFifteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_TwoThousandFifteenEquityIncentivePlanMember" name="TwoThousandFifteenEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_NonEmployeeDirectorMember" name="NonEmployeeDirectorMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" name="ModificationOfStockOptionsAssociatedWithResignationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" name="ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_FirstRSUAwardMember" name="FirstRSUAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_SecondRSUAwardMember" name="SecondRSUAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_WarrantsMember" name="WarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_OptionExpirationDateExtendedPeriod" name="OptionExpirationDateExtendedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_NumberOfBoardOfDirectors" name="NumberOfBoardOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_ModifiedOptionsExercisablePeriod" name="ModifiedOptionsExercisablePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ibrx_NumberOfAwardsGranted" name="NumberOfAwardsGranted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ibrx_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_ExpectedClinicalTrialExpense" name="ExpectedClinicalTrialExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ibrx_WorkOrderOneMember" name="WorkOrderOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_WorkOrderTwoMember" name="WorkOrderTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ibrx_PercentageOfSalesAgentCommission" name="PercentageOfSalesAgentCommission" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ibrx-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4036434+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="ibrx-20210331.xsd#TemplateLink" roleURI="http://www.immunitybio.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent" xlink:type="locator" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="ibrx_ConvertibleNoteReceivableNonCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="10070.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="10140.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ibrx_IncreaseDecreaseInOperatingLeaseLiability" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10060.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="ibrx_PrepaidEquipmentMaintenance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EquipmentDepositsCurrent" xlink:type="locator" xlink:label="ibrx_EquipmentDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="ibrx_InsurancePremiumFinancingAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidLicenseFees" xlink:type="locator" xlink:label="ibrx_PrepaidLicenseFees" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidServices" xlink:type="locator" xlink:label="ibrx_PrepaidServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_PrepaidServices" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_PrepaidLicenseFees" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_InsurancePremiumFinancingAsset" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidRent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_EquipmentDepositsCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_LeaseIncentiveReceivableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_PrepaidEquipmentMaintenance" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="ibrx_PrepaidSuppliesWithRelatedParty" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_SecurityDeposit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedCapitalExpenditures" xlink:type="locator" xlink:label="ibrx_AccruedCapitalExpenditures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedInsuranceCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedDissentingShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibrx_AccruedDissentingShares" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibrx_AccruedPreclinicalAndClinicalTrialCosts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibrx_AccruedResearchAndDevelopmentCosts" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ConstructionPayableCurrent" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibrx_AccruedLaboratoryEquipmentAndSupplies" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiability" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ibrx_AccruedCapitalExpenditures" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeInterest" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ibrx-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4036434+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="ibrx-20210331.xsd#TemplateLink" roleURI="http://www.immunitybio.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics" xlink:href="ibrx-20210331.xsd#Role_DisclosureEquityInvestmentInViractaTherapeutics" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MarketableDebtAndEquitySecuritiesMember" xlink:type="locator" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ibrx_MarketableDebtAndEquitySecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageByKeyExecutives" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageByKeyExecutives" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestMember" xlink:type="locator" xlink:label="ibrx_NantKwestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" xlink:type="locator" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ATMSalesAgreementWithJefferiesLLCMember" xlink:type="locator" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibrx_ATMSalesAgreementWithJefferiesLLCMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_NantCellIncMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_TitleOfIndividualAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_OwnershipAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantKwestMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OwnershipPercentageByKeyExecutives" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="11070.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestIncMember" xlink:type="locator" xlink:label="ibrx_NantKwestIncMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:type="locator" xlink:label="srt_ConsolidationEliminationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableLegalEntitiesMember" xlink:type="locator" xlink:label="srt_ReportableLegalEntitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventTable" xlink:type="locator" xlink:label="dei_NameChangeEventTable" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventLineItems" xlink:type="locator" xlink:label="dei_NameChangeEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_NameChangeEventLineItems" xlink:to="dei_NameChangeEventTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_NameChangeEventTable" xlink:to="srt_ConsolidationItemsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ReportableLegalEntitiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationEliminationsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_NameChangeEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantCellIncMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantKwestIncMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_Revenues" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_ProfitLoss" order="11120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" xlink:type="locator" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:type="locator" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestMember" xlink:type="locator" xlink:label="ibrx_NantKwestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="ibrx_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesTable" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_AccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_AtTheMarketOfferingProgramMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantKwestMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10780.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OutstandingStockOptionsMember" xlink:type="locator" xlink:label="ibrx_OutstandingStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ibrx_OutstandingStockOptionsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SunesisPharmaceuticalsIncMember" xlink:type="locator" xlink:label="ibrx_SunesisPharmaceuticalsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InterestAndInvestmentIncomeNetMember" xlink:type="locator" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="ibrx_InterestAndInvestmentIncomeNetMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_SunesisPharmaceuticalsIncMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="ibrx_PurchaseOfConvertibleNoteUponConversion" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="11090.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:type="locator" xlink:label="us-gaap_MutualFundMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NoncurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_NoncurrentAssetsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_2" order="10080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_CurrentAssetsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_NoncurrentAssetsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MutualFundMember" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" order="11440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" order="10580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:type="locator" xlink:label="us-gaap_MutualFundMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NoncurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_NoncurrentAssetsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_CurrentAssetsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_NoncurrentAssetsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MutualFundMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="12410.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SunesisPharmaceuticalsIncMember" xlink:type="locator" xlink:label="ibrx_SunesisPharmaceuticalsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_SunesisPharmaceuticalsIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10300.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PayableOutstanding" xlink:type="locator" xlink:label="ibrx_PayableOutstanding" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedReimbursableCostsPayable" xlink:type="locator" xlink:label="ibrx_AccruedReimbursableCostsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPaymentForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EtubicsCorporationMember" xlink:type="locator" xlink:label="ibrx_EtubicsCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CooperativeResearchAndDevelopmentAgreementMember" xlink:type="locator" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IosbioLtdExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NationalInstitutesOfHealthMember" xlink:type="locator" xlink:label="ibrx_NationalInstitutesOfHealthMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ClinicalTrialActivitiesMember" xlink:type="locator" xlink:label="ibrx_ClinicalTrialActivitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementTable" xlink:type="locator" xlink:label="ibrx_LicensingAgreementTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementLineItems" xlink:type="locator" xlink:label="ibrx_LicensingAgreementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_LicensingAgreementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ibrx_ClinicalTrialActivitiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="ibrx_NationalInstitutesOfHealthMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_IosbioLtdExclusiveLicenseAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_CooperativeResearchAndDevelopmentAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_EtubicsCorporationMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_AnnualPaymentForSupportOfResearchActivities" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_AccruedReimbursableCostsPayable" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_PayableOutstanding" order="11250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="locator" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPaymentForDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedPaymentForDissentingShares" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FairValueOfContingentConsiderationObligation" xlink:type="locator" xlink:label="ibrx_FairValueOfContingentConsiderationObligation" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ChangeInContingentConsideration" xlink:type="locator" xlink:label="ibrx_ChangeInContingentConsideration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:type="locator" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceLLCMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DrSoonShiongAndPelatedPartyMember" xlink:type="locator" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableBeforeDecember312026Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableAtDecember312022Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VivaBioCellMember" xlink:type="locator" xlink:label="ibrx_VivaBioCellMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ibrx_VivaBioCellMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_AltorBioScienceCorporationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ibrx_ContingentValueRightsPayableAtDecember312022Member" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_DrSoonShiongAndPelatedPartyMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_AltorBioScienceLLCMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_PercentageOfWhollyOwnedSubsidiary" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_ChangeInContingentConsideration" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_FairValueOfContingentConsiderationObligation" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_ContingentValueRightsPayable" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_AccruedPaymentForDissentingShares" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" order="11220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NCSCMember" xlink:type="locator" xlink:label="ibrx_NCSCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantMobileMember" xlink:type="locator" xlink:label="ibrx_NantMobileMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCapitalMember" xlink:type="locator" xlink:label="ibrx_NantCapitalMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantPharmaMember" xlink:type="locator" xlink:label="ibrx_NantPharmaMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksMember" xlink:type="locator" xlink:label="ibrx_NantWorksMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VariousMember" xlink:type="locator" xlink:label="ibrx_VariousMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantOmicsLLCMember" xlink:type="locator" xlink:label="ibrx_NantOmicsLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioIncMember" xlink:type="locator" xlink:label="ibrx_NantBioIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantBioIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantOmicsLLCMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_VariousMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DuleyRoadMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantPharmaMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCapitalMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantMobileMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NCSCMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="10800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNote" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseRelatedPayables" xlink:type="locator" xlink:label="ibrx_LeaseRelatedPayables" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseholdImprovementPayables" xlink:type="locator" xlink:label="ibrx_LeaseholdImprovementPayables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionsToExtendNumberOfTerms" xlink:type="locator" xlink:label="ibrx_OptionsToExtendNumberOfTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="ibrx_PeriodOfExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="ibrx_PrepaymentOfFundingAmount" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalance" xlink:type="locator" xlink:label="ibrx_PrepaidBalance" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="ibrx_NewAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionConditionalPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyInstallmentPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_InitialTermOfAgreement" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfOfficers" xlink:type="locator" xlink:label="ibrx_NumberOfOfficers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="ibrx_LeaseAgreementExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BaseMonthlyRent" xlink:type="locator" xlink:label="ibrx_BaseMonthlyRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_PromissoryNoteMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantMobileMember" xlink:type="locator" xlink:label="ibrx_NantMobileMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NCSCMember" xlink:type="locator" xlink:label="ibrx_NCSCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksMember" xlink:type="locator" xlink:label="ibrx_NantWorksMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyNotesPayableMember" xlink:type="locator" xlink:label="ibrx_RelatedPartyNotesPayableMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DemandPromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_DemandPromissoryNoteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCapitalMember" xlink:type="locator" xlink:label="ibrx_NantCapitalMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantPharmaMember" xlink:type="locator" xlink:label="ibrx_NantPharmaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SixZeroFiveNashLLCMember" xlink:type="locator" xlink:label="ibrx_SixZeroFiveNashLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadLLCMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="ibrx_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DougStLLCMember" xlink:type="locator" xlink:label="ibrx_DougStLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantOmicsLLCMember" xlink:type="locator" xlink:label="ibrx_NantOmicsLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VendorCostsPaymentsMember" xlink:type="locator" xlink:label="ibrx_VendorCostsPaymentsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EmployeeBonusesPaymentMember" xlink:type="locator" xlink:label="ibrx_EmployeeBonusesPaymentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BioreactorMember" xlink:type="locator" xlink:label="ibrx_BioreactorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SorrentoMember" xlink:type="locator" xlink:label="ibrx_SorrentoMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCancerStemCellLLCMember" xlink:type="locator" xlink:label="ibrx_NantCancerStemCellLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioScienceMember" xlink:type="locator" xlink:label="ibrx_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmendmentToExtendLeaseTermMember" xlink:type="locator" xlink:label="ibrx_AmendmentToExtendLeaseTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ReimbursementsMember" xlink:type="locator" xlink:label="ibrx_ReimbursementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SharedServicesAgreementMember" xlink:type="locator" xlink:label="ibrx_SharedServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksLimitedLiabilityCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_SharedServicesAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="ibrx_ReimbursementsMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_AmendmentToExtendLeaseTermMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicIncMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantBioScienceMember" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCancerStemCellLLCMember" order="11950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="12040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantCancerStemCellLLCMember" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="12120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantBioScienceMember" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ibrx_SorrentoMember" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="12240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="12250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="12270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_BioreactorMember" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_NantBioScienceMember" order="12370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_EmployeeBonusesPaymentMember" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_VendorCostsPaymentsMember" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_NantOmicsLLCMember" order="12550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DougStLLCMember" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ibrx_ElSegundoCaliforniaMember" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DuleyRoadLLCMember" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" order="13490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_SixZeroFiveNashLLCMember" order="13630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementScenarioAxis" order="13700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="13730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibrx_ElSegundoCaliforniaMember" order="13750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="13970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantPharmaMember" order="14110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCapitalMember" order="14190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="14290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_DemandPromissoryNoteMember" order="14310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_RelatedPartyNotesPayableMember" order="14430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksMember" order="14510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NCSCMember" order="14790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantMobileMember" order="15070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_PromissoryNoteMember" order="15450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="15940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="15980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="16050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="16120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NumberOfSquareFootOfFacilityLeased" order="16190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_BaseMonthlyRent" order="16230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AnnualPercentageIncreasesToBaseRent" order="16310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="16350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseAgreementExtendedPeriod" order="16390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="16430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NumberOfOfficers" order="16500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_InitialTermOfAgreement" order="16550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="16600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyInstallmentPayment" order="16640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyTransactionConditionalPayment" order="16680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NewAgreementTerminationNoticePeriod" order="16730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaidBalance" order="16900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyTransactionInitialTermOfAgreement" order="16990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" order="17030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaymentOfFundingAmount" order="17110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" order="17150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="17220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyAgreementRenewalTerm" order="17400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="17460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="17520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="17670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PeriodOfExtendedLeaseTerm" order="17930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="18090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" order="18240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent" order="18280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_OptionsToExtendNumberOfTerms" order="18400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="18440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="18590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseholdImprovementPayables" order="18910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseRelatedPayables" order="18990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SecurityDeposit" order="19150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="19280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="19370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TenantImprovements" order="19390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="19460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="19570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="19670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="19770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="19870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="20900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AmountOfAdvanceReceivedOnNote" order="20960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" order="21020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="21080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="locator" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantCellTwoThousandAndFifteenPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfAwardsGranted" xlink:type="locator" xlink:label="ibrx_NumberOfAwardsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModifiedOptionsExercisablePeriod" xlink:type="locator" xlink:label="ibrx_ModifiedOptionsExercisablePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfBoardOfDirectors" xlink:type="locator" xlink:label="ibrx_NumberOfBoardOfDirectors" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionExpirationDateExtendedPeriod" xlink:type="locator" xlink:label="ibrx_OptionExpirationDateExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WarrantsMember" xlink:type="locator" xlink:label="ibrx_WarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="locator" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SecondRSUAwardMember" xlink:type="locator" xlink:label="ibrx_SecondRSUAwardMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FirstRSUAwardMember" xlink:type="locator" xlink:label="ibrx_FirstRSUAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:type="locator" xlink:label="us-gaap_NatureOfExpenseAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonEmployeeDirectorMember" xlink:type="locator" xlink:label="ibrx_NonEmployeeDirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_TwoThousandFifteenEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibrx_NonEmployeeDirectorMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_NatureOfExpenseAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_FirstRSUAwardMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_SecondRSUAwardMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantCellTwoThousandAndFifteenPlanMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_NantCellIncMember" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ibrx_WarrantsMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_OptionExpirationDateExtendedPeriod" order="11650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_NumberOfBoardOfDirectors" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ModifiedOptionsExercisablePeriod" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_NumberOfAwardsGranted" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_MergerExchangeRatio" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="12780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="12870.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="11960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="12490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="12890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationRsusActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:type="locator" xlink:label="country_KR" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IT" xlink:type="locator" xlink:label="country_IT" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxTable" xlink:type="locator" xlink:label="ibrx_IncomeTaxTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxLineItems" xlink:type="locator" xlink:label="ibrx_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="ibrx_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ibrx_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IT" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KR" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfSalesAgentCommission" xlink:type="locator" xlink:label="ibrx_PercentageOfSalesAgentCommission" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:type="locator" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExpectedClinicalTrialExpense" xlink:type="locator" xlink:label="ibrx_ExpectedClinicalTrialExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderTwoMember" xlink:type="locator" xlink:label="ibrx_WorkOrderTwoMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderOneMember" xlink:type="locator" xlink:label="ibrx_WorkOrderOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="ibrx_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_AtTheMarketOfferingProgramMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_WorkOrderOneMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_WorkOrderTwoMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_ExpectedClinicalTrialExpense" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_PercentageOfSalesAgentCommission" order="10880.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ibrx-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4046635+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent" xlink:type="locator" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note receivable, non-current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ConvertibleNoteReceivableNonCurrent" xlink:to="ibrx_ConvertibleNoteReceivableNonCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-marketable equity investment (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Without Readily Determinable Fair Value Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible asset, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible note receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note Receivable Non Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets, net (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; DEFICIT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-party notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable Related Parties Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, less current portion (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; deficit:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 500,000,000 shares authorized; 383,067,321 and 382,243,142 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total ImmunityBio stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TreasuryStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and investment income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest And Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income, net (including amounts with related parties)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes and noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interests, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to ImmunityBio common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per ImmunityBio common share &#8211; basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive (loss) income, net of income taxes:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net unrealized losses on available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of net realized losses on available-for-sale securities included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive (loss) income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss attributable to noncontrolling interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss attributable ImmunityBio common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total ImmunityBio Stockholders&#8217; Equity (Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aoci Including Portion Attributable To Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling Interests</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units (RSUs)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted stock units (RSUs), Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for RSUs vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for RSUs vesting, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash interest (income) expense from operating activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:to="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right of use asset non cash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:to="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="ibrx_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized (gains) losses on equity securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni Unrealized Gain Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash interest items, net (including amounts with related parties)</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Interest Income Expense From Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense related to operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset Non Cash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of net premiums and discounts on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Activities Cash Flow Statement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable Trade</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Accounts Payable And Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due To Related Parties Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable debt securities, available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of related-party promissory notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercises of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net share settlement for RSUs vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents, and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents, and restricted cash, end of period:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted cash (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment purchases included in accounts payable, accrued expenses, and due to related parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains on marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="ibrx_FinancialStatementDetailsAbstract" />
    <link:label xml:lang="en-US" xlink:label="ibrx_FinancialStatementDetailsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial statement details.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="ibrx_FinancialStatementDetailsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_FinancialStatementDetailsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Statement Details [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Statement Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Viracta Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ViractaTherapeuticsIncMember" xlink:to="ibrx_ViractaTherapeuticsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Viracta Therapeutics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ViractaTherapeuticsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Viracta Therapeutics Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MarketableDebtAndEquitySecuritiesMember" xlink:type="locator" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable debt and equity securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_MarketableDebtAndEquitySecuritiesMember" xlink:to="ibrx_MarketableDebtAndEquitySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Debt and Equity Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt And Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Inputs Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Development And Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Treatment of the Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risks And Uncertainties [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation Related Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and Diluted Net Loss Per Share of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Condensed Income Statement Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Excluded from the Computation of Potentially Dilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Current Assets Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Assets Noncurrent [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Investment Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:to="us-gaap_InterestAndOtherIncomeTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Available-for-Sale Marketable Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Carrying Amount of Contingent Consideration Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Information Regarding Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Balances of Related Party Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation Expenses Included on Operations Statement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarizes Stock Option Activity and Related Information Under Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity Table [Text Block]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ATMSalesAgreementWithJefferiesLLCMember" xlink:type="locator" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ATM sales agreement with Jefferies LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ATMSalesAgreementWithJefferiesLLCMember" xlink:to="ibrx_ATMSalesAgreementWithJefferiesLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Sales Agreement With Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A T M Sales Agreement With Jefferies L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantCell, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantCellIncMember" xlink:to="ibrx_NantCellIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantCell, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Cell Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" xlink:type="locator" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Executive Chairman and principal stockholder, and affiliates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" xlink:to="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive Chairman and Principal Stockholder and Affiliates</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Executive Chairman And Principal Stockholder And Affiliates [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_OwnershipDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestMember" xlink:type="locator" xlink:label="ibrx_NantKwestMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantKwestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantKwest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantKwestMember" xlink:to="ibrx_NantKwestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantKwestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Kwest [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of agreement and plan of merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Date Of Acquisition Agreement1</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MergerExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger exchange ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_MergerExchangeRatio" xlink:to="ibrx_MergerExchangeRatio_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MergerExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_MergerExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Merger Exchange Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective date of acquisition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Effective Date Of Acquisition1</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage acquired on fully diluted bases upon consummation of merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:to="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageByKeyExecutives" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageByKeyExecutives" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageByKeyExecutives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership percentage by key executives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OwnershipPercentageByKeyExecutives" xlink:to="ibrx_OwnershipPercentageByKeyExecutives_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage held by stockholders upon consummation of merger</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage Acquired On Fully Diluted Bases Upon Consummation Of Merger</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageByKeyExecutives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage held by Executive Chairman upon consummation of merger</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OwnershipPercentageByKeyExecutives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage By Key Executives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Merger Related Costs</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventTable" xlink:type="locator" xlink:label="dei_NameChangeEventTable" />
    <link:label xml:lang="en-US" xlink:label="dei_NameChangeEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name Change Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NameChangeEventTable" xlink:to="dei_NameChangeEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NameChangeEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Change Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidation Items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableLegalEntitiesMember" xlink:type="locator" xlink:label="srt_ReportableLegalEntitiesMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ReportableLegalEntitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reportable Legal Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ReportableLegalEntitiesMember" xlink:to="srt_ReportableLegalEntitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ReportableLegalEntitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reportable Legal Entities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:type="locator" xlink:label="srt_ConsolidationEliminationsMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationEliminationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intercompany Eliminations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationEliminationsMember" xlink:to="srt_ConsolidationEliminationsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidationEliminationsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Eliminations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestIncMember" xlink:type="locator" xlink:label="ibrx_NantKwestIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantKwestIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantKwest, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantKwestIncMember" xlink:to="ibrx_NantKwestIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantKwestIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantKwest, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantKwestIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Kwest Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventLineItems" xlink:type="locator" xlink:label="dei_NameChangeEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="dei_NameChangeEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name Change Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NameChangeEventLineItems" xlink:to="dei_NameChangeEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_NameChangeEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Change Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other (expense) income, net (including amounts with related parties)</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_AccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesTable" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="ibrx_AccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="ibrx_AtTheMarketOfferingProgramMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-The-Market offering program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AtTheMarketOfferingProgramMember" xlink:to="ibrx_AtTheMarketOfferingProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Offering Program</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AtTheMarketOfferingProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Program [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VIE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity Primary Beneficiary [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net cash used in operating activities</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:type="locator" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate market price of shares that may issue under a registered offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:to="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Market Price Of Shares That May Issue Under Registered Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership interest by parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest Ownership Percentage By Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ownership interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OutstandingStockOptionsMember" xlink:type="locator" xlink:label="ibrx_OutstandingStockOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OutstandingStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OutstandingStockOptionsMember" xlink:to="ibrx_OutstandingStockOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OutstandingStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OutstandingStockOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Options [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Related Party Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" xlink:type="locator" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nantcell two thousand and fifteen plan and nantcell warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" xlink:to="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NC 2015 Plan and NantCell Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nantcell Two Thousand And Fifteen Plan And Nantcell Warrants [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid preclinical and clinical trial services with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidServices" xlink:type="locator" xlink:label="ibrx_PrepaidServices" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidServices" xlink:to="ibrx_PrepaidServices_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidLicenseFees" xlink:type="locator" xlink:label="ibrx_PrepaidLicenseFees" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid license fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidLicenseFees" xlink:to="ibrx_PrepaidLicenseFees_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="ibrx_InsurancePremiumFinancingAsset" />
    <link:label xml:lang="en-US" xlink:label="ibrx_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Insurance premium financing asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_InsurancePremiumFinancingAsset" xlink:to="ibrx_InsurancePremiumFinancingAsset_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EquipmentDepositsCurrent" xlink:type="locator" xlink:label="ibrx_EquipmentDepositsCurrent" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EquipmentDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equipment deposits current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_EquipmentDepositsCurrent" xlink:to="ibrx_EquipmentDepositsCurrent_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="ibrx_PrepaidEquipmentMaintenance" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid equipment maintenance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidEquipmentMaintenance" xlink:to="ibrx_PrepaidEquipmentMaintenance_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid supplies with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidSuppliesWithRelatedParty" xlink:to="ibrx_PrepaidSuppliesWithRelatedParty_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid preclinical and clinical trial services &#8211; with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Preclinical And Clinical Trial Services With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance claim receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InsuranceSettlementsReceivableCurrent" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Settlements Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid services</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Services</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidLicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid License Fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Insurance premium financing asset</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_InsurancePremiumFinancingAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Insurance Premium Financing Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EquipmentDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment deposits</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EquipmentDepositsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment Deposits Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseIncentiveReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvement receivables &#8211; with related party (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseIncentiveReceivableCurrent" xlink:to="us-gaap_LeaseIncentiveReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseIncentiveReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Incentive Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid equipment maintenance</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidEquipmentMaintenance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Equipment Maintenance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable &#8211; marketable debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid supplies &#8211; with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Supplies With Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Software And Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture And Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid software license fees in other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" xlink:to="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid preclinical and clinical trial services with related party in other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VAT receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Value Added Tax Receivable Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security deposits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SecurityDeposit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid software license fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Software License Fees In Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due from related party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesNoncurrent" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid preclinical and clinical trial services &#8211; with related party (Note 9)</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Miscellaneous Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other assets</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedDissentingShares" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued dissenting shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedDissentingShares" xlink:to="ibrx_AccruedDissentingShares_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued preclinical and clinical trial costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:to="ibrx_AccruedPreclinicalAndClinicalTrialCosts_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedResearchAndDevelopmentCosts" xlink:to="ibrx_AccruedResearchAndDevelopmentCosts_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued laboratory equipment and supplies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedLaboratoryEquipmentAndSupplies" xlink:to="ibrx_AccruedLaboratoryEquipmentAndSupplies_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedCapitalExpenditures" xlink:type="locator" xlink:label="ibrx_AccruedCapitalExpenditures" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedCapitalExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued capital expenditures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedCapitalExpenditures" xlink:to="ibrx_AccruedCapitalExpenditures_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued bonus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued dissenting shares (Note 8)</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Dissenting Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional and service fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued preclinical and clinical trial costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Preclinical And Clinical Trial Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Salaries Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued construction costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionPayableCurrent" xlink:to="us-gaap_ConstructionPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contingent consideration payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued laboratory equipment and supplies</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Laboratory Equipment And Supplies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedInsuranceCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing obligation &#8211; current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedInsuranceCurrent" xlink:to="us-gaap_AccruedInsuranceCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedInsuranceCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Insurance Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued franchise, sales, use and property taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrual For Taxes Other Than Income Taxes Current</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedCapitalExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued capital expenditures</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedCapitalExpenditures_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Capital Expenditures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeNetAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) from equity securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt And Equity Securities Unrealized Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment amortization expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net realized losses on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Realized Investment Gains Losses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and investment income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2018 Note and Warrant Purchase Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:to="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Note and Warrant Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Eighteen Note And Warrant Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InterestAndInvestmentIncomeNetMember" xlink:type="locator" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and investment income net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_InterestAndInvestmentIncomeNetMember" xlink:to="ibrx_InterestAndInvestmentIncomeNetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Investment Income, Net</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Investment Income Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Interest Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Interest Issued Or Issuable By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Interest Issued or Issuable, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Interest Issued Or Issuable Type [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SunesisPharmaceuticalsIncMember" xlink:type="locator" xlink:label="ibrx_SunesisPharmaceuticalsIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SunesisPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sunesis Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SunesisPharmaceuticalsIncMember" xlink:to="ibrx_SunesisPharmaceuticalsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SunesisPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sunesis Pharmaceuticals, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SunesisPharmaceuticalsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sunesis Pharmaceuticals Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Investments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Investments [Line Items]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of convertible note upon conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PurchaseOfConvertibleNoteUponConversion" xlink:to="ibrx_PurchaseOfConvertibleNoteUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of convertible note</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Of Convertible Note Upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gains on marketable securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised to acquire shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on equity investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock investment converted into common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Shares Converted1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Equity Securities</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalents and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents And Marketable Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_CurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Current assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_CurrentAssetsMember" xlink:to="ibrx_CurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_CurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Assets [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NoncurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_NoncurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncurrent assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NoncurrentAssetsMember" xlink:to="ibrx_NoncurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NoncurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:type="locator" xlink:label="us-gaap_MutualFundMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MutualFundMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mutual Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MutualFundMember" xlink:to="us-gaap_MutualFundMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MutualFundMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mutual Fund [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtMember" xlink:to="us-gaap_ForeignGovernmentDebtMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignGovernmentDebtMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Government Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Available-for-sale, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-sale, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities debt securities period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:to="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, Weighted- Average Remaining Contractual Life</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Period</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale securities period of unrealized loss positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:to="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesMember" xlink:to="us-gaap_DebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities, period of unrealized loss positions</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Period Of Unrealized Loss Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of available-for-sale securities in unrealized loss positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than temporary impairment losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in marketable equity securities with readily determinable fair values</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gains (losses) from equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gains or losses on sales of equity securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:to="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt And Equity Securities Realized Gain Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets measured at fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Contingent consideration obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, end of period</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPaymentForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual payment for support of research activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AnnualPaymentForSupportOfResearchActivities" xlink:to="ibrx_AnnualPaymentForSupportOfResearchActivities_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedReimbursableCostsPayable" xlink:type="locator" xlink:label="ibrx_AccruedReimbursableCostsPayable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedReimbursableCostsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued reimbursable costs payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedReimbursableCostsPayable" xlink:to="ibrx_AccruedReimbursableCostsPayable_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementAbstract" xlink:type="locator" xlink:label="ibrx_LicensingAgreementAbstract" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LicensingAgreementAbstract" xlink:to="ibrx_LicensingAgreementAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Abstract]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementLineItems" xlink:type="locator" xlink:label="ibrx_LicensingAgreementLineItems" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_LicensingAgreementLineItems_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementTable" xlink:type="locator" xlink:label="ibrx_LicensingAgreementTable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LicensingAgreementTable" xlink:to="ibrx_LicensingAgreementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ClinicalTrialActivitiesMember" xlink:type="locator" xlink:label="ibrx_ClinicalTrialActivitiesMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ClinicalTrialActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical trial activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ClinicalTrialActivitiesMember" xlink:to="ibrx_ClinicalTrialActivitiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ClinicalTrialActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical Trial Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ClinicalTrialActivitiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Trial Activities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities By Industry [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Industry [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NationalInstitutesOfHealthMember" xlink:type="locator" xlink:label="ibrx_NationalInstitutesOfHealthMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NationalInstitutesOfHealthMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">National institutes of health.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NationalInstitutesOfHealthMember" xlink:to="ibrx_NationalInstitutesOfHealthMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NationalInstitutesOfHealthMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institutes of Health</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NationalInstitutesOfHealthMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IosbioLtdExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">iosBio Ltd. Exclusive License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_IosbioLtdExclusiveLicenseAgreementMember" xlink:to="ibrx_IosbioLtdExclusiveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">iosBio Ltd. Exclusive License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Iosbio Ltd Exclusive License Agreement [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CooperativeResearchAndDevelopmentAgreementMember" xlink:type="locator" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cooperative research and development agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_CooperativeResearchAndDevelopmentAgreementMember" xlink:to="ibrx_CooperativeResearchAndDevelopmentAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CRADA</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cooperative Research And Development Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EtubicsCorporationMember" xlink:type="locator" xlink:label="ibrx_EtubicsCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EtubicsCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Etubics Corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_EtubicsCorporationMember" xlink:to="ibrx_EtubicsCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EtubicsCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Etubics Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EtubicsCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Etubics Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">CRADA</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LicensingAgreementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual payment for support of research activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Payment For Support Of Research Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedReimbursableCostsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued reimbursable costs payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedReimbursableCostsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Reimbursable Costs Payable</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual payments for support of research activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" xlink:to="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated unpaid research and development expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" xlink:to="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual payments for support of research activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Payments For Support Of Research Activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated unpaid research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Unpaid Research And Development Expense</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PayableOutstanding" xlink:type="locator" xlink:label="ibrx_PayableOutstanding" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PayableOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payable outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PayableOutstanding" xlink:to="ibrx_PayableOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PayableOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PayableOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payable Outstanding</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:type="locator" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of wholly-owned subsidiary.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:to="ibrx_PercentageOfWhollyOwnedSubsidiary_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ChangeInContingentConsideration" xlink:type="locator" xlink:label="ibrx_ChangeInContingentConsideration" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in contingent consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ChangeInContingentConsideration" xlink:to="ibrx_ChangeInContingentConsideration_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FairValueOfContingentConsiderationObligation" xlink:type="locator" xlink:label="ibrx_FairValueOfContingentConsiderationObligation" />
    <link:label xml:lang="en-US" xlink:label="ibrx_FairValueOfContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of contingent consideration obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_FairValueOfContingentConsiderationObligation" xlink:to="ibrx_FairValueOfContingentConsiderationObligation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VivaBioCellMember" xlink:type="locator" xlink:label="ibrx_VivaBioCellMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VivaBioCellMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">VivaBioCell.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_VivaBioCellMember" xlink:to="ibrx_VivaBioCellMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VivaBioCellMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VivaBioCell</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_VivaBioCellMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Viva Bio Cell [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceCorporationMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Altor BioScience Corporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AltorBioScienceCorporationMember" xlink:to="ibrx_AltorBioScienceCorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Altor BioScience Corporation</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Altor Bio Science Corporation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableAtDecember312022Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights payable at December 31, 2022.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ContingentValueRightsPayableAtDecember312022Member" xlink:to="ibrx_ContingentValueRightsPayableAtDecember312022Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Payable if Certain Conditions are met by December 31, 2022</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Payable At December312022 [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableBeforeDecember312026Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights payable before December 31, 2026.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" xlink:to="ibrx_ContingentValueRightsPayableBeforeDecember312026Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Payable if Certain Conditions are met on or before December 31, 2026</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Payable Before December312026 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DrSoonShiongAndPelatedPartyMember" xlink:type="locator" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dr. Soon-Shiong and related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_DrSoonShiongAndPelatedPartyMember" xlink:to="ibrx_DrSoonShiongAndPelatedPartyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dr. Soon-Shiong and Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dr Soon Shiong And Pelated Party [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceLLCMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Altor BioScience, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AltorBioScienceLLCMember" xlink:to="ibrx_AltorBioScienceLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Altor BioScience, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AltorBioScienceLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Altor Bio Science L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage acquired</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Wholly Owned Subsidiary</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination, consideration transferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment due if certain conditions are met</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ChangeInContingentConsideration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_FairValueOfContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of contingent consideration obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_FairValueOfContingentConsiderationObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Contingent Consideration Obligation</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ContingentValueRightsPayable" xlink:to="ibrx_ContingentValueRightsPayable_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum net sales milestone contingent value rights payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" xlink:to="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum net sales milestone for contingent value rights payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Net Sales Milestone Contingent Value Rights Payable</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPaymentForDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedPaymentForDissentingShares" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPaymentForDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued payment for dissenting shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AccruedPaymentForDissentingShares" xlink:to="ibrx_AccruedPaymentForDissentingShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPaymentForDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrual for dissenting shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AccruedPaymentForDissentingShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Payment For Dissenting Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of lease arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional extended lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Flow Operating Activities Lessee [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Operating Activities Lessee [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows for operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="locator" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease payments related to options to extend lease terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:to="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payments related to options to extend lease terms</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments Related To Options To Extend Lease Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 (excluding the three months ended March 31, 2021)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total future minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Present value of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioIncMember" xlink:type="locator" xlink:label="ibrx_NantBioIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nant Bio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantBioIncMember" xlink:to="ibrx_NantBioIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantBio</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Bio Inc [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantOmicsLLCMember" xlink:type="locator" xlink:label="ibrx_NantOmicsLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantOmics, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantOmicsLLCMember" xlink:to="ibrx_NantOmicsLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantOmics</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantOmicsLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Omics L L C [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VariousMember" xlink:type="locator" xlink:label="ibrx_VariousMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VariousMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Various.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_VariousMember" xlink:to="ibrx_VariousMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VariousMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Various</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_VariousMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Various [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksMember" xlink:type="locator" xlink:label="ibrx_NantWorksMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantWorks.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantWorksMember" xlink:to="ibrx_NantWorksMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantWorks</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Works [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Duley Road.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_DuleyRoadMember" xlink:to="ibrx_DuleyRoadMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duley Road</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Duley Road [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Immuno-Oncology Clinic.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ImmunoOncologyClinicMember" xlink:to="ibrx_ImmunoOncologyClinicMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immuno-Oncology Clinic</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Immuno Oncology Clinic [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantPharmaMember" xlink:type="locator" xlink:label="ibrx_NantPharmaMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantPharma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantPharmaMember" xlink:to="ibrx_NantPharmaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantPharma</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantPharmaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Pharma [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCapitalMember" xlink:type="locator" xlink:label="ibrx_NantCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantCapital.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantCapitalMember" xlink:to="ibrx_NantCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nant Capital</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Capital [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantMobileMember" xlink:type="locator" xlink:label="ibrx_NantMobileMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantMobileMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nant Mobile.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantMobileMember" xlink:to="ibrx_NantMobileMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantMobileMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantMobile</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantMobileMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Mobile [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NCSCMember" xlink:type="locator" xlink:label="ibrx_NCSCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NCSCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NCSC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NCSCMember" xlink:to="ibrx_NCSCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NCSCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NCSC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NCSCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">N C S C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total due from related parties</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total due to related parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total related-party notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due To Related Parties Noncurrent</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nant Works LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantWorksLimitedLiabilityCompanyMember" xlink:to="ibrx_NantWorksLimitedLiabilityCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantWorks</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Works Limited Liability Company [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SharedServicesAgreementMember" xlink:type="locator" xlink:label="ibrx_SharedServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shared services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SharedServicesAgreementMember" xlink:to="ibrx_SharedServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shared Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SharedServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shared Services Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ReimbursementsMember" xlink:type="locator" xlink:label="ibrx_ReimbursementsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ReimbursementsMember" xlink:to="ibrx_ReimbursementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursements</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ReimbursementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmendmentToExtendLeaseTermMember" xlink:type="locator" xlink:label="ibrx_AmendmentToExtendLeaseTermMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AmendmentToExtendLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amendment to extend lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AmendmentToExtendLeaseTermMember" xlink:to="ibrx_AmendmentToExtendLeaseTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AmendmentToExtendLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment to Extend Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AmendmentToExtendLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment To Extend Lease Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicIncMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Immuno Oncology Clinic Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ImmunoOncologyClinicIncMember" xlink:to="ibrx_ImmunoOncologyClinicIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immuno-Oncology Clinic, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ImmunoOncologyClinicIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Immuno Oncology Clinic Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioScienceMember" xlink:type="locator" xlink:label="ibrx_NantBioScienceMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantBioScience.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantBioScienceMember" xlink:to="ibrx_NantBioScienceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NantBioScience</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantBioScienceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Bio Science [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCancerStemCellLLCMember" xlink:type="locator" xlink:label="ibrx_NantCancerStemCellLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCancerStemCellLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantCancerStemCell, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantCancerStemCellLLCMember" xlink:to="ibrx_NantCancerStemCellLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCancerStemCellLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nant Cancer Stem Cell L L C</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCancerStemCellLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Cancer Stem Cell L L C [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SorrentoMember" xlink:type="locator" xlink:label="ibrx_SorrentoMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SorrentoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sorrento.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SorrentoMember" xlink:to="ibrx_SorrentoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SorrentoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sorrento</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SorrentoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sorrento [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BioreactorMember" xlink:type="locator" xlink:label="ibrx_BioreactorMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_BioreactorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bioreactor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_BioreactorMember" xlink:to="ibrx_BioreactorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_BioreactorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bioreactors</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_BioreactorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bioreactor [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EmployeeBonusesPaymentMember" xlink:type="locator" xlink:label="ibrx_EmployeeBonusesPaymentMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EmployeeBonusesPaymentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee bonuses payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_EmployeeBonusesPaymentMember" xlink:to="ibrx_EmployeeBonusesPaymentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_EmployeeBonusesPaymentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Bonuses Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_EmployeeBonusesPaymentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Bonuses Payment [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VendorCostsPaymentsMember" xlink:type="locator" xlink:label="ibrx_VendorCostsPaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VendorCostsPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vendor costs payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_VendorCostsPaymentsMember" xlink:to="ibrx_VendorCostsPaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_VendorCostsPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vendor Costs Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_VendorCostsPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vendor Costs Payments [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DougStLLCMember" xlink:type="locator" xlink:label="ibrx_DougStLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Doug St LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_DougStLLCMember" xlink:to="ibrx_DougStLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">605 Doug St, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_DougStLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Doug St L L C [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="ibrx_ElSegundoCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">El Segundo, California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ElSegundoCaliforniaMember" xlink:to="ibrx_ElSegundoCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">El Segundo California</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ElSegundoCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">El Segundo California [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadLLCMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Duley Road, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_DuleyRoadLLCMember" xlink:to="ibrx_DuleyRoadLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duley Road, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_DuleyRoadLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Duley Road L L C [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Seven year term commencing in September 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" xlink:to="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">7-Year Term Commencing in September 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Seven Year Term Commencing In September Twenty Nineteen [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Seven-year term commencing in July 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" xlink:to="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seven-Year Term Commencing in July 2019</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Seven Year Term Commencing In July Twenty Nineteen [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SixZeroFiveNashLLCMember" xlink:type="locator" xlink:label="ibrx_SixZeroFiveNashLLCMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SixZeroFiveNashLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">605 Nash, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SixZeroFiveNashLLCMember" xlink:to="ibrx_SixZeroFiveNashLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SixZeroFiveNashLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">605 Nash, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SixZeroFiveNashLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Six Zero Five Nash L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DemandPromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_DemandPromissoryNoteMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DemandPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Demand promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_DemandPromissoryNoteMember" xlink:to="ibrx_DemandPromissoryNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_DemandPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Demand Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_DemandPromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Demand Promissory Note [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyNotesPayableMember" xlink:type="locator" xlink:label="ibrx_RelatedPartyNotesPayableMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyNotesPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related-party notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_RelatedPartyNotesPayableMember" xlink:to="ibrx_RelatedPartyNotesPayableMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyNotesPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyNotesPayableMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Notes Payable [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_PromissoryNoteMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Promissory note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PromissoryNoteMember" xlink:to="ibrx_PromissoryNoteMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Promissory Note</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PromissoryNoteMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Promissory Note [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, general and administrative expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current And Noncurrent</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of square foot of facility leased.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NumberOfSquareFootOfFacilityLeased" xlink:to="ibrx_NumberOfSquareFootOfFacilityLeased_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BaseMonthlyRent" xlink:type="locator" xlink:label="ibrx_BaseMonthlyRent" />
    <link:label xml:lang="en-US" xlink:label="ibrx_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Base monthly rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_BaseMonthlyRent" xlink:to="ibrx_BaseMonthlyRent_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual percentage increases to base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AnnualPercentageIncreasesToBaseRent" xlink:to="ibrx_AnnualPercentageIncreasesToBaseRent_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="ibrx_LeaseAgreementExtendedPeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement extended period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LeaseAgreementExtendedPeriod" xlink:to="ibrx_LeaseAgreementExtendedPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of square foot of facility leased</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Square Foot Of Facility Leased</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Base rent - monthly</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_BaseMonthlyRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Base Monthly Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increases of base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Percentage Increases To Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement extended lease period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseAgreementExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreement Extended Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfOfficers" xlink:type="locator" xlink:label="ibrx_NumberOfOfficers" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of officers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NumberOfOfficers" xlink:to="ibrx_NumberOfOfficers_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of officers</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfOfficers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Officers</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_InitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="ibrx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_InitialTermOfAgreement" xlink:to="ibrx_InitialTermOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Agreement</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyInstallmentPayment" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party installment payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_RelatedPartyInstallmentPayment" xlink:to="ibrx_RelatedPartyInstallmentPayment_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionConditionalPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction conditional payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_RelatedPartyTransactionConditionalPayment" xlink:to="ibrx_RelatedPartyTransactionConditionalPayment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated cost for new agreement with clinic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Amounts Of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction installment payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyInstallmentPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Installment Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party transaction conditional payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Conditional Payment</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="ibrx_NewAgreementTerminationNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">New agreement termination notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NewAgreementTerminationNoticePeriod" xlink:to="ibrx_NewAgreementTerminationNoticePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice period to terminate new agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NewAgreementTerminationNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Agreement Termination Notice Period</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalance" xlink:type="locator" xlink:label="ibrx_PrepaidBalance" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidBalance" xlink:to="ibrx_PrepaidBalance_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid balance related to Clinic Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Balance</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party transaction initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_RelatedPartyTransactionInitialTermOfAgreement" xlink:to="ibrx_RelatedPartyTransactionInitialTermOfAgreement_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense ratable payment period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:to="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="ibrx_PrepaymentOfFundingAmount" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment of funding amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaymentOfFundingAmount" xlink:to="ibrx_PrepaymentOfFundingAmount_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid balance included in prepaid expenses and other current assets and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:to="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement entered into with the related party by the entity</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Initial Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense, ratable payment period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Ratable Payment Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment for services amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaymentOfFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment Of Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid balance included in prepaid expenses and other current assets and other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Balance Included In Prepaid Expenses And Other Current Assets And Other Assets</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party agreement renewal term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_RelatedPartyAgreementRenewalTerm" xlink:to="ibrx_RelatedPartyAgreementRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related party, agreement renewal term</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Agreement Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="ibrx_PeriodOfExtendedLeaseTerm" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of extended lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PeriodOfExtendedLeaseTerm" xlink:to="ibrx_PeriodOfExtendedLeaseTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Optional extended lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PeriodOfExtendedLeaseTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Extended Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Due between the parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Due From To Related Party</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual percentage increases to monthly fixed charge.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" xlink:to="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionsToExtendNumberOfTerms" xlink:type="locator" xlink:label="ibrx_OptionsToExtendNumberOfTerms" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionsToExtendNumberOfTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to extend number of terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OptionsToExtendNumberOfTerms" xlink:to="ibrx_OptionsToExtendNumberOfTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual percentage increases to monthly fixed charge</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Percentage Increases To Monthly Fixed Charge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Rent Current And Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionsToExtendNumberOfTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to extend number of terms</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionsToExtendNumberOfTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Extend Number Of Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseholdImprovementPayables" xlink:type="locator" xlink:label="ibrx_LeaseholdImprovementPayables" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseholdImprovementPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Leasehold improvement payables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LeaseholdImprovementPayables" xlink:to="ibrx_LeaseholdImprovementPayables_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseRelatedPayables" xlink:type="locator" xlink:label="ibrx_LeaseRelatedPayables" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseRelatedPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease-related payables.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_LeaseRelatedPayables" xlink:to="ibrx_LeaseRelatedPayables_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseholdImprovementPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvement payables</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseholdImprovementPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvement Payables</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseRelatedPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease-related payables</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_LeaseRelatedPayables_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Related Payables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TenantImprovements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Purchases From Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note interest rate per annum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of note borrowed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and unpaid interest on note</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current And Noncurrent</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNote" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of advance received on note.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AmountOfAdvanceReceivedOnNote" xlink:to="ibrx_AmountOfAdvanceReceivedOnNote_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" />
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of advance received on note outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" xlink:to="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Note interest rate term, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of advance received</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Advance Received On Note</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of advance received on note outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Of Advance Received On Note Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="locator" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">NantCell two thousand and fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:to="ibrx_NantCellTwoThousandAndFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NC 2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nant Cell Two Thousand And Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total amount authorized for repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Authorized Amount1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining authorized repurchase amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Remaining Authorized Repurchase Amount1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total shares reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="ibrx_TwoThousandFifteenEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Thousand Fifteen Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonEmployeeDirectorMember" xlink:type="locator" xlink:label="ibrx_NonEmployeeDirectorMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NonEmployeeDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-employee director.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NonEmployeeDirectorMember" xlink:to="ibrx_NonEmployeeDirectorMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NonEmployeeDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee Director</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NonEmployeeDirectorMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employee Director [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:type="locator" xlink:label="us-gaap_NatureOfExpenseAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfExpenseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Expense [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interim Period, Costs Not Allocable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interim Period Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of stock options associated with resignation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of Stock Options Associated with Resignation</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Modification Of Stock Options Associated With Resignation [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Modification of stock options associated with postponement of termination date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modification of Stock Options Associated with Postponement of Termination Date</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Modification Of Stock Options Associated With Postponement Of Termination Date [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FirstRSUAwardMember" xlink:type="locator" xlink:label="ibrx_FirstRSUAwardMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_FirstRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First RSU award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_FirstRSUAwardMember" xlink:to="ibrx_FirstRSUAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_FirstRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First RSU Award</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_FirstRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First R S U Award [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SecondRSUAwardMember" xlink:type="locator" xlink:label="ibrx_SecondRSUAwardMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SecondRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second RSU award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_SecondRSUAwardMember" xlink:to="ibrx_SecondRSUAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_SecondRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second RSU Award</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_SecondRSUAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second R S U Award [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WarrantsMember" xlink:type="locator" xlink:label="ibrx_WarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_WarrantsMember" xlink:to="ibrx_WarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_WarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Selling, General and Administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionExpirationDateExtendedPeriod" xlink:type="locator" xlink:label="ibrx_OptionExpirationDateExtendedPeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionExpirationDateExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option expiration date extended period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_OptionExpirationDateExtendedPeriod" xlink:to="ibrx_OptionExpirationDateExtendedPeriod_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfBoardOfDirectors" xlink:type="locator" xlink:label="ibrx_NumberOfBoardOfDirectors" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfBoardOfDirectors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of board of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NumberOfBoardOfDirectors" xlink:to="ibrx_NumberOfBoardOfDirectors_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModifiedOptionsExercisablePeriod" xlink:type="locator" xlink:label="ibrx_ModifiedOptionsExercisablePeriod" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ModifiedOptionsExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Modified options exercisable period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ModifiedOptionsExercisablePeriod" xlink:to="ibrx_ModifiedOptionsExercisablePeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionExpirationDateExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration date extended period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_OptionExpirationDateExtendedPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Expiration Date Extended Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfBoardOfDirectors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of board of directors</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfBoardOfDirectors_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Board Of Directors</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award options vested number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ModifiedOptionsExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Modified options exercisable period</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ModifiedOptionsExercisablePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Modified Options Exercisable Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options,Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Ending Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life, Vested and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options, options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price, options granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, award vesting rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from stock options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock option exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Vested and Exercisable</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Number of Shares, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, Unvested, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Forfeited/canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, Unvested, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to non-vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfAwardsGranted" xlink:type="locator" xlink:label="ibrx_NumberOfAwardsGranted" />
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of awards granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_NumberOfAwardsGranted" xlink:to="ibrx_NumberOfAwardsGranted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants of restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of awards granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_NumberOfAwardsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Awards Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, award requisite service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated benefit at grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deemed dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Not Settleable In Cash Fair Value Disclosure</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxLineItems" xlink:type="locator" xlink:label="ibrx_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="ibrx_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxTable" xlink:type="locator" xlink:label="ibrx_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_IncomeTaxTable" xlink:to="ibrx_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IT" xlink:type="locator" xlink:label="country_IT" />
    <link:label xml:lang="en-US" xlink:label="country_IT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Italy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IT" xlink:to="country_IT_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_IT_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">ITALY</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:type="locator" xlink:label="country_KR" />
    <link:label xml:lang="en-US" xlink:label="country_KR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">South Korea</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_KR" xlink:to="country_KR_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_KR_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">KOREA, REPUBLIC OF</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company&apos;s effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExpectedClinicalTrialExpense" xlink:type="locator" xlink:label="ibrx_ExpectedClinicalTrialExpense" />
    <link:label xml:lang="en-US" xlink:label="ibrx_ExpectedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected clinical trial expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_ExpectedClinicalTrialExpense" xlink:to="ibrx_ExpectedClinicalTrialExpense_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderOneMember" xlink:type="locator" xlink:label="ibrx_WorkOrderOneMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Work order one.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_WorkOrderOneMember" xlink:to="ibrx_WorkOrderOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work Order 1</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Work Order One [Member]</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderTwoMember" xlink:type="locator" xlink:label="ibrx_WorkOrderTwoMember" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Work order two.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_WorkOrderTwoMember" xlink:to="ibrx_WorkOrderTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work Order 2</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_WorkOrderTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Work Order Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ExpectedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected clinical trial expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_ExpectedClinicalTrialExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Clinical Trial Expense</link:label>
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfSalesAgentCommission" xlink:type="locator" xlink:label="ibrx_PercentageOfSalesAgentCommission" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfSalesAgentCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sales agent commission.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibrx_PercentageOfSalesAgentCommission" xlink:to="ibrx_PercentageOfSalesAgentCommission_lbl" />
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfSalesAgentCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of sales agent commission</link:label>
    <link:label xml:lang="en-US" xlink:label="ibrx_PercentageOfSalesAgentCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Sales Agent Commission</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ibrx-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-14T03:23:14.4046635+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 8db817cc67994bc485d23e6d0b13d00d -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/role/TemplateLink" xlink:href="ibrx-20210331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ibrx-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ConvertibleNoteReceivableNonCurrent" xlink:type="locator" xlink:label="ibrx_ConvertibleNoteReceivableNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="ibrx_ConvertibleNoteReceivableNonCurrent" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares" xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:type="locator" xlink:label="us-gaap_InterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterestAndDividend" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterestAndDividend" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ProfitLoss" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="ibrx-20210331.xsd#Role_StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="ibrx_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="locator" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" xlink:type="locator" xlink:label="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" xlink:type="locator" xlink:label="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ibrx_NonCashInterestIncomeExpenseFromOperatingActivities" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ibrx_IncreaseDecreaseInOperatingLeaseLiability" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="ibrx_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics" xlink:href="ibrx-20210331.xsd#Role_DisclosureEquityInvestmentInViractaTherapeutics" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MarketableDebtAndEquitySecuritiesMember" xlink:type="locator" xlink:label="ibrx_MarketableDebtAndEquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="ibrx_MarketableDebtAndEquitySecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="ibrx-20210331.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockholdersDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ibrx-20210331.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents" xlink:href="ibrx-20210331.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:type="locator" xlink:label="us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UnusualRisksAndUncertaintiesTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncomeTableTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="ibrx_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_InterestAndOtherIncomeTableTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageByKeyExecutives" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageByKeyExecutives" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" xlink:type="locator" xlink:label="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestMember" xlink:type="locator" xlink:label="ibrx_NantKwestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" xlink:type="locator" xlink:label="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ATMSalesAgreementWithJefferiesLLCMember" xlink:type="locator" xlink:label="ibrx_ATMSalesAgreementWithJefferiesLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:type="locator" xlink:label="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibrx_ATMSalesAgreementWithJefferiesLLCMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_NantCellIncMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_OwnershipAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantKwestMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="ibrx_OwnershipPercentageByKeyExecutives" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventLineItems" xlink:type="locator" xlink:label="dei_NameChangeEventLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestIncMember" xlink:type="locator" xlink:label="ibrx_NantKwestIncMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:type="locator" xlink:label="srt_ConsolidationEliminationsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ReportableLegalEntitiesMember" xlink:type="locator" xlink:label="srt_ReportableLegalEntitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain" xlink:type="locator" xlink:label="srt_ConsolidationItemsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis" xlink:type="locator" xlink:label="srt_ConsolidationItemsAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NameChangeEventTable" xlink:type="locator" xlink:label="dei_NameChangeEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="dei_NameChangeEventTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="srt_ConsolidationItemsAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ReportableLegalEntitiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationEliminationsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10090.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantCellIncMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantKwestIncMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventTable" xlink:to="dei_NameChangeEventLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_Revenues" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_NameChangeEventLineItems" xlink:to="us-gaap_ProfitLoss" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" xlink:type="locator" xlink:label="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:type="locator" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesLineItems" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="locator" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantKwestMember" xlink:type="locator" xlink:label="ibrx_NantKwestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="ibrx_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccountingPoliciesTable" xlink:type="locator" xlink:label="ibrx_AccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibrx_AccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_AtTheMarketOfferingProgramMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_OwnershipAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantKwestMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="ibrx_AccountingPoliciesLineItems" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesTable" xlink:to="us-gaap_PlanNameAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_AccountingPoliciesLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OutstandingStockOptionsMember" xlink:type="locator" xlink:label="ibrx_OutstandingStockOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ibrx_OutstandingStockOptionsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSuppliesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidSuppliesWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidEquipmentMaintenance" xlink:type="locator" xlink:label="ibrx_PrepaidEquipmentMaintenance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseIncentiveReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_LeaseIncentiveReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EquipmentDepositsCurrent" xlink:type="locator" xlink:label="ibrx_EquipmentDepositsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidRent" xlink:type="locator" xlink:label="us-gaap_PrepaidRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InsurancePremiumFinancingAsset" xlink:type="locator" xlink:label="ibrx_InsurancePremiumFinancingAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidInsurance" xlink:type="locator" xlink:label="us-gaap_PrepaidInsurance" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidLicenseFees" xlink:type="locator" xlink:label="ibrx_PrepaidLicenseFees" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidServices" xlink:type="locator" xlink:label="ibrx_PrepaidServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InsuranceSettlementsReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InsuranceSettlementsReceivableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InsuranceSettlementsReceivableCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_PrepaidServices" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_PrepaidLicenseFees" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_InsurancePremiumFinancingAsset" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidRent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_EquipmentDepositsCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_LeaseIncentiveReceivableCurrent" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_PrepaidEquipmentMaintenance" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="ibrx_PrepaidSuppliesWithRelatedParty" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="locator" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="ibrx_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FinancialStatementDetailsAbstract" xlink:type="locator" xlink:label="ibrx_FinancialStatementDetailsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_FinancialStatementDetailsAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsOtherAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMiscellaneousNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsMiscellaneousNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:type="locator" xlink:label="us-gaap_ValueAddedTaxReceivableNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_ValueAddedTaxReceivableNoncurrent" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_SecurityDeposit" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="ibrx_PrepaidSoftwareLicenseFeesInOtherAssets" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesNoncurrent" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsMiscellaneousNoncurrent" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedCapitalExpenditures" xlink:type="locator" xlink:label="ibrx_AccruedCapitalExpenditures" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="locator" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedInsuranceCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedInsuranceCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedLaboratoryEquipmentAndSupplies" xlink:type="locator" xlink:label="ibrx_AccruedLaboratoryEquipmentAndSupplies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionPayableCurrent" xlink:type="locator" xlink:label="us-gaap_ConstructionPayableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedResearchAndDevelopmentCosts" xlink:type="locator" xlink:label="ibrx_AccruedResearchAndDevelopmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPreclinicalAndClinicalTrialCosts" xlink:type="locator" xlink:label="ibrx_AccruedPreclinicalAndClinicalTrialCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedDissentingShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedBonusesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ibrx_AccruedDissentingShares" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ibrx_AccruedPreclinicalAndClinicalTrialCosts" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ibrx_AccruedResearchAndDevelopmentCosts" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ConstructionPayableCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ibrx_AccruedLaboratoryEquipmentAndSupplies" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedInsuranceCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ibrx_AccruedCapitalExpenditures" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses" xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentIncomeNetAbstract" xlink:to="us-gaap_InvestmentIncomeNet" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PurchaseOfConvertibleNoteUponConversion" xlink:type="locator" xlink:label="ibrx_PurchaseOfConvertibleNoteUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SunesisPharmaceuticalsIncMember" xlink:type="locator" xlink:label="ibrx_SunesisPharmaceuticalsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InterestAndInvestmentIncomeNetMember" xlink:type="locator" xlink:label="ibrx_InterestAndInvestmentIncomeNetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" xlink:type="locator" xlink:label="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_ScheduleOfInvestmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="dei_LegalEntityAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="ibrx_InterestAndInvestmentIncomeNetMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_SunesisPharmaceuticalsIncMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="ibrx_PurchaseOfConvertibleNoteUponConversion" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:type="locator" xlink:label="us-gaap_MutualFundMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NoncurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_NoncurrentAssetsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_CurrentAssetsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_NoncurrentAssetsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MutualFundMember" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" xlink:type="locator" xlink:label="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtAndEquitySecuritiesRealizedGainLoss" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:type="locator" xlink:label="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_CashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignGovernmentDebtMember" xlink:type="locator" xlink:label="us-gaap_ForeignGovernmentDebtMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MutualFundMember" xlink:type="locator" xlink:label="us-gaap_MutualFundMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NoncurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_NoncurrentAssetsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CurrentAssetsMember" xlink:type="locator" xlink:label="ibrx_CurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_CurrentAssetsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_NoncurrentAssetsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MutualFundMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ForeignGovernmentDebtMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesEquitySecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesEquitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ViractaTherapeuticsIncMember" xlink:type="locator" xlink:label="ibrx_ViractaTherapeuticsIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SunesisPharmaceuticalsIncMember" xlink:type="locator" xlink:label="ibrx_SunesisPharmaceuticalsIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:type="locator" xlink:label="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_SunesisPharmaceuticalsIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="dei_LegalEntityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ibrx_ViractaTherapeuticsIncMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesEquitySecurities" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PayableOutstanding" xlink:type="locator" xlink:label="ibrx_PayableOutstanding" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedReimbursableCostsPayable" xlink:type="locator" xlink:label="ibrx_AccruedReimbursableCostsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPaymentForSupportOfResearchActivities" xlink:type="locator" xlink:label="ibrx_AnnualPaymentForSupportOfResearchActivities" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementLineItems" xlink:type="locator" xlink:label="ibrx_LicensingAgreementLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CooperativeResearchAndDevelopmentAgreementMember" xlink:type="locator" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember_li0l2" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EtubicsCorporationMember" xlink:type="locator" xlink:label="ibrx_EtubicsCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_CooperativeResearchAndDevelopmentAgreementMember" xlink:type="locator" xlink:label="ibrx_CooperativeResearchAndDevelopmentAgreementMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IosbioLtdExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="ibrx_IosbioLtdExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NationalInstitutesOfHealthMember" xlink:type="locator" xlink:label="ibrx_NationalInstitutesOfHealthMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesIndustryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ClinicalTrialActivitiesMember" xlink:type="locator" xlink:label="ibrx_ClinicalTrialActivitiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementTable" xlink:type="locator" xlink:label="ibrx_LicensingAgreementTable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LicensingAgreementAbstract" xlink:type="locator" xlink:label="ibrx_LicensingAgreementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementAbstract" xlink:to="ibrx_LicensingAgreementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ibrx_ClinicalTrialActivitiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="ibrx_NationalInstitutesOfHealthMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_IosbioLtdExclusiveLicenseAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_CooperativeResearchAndDevelopmentAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_EtubicsCorporationMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_CooperativeResearchAndDevelopmentAgreementMember_li0l2" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementTable" xlink:to="ibrx_LicensingAgreementLineItems" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_AnnualPaymentForSupportOfResearchActivities" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_AccruedReimbursableCostsPayable" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_EstimatedUnpaidResearchAndDevelopmentExpense" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_LicensingAgreementLineItems" xlink:to="ibrx_PayableOutstanding" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" xlink:type="locator" xlink:label="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AccruedPaymentForDissentingShares" xlink:type="locator" xlink:label="ibrx_AccruedPaymentForDissentingShares" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayable" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayable" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FairValueOfContingentConsiderationObligation" xlink:type="locator" xlink:label="ibrx_FairValueOfContingentConsiderationObligation" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ChangeInContingentConsideration" xlink:type="locator" xlink:label="ibrx_ChangeInContingentConsideration" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfWhollyOwnedSubsidiary" xlink:type="locator" xlink:label="ibrx_PercentageOfWhollyOwnedSubsidiary" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceLLCMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DrSoonShiongAndPelatedPartyMember" xlink:type="locator" xlink:label="ibrx_DrSoonShiongAndPelatedPartyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableBeforeDecember312026Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ContingentValueRightsPayableAtDecember312022Member" xlink:type="locator" xlink:label="ibrx_ContingentValueRightsPayableAtDecember312022Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AltorBioScienceCorporationMember" xlink:type="locator" xlink:label="ibrx_AltorBioScienceCorporationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VivaBioCellMember" xlink:type="locator" xlink:label="ibrx_VivaBioCellMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ibrx_VivaBioCellMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_AltorBioScienceCorporationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ibrx_ContingentValueRightsPayableAtDecember312022Member" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ibrx_ContingentValueRightsPayableBeforeDecember312026Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_DrSoonShiongAndPelatedPartyMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_AltorBioScienceLLCMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_PercentageOfWhollyOwnedSubsidiary" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_ChangeInContingentConsideration" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_FairValueOfContingentConsiderationObligation" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_ContingentValueRightsPayable" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_AccruedPaymentForDissentingShares" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost" xlink:type="locator" xlink:label="us-gaap_LeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:type="locator" xlink:label="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NCSCMember" xlink:type="locator" xlink:label="ibrx_NCSCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantMobileMember" xlink:type="locator" xlink:label="ibrx_NantMobileMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCapitalMember" xlink:type="locator" xlink:label="ibrx_NantCapitalMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantPharmaMember" xlink:type="locator" xlink:label="ibrx_NantPharmaMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksMember" xlink:type="locator" xlink:label="ibrx_NantWorksMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VariousMember" xlink:type="locator" xlink:label="ibrx_VariousMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantOmicsLLCMember" xlink:type="locator" xlink:label="ibrx_NantOmicsLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioIncMember" xlink:type="locator" xlink:label="ibrx_NantBioIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantBioIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantOmicsLLCMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_VariousMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DuleyRoadMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantPharmaMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCapitalMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantMobileMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NCSCMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureRelatedPartyAgreementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmountOfAdvanceReceivedOnNote" xlink:type="locator" xlink:label="ibrx_AmountOfAdvanceReceivedOnNote" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateTerms" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_NotesPayableRelatedPartiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TenantImprovements" xlink:type="locator" xlink:label="us-gaap_TenantImprovements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecurityDeposit" xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseRelatedPayables" xlink:type="locator" xlink:label="ibrx_LeaseRelatedPayables" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseholdImprovementPayables" xlink:type="locator" xlink:label="ibrx_LeaseholdImprovementPayables" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionsToExtendNumberOfTerms" xlink:type="locator" xlink:label="ibrx_OptionsToExtendNumberOfTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedRentCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_AccruedRentCurrentAndNoncurrent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PeriodOfExtendedLeaseTerm" xlink:type="locator" xlink:label="ibrx_PeriodOfExtendedLeaseTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyAgreementRenewalTerm" xlink:type="locator" xlink:label="ibrx_RelatedPartyAgreementRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="locator" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" xlink:type="locator" xlink:label="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaymentOfFundingAmount" xlink:type="locator" xlink:label="ibrx_PrepaymentOfFundingAmount" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" xlink:type="locator" xlink:label="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionInitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionInitialTermOfAgreement" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PrepaidBalance" xlink:type="locator" xlink:label="ibrx_PrepaidBalance" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NewAgreementTerminationNoticePeriod" xlink:type="locator" xlink:label="ibrx_NewAgreementTerminationNoticePeriod" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyTransactionConditionalPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyTransactionConditionalPayment" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyInstallmentPayment" xlink:type="locator" xlink:label="ibrx_RelatedPartyInstallmentPayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_InitialTermOfAgreement" xlink:type="locator" xlink:label="ibrx_InitialTermOfAgreement" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfOfficers" xlink:type="locator" xlink:label="ibrx_NumberOfOfficers" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_LeaseAgreementExtendedPeriod" xlink:type="locator" xlink:label="ibrx_LeaseAgreementExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AnnualPercentageIncreasesToBaseRent" xlink:type="locator" xlink:label="ibrx_AnnualPercentageIncreasesToBaseRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BaseMonthlyRent" xlink:type="locator" xlink:label="ibrx_BaseMonthlyRent" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfSquareFootOfFacilityLeased" xlink:type="locator" xlink:label="ibrx_NumberOfSquareFootOfFacilityLeased" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_PromissoryNoteMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantMobileMember" xlink:type="locator" xlink:label="ibrx_NantMobileMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NCSCMember" xlink:type="locator" xlink:label="ibrx_NCSCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksMember" xlink:type="locator" xlink:label="ibrx_NantWorksMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_RelatedPartyNotesPayableMember" xlink:type="locator" xlink:label="ibrx_RelatedPartyNotesPayableMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DemandPromissoryNoteMember" xlink:type="locator" xlink:label="ibrx_DemandPromissoryNoteMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCapitalMember" xlink:type="locator" xlink:label="ibrx_NantCapitalMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantPharmaMember" xlink:type="locator" xlink:label="ibrx_NantPharmaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SixZeroFiveNashLLCMember" xlink:type="locator" xlink:label="ibrx_SixZeroFiveNashLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" xlink:type="locator" xlink:label="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DuleyRoadLLCMember" xlink:type="locator" xlink:label="ibrx_DuleyRoadLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ElSegundoCaliforniaMember" xlink:type="locator" xlink:label="ibrx_ElSegundoCaliforniaMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_DougStLLCMember" xlink:type="locator" xlink:label="ibrx_DougStLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantOmicsLLCMember" xlink:type="locator" xlink:label="ibrx_NantOmicsLLCMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_VendorCostsPaymentsMember" xlink:type="locator" xlink:label="ibrx_VendorCostsPaymentsMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_EmployeeBonusesPaymentMember" xlink:type="locator" xlink:label="ibrx_EmployeeBonusesPaymentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_BioreactorMember" xlink:type="locator" xlink:label="ibrx_BioreactorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SorrentoMember" xlink:type="locator" xlink:label="ibrx_SorrentoMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain" xlink:type="locator" xlink:label="srt_OwnershipDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis" xlink:type="locator" xlink:label="srt_OwnershipAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCancerStemCellLLCMember" xlink:type="locator" xlink:label="ibrx_NantCancerStemCellLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:type="locator" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantBioScienceMember" xlink:type="locator" xlink:label="ibrx_NantBioScienceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AmendmentToExtendLeaseTermMember" xlink:type="locator" xlink:label="ibrx_AmendmentToExtendLeaseTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ReimbursementsMember" xlink:type="locator" xlink:label="ibrx_ReimbursementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SharedServicesAgreementMember" xlink:type="locator" xlink:label="ibrx_SharedServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantWorksLimitedLiabilityCompanyMember" xlink:type="locator" xlink:label="ibrx_NantWorksLimitedLiabilityCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksLimitedLiabilityCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_SharedServicesAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="ibrx_ReimbursementsMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_AmendmentToExtendLeaseTermMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicIncMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementGeographicalAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantBioScienceMember" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCancerStemCellLLCMember" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_OwnershipAxis" order="10030.16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain" xlink:to="ibrx_NantCancerStemCellLLCMember" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ibrx_NantBioScienceMember" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="dei_LegalEntityAxis" order="10030.20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="ibrx_SorrentoMember" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10030.22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_BioreactorMember" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="12340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_NantBioScienceMember" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_EmployeeBonusesPaymentMember" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_VendorCostsPaymentsMember" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ibrx_NantOmicsLLCMember" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DougStLLCMember" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ibrx_ElSegundoCaliforniaMember" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_DuleyRoadLLCMember" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember" order="13480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_SixZeroFiveNashLLCMember" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_StatementScenarioAxis" order="10030.26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="13720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibrx_ElSegundoCaliforniaMember" order="13740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantPharmaMember" order="14100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantCapitalMember" order="14180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="14280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_DemandPromissoryNoteMember" order="14300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ibrx_RelatedPartyNotesPayableMember" order="14420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantWorksMember" order="14500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NCSCMember" order="14780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_NantMobileMember" order="15060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibrx_PromissoryNoteMember" order="15440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="15920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="15930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="15970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="16040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="16110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NumberOfSquareFootOfFacilityLeased" order="16180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_BaseMonthlyRent" order="16220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AnnualPercentageIncreasesToBaseRent" order="16300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="16340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseAgreementExtendedPeriod" order="16380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="16420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NumberOfOfficers" order="16490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_InitialTermOfAgreement" order="16540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="16590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyInstallmentPayment" order="16630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyTransactionConditionalPayment" order="16670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_NewAgreementTerminationNoticePeriod" order="16720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaidBalance" order="16890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyTransactionInitialTermOfAgreement" order="16980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod" order="17020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaymentOfFundingAmount" order="17100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets" order="17140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" order="17210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_RelatedPartyAgreementRenewalTerm" order="17390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="17450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="17510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="17660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_PeriodOfExtendedLeaseTerm" order="17920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" order="18080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge" order="18230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccruedRentCurrentAndNoncurrent" order="18270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_OptionsToExtendNumberOfTerms" order="18390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="18430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="18580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseholdImprovementPayables" order="18900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_LeaseRelatedPayables" order="18980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SecurityDeposit" order="19140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="19270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConstructionInProgressGross" order="19360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_TenantImprovements" order="19380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" order="19450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="19560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="19660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_NotesPayableRelatedPartiesNoncurrent" order="19760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" order="19860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="20890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AmountOfAdvanceReceivedOnNote" order="20950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibrx_AmountOfAdvanceReceivedOnNoteOutstanding" order="21010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="21070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockholdersDeficitAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="locator" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="locator" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantCellTwoThousandAndFifteenPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ibrx_MergerExchangeRatio" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_MergerExchangeRatio" xlink:type="locator" xlink:label="ibrx_MergerExchangeRatio" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfAwardsGranted" xlink:type="locator" xlink:label="ibrx_NumberOfAwardsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModifiedOptionsExercisablePeriod" xlink:type="locator" xlink:label="ibrx_ModifiedOptionsExercisablePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NumberOfBoardOfDirectors" xlink:type="locator" xlink:label="ibrx_NumberOfBoardOfDirectors" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_OptionExpirationDateExtendedPeriod" xlink:type="locator" xlink:label="ibrx_OptionExpirationDateExtendedPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WarrantsMember" xlink:type="locator" xlink:label="ibrx_WarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellIncMember" xlink:type="locator" xlink:label="ibrx_NantCellIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NantCellTwoThousandAndFifteenPlanMember" xlink:type="locator" xlink:label="ibrx_NantCellTwoThousandAndFifteenPlanMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_SecondRSUAwardMember" xlink:type="locator" xlink:label="ibrx_SecondRSUAwardMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_FirstRSUAwardMember" xlink:type="locator" xlink:label="ibrx_FirstRSUAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" xlink:type="locator" xlink:label="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:type="locator" xlink:label="us-gaap_NatureOfExpenseAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_NonEmployeeDirectorMember" xlink:type="locator" xlink:label="ibrx_NonEmployeeDirectorMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_TwoThousandFifteenEquityIncentivePlanMember" xlink:type="locator" xlink:label="ibrx_TwoThousandFifteenEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_TwoThousandFifteenEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibrx_NonEmployeeDirectorMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_NatureOfExpenseAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithResignationMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_FirstRSUAwardMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_SecondRSUAwardMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibrx_NantCellTwoThousandAndFifteenPlanMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="ibrx_NantCellIncMember" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ibrx_WarrantsMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_OptionExpirationDateExtendedPeriod" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_NumberOfBoardOfDirectors" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ModifiedOptionsExercisablePeriod" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="12070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_li0l2" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="12280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_NumberOfAwardsGranted" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_MergerExchangeRatio" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="12860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember" xlink:type="locator" xlink:label="us-gaap_StockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_StockOptionMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationStockOptionActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_li0l2" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" xlink:type="locator" xlink:label="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureStockBasedCompensationRsusActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxLineItems" xlink:type="locator" xlink:label="ibrx_IncomeTaxLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_KR" xlink:type="locator" xlink:label="country_KR" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_IT" xlink:type="locator" xlink:label="country_IT" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_IncomeTaxTable" xlink:type="locator" xlink:label="ibrx_IncomeTaxTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ibrx_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_IncomeTaxTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_IT" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_KR" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_IncomeTaxTable" xlink:to="ibrx_IncomeTaxLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibrx_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="ibrx-20210331.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_PercentageOfSalesAgentCommission" xlink:type="locator" xlink:label="ibrx_PercentageOfSalesAgentCommission" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" xlink:type="locator" xlink:label="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ExpectedClinicalTrialExpense" xlink:type="locator" xlink:label="ibrx_ExpectedClinicalTrialExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderTwoMember" xlink:type="locator" xlink:label="ibrx_WorkOrderTwoMember" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_WorkOrderOneMember" xlink:type="locator" xlink:label="ibrx_WorkOrderOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_ImmunoOncologyClinicIncMember" xlink:type="locator" xlink:label="ibrx_ImmunoOncologyClinicIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="ibrx-20210331.xsd#ibrx_AtTheMarketOfferingProgramMember" xlink:type="locator" xlink:label="ibrx_AtTheMarketOfferingProgramMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibrx_AtTheMarketOfferingProgramMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ibrx_ImmunoOncologyClinicIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_WorkOrderOneMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibrx_WorkOrderTwoMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_ExpectedClinicalTrialExpense" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibrx_PercentageOfSalesAgentCommission" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ibrx-10q_20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:ibrx="http://www.immunitybio.com/20210331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ibrx-20210331.xsd" xlink:type="simple"/>
    <context id="C_0001326110_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_20210512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-05-12</instant>
        </period>
    </context>
    <context id="C_0001326110_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">ibrx:MarketableDebtAndEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="C_0001326110_20210309_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="C_0001326110_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantKwestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20201221_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-21</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantKwestIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableLegalEntitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-30</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:OutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ibrx:OutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-09</startDate>
            <endDate>2021-03-09</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190130_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-30</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_ibrxInterestAndInvestmentIncomeNetMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ibrx:InterestAndInvestmentIncomeNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:SunesisPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-25</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:ViractaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:NoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ForeignGovernmentDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-02</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EtubicsCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-02</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">ibrx:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:CooperativeResearchAndDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:ClinicalTrialActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ibrx:ClinicalTrialActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:IosbioLtdExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-04-10</instant>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-10</startDate>
            <endDate>2015-04-10</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-15</startDate>
            <endDate>2015-06-15</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:VivaBioCellMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableAtDecember312022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ibrx:ContingentValueRightsPayableBeforeDecember312026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:DrSoonShiongAndPelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:AltorBioScienceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMinimumMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMaximumMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VariousMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">ibrx:ReimbursementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibrx:SharedServicesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-11-01</startDate>
            <endDate>2015-11-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:AmendmentToExtendLeaseTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksLimitedLiabilityCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20151130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-30</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantBioScienceMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001326110_deiLegalEntityAxis_ibrxSorrentoMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibrx:SorrentoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:BioreactorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:BioreactorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCancerStemCellLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:VendorCostsPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantBioScienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:EmployeeBonusesPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ibrx:NantOmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DougStLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInSeptemberTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibrx:SevenYearTermCommencingInJulyTwentyNineteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:DuleyRoadLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibrx:ElSegundoCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:SixZeroFiveNashLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantWorksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20180831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NCSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:DemandPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantMobileMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ibrx:RelatedPartyNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210226_20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-26</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibrx:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:NantCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibrx:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithResignationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">ibrx:ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-18</startDate>
            <endDate>2021-03-18</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-29</startDate>
            <endDate>2021-03-29</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:FirstRSUAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:SecondRSUAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-05</startDate>
            <endDate>2021-02-05</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibrx:NantCellTwoThousandAndFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-04</startDate>
            <endDate>2021-03-04</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ibrx:NantCellIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ibrx:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:WorkOrderOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderTwoMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326110</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibrx:WorkOrderTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ibrx:ImmunoOncologyClinicIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_ibrxSecurity">
        <measure>ibrx:Security</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_ibrxOfficer">
        <measure>ibrx:Officer</measure>
    </unit>
    <unit id="U_ibrxTerm">
        <measure>ibrx:Term</measure>
    </unit>
    <unit id="U_ibrxDirector">
        <measure>ibrx:Director</measure>
    </unit>
    <unit id="U_ibrxAward">
        <measure>ibrx:Award</measure>
    </unit>
    <dei:DocumentType contextRef="C_0001326110_20210101_20210331" id="F_000000">10-Q</dei:DocumentType>
    <dei:AmendmentFlag contextRef="C_0001326110_20210101_20210331" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="C_0001326110_20210101_20210331" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001326110_20210101_20210331" id="F_000004">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001326110_20210101_20210331" id="F_000007">0001326110</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001326110_20210101_20210331" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCurrentReportingStatus contextRef="C_0001326110_20210101_20210331" id="F_000013">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001326110_20210101_20210331" id="F_000014">Yes</dei:EntityInteractiveDataCurrent>
    <ibrx:OptionExpirationDateExtendedPeriod contextRef="C_0001326110_20210101_20210331" id="F_000959">P30D</ibrx:OptionExpirationDateExtendedPeriod>
    <ibrx:ModifiedOptionsExercisablePeriod contextRef="C_0001326110_20210101_20210331" id="F_000962">P90D</ibrx:ModifiedOptionsExercisablePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331"
      id="F_001016">P70M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210101_20210331"
      decimals="INF"
      id="F_000650"
      unitRef="U_iso4217USD">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210331"
      id="F_000742">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210331"
      id="F_000741">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_20210331"
      id="F_000744">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_20210331"
      id="F_000743">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ibrx:RelatedPartyTransactionInitialTermOfAgreement
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831"
      id="F_000837">P5Y</ibrx:RelatedPartyTransactionInitialTermOfAgreement>
    <ibrx:RelatedPartyAgreementRenewalTerm
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20180801_20180831"
      id="F_000838">P1Y</ibrx:RelatedPartyAgreementRenewalTerm>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331"
      id="F_000854">P3Y</ibrx:PeriodOfExtendedLeaseTerm>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228"
      id="F_000868">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      id="F_000873">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      id="F_000874">P7Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      id="F_000875">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228"
      id="F_000890">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="C_0001326110_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331"
      id="F_001015">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <ibrx:InitialTermOfAgreement
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731"
      id="F_000816">P1Y</ibrx:InitialTermOfAgreement>
    <ibrx:RelatedPartyTransactionInitialTermOfAgreement
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331"
      id="F_000828">P5Y</ibrx:RelatedPartyTransactionInitialTermOfAgreement>
    <ibrx:PeriodOfExtendedLeaseTerm
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      id="F_000876">P5Y</ibrx:PeriodOfExtendedLeaseTerm>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000075"
      unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000075_2"
      unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000076_2"
      unitRef="U_iso4217USD">0</us-gaap:CommitmentsAndContingencies>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210101_20210331"
      id="F_000607">P2M12D</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210101_20210331"
      id="F_000608">P5Y1M6D</ibrx:AvailableForSaleSecuritiesDebtSecuritiesPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000978">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000979">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000980">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000990">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentQuarterlyReport contextRef="C_0001326110_20210101_20210331" id="F_000027">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001326110_20210101_20210331" id="F_000002">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="C_0001326110_20210101_20210331" id="F_000028">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001326110_20210101_20210331" id="F_000018">001-37507</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001326110_20210101_20210331" id="F_000006">IMMUNITYBIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001326110_20210101_20210331" id="F_000019">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001326110_20210101_20210331" id="F_000020">43-1979754</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001326110_20210101_20210331" id="F_000021">3530 John Hopkins Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0001326110_20210101_20210331" id="F_000022">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001326110_20210101_20210331" id="F_000023">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001326110_20210101_20210331" id="F_000024">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001326110_20210101_20210331" id="F_000025">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001326110_20210101_20210331" id="F_000026">633-0300</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001326110_20210101_20210331" id="F_000016">Common Stock, par&#160;value&#160;$0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001326110_20210101_20210331" id="F_000005">IBRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001326110_20210101_20210331" id="F_000017">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityFilerCategory contextRef="C_0001326110_20210101_20210331" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001326110_20210101_20210331" id="F_000011">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001326110_20210101_20210331" id="F_000010">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001326110_20210101_20210331" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001326110_20210512"
      decimals="INF"
      id="F_000012"
      unitRef="U_xbrlishares">383905840</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000029"
      unitRef="U_iso4217USD">44679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">34915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">38594000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">61146000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">2057000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">2003000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">14242000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">13649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">99572000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">111713000</us-gaap:AssetsCurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">1000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">950000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">80875000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">72541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">7849000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">1438000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">1463000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <ibrx:ConvertibleNoteReceivableNonCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">6191000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <ibrx:ConvertibleNoteReceivableNonCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">6129000</ibrx:ConvertibleNoteReceivableNonCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">18447000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">18138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">1905000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">2598000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">209428000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">221381000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">20097000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">11510000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">36793000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">36771000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">17817000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">14838000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">5156000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">5015000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">79863000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">68134000</us-gaap:LiabilitiesCurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">297286000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">254353000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">16554000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">16179000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">170000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">170000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">891000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">1035000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000073"
      unitRef="U_iso4217USD">394764000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000074"
      unitRef="U_iso4217USD">339871000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000093"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001326110_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">383067321</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">383067321</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001326110_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">382243142</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_20201231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">382243142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockShares
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">163800</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="C_0001326110_20201231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">163800</us-gaap:TreasuryStockShares>
    <us-gaap:CommonStockValue
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">38000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">38000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">1508958000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">1495163000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">-1694745000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">-1615131000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">-38000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">122000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">-185787000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">-119808000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">451000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">1318000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">-185336000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">-118490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">209428000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">221381000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">139000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">165000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">41128000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">27374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">45275000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">9493000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">86403000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">36867000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-86264000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">-36702000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">8944000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">78000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">3168000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">1889000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">13000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">1104000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">5789000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-707000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-80475000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-37409000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-80481000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-37427000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-867000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-389000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-79614000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-37038000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001326110_20210101_20210331"
      decimals="2"
      id="F_000131"
      unitRef="U_iso4217USD_xbrlishares">-0.21</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001326110_20200101_20200331"
      decimals="2"
      id="F_000132"
      unitRef="U_iso4217USD_xbrlishares">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001326110_20210101_20210331"
      decimals="0"
      id="F_000133"
      unitRef="U_xbrlishares">382741464</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001326110_20200101_20200331"
      decimals="0"
      id="F_000134"
      unitRef="U_xbrlishares">371989232</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-80481000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">-37427000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">-24000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">-162000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">70000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">-3000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">-1000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-160000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">-80641000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">-37380000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-867000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-389000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-79774000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-36991000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">382243142</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">1495163000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-1615131000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">122000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-119808000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">1318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">-118490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">15298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">15298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">15298000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000167"
      unitRef="U_xbrlishares">690465</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">1121000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">1121000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">1121000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000175"
      unitRef="U_xbrlishares">235725</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000183"
      unitRef="U_xbrlishares">102011</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">2624000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">2624000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">2624000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">-160000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-160000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-160000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-79614000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20210331"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">-79614000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210101_20210331"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">-867000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">-80481000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000207"
      unitRef="U_xbrlishares">383067321</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">1508958000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">-1694745000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210331"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">-38000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20210331"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">-185787000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20210331"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">-185336000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000215"
      unitRef="U_xbrlishares">371976995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">1406002000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">-1393280000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">-87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20191231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">12672000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">3654000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20191231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">16326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">480000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="INF"
      id="F_000231"
      unitRef="U_xbrlishares">63750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="INF"
      id="F_000239"
      unitRef="U_xbrlishares">25722</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">123000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">123000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">0</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">123000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">47000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">-37038000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20200331"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">-37038000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200101_20200331"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">-389000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">-37427000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="INF"
      id="F_000263"
      unitRef="U_xbrlishares">372015023</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">1406359000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">-1430318000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200331"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">-40000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapAociIncludingPortionAttributableToNoncontrollingInterestMember_20200331"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">-23962000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20200331"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">3265000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0001326110_20200331"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">-20697000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">-80481000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">-37427000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">15298000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">480000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">8834000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">-202000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <ibrx:NonCashInterestIncomeExpenseFromOperatingActivities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">-3435000</ibrx:NonCashInterestIncomeExpenseFromOperatingActivities>
    <ibrx:NonCashInterestIncomeExpenseFromOperatingActivities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">-1965000</ibrx:NonCashInterestIncomeExpenseFromOperatingActivities>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">2972000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">3461000</us-gaap:DepreciationDepletionAndAmortization>
    <ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">1555000</ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense>
    <ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">1177000</ibrx:OperatingLeaseRightOfUseAssetNonCashLeaseExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">-225000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">-45000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">-1067000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">-125000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">4000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">934000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">4020000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">-693000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">-322000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">6497000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">-1724000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">-1893000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">8228000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">2597000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">-2411000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
    <ibrx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">-1474000</ibrx:IncreaseDecreaseInOperatingLeaseLiability>
    <ibrx:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">-342000</ibrx:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">-60469000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">-31107000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">7083000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">315000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">91000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">10300000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">31925000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">23109000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">7094000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">1500000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">31845000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">13994000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">40000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">1121000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">2624000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">123000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">38497000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">-123000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">-109000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">89000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">9764000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">-17147000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">35094000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20191231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">75980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">44858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20200331"
      decimals="-3"
      id="F_000328"
      unitRef="U_iso4217USD">58833000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000329"
      unitRef="U_iso4217USD">44679000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001326110_20200331"
      decimals="-3"
      id="F_000330"
      unitRef="U_iso4217USD">58654000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_0001326110_20200331"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">44858000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001326110_20200331"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">58833000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">12000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">7000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">4267000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">367000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">1388000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000343"
      unitRef="U_iso4217USD">14000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000344"
      unitRef="U_iso4217USD">23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NatureOfOperations contextRef="C_0001326110_20210101_20210331" id="F_000345">
&lt;p id="N1___DESCRIPTION_BUSINESS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. &#160;&#160;&#160;&#160;Description of Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Organization&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We were &lt;/span&gt;incorporated in Illinois on October&#160;7,&#160;2002 under the name ZelleRx Corporation. On January&#160;22,&#160;2010, we changed our name to Conkwest,&#160;Inc. In March&#160;2014, we formed Conkwest, Inc., our wholly-owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March&#160;2014, we merged with an into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July&#160;10,&#160;2015, we changed our name to NantKwest,&#160;Inc. On March 9,&#160;2021, we completed a merger with NantCell,&#160;Inc. (formerly known as ImmunityBio, Inc., a private company) and we changed our name to ImmunityBio,&#160;Inc. Our principal executive offices are located in San&#160;Diego, California. In these notes to unaudited condensed combined consolidated financial statements, the terms &#x201c;ImmunityBio,&#x201d; &#x201c;the company,&#x201d; &#x201c;the combined company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to ImmunityBio and subsidiaries.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We established ImmunityBio to advance the next-generation immunotherapies and to address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our four&#160;key modalities:&#160;(1)&#160;activating natural killer, or NK, and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4)&#160;off-the-shelf natural killer cells from the NK&#x2011;92 cell line and memory-like cytokine-enhanced natural killer cells (m&#x2011;ceNK) from allogenic and autologous donors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL&#x2011;15 superagonist&#160;(N&#x2011;803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator&#160;(aldoxorubicin), second-generation adenovirus&#160;(hAd5) and yeast vaccine technologies&#160;(targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK cell product for cancer that is an autologous Memory cytokine enhanced Natural Killer cells, macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD&#x2011;L1, TGF&#x2011;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;font-family:'Times New Roman';"&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;b&lt;/span&gt;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; and IL&#x2011;12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In December 2019, the &lt;/span&gt;United States, or U.S., Food and Drug Administration&lt;span style="Background-color:#FFFFFF;"&gt;, or FDA, granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#xe9;rin, or BCG, unresponsive carcinoma in situ non-muscle invasive bladder cancer. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The Merger&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On December&#160;21, 2020, we and NantCell, Inc.&#160;(formerly known as ImmunityBio,&#160;Inc., a private company)&#160;(&#x201c;NantCell&#x201d;) entered into an Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell&#160;(the&#160;&#x201c;Merger&#x201d;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;On March&#160;9, 2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#x201c;Effective Time&#x201d;), each share of NantCell common stock&lt;/span&gt;, par value $0.001&#160;per share, &lt;span style="Background-color:#FFFFFF;"&gt;issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;0.8190&#160;(the &#x201c;Exchange Ratio&#x201d;) newly&lt;/span&gt; issued shares of common stock, par value $0.0001&#160;per share, of the company&#160;(&#x201c;Company Common Stock&#x201d;), with cash paid in lieu of any fractional shares.&lt;span style="Background-color:#FFFFFF;"&gt; At the Effective Time, each share of the company&#x2019;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;71.5%&#160;of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately 28.5%&#160;of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially own, in the aggregate, approximately 81.8%&#160;of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company&#x2019;s common stock are now listed on the Nasdaq Global Select Market under the symbol &#x201c;IBRX.&#x201d;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We incurred costs totaling $23.2&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $12.9&#160;million was recorded during the three&#160;months ended March&#160;31,&#160;2021. Merger-related costs are&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt; reported in &lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;selling, general and administrative expense&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, on the condensed combined consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Treatment of the Merger&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&#160;805-50,&#160;&lt;span style="font-style:italic;"&gt;Mergers&lt;/span&gt;, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of each of the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#x2019;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March&#160;31, 2021 and 2020 (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantCell&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantKwest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intercompany&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eliminations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (including amounts&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; with related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (expense) income, net (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,637&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(80,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantCell&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantKwest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intercompany&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eliminations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (including amounts&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; with related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,702&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (expense) income, net (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331"
      id="F_000389">2020-12-21</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
    <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="C_0001326110_20210101_20210331" id="F_000393">2021-03-09</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309"
      decimals="3"
      id="F_000390"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_20210309_20210309"
      decimals="4"
      id="F_000391"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20210309"
      decimals="4"
      id="F_000392"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309"
      decimals="3"
      id="F_000394"
      unitRef="U_xbrlipure">0.715</ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger>
    <ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger
      contextRef="C_0001326110_srtOwnershipAxis_ibrxNantKwestMember_20210309"
      decimals="3"
      id="F_000395"
      unitRef="U_xbrlipure">0.285</ibrx:OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger>
    <ibrx:OwnershipPercentageByKeyExecutives
      contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember_20210309_20210309"
      decimals="3"
      id="F_000396"
      unitRef="U_xbrlipure">0.818</ibrx:OwnershipPercentageByKeyExecutives>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20201221_20210331"
      decimals="-5"
      id="F_000397"
      unitRef="U_iso4217USD">23200000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331"
      decimals="-5"
      id="F_000398"
      unitRef="U_iso4217USD">12900000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:BusinessCombinationsPolicy contextRef="C_0001326110_20210101_20210331" id="F_000360">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Treatment of the Merger&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&#160;805-50,&#160;&lt;span style="font-style:italic;"&gt;Mergers&lt;/span&gt;, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of each of the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#x2019;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000371">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March&#160;31, 2021 and 2020 (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantCell&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantKwest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intercompany&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eliminations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (including amounts&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; with related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,903&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(40,628&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,264&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (expense) income, net (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,637&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(46,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(33,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(80,481&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantCell&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NantKwest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intercompany&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Eliminations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunityBio, Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,234&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,374&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative (including amounts&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; with related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,120&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,373&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,493&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,702&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other (expense) income, net (including amounts with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related parties)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(910&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(707&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,383&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37,427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000399"
      unitRef="U_iso4217USD">183000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000400"
      unitRef="U_iso4217USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000401"
      unitRef="U_iso4217USD">-44000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000402"
      unitRef="U_iso4217USD">139000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000403"
      unitRef="U_iso4217USD">21509000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000404"
      unitRef="U_iso4217USD">19725000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000405"
      unitRef="U_iso4217USD">-106000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000406"
      unitRef="U_iso4217USD">41128000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000407"
      unitRef="U_iso4217USD">24382000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000408"
      unitRef="U_iso4217USD">20903000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000409"
      unitRef="U_iso4217USD">-10000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000410"
      unitRef="U_iso4217USD">45275000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">-45708000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">-40628000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000413"
      unitRef="U_iso4217USD">72000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000414"
      unitRef="U_iso4217USD">-86264000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000415"
      unitRef="U_iso4217USD">-848000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000416"
      unitRef="U_iso4217USD">6637000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">5789000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">-46556000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">-33997000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20210101_20210331"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">72000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">-80481000</us-gaap:ProfitLoss>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">168000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">21000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">-24000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">165000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">14252000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">13234000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">-112000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">27374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">4120000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">5373000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000437"
      unitRef="U_iso4217USD">0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">9493000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">-18204000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">-18586000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">88000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">-36702000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">-910000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">203000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">-707000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">18000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">-19132000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantKwestIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20200101_20200331"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">-18383000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_srtConsolidationItemsAxis_srtConsolidationEliminationsMember_20200101_20200331"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">88000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000454"
      unitRef="U_iso4217USD">-37427000</us-gaap:ProfitLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000346">
&lt;p id="N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as &lt;a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"&gt;&lt;span style="text-decoration:underline;"&gt;Exhibit&#160;99.2&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to our Current Report on Form&#160;8&#x2011;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, the company had an accumulated deficit of $1.7&#160;billion. We also had negative cash flows from operations of $60.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed combined consolidated financial statements are derived from the company&#x2019;s and NantCell&#x2019;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December&#160;31,&#160;2020 included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as &lt;a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"&gt;&lt;span style="text-decoration:underline;"&gt;Exhibit&#160;99.2&lt;/span&gt;&lt;/a&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to our Current Report on Form&#160;8&#x2011;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#x201c;at-the-market&#x201d; sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#x2019;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We apply the variable interest model under ASC Topic&#160;810,&#160;&lt;span style="font-style:italic;"&gt;Consolidation&lt;/span&gt;, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#x2019;s most significant economic activities and the ability to participate in the entity&#x2019;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in &lt;span style="font-style:italic;"&gt;interest and investment income, net&lt;/span&gt;, on the condensed combined consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, &lt;span style="font-style:italic;"&gt;Fair Value Measurement&lt;/span&gt;, or ASC&#160;820, we will apply the measurement alternative under ASC Topic&#160;321, &lt;span style="font-style:italic;"&gt;Investments&#x2014;Equity Securities&lt;/span&gt;, or ASC&#160;321, pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#x2019;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#x2019; earnings performance and clinical trial performance, change in the investees&#x2019; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#x2019;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#x2011;CoV&#x2011;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, &lt;span style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table details those securities that have been excluded from the computation of p&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;otentially dilutive securities:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,080,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,636,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding related-party warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,252,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,821,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#x201c;2015&#160;Plan&#x201d;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#x201c;2014&#160;Plan&#x201d;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#x201c;NC&#160;2015&#160;Plan&#x201d;) that, in the case of March&#160;31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March&#160;31, 2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;using the Merger Exchange Ratio of&#160;0.8190&lt;/span&gt;). See &lt;a href="#N11___STOCKBASED_COMPENSATION"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;11&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;, for further information.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&#160;2016, the FASB issued Accounting Standards Update, or ASU, 2016&#x2011;13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, or ASU&#160;2016-13. The FASB subsequently issued amendments to ASU&#160;2016&#x2011;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements and we do not intend to early adopt this new standard.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended March&#160;31,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000361">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, the company had an accumulated deficit of $1.7&#160;billion. We also had negative cash flows from operations of $60.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed combined consolidated financial statements are derived from the company&#x2019;s and NantCell&#x2019;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December&#160;31,&#160;2020 included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as &lt;a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"&gt;&lt;span style="text-decoration:underline;"&gt;Exhibit&#160;99.2&lt;/span&gt;&lt;/a&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to our Current Report on Form&#160;8&#x2011;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#x201c;at-the-market&#x201d; sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#x2019;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001326110_20210331"
      decimals="-8"
      id="F_000455"
      unitRef="U_iso4217USD">-1700000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001326110_20210101_20210331"
      decimals="-5"
      id="F_000456"
      unitRef="U_iso4217USD">-60500000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430"
      decimals="INF"
      id="F_000457"
      unitRef="U_iso4217USD">500000000.0</ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000362">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We apply the variable interest model under ASC Topic&#160;810,&#160;&lt;span style="font-style:italic;"&gt;Consolidation&lt;/span&gt;, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#x2019;s most significant economic activities and the ability to participate in the entity&#x2019;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in &lt;span style="font-style:italic;"&gt;interest and investment income, net&lt;/span&gt;, on the condensed combined consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, &lt;span style="font-style:italic;"&gt;Fair Value Measurement&lt;/span&gt;, or ASC&#160;820, we will apply the measurement alternative under ASC Topic&#160;321, &lt;span style="font-style:italic;"&gt;Investments&#x2014;Equity Securities&lt;/span&gt;, or ASC&#160;321, pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#x2019;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#x2019; earnings performance and clinical trial performance, change in the investees&#x2019; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#x2019;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMinimumMember_20210331"
      decimals="2"
      id="F_000458"
      unitRef="U_xbrlipure">0.20</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_us-gaapVariableInterestEntityPrimaryBeneficiaryMember_srtRangeAxis_srtMaximumMember_20210331"
      decimals="2"
      id="F_000459"
      unitRef="U_xbrlipure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UseOfEstimates contextRef="C_0001326110_20210101_20210331" id="F_000363">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.&lt;/p&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000364">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#x2011;CoV&#x2011;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.&lt;/p&gt;</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000365">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001326110_20210101_20210331" id="F_000366">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000367">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, &lt;span style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000368">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basic and Diluted Net Loss per Share of Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table details those securities that have been excluded from the computation of p&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;otentially dilutive securities:&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,080,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,636,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding related-party warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,252,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,821,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#x201c;2015&#160;Plan&#x201d;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#x201c;2014&#160;Plan&#x201d;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#x201c;NC&#160;2015&#160;Plan&#x201d;) that, in the case of March&#160;31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March&#160;31, 2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;using the Merger Exchange Ratio of&#160;0.8190&lt;/span&gt;). See &lt;a href="#N11___STOCKBASED_COMPENSATION"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;11&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;, for further information.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000372">&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table details those securities that have been excluded from the computation of p&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;otentially dilutive securities:&lt;/span&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,080,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,636,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,102,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding related-party warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,638,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,252,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,821,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20210101_20210331"
      decimals="0"
      id="F_000460"
      unitRef="U_xbrlishares">4978314</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ibrxOutstandingStockOptionsMember_20200101_20200331"
      decimals="0"
      id="F_000461"
      unitRef="U_xbrlishares">6080483</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="0"
      id="F_000462"
      unitRef="U_xbrlishares">7636132</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331"
      decimals="0"
      id="F_000463"
      unitRef="U_xbrlishares">1102528</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20210101_20210331"
      decimals="0"
      id="F_000464"
      unitRef="U_xbrlishares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapWarrantMember_20200101_20200331"
      decimals="0"
      id="F_000465"
      unitRef="U_xbrlishares">1638000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_20210101_20210331"
      decimals="0"
      id="F_000466"
      unitRef="U_xbrlishares">14252446</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001326110_20200101_20200331"
      decimals="0"
      id="F_000467"
      unitRef="U_xbrlishares">8821011</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309"
      decimals="4"
      id="F_000468"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000369">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Application of New or Revised Accounting Standards &#x2013; Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&#160;2016, the FASB issued Accounting Standards Update, or ASU, 2016&#x2011;13,&#160;&lt;span style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;, or ASU&#160;2016-13. The FASB subsequently issued amendments to ASU&#160;2016&#x2011;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements and we do not intend to early adopt this new standard.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended March&#160;31,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000347">
&lt;p id="N3___FINANCIAL_STATEMENT_DETAILS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. &#160;&#160;&#160;&#160;Financial Statement Details&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance claim receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid license fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premium financing asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tenant improvement receivables &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid equipment maintenance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable &lt;span style="font-size:9pt;"&gt;&#x2013;&lt;/span&gt; marketable debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid supplies &#x2013; with related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. &lt;span style="color:#000000;"&gt;Our insurance claims receivable as of March&#160;31,&#160;2021 and December&#160;31, 2020 are the result of the recovery of legal costs, which had been previously charged in prior periods to s&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;elling, general and administrative expense, &lt;/span&gt;&lt;span style="color:#000000;"&gt;on the condensed combined consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,420&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress at March&#160;31,&#160;2021 is related primarily to expansion of our hAd5 pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El&#160;Segundo, California&lt;span style="color:#1F497D;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense related to property, plant and equipment totaled $3.0&#160;million and $3.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;VAT receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid software license fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;455&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,905&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,947&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued dissenting shares (Note 8)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,769&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and service fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued contingent consideration payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued laboratory equipment and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing obligation &lt;span style="font-family:Calibri;"&gt;&#x2013;&lt;/span&gt; current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued franchise, sales, use and property taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued capital expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Interest and investment income, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and investment income, net consists of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains (losses) from equity securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investment amortization expense, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realized losses on investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and investment income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the three&#160;months ended March&#160;31,&#160;2021 and 2020.&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000373">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,648&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance claim receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,932&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,518&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,435&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid license fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,329&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;801&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,230&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Insurance premium financing asset&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;569&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tenant improvement receivables &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid equipment maintenance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest receivable &lt;span style="font-size:9pt;"&gt;&#x2013;&lt;/span&gt; marketable debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid supplies &#x2013; with related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;338&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,242&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,649&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">4648000</ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty>
    <ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">4626000</ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">2932000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <us-gaap:InsuranceSettlementsReceivableCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">2518000</us-gaap:InsuranceSettlementsReceivableCurrent>
    <ibrx:PrepaidServices
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">1435000</ibrx:PrepaidServices>
    <ibrx:PrepaidServices
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">1294000</ibrx:PrepaidServices>
    <ibrx:PrepaidLicenseFees
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">1329000</ibrx:PrepaidLicenseFees>
    <ibrx:PrepaidLicenseFees
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">801000</ibrx:PrepaidLicenseFees>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">1230000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">1365000</us-gaap:PrepaidInsurance>
    <ibrx:InsurancePremiumFinancingAsset
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">571000</ibrx:InsurancePremiumFinancingAsset>
    <ibrx:InsurancePremiumFinancingAsset
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">1421000</ibrx:InsurancePremiumFinancingAsset>
    <us-gaap:PrepaidRent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">569000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">589000</us-gaap:PrepaidRent>
    <ibrx:EquipmentDepositsCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">375000</ibrx:EquipmentDepositsCurrent>
    <ibrx:EquipmentDepositsCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">66000</ibrx:EquipmentDepositsCurrent>
    <us-gaap:LeaseIncentiveReceivableCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">313000</us-gaap:LeaseIncentiveReceivableCurrent>
    <us-gaap:LeaseIncentiveReceivableCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">0</us-gaap:LeaseIncentiveReceivableCurrent>
    <ibrx:PrepaidEquipmentMaintenance
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">239000</ibrx:PrepaidEquipmentMaintenance>
    <ibrx:PrepaidEquipmentMaintenance
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">243000</ibrx:PrepaidEquipmentMaintenance>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">132000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">473000</us-gaap:InterestReceivableCurrent>
    <ibrx:PrepaidSuppliesWithRelatedParty
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">131000</ibrx:PrepaidSuppliesWithRelatedParty>
    <ibrx:PrepaidSuppliesWithRelatedParty
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">143000</ibrx:PrepaidSuppliesWithRelatedParty>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">338000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">110000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">14242000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">13649000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000374">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,200&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,556&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,738&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,690&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,333&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture &amp;amp; fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,007&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross property, plant and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;125,420&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,545&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;41,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property, plant and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,875&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;72,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210331"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">52200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231"
      decimals="-3"
      id="F_000498"
      unitRef="U_iso4217USD">52251000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20210331"
      decimals="-3"
      id="F_000499"
      unitRef="U_iso4217USD">38556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20201231"
      decimals="-3"
      id="F_000500"
      unitRef="U_iso4217USD">34738000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20210331"
      decimals="-3"
      id="F_000501"
      unitRef="U_iso4217USD">22690000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20201231"
      decimals="-3"
      id="F_000502"
      unitRef="U_iso4217USD">22690000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20210331"
      decimals="-3"
      id="F_000503"
      unitRef="U_iso4217USD">8308000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20201231"
      decimals="-3"
      id="F_000504"
      unitRef="U_iso4217USD">1333000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20210331"
      decimals="-3"
      id="F_000505"
      unitRef="U_iso4217USD">2659000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_20201231"
      decimals="-3"
      id="F_000506"
      unitRef="U_iso4217USD">2376000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210331"
      decimals="-3"
      id="F_000507"
      unitRef="U_iso4217USD">1007000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231"
      decimals="-3"
      id="F_000508"
      unitRef="U_iso4217USD">1015000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000509"
      unitRef="U_iso4217USD">125420000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000510"
      unitRef="U_iso4217USD">114403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000511"
      unitRef="U_iso4217USD">44545000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">41862000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000513"
      unitRef="U_iso4217USD">80875000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000514"
      unitRef="U_iso4217USD">72541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001326110_20210101_20210331"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">3000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001326110_20200101_20200331"
      decimals="-5"
      id="F_000516"
      unitRef="U_iso4217USD">3500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000375">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;VAT receivable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;864&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid software license fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;227&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;455&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid preclinical and clinical trial services &#x2013; with&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related party (Note 9)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;92&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;316&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,905&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,598&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:ValueAddedTaxReceivableNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000517"
      unitRef="U_iso4217USD">810000</us-gaap:ValueAddedTaxReceivableNoncurrent>
    <us-gaap:ValueAddedTaxReceivableNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">864000</us-gaap:ValueAddedTaxReceivableNoncurrent>
    <us-gaap:SecurityDeposit
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">319000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">634000</us-gaap:SecurityDeposit>
    <ibrx:PrepaidSoftwareLicenseFeesInOtherAssets
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">227000</ibrx:PrepaidSoftwareLicenseFeesInOtherAssets>
    <ibrx:PrepaidSoftwareLicenseFeesInOtherAssets
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">455000</ibrx:PrepaidSoftwareLicenseFeesInOtherAssets>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">179000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DueFromRelatedPartiesNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">54000</us-gaap:DueFromRelatedPartiesNoncurrent>
    <us-gaap:DueFromRelatedPartiesNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000526"
      unitRef="U_iso4217USD">51000</us-gaap:DueFromRelatedPartiesNoncurrent>
    <ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000527"
      unitRef="U_iso4217USD">0</ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets>
    <ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000528"
      unitRef="U_iso4217USD">92000</ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000529"
      unitRef="U_iso4217USD">316000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000530"
      unitRef="U_iso4217USD">323000</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000531"
      unitRef="U_iso4217USD">1905000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000532"
      unitRef="U_iso4217USD">2598000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000376">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued bonus&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,947&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,288&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued dissenting shares (Note 8)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,769&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional and service fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,668&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued preclinical and clinical trial costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,656&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,349&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,891&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued construction costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued contingent consideration payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;822&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued laboratory equipment and supplies&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financing obligation &lt;span style="font-family:Calibri;"&gt;&#x2013;&lt;/span&gt; current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,421&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;263&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued franchise, sales, use and property taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;103&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued capital expenditures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,186&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses and other liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,793&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,771&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000533"
      unitRef="U_iso4217USD">6947000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000534"
      unitRef="U_iso4217USD">5288000</us-gaap:AccruedBonusesCurrent>
    <ibrx:AccruedDissentingShares
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000535"
      unitRef="U_iso4217USD">6854000</ibrx:AccruedDissentingShares>
    <ibrx:AccruedDissentingShares
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000536"
      unitRef="U_iso4217USD">6769000</ibrx:AccruedDissentingShares>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000537"
      unitRef="U_iso4217USD">6728000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000538"
      unitRef="U_iso4217USD">7668000</us-gaap:AccruedProfessionalFeesCurrent>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000539"
      unitRef="U_iso4217USD">4656000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <ibrx:AccruedPreclinicalAndClinicalTrialCosts
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000540"
      unitRef="U_iso4217USD">4339000</ibrx:AccruedPreclinicalAndClinicalTrialCosts>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000541"
      unitRef="U_iso4217USD">4349000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000542"
      unitRef="U_iso4217USD">3891000</us-gaap:AccruedSalariesCurrent>
    <ibrx:AccruedResearchAndDevelopmentCosts
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000543"
      unitRef="U_iso4217USD">2103000</ibrx:AccruedResearchAndDevelopmentCosts>
    <ibrx:AccruedResearchAndDevelopmentCosts
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000544"
      unitRef="U_iso4217USD">4002000</ibrx:AccruedResearchAndDevelopmentCosts>
    <us-gaap:ConstructionPayableCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000545"
      unitRef="U_iso4217USD">1931000</us-gaap:ConstructionPayableCurrent>
    <us-gaap:ConstructionPayableCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000546"
      unitRef="U_iso4217USD">0</us-gaap:ConstructionPayableCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000547"
      unitRef="U_iso4217USD">822000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000548"
      unitRef="U_iso4217USD">856000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <ibrx:AccruedLaboratoryEquipmentAndSupplies
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000549"
      unitRef="U_iso4217USD">681000</ibrx:AccruedLaboratoryEquipmentAndSupplies>
    <ibrx:AccruedLaboratoryEquipmentAndSupplies
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000550"
      unitRef="U_iso4217USD">641000</ibrx:AccruedLaboratoryEquipmentAndSupplies>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000551"
      unitRef="U_iso4217USD">571000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">1421000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">263000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">270000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000555"
      unitRef="U_iso4217USD">113000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000556"
      unitRef="U_iso4217USD">103000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <ibrx:AccruedCapitalExpenditures
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000557"
      unitRef="U_iso4217USD">16000</ibrx:AccruedCapitalExpenditures>
    <ibrx:AccruedCapitalExpenditures
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000558"
      unitRef="U_iso4217USD">337000</ibrx:AccruedCapitalExpenditures>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000559"
      unitRef="U_iso4217USD">759000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000560"
      unitRef="U_iso4217USD">1186000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000561"
      unitRef="U_iso4217USD">36793000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000562"
      unitRef="U_iso4217USD">36771000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestAndOtherIncomeTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000377">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and investment income, net consists of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized gains (losses) from equity securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(198&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;339&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;322&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investment amortization expense, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(225&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net realized losses on investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and investment income, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,944&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestAndOtherIncomeTableTextBlock>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000563"
      unitRef="U_iso4217USD">8833000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000564"
      unitRef="U_iso4217USD">-198000</us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000565"
      unitRef="U_iso4217USD">339000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000566"
      unitRef="U_iso4217USD">322000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000567"
      unitRef="U_iso4217USD">-225000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000568"
      unitRef="U_iso4217USD">-45000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000569"
      unitRef="U_iso4217USD">-3000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000570"
      unitRef="U_iso4217USD">-1000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000571"
      unitRef="U_iso4217USD">8944000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000572"
      unitRef="U_iso4217USD">78000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentTextBlock
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331"
      id="F_000348">
&lt;p id="N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. &#160;&#160;&#160;&#160;Equity Investment in Viracta Therapeutics&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $8.5&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company, which was initially recorded at cost. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#x2019;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June&#160;2018, Viracta executed a 2018&#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#x2019;s common stock. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#x2019;s common stock. Effective January&#160;31,&#160;2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#x2019;s Series&#160;B convertible preferred stock of $0.8&#160;million. In May&#160;2019, we exercised warrants to acquire 253,120&#160;shares of Viracta common stock.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the level of equity investment at risk, Viracta was not a VIE and therefore was not consolidated under the VIE model. In addition, we did not hold a controlling financial interest in Viracta, and therefore we did not consolidate Viracta under the voting interest model. As the preferred stock was not considered in-substance common stock, the investment was not within the scope of accounting for the investment under the equity method. As the preferred stock did not have a readily determinable fair value and did not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we had elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measured our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, our fair value assessment indicated that the offering of Viracta&#x2019;s Series&#160;E preferred stock in November&#160;2020, at a lower offering price per share than the per share carrying amount of our investment in Viracta, was a directional indicator representing an observable price change in an orderly transaction for a similar investment. On December&#160;31,&#160;2020, we reduced the carrying value by $1.4&#160;million due to the observable price change, which was included in &lt;span style="font-style:italic;"&gt;interest and investment income, net&lt;/span&gt;, on the condensed combined consolidated statements of operations for the year ended December&#160;31,&#160;2020. As of December&#160;31,&#160;2020, the carrying value of our investment in Viracta, which was reflected in &lt;span style="font-style:italic;"&gt;non-marketable equity investment,&lt;/span&gt; on the condensed combined consolidated balance sheets, was $7.8&#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&#160;24,&#160;2021, Sunesis Pharmaceuticals, Inc., a public company, completed a business combination with Viracta. In connection with this business combination, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. As of March&#160;31,&#160;2021, the carrying value of our investment in Viracta, which is reflected in &lt;span style="font-style:italic;"&gt;marketable securities&lt;/span&gt;, on the condensed combined consolidated balance sheets totaled $14.5&#160;million (including an unrealized gain of $6.6&#160;million). &lt;/p&gt;
</us-gaap:InvestmentTextBlock>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="C_0001326110_20170331"
      decimals="-5"
      id="F_000573"
      unitRef="U_iso4217USD">8500000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <ibrx:PurchaseOfConvertibleNoteUponConversion
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180601_20180630"
      decimals="-5"
      id="F_000574"
      unitRef="U_iso4217USD">400000</ibrx:PurchaseOfConvertibleNoteUponConversion>
    <ibrx:PurchaseOfConvertibleNoteUponConversion
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_20180901_20180930"
      decimals="-5"
      id="F_000575"
      unitRef="U_iso4217USD">400000</ibrx:PurchaseOfConvertibleNoteUponConversion>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20190130_20190131"
      decimals="-5"
      id="F_000576"
      unitRef="U_iso4217USD">800000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapDebtInstrumentAxis_ibrxTwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190531"
      decimals="INF"
      id="F_000577"
      unitRef="U_xbrlishares">253120</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_ibrxInterestAndInvestmentIncomeNetMember_20200101_20201231"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">1400000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="C_0001326110_20201231"
      decimals="-5"
      id="F_000579"
      unitRef="U_iso4217USD">7800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225"
      decimals="INF"
      id="F_000580"
      unitRef="U_xbrlishares">1562604</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331"
      decimals="-5"
      id="F_000581"
      unitRef="U_iso4217USD">14500000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331"
      decimals="-5"
      id="F_000582"
      unitRef="U_iso4217USD">6600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentTextBlock
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331"
      id="F_000349">
&lt;p id="N5___FINANCIAL_INSTRUMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. &#160;&#160;&#160;&#160;Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments in Marketable Debt Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000607"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000608"&gt;5.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021, a total of 14 of the securities were in unrealized loss positions. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment losses during the three&#160;months ended March&#160;31,&#160;2021. Realized gains and losses on sales of available-for-sale debt securities during the three&#160;months ended March&#160;31,&#160;2021 and 2020 were not material.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Marketable Equity Securities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We held investments in marketable equity securities with readily determinable fair values of $23.0 million and $6.3&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Unrealized gains recognized on equity securities with readily determinable fair values totaled $8.8&#160;million for the three&#160;months ended March&#160;31,&#160;2021, while unrealized losses recognized on equity securities with readily determinable fair values totaled $0.2&#160;million for the three&#160;months ended March&#160;31,&#160;2020. There were no realized gains or losses on sales of equity securities for the three&#160;months ended March&#160;31,&#160;2021 and 2020.&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000378">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000607"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,576&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000608"&gt;5.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;142&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,575&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,824&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,809&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent portion&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;861&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,685&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55,759&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000583"
      unitRef="U_iso4217USD">15541000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000589"
      unitRef="U_iso4217USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000595"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000601"
      unitRef="U_iso4217USD">15538000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000584"
      unitRef="U_iso4217USD">35000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000590"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000596"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000602"
      unitRef="U_iso4217USD">37000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000585"
      unitRef="U_iso4217USD">15576000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000591"
      unitRef="U_iso4217USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000597"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000603"
      unitRef="U_iso4217USD">15575000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000586"
      unitRef="U_iso4217USD">861000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000592"
      unitRef="U_iso4217USD">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000598"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000604"
      unitRef="U_iso4217USD">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000587"
      unitRef="U_iso4217USD">861000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000593"
      unitRef="U_iso4217USD">139000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000599"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20210331"
      decimals="-3"
      id="F_000605"
      unitRef="U_iso4217USD">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000588"
      unitRef="U_iso4217USD">16437000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000594"
      unitRef="U_iso4217USD">142000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000600"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000606"
      unitRef="U_iso4217USD">16575000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000609"
      unitRef="U_iso4217USD">54789000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000615"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000621"
      unitRef="U_iso4217USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000627"
      unitRef="U_iso4217USD">54772000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000610"
      unitRef="U_iso4217USD">35000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000616"
      unitRef="U_iso4217USD">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000622"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFinancialInstrumentAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000628"
      unitRef="U_iso4217USD">37000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000611"
      unitRef="U_iso4217USD">54824000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000617"
      unitRef="U_iso4217USD">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000623"
      unitRef="U_iso4217USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000629"
      unitRef="U_iso4217USD">54809000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000612"
      unitRef="U_iso4217USD">861000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000618"
      unitRef="U_iso4217USD">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000624"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000630"
      unitRef="U_iso4217USD">950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000613"
      unitRef="U_iso4217USD">861000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000619"
      unitRef="U_iso4217USD">89000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000625"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_20201231"
      decimals="-3"
      id="F_000631"
      unitRef="U_iso4217USD">950000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000614"
      unitRef="U_iso4217USD">55685000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000620"
      unitRef="U_iso4217USD">93000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000626"
      unitRef="U_iso4217USD">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000632"
      unitRef="U_iso4217USD">55759000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000379">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,535&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;More than 12 months&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,762&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000633"
      unitRef="U_iso4217USD">13535000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000635"
      unitRef="U_iso4217USD">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000637"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20210331"
      decimals="-3"
      id="F_000639"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000634"
      unitRef="U_iso4217USD">13535000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000636"
      unitRef="U_iso4217USD">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000638"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000640"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000641"
      unitRef="U_iso4217USD">42762000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000643"
      unitRef="U_iso4217USD">19000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000645"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapCorporateDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000647"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000642"
      unitRef="U_iso4217USD">42762000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000644"
      unitRef="U_iso4217USD">19000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000646"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000648"
      unitRef="U_iso4217USD">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="C_0001326110_us-gaapFinancialInstrumentAxis_us-gaapDebtSecuritiesMember_20210331"
      decimals="INF"
      id="F_000649"
      unitRef="U_ibrxSecurity">14</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331"
      decimals="-5"
      id="F_000651"
      unitRef="U_iso4217USD">23000000.0</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-5"
      id="F_000652"
      unitRef="U_iso4217USD">6300000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331"
      decimals="-5"
      id="F_000653"
      unitRef="U_iso4217USD">8800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331"
      decimals="-5"
      id="F_000654"
      unitRef="U_iso4217USD">-200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210101_20210331"
      decimals="INF"
      id="F_000655"
      unitRef="U_iso4217USD">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:DebtAndEquitySecuritiesRealizedGainLoss
      contextRef="C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20200101_20200331"
      decimals="INF"
      id="F_000656"
      unitRef="U_iso4217USD">0</us-gaap:DebtAndEquitySecuritiesRealizedGainLoss>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000350">
&lt;p id="N6___FAIR_VALUE_MEASUREMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. &#160;&#160;&#160;&#160;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three tiers are defined as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recurring Valuations&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity securities (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Our equity securities include our investment in Viracta totaling $14.5&#160;million, which was previously accounted for by applying the measurement alternative under ASC&#160;321. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. See &lt;/span&gt;&lt;a href="#N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT"&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Note&#160;4&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Equity Investment in Viracta Therapeutics&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See &lt;/span&gt;&lt;a href="#N8___COMMITMENTS_CONTINGENCIES"&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Note&#160;8&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Commitments and Contingencies,&lt;/span&gt;&lt;span style="color:#000000;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Non-recurring Valuations&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the three&#160;months ended March&#160;31,&#160;2021 and 2020.&lt;/p&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000370">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The three tiers are defined as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;1&#x2014;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;2&#x2014;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level&#160;3&#x2014;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.&lt;/p&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000380">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity securities (1)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;84,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,735&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,538&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements as of December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Equity securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mutual funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Noncurrent:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total assets measured at fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;97,011&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent consideration obligations (2)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Our equity securities include our investment in Viracta totaling $14.5&#160;million, which was previously accounted for by applying the measurement alternative under ASC&#160;321. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. See &lt;/span&gt;&lt;a href="#N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT"&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Note&#160;4&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Equity Investment in Viracta Therapeutics&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;, for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.63%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See &lt;/span&gt;&lt;a href="#N8___COMMITMENTS_CONTINGENCIES"&gt;&lt;span style="text-decoration:underline;color:#000000;"&gt;Note&#160;8&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Commitments and Contingencies,&lt;/span&gt;&lt;span style="color:#000000;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000657"
      unitRef="U_iso4217USD">44679000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000658"
      unitRef="U_iso4217USD">44679000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">23019000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">23019000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331"
      decimals="-3"
      id="F_000663"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331"
      decimals="-3"
      id="F_000664"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000665"
      unitRef="U_iso4217USD">15538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000666"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000667"
      unitRef="U_iso4217USD">15538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000668"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000669"
      unitRef="U_iso4217USD">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000670"
      unitRef="U_iso4217USD">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000671"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20210331"
      decimals="-3"
      id="F_000672"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000673"
      unitRef="U_iso4217USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000674"
      unitRef="U_iso4217USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000675"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20210331"
      decimals="-3"
      id="F_000676"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000677"
      unitRef="U_iso4217USD">84273000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000678"
      unitRef="U_iso4217USD">68735000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000679"
      unitRef="U_iso4217USD">15538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000680"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000681"
      unitRef="U_iso4217USD">844000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000682"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000683"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000684"
      unitRef="U_iso4217USD">844000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000685"
      unitRef="U_iso4217USD">34915000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000686"
      unitRef="U_iso4217USD">34915000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000687"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCashAndCashEquivalentsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000688"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000689"
      unitRef="U_iso4217USD">54772000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000690"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000691"
      unitRef="U_iso4217USD">54772000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByAssetClassAxis_us-gaapCorporateDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000692"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000693"
      unitRef="U_iso4217USD">6337000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000694"
      unitRef="U_iso4217USD">6337000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000695"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20201231"
      decimals="-3"
      id="F_000696"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000697"
      unitRef="U_iso4217USD">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000698"
      unitRef="U_iso4217USD">37000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000699"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxCurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMutualFundMember_20201231"
      decimals="-3"
      id="F_000700"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000701"
      unitRef="U_iso4217USD">950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000702"
      unitRef="U_iso4217USD">950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000703"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxNoncurrentAssetsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapForeignGovernmentDebtMember_20201231"
      decimals="-3"
      id="F_000704"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000705"
      unitRef="U_iso4217USD">97011000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000706"
      unitRef="U_iso4217USD">42239000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000707"
      unitRef="U_iso4217USD">54772000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000708"
      unitRef="U_iso4217USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000709"
      unitRef="U_iso4217USD">972000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000710"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000711"
      unitRef="U_iso4217USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0001326110_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000712"
      unitRef="U_iso4217USD">972000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesEquitySecurities
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331"
      decimals="-5"
      id="F_000713"
      unitRef="U_iso4217USD">14500000</us-gaap:AvailableForSaleSecuritiesEquitySecurities>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_us-gaapBusinessAcquisitionAxis_ibrxSunesisPharmaceuticalsIncMember_us-gaapEquityInterestIssuedOrIssuableByTypeAxis_us-gaapCommonStockMember_20210225_20210225"
      decimals="INF"
      id="F_000714"
      unitRef="U_xbrlishares">1562604</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000381">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value, beginning of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(972&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value, end of period&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,727&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231"
      decimals="-3"
      id="F_000715"
      unitRef="U_iso4217USD">-972000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231"
      decimals="-3"
      id="F_000716"
      unitRef="U_iso4217USD">-1725000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210101_20210331"
      decimals="-3"
      id="F_000717"
      unitRef="U_iso4217USD">128000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200101_20200331"
      decimals="-3"
      id="F_000718"
      unitRef="U_iso4217USD">-2000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331"
      decimals="-3"
      id="F_000719"
      unitRef="U_iso4217USD">-844000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200331"
      decimals="-3"
      id="F_000720"
      unitRef="U_iso4217USD">-1727000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000351">
&lt;p id="N7___COLLABORATION_LICENSE_AGREEMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. &#160;&#160;&#160;&#160;Collaboration and License Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;National Cancer Institute&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2015, Etubics Corporation, or Etubics, entered into a Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services as represented by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA, NIH provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the term of the CRADA, we are required to make annual payments of $0.6&#160;million to the NIH for support of research activities. We made a payment of $0.6&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The&#160;CRADA expires in May&#160;2023.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2018, we entered into an amendment to a CRADA with NIH that was originally executed between NIH and Amgen,&#160;Inc., or Amgen, in May&#160;2012 and subsequently assigned by Amgen to the company effective as of December&#160;17,&#160;2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor&#160;one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing February&#160;20,&#160;2018 and expiring on February&#160;20,&#160;2023.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the term of the agreement, we are required to make minimum annual payments of $0.2&#160;million to NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $0.4&#160;million and $0.6&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&#160;2021, we entered into a CRADA with NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant natural killer&#160;(NK) cells and/or monoclonal antibodies&#160;(mAbs) alone or in combination for the treatment of cancer and to pre-clinically study such agents. The CRADA has a two-year term commencing February&#160;22, 2021 and expiring on February&#160;22, 2023. During the term of the agreement, we are required to provide $0.1&#160;million per year to NIH for support of research activities. We have $8,000 payable outstanding as of March&#160;31, 2021 in connection with this CRADA agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All CRADA agreements may be terminated at any time upon the mutual written consent of the company and NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60&#160;days before the desired termination date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Royalties and In-licensing Agreements&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;iosBio Ltd. Exclusive License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. (&#x201c;iosBio&#x201d;), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio&#x2019;s intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants to iosBio and its affiliates a non-exclusive, worldwide license under the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we accrued $0.1&#160;million and $0.5&#160;million payable, respectively, to iosBio for reimbursable costs related to the clinical trial activities initiated by iosBio.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <ibrx:AnnualPaymentForSupportOfResearchActivities
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131"
      decimals="-5"
      id="F_000721"
      unitRef="U_iso4217USD">600000</ibrx:AnnualPaymentForSupportOfResearchActivities>
    <ibrx:AnnualPaymentForSupportOfResearchActivities
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapRelatedPartyTransactionAxis_ibrxEtubicsCorporationMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000722"
      unitRef="U_iso4217USD">600000</ibrx:AnnualPaymentForSupportOfResearchActivities>
    <ibrx:MinimumAnnualPaymentsForSupportOfResearchActivities
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20180102_20180131"
      decimals="-5"
      id="F_000723"
      unitRef="U_iso4217USD">200000</ibrx:MinimumAnnualPaymentsForSupportOfResearchActivities>
    <ibrx:EstimatedUnpaidResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000724"
      unitRef="U_iso4217USD">400000</ibrx:EstimatedUnpaidResearchAndDevelopmentExpense>
    <ibrx:EstimatedUnpaidResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000725"
      unitRef="U_iso4217USD">600000</ibrx:EstimatedUnpaidResearchAndDevelopmentExpense>
    <ibrx:AnnualPaymentForSupportOfResearchActivities
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228"
      decimals="-5"
      id="F_000726"
      unitRef="U_iso4217USD">100000</ibrx:AnnualPaymentForSupportOfResearchActivities>
    <ibrx:PayableOutstanding
      contextRef="C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210331"
      decimals="0"
      id="F_000727"
      unitRef="U_iso4217USD">8000</ibrx:PayableOutstanding>
    <ibrx:AccruedReimbursableCostsPayable
      contextRef="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20210331"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">100000</ibrx:AccruedReimbursableCostsPayable>
    <ibrx:AccruedReimbursableCostsPayable
      contextRef="C_0001326110_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ibrxClinicalTrialActivitiesMember_us-gaapTypeOfArrangementAxis_ibrxIosbioLtdExclusiveLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">500000</ibrx:AccruedReimbursableCostsPayable>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000352">
&lt;p id="N8___COMMITMENTS_CONTINGENCIES" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. &#160;&#160;&#160;&#160;Commitments and Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Related to Business Combinations&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;VivaBioCell, S.p.A.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&#160;10, 2015, NantWorks, a related party, acquired a 100%&#160;interest in VivaBioCell, S.p.A., or VivaBioCell, through its wholly-owned subsidiary, VBC&#160;Holdings, LLC, or VBC&#160;Holdings, for $0.7&#160;million, less working capital adjustments. On June&#160;15,&#160;2015, NantWorks contributed its equity interest in VBC&#160;Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $3.7&#160;million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $0.1&#160;million during the three&#160;months ended March&#160;31,&#160;2021 to $0.8&#160;million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Altor BioScience Corporation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with our July&#160;2017 acquisition of Altor BioScience Corporation, or Altor, we issued contingent value rights, or CVRs, under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million upon successful approval of the Biologics License Application, or BLA, or foreign equivalent, for Anktiva by December&#160;31,&#160;2022 and approximately $304.0&#160;million upon the first calendar year before December&#160;31,&#160;2026 in which worldwide net sales of Anktiva exceed $1.0&#160;billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately $279.5&#160;million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company&#x2019;s common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Altor BioScience, LLC &lt;/span&gt;&lt;span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The first action, Gray v.&#160;Soon-Shiong, et al.&#160;(Delaware Chancery Court, Case No.&#160;2017-466-JRS), was filed on June&#160;21,&#160;2017, by plaintiffs Clayland Boyden Gray, or Gray, and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for&#160;(1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion on July&#160;25,&#160;2017, and permitted the merger to close. On September&#160;1,&#160;2017, plaintiffs (joined by two&#160;additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson, or Henderson) filed a second&#160;amended complaint, asserting claims for (1)&#160;appraisal; (2)&#160;quasi-appraisal; (3)&#160;breach of fiduciary duty; and (4)&#160;aiding and abetting breach of fiduciary duty. On September&#160;18,&#160;2017, defendants moved to dismiss the second&#160;amended complaint, raising grounds that included a &#x201c;standstill&#x201d; agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman, or the Waldman&#x2019;s, agreed not to bring the lawsuit. In the second&#160;action, Dyad Pharmaceutical Corp. v.&#160;Altor BioScience,&#160;LLC&#160;(Delaware Chancery Court, Case No.&#160;2017-848-JRS), commenced November&#160;28,&#160;2017, Dyad Pharmaceutical Corporation, or Dyad, filed a petition for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition on January&#160;26,&#160;2018, arguing in part that the petition was barred by the same &#x201c;standstill&#x201d; agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&#160;23,&#160;2018, the court heard oral arguments on the motions to dismiss in both consolidated cases, and on June&#160;26,&#160;2018, the court converted the motions to dismiss into motions for summary judgment with regard to the &#x201c;standstill&#x201d; agreement argument, or the Converted Motions. The court permitted discovery into the meaning and intended scope of the &#x201c;standstill&#x201d; agreements, which the parties completed on December&#160;19,&#160;2018. The parties completed a briefing on the Converted Motions on March&#160;15,&#160;2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The court heard an oral argument on the Converted Motions on May&#160;7,&#160;2019, and issued an oral ruling on May&#160;15,&#160;2019. The court&#160;(1)&#160;dismissed all claims brought by Gray and the Waldman&#x2019;s except for their appraisal claims; (2)&#160;dismissed all plaintiffs&#x2019; quasi-appraisal claims; (3)&#160;dismissed the disclosure-based breach of fiduciary duty claims; and (4)&#160;dismissed Altor BioScience from the action. The following claims remain: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience, LLC), and (b)&#160;Henderson&#x2019;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June&#160;14,&#160;2019, the defendants answered the second&#160;amended complaint, and the respondent answered Dyad&#x2019;s appraisal petition. In their answer, defendants asserted counterclaims against Gray and the Waldman&#x2019;s for breach of the &#x201c;standstill&#x201d; agreements and are seeking as damages the attorneys&#x2019; fees and costs they were forced to expend as a result of the breach. On June&#160;20,&#160;2019, the court issued a written order implementing its ruling on the Converted Motions, or the Implementing Order. In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. On July&#160;11,&#160;2019, Gray and the Waldman&#x2019;s filed answers denying the counterclaims and asserting defenses.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September&#160;30,&#160;2019, plaintiffs moved for leave to file a third&#160;amended complaint. The proposed amendment sought to add two&#160;former Altor stockholders as plaintiffs and to add a fiduciary duty claim on behalf of a purported class of former Altor stockholders. On October&#160;25,&#160;2019, the defendants opposed the motion, and a briefing was completed on February&#160;28,&#160;2020. The court heard an oral argument on March&#160;12,&#160;2020, and granted the motion. The plaintiffs filed the third&#160;amended complaint on June&#160;8,&#160;2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June&#160;29,&#160;2020, defendants answered the third&#160;amended complaint and asserted counter claims against the plaintiffs. As damages, defendants seek the attorneys&#x2019; fees and costs incurred as a result of these breaches. On July&#160;14,&#160;2020, the plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October&#160;2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date, and when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had accrued $6.9&#160;million and $6.8&#160;million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic&#160;450, &lt;span style="font-style:italic;"&gt;Contingencies&lt;/span&gt;, after considering the reasonable outcomes for settling the dissenting shareholder dispute along with any accrued statutory interest. We cannot reasonably estimate a range of loss beyond the amounts recorded as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, as the dissenting stockholders have not yet provided a quantified value of their claim and, therefore, an upper end of the range of loss cannot be determined. We reassess the reasonableness of the recorded amount at each reporting period. We believe the claims lack merit and intend to continue defending the case vigorously.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Sorrento Therapeutics, Inc. Litigation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sorrento Therapeutics, Inc. v. NantCell, Inc., et al. Sorrento Therapeutics, Inc., or Sorrento, derivatively on behalf of NANTibody, LLC, or NANTibody, filed an action in the Superior Court of California, Los&#160;Angeles County, or the Superior Court, against the company, Dr.&#160;Soon-Shiong and Charles&#160;Kim. The action alleges that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. from our affiliate NantPharma,&#160;LLC, or NantPharma, and seeks to have the transaction undone, and seeks to have the purchase amount returned to NANTibody. Sorrento filed a related arbitration proceeding, or the Cynviloq arbitration, against Dr.&#160;Soon-Shiong and NantPharma; the company is not named in the Cynviloq arbitration. On May&#160;15,&#160;2019, we filed a demurrer to several causes of action alleged in the Superior Court action. On July&#160;18,&#160;2019, Sorrento filed an amended complaint, eliminating Charles&#160;Kim as a defendant and dropping the causes of action we had challenged in its demurrer. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May&#160;24,&#160;2019, we and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. We and Dr.&#160;Soon-Shiong allege that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#x2019;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&#160;9,&#160;2019, the Superior Court ruled that our claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#x2019;s claims could be pursued in Superior Court.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February&#160;13,&#160;2020, after a full briefing, the Superior Court heard oral argument and granted Dr.&#160;Soon-Shiong&#x2019;s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr.&#160;Soon-Shiong in the Superior Court on March&#160;3,&#160;2020, and at Sorrento&#x2019;s request, the arbitrator entered an order dismissing Sorrento&#x2019;s claims against Dr.&#160;Soon-Shiong in the Cynviloq arbitration on March&#160;6,&#160;2020. The hearing in the Cynviloq arbitration has been scheduled to commence in June&#160;2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October&#160;24,&#160;2019, we, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration on May&#160;4,&#160;2020, and requested leave to file a dispositive motion on May&#160;1,&#160;2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January&#160;29,&#160;2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter on April&#160;10,&#160;2020, purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements. We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time. The hearings in the antibody arbitration commenced in April&#160;2021 and are anticipated to be concluded in late July or early August&#160;2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Shenzhen Beike Biotechnology Corporation Litigation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation, or Beike. The arbitration relates to a license, development, and commercialization agreement that Altor&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC, or Altor) entered into with Beike in September&#160;2014, which agreement was amended and restated in September&#160;2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten&#160;calendar days&#x2019; notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by May&#160;31,&#160;2021 of any further developments.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fox Chase Litigation&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July&#160;21,&#160;2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San&#160;Diego County, California, naming Fox&#160;Chase Cancer Center Foundation and Institute for Cancer Research as the defendants&#160;(hereafter collectively &#x201c;Fox&#160;Chase&#x201d;). This litigation relates to the license with Fox&#160;Chase and includes various intellectual property rights (the&#160;&#x201c;2004&#160;License&#x201d;). Our initial court filing requested that the Court find that we have not breached any material obligation under the 2004&#160;License and that Fox&#160;Chase has not and cannot terminate the 2004&#160;License. Fox&#160;Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. See Part&#160;II, Item&#160;1A.,&#160;&#x201c;&lt;span style="font-style:italic;"&gt;Risk Factors&lt;/span&gt;&#x201d; of this Quarterly Report on Form&#160;10-Q for a more detailed discussion. While the litigation is in the early stage, its outcome cannot be predicted. We do not consider the 2004&#160;License to be material to our business.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation Related to the Merger with ImmunityBio, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Merger with &lt;span style="letter-spacing:-0.05pt;"&gt;NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest&#160;(the &#x201c;Merger&#160;Sub&#x201d;), &lt;/span&gt;seven&#160;complaints have been filed as individual actions in United States District Courts. Three&#160;complaints have been filed in the United States District Court for the District of Delaware against NantKwest and its directors and are captioned&#160;&lt;span style="font-style:italic;"&gt;Hargett v. NantKwest, Inc., et al.&lt;/span&gt;, 1:21&#x2011;cv&#x2011;00197&#160;(filed February&#160;11,&#160;2021) (the &#x201c;Hargett Complaint&#x201d;),&#160;&lt;span style="font-style:italic;"&gt;Franchi v. NantKwest, Inc., et al.&lt;/span&gt;, 1:21&#x2011;cv&#x2011;00218&#160;(filed February&#160;16,&#160;2021) (the&#160;&#x201c;Franchi Complaint&#x201d;), and &lt;span style="font-style:italic;"&gt;Gross&#160;v.&#160;NantKwest,&#160;Inc., et al.&lt;/span&gt;, 1:21&#x2011;cv&#x2011;00223&#160;(filed February&#160;17,&#160;2021) (the &#x201c;Gross Complaint&#x201d;). One&#160;complaint has been filed in the United States District Court for the Southern District of New York and is captioned &lt;span style="font-style:italic;"&gt;Leaman&#160;v.&#160;NantKwest,&#160;Inc., et al.&lt;/span&gt;, 1:21&#x2011;cv&#x2011;01351&#160;(filed February&#160;16,&#160;2021) (the&#160;&#x201c;Leaman Complaint&#x201d;). Two&#160;complaints have been filed in the United States District Court for the Southern District of California and are captioned &lt;span style="font-style:italic;"&gt;Weiss&#160;v.&#160;NantKwest,&#160;Inc., et al.&lt;/span&gt;, 3:21&#x2011;cv&#x2011;00280&#160;(filed February&#160;16,&#160;2021) (the&#160;&#x201c;Weiss Complaint&#x201d;) and &lt;span style="font-style:italic;"&gt;Carlisle&#160;v.&#160;NantKwest,&#160;Inc., et al.&lt;/span&gt;, 3:21&#x2011;cv&#x2011;00304&#160;(filed February&#160;19,&#160;2021) (the&#160;&#x201c;Carlisle Complaint&#x201d;). One&#160;complaint has been filed in the United States District Court for the Eastern District of New York and was captioned &lt;span style="font-style:italic;"&gt;Shenk&#160;v.&#160;NantKwest,&#160;Inc., et al.&lt;/span&gt;, 1:21&#x2011;cv&#x2011;00871&#160;(filed February&#160;18,&#160;2021) (the &#x201c;Shenk Complaint,&#x201d; and collectively with the Hargett Complaint, the Franchi Complaint, the Gross Complaint, the Leaman Complaint, the Weiss Complaint, and the Carlisle Complaint, the &#x201c;Merger Actions&#x201d;). The Shenk Complaint was voluntarily dismissed on March&#160;10,&#160;2021. The Franchi Complaint was voluntarily dismissed on May&#160;6,&#160;2021. The Leaman Complaint was voluntarily dismissed on May&#160;7,&#160;2021. The Hargett Complaint and the Gross Complaint also bring claims against ImmunityBio, and Merger&#160;Sub. The Merger Actions generally allege that the Definitive Proxy Statement filed with the SEC on February&#160;2,&#160;2021 misrepresents and/or omits certain purportedly material information relating to financial projections, analysis performed by the financial advisor to NantKwest&#x2019;s Special Committee, alleged past engagements of the Special Committee&#x2019;s financial advisor and industry consultant, and the terms of the engagement of such consultant. The Merger Actions assert violations of Sections&#160;14(a) of the Securities Exchange Act of&#160;1934, as amended (the&#160;&#x201c;Exchange Act&#x201d;), and Rule&#160;14a-9 promulgated thereunder against all defendants and violations of Section&#160;20(a) of the Exchange Act against NantKwest&#x2019;s directors. The Merger Actions seek, among other things, an injunction enjoining the stockholder vote on the Merger and the consummation of the Merger unless and until certain additional information is disclosed to NantKwest&#x2019;s stockholders, costs of the action, including plaintiffs&#x2019; attorneys&#x2019; fees and experts&#x2019; fees, and other relief the Court may deem just and proper. Neither the stockholder vote on the Merger nor the Merger were enjoined and occurred on March&#160;8 and March&#160;9,&#160;2021, respectively. The company cannot predict the outcome of the Merger Actions. The company believes the Merger Actions are without merit and the company and the individual defendants intend to vigorously defend against the Merger Actions and any subsequently filed similar actions. If additional similar complaints are filed, absent new or significantly different allegations, the company will not necessarily disclose such additional filings.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Lease Arrangements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El&#160;Segundo, California&#160;(general corporate and administrative activities, research and development and regulatory from related parties); San&#160;Diego, California&#160;(research facility and office space); Culver&#160;City, California&#160;(research and manufacturing space from a related party); Torrance, California&#160;(a research facility from a related party); Miramar, Florida&#160;(clinical development); Seattle, Washington&#160;(research and development); Louisville, Colorado&#160;(research and development and manufacturing); Woburn, Massachusetts&#160;(research facility); and Udine and Tavangnacco, Italy&#160;(GMP-in-a-Box, research facility and office space). See&#160;&lt;a href="#N9___RELATED_PARTY_AGREEMENTS"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;9&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&#160;&lt;/span&gt;&lt;span style="font-style:italic;"&gt;Related Party Agreements&lt;/span&gt;, for further information.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our leases generally have initial terms ranging from &lt;span style="-sec-ix-hidden:F_000741"&gt;two to ten&#160;years&lt;/span&gt; and often include one&#160;or more options to renew. These renewal terms can extend the lease term from &lt;span style="-sec-ix-hidden:F_000743"&gt;one to five&#160;years&lt;/span&gt;, and are included in the lease term when it is reasonably certain that we will exercise the option.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information regarding our leases is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.6 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,782&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Operating cash flows for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments as of March&#160;31,&#160;2021, including $4.9&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021 (excluding the three months ended March 31, 2021)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,889&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,622&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&#160;2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional three-year&#160;term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of 3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. See&#160;&lt;a href="#N9___RELATED_PARTY_AGREEMENTS"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;9&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Related Party Agreements&lt;/span&gt;, for further information.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as &lt;a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"&gt;&lt;span style="text-decoration:underline;"&gt;Exhibit&#160;99.2&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to our Current Report on Form&#160;8&#x2011;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Commitments&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We did not enter into any significant contracts during the three&#160;months ended March&#160;31,&#160;2021, other than those disclosed in these condensed combined consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as &lt;a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"&gt;&lt;span style="text-decoration:underline;"&gt;Exhibit&#160;99.2&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; to our Current Report on Form&#160;8&#x2011;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ibrx:PercentageOfWhollyOwnedSubsidiary
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410"
      decimals="INF"
      id="F_000730"
      unitRef="U_xbrlipure">1</ibrx:PercentageOfWhollyOwnedSubsidiary>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150410_20150410"
      decimals="-5"
      id="F_000731"
      unitRef="U_iso4217USD">700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20150615_20150615"
      decimals="-5"
      id="F_000732"
      unitRef="U_iso4217USD">3700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh>
    <ibrx:ChangeInContingentConsideration
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210101_20210331"
      decimals="-5"
      id="F_000733"
      unitRef="U_iso4217USD">100000</ibrx:ChangeInContingentConsideration>
    <ibrx:FairValueOfContingentConsiderationObligation
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxVivaBioCellMember_20210331"
      decimals="-5"
      id="F_000734"
      unitRef="U_iso4217USD">800000</ibrx:FairValueOfContingentConsiderationObligation>
    <ibrx:ContingentValueRightsPayable
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableAtDecember312022Member_20210331"
      decimals="-5"
      id="F_000735"
      unitRef="U_iso4217USD">304000000.0</ibrx:ContingentValueRightsPayable>
    <ibrx:ContingentValueRightsPayable
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapContingentConsiderationByTypeAxis_ibrxContingentValueRightsPayableBeforeDecember312026Member_20210331"
      decimals="-5"
      id="F_000736"
      unitRef="U_iso4217USD">304000000.0</ibrx:ContingentValueRightsPayable>
    <ibrx:MinimumNetSalesMilestoneContingentValueRightsPayable
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_20210101_20210331"
      decimals="-8"
      id="F_000737"
      unitRef="U_iso4217USD">1000000000.0</ibrx:MinimumNetSalesMilestoneContingentValueRightsPayable>
    <ibrx:ContingentValueRightsPayable
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceCorporationMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxDrSoonShiongAndPelatedPartyMember_20210331"
      decimals="-5"
      id="F_000738"
      unitRef="U_iso4217USD">279500000</ibrx:ContingentValueRightsPayable>
    <ibrx:AccruedPaymentForDissentingShares
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20210331"
      decimals="-5"
      id="F_000739"
      unitRef="U_iso4217USD">6900000</ibrx:AccruedPaymentForDissentingShares>
    <ibrx:AccruedPaymentForDissentingShares
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxAltorBioScienceLLCMember_20201231"
      decimals="-5"
      id="F_000740"
      unitRef="U_iso4217USD">6800000</ibrx:AccruedPaymentForDissentingShares>
    <us-gaap:LeaseCostTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000382">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information regarding our leases is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:9.35pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.6 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.9 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The components of lease expense consist of the following&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:1pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,147&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,782&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Variable lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;666&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;848&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease costs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; Operating cash flows for operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,679&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001326110_20210331" id="F_000745">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001326110_20201231" id="F_000746">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001326110_20210331"
      decimals="2"
      id="F_000747"
      unitRef="U_xbrlipure">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001326110_20201231"
      decimals="2"
      id="F_000748"
      unitRef="U_xbrlipure">0.09</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">2147000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">1782000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">666000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">848000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">2813000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">2630000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">1679000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000756"
      unitRef="U_iso4217USD">1355000</us-gaap:OperatingLeasePayments>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000383">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Future minimum lease payments as of March&#160;31,&#160;2021, including $4.9&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years ending December 31:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021 (excluding the three months ended March 31, 2021)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,193&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,889&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,135&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,622&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,183&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total future minimum lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,710&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms
      contextRef="C_0001326110_20210101_20210331"
      decimals="-5"
      id="F_000757"
      unitRef="U_iso4217USD">4900000</ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000758"
      unitRef="U_iso4217USD">5193000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000759"
      unitRef="U_iso4217USD">6889000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000760"
      unitRef="U_iso4217USD">5135000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000761"
      unitRef="U_iso4217USD">3622000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000762"
      unitRef="U_iso4217USD">3183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ibrx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000763"
      unitRef="U_iso4217USD">2487000</ibrx:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000764"
      unitRef="U_iso4217USD">26509000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000765"
      unitRef="U_iso4217USD">4799000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000766"
      unitRef="U_iso4217USD">21710000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000353">
&lt;p id="N9___RELATED_PARTY_AGREEMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. &#160;&#160;&#160;&#160;Related Party Agreements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;width:14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party &#x2013; NantBio&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party &#x2013; NantOmics&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related parties &#x2013; Various&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.25pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total due from related parties&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantWorks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Duley Road&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,787&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantBio&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Immuno-Oncology Clinic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Nant Capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantPharma&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total due to related parties&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; Nant Capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NantMobile&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NantWorks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NCSC&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total related-party notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297,286&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;NantWorks&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $1.8&#160;million and $1.5&#160;million, respectively, in &lt;span style="font-style:italic;"&gt;selling, general and administrative expense&lt;/span&gt;, and $0.3&#160;million and $1.0&#160;million, respectively, of expense reimbursements under this arrangement in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#x2019; invoiced amounts without markup by NantWorks.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021 and December&#160;31, 2020, we owed NantWorks a net amount of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.8&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million and $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, respectively, for all agreements between the two affiliates, which is included in &lt;/span&gt;&lt;span style="font-style:italic;"&gt;due to related parties&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; on the condensed &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated balance sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We also recorded $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million and $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.1&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021 and December&#160;31,&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020, respectively, which are included in &lt;/span&gt;&lt;span style="font-style:italic;"&gt;prepaid expenses and other current assets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; on the condensed &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;consolidated balance sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&#160;2015, we entered into a facility license agreement with NantWorks&#160;LLC, or NantWorks, a related party, for approximately 9,500&#160;square feet of office space in Culver&#160;City, California, which has been converted to a research and development laboratory and a cGMP&#160;manufacturing facility. The initial license was effective from May&#160;2015 through December&#160;2020. Base monthly rent for the initial lease term was $47,000, with annual increases of 3% beginning in January&#160;2017. In September&#160;2020, we amended this agreement to extend the term of this lease through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2021, the monthly rent increased by 3% to $54,500. Subsequent to December&#160;31,&#160;2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30&#160;days&#x2019; prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December&#160;31,&#160;2022. If we exercise the option to extend the lease through December&#160;31,&#160;2022, or continue on a month-to-month basis, the monthly rent will increase by 3% annually commencing on January&#160;1 of each year. On the date of amendment, we recognized an increase of $1.2&#160;million in both &lt;span style="font-style:italic;"&gt;operating lease right-of-use assets&lt;/span&gt;, and &lt;span style="font-style:italic;"&gt;operating lease liabilities&lt;/span&gt;, on the condensed combined consolidated balance sheets, reflecting our belief that we will extend the term of this lease through December&#160;31,&#160;2022. Lease expense for this facility totaling $0.2&#160;million and $0.1&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, was recorded in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Immuno-Oncology Clinic, Inc.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic (dba&#160;Chan Soon-Shiong Institutes for Medicine, in El&#160;Segundo, California), to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by one officer of the company and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30,&#160;2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the Clinic.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July&#160;2019, we entered into a new agreement with the Clinic (the Clinic Agreement), which became effective on July&#160;1,&#160;2019. The Clinic Agreement, as amended on March&#160;31,&#160;2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1,&#160;2019, and prospective clinical trials and research projects. The Clinic Agreement also specifies certain services and related costs that are excluded from the Clinic Agreement. Prior to commencing any work under the Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July&#160;1,&#160;2019, fees incurred for services performed after July&#160;1,&#160;2019 are covered under the Clinic Agreement and applied towards the below-mentioned prepayments. The Clinic Agreement allows for automatic renewal and additional extensions beyond the initial &lt;span style="-sec-ix-hidden:F_000816"&gt;one-year&lt;/span&gt; term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration of the services to be performed under the Clinic Agreement, as amended on March&#160;31,&#160;2020, we agreed to make payments of up to $7.5&#160;million to the Clinic, of which $3.75&#160;million and $1.88&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. As amended, a conditional payment of $1.88&#160;million shall be due and payable at such time, if any, that the payments made in July&#160;2019 and October&#160;2019 have been earned by the Clinic through the performance of services. On a quarterly basis, our prepayment is increased by an interest credit computed in accordance with terms specified in the Clinic Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the Clinic Agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the Clinic Agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the Clinic Agreement for up to three additional one&#160;year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July&#160;2019, we executed a clinical trial work order under the Clinic Agreement for an open-label, Phase&#160;I study of PD&#x2011;L1.t&#x2011;haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July&#160;2020, but effective on June&#160;22,&#160;2020, we and NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company) executed a clinical trial work order under our existing master agreement with the Clinic for an open-label, randomized, comparative Phase&#160;II study of NantCell&#x2019;s proprietary IL&#x2011;15 superagonist (N&#x2011;803) and Aldoxorubicin Hydrochloride&#160;(Aldoxorubicin) and our PD&#x2011;L1.t&#x2011;haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the three&#160;months ended March&#160;31,&#160;2021 and 2020, $0.3&#160;million and $0.1&#160;million, respectively, was recognized in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations related to clinical trial and research-related activities conducted for us by the Clinic. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we owed the Clinic $0.5&#160;million and $0.3&#160;million, respectively, for services excluded from the Clinic Agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had prepaid balances related to the Clinic Agreement of $4.6&#160;million and $4.7&#160;million, respectively. We anticipate that the remaining prepayment amount as of March&#160;31,&#160;2021 will be utilized in future periods as the Clinic provides additional services pursuant to the Clinic Agreement.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;NantBio, Inc.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March&#160;2016, NantBio and the National Cancer Institute, or the NCI, entered into a cooperative research and development agreement. The initial &lt;span style="-sec-ix-hidden:F_000828"&gt;five-year&lt;/span&gt; agreement covered NantBio and its affiliates, including us. Under the agreement, the parties collaborated on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and combination immunotherapies. In each of the contractual years under the agreement we paid $0.6&#160;million to the NCI as a payment for services under the agreement. We recognized research and development expense related to this agreement ratably over a 12-month period for each funding year and recorded $0.1&#160;million of expense related to this agreement in each of the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0 and $0.1&#160;million, respectively, in &lt;span style="font-style:italic;"&gt;prepaid expenses&lt;/span&gt; &lt;span style="font-style:italic;"&gt;and other current assets&lt;/span&gt;, on the condensed combined consolidated balance sheets related to this agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC, or NCSC, a 60% owned subsidiary of NantBio (with the other 40%&#160;owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#x2019;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of &lt;span style="-sec-ix-hidden:F_000837"&gt;five&#160;years&lt;/span&gt; and renews automatically for successive &lt;span style="-sec-ix-hidden:F_000838"&gt;one-year&lt;/span&gt; terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#x2019; prior written notice by NCSC. No revenue was recognized during the three&#160;months ended March&#160;31,&#160;2021 and 2020. We recorded $0.3&#160;million and $0.4&#160;million of deferred revenue for bioreactors that were delivered but not installed as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0.9&#160;million in &lt;span style="font-style:italic;"&gt;due to related parties&lt;/span&gt;, on the condensed combined consolidated balance sheets related to this agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio&#x2019;s business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a net receivable from NantBio of $1.3&#160;million, which included $1.0&#160;million for employee bonuses and $0.3&#160;million for vendor costs we paid on behalf of NantBio.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;NantOmics&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC, or NantOmics, a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December&#160;31,&#160;2020 and recorded a $0.6&#160;million receivable from NantOmics as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;605&#160;Doug&#160;St,&#160;LLC&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman, for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional &lt;span style="-sec-ix-hidden:F_000854"&gt;three-year&lt;/span&gt; term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% which began in July&#160;2017. Lease expense of $0.2&#160;million for this facility for each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, is recorded in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, there were no balances due between the parties.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Duley Road, LLC&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February&#160;2017, Altor BioScience Corporation&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC), or Altor, through its wholly-owned subsidiary, entered into a lease agreement with Duley Road,&#160;LLC, or Duley Road, a related party, that is indirectly controlled by our Executive Chairman, for approximately 12,000&#160;square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive &lt;span style="-sec-ix-hidden:F_000868"&gt;five-year&lt;/span&gt; periods through July&#160;2034. The monthly rent is $40,700 with annual increases of 3% which began in November&#160;2018. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded rent payable to Duley Road of $1.5&#160;million and $1.0&#160;million, respectively. For the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded rent expense of $0.4&#160;million and $0.1&#160;million, respectively, which is reflected in &lt;span style="font-style:italic;"&gt;research&lt;/span&gt; &lt;span style="font-style:italic;"&gt;and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second building located in El&#160;Segundo, California. The first lease is for the first floor of the building with approximately 5,650&#160;square feet. The lease has a &lt;span style="-sec-ix-hidden:F_000873"&gt;seven-year&lt;/span&gt;&#160;term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488&#160;square feet. The lease has a &lt;span style="-sec-ix-hidden:F_000874"&gt;seven-year&lt;/span&gt; term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive &lt;span style="-sec-ix-hidden:F_000875"&gt;&lt;span style="-sec-ix-hidden:F_000876"&gt;five-year&lt;/span&gt;&lt;/span&gt; periods through 2036. The monthly rent for the two&#160;leases is $35,800, which increases at a rate of 3%&#160;per year.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0.9&#160;million and $0.7&#160;million of leasehold improvement payables, respectively, and $0.8&#160;million and $1.1&#160;million of lease-related payables to Duley Road, which were included in &lt;span style="font-style:italic;"&gt;due to related parties&lt;/span&gt;, on the condensed combined consolidated balance sheets. For each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $0.1&#160;million of rent expense for the two&#160;leases, which is included in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, on the condensed combined consolidated statements of operations. The security deposits for the leases totals $0.1&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, which are included in &lt;span style="font-style:italic;"&gt;other assets&lt;/span&gt;, on the condensed combined consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;605 Nash, LLC&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In February 2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional &lt;span style="-sec-ix-hidden:F_000890"&gt;three-year&lt;/span&gt; term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of&#160;3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;We are responsible for the build out of the facility space and have incurred costs of approximately $7.0&#160;million as of March&#160;31,&#160;2021, which is reflected as construction in progress within &lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;property, plant and equipment, net&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, on the condensed combined consolidated balance sheets. We are also entitled to a tenant improvement allowance of $0.3&#160;million associated with the buildout costs, which is recorded in &lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;prepaid expenses and other current assets&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; on the condensed combined consolidated balance sheets. For the three months ended March&#160;31,&#160;2021, we recorded rent expense of $0.1&#160;million, which is reflected in &lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt;research and development expense&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; on the condensed combined consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;NantPharma&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2018, Altor BioScience, LLC and GlobeImmune, Inc. purchased a total of $0.2&#160;million in laboratory equipment from NantPharma. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a $0.2&#160;million payable to NantPharma.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Related Party Notes Payable&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2015, we executed a demand promissory note with Nant Capital. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020 and August&#160;2020, we borrowed $10.0&#160;million and $3.7&#160;million from Nant Capital, respectively. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. The principal amount of advances made by the related party pursuant to these notes totaled $55.2&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Accrued and unpaid interest on this note totaled $4.0&#160;million and $3.3&#160;million as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Amounts due under this promissory note are included in &lt;span style="font-style:italic;"&gt;related-party notes&lt;/span&gt; &lt;span style="font-style:italic;"&gt;payable&lt;/span&gt;, on the condensed combined consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2017, we executed a demand promissory note with NantWorks. The note bears interest at a per annum rate of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantWorks. All outstanding amounts under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43.4&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;million&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, all of which was outstanding&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note totaled $&lt;/span&gt;8.8&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.1&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts due under this promissory note are included in &lt;/span&gt;&lt;span style="font-style:italic;"&gt;related-party&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-style:italic;"&gt;notes payable&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;,&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; on the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;condensed combined&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, we executed a demand promissory note with NCSC. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $33.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $4.3&#160;million and $3.9&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in &lt;span style="font-style:italic;"&gt;related-party notes payable&lt;/span&gt;, on the condensed combined consolidated balance sheets. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, we executed a demand promissory note with NantMobile. The note bears interest at a per annum rate of 3.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantMobile. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount advanced by the related party pursuant to this note was $55.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $2.1&#160;million and $1.7&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in &lt;span style="font-style:italic;"&gt;related-party notes payable&lt;/span&gt;, on the condensed combined consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2020, we executed a promissory note with Nant Capital for an advance of the principal of $50.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020. The note bears interest at a per annum rate of 6.0%, compounded annually and computed on the basis of 365 or 366 days. The outstanding principal and accrued and unpaid interest are due and payable on September&#160;30,&#160;2025. Accrued and unpaid interest on this note amounted to $1.5&#160;million and $0.8&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in &lt;span style="font-style:italic;"&gt;related-party notes payable&lt;/span&gt;, on the condensed combined consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, we executed a promissory note with Nant Capital. The outstanding principal amount of each advance made by Nant Capital bears interest at a per annum rate of 6.0%, compounded annually and computed based on 365 or 366 days. On February&#160;26,&#160;2021, we received a $40.0&#160;million advance pursuant to this promissory note, all of which is outstanding as of March&#160;31,&#160;2021. The accrued interest shall be paid quarterly commencing on June&#160;30,&#160;2021. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;30,&#160;2025. We may prepay the outstanding principal amount and accrued interest at any time without premium or penalty and the prior consent of Nant Capital. Accrued interest payable on this note amounted to $0.2&#160;million as of March&#160;31,&#160;2021, and was included in &lt;span style="font-style:italic;"&gt;due to&lt;/span&gt; &lt;span style="font-style:italic;"&gt;related parties&lt;/span&gt;, on the condensed combined consolidated balance sheets. The principal amount due under this promissory note is included in &lt;span style="font-style:italic;"&gt;related-party notes payable&lt;/span&gt;, on the condensed combined consolidated balance sheets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All demand promissory notes have no equity or equity-linked convertible rights.&lt;/p&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000384">Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;width:14%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party &#x2013; NantBio&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,294&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related party &#x2013; NantOmics&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due from related parties &#x2013; Various&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;172&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;118&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.25pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total due from related parties&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,057&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,003&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantWorks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,799&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,650&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Duley Road&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,787&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantBio&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Immuno-Oncology Clinic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;503&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;271&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; Nant Capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Due to related party &#x2013; NantPharma&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;187&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total due to related parties&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,817&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,838&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; Nant Capital&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;150,695&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;109,246&lt;/p&gt;&lt;/td&gt;
&lt;td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NantMobile&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,078&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NantWorks&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52,165&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,546&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Related-party notes payable &#x2013; NCSC&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,348&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total related-party notes payable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297,286&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;254,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="border:none;padding:0;"/&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331"
      decimals="-3"
      id="F_000767"
      unitRef="U_iso4217USD">1294000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231"
      decimals="-3"
      id="F_000768"
      unitRef="U_iso4217USD">1294000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20210331"
      decimals="-3"
      id="F_000769"
      unitRef="U_iso4217USD">591000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantOmicsLLCMember_20201231"
      decimals="-3"
      id="F_000770"
      unitRef="U_iso4217USD">591000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20210331"
      decimals="-3"
      id="F_000771"
      unitRef="U_iso4217USD">172000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVariousMember_20201231"
      decimals="-3"
      id="F_000772"
      unitRef="U_iso4217USD">118000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000773"
      unitRef="U_iso4217USD">2057000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000774"
      unitRef="U_iso4217USD">2003000</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331"
      decimals="-3"
      id="F_000775"
      unitRef="U_iso4217USD">12799000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231"
      decimals="-3"
      id="F_000776"
      unitRef="U_iso4217USD">10650000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20210331"
      decimals="-3"
      id="F_000777"
      unitRef="U_iso4217USD">3161000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadMember_20201231"
      decimals="-3"
      id="F_000778"
      unitRef="U_iso4217USD">2787000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20210331"
      decimals="-3"
      id="F_000779"
      unitRef="U_iso4217USD">943000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioIncMember_20201231"
      decimals="-3"
      id="F_000780"
      unitRef="U_iso4217USD">943000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20210331"
      decimals="-3"
      id="F_000781"
      unitRef="U_iso4217USD">503000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicMember_20201231"
      decimals="-3"
      id="F_000782"
      unitRef="U_iso4217USD">271000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-3"
      id="F_000783"
      unitRef="U_iso4217USD">224000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-3"
      id="F_000784"
      unitRef="U_iso4217USD">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331"
      decimals="-3"
      id="F_000785"
      unitRef="U_iso4217USD">187000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231"
      decimals="-3"
      id="F_000786"
      unitRef="U_iso4217USD">187000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000787"
      unitRef="U_iso4217USD">17817000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000788"
      unitRef="U_iso4217USD">14838000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-3"
      id="F_000789"
      unitRef="U_iso4217USD">150695000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-3"
      id="F_000790"
      unitRef="U_iso4217USD">109246000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331"
      decimals="-3"
      id="F_000791"
      unitRef="U_iso4217USD">57078000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231"
      decimals="-3"
      id="F_000792"
      unitRef="U_iso4217USD">56660000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331"
      decimals="-3"
      id="F_000793"
      unitRef="U_iso4217USD">52165000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231"
      decimals="-3"
      id="F_000794"
      unitRef="U_iso4217USD">51546000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331"
      decimals="-3"
      id="F_000795"
      unitRef="U_iso4217USD">37348000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231"
      decimals="-3"
      id="F_000796"
      unitRef="U_iso4217USD">36901000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_20210331"
      decimals="-3"
      id="F_000797"
      unitRef="U_iso4217USD">297286000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent
      contextRef="C_0001326110_20201231"
      decimals="-3"
      id="F_000798"
      unitRef="U_iso4217USD">254353000</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000799"
      unitRef="U_iso4217USD">1800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000800"
      unitRef="U_iso4217USD">1500000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000801"
      unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000802"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331"
      decimals="-5"
      id="F_000803"
      unitRef="U_iso4217USD">12800000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTransactionTypeAxis_ibrxReimbursementsMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231"
      decimals="-5"
      id="F_000804"
      unitRef="U_iso4217USD">10700000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20210331"
      decimals="-5"
      id="F_000805"
      unitRef="U_iso4217USD">1300000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_us-gaapTypeOfArrangementAxis_ibrxSharedServicesAgreementMember_20201231"
      decimals="-5"
      id="F_000806"
      unitRef="U_iso4217USD">1100000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151130"
      decimals="INF"
      id="F_000807"
      unitRef="U_utrsqft">9500</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20151101_20151130"
      decimals="0"
      id="F_000808"
      unitRef="U_iso4217USD">47000</ibrx:BaseMonthlyRent>
    <ibrx:LeaseAgreementExtendedPeriod
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930"
      id="F_000812">2021-12-31</ibrx:LeaseAgreementExtendedPeriod>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101"
      decimals="0"
      id="F_000809"
      unitRef="U_iso4217USD">54500</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210101"
      decimals="2"
      id="F_000810"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxAmendmentToExtendLeaseTermMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200901_20200930"
      decimals="-5"
      id="F_000811"
      unitRef="U_iso4217USD">1200000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20210101_20210331"
      decimals="-5"
      id="F_000813"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksLimitedLiabilityCompanyMember_20200101_20200331"
      decimals="-5"
      id="F_000814"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfOfficers
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20151130"
      decimals="INF"
      id="F_000815"
      unitRef="U_ibrxOfficer">1</ibrx:NumberOfOfficers>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731"
      decimals="-5"
      id="F_000817"
      unitRef="U_iso4217USD">7500000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <ibrx:RelatedPartyInstallmentPayment
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190701_20190731"
      decimals="-4"
      id="F_000818"
      unitRef="U_iso4217USD">3750000</ibrx:RelatedPartyInstallmentPayment>
    <ibrx:RelatedPartyInstallmentPayment
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20191001_20191031"
      decimals="-4"
      id="F_000819"
      unitRef="U_iso4217USD">1880000</ibrx:RelatedPartyInstallmentPayment>
    <ibrx:RelatedPartyTransactionConditionalPayment
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20190731"
      decimals="-4"
      id="F_000820"
      unitRef="U_iso4217USD">1880000</ibrx:RelatedPartyTransactionConditionalPayment>
    <ibrx:NewAgreementTerminationNoticePeriod
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331"
      id="F_000821">P60D</ibrx:NewAgreementTerminationNoticePeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210101_20210331"
      decimals="-5"
      id="F_000822"
      unitRef="U_iso4217USD">300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20200101_20200331"
      decimals="-5"
      id="F_000823"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331"
      decimals="-5"
      id="F_000824"
      unitRef="U_iso4217USD">500000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231"
      decimals="-5"
      id="F_000825"
      unitRef="U_iso4217USD">300000</us-gaap:DueToRelatedPartiesCurrent>
    <ibrx:PrepaidBalance
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20210331"
      decimals="-5"
      id="F_000826"
      unitRef="U_iso4217USD">4600000</ibrx:PrepaidBalance>
    <ibrx:PrepaidBalance
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryCA_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_20201231"
      decimals="-5"
      id="F_000827"
      unitRef="U_iso4217USD">4700000</ibrx:PrepaidBalance>
    <ibrx:PrepaymentOfFundingAmount
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331"
      decimals="-5"
      id="F_000832"
      unitRef="U_iso4217USD">600000</ibrx:PrepaymentOfFundingAmount>
    <ibrx:ResearchAndDevelopmentExpenseRatablePaymentPeriod
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331"
      id="F_000829">P12M</ibrx:ResearchAndDevelopmentExpenseRatablePaymentPeriod>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210101_20210331"
      decimals="-5"
      id="F_000830"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20200101_20200331"
      decimals="-5"
      id="F_000831"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20210331"
      decimals="-6"
      id="F_000833"
      unitRef="U_iso4217USD">0</ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets>
    <ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxNantBioScienceMember_20201231"
      decimals="-5"
      id="F_000834"
      unitRef="U_iso4217USD">100000</ibrx:PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantBioScienceMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831"
      decimals="2"
      id="F_000835"
      unitRef="U_xbrlipure">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="C_0001326110_deiLegalEntityAxis_ibrxSorrentoMember_srtOwnershipAxis_ibrxNantCancerStemCellLLCMember_20180831"
      decimals="2"
      id="F_000836"
      unitRef="U_xbrlipure">0.40</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210101_20210331"
      decimals="-6"
      id="F_000839"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20200101_20200331"
      decimals="-6"
      id="F_000840"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331"
      decimals="-5"
      id="F_000841"
      unitRef="U_iso4217USD">300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231"
      decimals="-5"
      id="F_000842"
      unitRef="U_iso4217USD">400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20201231"
      decimals="-5"
      id="F_000844"
      unitRef="U_iso4217USD">900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxBioreactorMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCancerStemCellLLCMember_20210331"
      decimals="-5"
      id="F_000843"
      unitRef="U_iso4217USD">900000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231"
      decimals="-5"
      id="F_000846"
      unitRef="U_iso4217USD">1300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331"
      decimals="-5"
      id="F_000845"
      unitRef="U_iso4217USD">1300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231"
      decimals="-5"
      id="F_000848"
      unitRef="U_iso4217USD">1000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331"
      decimals="-5"
      id="F_000847"
      unitRef="U_iso4217USD">1000000.0</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20201231"
      decimals="-5"
      id="F_000850"
      unitRef="U_iso4217USD">300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxVendorCostsPaymentsMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331"
      decimals="-5"
      id="F_000849"
      unitRef="U_iso4217USD">300000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20201231"
      decimals="-5"
      id="F_000852"
      unitRef="U_iso4217USD">600000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxEmployeeBonusesPaymentMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantOmicsLLCMember_20210331"
      decimals="-5"
      id="F_000851"
      unitRef="U_iso4217USD">600000</us-gaap:DueFromRelatedParties>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331"
      decimals="0"
      id="F_000853"
      unitRef="U_utrsqft">24250</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331"
      decimals="-5"
      id="F_000855"
      unitRef="U_iso4217USD">100000</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331"
      decimals="2"
      id="F_000856"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210101_20210331"
      decimals="-5"
      id="F_000857"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20200101_20200331"
      decimals="-5"
      id="F_000858"
      unitRef="U_iso4217USD">200000</us-gaap:OperatingLeaseExpense>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20210331"
      decimals="-6"
      id="F_000859"
      unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedParty
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDougStLLCMember_20201231"
      decimals="-6"
      id="F_000860"
      unitRef="U_iso4217USD">0</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170228"
      decimals="INF"
      id="F_000861"
      unitRef="U_utrsqft">12000</ibrx:NumberOfSquareFootOfFacilityLeased>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      id="F_000870">The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through July&#160;2034. The monthly rent is $40,700 with annual increases of 3% which began in November&#160;2018.</us-gaap:LesseeOperatingLeaseDescription>
    <ibrx:OptionsToExtendNumberOfTerms
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228"
      decimals="INF"
      id="F_000869"
      unitRef="U_ibrxTerm">2</ibrx:OptionsToExtendNumberOfTerms>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228"
      decimals="0"
      id="F_000862"
      unitRef="U_iso4217USD">40700</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToMonthlyFixedCharge
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20170201_20170228"
      decimals="2"
      id="F_000863"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToMonthlyFixedCharge>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="-5"
      id="F_000864"
      unitRef="U_iso4217USD">1500000</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:AccruedRentCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231"
      decimals="-5"
      id="F_000865"
      unitRef="U_iso4217USD">1000000.0</us-gaap:AccruedRentCurrentAndNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="-5"
      id="F_000866"
      unitRef="U_iso4217USD">400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331"
      decimals="-5"
      id="F_000867"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLeaseExpense>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="0"
      id="F_000871"
      unitRef="U_utrsqft">5650</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_srtStatementGeographicalAxis_ibrxElSegundoCaliforniaMember_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="0"
      id="F_000872"
      unitRef="U_utrsqft">6488</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="0"
      id="F_000877"
      unitRef="U_iso4217USD">35800</ibrx:BaseMonthlyRent>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="0"
      id="F_000878"
      unitRef="U_iso4217USD">35800</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInSeptemberTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="2"
      id="F_000879"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="C_0001326110_us-gaapLeaseContractualTermAxis_ibrxSevenYearTermCommencingInJulyTwentyNineteenMember_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="2"
      id="F_000880"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <ibrx:LeaseholdImprovementPayables
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="-5"
      id="F_000881"
      unitRef="U_iso4217USD">900000</ibrx:LeaseholdImprovementPayables>
    <ibrx:LeaseholdImprovementPayables
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231"
      decimals="-5"
      id="F_000882"
      unitRef="U_iso4217USD">700000</ibrx:LeaseholdImprovementPayables>
    <ibrx:LeaseRelatedPayables
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="-5"
      id="F_000883"
      unitRef="U_iso4217USD">800000</ibrx:LeaseRelatedPayables>
    <ibrx:LeaseRelatedPayables
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231"
      decimals="-5"
      id="F_000884"
      unitRef="U_iso4217USD">1100000</ibrx:LeaseRelatedPayables>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210101_20210331"
      decimals="-5"
      id="F_000885"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20200101_20200331"
      decimals="-5"
      id="F_000886"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SecurityDeposit
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20210331"
      decimals="-5"
      id="F_000887"
      unitRef="U_iso4217USD">100000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxDuleyRoadLLCMember_20201231"
      decimals="-5"
      id="F_000888"
      unitRef="U_iso4217USD">100000</us-gaap:SecurityDeposit>
    <ibrx:NumberOfSquareFootOfFacilityLeased
      contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210228"
      decimals="INF"
      id="F_000889"
      unitRef="U_utrsqft">6883</ibrx:NumberOfSquareFootOfFacilityLeased>
    <ibrx:BaseMonthlyRent
      contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228"
      decimals="0"
      id="F_000891"
      unitRef="U_iso4217USD">20300</ibrx:BaseMonthlyRent>
    <ibrx:AnnualPercentageIncreasesToBaseRent
      contextRef="C_0001326110_srtStatementScenarioAxis_ibrxElSegundoCaliforniaMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210201_20210228"
      decimals="2"
      id="F_000892"
      unitRef="U_xbrlipure">0.03</ibrx:AnnualPercentageIncreasesToBaseRent>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPropertyPlantAndEquipmentMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331"
      decimals="-5"
      id="F_000893"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ConstructionInProgressGross>
    <us-gaap:TenantImprovements
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210331"
      decimals="-5"
      id="F_000894"
      unitRef="U_iso4217USD">300000</us-gaap:TenantImprovements>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_us-gaapRelatedPartyTransactionAxis_ibrxSixZeroFiveNashLLCMember_20210101_20210331"
      decimals="-5"
      id="F_000895"
      unitRef="U_iso4217USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20180101_20181231"
      decimals="-5"
      id="F_000896"
      unitRef="U_iso4217USD">200000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20201231"
      decimals="-5"
      id="F_000898"
      unitRef="U_iso4217USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="C_0001326110_us-gaapRelatedPartyTransactionAxis_ibrxNantPharmaMember_20210331"
      decimals="-5"
      id="F_000897"
      unitRef="U_iso4217USD">200000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20151231"
      decimals="INF"
      id="F_000899"
      unitRef="U_xbrlipure">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200731"
      decimals="-5"
      id="F_000900"
      unitRef="U_iso4217USD">10000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200831"
      decimals="-5"
      id="F_000901"
      unitRef="U_iso4217USD">3700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-5"
      id="F_000903"
      unitRef="U_iso4217USD">55200000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000902"
      unitRef="U_iso4217USD">55200000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000904"
      unitRef="U_iso4217USD">4000000.0</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-5"
      id="F_000905"
      unitRef="U_iso4217USD">3300000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20170630"
      decimals="INF"
      id="F_000906"
      unitRef="U_xbrlipure">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331"
      decimals="-5"
      id="F_000907"
      unitRef="U_iso4217USD">43400000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231"
      decimals="-5"
      id="F_000908"
      unitRef="U_iso4217USD">43400000</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20210331"
      decimals="-5"
      id="F_000909"
      unitRef="U_iso4217USD">8800000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantWorksMember_20201231"
      decimals="-5"
      id="F_000910"
      unitRef="U_iso4217USD">8100000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20180831"
      decimals="INF"
      id="F_000911"
      unitRef="U_xbrlipure">0.050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331"
      decimals="-5"
      id="F_000912"
      unitRef="U_iso4217USD">33000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231"
      decimals="-5"
      id="F_000913"
      unitRef="U_iso4217USD">33000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20210331"
      decimals="-5"
      id="F_000914"
      unitRef="U_iso4217USD">4300000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNCSCMember_20201231"
      decimals="-5"
      id="F_000915"
      unitRef="U_iso4217USD">3900000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20191231"
      decimals="INF"
      id="F_000916"
      unitRef="U_xbrlipure">0.030</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331"
      decimals="-5"
      id="F_000917"
      unitRef="U_iso4217USD">55000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231"
      decimals="-5"
      id="F_000918"
      unitRef="U_iso4217USD">55000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20210331"
      decimals="-5"
      id="F_000919"
      unitRef="U_iso4217USD">2100000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxDemandPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantMobileMember_20201231"
      decimals="-5"
      id="F_000920"
      unitRef="U_iso4217USD">1700000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930"
      decimals="-5"
      id="F_000922"
      unitRef="U_iso4217USD">50000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000923"
      unitRef="U_iso4217USD">50000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:NotesPayableRelatedPartiesNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-5"
      id="F_000924"
      unitRef="U_iso4217USD">50000000.0</us-gaap:NotesPayableRelatedPartiesNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20200930"
      decimals="INF"
      id="F_000921"
      unitRef="U_xbrlipure">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000925"
      unitRef="U_iso4217USD">1500000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20201231"
      decimals="-5"
      id="F_000926"
      unitRef="U_iso4217USD">800000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210228"
      decimals="INF"
      id="F_000927"
      unitRef="U_xbrlipure">0.060</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ibrx:AmountOfAdvanceReceivedOnNote
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210226_20210226"
      decimals="-5"
      id="F_000928"
      unitRef="U_iso4217USD">40000000.0</ibrx:AmountOfAdvanceReceivedOnNote>
    <ibrx:AmountOfAdvanceReceivedOnNoteOutstanding
      contextRef="C_0001326110_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000929"
      unitRef="U_iso4217USD">40000000.0</ibrx:AmountOfAdvanceReceivedOnNoteOutstanding>
    <us-gaap:InterestPayableCurrent
      contextRef="C_0001326110_us-gaapBalanceSheetLocationAxis_ibrxRelatedPartyNotesPayableMember_us-gaapDebtInstrumentAxis_ibrxPromissoryNoteMember_us-gaapRelatedPartyTransactionAxis_ibrxNantCapitalMember_20210331"
      decimals="-5"
      id="F_000930"
      unitRef="U_iso4217USD">200000</us-gaap:InterestPayableCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000355">
&lt;p id="N10___STOCKHOLDERS_DEFICIT" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. &#160;&#160;&#160;&#160;Stockholders&#x2019; Deficit&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merger with NantCell&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock&lt;/span&gt;, par value $0.001&#160;per share, &lt;span style="Background-color:#FFFFFF;"&gt;issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190&#160;newly issued shares of common stock&lt;/span&gt;, par value $0.0001&#160;per share, resulting in the issuance of approximately 273.7&#160;million shares of Company Common Stock.&lt;span style="Background-color:#FFFFFF;"&gt; &lt;/span&gt;From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. &lt;span style="Background-color:#FFFFFF;"&gt;At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed combined consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company&#x2019;s par value of $0.0001&#160;per share. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Repurchases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November&#160;2015, the board of directors approved a share repurchase program, or the 2015&#160;Share Repurchase Program, allowing the Chief Executive officer, or CEO, or Chief Financial Officer, or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through board approval upon repurchase. No&#160;shares were repurchased during the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021, $18.3&#160;million remained authorized for repurchase under the 2015&#160;Share Repurchase Program. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021, a total of approximately 12.6&#160;million shares of common stock were reserved for issuance, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;including awards issued under the NC&#160;2015&#160;Plan that were outstanding immediately prior to the Effective Time of the Merger. &lt;/span&gt;At the Effective Time, all outstanding equity awards granted under the NC&#160;2015&#160;Plan to purchase NantCell common stock were converted into equity awards to purchase shares of Company Common Stock (using the Merger Exchange Ratio of 0.8190), on the same terms and conditions as immediately prior to the Effective Time. As of March&#160;31,&#160;2021, there were approximately 7.0&#160;million RSUs and 1.3&#160;million stock options outstanding under the NC&#160;2015&#160;Plan, and there were no additional shares available for future grant.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_20210309_20210309"
      decimals="4"
      id="F_000931"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20210309"
      decimals="INF"
      id="F_000932"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001326110_20210309_20210309"
      decimals="-5"
      id="F_000933"
      unitRef="U_xbrlishares">273700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20210331"
      decimals="INF"
      id="F_000934"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="C_0001326110_20210331"
      decimals="-5"
      id="F_000935"
      unitRef="U_iso4217USD">50000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_0001326110_20210101_20210331"
      decimals="INF"
      id="F_000937"
      unitRef="U_xbrlishares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_0001326110_20200101_20200331"
      decimals="INF"
      id="F_000938"
      unitRef="U_xbrlishares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_0001326110_20210331"
      decimals="-5"
      id="F_000936"
      unitRef="U_iso4217USD">18300000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001326110_20210331"
      decimals="-5"
      id="F_000939"
      unitRef="U_xbrlishares">12600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_20210309_20210309"
      decimals="4"
      id="F_000940"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331"
      decimals="-5"
      id="F_000941"
      unitRef="U_xbrlishares">7000000.0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331"
      decimals="-5"
      id="F_000942"
      unitRef="U_xbrlishares">1300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210331"
      decimals="INF"
      id="F_000943"
      unitRef="U_xbrlishares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000356">
&lt;p id="N11___STOCKBASED_COMPENSATION" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. &#160;&#160;&#160;&#160;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2015 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July&#160;2015, the company&#x2019;s board of directors adopted, and the company&#x2019;s stockholders approved the 2015&#160;Plan. As of March&#160;31,&#160;2021, the 2015&#160;Plan is the only equity plan of the company available for grant of equity awards to employees, directors and consultants of the company. As of March&#160;31,&#160;2021, a total of approximately 6.2&#160;million shares were available for future grant under the 2015&#160;Plan.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;18,&#160;2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30)&#160;days following our registration statement effective date. We recognized incremental stock-based compensation expense of approximately $2.7&#160;million for this stock option modification.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;29,&#160;2021, in connection with the resignation of two&#160;former directors, the Board of Directors approved the acceleration of vesting of 83,333&#160;shares of unvested stock options of each of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90)&#160;days after the date of the modification. We recognized incremental stock-based compensation expense of approximately $2.3&#160;million for this stock option modification.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recognized in &lt;span style="font-style:italic;"&gt;selling, general and administrative expenses&lt;/span&gt;, on the condensed combined consolidated statements of operations during the three&#160;months ended March&#160;31,&#160;2021.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Stock Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity and related information for three&#160;months ended March&#160;31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,996,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000978"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(752,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,279&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000979"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:10.05pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,815,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000980"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;February&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;5,&#160;2021, the&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;compensation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;committee&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; the&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;board&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;directors&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; the c&lt;/span&gt;ompany&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;granted&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Richard&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Adcock,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;hief&lt;span style="letter-spacing:-0.15pt;"&gt; e&lt;/span&gt;xecutive&lt;span style="letter-spacing:-0.1pt;"&gt; o&lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;fficer, a stock option award&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;(the&lt;span style="letter-spacing:-0.15pt;"&gt; &#x201c;&lt;/span&gt;Option&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Grant&#x201d;)&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;purchase&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;750,000&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;shares&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:1.15pt;"&gt; &lt;/span&gt;common&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;stock&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;pursuant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;2015&#160;Plan.&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Option&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Grant&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;has&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;an&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;exercise&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;price&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of $23.72&#160;per share,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;closing&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;price&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;reported&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.1pt;"&gt; the &lt;/span&gt;Nasdaq&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;date&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;grant.&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;In&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;addition,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Option&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Grant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shall&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;vest&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;according&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;following&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vesting&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;schedule:&#160;one-third&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Option&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;Grant&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;(i.e.,&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;250,000&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;options)&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shall&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;vest&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;equal&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;installments&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;each&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;first,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;second,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;third&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;anniversaries&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; date of &lt;/span&gt;grant,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;such&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;all&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shall&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;fully&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vested&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;third&#160;anniversary&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; date of grant&lt;/span&gt;,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;subject&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt;&#160;&lt;/span&gt;Adcock&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;remaining&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;ontinuous&lt;span style="letter-spacing:-0.1pt;"&gt; s&lt;/span&gt;ervice&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;defined&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; 2015&#160;&lt;/span&gt;Plan&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;through&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;applicable&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vesting&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;dates. This&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;equity&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.55pt;"&gt;&#160;&lt;/span&gt;Adcock&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;made&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;connection&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;his&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;appointment&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;hief&lt;span style="letter-spacing:-0.15pt;"&gt; e&lt;/span&gt;xecutive&lt;span style="letter-spacing:-0.1pt;"&gt; o&lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;fficer&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;ompany, &lt;/span&gt;which&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;effective&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;October&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;26,&#160;2020,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:1.25pt;"&gt; &lt;/span&gt;modified&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;recommended&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;equity&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;described&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;Adcock&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;offer&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;employment&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31,&#160;2021, the unrecognized compensation cost related to outstanding stock options was $13.9&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.8&#160;years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total intrinsic value of stock options exercised during the three&#160;months ended March&#160;31,&#160;2021 was $11.1&#160;million. Cash proceeds received from stock option exercises during the three&#160;months ended March&#160;31,&#160;2021 was $1.1&#160;million. There were no stock options exercised during the three&#160;months ended March&#160;31,&#160;2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&#160;31,&#160;2020, a total of 4,345,497&#160;vested and exercisable shares were outstanding.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000990"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#x2019;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future. There were no stock options granted during the three&#160;months ended March&#160;31,&#160;2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes RSU activity for the three&#160;months ended March&#160;31,&#160;2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;466,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,521,110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,636,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March&#160;31, 2021, there was $179.2&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 3.9&#160;years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in &lt;a href="#N9___RELATED_PARTY_AGREEMENTS"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;9&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Related Party Agreements&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;February&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;5,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;2021, the&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;compensation&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;committee&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; the&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;board&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;directors&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; the c&lt;/span&gt;ompany&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;granted&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;Mr.&#160;Adcock&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;two&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;awards&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;totaling&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;400,000&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;RSUs&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;(each&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;an&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&#x201c;RSU&lt;span style="letter-spacing:-0.15pt;"&gt; Award&#x201d;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;collectively,&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;&#x201c;RSU&lt;span style="letter-spacing:-0.15pt;"&gt; Awards&#x201d;) &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;common&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;stock&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;pursuant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; 2015&#160;&lt;/span&gt;Plan.&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;RSU&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt;Awards &lt;/span&gt;are&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;comprised&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;two&#160;separate&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;awards,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;one&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;settled&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;by&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;issuing&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;150,000&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;shares&lt;span style="letter-spacing:1.05pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;common&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;stock&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;other&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;settled&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;by&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;issuing&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;250,000&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;shares&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;our&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;common&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;stock&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;upon&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vesting.&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;The&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;first&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;RSU&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Aw&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt;a&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;rd&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;vested&lt;span style="letter-spacing:1.15pt;"&gt; &lt;/span&gt;immediately&lt;span style="letter-spacing:1.15pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; date of grant &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; c&lt;/span&gt;ompany&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;retaining&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;equal&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;value&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;ompany&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;tax&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;withholding&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;obligations. The&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;second&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;RSU&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Aw&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt;a&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;rd&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;will&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vest&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;according&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;following&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;schedule:&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;one-third&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;(i.e.&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;83,333)&lt;span style="letter-spacing:-0.15pt;"&gt;&#160;&lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;subject&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;RSU&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Aw&lt;/span&gt;&lt;span style="letter-spacing:-0.25pt;"&gt;a&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;rd&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;shall&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;vest&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;equal&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;annual&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;installments&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;each&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:1.15pt;"&gt; &lt;/span&gt;first,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;second&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;third&#160;anniversaries&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; date of grant&lt;/span&gt;,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;such&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;all&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;shares&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;shall&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;be&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;fully&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;vested&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;on&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;third&#160;anniversary&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.1pt;"&gt; date of g&lt;/span&gt;rant,&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;subject&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;to &lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt;&#160;&lt;/span&gt;Adcock&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;remaining&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;ontinuous&lt;span style="letter-spacing:-0.1pt;"&gt; s&lt;/span&gt;ervice&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;defined&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; 2015&#160;&lt;/span&gt;Plan&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;through&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;applicable&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;vesting&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;dates.&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;This&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;equity&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;awards&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;to&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.55pt;"&gt;&#160;&lt;/span&gt;Adcock&lt;span style="letter-spacing:1.1pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;made&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;connection&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;with&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;his&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;appointment&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;hief&lt;span style="letter-spacing:-0.15pt;"&gt; e&lt;/span&gt;xecutive&lt;span style="letter-spacing:-0.1pt;"&gt; o&lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;fficer&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; c&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;ompany, &lt;/span&gt;which&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;effective&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;October&lt;span style="letter-spacing:-0.1pt;"&gt;&#160;&lt;/span&gt;26,&#160;2020,&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;and&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;was&lt;span style="letter-spacing:1.25pt;"&gt; &lt;/span&gt;modified&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;from&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;the&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;recommended&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;equity&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;grant&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;described&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;in&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt;Mr.&lt;/span&gt;&lt;span style="letter-spacing:-0.6pt;"&gt;&#160;&lt;/span&gt;&lt;span style="letter-spacing:-0.1pt;"&gt;Adcock&#x2019;s&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;&lt;span style="letter-spacing:-0.05pt;"&gt;offer&lt;/span&gt;&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;employment&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;as&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;of&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;that&lt;span style="letter-spacing:-0.15pt;"&gt; &lt;/span&gt;date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;4,&#160;2021, prior to the Merger, NantCell awarded 7,121,110&#160;RSUs (adjusted for the exchange ratio of 0.8190) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC&#160;2015&#160;Plan. These RSU awards were subject to a performance condition in connection with a &#x201c;Liquidity Event&#x201d;, defined as either (i)&#160;NantCell&#x2019;s registration of shares for issuance on a securities offering or (ii)&#160;the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March&#160;9,&#160;2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March&#160;4,&#160;2021 and was derived primarily from the estimated probabilities of the Merger close on March&#160;9, 2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March&#160;9, 2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from &lt;span style="-sec-ix-hidden:F_001015"&gt;six-month&lt;/span&gt; to seventy&#160;(70)-month vesting periods. During the three&#160;months ended March&#160;31,&#160;2021, we recognized approximately $5.1&#160;million of stock-based compensation expense related to these awards, of which approximately $2.9&#160;million was recorded in &lt;span style="font-style:italic;"&gt;research and development expense&lt;/span&gt;, and approximately $2.2&#160;million was recorded in &lt;span style="font-style:italic;"&gt;selling, general and administrative expense&lt;/span&gt;, respectively, on the condensed combined consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU&#160;2018-07, &lt;span style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation (Topic&#160;718)&lt;/span&gt;, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in &lt;a href="#N9___RELATED_PARTY_AGREEMENTS"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;9&lt;/span&gt;&lt;/a&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;"&gt;Related Party Agreements&lt;/span&gt;. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million and recognized $0.1&#160;million of deemed dividends for the three&#160;months ended March&#160;31,&#160;2021, which was recorded in &lt;span style="font-style:italic;"&gt;additional paid in capital,&lt;/span&gt; on the condensed combined consolidated balance sheets, with a corresponding credit to stock compensation expense.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Warrants&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#x2019;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share, with vesting subject to the achievement of a certain performance condition pertaining to building manufacturing capacity, were outstanding as of March&#160;31,&#160;2021. The fair value of $18.0&#160;million assigned to the unvested warrants will be recognized upon achievement of a performance-based vesting condition &lt;span style="color:#000000;"&gt;pertaining to building manufacturing capacity to support supply requirements for one of our product candidates&lt;/span&gt;. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000944"
      unitRef="U_xbrlishares">6200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000385">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in&#160;thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,943&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense in operating expenses:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,888&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;161&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Selling, general and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;319&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;480&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210331"
      decimals="-3"
      id="F_000945"
      unitRef="U_iso4217USD">6355000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20200101_20200331"
      decimals="-3"
      id="F_000946"
      unitRef="U_iso4217USD">130000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="-3"
      id="F_000947"
      unitRef="U_iso4217USD">8943000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200101_20200331"
      decimals="-3"
      id="F_000948"
      unitRef="U_iso4217USD">350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000949"
      unitRef="U_iso4217USD">15298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">2888000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">161000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">12410000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20200101_20200331"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_20210101_20210331"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">15298000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_20200101_20200331"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember_20210318_20210318"
      decimals="-5"
      id="F_000958"
      unitRef="U_iso4217USD">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ibrx:NumberOfBoardOfDirectors
      contextRef="C_0001326110_20210101_20210331"
      decimals="INF"
      id="F_000960"
      unitRef="U_ibrxDirector">2</ibrx:NumberOfBoardOfDirectors>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210329_20210329"
      decimals="INF"
      id="F_000961"
      unitRef="U_xbrlishares">83333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_srtTitleOfIndividualAxis_ibrxNonEmployeeDirectorMember_us-gaapNatureOfExpenseAxis_ibrxModificationOfStockOptionsAssociatedWithResignationMember_20210101_20210331"
      decimals="-5"
      id="F_000957"
      unitRef="U_iso4217USD">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000386">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity and related information for three&#160;months ended March&#160;31, 2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,996,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.96&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000978"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;750,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(752,310&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,660&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.27&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,978,314&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;54,279&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000979"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:10.05pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested and exercisable at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,815,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.07&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,363&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000980"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="INF"
      id="F_000963"
      unitRef="U_xbrlishares">4996284</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="2"
      id="F_000969"
      unitRef="U_iso4217USD_xbrlishares">9.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="-3"
      id="F_000975"
      unitRef="U_iso4217USD">29746000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="INF"
      id="F_000964"
      unitRef="U_xbrlishares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000970"
      unitRef="U_iso4217USD_xbrlishares">23.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="INF"
      id="F_000965"
      unitRef="U_xbrlishares">752310</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000971"
      unitRef="U_iso4217USD_xbrlishares">2.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="INF"
      id="F_000966"
      unitRef="U_xbrlishares">15660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="2"
      id="F_000972"
      unitRef="U_iso4217USD_xbrlishares">6.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="INF"
      id="F_000967"
      unitRef="U_xbrlishares">4978314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="2"
      id="F_000973"
      unitRef="U_iso4217USD_xbrlishares">13.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="-3"
      id="F_000976"
      unitRef="U_iso4217USD">54279000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="INF"
      id="F_000968"
      unitRef="U_xbrlishares">3815630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="2"
      id="F_000974"
      unitRef="U_iso4217USD_xbrlishares">12.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="-3"
      id="F_000977"
      unitRef="U_iso4217USD">46363000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205"
      decimals="INF"
      id="F_000983"
      unitRef="U_xbrlishares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205"
      decimals="INF"
      id="F_000984"
      unitRef="U_iso4217USD_xbrlishares">23.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000985">one-third of the Option Grant&#160;(i.e.,&#160;250,000 options) shall vest in equal installments on each of the first, second, and third anniversaries of the date of grant, such that all shares shall be fully vested on the third&#160;anniversary of the date of grant, subject to Mr.&#160;Adcock remaining in continuous service as defined in the 2015&#160;Plan through the applicable vesting dates.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="-5"
      id="F_000981"
      unitRef="U_iso4217USD">13900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000982">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="-5"
      id="F_000986"
      unitRef="U_iso4217USD">11100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="-5"
      id="F_000987"
      unitRef="U_iso4217USD">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331"
      decimals="INF"
      id="F_000988"
      unitRef="U_xbrlishares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="INF"
      id="F_000989"
      unitRef="U_xbrlishares">4345497</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000387">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ended&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Unaudited)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000990"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average grant date fair value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="3"
      id="F_000991"
      unitRef="U_xbrlipure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="3"
      id="F_000992"
      unitRef="U_xbrlipure">1.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="3"
      id="F_000993"
      unitRef="U_xbrlipure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210331"
      decimals="2"
      id="F_000994"
      unitRef="U_iso4217USD_xbrlishares">18.63</ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20200331"
      decimals="INF"
      id="F_000995"
      unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000388">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes RSU activity for the three&#160;months ended March&#160;31,&#160;2021:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;466,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.52&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,521,110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(235,725&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.34&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited/canceled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(116,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25.49&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested balance at March&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,636,132&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="INF"
      id="F_000996"
      unitRef="U_xbrlishares">466842</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231"
      decimals="2"
      id="F_001001"
      unitRef="U_iso4217USD_xbrlishares">2.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="INF"
      id="F_000997"
      unitRef="U_xbrlishares">7521110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="2"
      id="F_001002"
      unitRef="U_iso4217USD_xbrlishares">25.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="INF"
      id="F_000998"
      unitRef="U_xbrlishares">235725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="2"
      id="F_001003"
      unitRef="U_iso4217USD_xbrlishares">16.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="INF"
      id="F_000999"
      unitRef="U_xbrlishares">116095</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      decimals="2"
      id="F_001004"
      unitRef="U_iso4217USD_xbrlishares">25.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331"
      decimals="INF"
      id="F_001000"
      unitRef="U_xbrlishares">7636132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331"
      decimals="2"
      id="F_001005"
      unitRef="U_iso4217USD_xbrlishares">24.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210331"
      decimals="-5"
      id="F_001006"
      unitRef="U_iso4217USD">179200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20210331"
      id="F_001007">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ibrx:NumberOfAwardsGranted
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205"
      decimals="INF"
      id="F_001009"
      unitRef="U_ibrxAward">2</ibrx:NumberOfAwardsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_ibrxTwoThousandFifteenEquityIncentivePlanMember_20210205_20210205"
      decimals="INF"
      id="F_001008"
      unitRef="U_xbrlishares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxFirstRSUAwardMember_20210205_20210205"
      decimals="INF"
      id="F_001010"
      unitRef="U_xbrlishares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxSecondRSUAwardMember_20210205_20210205"
      decimals="INF"
      id="F_001011"
      unitRef="U_xbrlishares">250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210205_20210205"
      decimals="INF"
      id="F_001012"
      unitRef="U_xbrlishares">83333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304"
      decimals="INF"
      id="F_001013"
      unitRef="U_xbrlishares">7121110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_us-gaapPlanNameAxis_ibrxNantCellTwoThousandAndFifteenPlanMember_20210304_20210304"
      decimals="4"
      id="F_001014"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210101_20210331"
      decimals="-5"
      id="F_001017"
      unitRef="U_iso4217USD">5100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-5"
      id="F_001018"
      unitRef="U_iso4217USD">2900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_us-gaapIncomeStatementLocationAxis_us-gaapSellingGeneralAndAdministrativeExpensesMember_20210101_20210331"
      decimals="-5"
      id="F_001019"
      unitRef="U_iso4217USD">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue
      contextRef="C_0001326110_20210101_20210331"
      decimals="-5"
      id="F_001020"
      unitRef="U_iso4217USD">4000000.0</ibrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
      contextRef="C_0001326110_20210101_20210331"
      decimals="-5"
      id="F_001021"
      unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0001326110_us-gaapAwardTypeAxis_ibrxWarrantsMember_20210331"
      decimals="INF"
      id="F_001022"
      unitRef="U_xbrlishares">1638000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001326110_20210331"
      decimals="2"
      id="F_001023"
      unitRef="U_iso4217USD_xbrlishares">3.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_0001326110_20210331"
      decimals="-5"
      id="F_001024"
      unitRef="U_iso4217USD">18000000.0</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000358">
&lt;p id="N12___INCOME_TAXES" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. &#160;&#160;&#160;&#160;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March&#160;9, 2021, the company completed the Merger with NantCell. The merger is accounted for as a transaction between entities under common control. The Merger is also considered a nontaxable transaction for U.S. income tax purposes and it is intended to qualify as a &#x201c;reorganization&#x201d; within the meaning of Section&#160;368(a) of the Internal Revenue Code of&#160;1986, as amended.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S.&#160;activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. No tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The difference between the federal statutory tax rate of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% and &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the company&#x2019;s&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% tax rate is due to losses from which &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;the company&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; cannot benefit.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The company is no longer subject to income tax examination by the U.S.&#160;federal, state or local tax authorities for years ended December&#160;31,&#160;2015 or prior; however, its tax attributes, such as net operating loss&#160;(&#x201c;NOL&#x201d;) carryforwards and tax credits, are still subject to examination in the year they are used.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryUS_20210101_20210331"
      decimals="INF"
      id="F_001025"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryIT_20210101_20210331"
      decimals="INF"
      id="F_001026"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001326110_srtStatementGeographicalAxis_countryKR_20210101_20210331"
      decimals="INF"
      id="F_001027"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001326110_20210101_20210331"
      decimals="2"
      id="F_001028"
      unitRef="U_xbrlipure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001326110_20210101_20210331"
      decimals="2"
      id="F_001029"
      unitRef="U_xbrlipure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001326110_20210101_20210331" id="F_000359">
&lt;p id="N13___SUBSEQUENT_EVENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. &#160;&#160;&#160;&#160;Subsequent Events&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Immuno-Oncology Clinic, Inc. Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During April&#160;2021, ImmunityBio executed two&#160;work orders under an existing master agreement with &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Immuno-Oncology Clinic,&#160;Inc.&#160;(the &#x201c;Clinic&#x201d;), a related party. Under these work orders, the parties agreed that the Clinic would serve as a site for the following multi-site clinical trials:&lt;/span&gt;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;"&gt;A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike &amp;amp; nucleocapsid-targeted COVID&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#x2011;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use; and&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:3.33%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#FFFFFF;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of a supplemental spike &amp;amp; nucleocapsid-targeted COVID&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;&#x2011;&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to our existing agreement with the Clinic, our share of qualifying expenses shall be deducted from amounts previously paid to the Clinic as described in further detail in &lt;a href="#N9___RELATED_PARTY_AGREEMENTS"&gt;&lt;span style="text-decoration:underline;"&gt;Note&#160;9&lt;/span&gt;&lt;/a&gt;&lt;span style="Background-color:#FFFFFF;"&gt;, &lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;color:#000000;"&gt;Related Party Agreements&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;. We expect to incur up to $0.2&#160;million of qualifying clinical trial expenses under each work order, subject to changes dependent on clinical trial enrollments and progress.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Open Market Sale Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April&#160;30, 2021, we entered into an Open Market Sale Agreement&#160;(the &#x201c;Sale Agreement&#x201d;) with respect to an at-the-market&#160;(&#x201c;ATM&#x201d;) offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0&#160;million through our sales agent. We will pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We are not obligated to sell any shares under the Sale Agreement and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
    <ibrx:ExpectedClinicalTrialExpense
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430"
      decimals="-5"
      id="F_001030"
      unitRef="U_iso4217USD">200000</ibrx:ExpectedClinicalTrialExpense>
    <ibrx:ExpectedClinicalTrialExpense
      contextRef="C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderTwoMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430"
      decimals="-5"
      id="F_001031"
      unitRef="U_iso4217USD">200000</ibrx:ExpectedClinicalTrialExpense>
    <ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430"
      decimals="INF"
      id="F_001032"
      unitRef="U_iso4217USD">500000000.0</ibrx:AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering>
    <ibrx:PercentageOfSalesAgentCommission
      contextRef="C_0001326110_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_ibrxAtTheMarketOfferingProgramMember_20210430_20210430"
      decimals="3"
      id="F_001033"
      unitRef="U_xbrlipure">0.030</ibrx:PercentageOfSalesAgentCommission>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_us-gaapBusinessAcquisitionAxis_ibrxNantCellIncMember_20210309"
      decimals="3"
      id="F_000390_2"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <ibrx:MergerExchangeRatio
      contextRef="C_0001326110_20210309_20210309"
      decimals="4"
      id="F_000391_2"
      unitRef="U_xbrlipure">0.8190</ibrx:MergerExchangeRatio>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001326110_20210309"
      decimals="4"
      id="F_000392_2"
      unitRef="U_iso4217USD_xbrlishares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329322552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>May 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUNITYBIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,905,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par&#160;value&#160;$0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">43-1979754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3530 John Hopkins Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">633-0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328494776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Combined Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 44,679<span></span>
</td>
<td class="nump">$ 34,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">38,594<span></span>
</td>
<td class="nump">61,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">2,057<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (including amounts with related parties)</a></td>
<td class="nump">14,242<span></span>
</td>
<td class="nump">13,649<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">99,572<span></span>
</td>
<td class="nump">111,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">80,875<span></span>
</td>
<td class="nump">72,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Non-marketable equity investment (Note 4)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible asset, net</a></td>
<td class="nump">1,438<span></span>
</td>
<td class="nump">1,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ConvertibleNoteReceivableNonCurrent', window );">Convertible note receivable</a></td>
<td class="nump">6,191<span></span>
</td>
<td class="nump">6,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net (including amounts with related parties)</a></td>
<td class="nump">18,447<span></span>
</td>
<td class="nump">18,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets (including amounts with related parties)</a></td>
<td class="nump">1,905<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">209,428<span></span>
</td>
<td class="nump">221,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,097<span></span>
</td>
<td class="nump">11,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">36,793<span></span>
</td>
<td class="nump">36,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">17,817<span></span>
</td>
<td class="nump">14,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities (including amounts with related parties)</a></td>
<td class="nump">5,156<span></span>
</td>
<td class="nump">5,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">79,863<span></span>
</td>
<td class="nump">68,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="nump">297,286<span></span>
</td>
<td class="nump">254,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, less current portion (including amounts with related parties)</a></td>
<td class="nump">16,554<span></span>
</td>
<td class="nump">16,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax liability</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">1,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">394,764<span></span>
</td>
<td class="nump">339,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized; 383,067,321 and 382,243,142 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,508,958<span></span>
</td>
<td class="nump">1,495,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,694,745)<span></span>
</td>
<td class="num">(1,615,131)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(38)<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total ImmunityBio stockholders&#8217; deficit</a></td>
<td class="num">(185,787)<span></span>
</td>
<td class="num">(119,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">451<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(185,336)<span></span>
</td>
<td class="num">(118,490)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 209,428<span></span>
</td>
<td class="nump">$ 221,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ConvertibleNoteReceivableNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible note receivable, non-current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ConvertibleNoteReceivableNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323889864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Combined Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">383,067,321<span></span>
</td>
<td class="nump">382,243,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">383,067,321<span></span>
</td>
<td class="nump">382,243,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, Shares</a></td>
<td class="nump">163,800<span></span>
</td>
<td class="nump">163,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329730776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Combined Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">41,128<span></span>
</td>
<td class="nump">27,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">45,275<span></span>
</td>
<td class="nump">9,493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">86,403<span></span>
</td>
<td class="nump">36,867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(86,264)<span></span>
</td>
<td class="num">(36,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest and investment income, net</a></td>
<td class="nump">8,944<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense (including amounts with related parties)</a></td>
<td class="num">(3,168)<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net (including amounts with related parties)</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes and noncontrolling interests</a></td>
<td class="num">(80,475)<span></span>
</td>
<td class="num">(37,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(80,481)<span></span>
</td>
<td class="num">(37,427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests, net of tax</a></td>
<td class="num">(867)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to ImmunityBio common stockholders</a></td>
<td class="num">$ (79,614)<span></span>
</td>
<td class="num">$ (37,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per ImmunityBio common share &#8211; basic and diluted</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares used in computing net loss per share &#8211; basic and diluted</a></td>
<td class="nump">382,741,464<span></span>
</td>
<td class="nump">371,989,232<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328237480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,481)<span></span>
</td>
<td class="num">$ (37,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income, net of income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax', window );">Net unrealized losses on available-for-sale securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(162)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification of net realized losses on available-for-sale securities included in net loss</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(160)<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(80,641)<span></span>
</td>
<td class="num">(37,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(867)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable ImmunityBio common stockholders</a></td>
<td class="num">$ (79,774)<span></span>
</td>
<td class="num">$ (36,991)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062414151464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Total ImmunityBio Stockholders&#8217; Equity (Deficit)</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 16,326<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,406,002<span></span>
</td>
<td class="num">$ (1,393,280)<span></span>
</td>
<td class="num">$ (87)<span></span>
</td>
<td class="nump">$ 12,672<span></span>
</td>
<td class="nump">$ 3,654<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,976,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(123)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(37,427)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,038)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(37,038)<span></span>
</td>
<td class="num">(389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="num">(20,697)<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">1,406,359<span></span>
</td>
<td class="num">(1,430,318)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="num">(23,962)<span></span>
</td>
<td class="nump">3,265<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,015,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="num">$ (118,490)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">1,495,163<span></span>
</td>
<td class="num">(1,615,131)<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="num">(119,808)<span></span>
</td>
<td class="nump">1,318<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2020</a></td>
<td class="nump">382,243,142<span></span>
</td>
<td class="nump">382,243,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,298<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">15,298<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,298<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (RSUs), Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(2,624)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,624)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(160)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(80,481)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(79,614)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(79,614)<span></span>
</td>
<td class="num">(867)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="num">$ (185,336)<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 1,508,958<span></span>
</td>
<td class="num">$ (1,694,745)<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (185,787)<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending Balance, Shares at Mar. 31, 2021</a></td>
<td class="nump">383,067,321<span></span>
</td>
<td class="nump">383,067,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062415886840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Combined Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (80,481)<span></span>
</td>
<td class="num">$ (37,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">15,298<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized (gains) losses on equity securities</a></td>
<td class="num">(8,834)<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities', window );">Non-cash interest items, net (including amounts with related parties)</a></td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,972<span></span>
</td>
<td class="nump">3,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense', window );">Non-cash lease expense related to operating lease right-of-use assets</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of net premiums and discounts on marketable debt securities</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(934)<span></span>
</td>
<td class="num">(4,020)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">693<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="nump">6,497<span></span>
</td>
<td class="num">(1,724)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(1,893)<span></span>
</td>
<td class="nump">8,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Related parties</a></td>
<td class="nump">2,597<span></span>
</td>
<td class="num">(2,411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(1,474)<span></span>
</td>
<td class="num">(342)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(60,469)<span></span>
</td>
<td class="num">(31,107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(7,083)<span></span>
</td>
<td class="num">(315)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities, available-for-sale</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(10,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of marketable debt securities</a></td>
<td class="nump">31,925<span></span>
</td>
<td class="nump">23,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">7,094<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">31,845<span></span>
</td>
<td class="nump">13,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of related-party promissory notes</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Net share settlement for RSUs vesting</a></td>
<td class="num">(2,624)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">38,497<span></span>
</td>
<td class="num">(123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(109)<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">9,764<span></span>
</td>
<td class="num">(17,147)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">35,094<span></span>
</td>
<td class="nump">75,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">44,858<span></span>
</td>
<td class="nump">58,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash, end of period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">44,679<span></span>
</td>
<td class="nump">58,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash (Note 3)</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">44,858<span></span>
</td>
<td class="nump">58,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable, accrued expenses, and due to related parties</a></td>
<td class="num">(4,267)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains on marketable debt securities</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NonCashInterestIncomeExpenseFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash interest (income) expense from operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NonCashInterestIncomeExpenseFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset non cash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329061704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">
<p id="N1___DESCRIPTION_BUSINESS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. &#160;&#160;&#160;&#160;Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We were </span>incorporated in Illinois on October&#160;7,&#160;2002 under the name ZelleRx Corporation. On January&#160;22,&#160;2010, we changed our name to Conkwest,&#160;Inc. In March&#160;2014, we formed Conkwest, Inc., our wholly-owned subsidiary in the state of Delaware, or Conkwest Delaware, for the purposes of changing the state of our incorporation to the state of Delaware. In March&#160;2014, we merged with an into Conkwest Delaware, with Conkwest Delaware surviving the merger. On July&#160;10,&#160;2015, we changed our name to NantKwest,&#160;Inc. On March 9,&#160;2021, we completed a merger with NantCell,&#160;Inc. (formerly known as ImmunityBio, Inc., a private company) and we changed our name to ImmunityBio,&#160;Inc. Our principal executive offices are located in San&#160;Diego, California. In these notes to unaudited condensed combined consolidated financial statements, the terms &#8220;ImmunityBio,&#8221; &#8220;the company,&#8221; &#8220;the combined company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to ImmunityBio and subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We established ImmunityBio to advance the next-generation immunotherapies and to address unmet needs within oncology and infectious disease. Our platform is designed to overcome limitations of the current standards of T&#160;cell-based immunotherapies, including checkpoint inhibitors and CAR-T&#160;cells and is based on our four&#160;key modalities:&#160;(1)&#160;activating natural killer, or NK, and T&#160;cells using antibody cytokine fusion proteins, (2)&#160;activating tumoricidal macrophages using low-dose synthetic immunomodulators, (3)&#160;generating memory T&#160;cells using vaccine candidates developed with our second-generation adenovirus, or hAd5, technology, and (4)&#160;off-the-shelf natural killer cells from the NK&#8209;92 cell line and memory-like cytokine-enhanced natural killer cells (m&#8209;ceNK) from allogenic and autologous donors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We own a broad, clinical-stage immunotherapy pipeline, including an antibody cytokine fusion protein&#160;(an IL&#8209;15 superagonist&#160;(N&#8209;803) known as Anktiva), an albumin-associated anthracycline synthetic immunomodulator&#160;(aldoxorubicin), second-generation adenovirus&#160;(hAd5) and yeast vaccine technologies&#160;(targeting tumor-associated antigens and neoepitopes), off-the-shelf genetically engineered natural killer cell lines inducing cancer and virally infected cell death through a variety of concurrent mechanisms (including innate killing, antibody-mediated killing, and CAR-directed killing), patient specific NK cell product for cancer that is an autologous Memory cytokine enhanced Natural Killer cells, macrophage polarizing peptides, and bi-specific fusion proteins targeting CD20, PD&#8209;L1, TGF&#8209;</span><span style="Background-color:#FFFFFF;font-family:'Times New Roman';"><span style="font-size:10pt;font-family:'Times New Roman'">b</span></span><span style="Background-color:#FFFFFF;"> and IL&#8209;12. Our immunotherapy clinical pipeline consists of over 40&#160;clinical trials in Phase&#160;1, 2, or 3&#160;development across 19&#160;indications in solid and liquid cancers and infectious diseases. We have an expansive clinical-stage pipeline and intellectual property portfolio with 17&#160;first-in-human assets in 25&#160;Phase&#160;II to III&#160;clinical trials.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In December 2019, the </span>United States, or U.S., Food and Drug Administration<span style="Background-color:#FFFFFF;">, or FDA, granted Breakthrough Therapy designation to Anktiva for bacillus Calmette-Gu&#233;rin, or BCG, unresponsive carcinoma in situ non-muscle invasive bladder cancer. Other indications currently with registration-potential studies include BCG unresponsive papillary bladder cancer, first- and second-line lung cancer, and metastatic pancreatic cancer.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On December&#160;21, 2020, we and NantCell, Inc.&#160;(formerly known as ImmunityBio,&#160;Inc., a private company)&#160;(&#8220;NantCell&#8221;) entered into an Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), pursuant to which we and NantCell agreed to combine our businesses. The Merger Agreement provided that a wholly-owned subsidiary of the company would merge with and into NantCell&#160;(the&#160;&#8220;Merger&#8221;), with NantCell surviving the Merger as a wholly-owned subsidiary of the company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On March&#160;9, 2021, we completed the Merger pursuant to the terms of the Merger Agreement. Under the terms of the Merger Agreement, at the effective time of the Merger&#160;(the &#8220;Effective Time&#8221;), each share of NantCell common stock</span>, par value $0.001&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive&#160;0.8190&#160;(the &#8220;Exchange Ratio&#8221;) newly</span> issued shares of common stock, par value $0.0001&#160;per share, of the company&#160;(&#8220;Company Common Stock&#8221;), with cash paid in lieu of any fractional shares.<span style="Background-color:#FFFFFF;"> At the Effective Time, each share of the company&#8217;s common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company. At the Effective Time, each outstanding option, warrant or restricted stock unit to purchase NantCell common stock was converted using the Exchange Ratio into an option, warrant or restricted stock unit, respectively, on the same terms and conditions immediately prior to the Effective Time, to purchase shares of Company Common Stock.</span></p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Immediately following the Effective Time, the former stockholders of NantCell held approximately&#160;71.5%&#160;of the outstanding shares of Company Common Stock and the stockholders of the company as of immediately prior to the Merger held approximately 28.5%&#160;of the outstanding shares of Company Common Stock. As a result of the Merger and immediately following the Effective Time, Dr.&#160;Patrick Soon-Shiong, our Executive Chairman, and his affiliates beneficially own, in the aggregate, approximately 81.8%&#160;of the outstanding shares of Company Common Stock. Following the consummation of the Merger, shares of the company&#8217;s common stock are now listed on the Nasdaq Global Select Market under the symbol &#8220;IBRX.&#8221;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We incurred costs totaling $23.2&#160;million in connection with the Merger, consisting of financial advisory, legal and other professional fees, of which $12.9&#160;million was recorded during the three&#160;months ended March&#160;31,&#160;2021. Merger-related costs are</span><span style="Background-color:#FFFFFF;color:#000000;"> reported in </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">selling, general and administrative expense</span><span style="Background-color:#FFFFFF;color:#000000;">, on the condensed combined consolidated statements of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of each of the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March&#160;31, 2021 and 2020 (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,903</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,275</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,637</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,373</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,702</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(707</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,383</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,427</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329044376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<p id="N2___SUMMARY_SIGNIFICANT_ACCOUNTING_POLI" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. &#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes to our significant accounting policies from those described in the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the company had an accumulated deficit of $1.7&#160;billion. We also had negative cash flows from operations of $60.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements are derived from the company&#8217;s and NantCell&#8217;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December&#160;31,&#160;2020 included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under ASC Topic&#160;810,&#160;<span style="font-style:italic;">Consolidation</span>, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#8217;s most significant economic activities and the ability to participate in the entity&#8217;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed combined consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, <span style="font-style:italic;">Fair Value Measurement</span>, or ASC&#160;820, we will apply the measurement alternative under ASC Topic&#160;321, <span style="font-style:italic;">Investments&#8212;Equity Securities</span>, or ASC&#160;321, pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#8217;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span>, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table details those securities that have been excluded from the computation of p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otentially dilutive securities:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,314</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,080,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,636,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding related-party warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,252,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,821,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#8220;2015&#160;Plan&#8221;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#8220;2014&#160;Plan&#8221;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#8220;NC&#160;2015&#160;Plan&#8221;) that, in the case of March&#160;31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March&#160;31, 2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted <span style="Background-color:#FFFFFF;color:#000000;">using the Merger Exchange Ratio of&#160;0.8190</span>). See <a href="#N11___STOCKBASED_COMPENSATION"><span style="text-decoration:underline;">Note&#160;11</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Stock-Based Compensation</span>, for further information.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued Accounting Standards Update, or ASU, 2016&#8209;13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments</span>, or ASU&#160;2016-13. The FASB subsequently issued amendments to ASU&#160;2016&#8209;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements and we do not intend to early adopt this new standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended March&#160;31,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328870696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Financial Statement Details</a></td>
<td class="text">
<p id="N3___FINANCIAL_STATEMENT_DETAILS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. &#160;&#160;&#160;&#160;Financial Statement Details</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,518</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant improvement receivables &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable <span style="font-size:9pt;">&#8211;</span> marketable debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies &#8211; with related party (Note 9)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,242</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have reflected our right to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund. <span style="color:#000000;">Our insurance claims receivable as of March&#160;31,&#160;2021 and December&#160;31, 2020 are the result of the recovery of legal costs, which had been previously charged in prior periods to s</span><span style="font-style:italic;color:#000000;">elling, general and administrative expense, </span><span style="color:#000000;">on the condensed combined consolidated statements of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,738</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property, plant and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,420</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress at March&#160;31,&#160;2021 is related primarily to expansion of our hAd5 pharmaceutical development and manufacturing facilities, including construction of a new filling suite at our leased facilities in El&#160;Segundo, California<span style="color:#1F497D;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense related to property, plant and equipment totaled $3.0&#160;million and $3.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">810</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software license fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash is comprised of a certificate of deposit that serves as collateral for a letter of credit required by our landlord as a security deposit related to our facility in San Diego, California.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,947</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dissenting shares (Note 8)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,769</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,891</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,002</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contingent consideration payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation <span style="font-family:Calibri;">&#8211;</span> current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales, use and property taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued capital expenditures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and investment income, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net consists of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains (losses) from equity securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment amortization expense, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized losses on investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income includes interest from marketable securities, convertible notes receivable, other assets, and interest from bank deposits. We did not recognize an impairment loss on any investments during the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328933464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Investment in Viracta Therapeutics<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment</a></td>
<td class="text">
<p id="N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. &#160;&#160;&#160;&#160;Equity Investment in Viracta Therapeutics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2017, we participated in a Series&#160;B convertible preferred stock financing and invested $8.5&#160;million in Viracta Therapeutics, Inc., or Viracta, a clinical stage drug development company, which was initially recorded at cost. In May&#160;2017, we executed an exclusive worldwide license with Viracta to develop and commercialize Viracta&#8217;s proprietary histone deacetylase inhibitor drug candidate for use in combination with natural killer cell therapy and possibly additional therapies.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2018, Viracta executed a 2018&#160;Note and Warrant Purchase Agreement with existing and new investors, including us. The initial closing under the Purchase Agreement occurred in June&#160;2018, at which point we purchased a convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common stock. In September&#160;2018, a milestone closing under the Purchase Agreement occurred, at which point we purchased an additional convertible note for $0.4&#160;million, which under certain circumstances was convertible into preferred stock of Viracta, and a warrant to purchase Viracta&#8217;s common stock. Effective January&#160;31,&#160;2019, the notes, together with accrued interest then outstanding, were converted to Series&#160;B preferred stock resulting in an increase to our investment in Viracta&#8217;s Series&#160;B convertible preferred stock of $0.8&#160;million. In May&#160;2019, we exercised warrants to acquire 253,120&#160;shares of Viracta common stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the level of equity investment at risk, Viracta was not a VIE and therefore was not consolidated under the VIE model. In addition, we did not hold a controlling financial interest in Viracta, and therefore we did not consolidate Viracta under the voting interest model. As the preferred stock was not considered in-substance common stock, the investment was not within the scope of accounting for the investment under the equity method. As the preferred stock did not have a readily determinable fair value and did not qualify for the practical expedient to estimate fair value in accordance with ASC&#160;820, we had elected to apply the measurement alternative under ASC&#160;321, pursuant to which we measured our investment in Viracta at cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, our fair value assessment indicated that the offering of Viracta&#8217;s Series&#160;E preferred stock in November&#160;2020, at a lower offering price per share than the per share carrying amount of our investment in Viracta, was a directional indicator representing an observable price change in an orderly transaction for a similar investment. On December&#160;31,&#160;2020, we reduced the carrying value by $1.4&#160;million due to the observable price change, which was included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed combined consolidated statements of operations for the year ended December&#160;31,&#160;2020. As of December&#160;31,&#160;2020, the carrying value of our investment in Viracta, which was reflected in <span style="font-style:italic;">non-marketable equity investment,</span> on the condensed combined consolidated balance sheets, was $7.8&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;24,&#160;2021, Sunesis Pharmaceuticals, Inc., a public company, completed a business combination with Viracta. In connection with this business combination, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. As of March&#160;31,&#160;2021, the carrying value of our investment in Viracta, which is reflected in <span style="font-style:italic;">marketable securities</span>, on the condensed combined consolidated balance sheets totaled $14.5&#160;million (including an unrealized gain of $6.6&#160;million). </p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062324886936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=ibrx_MarketableDebtAndEquitySecuritiesMember', window );">Marketable Debt and Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investment</a></td>
<td class="text">
<p id="N5___FINANCIAL_INSTRUMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. &#160;&#160;&#160;&#160;Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments in Marketable Debt Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">5.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,<span style="color:#000000;">&#160;</span>2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,762</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, a total of 14 of the securities were in unrealized loss positions. We evaluated our securities for other-than-temporary impairment and concluded that the decline in value was primarily caused by current economic and market conditions. We do not intend to sell the investments and it is not more likely than not that we will be required to sell these investments before recovery of their amortized cost bases. Therefore, we did not recognize any other-than-temporary impairment losses during the three&#160;months ended March&#160;31,&#160;2021. Realized gains and losses on sales of available-for-sale debt securities during the three&#160;months ended March&#160;31,&#160;2021 and 2020 were not material.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Marketable Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We held investments in marketable equity securities with readily determinable fair values of $23.0 million and $6.3&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Unrealized gains recognized on equity securities with readily determinable fair values totaled $8.8&#160;million for the three&#160;months ended March&#160;31,&#160;2021, while unrealized losses recognized on equity securities with readily determinable fair values totaled $0.2&#160;million for the three&#160;months ended March&#160;31,&#160;2020. There were no realized gains or losses on sales of equity securities for the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=ibrx_MarketableDebtAndEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=ibrx_MarketableDebtAndEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328968920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p id="N6___FAIR_VALUE_MEASUREMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. &#160;&#160;&#160;&#160;Fair Value Measurements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recurring Valuations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities (1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,735</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Our equity securities include our investment in Viracta totaling $14.5&#160;million, which was previously accounted for by applying the measurement alternative under ASC&#160;321. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. See </span><a href="#N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT"><span style="text-decoration:underline;color:#000000;">Note&#160;4</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Equity Investment in Viracta Therapeutics</span><span style="Background-color:#FFFFFF;color:#000000;">, for additional information.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;color:#000000;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Commitments and Contingencies,</span><span style="color:#000000;"> for additional information.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,727</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Non-recurring Valuations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-financial assets and liabilities are recognized at fair value subsequent to initial recognition when they are deemed to be other-than-temporarily impaired. There were no material non-financial assets and liabilities deemed to be other-than-temporarily impaired and measured at fair value on a non-recurring basis during the three&#160;months ended March&#160;31,&#160;2021 and 2020.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328851704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">
<p id="N7___COLLABORATION_LICENSE_AGREEMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. &#160;&#160;&#160;&#160;Collaboration and License Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">National Cancer Institute</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2015, Etubics Corporation, or Etubics, entered into a Cooperative Research and Development Agreement, or CRADA, with the U.S. Department of Health and Human Services as represented by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, to collaborate on the preclinical and clinical development of an adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. In January&#160;2016, we acquired all of the outstanding equity interests in Etubics and Etubics became a wholly-owned subsidiary.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective January 2018, we assumed the CRADA and it was amended to cover a collaboration for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens and proprietary adenovirus technology expressing tumor-associated antigens for cancer immunotherapy. Pursuant to the CRADA, NIH provides scientific staff and other support necessary to conduct research and related activities as described in the CRADA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the CRADA, we are required to make annual payments of $0.6&#160;million to the NIH for support of research activities. We made a payment of $0.6&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The&#160;CRADA expires in May&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into an amendment to a CRADA with NIH that was originally executed between NIH and Amgen,&#160;Inc., or Amgen, in May&#160;2012 and subsequently assigned by Amgen to the company effective as of December&#160;17,&#160;2015. The research goal of this CRADA, as amended, is for the non-clinical and clinical development of ganitumab, our licensed monoclonal antibody targeting insulin-like growth factor&#160;one receptor, to evaluate its safety and efficacy in patients with hematological malignancies and solid tumors. The CRADA has a five-year term commencing February&#160;20,&#160;2018 and expiring on February&#160;20,&#160;2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the term of the agreement, we are required to make minimum annual payments of $0.2&#160;million to NIH for support of research activities and additional payments for the clinical trials based on the scope and phase of the clinical trials. Unpaid research and development expense was estimated at $0.4&#160;million and $0.6&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2021, we entered into a CRADA with NIH to conduct collaborative analysis of human clinical trial samples from clinical trials utilizing our proprietary recombinant natural killer&#160;(NK) cells and/or monoclonal antibodies&#160;(mAbs) alone or in combination for the treatment of cancer and to pre-clinically study such agents. The CRADA has a two-year term commencing February&#160;22, 2021 and expiring on February&#160;22, 2023. During the term of the agreement, we are required to provide $0.1&#160;million per year to NIH for support of research activities. We have $8,000 payable outstanding as of March&#160;31, 2021 in connection with this CRADA agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All CRADA agreements may be terminated at any time upon the mutual written consent of the company and NIH. Either party may unilaterally terminate either of the CRADAs at any time by providing written notice to the other party at least 60&#160;days before the desired termination date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the terms of the CRADAs, we have an option to elect to negotiate an exclusive or non-exclusive commercialization license to any inventions discovered in the performance of either of the CRADAs, whether solely by an NIH employee or jointly with a company employee for which a patent application has been filed. The parties jointly own any inventions and materials that are jointly produced by employees of both parties in the course of performing activities under the CRADAs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Royalties and In-licensing Agreements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">iosBio Ltd. Exclusive License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, we executed an exclusive license agreement with iosBio Ltd., formerly Stabilitech Biopharma Ltd. (&#8220;iosBio&#8221;), pursuant to which we and our affiliates will receive an exclusive, worldwide license to certain of iosBio&#8217;s intellectual property rights relating to the SARS-CoV-2 and successor vaccine candidates. In return, we are required to pay mid-to-high single-digit royalties on net sales of the resulting licensed products. Concurrently we entered into a non-exclusive license agreement with iosBio, which grants to iosBio and its affiliates a non-exclusive, worldwide license under the intellectual property and technology relating to our adenovirus constructs for the prevention and treatment of shingles and other infectious disease targets to be mutually agreed by the parties in good faith. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we accrued $0.1&#160;million and $0.5&#160;million payable, respectively, to iosBio for reimbursable costs related to the clinical trial activities initiated by iosBio.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062423624248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p id="N8___COMMITMENTS_CONTINGENCIES" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. &#160;&#160;&#160;&#160;Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingent Consideration Related to Business Combinations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">VivaBioCell, S.p.A.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;10, 2015, NantWorks, a related party, acquired a 100%&#160;interest in VivaBioCell, S.p.A., or VivaBioCell, through its wholly-owned subsidiary, VBC&#160;Holdings, LLC, or VBC&#160;Holdings, for $0.7&#160;million, less working capital adjustments. On June&#160;15,&#160;2015, NantWorks contributed its equity interest in VBC&#160;Holdings to the company, in exchange for cash consideration equal to its cost basis in the investment. VivaBioCell develops bioreactors and products based on cell culture and tissue engineering in Italy. In connection with this transaction, we are obligated to pay the former owners up to $3.7&#160;million upon the achievement of certain sales milestones relating to scaffold technology and certain clinical and regulatory milestones relating to the GMP-in-a-Box technology. The fair value of the contingent consideration obligation decreased $0.1&#160;million during the three&#160;months ended March&#160;31,&#160;2021 to $0.8&#160;million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience Corporation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our July&#160;2017 acquisition of Altor BioScience Corporation, or Altor, we issued contingent value rights, or CVRs, under which we agreed to pay the prior stockholders of Altor approximately $304.0&#160;million upon successful approval of the Biologics License Application, or BLA, or foreign equivalent, for Anktiva by December&#160;31,&#160;2022 and approximately $304.0&#160;million upon the first calendar year before December&#160;31,&#160;2026 in which worldwide net sales of Anktiva exceed $1.0&#160;billion (with amounts payable in cash or shares of our common stock or a combination thereof). Dr.&#160;Soon-Shiong and his related party hold approximately $279.5&#160;million in the aggregate of CVRs and they have both irrevocably agreed to receive shares of the company&#8217;s common stock in satisfaction of their CVRs. As the transaction was recorded as an asset acquisition, future CVR payments will be recorded when the corresponding events are probable of achievement or the consideration becomes payable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances where our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Altor BioScience, LLC </span><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The first action, Gray v.&#160;Soon-Shiong, et al.&#160;(Delaware Chancery Court, Case No.&#160;2017-466-JRS), was filed on June&#160;21,&#160;2017, by plaintiffs Clayland Boyden Gray, or Gray, and Adam R. Waldman. The plaintiffs, two&#160;minority stockholders, asserted claims against the company and other defendants for&#160;(1)&#160;breach of fiduciary duty and (2)&#160;aiding and abetting breach of fiduciary duty and filed a motion to enjoin the merger. The court denied the motion on July&#160;25,&#160;2017, and permitted the merger to close. On September&#160;1,&#160;2017, plaintiffs (joined by two&#160;additional minority stockholders, Barbara Sturm Waldman and Douglas E. Henderson, or Henderson) filed a second&#160;amended complaint, asserting claims for (1)&#160;appraisal; (2)&#160;quasi-appraisal; (3)&#160;breach of fiduciary duty; and (4)&#160;aiding and abetting breach of fiduciary duty. On September&#160;18,&#160;2017, defendants moved to dismiss the second&#160;amended complaint, raising grounds that included a &#8220;standstill&#8221; agreement under which defendants maintained that Gray and Adam R. Waldman and Barbara Strum Waldman, or the Waldman&#8217;s, agreed not to bring the lawsuit. In the second&#160;action, Dyad Pharmaceutical Corp. v.&#160;Altor BioScience,&#160;LLC&#160;(Delaware Chancery Court, Case No.&#160;2017-848-JRS), commenced November&#160;28,&#160;2017, Dyad Pharmaceutical Corporation, or Dyad, filed a petition for appraisal in connection with the merger. Respondent moved to dismiss the appraisal petition on January&#160;26,&#160;2018, arguing in part that the petition was barred by the same &#8220;standstill&#8221; agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;23,&#160;2018, the court heard oral arguments on the motions to dismiss in both consolidated cases, and on June&#160;26,&#160;2018, the court converted the motions to dismiss into motions for summary judgment with regard to the &#8220;standstill&#8221; agreement argument, or the Converted Motions. The court permitted discovery into the meaning and intended scope of the &#8220;standstill&#8221; agreements, which the parties completed on December&#160;19,&#160;2018. The parties completed a briefing on the Converted Motions on March&#160;15,&#160;2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The court heard an oral argument on the Converted Motions on May&#160;7,&#160;2019, and issued an oral ruling on May&#160;15,&#160;2019. The court&#160;(1)&#160;dismissed all claims brought by Gray and the Waldman&#8217;s except for their appraisal claims; (2)&#160;dismissed all plaintiffs&#8217; quasi-appraisal claims; (3)&#160;dismissed the disclosure-based breach of fiduciary duty claims; and (4)&#160;dismissed Altor BioScience from the action. The following claims remain: (a)&#160;the appraisal claims by all plaintiffs and Dyad (against Altor BioScience, LLC), and (b)&#160;Henderson&#8217;s claims for breach of fiduciary duty and aiding and abetting breach of fiduciary duty.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;14,&#160;2019, the defendants answered the second&#160;amended complaint, and the respondent answered Dyad&#8217;s appraisal petition. In their answer, defendants asserted counterclaims against Gray and the Waldman&#8217;s for breach of the &#8220;standstill&#8221; agreements and are seeking as damages the attorneys&#8217; fees and costs they were forced to expend as a result of the breach. On June&#160;20,&#160;2019, the court issued a written order implementing its ruling on the Converted Motions, or the Implementing Order. In the Implementing Order, the court confirmed that all fiduciary duty claims brought by Gray, both individually and as trustee of the Gordon Gray Trust f/b/o C. Boyden Gray, were dismissed. On July&#160;11,&#160;2019, Gray and the Waldman&#8217;s filed answers denying the counterclaims and asserting defenses.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;30,&#160;2019, plaintiffs moved for leave to file a third&#160;amended complaint. The proposed amendment sought to add two&#160;former Altor stockholders as plaintiffs and to add a fiduciary duty claim on behalf of a purported class of former Altor stockholders. On October&#160;25,&#160;2019, the defendants opposed the motion, and a briefing was completed on February&#160;28,&#160;2020. The court heard an oral argument on March&#160;12,&#160;2020, and granted the motion. The plaintiffs filed the third&#160;amended complaint on June&#160;8,&#160;2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June&#160;29,&#160;2020, defendants answered the third&#160;amended complaint and asserted counter claims against the plaintiffs. As damages, defendants seek the attorneys&#8217; fees and costs incurred as a result of these breaches. On July&#160;14,&#160;2020, the plaintiffs filed an answer denying the counterclaims and asserting defenses. The trial has been set to commence in October&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares of these former Altor stockholders met the definition of dissenting shares under the merger agreement and were not entitled to receive any portion of the merger consideration at the closing date. However, these dissenting shares will automatically be converted to receive the portion of the merger consideration they were entitled to, on the later of the closing date, and when the stockholder withdraws or loses the right to demand appraisal rights. Payment for dissenting shares will be on the same terms and conditions originally stated in the merger agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had accrued $6.9&#160;million and $6.8&#160;million related to these obligations, respectively. The accrued amount represents the estimated low-end of the range of currently estimated payout amounts in accordance with ASC Topic&#160;450, <span style="font-style:italic;">Contingencies</span>, after considering the reasonable outcomes for settling the dissenting shareholder dispute along with any accrued statutory interest. We cannot reasonably estimate a range of loss beyond the amounts recorded as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, as the dissenting stockholders have not yet provided a quantified value of their claim and, therefore, an upper end of the range of loss cannot be determined. We reassess the reasonableness of the recorded amount at each reporting period. We believe the claims lack merit and intend to continue defending the case vigorously.</p>

<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sorrento Therapeutics, Inc. v. NantCell, Inc., et al. Sorrento Therapeutics, Inc., or Sorrento, derivatively on behalf of NANTibody, LLC, or NANTibody, filed an action in the Superior Court of California, Los&#160;Angeles County, or the Superior Court, against the company, Dr.&#160;Soon-Shiong and Charles&#160;Kim. The action alleges that the defendants improperly caused NANTibody to acquire IgDraSol,&#160;Inc. from our affiliate NantPharma,&#160;LLC, or NantPharma, and seeks to have the transaction undone, and seeks to have the purchase amount returned to NANTibody. Sorrento filed a related arbitration proceeding, or the Cynviloq arbitration, against Dr.&#160;Soon-Shiong and NantPharma; the company is not named in the Cynviloq arbitration. On May&#160;15,&#160;2019, we filed a demurrer to several causes of action alleged in the Superior Court action. On July&#160;18,&#160;2019, Sorrento filed an amended complaint, eliminating Charles&#160;Kim as a defendant and dropping the causes of action we had challenged in its demurrer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May&#160;24,&#160;2019, we and Dr.&#160;Soon-Shiong filed cross-claims in the Superior Court action against Sorrento and its Chief Executive Officer Henry&#160;Ji, asserting claims for fraud, breach of contract, breach of the covenant of good faith and fair dealing, tortious interference with contract, unjust enrichment, and declaratory relief. We and Dr.&#160;Soon-Shiong allege that Dr.&#160;Ji and Sorrento breached the terms of an exclusive license agreement between the company and Sorrento related to Sorrento&#8217;s antibody library and that Sorrento did not perform its obligations under the exclusive license agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;9,&#160;2019, the Superior Court ruled that our claims should be pursued in arbitration and that Dr.&#160;Soon-Shiong&#8217;s claims could be pursued in Superior Court.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February&#160;13,&#160;2020, after a full briefing, the Superior Court heard oral argument and granted Dr.&#160;Soon-Shiong&#8217;s request for a preliminary injunction barring Sorrento from pursuing claims against him in the Cynviloq arbitration. Sorrento then filed the claims it had previously asserted in arbitration against Dr.&#160;Soon-Shiong in the Superior Court on March&#160;3,&#160;2020, and at Sorrento&#8217;s request, the arbitrator entered an order dismissing Sorrento&#8217;s claims against Dr.&#160;Soon-Shiong in the Cynviloq arbitration on March&#160;6,&#160;2020. The hearing in the Cynviloq arbitration has been scheduled to commence in June&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;24,&#160;2019, we, along with NANTibody, filed an arbitration against Sorrento and Dr.&#160;Ji asserting our claims relating to the exclusive license agreement. Sorrento filed counterclaims against the company and NANTibody in the arbitration on May&#160;4,&#160;2020, and requested leave to file a dispositive motion on May&#160;1,&#160;2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January&#160;29,&#160;2020, Sorrento sent letters purporting to terminate the exclusive license agreement with the company, and an exclusive license agreement with NANTibody and demanding the return of its confidential information and transfer of all regulatory filings and related materials. As required pursuant to the exclusive license agreements, both parties must engage in good-faith negotiations before attempting to invoke any termination provision contained in the agreement. Notwithstanding such negotiations, Sorrento sent a letter on April&#160;10,&#160;2020, purporting to terminate the exclusive license agreements, maintaining the negotiations did not reach a successful resolution. We believe we have cured any perceived breaches during the 90-day contractual cure period provided under the agreements. We intend to prosecute our claims, and to defend the claims asserted against us, vigorously. An estimate of the possible loss or range of loss cannot be made at this time. The hearings in the antibody arbitration commenced in April&#160;2021 and are anticipated to be concluded in late July or early August&#160;2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Shenzhen Beike Biotechnology Corporation Litigation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we received a Request for Arbitration before the International Chamber of Commerce, International Court of Arbitration, served by Shenzhen Beike Biotechnology Corporation, or Beike. The arbitration relates to a license, development, and commercialization agreement that Altor&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC, or Altor) entered into with Beike in September&#160;2014, which agreement was amended and restated in September&#160;2017, pursuant to which Altor granted to Beike an exclusive license to use, research, develop and commercialize products based on Anktiva in China for human therapeutic uses. In the arbitration, Beike is asserting a claim for breach of contract under the license agreement. Among other things, Beike alleges that we failed to use commercially reasonable efforts to deliver to Beike materials and data related to Anktiva. Beike is seeking specific performance, or in the alternative, damages for the alleged breaches. On September&#160;25,&#160;2020, the parties entered into a standstill and tolling agreement under which, among other things, the parties affirmed they will perform certain of their obligations under the license agreement by specified dates and agreed that all deadlines in the arbitration are indefinitely extended. The standstill agreement may be terminated by any party on ten&#160;calendar days&#8217; notice, and upon termination, the parties will have the right to pursue claims arising from the license agreement in any appropriate tribunal. The parties have been asked to provide an update to the International Chamber of Commerce by May&#160;31,&#160;2021 of any further developments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Given that this action remains at the pleading stage and no discovery has occurred, it remains too early to evaluate the likely outcome of the case or to estimate any range of potential loss. We believe the claims lack merit and intend to defend the case vigorously and that we may have counterclaims.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Fox Chase Litigation</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July&#160;21,&#160;2020, ImmunityBio filed a declaratory judgment lawsuit in the Superior Court for San&#160;Diego County, California, naming Fox&#160;Chase Cancer Center Foundation and Institute for Cancer Research as the defendants&#160;(hereafter collectively &#8220;Fox&#160;Chase&#8221;). This litigation relates to the license with Fox&#160;Chase and includes various intellectual property rights (the&#160;&#8220;2004&#160;License&#8221;). Our initial court filing requested that the Court find that we have not breached any material obligation under the 2004&#160;License and that Fox&#160;Chase has not and cannot terminate the 2004&#160;License. Fox&#160;Chase filed a Cross-Complaint raising a patent inventorship challenge and moved the case to federal court. See Part&#160;II, Item&#160;1A.,&#160;&#8220;<span style="font-style:italic;">Risk Factors</span>&#8221; of this Quarterly Report on Form&#160;10-Q for a more detailed discussion. While the litigation is in the early stage, its outcome cannot be predicted. We do not consider the 2004&#160;License to be material to our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation Related to the Merger with ImmunityBio, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;letter-spacing:0.05pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger with <span style="letter-spacing:-0.05pt;">NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company), a Delaware corporation, via a wholly-owned subsidiary of NantKwest&#160;(the &#8220;Merger&#160;Sub&#8221;), </span>seven&#160;complaints have been filed as individual actions in United States District Courts. Three&#160;complaints have been filed in the United States District Court for the District of Delaware against NantKwest and its directors and are captioned&#160;<span style="font-style:italic;">Hargett v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00197&#160;(filed February&#160;11,&#160;2021) (the &#8220;Hargett Complaint&#8221;),&#160;<span style="font-style:italic;">Franchi v. NantKwest, Inc., et al.</span>, 1:21&#8209;cv&#8209;00218&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Franchi Complaint&#8221;), and <span style="font-style:italic;">Gross&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00223&#160;(filed February&#160;17,&#160;2021) (the &#8220;Gross Complaint&#8221;). One&#160;complaint has been filed in the United States District Court for the Southern District of New York and is captioned <span style="font-style:italic;">Leaman&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;01351&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Leaman Complaint&#8221;). Two&#160;complaints have been filed in the United States District Court for the Southern District of California and are captioned <span style="font-style:italic;">Weiss&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00280&#160;(filed February&#160;16,&#160;2021) (the&#160;&#8220;Weiss Complaint&#8221;) and <span style="font-style:italic;">Carlisle&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 3:21&#8209;cv&#8209;00304&#160;(filed February&#160;19,&#160;2021) (the&#160;&#8220;Carlisle Complaint&#8221;). One&#160;complaint has been filed in the United States District Court for the Eastern District of New York and was captioned <span style="font-style:italic;">Shenk&#160;v.&#160;NantKwest,&#160;Inc., et al.</span>, 1:21&#8209;cv&#8209;00871&#160;(filed February&#160;18,&#160;2021) (the &#8220;Shenk Complaint,&#8221; and collectively with the Hargett Complaint, the Franchi Complaint, the Gross Complaint, the Leaman Complaint, the Weiss Complaint, and the Carlisle Complaint, the &#8220;Merger Actions&#8221;). The Shenk Complaint was voluntarily dismissed on March&#160;10,&#160;2021. The Franchi Complaint was voluntarily dismissed on May&#160;6,&#160;2021. The Leaman Complaint was voluntarily dismissed on May&#160;7,&#160;2021. The Hargett Complaint and the Gross Complaint also bring claims against ImmunityBio, and Merger&#160;Sub. The Merger Actions generally allege that the Definitive Proxy Statement filed with the SEC on February&#160;2,&#160;2021 misrepresents and/or omits certain purportedly material information relating to financial projections, analysis performed by the financial advisor to NantKwest&#8217;s Special Committee, alleged past engagements of the Special Committee&#8217;s financial advisor and industry consultant, and the terms of the engagement of such consultant. The Merger Actions assert violations of Sections&#160;14(a) of the Securities Exchange Act of&#160;1934, as amended (the&#160;&#8220;Exchange Act&#8221;), and Rule&#160;14a-9 promulgated thereunder against all defendants and violations of Section&#160;20(a) of the Exchange Act against NantKwest&#8217;s directors. The Merger Actions seek, among other things, an injunction enjoining the stockholder vote on the Merger and the consummation of the Merger unless and until certain additional information is disclosed to NantKwest&#8217;s stockholders, costs of the action, including plaintiffs&#8217; attorneys&#8217; fees and experts&#8217; fees, and other relief the Court may deem just and proper. Neither the stockholder vote on the Merger nor the Merger were enjoined and occurred on March&#160;8 and March&#160;9,&#160;2021, respectively. The company cannot predict the outcome of the Merger Actions. The company believes the Merger Actions are without merit and the company and the individual defendants intend to vigorously defend against the Merger Actions and any subsequently filed similar actions. If additional similar complaints are filed, absent new or significantly different allegations, the company will not necessarily disclose such additional filings.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Lease Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our operating lease right-of-use assets and operating lease liabilities relate to facilities leases. We have leases in multiple facilities across the U.S. and Italy, including El&#160;Segundo, California&#160;(general corporate and administrative activities, research and development and regulatory from related parties); San&#160;Diego, California&#160;(research facility and office space); Culver&#160;City, California&#160;(research and manufacturing space from a related party); Torrance, California&#160;(a research facility from a related party); Miramar, Florida&#160;(clinical development); Seattle, Washington&#160;(research and development); Louisville, Colorado&#160;(research and development and manufacturing); Woburn, Massachusetts&#160;(research facility); and Udine and Tavangnacco, Italy&#160;(GMP-in-a-Box, research facility and office space). See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,&#160;</span><span style="font-style:italic;">Related Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our leases generally have initial terms ranging from <span style="-sec-ix-hidden:F_000741">two to ten&#160;years</span> and often include one&#160;or more options to renew. These renewal terms can extend the lease term from <span style="-sec-ix-hidden:F_000743">one to five&#160;years</span>, and are included in the lease term when it is reasonably certain that we will exercise the option.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our leases is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:5pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,782</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">666</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,355</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments as of March&#160;31,&#160;2021, including $4.9&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (excluding the three months ended March 31, 2021)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,889</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,622</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional three-year&#160;term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of 3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. See&#160;<a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>, for further information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no other material changes related to our existing lease agreements from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Commitments</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not enter into any significant contracts during the three&#160;months ended March&#160;31,&#160;2021, other than those disclosed in these condensed combined consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are also a party to various contracts with contract research organizations and contract manufacturers that generally provide for termination on notice, with the exact amounts in the event of termination to be based on the timing of the termination and the terms of the agreement. There have been no material changes in unconditional purchase commitments from those disclosed in Note&#160;8 of the Notes to Combined Consolidated Financial Statements included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019 (including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the Securities and Exchange Commission, or SEC, on April&#160;22,&#160;2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328390680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Agreements</a></td>
<td class="text">
<p id="N9___RELATED_PARTY_AGREEMENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. &#160;&#160;&#160;&#160;Related Party Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct business with several affiliates under written agreements and informal arrangements. Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td colspan="2" style="background-color:#FFFFFF;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;width:14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantBio</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantOmics</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties &#8211; Various</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.25pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due from related parties</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,057</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantWorks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Duley Road</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,161</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,787</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantBio</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Immuno-Oncology Clinic</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Nant Capital</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantPharma</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due to related parties</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,817</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; Nant Capital</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,695</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,246</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantMobile</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantWorks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NCSC</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,348</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total related-party notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,286</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Executive Chairman, and principal stockholder, founded and has a controlling interest in NantWorks, which is a collection of multiple companies in the healthcare and technology space. As described below, we have entered into arrangements with NantWorks, and certain affiliates of NantWorks, to facilitate the development of new genetically modified NK&#160;cells for our product pipeline. Affiliates of NantWorks are also affiliates of the company due to the common control by and/or common ownership interest of our Executive Chairman.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantWorks</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the NantWorks shared services agreement executed in November&#160;2015, but effective August&#160;2015, NantWorks provides corporate, general and administrative, manufacturing strategy, research and development, regulatory and clinical trial strategy, and other support services. We are charged for the services at cost plus reasonable allocations of employee benefits, facilities and other direct or fairly allocated indirect costs that relate to the employees providing the services. During the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $1.8&#160;million and $1.5&#160;million, respectively, in <span style="font-style:italic;">selling, general and administrative expense</span>, and $0.3&#160;million and $1.0&#160;million, respectively, of expense reimbursements under this arrangement in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. These amounts exclude certain general and administrative expenses provided by third-party vendors directly for our benefit, which have been reimbursed to NantWorks based on those vendors&#8217; invoiced amounts without markup by NantWorks.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31, 2020, we owed NantWorks a net amount of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.8&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, respectively, for all agreements between the two affiliates, which is included in </span><span style="font-style:italic;">due to related parties</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also recorded $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million and $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million of prepaid expenses for services that have been passed through to the company from NantWorks as of March&#160;31,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 and December&#160;31,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, respectively, which are included in </span><span style="font-style:italic;">prepaid expenses and other current assets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the condensed </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consolidated balance sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, we entered into a facility license agreement with NantWorks&#160;LLC, or NantWorks, a related party, for approximately 9,500&#160;square feet of office space in Culver&#160;City, California, which has been converted to a research and development laboratory and a cGMP&#160;manufacturing facility. The initial license was effective from May&#160;2015 through December&#160;2020. Base monthly rent for the initial lease term was $47,000, with annual increases of 3% beginning in January&#160;2017. In September&#160;2020, we amended this agreement to extend the term of this lease through December&#160;31,&#160;2021. Commencing January&#160;1,&#160;2021, the monthly rent increased by 3% to $54,500. Subsequent to December&#160;31,&#160;2021, the lease term will automatically renew on a month-to-month basis, terminable by either party with at least 30&#160;days&#8217; prior written notice to the other party. In addition, we have a one-time option to extend the lease term through December&#160;31,&#160;2022. If we exercise the option to extend the lease through December&#160;31,&#160;2022, or continue on a month-to-month basis, the monthly rent will increase by 3% annually commencing on January&#160;1 of each year. On the date of amendment, we recognized an increase of $1.2&#160;million in both <span style="font-style:italic;">operating lease right-of-use assets</span>, and <span style="font-style:italic;">operating lease liabilities</span>, on the condensed combined consolidated balance sheets, reflecting our belief that we will extend the term of this lease through December&#160;31,&#160;2022. Lease expense for this facility totaling $0.2&#160;million and $0.1&#160;million for the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, was recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in 2017, we entered into multiple agreements with Immuno-Oncology Clinic, Inc., or the Clinic (dba&#160;Chan Soon-Shiong Institutes for Medicine, in El&#160;Segundo, California), to conduct clinical trials related to certain of our product candidates. The Clinic is a related party as it is owned by one officer of the company and NantWorks manages the administrative operations of the Clinic. Prior to June&#160;30,&#160;2019, one of our officers was an investigator or sub-investigator for all of our trials conducted at the Clinic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we entered into a new agreement with the Clinic (the Clinic Agreement), which became effective on July&#160;1,&#160;2019. The Clinic Agreement, as amended on March&#160;31,&#160;2020, covers clinical trial and research-related activities on a non-exclusive basis relating to our existing clinical trials, commenced prior to July&#160;1,&#160;2019, and prospective clinical trials and research projects. The Clinic Agreement also specifies certain services and related costs that are excluded from the Clinic Agreement. Prior to commencing any work under the Clinic Agreement, the parties have agreed to execute written work orders setting forth the terms and conditions related to specific services to be performed, including financial terms. For clinical trials that commenced prior to July&#160;1,&#160;2019, fees incurred for services performed after July&#160;1,&#160;2019 are covered under the Clinic Agreement and applied towards the below-mentioned prepayments. The Clinic Agreement allows for automatic renewal and additional extensions beyond the initial <span style="-sec-ix-hidden:F_000816">one-year</span> term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration of the services to be performed under the Clinic Agreement, as amended on March&#160;31,&#160;2020, we agreed to make payments of up to $7.5&#160;million to the Clinic, of which $3.75&#160;million and $1.88&#160;million were paid in July&#160;2019 and October&#160;2019, respectively. As amended, a conditional payment of $1.88&#160;million shall be due and payable at such time, if any, that the payments made in July&#160;2019 and October&#160;2019 have been earned by the Clinic through the performance of services. On a quarterly basis, our prepayment is increased by an interest credit computed in accordance with terms specified in the Clinic Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent any portion of the prepayments remain unearned by the Clinic on the third anniversary of the Clinic Agreement, we may elect at our sole discretion either to&#160;(i)&#160;not extend the term of the Clinic Agreement and have the Clinic reimburse us for the total amount of any remaining unused portion of the prepayments, or (ii)&#160;extend the term of the Clinic Agreement for up to three additional one&#160;year periods, at which time the Clinic will reimburse us for the total amount of any remaining unused portion of the prepayments plus interest if reimbursement is not made within 60&#160;days of expiration. The Clinic may terminate this agreement upon each anniversary date upon sixty&#160;(60)&#160;days prior written notice and reimbursement in full to us of any outstanding unearned balance of the prepayments, provided that any such termination by the Clinic will not apply with respect to any work orders still in effect at the time of such termination.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2019, we executed a clinical trial work order under the Clinic Agreement for an open-label, Phase&#160;I study of PD&#8209;L1.t&#8209;haNK for infusion in subjects with locally advanced or metastatic solid cancers. In July&#160;2020, but effective on June&#160;22,&#160;2020, we and NantCell, Inc.&#160;(formerly known as ImmunityBio, Inc., a private company) executed a clinical trial work order under our existing master agreement with the Clinic for an open-label, randomized, comparative Phase&#160;II study of NantCell&#8217;s proprietary IL&#8209;15 superagonist (N&#8209;803) and Aldoxorubicin Hydrochloride&#160;(Aldoxorubicin) and our PD&#8209;L1.t&#8209;haNK with standard-of-care chemotherapy versus standard-of-care chemotherapy for first and second-line treatment of locally or advanced metastatic pancreatic cancer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three&#160;months ended March&#160;31,&#160;2021 and 2020, $0.3&#160;million and $0.1&#160;million, respectively, was recognized in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations related to clinical trial and research-related activities conducted for us by the Clinic. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we owed the Clinic $0.5&#160;million and $0.3&#160;million, respectively, for services excluded from the Clinic Agreement. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we had prepaid balances related to the Clinic Agreement of $4.6&#160;million and $4.7&#160;million, respectively. We anticipate that the remaining prepayment amount as of March&#160;31,&#160;2021 will be utilized in future periods as the Clinic provides additional services pursuant to the Clinic Agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantBio, Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2016, NantBio and the National Cancer Institute, or the NCI, entered into a cooperative research and development agreement. The initial <span style="-sec-ix-hidden:F_000828">five-year</span> agreement covered NantBio and its affiliates, including us. Under the agreement, the parties collaborated on the preclinical and clinical development of proprietary recombinant natural killer cells and monoclonal antibodies in monotherapy and combination immunotherapies. In each of the contractual years under the agreement we paid $0.6&#160;million to the NCI as a payment for services under the agreement. We recognized research and development expense related to this agreement ratably over a 12-month period for each funding year and recorded $0.1&#160;million of expense related to this agreement in each of the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0 and $0.1&#160;million, respectively, in <span style="font-style:italic;">prepaid expenses</span> <span style="font-style:italic;">and other current assets</span>, on the condensed combined consolidated balance sheets related to this agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we entered into a supply agreement with NantCancerStemCell, LLC, or NCSC, a 60% owned subsidiary of NantBio (with the other 40%&#160;owned by Sorrento). Under this agreement, we agreed to supply VivaBioCell&#8217;s proprietary GMP-in-a-Box bioreactors and related consumables, made according to specifications mutually agreed to with both companies. The agreement has an initial term of <span style="-sec-ix-hidden:F_000837">five&#160;years</span> and renews automatically for successive <span style="-sec-ix-hidden:F_000838">one-year</span> terms unless terminated by either party in the event of material default upon prior written notice of such default and the failure of the defaulting party to remedy the default within 30&#160;days of the delivery of such notice, or upon 90&#160;days&#8217; prior written notice by NCSC. No revenue was recognized during the three&#160;months ended March&#160;31,&#160;2021 and 2020. We recorded $0.3&#160;million and $0.4&#160;million of deferred revenue for bioreactors that were delivered but not installed as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0.9&#160;million in <span style="font-style:italic;">due to related parties</span>, on the condensed combined consolidated balance sheets related to this agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, we entered into a shared service agreement, pursuant to which, we are charged for services at cost, without mark-up or profit for NantBio, but including reasonable allocations of employee benefits that relate to the employees providing the services. In April&#160;2019, we agreed with NantBio to transfer certain NantBio employees and associated research and development projects, comprising the majority of NantBio&#8217;s business, to the company. After the transfer, NantBio continued to make payments on our behalf for certain employee benefits and vendor costs related to the research and development projects that were transferred to the company. In addition, we settled certain employee bonuses and benefits that were accrued by NantBio for 2018. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a net receivable from NantBio of $1.3&#160;million, which included $1.0&#160;million for employee bonuses and $0.3&#160;million for vendor costs we paid on behalf of NantBio.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantOmics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, we made a strategic decision and transferred certain employees from NantOmics, LLC, or NantOmics, a related party that is controlled by our Executive Chairman, to the company. After the transfer, we settled certain employee bonuses and benefits that were accrued by NantOmics for the year ended December&#160;31,&#160;2020 and recorded a $0.6&#160;million receivable from NantOmics as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">605&#160;Doug&#160;St,&#160;LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September&#160;2016, we entered into a lease agreement with 605&#160;Doug&#160;St,&#160;LLC, an entity owned by our Executive Chairman, for approximately 24,250&#160;square feet in El Segundo, California, which has been converted to a research and development laboratory and a cGMP manufacturing facility. The lease runs from July&#160;2016 through July&#160;2023. We have the option to extend the lease for an additional <span style="-sec-ix-hidden:F_000854">three-year</span> term through July&#160;2026. The monthly rent is $0.1&#160;million with annual increases of 3% which began in July&#160;2017. Lease expense of $0.2&#160;million for this facility for each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, respectively, is recorded in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, there were no balances due between the parties.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Duley Road, LLC</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February&#160;2017, Altor BioScience Corporation&#160;(succeeded by our wholly-owned subsidiary Altor BioScience,&#160;LLC), or Altor, through its wholly-owned subsidiary, entered into a lease agreement with Duley Road,&#160;LLC, or Duley Road, a related party, that is indirectly controlled by our Executive Chairman, for approximately 12,000&#160;square feet of office and cGMP manufacturing facility space in El&#160;Segundo, California. The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive <span style="-sec-ix-hidden:F_000868">five-year</span> periods through July&#160;2034. The monthly rent is $40,700 with annual increases of 3% which began in November&#160;2018. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded rent payable to Duley Road of $1.5&#160;million and $1.0&#160;million, respectively. For the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded rent expense of $0.4&#160;million and $0.1&#160;million, respectively, which is reflected in <span style="font-style:italic;">research</span> <span style="font-style:italic;">and development expense</span>, on the condensed combined consolidated statements of operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective in January&#160;2019, we entered into two&#160;lease agreements with Duley Road for a second building located in El&#160;Segundo, California. The first lease is for the first floor of the building with approximately 5,650&#160;square feet. The lease has a <span style="-sec-ix-hidden:F_000873">seven-year</span>&#160;term commencing in September&#160;2019. The second&#160;lease is for the second&#160;floor of the building with approximately 6,488&#160;square feet. The lease has a <span style="-sec-ix-hidden:F_000874">seven-year</span> term commencing in July&#160;2019. Both floors of the building are used for research and development and office space. We have options to extend the initial terms of both leases for two&#160;consecutive <span style="-sec-ix-hidden:F_000875"><span style="-sec-ix-hidden:F_000876">five-year</span></span> periods through 2036. The monthly rent for the two&#160;leases is $35,800, which increases at a rate of 3%&#160;per year.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded $0.9&#160;million and $0.7&#160;million of leasehold improvement payables, respectively, and $0.8&#160;million and $1.1&#160;million of lease-related payables to Duley Road, which were included in <span style="font-style:italic;">due to related parties</span>, on the condensed combined consolidated balance sheets. For each of the three&#160;months ended March&#160;31,&#160;2021 and 2020, we recorded $0.1&#160;million of rent expense for the two&#160;leases, which is included in <span style="font-style:italic;">research and development expense</span>, on the condensed combined consolidated statements of operations. The security deposits for the leases totals $0.1&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, which are included in <span style="font-style:italic;">other assets</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">605 Nash, LLC</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In February 2021, but effective on January&#160;1,&#160;2021, we entered into a lease agreement with 605&#160;Nash, LLC, a related party, whereby we leased approximately 6,883&#160;square feet in El&#160;Segundo, California. This facility is used primarily for pharmaceutical development and manufacturing purposes. The lease runs from January&#160;2021 through December&#160;2027, and includes an option to extend the lease for an additional <span style="-sec-ix-hidden:F_000890">three-year</span> term through December&#160;2030. Base rent for the term of the lease is approximately $20,300&#160;per month with an annual increase of&#160;3% on January&#160;1 of each year during the initial term and, if applicable, during the option term. In addition, under the agreement, we are required to pay our share of estimated property taxes and operating expenses. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">We are responsible for the build out of the facility space and have incurred costs of approximately $7.0&#160;million as of March&#160;31,&#160;2021, which is reflected as construction in progress within </span><span style="font-style:italic;Background-color:#FFFFFF;">property, plant and equipment, net</span><span style="Background-color:#FFFFFF;">, on the condensed combined consolidated balance sheets. We are also entitled to a tenant improvement allowance of $0.3&#160;million associated with the buildout costs, which is recorded in </span><span style="font-style:italic;Background-color:#FFFFFF;">prepaid expenses and other current assets</span><span style="Background-color:#FFFFFF;"> on the condensed combined consolidated balance sheets. For the three months ended March&#160;31,&#160;2021, we recorded rent expense of $0.1&#160;million, which is reflected in </span><span style="font-style:italic;Background-color:#FFFFFF;">research and development expense</span><span style="Background-color:#FFFFFF;"> on the condensed combined consolidated statements of operations.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">NantPharma</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018, Altor BioScience, LLC and GlobeImmune, Inc. purchased a total of $0.2&#160;million in laboratory equipment from NantPharma. As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, we recorded a $0.2&#160;million payable to NantPharma.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Notes Payable</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, we executed a demand promissory note with Nant Capital. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020 and August&#160;2020, we borrowed $10.0&#160;million and $3.7&#160;million from Nant Capital, respectively. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. The principal amount of advances made by the related party pursuant to these notes totaled $55.2&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Accrued and unpaid interest on this note totaled $4.0&#160;million and $3.3&#160;million as of March&#160;31,&#160;2021 and December&#160;31, 2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes</span> <span style="font-style:italic;">payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2017, we executed a demand promissory note with NantWorks. The note bears interest at a per annum rate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantWorks. All outstanding amounts under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43.4</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, all of which was outstanding</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note totaled $</span>8.8<span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million and $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts due under this promissory note are included in </span><span style="font-style:italic;">related-party</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-style:italic;">notes payable</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condensed combined</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> consolidated balance sheets.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, we executed a demand promissory note with NCSC. The note bears interest at a per annum rate of 5.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount of advances made by the related party pursuant to these notes totaled $33.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $4.3&#160;million and $3.9&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, we executed a demand promissory note with NantMobile. The note bears interest at a per annum rate of 3.0%, compounded annually and computed on the basis of 365 or 366 days. In July&#160;2020, this note was amended and restated to provide that all outstanding principal and accrued and unpaid interest is due and payable on September&#160;30,&#160;2025, and not on demand. We may prepay the outstanding principal amount at any time without premium or penalty and the prior consent of NantMobile. All amounts outstanding under the note will also become immediately due and payable upon certain bankruptcy and insolvency-related events. The principal amount advanced by the related party pursuant to this note was $55.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Accrued and unpaid interest on this note amounted to $2.1&#160;million and $1.7&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2020, we executed a promissory note with Nant Capital for an advance of the principal of $50.0&#160;million, all of which was outstanding as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020. The note bears interest at a per annum rate of 6.0%, compounded annually and computed on the basis of 365 or 366 days. The outstanding principal and accrued and unpaid interest are due and payable on September&#160;30,&#160;2025. Accrued and unpaid interest on this note amounted to $1.5&#160;million and $0.8&#160;million as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively. Amounts due under this promissory note are included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we executed a promissory note with Nant Capital. The outstanding principal amount of each advance made by Nant Capital bears interest at a per annum rate of 6.0%, compounded annually and computed based on 365 or 366 days. On February&#160;26,&#160;2021, we received a $40.0&#160;million advance pursuant to this promissory note, all of which is outstanding as of March&#160;31,&#160;2021. The accrued interest shall be paid quarterly commencing on June&#160;30,&#160;2021. The outstanding principal amount and any accrued and unpaid interest are due on September&#160;30,&#160;2025. We may prepay the outstanding principal amount and accrued interest at any time without premium or penalty and the prior consent of Nant Capital. Accrued interest payable on this note amounted to $0.2&#160;million as of March&#160;31,&#160;2021, and was included in <span style="font-style:italic;">due to</span> <span style="font-style:italic;">related parties</span>, on the condensed combined consolidated balance sheets. The principal amount due under this promissory note is included in <span style="font-style:italic;">related-party notes payable</span>, on the condensed combined consolidated balance sheets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All demand promissory notes have no equity or equity-linked convertible rights.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328695704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Deficit</a></td>
<td class="text">
<p id="N10___STOCKHOLDERS_DEFICIT" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. &#160;&#160;&#160;&#160;Stockholders&#8217; Deficit</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger with NantCell</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Under the terms of the Merger Agreement, at the Effective Time of the Merger, each share of NantCell common stock</span>, par value $0.001&#160;per share, <span style="Background-color:#FFFFFF;">issued and outstanding immediately prior to the Effective Time, subject to certain exceptions as set forth in the Merger Agreement, was converted automatically into a right to receive 0.8190&#160;newly issued shares of common stock</span>, par value $0.0001&#160;per share, resulting in the issuance of approximately 273.7&#160;million shares of Company Common Stock.<span style="Background-color:#FFFFFF;"> </span>From and after the Effective Time, all of such NantCell shares ceased to be outstanding, were canceled and ceased to exist. <span style="Background-color:#FFFFFF;">At the Effective Time, each share of our common stock issued and outstanding immediately prior to the Effective Time, remained an issued and outstanding share of the combined company.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Merger has been accounted for as a transaction between entities under common control, the outstanding shares presented on the condensed combined consolidated financial statements assume that NantCell outstanding common stock was converted into shares of Company Common Stock for all periods presented, and in connection with the conversion, those shares of common stock have been recorded at the company&#8217;s par value of $0.0001&#160;per share. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Repurchases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November&#160;2015, the board of directors approved a share repurchase program, or the 2015&#160;Share Repurchase Program, allowing the Chief Executive officer, or CEO, or Chief Financial Officer, or CFO, on behalf of the company, to repurchase from time to time, in the open market or in privately negotiated transactions, up to $50.0&#160;million of our outstanding shares of common stock, exclusive of any commissions, markups or expenses. The timing and amounts of any purchases were and will continue to be based on market conditions and other factors, including price, regulatory requirements and other corporate considerations. The 2015&#160;Share Repurchase Program does not require the purchase of any minimum number of shares and may be suspended, modified, or discontinued at any time without prior notice. We have financed, and expect to continue to finance, the purchases with existing cash balances. Shares repurchased under this program are formally retired through board approval upon repurchase. No&#160;shares were repurchased during the three&#160;months ended March&#160;31,&#160;2021 and 2020. As of March&#160;31,&#160;2021, $18.3&#160;million remained authorized for repurchase under the 2015&#160;Share Repurchase Program. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, a total of approximately 12.6&#160;million shares of common stock were reserved for issuance, <span style="Background-color:#FFFFFF;color:#000000;">including awards issued under the NC&#160;2015&#160;Plan that were outstanding immediately prior to the Effective Time of the Merger. </span>At the Effective Time, all outstanding equity awards granted under the NC&#160;2015&#160;Plan to purchase NantCell common stock were converted into equity awards to purchase shares of Company Common Stock (using the Merger Exchange Ratio of 0.8190), on the same terms and conditions as immediately prior to the Effective Time. As of March&#160;31,&#160;2021, there were approximately 7.0&#160;million RSUs and 1.3&#160;million stock options outstanding under the NC&#160;2015&#160;Plan, and there were no additional shares available for future grant.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062322233048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p id="N11___STOCKBASED_COMPENSATION" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. &#160;&#160;&#160;&#160;Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Equity Incentive Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July&#160;2015, the company&#8217;s board of directors adopted, and the company&#8217;s stockholders approved the 2015&#160;Plan. As of March&#160;31,&#160;2021, the 2015&#160;Plan is the only equity plan of the company available for grant of equity awards to employees, directors and consultants of the company. As of March&#160;31,&#160;2021, a total of approximately 6.2&#160;million shares were available for future grant under the 2015&#160;Plan.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock-based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,298</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,298</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;18,&#160;2021, the Board of Directors approved to modify certain non-qualified stock options that were assumed in the Merger and otherwise would have expired during a period when the grantees were legally restricted from exercising these awards. The expiration date of these options was extended to thirty (30)&#160;days following our registration statement effective date. We recognized incremental stock-based compensation expense of approximately $2.7&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;29,&#160;2021, in connection with the resignation of two&#160;former directors, the Board of Directors approved the acceleration of vesting of 83,333&#160;shares of unvested stock options of each of the former directors on the date of their respective resignations. The modified options are exercisable for ninety (90)&#160;days after the date of the modification. We recognized incremental stock-based compensation expense of approximately $2.3&#160;million for this stock option modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock option modifications were measured as the excess of the fair value of the modified awards over the fair value of the original awards immediately before the modifications. The incremental stock-based compensation was recognized in <span style="font-style:italic;">selling, general and administrative expenses</span>, on the condensed combined consolidated statements of operations during the three&#160;months ended March&#160;31,&#160;2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity and related information for three&#160;months ended March&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,996,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,746</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000978">4.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(752,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,314</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,279</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000979">5.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:10.05pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,815,630</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.07</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000980">4.2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,&#160;2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Richard<span style="letter-spacing:-0.15pt;"> </span>Adcock,<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer, a stock option award</span><span style="letter-spacing:-0.15pt;"> </span>(the<span style="letter-spacing:-0.15pt;"> &#8220;</span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant&#8221;)<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>purchase<span style="letter-spacing:-0.1pt;"> </span>750,000<span style="letter-spacing:-0.15pt;">&#160;</span>shares<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:1.15pt;"> </span>common<span style="letter-spacing:-0.15pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>2015&#160;Plan.<span style="letter-spacing:-0.15pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.15pt;"> </span>Grant<span style="letter-spacing:-0.1pt;"> </span>has<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>exercise<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.15pt;"> </span>of $23.72&#160;per share,<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>closing<span style="letter-spacing:-0.15pt;"> </span>price<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.1pt;"> </span>reported<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> the </span>Nasdaq<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>date<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>grant.<span style="letter-spacing:-0.15pt;"> </span>In<span style="letter-spacing:-0.1pt;"> </span>addition,<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>schedule:&#160;one-third<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>Option<span style="letter-spacing:-0.1pt;"> </span>Grant<span style="letter-spacing:-0.15pt;">&#160;</span><span style="letter-spacing:-0.05pt;">(i.e.,</span><span style="letter-spacing:-0.1pt;">&#160;</span>250,000<span style="letter-spacing:-0.1pt;"> </span>options)<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second,<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third<span style="letter-spacing:-0.1pt;"> </span>anniversaries<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of </span>grant,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.1pt;"> </span>all<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.15pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:1.05pt;"> </span>defined<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.15pt;"> </span>through<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.15pt;"> </span>vesting<span style="letter-spacing:-0.1pt;"> </span>dates. This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021, the unrecognized compensation cost related to outstanding stock options was $13.9&#160;million, which is expected to be recognized over a remaining weighted-average period of 2.8&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total intrinsic value of stock options exercised during the three&#160;months ended March&#160;31,&#160;2021 was $11.1&#160;million. Cash proceeds received from stock option exercises during the three&#160;months ended March&#160;31,&#160;2021 was $1.1&#160;million. There were no stock options exercised during the three&#160;months ended March&#160;31,&#160;2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,&#160;2020, a total of 4,345,497&#160;vested and exercisable shares were outstanding.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000990">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected term was estimated using the average of the contractual term and the weighted-average vesting term of the options. The risk-free interest rate was based on the U.S.&#160;Treasury&#8217;s rates for U.S.&#160;Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected volatility was estimated based on the historical volatility of our common stock. The assumed dividend yield was based on our expectation of not paying dividends in the foreseeable future. There were no stock options granted during the three&#160;months ended March&#160;31,&#160;2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity for the three&#160;months ended March&#160;31,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">466,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,521,110</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,636,132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, there was $179.2&#160;million of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 3.9&#160;years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may grant RSUs to both employees and directors of the company and to employees of related parties that provide shared services to the company under our shared services agreement with NantWorks as discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On<span style="letter-spacing:-0.2pt;"> </span>February<span style="letter-spacing:-0.15pt;">&#160;</span>5,<span style="letter-spacing:-0.15pt;"> </span>2021, the<span style="letter-spacing:-0.2pt;"> </span>compensation<span style="letter-spacing:-0.15pt;"> </span>committee<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the</span><span style="letter-spacing:-0.2pt;"> </span>board<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>directors<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> the c</span>ompany<span style="letter-spacing:-0.1pt;"> </span>granted<span style="letter-spacing:-0.15pt;"> </span>Mr.&#160;Adcock<span style="letter-spacing:-0.1pt;"> </span>two<span style="letter-spacing:-0.1pt;">&#160;</span>awards<span style="letter-spacing:-0.15pt;"> </span>totaling<span style="letter-spacing:-0.15pt;"> </span>400,000<span style="letter-spacing:-0.15pt;">&#160;</span>RSUs<span style="letter-spacing:-0.15pt;"> </span>(each<span style="letter-spacing:-0.15pt;"> </span>an<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Award&#8221;</span><span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">collectively,</span><span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>&#8220;RSU<span style="letter-spacing:-0.15pt;"> Awards&#8221;) </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.15pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.15pt;"> </span>pursuant<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.15pt;">Awards </span>are<span style="letter-spacing:-0.1pt;"> </span>comprised<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>two&#160;separate<span style="letter-spacing:-0.15pt;"> </span>awards,<span style="letter-spacing:-0.1pt;"> </span>one<span style="letter-spacing:-0.15pt;"> </span>settled<span style="letter-spacing:-0.15pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.15pt;"> </span>150,000<span style="letter-spacing:-0.1pt;">&#160;</span>shares<span style="letter-spacing:1.05pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>other<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>settled<span style="letter-spacing:-0.1pt;"> </span>by<span style="letter-spacing:-0.1pt;"> </span>issuing<span style="letter-spacing:-0.1pt;"> </span>250,000<span style="letter-spacing:-0.15pt;">&#160;</span>shares<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>our<span style="letter-spacing:-0.1pt;"> </span>common<span style="letter-spacing:-0.1pt;"> </span>stock<span style="letter-spacing:-0.1pt;"> </span>upon<span style="letter-spacing:-0.15pt;"> </span>vesting.<span style="letter-spacing:-0.1pt;"> </span>The<span style="letter-spacing:-0.1pt;"> </span>first<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>vested<span style="letter-spacing:1.15pt;"> </span>immediately<span style="letter-spacing:1.15pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant </span>with<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> c</span>ompany<span style="letter-spacing:-0.15pt;"> </span>retaining<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.15pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>value<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span>tax<span style="letter-spacing:-0.1pt;"> </span>withholding<span style="letter-spacing:-0.15pt;"> </span>obligations. The<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>RSU<span style="letter-spacing:-0.15pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.1pt;"> </span>will<span style="letter-spacing:-0.15pt;"> </span>vest<span style="letter-spacing:1.1pt;"> </span>according<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>following<span style="letter-spacing:-0.15pt;"> </span>schedule:<span style="letter-spacing:-0.1pt;">&#160;</span>one-third<span style="letter-spacing:-0.15pt;"> </span>(i.e.<span style="letter-spacing:-0.1pt;">&#160;</span>83,333)<span style="letter-spacing:-0.15pt;">&#160;</span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>RSU<span style="letter-spacing:-0.1pt;">&#160;</span><span style="letter-spacing:-0.2pt;">Aw</span><span style="letter-spacing:-0.25pt;">a</span><span style="letter-spacing:-0.2pt;">rd</span><span style="letter-spacing:-0.15pt;"> </span>shall<span style="letter-spacing:-0.1pt;"> </span>vest<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.1pt;"> </span>equal<span style="letter-spacing:-0.15pt;"> </span>annual<span style="letter-spacing:-0.1pt;"> </span>installments<span style="letter-spacing:-0.15pt;"> </span>on<span style="letter-spacing:-0.1pt;"> </span>each<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:1.15pt;"> </span>first,<span style="letter-spacing:-0.15pt;"> </span>second<span style="letter-spacing:-0.1pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>third&#160;anniversaries<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.1pt;"> </span>the<span style="letter-spacing:-0.15pt;"> date of grant</span>,<span style="letter-spacing:-0.15pt;"> </span>such<span style="letter-spacing:-0.1pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>all<span style="letter-spacing:-0.1pt;"> </span>shares<span style="letter-spacing:-0.1pt;"> </span>shall<span style="letter-spacing:-0.15pt;"> </span>be<span style="letter-spacing:-0.1pt;"> </span>fully<span style="letter-spacing:-0.15pt;"> </span>vested<span style="letter-spacing:-0.1pt;"> </span>on<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> </span>third&#160;anniversary<span style="letter-spacing:-0.1pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.1pt;"> date of g</span>rant,<span style="letter-spacing:-0.1pt;"> </span>subject<span style="letter-spacing:-0.1pt;"> </span>to <span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span>Adcock<span style="letter-spacing:-0.1pt;"> </span>remaining<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> c</span>ontinuous<span style="letter-spacing:-0.1pt;"> s</span>ervice<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>defined<span style="letter-spacing:-0.1pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> 2015&#160;</span>Plan<span style="letter-spacing:-0.1pt;"> </span>through<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>applicable<span style="letter-spacing:-0.1pt;"> </span>vesting<span style="letter-spacing:-0.15pt;"> </span>dates.<span style="letter-spacing:-0.15pt;"> </span>This<span style="letter-spacing:-0.1pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.1pt;"> </span>awards<span style="letter-spacing:-0.15pt;"> </span>to<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.55pt;">&#160;</span>Adcock<span style="letter-spacing:1.1pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span>made<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span>connection<span style="letter-spacing:-0.1pt;"> </span>with<span style="letter-spacing:-0.15pt;"> </span>his<span style="letter-spacing:-0.15pt;"> </span>appointment<span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> c</span>hief<span style="letter-spacing:-0.15pt;"> e</span>xecutive<span style="letter-spacing:-0.1pt;"> o</span><span style="letter-spacing:-0.05pt;">fficer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> c</span><span style="letter-spacing:-0.1pt;">ompany, </span>which<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">effective</span><span style="letter-spacing:-0.1pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>October<span style="letter-spacing:-0.1pt;">&#160;</span>26,&#160;2020,<span style="letter-spacing:-0.15pt;"> </span>and<span style="letter-spacing:-0.15pt;"> </span>was<span style="letter-spacing:1.25pt;"> </span>modified<span style="letter-spacing:-0.15pt;"> </span>from<span style="letter-spacing:-0.15pt;"> </span>the<span style="letter-spacing:-0.15pt;"> </span>recommended<span style="letter-spacing:-0.15pt;"> </span>equity<span style="letter-spacing:-0.15pt;"> </span>grant<span style="letter-spacing:-0.15pt;"> </span>described<span style="letter-spacing:-0.15pt;"> </span>in<span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.2pt;">Mr.</span><span style="letter-spacing:-0.6pt;">&#160;</span><span style="letter-spacing:-0.1pt;">Adcock&#8217;s</span><span style="letter-spacing:-0.15pt;"> </span><span style="letter-spacing:-0.05pt;">offer</span><span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>employment<span style="letter-spacing:-0.15pt;"> </span>as<span style="letter-spacing:-0.15pt;"> </span>of<span style="letter-spacing:-0.15pt;"> </span>that<span style="letter-spacing:-0.15pt;"> </span>date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;4,&#160;2021, prior to the Merger, NantCell awarded 7,121,110&#160;RSUs (adjusted for the exchange ratio of 0.8190) to employees and consultants of NantCell and its affiliated companies, pursuant to the NC&#160;2015&#160;Plan. These RSU awards were subject to a performance condition in connection with a &#8220;Liquidity Event&#8221;, defined as either (i)&#160;NantCell&#8217;s registration of shares for issuance on a securities offering or (ii)&#160;the closing of a corporate transaction. In addition, the vesting of certain performance-based RSU grants accelerates upon obtaining approval by the FDA of a BLA or equivalent application for approval of Anktiva for use in the treatment of non-muscle-invasive bladder cancer. These performance-based RSUs are also subject to service conditions and are scheduled to cliff vest on the last date of each tranche as defined by the individual grant agreements. On March&#160;9,&#160;2021, we completed the Merger with NantCell, and the performance condition related to the Liquidity Event was met.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the RSUs was estimated based on a third-party valuation as of the grant date of March&#160;4,&#160;2021 and was derived primarily from the estimated probabilities of the Merger close on March&#160;9, 2021 and the other exit assumptions. Once the liquidity event related performance condition was met as of March&#160;9, 2021 due to the Merger, compensation expense for these RSUs began to be recognized on a graded vesting attribution approach over the requisite service period for each participant, which ranges from <span style="-sec-ix-hidden:F_001015">six-month</span> to seventy&#160;(70)-month vesting periods. During the three&#160;months ended March&#160;31,&#160;2021, we recognized approximately $5.1&#160;million of stock-based compensation expense related to these awards, of which approximately $2.9&#160;million was recorded in <span style="font-style:italic;">research and development expense</span>, and approximately $2.2&#160;million was recorded in <span style="font-style:italic;">selling, general and administrative expense</span>, respectively, on the condensed combined consolidated statements of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RSUs awarded to employees and consultants of affiliated companies were accounted for as stock-based compensation in accordance with ASU&#160;2018-07, <span style="font-style:italic;">Compensation&#8212;Stock Compensation (Topic&#160;718)</span>, as the compensation was in exchange for continued support or services expected to be provided to the company over the vesting periods under the NantWorks shared services agreement discussed in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Related Party Agreements</span>. We have evaluated the associated benefit of these awards to the affiliated companies under common control and determined that the benefit is limited to the retention of their employees. We estimated such benefit at the grant date fair value of $4.0&#160;million and recognized $0.1&#160;million of deemed dividends for the three&#160;months ended March&#160;31,&#160;2021, which was recorded in <span style="font-style:italic;">additional paid in capital,</span> on the condensed combined consolidated balance sheets, with a corresponding credit to stock compensation expense.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Warrants</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Merger, warrants issued to NantWorks, a related party, in connection with NantCell&#8217;s acquisition of Altor were assumed by the company. After applying the Exchange Ratio at the Effective Time of the Merger, a total of 1,638,000&#160;warrants with an exercise price of $3.24&#160;per share, with vesting subject to the achievement of a certain performance condition pertaining to building manufacturing capacity, were outstanding as of March&#160;31,&#160;2021. The fair value of $18.0&#160;million assigned to the unvested warrants will be recognized upon achievement of a performance-based vesting condition <span style="color:#000000;">pertaining to building manufacturing capacity to support supply requirements for one of our product candidates</span>. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323773624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p id="N12___INCOME_TAXES" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. &#160;&#160;&#160;&#160;Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March&#160;9, 2021, the company completed the Merger with NantCell. The merger is accounted for as a transaction between entities under common control. The Merger is also considered a nontaxable transaction for U.S. income tax purposes and it is intended to qualify as a &#8220;reorganization&#8221; within the meaning of Section&#160;368(a) of the Internal Revenue Code of&#160;1986, as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is subject to taxation in the United States, various state, and foreign jurisdictions. Earnings from non-U.S.&#160;activities are subject to local country income tax. The company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. No tax benefit was provided for losses incurred in the United States, Italy, and South Korea because those losses are offset by a full valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The difference between the federal statutory tax rate of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the company&#8217;s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% tax rate is due to losses from which </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the company</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> cannot benefit.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The company is no longer subject to income tax examination by the U.S.&#160;federal, state or local tax authorities for years ended December&#160;31,&#160;2015 or prior; however, its tax attributes, such as net operating loss&#160;(&#8220;NOL&#8221;) carryforwards and tax credits, are still subject to examination in the year they are used.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323845656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p id="N13___SUBSEQUENT_EVENTS" style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. &#160;&#160;&#160;&#160;Subsequent Events</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Immuno-Oncology Clinic, Inc. Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During April&#160;2021, ImmunityBio executed two&#160;work orders under an existing master agreement with <span style="Background-color:#FFFFFF;color:#000000;">Immuno-Oncology Clinic,&#160;Inc.&#160;(the &#8220;Clinic&#8221;), a related party. Under these work orders, the parties agreed that the Clinic would serve as a site for the following multi-site clinical trials:</span></p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of subcutaneously- and orally-administered supplemental spike &amp; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:3.33%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#FFFFFF;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#FFFFFF;text-decoration:none;"/><span style="color:#000000;"/><span style="Background-color:#FFFFFF;color:#000000;">A Phase&#160;I study of the safety, reactogenicity, and immunogenicity of a supplemental spike &amp; nucleocapsid-targeted COVID</span><span style="Background-color:#FFFFFF;">&#8209;</span><span style="Background-color:#FFFFFF;color:#000000;">19 vaccine to enhance T&#160;cell-based immunogenicity in participants who have already received a vaccine authorized for emergency use.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to our existing agreement with the Clinic, our share of qualifying expenses shall be deducted from amounts previously paid to the Clinic as described in further detail in <a href="#N9___RELATED_PARTY_AGREEMENTS"><span style="text-decoration:underline;">Note&#160;9</span></a><span style="Background-color:#FFFFFF;">, </span><span style="font-style:italic;Background-color:#FFFFFF;color:#000000;">Related Party Agreements</span><span style="Background-color:#FFFFFF;color:#000000;">. We expect to incur up to $0.2&#160;million of qualifying clinical trial expenses under each work order, subject to changes dependent on clinical trial enrollments and progress.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Open Market Sale Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April&#160;30, 2021, we entered into an Open Market Sale Agreement&#160;(the &#8220;Sale Agreement&#8221;) with respect to an at-the-market&#160;(&#8220;ATM&#8221;) offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, having an aggregate offering price of up to $500.0&#160;million through our sales agent. We will pay our sales agent a commission of up to 3.0%&#160;of the gross sales proceeds of any shares of our common stock sold through them under the Sale Agreement, and also have provided them with customary indemnification and contribution rights.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not obligated to sell any shares under the Sale Agreement and may at any time suspend solicitation and offers under the Sale Agreement. The Sale Agreement may be terminated by us at any time given written notice to the sales agent for any reason or by the sales agent at any time by giving written notice to us for any reason or immediately under certain circumstances, and shall automatically terminate upon the issuance and sale of all of the shares.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062414318104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Accounting Treatment of the Merger</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Treatment of the Merger</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Merger represents a business combination pursuant to Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic&#160;805-50,&#160;<span style="font-style:italic;">Mergers</span>, which is accounted for as a transaction between entities under common control as Dr.&#160;Soon-Shiong and his affiliates were the controlling stockholders of each of the company and NantCell for all of the periods presented in this report. As a result, all of the assets and liabilities of NantCell were combined with ours at their historical carrying amounts on the closing date of the Merger. We have recast our prior period financial statements to reflect the conveyance of NantCell&#8217;s common shares as if the Merger had occurred as of the earliest date of the financial statements presented. All material intercompany accounts and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S.&#160;GAAP, and pursuant to the rules and regulations of the SEC. The unaudited condensed combined consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary for a fair presentation of our financial position and results of operations. The unaudited condensed combined consolidated financial statements do not include all information and notes required by U.S.&#160;GAAP for annual reports.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the company had an accumulated deficit of $1.7&#160;billion. We also had negative cash flows from operations of $60.5&#160;million for the three&#160;months ended March&#160;31,&#160;2021. The company will likely need additional capital to further fund the development of, and seek regulatory approvals for, our product candidates, and to begin to commercialize any approved products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements are derived from the company&#8217;s and NantCell&#8217;s respective historical consolidated financial statements for each period presented. Since the entities have been under common control for all periods presented, the condensed combined consolidated financial statements assume that the Merger took place at the beginning of the earliest period for which the condensed combined consolidated financial statements are presented. Accordingly, these financial statements should be read in conjunction with the audited combined consolidated financial statements and notes thereto for the fiscal year ended December&#160;31,&#160;2020 included in the Combined Consolidated Financial Statements of ImmunityBio,&#160;Inc. as of December&#160;31,&#160;2020 and December&#160;31,&#160;2019&#160;(including NantCell,&#160;Inc.) filed as <a href="http://www.sec.gov/Archives/edgar/data/0001326110/000119312521126681/d84467dex992.htm"><span style="text-decoration:underline;">Exhibit&#160;99.2</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to our Current Report on Form&#160;8&#8209;K/A filed with the SEC on April&#160;22,&#160;2021. Interim operating results are not necessarily indicative of operating results for the full year.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed combined consolidated financial statements have been prepared assuming the company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of the uncertainty of our ability to continue as a going concern. As a result of continuing anticipated operating cash outflows, we believe that substantial doubt exists regarding our ability to continue as a going concern without additional funding or financial support. However, we believe our existing cash, cash equivalents, and investments in marketable securities, together with capital to be raised through equity offerings, including but not limited to the offering, issuance and sale by us of up to a maximum aggregate offering of $500.0&#160;million of our common stock that may be issued and sold under an &#8220;at-the-market&#8221; sales agreement with Jefferies LLC, or the ATM, and our potential ability to borrow from affiliated entities, will be sufficient to fund operations through at least the next 12&#160;months following the issuance date of the financial statements based primarily upon our Executive Chairman&#8217;s intent and ability to support our operations with additional funds, including loans from affiliated entities, as required, which we believe alleviates such doubt. We may also seek to sell additional equity, through one or more follow-on public offerings, or in separate financings, or obtain a credit facility. However, we may not be able to secure such financing in a timely manner or on favorable terms. Without additional funds, we may choose to delay or reduce our operating or investment expenditures. Further, because of the risk and uncertainties associated with the commercialization of our product candidates in development, we may need additional funds to meet our needs sooner than planned.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited condensed combined consolidated financial statements include the accounts of the company and its subsidiaries. All intercompany amounts have been eliminated. For consolidated entities where we have less than 100% of ownership, we record net loss attributable to noncontrolling interest in our condensed combined consolidated statements of operations equal to the percentage of the ownership interest retained in such entities by the respective noncontrolling parties.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We apply the variable interest model under ASC Topic&#160;810,&#160;<span style="font-style:italic;">Consolidation</span>, to any entity in which we hold an equity investment or to which we have the power to direct the entity&#8217;s most significant economic activities and the ability to participate in the entity&#8217;s economics. If the entity is within the scope of the variable interest model and meets the definition of a variable interest entity, or VIE, we consider whether we must consolidate the VIE or provide additional disclosures regarding our involvement with the VIE. If we determine that we are the primary beneficiary of the VIE, we will consolidate the VIE. This analysis is performed at the initial investment in the entity or upon any reconsideration event.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For entities we hold as an equity investment that are not consolidated under the VIE model, we consider whether our investment constitutes ownership of a majority of the voting interests in the entity and therefore should be considered for consolidation under the voting interest model.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconsolidated equity investments in the common stock or in-substance common stock of an entity under which we are able to exercise significant influence, but not control, are accounted for using the equity method. Our ability to exercise significant influence is generally indicated by ownership of 20% to 50% interest in the voting securities of the entity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other unconsolidated equity investments on which we are not able to exercise significant influence will be subsequently measured at fair value with unrealized holding gains and losses included in <span style="font-style:italic;">interest and investment income, net</span>, on the condensed combined consolidated statements of operations. In the instance the equity investment does not have a readily determinable fair value and does not qualify for the practical expedient to estimate fair value in accordance with ASC Topic&#160;820, <span style="font-style:italic;">Fair Value Measurement</span>, or ASC&#160;820, we will apply the measurement alternative under ASC Topic&#160;321, <span style="font-style:italic;">Investments&#8212;Equity Securities</span>, or ASC&#160;321, pursuant to which we will measure the investment at its cost, less impairment, adjusted for observable price changes in an orderly market for an identical or similar investment of the same issuer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to March&#160;31,&#160;2021, we owned non-marketable equity securities that were accounted for using the measurement alternative under ASC&#160;321 because the preferred stock held by us was not considered in-substance common stock and such preferred stock did not have a readily determinable fair value. All investments are reviewed for possible impairment on a regular basis. If an investment&#8217;s fair value is determined to be less than its net carrying value, the investment is written down to its fair value. Such an evaluation is judgmental and dependent on specific facts and circumstances. Factors considered in determining whether an impairment indicator is present include:&#160;the investees&#8217; earnings performance and clinical trial performance, change in the investees&#8217; industry and geographic area in which it operates, offers to purchase or sell the security for a price less than the cost of the investment, issues that raise concerns about the investee&#8217;s ability to continue as a going concern, and any other information that we may be aware of related to the investment. Factors considered in determining whether an observable price change has occurred include:&#160;the price at which the investee issues equity instruments similar to those of our investment and the rights and preferences of those equity instruments compared to ours.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed combined consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed combined consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, we evaluate our estimates, including those related to the valuation of equity-based awards, deferred income taxes and related valuation allowances, preclinical and clinical trial accruals, impairment assessments, contingent value right measurement and assessments, the measurement of right-of-use assets and lease liabilities, useful lives of long-lived assets, loss contingencies, fair value measurements, and the assessment of our ability to fund our operations for at least the next 12&#160;months from the date of issuance of these financial statements. We base our estimates on historical experience and on various other market-specific and relevant assumptions that we believe to be reasonable under the circumstances. Estimates are assessed each period and updated to reflect current information, such as the economic considerations related to the impact that the ongoing coronavirus pandemic could have on our significant accounting estimates. Actual results could differ from those estimates.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March&#160;2020, the World Health Organization declared the novel strain of coronavirus disease&#160;(SARS&#8209;CoV&#8209;2) a pandemic. To date, our operations have not been significantly disadvantaged by the pandemic. However, we cannot at this time predict the specific extent, duration, or full impact that this pandemic may have on our financial condition and results of operations, including ongoing and planned clinical trials. More specifically, the pandemic may result in prolonged impacts that we cannot predict at this time and we expect that such uncertainties will continue to exist for the foreseeable future. The impact of the pandemic on our financial performance will depend on future developments, including the duration and spread of the outbreak, impact of potential variants and the related governmental advisories and restrictions. These developments and the impact of the ongoing pandemic on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, our results may be adversely affected.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for loss contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. We evaluate, on a quarterly basis, developments in legal proceedings and other matters that could cause a change in the potential amount of the liability recorded or of the range of potential losses disclosed. Moreover, we record gain contingencies only when they are realizable, and the amount is known. Additionally, we record our rights to insurance recoveries, limited to the extent of incurred or probable losses, as a receivable when such recoveries have been agreed to with our third-party insurers and when receipt is deemed probable. This includes instances when our third-party insurers have agreed to pay, on our behalf, certain legal defense costs and settlement amounts directly to applicable law firms and a settlement fund.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject us to concentrations of risk consist principally of cash and cash equivalents, marketable securities, and a convertible note receivable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our cash and cash equivalents are held by one major financial institution in the U.S., one in South&#160;Korea and one in Italy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates developed by us will require approvals or clearances from the FDA or international regulatory agencies prior to commercial sales. There can be no assurance that any of our product candidates will receive any of the required approvals or clearances. If we were to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on us.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for stock-based compensation under the provisions of FASB ASC Topic&#160;718, <span style="font-style:italic;">Compensation&#8212;Stock Compensation</span>, or ASC&#160;718. We measure the fair value of an equity-classified award at the grant date and recognize the stock-based compensation expense over the period of vesting on the straight-line basis for our outstanding share awards that do not contain a performance condition. For awards subject to performance-based vesting conditions, we assess the probability of the individual milestones under the award being achieved and stock-based compensation expense is recognized over the service period using the graded vesting method once management believes the performance criteria is probable of being met. For awards with service or performance conditions, we recognize the effect of forfeitures in compensation cost in the period that the award was forfeited.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share of Common Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basic and Diluted Net Loss per Share of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share is computed by dividing net loss attributable to ImmunityBio common stockholders by the weighted-average number of common shares, including the number of additional shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table details those securities that have been excluded from the computation of p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otentially dilutive securities:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,314</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,080,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,636,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding related-party warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,252,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,821,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts in the table above reflect the common stock equivalents of the noted instruments, including awards issued under the NantKwest 2015&#160;Equity Incentive Plan&#160;(the &#8220;2015&#160;Plan&#8221;), the NantKwest 2014&#160;Equity Incentive Plan&#160;(the &#8220;2014&#160;Plan&#8221;), and awards issued under the NantCell,&#160;Inc. 2015&#160;Stock Incentive Plan&#160;(the &#8220;NC&#160;2015&#160;Plan&#8221;) that, in the case of March&#160;31, 2021, were outstanding immediately prior to the Effective Time of the Merger and in the case of March&#160;31, 2020 have been adjusted to include the combined NC&#160;2015&#160;Plan and NantCell warrants then outstanding (in both cases adjusted <span style="Background-color:#FFFFFF;color:#000000;">using the Merger Exchange Ratio of&#160;0.8190</span>). See <a href="#N11___STOCKBASED_COMPENSATION"><span style="text-decoration:underline;">Note&#160;11</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;">Stock-Based Compensation</span>, for further information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Application of New or Revised Accounting Standards &#8211; Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June&#160;2016, the FASB issued Accounting Standards Update, or ASU, 2016&#8209;13,&#160;<span style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic&#160;326):&#160;Measurement of Credit Losses on Financial Instruments</span>, or ASU&#160;2016-13. The FASB subsequently issued amendments to ASU&#160;2016&#8209;13, which have the same effective date and transition dates as described below. The new guidance supersedes existing U.S.&#160;GAAP for measuring and recording of credit losses on financial assets measured at amortized cost by replacing the incurred-loss model with an expected-loss model. Accordingly, these financial assets will be presented at the net amount expected to be collected. This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the current, other-than-temporary-impairment model. For public business entities that meet the definition of an SEC filer, except entities that are eligible to be a smaller reporting company as defined by the SEC, the standard is effective for annual periods beginning after December&#160;15,&#160;2019, and interim periods therein. For all other entities, including us, the standard is effective for annual periods beginning after December&#160;15,&#160;2022, and interim periods therein. Early adoption is permitted for all entities for annual periods beginning after December&#160;15,&#160;2018. With certain exceptions, adjustments are to be applied using a modified-retrospective approach by reflecting adjustments through a cumulative-effect impact on retained earnings as of the beginning of the fiscal year of adoption. We continue to evaluate the impact that this new standard and its related amendments will have on our consolidated financial statements and we do not intend to early adopt this new standard.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other recent authoritative guidance issued by the FASB (including technical corrections to the ASC), the American Institute of Certified Public Accountants, and the SEC during the three&#160;months ended March&#160;31,&#160;2021 did not, or are not expected to, have a material effect on our consolidated financial statements.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value is defined as an exit price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. We use a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The&#160;hierarchy requires us to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The three tiers are defined as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;1&#8212;Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets at the measurement date. Since valuations are based on quoted prices that are readily and regularly available in an active market, the valuation of these products does not entail a significant degree of judgment. Our Level&#160;1 assets consist of bank deposits, money market funds, and marketable equity securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;2&#8212;Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities. Our Level&#160;2 assets consist of corporate debt securities including commercial paper, government-sponsored securities and corporate bonds, as well as foreign municipal securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level&#160;3&#8212;Valuations based on inputs that are unobservable and significant to the overall fair value measurement.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We utilize a third-party pricing service to assist in obtaining fair value pricing for our investments in marketable debt securities. Inputs are documented in accordance with the fair value disclosure hierarchy. The fair values of financial instruments other than marketable securities and cash and cash equivalents are determined through a combination of management estimates and third-party valuations.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323927320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides the impact of the change in reporting entity on our unaudited condensed combined consolidated statements of operations for the three months ended March&#160;31, 2021 and 2020 (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,382</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,903</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,275</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,628</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,264</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,637</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,481</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantCell</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NantKwest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intercompany</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Eliminations</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ImmunityBio, Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">165</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,234</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,374</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative (including amounts</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; with related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,120</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,373</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,493</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,702</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other (expense) income, net (including amounts with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related parties)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(910</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(707</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,383</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37,427</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 3<br> -Paragraph i<br> -Subsection 10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323896008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Securities Excluded from the Computation of Potentially Dilutive Securities</a></td>
<td class="text"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table details those securities that have been excluded from the computation of p</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">otentially dilutive securities:</span>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding stock options</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,314</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,080,483</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,636,132</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,102,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding related-party warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,638,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,252,446</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,821,011</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323625992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, prepaid expenses and other current assets consist of the following (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.2%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,648</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance claim receivable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,932</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,518</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid services</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,435</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid license fees</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,329</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">801</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid insurance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,230</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,365</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insurance premium financing asset</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid rent</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">569</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant improvement receivables &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid equipment maintenance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable <span style="font-size:9pt;">&#8211;</span> marketable debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid supplies &#8211; with related party (Note 9)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">338</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,242</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,649</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, property, plant and equipment, net, consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,200</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,556</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,738</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,690</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,308</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,333</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,659</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,376</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture &amp; fixtures</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,007</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross property, plant and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,420</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,545</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,875</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Other Assets</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31,&#160;2021 and December&#160;31,&#160;2020, other assets consist of the following&#160;(in&#160;thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">VAT receivable</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">810</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security deposits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid software license fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">227</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">455</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid preclinical and clinical trial services &#8211; with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related party (Note 9)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">316</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">323</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.36%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,905</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,598</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021 and December&#160;31,&#160;2020, accrued expenses and other liabilities consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.7%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:14.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonus</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,947</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,288</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued dissenting shares (Note 8)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,769</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional and service fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,668</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued preclinical and clinical trial costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,656</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,349</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,891</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,002</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued construction costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,931</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contingent consideration payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">822</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued laboratory equipment and supplies</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">681</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing obligation <span style="font-family:Calibri;">&#8211;</span> current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,421</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued franchise, sales, use and property taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.42%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued capital expenditures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,186</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.7%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,793</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,771</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTableTextBlock', window );">Interest and Investment Income, Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net consists of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="3" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains (losses) from equity securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(198</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">339</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">322</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investment amortization expense, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(225</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net realized losses on investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.48%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and investment income, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,944</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329371704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Available-for-Sale Marketable Debt Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;31, 2021, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="16" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000607">0.2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,541</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,576</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000608">5.1</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,575</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, the amortized cost, gross unrealized gains, gross unrealized losses and fair value of marketable debt securities, which were considered as available-for-sale, by type of security were as follows (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,<span style="color:#000000;">&#160;</span>2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,824</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,809</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent portion</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">861</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,685</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,759</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock', window );">Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated unrealized losses on debt securities classified as available-for-sale that have been in a continuous loss position for less than 12&#160;months and for more than 12&#160;months as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020 were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,535</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More than 12 months</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,762</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,762</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328376520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets and liabilities measured at fair value on a recurring basis are summarized below as of March&#160;31,&#160;2021 and December&#160;31,&#160;2020&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of March 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities (1)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,735</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,538</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements as of December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,337</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutual funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncurrent:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets measured at fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,011</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,239</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration obligations (2)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Our equity securities include our investment in Viracta totaling $14.5&#160;million, which was previously accounted for by applying the measurement alternative under ASC&#160;321. In February&#160;2021, Viracta merged with Sunesis Pharmaceuticals, Inc., a public company. In connection with this transaction, our preferred stock investment in Viracta was converted into 1,562,604&#160;shares of Viracta common stock effective February&#160;25,&#160;2021. See </span><a href="#N4___EQUITY_INVESTMENT_IN_VIRACTA_RAPEUT"><span style="text-decoration:underline;color:#000000;">Note&#160;4</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Equity Investment in Viracta Therapeutics</span><span style="Background-color:#FFFFFF;color:#000000;">, for additional information.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.63%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Contingent consideration obligations are recorded at their estimated fair values and are revalued each reporting period until the related contingencies are resolved. The fair value measurements of these obligations are based on inputs that are unobservable and significant to the overall fair value measurement (i.e., a Level&#160;3 measurement within the fair value hierarchy) and are reviewed periodically by management. See </span><a href="#N8___COMMITMENTS_CONTINGENCIES"><span style="text-decoration:underline;color:#000000;">Note&#160;8</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </span><span style="font-style:italic;color:#000000;">Commitments and Contingencies,</span><span style="color:#000000;"> for additional information.</span></p></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Carrying Amount of Contingent Consideration Obligations</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in the carrying amount of contingent consideration obligations were as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, beginning of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(972</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net change in fair value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value, end of period</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,727</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062415866184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Information Regarding Leases</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information regarding our leases is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:9.35pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The components of lease expense consist of the following&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:1pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:5pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:5pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,147</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,782</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable lease costs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">666</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">848</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease costs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities is as follows&#160;(in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; Operating cash flows for operating leases</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,679</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,355</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Future minimum lease payments as of March&#160;31,&#160;2021, including $4.9&#160;million related to options to extend lease terms that are reasonably certain of being exercised, are presented in the following table&#160;(in&#160;thousands). Common area maintenance costs and taxes are not included in these payments.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ending December 31:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021 (excluding the three months ended March 31, 2021)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,193</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,889</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,135</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,622</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,183</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,487</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,509</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,710</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328735192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of Outstanding Balances of Related Party Agreements</a></td>
<td class="text">Below is a summary of outstanding balances and a description of significant relationships&#160;(in&#160;thousands):
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td colspan="2" style="background-color:#FFFFFF;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;width:14%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:9pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantBio</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,294</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related party &#8211; NantOmics</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due from related parties &#8211; Various</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">172</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.25pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due from related parties</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,057</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,003</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantWorks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,799</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,650</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Duley Road</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,161</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,787</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantBio</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Immuno-Oncology Clinic</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">503</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">271</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; Nant Capital</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Due to related party &#8211; NantPharma</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total due to related parties</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,817</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,838</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; Nant Capital</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150,695</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109,246</p></td>
<td style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantMobile</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,078</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,660</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NantWorks</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,165</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,546</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party notes payable &#8211; NCSC</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,348</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total related-party notes payable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,286</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">254,353</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"/>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062324107688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock Based Compensation Expenses Included on Operations Statement</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents stock-based compensation included on the condensed combined consolidated statements of operations (in&#160;thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,355</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,943</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,298</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense in operating expenses:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,888</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Selling, general and administrative</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,410</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">319</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,298</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">480</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarizes Stock Option Activity and Related Information Under Equity Incentive Plans</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity and related information for three&#160;months ended March&#160;31, 2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,996,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.96</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,746</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000978">4.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(752,310</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,660</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.27</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at March&#160;31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,978,314</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,279</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000979">5.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:10.05pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and exercisable at March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,815,630</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.07</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,363</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000980">4.2</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option issued was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000990">6.0</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average grant date fair value</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.63</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">RSUs Activity</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes RSU activity for the three&#160;months ended March&#160;31,&#160;2021:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">466,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.52</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,521,110</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.35</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(235,725</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.34</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited/canceled</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(116,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.49</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested balance at March&#160;31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,636,132</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329802568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Effective date of acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  09,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NantKwestMember', window );">NantKwest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger', window );">Ownership percentage held by stockholders upon consummation of merger</a></td>
<td class="nump">28.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember', window );">Executive Chairman and Principal Stockholder and Affiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OwnershipPercentageByKeyExecutives', window );">Ownership percentage held by Executive Chairman upon consummation of merger</a></td>
<td class="nump">81.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellIncMember', window );">NantCell, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Date of agreement and plan of merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 21,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger', window );">Ownership percentage held by stockholders upon consummation of merger</a></td>
<td class="nump">71.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Merger related costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage acquired on fully diluted bases upon consummation of merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OwnershipPercentageByKeyExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership percentage by key executives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OwnershipPercentageByKeyExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the business acquisition agreement was executed, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e848-128460<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116868678&amp;loc=d3e845-128460<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_NantKwestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_NantKwestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_NantCellIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328464968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">41,128<span></span>
</td>
<td class="nump">27,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">45,275<span></span>
</td>
<td class="nump">9,493<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(86,264)<span></span>
</td>
<td class="num">(36,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="num">(707)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(80,481)<span></span>
</td>
<td class="num">(37,427)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember', window );">Reportable Legal Entities | NantCell, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">21,509<span></span>
</td>
<td class="nump">14,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">24,382<span></span>
</td>
<td class="nump">4,120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(45,708)<span></span>
</td>
<td class="num">(18,204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(46,556)<span></span>
</td>
<td class="num">(19,132)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember', window );">Reportable Legal Entities | NantKwest, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="nump">19,725<span></span>
</td>
<td class="nump">13,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="nump">20,903<span></span>
</td>
<td class="nump">5,373<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,628)<span></span>
</td>
<td class="num">(18,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">6,637<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(33,997)<span></span>
</td>
<td class="num">(18,383)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Intercompany Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NameChangeEventLineItems', window );"><strong>Name Change Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (including amounts with related parties)</a></td>
<td class="num">(106)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative (including amounts with related parties)</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income, net (including amounts with related parties)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NameChangeEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NameChangeEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableLegalEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantCellIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantCellIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantKwestIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantKwestIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062414367128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 09, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,694,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,615,131,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,469,000<span></span>
</td>
<td class="nump">$ 31,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember', window );">NC 2015 Plan and NantCell Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | VIE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | VIE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program | Subsequent Events | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate market price of shares that may issue under a registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329816264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">14,252,446<span></span>
</td>
<td class="nump">8,821,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_OutstandingStockOptionsMember', window );">Outstanding Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">4,978,314<span></span>
</td>
<td class="nump">6,080,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">7,636,132<span></span>
</td>
<td class="nump">1,102,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding Related Party Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount</a></td>
<td class="nump">1,638,000<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_OutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ibrx_OutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062419948104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense And Other Assets Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty', window );">Prepaid preclinical and clinical trial services &#8211; with related party (Note 9)</a></td>
<td class="nump">$ 4,648<span></span>
</td>
<td class="nump">$ 4,626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceSettlementsReceivableCurrent', window );">Insurance claim receivable</a></td>
<td class="nump">2,932<span></span>
</td>
<td class="nump">2,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidServices', window );">Prepaid services</a></td>
<td class="nump">1,435<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidLicenseFees', window );">Prepaid license fees</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_InsurancePremiumFinancingAsset', window );">Insurance premium financing asset</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_EquipmentDepositsCurrent', window );">Equipment deposits</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseIncentiveReceivableCurrent', window );">Tenant improvement receivables &#8211; with related party (Note 9)</a></td>
<td class="nump">313<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidEquipmentMaintenance', window );">Prepaid equipment maintenance</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable &#8211; marketable debt securities</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidSuppliesWithRelatedParty', window );">Prepaid supplies &#8211; with related party (Note 9)</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">338<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 14,242<span></span>
</td>
<td class="nump">$ 13,649<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EquipmentDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment deposits current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EquipmentDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_InsurancePremiumFinancingAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance premium financing asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_InsurancePremiumFinancingAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidEquipmentMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid equipment maintenance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidEquipmentMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid preclinical and clinical trial services with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidSuppliesWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid supplies with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidSuppliesWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceSettlementsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceSettlementsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseIncentiveReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.  The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseIncentiveReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062327289416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Property, Plant and Equipment, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 125,420<span></span>
</td>
<td class="nump">$ 114,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="nump">44,545<span></span>
</td>
<td class="nump">41,862<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">80,875<span></span>
</td>
<td class="nump">72,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">52,200<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">38,556<span></span>
</td>
<td class="nump">34,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">22,690<span></span>
</td>
<td class="nump">22,690<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">8,308<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,659<span></span>
</td>
<td class="nump">2,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture And Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,007<span></span>
</td>
<td class="nump">$ 1,015<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062425344136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_FinancialStatementDetailsAbstract', window );"><strong>Financial Statement Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 2,972<span></span>
</td>
<td class="nump">$ 3,461<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FinancialStatementDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial statement details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FinancialStatementDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062424152728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Other Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets Noncurrent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableNoncurrent', window );">VAT receivable</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidSoftwareLicenseFeesInOtherAssets', window );">Prepaid software license fees</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Due from related party</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets', window );">Prepaid preclinical and clinical trial services &#8211; with related party (Note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousNoncurrent', window );">Other</a></td>
<td class="nump">316<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">$ 1,905<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid preclinical and clinical trial services with related party in other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidSoftwareLicenseFeesInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid software license fees in other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidSoftwareLicenseFeesInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329737848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus</a></td>
<td class="nump">$ 6,947<span></span>
</td>
<td class="nump">$ 5,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedDissentingShares', window );">Accrued dissenting shares (Note 8)</a></td>
<td class="nump">6,854<span></span>
</td>
<td class="nump">6,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and service fees</a></td>
<td class="nump">6,728<span></span>
</td>
<td class="nump">7,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts', window );">Accrued preclinical and clinical trial costs</a></td>
<td class="nump">4,656<span></span>
</td>
<td class="nump">4,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,349<span></span>
</td>
<td class="nump">3,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedResearchAndDevelopmentCosts', window );">Accrued research and development costs</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">4,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrent', window );">Accrued construction costs</a></td>
<td class="nump">1,931<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Accrued contingent consideration payable</a></td>
<td class="nump">822<span></span>
</td>
<td class="nump">856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedLaboratoryEquipmentAndSupplies', window );">Accrued laboratory equipment and supplies</a></td>
<td class="nump">681<span></span>
</td>
<td class="nump">641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Financing obligation &#8211; current portion</a></td>
<td class="nump">571<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Accrued franchise, sales, use and property taxes</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedCapitalExpenditures', window );">Accrued capital expenditures</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">$ 36,793<span></span>
</td>
<td class="nump">$ 36,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedCapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued capital expenditures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedCapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedDissentingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued dissenting shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedDissentingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedLaboratoryEquipmentAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued laboratory equipment and supplies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedLaboratoryEquipmentAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedPreclinicalAndClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued preclinical and clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedPreclinicalAndClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6419918&amp;loc=d3e35281-107843<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323673064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Statement Details - Interest and Investment Income, Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAbstract', window );"><strong>Investment Income Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) from equity securities</a></td>
<td class="nump">$ 8,833<span></span>
</td>
<td class="num">$ (198)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Investment amortization expense, net</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Net realized losses on investments</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest and investment income, net</a></td>
<td class="nump">$ 8,944<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062327936136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Investment in Viracta Therapeutics - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Non-marketable equity investment (Note 4)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ibrx_InterestAndInvestmentIncomeNetMember', window );">Interest and Investment Income, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount', window );">Unrealized loss on equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember', window );">Viracta Therapeutics, Inc. | Common Stock | Sunesis Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock investment converted into common stock, shares</a></td>
<td class="nump">1,562,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement | Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PurchaseOfConvertibleNoteUponConversion', window );">Purchase of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement | Series B Preferred Stock | Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gains on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember', window );">2018 Note and Warrant Purchase Agreement | Common Stock | Viracta Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule Of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised to acquire shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PurchaseOfConvertibleNoteUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of convertible note upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PurchaseOfConvertibleNoteUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ibrx_InterestAndInvestmentIncomeNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ibrx_InterestAndInvestmentIncomeNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_SunesisPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_SunesisPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062438527080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 16,437<span></span>
</td>
<td class="nump">$ 55,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">16,575<span></span>
</td>
<td class="nump">55,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">15,576<span></span>
</td>
<td class="nump">54,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">15,575<span></span>
</td>
<td class="nump">54,809<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">15,541<span></span>
</td>
<td class="nump">54,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 15,538<span></span>
</td>
<td class="nump">54,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember', window );">Current Assets | Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember', window );">Noncurrent Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember', window );">Noncurrent Assets | Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale, Amortized Cost</a></td>
<td class="nump">861<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, Fair Value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod', window );">Available-for-sale, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">5 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale securities debt securities period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062413136120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) from equity securities</a></td>
<td class="nump">$ 8,834,000<span></span>
</td>
<td class="num">$ (202,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Investments in marketable equity securities with readily determinable fair values</a></td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gains (losses) from equity securities</a></td>
<td class="nump">8,800,000<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss', window );">Realized gains or losses on sales of equity securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of available-for-sale securities in unrealized loss positions | Security</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet', window );">Other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120269885&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328252264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">$ 13,535<span></span>
</td>
<td class="nump">$ 42,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Available-for-Sale Investments, Less than 12 months, Estimated Fair Value</a></td>
<td class="nump">13,535<span></span>
</td>
<td class="nump">42,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Available-for-Sale Investments, More than 12 months, Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062324821112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 84,273<span></span>
</td>
<td class="nump">$ 97,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent consideration obligations</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">44,679<span></span>
</td>
<td class="nump">34,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,538<span></span>
</td>
<td class="nump">54,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">23,019<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Current Assets | Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Noncurrent Assets | Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">68,735<span></span>
</td>
<td class="nump">42,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">44,679<span></span>
</td>
<td class="nump">34,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">23,019<span></span>
</td>
<td class="nump">6,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Current Assets | Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Noncurrent Assets | Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,538<span></span>
</td>
<td class="nump">54,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent consideration obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">15,538<span></span>
</td>
<td class="nump">54,772<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Current Assets | Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Noncurrent Assets | Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Contingent consideration obligations</a></td>
<td class="num">(844)<span></span>
</td>
<td class="num">(972)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Current Assets | Mutual Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Noncurrent Assets | Foreign Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets measured at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_NoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ForeignGovernmentDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062324379656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail) - Viracta Therapeutics, Inc. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Feb. 25, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember', window );">Common Stock | Sunesis Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Preferred stock investment converted into common stock, shares</a></td>
<td class="nump">1,562,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity securities categorized neither as held-to-maturity nor as trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_ViractaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_SunesisPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_SunesisPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062322428584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="num">$ (972)<span></span>
</td>
<td class="num">$ (1,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Net change in fair value</a></td>
<td class="nump">128<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="num">$ (844)<span></span>
</td>
<td class="num">$ (1,727)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329516392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalInstitutesOfHealthMember', window );">National Institutes of Health | CRADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPaymentForSupportOfResearchActivities', window );">Annual payment for support of research activities</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities', window );">Minimum annual payments for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_EstimatedUnpaidResearchAndDevelopmentExpense', window );">Estimated unpaid research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PayableOutstanding', window );">Payable outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalInstitutesOfHealthMember', window );">National Institutes of Health | CRADA | Etubics Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPaymentForSupportOfResearchActivities', window );">Annual payment for support of research activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_ClinicalTrialActivitiesMember', window );">Clinical Trial Activities | iosBio Ltd. Exclusive License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LicensingAgreementLineItems', window );"><strong>Licensing Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedReimbursableCostsPayable', window );">Accrued reimbursable costs payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedReimbursableCostsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued reimbursable costs payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedReimbursableCostsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPaymentForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual payment for support of research activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPaymentForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_EstimatedUnpaidResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated unpaid research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_EstimatedUnpaidResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LicensingAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LicensingAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual payments for support of research activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PayableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PayableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=ibrx_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_CooperativeResearchAndDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_EtubicsCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_EtubicsCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_ClinicalTrialActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ibrx_ClinicalTrialActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_IosbioLtdExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_IosbioLtdExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328634056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2015</div></th>
<th class="th"><div>Apr. 10, 2015</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms', window );">Operating lease payments related to options to extend lease terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable', window );">Minimum net sales milestone for contingent value rights payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Dr. Soon-Shiong and Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ContingentValueRightsPayable', window );">Contingent value rights payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable if Certain Conditions are met by December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ContingentValueRightsPayable', window );">Contingent value rights payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember', window );">Altor BioScience Corporation | Contingent Value Rights Payable if Certain Conditions are met on or before December 31, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ContingentValueRightsPayable', window );">Contingent value rights payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember', window );">Altor BioScience, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AccruedPaymentForDissentingShares', window );">Accrual for dissenting shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember', window );">VivaBioCell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PercentageOfWhollyOwnedSubsidiary', window );">Ownership percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh', window );">Maximum milestone payment due if certain conditions are met</a></td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ChangeInContingentConsideration', window );">Change in fair value of contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_FairValueOfContingentConsiderationObligation', window );">Fair value of contingent consideration obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AccruedPaymentForDissentingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued payment for dissenting shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AccruedPaymentForDissentingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ChangeInContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ChangeInContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ContingentValueRightsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ContingentValueRightsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_FairValueOfContingentConsiderationObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_FairValueOfContingentConsiderationObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum net sales milestone contingent value rights payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease payments related to options to extend lease terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfWhollyOwnedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of wholly-owned subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfWhollyOwnedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndPelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_DrSoonShiongAndPelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsPayableAtDecember312022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsPayableAtDecember312022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsPayableBeforeDecember312026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ibrx_ContingentValueRightsPayableBeforeDecember312026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_AltorBioScienceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_VivaBioCellMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_VivaBioCellMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329028168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Information Regarding Leases (Detail)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328419544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Components of Lease Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2,147<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,813<span></span>
</td>
<td class="nump">$ 2,630<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062323906936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash Flow Operating Activities Lessee [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 1,679<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062322538648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the three months ended March 31, 2021)</a></td>
<td class="nump">$ 5,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">6,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">3,622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">2,487<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">26,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">4,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 21,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329928456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">$ 2,057<span></span>
</td>
<td class="nump">$ 2,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">17,817<span></span>
</td>
<td class="nump">14,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total related-party notes payable</a></td>
<td class="nump">297,286<span></span>
</td>
<td class="nump">254,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember', window );">NantBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">1,294<span></span>
</td>
<td class="nump">1,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">943<span></span>
</td>
<td class="nump">943<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantOmicsLLCMember', window );">NantOmics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember', window );">Various</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Total due from related parties</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">12,799<span></span>
</td>
<td class="nump">10,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total related-party notes payable</a></td>
<td class="nump">52,165<span></span>
</td>
<td class="nump">51,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember', window );">Duley Road</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="nump">2,787<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember', window );">Immuno-Oncology Clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember', window );">NantPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Total due to related parties</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total related-party notes payable</a></td>
<td class="nump">150,695<span></span>
</td>
<td class="nump">109,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total related-party notes payable</a></td>
<td class="nump">57,078<span></span>
</td>
<td class="nump">56,660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Total related-party notes payable</a></td>
<td class="nump">$ 37,348<span></span>
</td>
<td class="nump">$ 36,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantOmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantOmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_VariousMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062303077480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Agreements - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Term</div>
</th>
<th class="th">
<div>Nov. 30, 2015 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Officer</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,275,000<span></span>
</td>
<td class="nump">$ 9,493,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,128,000<span></span>
</td>
<td class="nump">27,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,817,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,838,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,388,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">634,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioScienceMember', window );">NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Net receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NantCancerStemCellLLCMember', window );">Nant Cancer Stem Cell L L C | Sorrento</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ibrx_NantCancerStemCellLLCMember', window );">Nant Cancer Stem Cell L L C | NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of ownership interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LeaseAgreementExtendedPeriod', window );">Lease agreement extended lease period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Amendment to Extend Lease Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Shared Services Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember', window );">NantWorks | Shared Services Agreement | Reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfOfficers', window );">Number of officers | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_RelatedPartyInstallmentPayment', window );">Related party transaction installment payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,880,000<span></span>
</td>
<td class="nump">$ 3,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionConditionalPayment', window );">Related party transaction conditional payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NewAgreementTerminationNoticePeriod', window );">Notice period to terminate new agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidBalance', window );">Prepaid balance related to Clinic Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Estimated cost for new agreement with clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioScienceMember', window );">NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod', window );">Research and development expense, ratable payment period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaymentOfFundingAmount', window );">Prepayment for services amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioScienceMember', window );">NantBioScience | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets', window );">Prepaid balance included in prepaid expenses and other current assets and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellLLCMember', window );">Nant Cancer Stem Cell L L C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_RelatedPartyTransactionInitialTermOfAgreement', window );">Initial term of agreement entered into with the related party by the entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_RelatedPartyAgreementRenewalTerm', window );">Related party, agreement renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellLLCMember', window );">Nant Cancer Stem Cell L L C | Bioreactors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_EmployeeBonusesPaymentMember', window );">Employee Bonuses Payment | NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Net receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_EmployeeBonusesPaymentMember', window );">Employee Bonuses Payment | NantOmics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Net receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VendorCostsPaymentsMember', window );">Vendor Costs Payments | NantBioScience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Net receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DougStLLCMember', window );">605 Doug St, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Due between the parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DougStLLCMember', window );">605 Doug St, LLC | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DougStLLCMember', window );">605 Doug St, LLC | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge', window );">Annual percentage increases to monthly fixed charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrentAndNoncurrent', window );">Rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OptionsToExtendNumberOfTerms', window );">Options to extend number of terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Period of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease term is from February&#160;2017 through October&#160;2024. We have the option to extend the initial term for two&#160;consecutive five-year periods through July&#160;2034. The monthly rent is $40,700 with annual increases of 3% which began in November&#160;2018.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LeaseholdImprovementPayables', window );">Leasehold improvement payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_LeaseRelatedPayables', window );">Lease-related payables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | 7-Year Term Commencing in September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | 7-Year Term Commencing in September 2019 | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Seven-Year Term Commencing in July 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PeriodOfExtendedLeaseTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial term of lease arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember', window );">Duley Road, LLC | Seven-Year Term Commencing in July 2019 | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | El Segundo California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfSquareFootOfFacilityLeased', window );">Number of square foot of facility leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_BaseMonthlyRent', window );">Base rent - monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AnnualPercentageIncreasesToBaseRent', window );">Percentage of annual increases of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Optional extended lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Property, Plant and Equipment, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember', window );">605 Nash, LLC | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember', window );">NantPharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Laboratory equipment purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Amount of note borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital | Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AmountOfAdvanceReceivedOnNote', window );">Amount of advance received</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AmountOfAdvanceReceivedOnNoteOutstanding', window );">Amount of advance received on note outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital | Related Party Notes Payable | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest on note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember', window );">Nant Capital | Related Party Notes Payable | Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest on note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,799,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember', window );">NantWorks | Related Party Notes Payable | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest on note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember', window );">NCSC | Related Party Notes Payable | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest on note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Note interest rate per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember', window );">NantMobile | Related Party Notes Payable | Demand Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Related-party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued and unpaid interest on note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AmountOfAdvanceReceivedOnNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance received on note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AmountOfAdvanceReceivedOnNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AmountOfAdvanceReceivedOnNoteOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of advance received on note outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AmountOfAdvanceReceivedOnNoteOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPercentageIncreasesToBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPercentageIncreasesToBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual percentage increases to monthly fixed charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_BaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base monthly rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_BaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseAgreementExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement extended period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseAgreementExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseRelatedPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease-related payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseRelatedPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_LeaseholdImprovementPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leasehold improvement payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_LeaseholdImprovementPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NewAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New agreement termination notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NewAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of officers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfSquareFootOfFacilityLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of square foot of facility leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfSquareFootOfFacilityLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionsToExtendNumberOfTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Options to extend number of terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionsToExtendNumberOfTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PeriodOfExtendedLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of extended lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PeriodOfExtendedLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid balance included in prepaid expenses and other current assets and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PrepaymentOfFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment of funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PrepaymentOfFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party agreement renewal term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyInstallmentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party installment payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyInstallmentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyTransactionConditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction conditional payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyTransactionConditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_RelatedPartyTransactionInitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party transaction initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_RelatedPartyTransactionInitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expense ratable payment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantBioScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibrx_NantCancerStemCellLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibrx_NantCancerStemCellLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibrx_SorrentoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibrx_SorrentoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ibrx_NantBioScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ibrx_NantBioScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_AmendmentToExtendLeaseTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_AmendmentToExtendLeaseTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_SharedServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=ibrx_ReimbursementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioScienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantBioScienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCancerStemCellLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibrx_BioreactorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibrx_BioreactorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_EmployeeBonusesPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_EmployeeBonusesPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantOmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ibrx_NantOmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_VendorCostsPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_VendorCostsPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DougStLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_DougStLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ibrx_ElSegundoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ibrx_ElSegundoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_DuleyRoadLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_SixZeroFiveNashLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibrx_ElSegundoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibrx_ElSegundoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_DemandPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_DemandPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibrx_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibrx_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ibrx_RelatedPartyNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ibrx_RelatedPartyNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantWorksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NCSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_NantMobileMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329510984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Additional Information (Detail)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Mar. 04, 2021</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">273,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Total amount authorized for repurchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized repurchase amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062325347576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 29, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 18, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 04, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 05, 2021 </div>
<div>Award </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,298<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_OptionExpirationDateExtendedPeriod', window );">Option expiration date extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfBoardOfDirectors', window );">Number of board of directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ModifiedOptionsExercisablePeriod', window );">Modified options exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,121<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue', window );">Estimated benefit at grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments', window );">Deemed dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,410<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based compensation arrangement by share-based payment award options vested number of shares | shares</a></td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share-based compensation arrangement by share-based payment award, award vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-third of the Option Grant&#160;(i.e.,&#160;250,000 options) shall vest in equal installments on each of the first, second, and third anniversaries of the date of grant, such that all shares shall be fully vested on the third&#160;anniversary of the date of grant, subject to Mr.&#160;Adcock remaining in continuous service as defined in the 2015&#160;Plan through the applicable vesting dates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock option exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">752,310<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock Options, Vested and Exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,815,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,345,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,943<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based compensation arrangement by share-based payment award options vested number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,521,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantCell, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantCell, Inc. | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantCell, Inc. | Selling General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantCell, Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Outstanding RSUs | NantCell, Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share-based compensation arrangement by share-based payment award, award requisite service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">70 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember', window );">Modification of Stock Options Associated with Postponement of Termination Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibrx_NonEmployeeDirectorMember', window );">Non-employee Director | Modification of Stock Options Associated with Resignation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember', window );">Two Thousand Fifteen Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future grants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_NumberOfAwardsGranted', window );">Number of awards granted | Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember', window );">Two Thousand Fifteen Equity Incentive Plan | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options, options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options granted | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Options granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember', window );">Two Thousand Fifteen Equity Incentive Plan | Outstanding RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_FirstRSUAwardMember', window );">First RSU Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_SecondRSUAwardMember', window );">Second RSU Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_MergerExchangeRatio', window );">Merger exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember', window );">NC 2015 Plan | NantCell, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grants of restricted stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,121,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_MergerExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Merger exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_MergerExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ModifiedOptionsExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Modified options exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ModifiedOptionsExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_NumberOfBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of board of directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_NumberOfBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_OptionExpirationDateExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option expiration date extended period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_OptionExpirationDateExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ibrx_NantCellIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ibrx_NantCellIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ibrx_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ibrx_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibrx_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibrx_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=ibrx_ModificationOfStockOptionsAssociatedWithResignationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=ibrx_ModificationOfStockOptionsAssociatedWithResignationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_FirstRSUAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_FirstRSUAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_SecondRSUAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_SecondRSUAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibrx_NantCellTwoThousandAndFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062489815160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 15,298<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">6,355<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">8,943<span></span>
</td>
<td class="nump">350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,888<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 12,410<span></span>
</td>
<td class="nump">$ 319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062423448616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Detail) - Stock Option - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Beginning Balance</a></td>
<td class="nump">4,996,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Options granted</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Options exercised</a></td>
<td class="num">(752,310)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock Options,Options forfeited</a></td>
<td class="num">(15,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Ending Balance</a></td>
<td class="nump">4,978,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,996,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock Options, Vested and Exercisable</a></td>
<td class="nump">3,815,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,345,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning balance</a></td>
<td class="nump">$ 9.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options granted</a></td>
<td class="nump">23.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options exercised</a></td>
<td class="nump">2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options forfeited</a></td>
<td class="nump">6.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending balance</a></td>
<td class="nump">13.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Exercisable</a></td>
<td class="nump">$ 12.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance</a></td>
<td class="nump">$ 29,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending balance</a></td>
<td class="nump">54,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Exercisable</a></td>
<td class="nump">$ 46,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Outstanding</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Vested and Exercisable</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062322419560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option - Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">100.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice', window );">Weighted-average grant date fair value</a></td>
<td class="nump">$ 18.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062328719752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSUs Activity (Detail) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning balance | shares</a></td>
<td class="nump">466,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">7,521,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(235,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Forfeited/canceled | shares</a></td>
<td class="num">(116,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending balance | shares</a></td>
<td class="nump">7,636,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, beginning balance | $ / shares</a></td>
<td class="nump">$ 2.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">25.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">16.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited/canceled | $ / shares</a></td>
<td class="nump">25.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Unvested, ending balance | $ / shares</a></td>
<td class="nump">$ 24.23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062329287000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Company's effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KR', window );">South Korea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140062322824744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Subsequent Events - Maximum<br></strong></div></th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | Work Order 1</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ExpectedClinicalTrialExpense', window );">Expected clinical trial expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember', window );">Immuno-Oncology Clinic, Inc. | Work Order 2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_ExpectedClinicalTrialExpense', window );">Expected clinical trial expense</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 500,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ibrx_PercentageOfSalesAgentCommission', window );">Percentage of sales agent commission</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate market price of shares that may issue under a registered offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_ExpectedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected clinical trial expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_ExpectedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibrx_PercentageOfSalesAgentCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales agent commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibrx_PercentageOfSalesAgentCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ibrx_ImmunoOncologyClinicIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibrx_WorkOrderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibrx_WorkOrderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibrx_WorkOrderTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibrx_WorkOrderTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibrx_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -" KE('04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #0@*Y2#>SVB.X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.NF@AZC+91,GD)"8!.(6)=X6K6FBQ*C=V].6K1."!^ 8^\_G
MSY(;$Z4)"5]2B)C(8;X;?-ME:>*:'8FB!,CFB%[G<DQT8W,?DM<T/M,!HC8G
M?4"H.*_!(VFK2<,$+.)"9*JQ1IJ$FD*ZX*U9\/$SM3/,&L 6/7:4090"F)HF
MQO/0-G #3##"Y/-W >U"G*M_8N<.L$MRR&Y)]7U?]JLY-^X@X/WYZ75>MW!=
M)MT9'']E)^D<<<VND]]6F^WND:F*5Z+@#X6XWXE:\EJ*ZF-R_>%W$_;!NKW[
MQ\970=7 K[M07U!+ P04    " #0@*Y2F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M -" KE(\L5\K204  (,5   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
ME9A=<^(V%(:OM[]"0SN==B8$2X( VX090I)=VLTGV;;;3B^$+; GMN7*<@C_
MOD>VL9.,.:8WB;_.R^,CZ3W'.MTH_93Z4AKR$H5Q>M;QC4D^]GJIZ\M(I,<J
MD3'<62D="0.G>MU+$RV%EP=%88\YSDDO$D'<F9SFU^[TY%1E)@QB>:=)FD61
MT-MS&:K-68=V=A<>@K5O[(7>Y#01:[F0YFMRI^&L5ZEX023C-% QT7)UUIG2
MCS/.;$#^Q.^!W*2OCHE]E:523_9D[IUU'$LD0^D:*R'@W[.<R3"T2L#Q;RG:
MJ7[3!KX^WJE?Y2\/+[,4J9RI\(_ ,_Y99]0AGER)+#0/:O-9EB\TL'JN"M/\
M+]D4S_;['>)FJ5%1&0P$41 7_\5+F8C7 6Q/ "L#V+L RO<$\#* YR]:D.6O
M=2&,F)QJM2':/@UJ]B#/31X-;Q/$=A@71L/= .+,Y$*Y&8R*(2+VR&5L K,E
M\[B8'C;-79+Z0LOTM&?@UVQ,SRV5SPMEMD>9DVL5&S\%54]Z;^-[0%FALAWJ
M.4,%KX4^)IP>$>8PVL S:PO?$LJ:HM_0\"IQ/)?C>^1FZEEJ\O=TF1H-<_$?
M1+)?2?9SR7[;6#QN$]F4<#R<.MU[A&)040Q0F2D@>#G&52C631AX_$J$J40X
M3BJ.D\.R<2=UH.SD] A,\<;$X$J[B?/=AP\M@S^LV(:'L5T%J2M"\DT*3:[@
M8N,ZP;5:D$85TNA_(959VPN%J]UC2.,*:8R*/&KA!?&:++;14H5-$'C\_/SA
M3P2#.K7'.:A0Z6L/<AW8U0I)NA%1XT1J$9I?7W^]F3]^.Y_?'I'YS>P8PWME
MP?00O!F,GH:1FX-?OI#?Y+81$)=R'(=R=D*I@Y&QFHRA<K-,Z_?3'%N'+7+=
M+F5=CDTM6MLOY8<D[2H(P89GP+-6NCECN,Z-BKO"=:&OT"#B%8(88>WF%/?C
MDO RDGIME\$G4# ^F:DH$7$S*B[8YJRTMGB*>W2)MHA$&)+S+(7;:7.)QW6,
MSE"@VNLI;M&[):"B")J.A5'NTQ%9Y)T'N<U,:J ]@1PV5?U2>9 KVZ[U><)'
M?.P,1GU8!,]-6+7-4]R;=UCE,GB0B=(FMS0C3+.OMBA^>]]*O26KW9[B!EVU
M:D;JHA6VBU+L4!O)<,46LMKT*>[:N[GE0VN.3G9<IFVRL]K]&6[:CX$))5$K
MZ/Y^6OY,%M+--! V,;4HO9V>B= _?D]/G%^>19C)XO 'Y]A:,$G E/+&&7N#
MND PW-5WR.3RQ?5%O)9[ZU>+T,UT<3'%FD16EP:&>_DK_R4W6;1\;YHE#RX"
MJ>KRX< 98DAU26 'E81Y["H-"S7_@#G*ERH,/Q0)E4&!M2;C-><.5[^XQ"#K
MJL .J@J/XH7,/5BIP2IPBT\M)(NX9)]WZ7@X'@[Z&&%='-A!Q6'J>>"^Z='N
M@'R!Y\AMW)P[7)(/N$-^57Y,/JOD*8A3.QC:8+AUZ6 'E8X*=V;/8+@?U29N
M1,7E%B(F%P%T$QA<74#8006D@JLFXYU6ST'L-B<3UYQ-,;2Z@K"#*DB%=J>@
MRH;DKR#9OT)PQ3&CZ*<,JVL(P\T_'\.IEF(_"BXP&HRP;_RZ=G#<\;^H_%O*
M5S'F<BTB)YQW'>Y@+3FO:P''+;SZSKO/A(;B'V[+MJ01#-=J:=]X70PX[N/U
MS@5\7:5!;F<(%2ZVM_+W7FUSV:8ZW_U+B6M]O=CQJJY6.XS3?%^M5S]>;$]>
M"]N3IR24*PAUCH?@7[K8\2M.C$KR3;.E,D9%^:$OA2>U?0#NKY0RNQ/[ ]6^
MZ^0_4$L#!!0    ( -" KE+ H =KZ08  "$<   8    >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&ULK9G;;MLX$(9?A? 6BQ:P8Y'4L3D ;8+%]F+;HFEWKQF9
MCH5*HI>D<MBGWZ&D2+9(L0G:BS:2/:3^&0WG&])G]T)^5SO.-7JHREJ=+W9:
M[]^NURK?\8JI$['G-7RS%;)B&F[E[5KM)6>;=E!5KDD0Q.N*%?7BXJS][+.\
M.!.-+HN:?Y9(-57%Y.-[7HK[\P5>/'WPI;C=:?/!^N)LSV[Y-=??]I\EW*V'
M639%Q6M5B!I)OCU?O,-O+VEL!K06?Q?\7AU<(^/*C1#?S<V'S?DB,(IXR7-M
MIF#PYXY?\K(T,X&.?_M)%\,SS<##ZZ?9_VB=!V=NF.*7HORGV.C=^2)=H W?
MLJ;47\3]G[QW*#+SY:)4[?_HOK<-%BAOE!95/Q@45$7=_64/?2 .!N!P9@#I
M!Y#G#J#] -HZVBEKW;IBFEV<27&/I+&&V<Q%&YMV-'A3U.8U7FL)WQ8P3E]<
MBGH#+X5OT*6H;N!+<U$K418;IN'F/2M9G7-T;9Z@T I]N[Y"KU^]0:]04:.O
M.]$H5F_4V5J#&#/E.N\?_+Y[,)EY\%],GB"*EX@$!#N&7_J'7_%\&!X<#U]#
M"(8XD"$.I)V/SL6AD9+7&C&EP,^WGAGI,"-M9PSG9F1JAR V*#<7_-^FN&,E
M/,(9JVZJN)W*K+R[BS",D^QL?7<8$MN*AAF.!JLCG>&@,_3JA!?QG6MV4W*D
M>-[(0A?<J;&;)CI\>AIEX42C;15C',9NC=&@,?)JO&HXVDI10>$HV[3<,SDG
M,[($D"!*)BI=1@%UBXP'D;%7Y&?)]ZS8(/ZP-RM*M2]?Z!V7L) /LPN]+NJ\
M;#9%?8M8)1K("5CU>C?U[HW+O=A2CD,2DHE_#BL:AYG;P61P,/$Z^%5H5DY\
M<4E,K(=G691,)=I6&.,$S[R$=-"8OCR;EZ@6=:_;)3BUI01!,-%K&V51X!:;
M#6*S'V0,X%CJQR7:0Y75;<*80K$'3FH0S9UJ,TM(&J1)-)%K6R4D"K%;, Y&
M7 1>R1]%O:K&&!NU^A%0<,>5-JK1ZX]"<Q0Z<[>?^U#4-,H.DR2=2UQ\0#GL
ME?VAUJR^+8SD-F]G@]O/<[R^:#I5Z;**9U(7CPS"Q(\, 7&$I6]DUB:,DN<<
ML 'W3JW$46LS/-7JLB)S$1WIAOUX^P29R[0I826'-@I)TR^MQ';5J#[&J@WR
M3Q6[7L-1G-,PG%9SIQD^>&O'/HYDQ'XT?FJ+]R\HVMBF(LZ"Z9)U6)$HF_-B
M9"?VP[,KV_/E&KM@F(7$2GJ''8$HS]64D9LX?E;O51;LIBC;BNUKP/#(*^P'
MUKL\[U[4GCW.+B*;0] *9%:*N7 5X1D X!%7V,\KD"@;[FP:#L+A%&X#B4++
M2*?"G6;)W$L;T87][#(MF1;/:<BPC2*<I-B*L,,L3.<6,1F)1?S$FA:J@[#^
MU)HF-JDB',43KUQ6P5S+3D:>$3_/CENQ'V0*L6F59&D\S12'60Q5-)S1>K"S
M\E/M2Q?,E0GF8\LU[X(D-J](EI#4BJS#+@II-$-A,I*-O(QL!]%=PD=*#7'?
M"]F>1?Q4&CG8%4?1=%OE-,/)#,;)B#CB1]P5WW)P9@,M7"XJ6-+L87#XT:G7
M@;)DVL7]P.A8ZP@RX@?9I^>416)3*K5Z(H<1#NC<JAQ!1OP[P&Y5_DB@O3>C
M69C$UAMWV-$LG:O<9*0B\5/Q4E15T3;K'6UR49MLYW7>EL2V?T_=N6I#T'KS
M/I-CP2,C2>KM#ZZUR+_O1+GA4OW^6TIP<FI.ZHJ\T+X^@8PL(WZ6F8C ,E;F
M.4OT*CB!W1\VJQ;=L;+AIR@*@F70_4-JQZ3A=*-W0A;_\<TIHBE=!G&RI 2W
M$:4I69*0+F%G_F1>*&4PW]*]T0IV(UVY4$AL$6Q:\]UP&-8:74'G7]U NC^=
M<2VAFJ@];T\]R\=3:!B>2HZ64*8:^?BD'\=TF8Y"?\7CG,E@\]K:)_EMCH_5
M1J!3/]#?;3:%*;NPU,QYRZJH4<[V!2P]Y\F:#6 <!6D63;6Z#,,LPG/;.CK"
MFOIA#3U>4S4="OJ\=2JU^;O",92&<+I1<%M".TIGB@,=84W]L#[4VI]=B6HO
M^<Z<W-]Q]+H42KWI:>'TPL;RRLH+AQ$F9$;[P8&K']Q=^?U054T-\'I?B&Y%
MN"N'4[L-V15.HR2=]JI.0YREP5QRCSRF?AY_%+6IQU*4I5FP1:TY+,290V.;
MLF$T19W#"-)D3N?(8OJ<3>5+XVMCU\27TFEOYS2$G7\VPQ(Z(IJ^$-%M^7NI
M'[%U$._<,;OL7#OF]<'O-^;',RC0MT6MH-G<PL#@)(% R.[WJ.Y&BWW[D\Z-
MT%I4[>6.,U!O#.#[K0"(]S?F5Z+A5\&+_P%02P,$%     @ T("N4H-B./2;
M @  4P<  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R5E=]OVC 0Q_\5
M*]K#)G7D%R15!9%:JFI[F(;*?CQ,>S#)0:PZ=F8[T/:OW]D)$6T#;7D _[CO
MW>?.YCS=276G2P!#[BLN],PKC:DO?%_G)514CV0- G?64E74X%1M?%TKH(43
M5=R/@B#Q*\J$ETW=VD)E4]D8S@0L%-%-55'U< 5<[F9>Z.T7;MFF-';!SZ8U
MW< 2S,]ZH7#F]UX*5H'03 JB8#WS+L.+>6KMG<$O!CM],"8VDY64=W;RM9AY
M@04"#KFQ'BC^;&$.G%M'B/&O\^GU(:WP<+SW?N-RQUQ65,-<\M^L,.7,._=(
M 6O:<',K=U^@RV=B_>62:_=-=JUMFG@D;[2152=&@HJ)]I?>=W4X$(3C(X*H
M$T1O%<2=(':)MF0NK6MJ:#95<D>4M49O=N!JX]28#1/V%)=&X2Y#G<GF4A1X
M)E"0N:Q6N&D'0DO."FIP<D4Y%3F0I8V@R<<%52!,"8;EE'\BG\D'XA-=XJJ>
M^@:!K%L_[X)?M<&C(\&_434B<7A&HB *!^3ST_)KR'MY\%3N8QGZ6D1]+2+G
M+S[B;VDP9;RAAGQ?DQLF,'%&.5E(S=R5^W.YTD;AQ?M[(EC<!XM=L/'1PE<5
M^L0#SN_.2$T5V5+>P% 16T>I<V3_E=LL& 5!@!7;'A;K5;,GG..><_P.SO:D
M"6U,*15[A&*(MW4X.0"9!-WG&?);+)]03WKJR?NIF=;-,/'D!4=\'@=)&D?/
MBSQD&47C.!Q'P\1)3YR\GQC;KC94%$QLAK"3-V,/69[$3GOL]"3V#WPZ=*,>
MR+(%7QYM!>D+A#")SU]<B5?-6DS_H.79YP9;R88)33BL41B,4O2@VA;>3HRL
M71=<28,]U0U+?/5 60/<7TMI]A/;6/MW-/L/4$L#!!0    ( -" KE(E*A>7
MY 0  # 1   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULI5AM;]LV$/XK
MA%<,"1!'HB3K)7,,).Z*!5BW(&G7#\,^T!9M"9%(CZ3L]-_O1,F2(E%JL7Z)
M)>KN^#S'>^%E>>+B12:4*O2:9TS>SA*E#C>6);<)S8F\Y@?*X,N.BYPH>!5[
M2QX$);%6RC/+L6W?RDG*9JNE7GL4JR4O5)8R^BB0+/*<B*_W-..GVQF>G1>>
MTGVBR@5KM3R0/7VFZO/A4<";U5B)TYPRF7*&!-W=SN[PS=K1"EKBKY2>9.<9
ME50VG+^4+P_Q[<PN$=&,;E5I@L#/D:YIEI66 ,>_M=%9LV>IV'T^6_^@R0.9
M#9%TS;,O::R2VUDX0S'=D2)33_ST&ZT)+4I[6YY)_1>=:EE[AK:%5#ROE0%!
MGK+JE[S6CN@H@!VS@E,K.'T%;T3!K15<3;1"IFF])XJLEH*?D"BEP5KYH'VC
MM8%-RLIC?%8"OJ:@IU9KSF(X%!JC-<\W\+%\8))G:4P4O#PK^(%C4Q+Q'?KS
M0 4IW2_1Q6=&BC@%F4LT1Y^?WZ.+=Y?H'4H9^I3P0A(6RZ6E &*YD;6MX=Q7
M<)P1."[ZR)E*)/H58,5O]2V@UO!SSOSNG4F#'XFX1BZ^0H[M8 .>]?>KVQ-P
MW,;=KK;GCMA[8%N>T]:KZ.^[C50"@OF?">M>8]W3UKT1ZT_T2%E!36ZO%'VM
M6*;V<87=:&D=NZXPR/B+1N8-HD6#:#')MPX8MD?T]5#&F;R9X.DW5OUO\)24
MB&V"(,@@9X]0C [:FQ<IVV80E; ?R7E11NTI50G4FTQ'\X$(E5)Y:?)0M>6B
MP][#V E[/AI*.8$;>&8O!0V?8)+/,U0QP'R%]I2!OS+-B\20[FD9'&6A^R%J
MP9#:P@D6/6I#J<B+7#.SL&$63C+[Q!70X8,H,*$,!_N'OF>[/91#*=</_< ,
M,VI@1I,P?^=2HIW@^1DJ5#@3Q&BP^3ST'=_K832(N7Y@.V:0V&YKM3V=32JA
M BJLKB$7M2\OIS(*=_H GG3! U-44*ET[*7L"(\ZI:K=KA"CREC.\?#4(J_O
M$(-4$(YXPVD1.]^'N';$#Z5(O=?;,\-^/_U-8C@,HQ$N;5O [B27[LEJ7_\8
M&7> $O?SR"2#[9%"AML.A*=;4)WPQD U0O4&,!9!V.],!JEY8(\D/6Z;$UY\
M.^TW%"[#] Q6D5<J=0XP#BM,":YK,WROHLU\J5D8"H/M#4JL20ZZAST6/VU#
MQ-,=\:%!?\X&(\QA]YK[?8@&&3R6JVV#P],=[@^(Z R\;40U;#RE\T+<1V:0
M ^<Y8V'0]B@\W:3.X!!12J2;0I%-!K[DHR%092C<A\'?1D;#)C7O]JB:CT'*
M'2TE;2O#T[ULE,U#GA<L55_O4XX@6G(8HF"\V+XD/(NI,!]--+@2SH/(QX/Z
M;I!S ]L=B1NG[7B._7UDH"T;"20$<O?GGT('XU_*>2[=5I?"-"M4?X"HYX5J
MQ["+U;YV^M%F%L,CA-HVZTRWV2]ZKJ3QG!SAHK&GB!7Y!KA!,'4I2524,QD,
M4[!Z*/3=B75]\7^(#YNP&SJ!A[W!!<8D&N HC!RW?XFQ.K-G3L5>C^028$/+
MJL:T9K49^^_TL-M;O\<WZVIX;\U4_TN (6R?PLB9T1V8M*\#P"6J\;QZ4?R@
M)]P-5S OZ\>$$@CJ4@"^[SA7YY=R@^:?)*O_ %!+ P04    " #0@*Y2=A1N
MQ+,#   4"P  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM;*56VV[C-A#]
M%4+8AP381+(D6W9@&XB]+1I@MQLDF_:AZ ,MC2TV%.F2E)WTZSN4%,66:6T7
M?;%YF<LY,\/13/=2/>L<P)"7@@L]\W)CMC>^K],<"JJOY18$WJRE*JC!K=KX
M>JN 9I52P?TP"$9^09GPYM/J[%[-I[(TG FX5T2714'5ZP*XW,^\@?=V\, V
MN;$'_GRZI1MX!/.TO5>X\ULK&2M :"8%4;">>;>#F^4@M J5Q&\,]OI@32R5
ME93/=G.7S;S (@(.J;$F*/[M8 F<6TN(X^_&J-?ZM(J'ZS?K/U?DD<R*:EA*
M_CO+3#[SQA[)8$U+;A[D_A=H" VMO51R7?V2?2,;>"0MM9%%HXP("B;J?_K2
M!.)  >VX%<)&(>PJQ&<4HD8AJHC6R"I:GZBA\ZF2>Z*L-%JSBRHVE3:R8<*F
M\=$HO&6H9^9+*3),"F1D*8L57MJ%T)*SC!K</!K\P[093>3:RF"QY#:+.R"?
MI=;DXDG0,F,H>TFNR-/C)W+QX9)\($R0;[DL-169GOH&H5J'?MK 6M2PPC.P
M(O)%"I-K\A/"RX[U?:38\@S?>"["7H-?J+HFT> C"8-PX,"S_._J00^<J U[
M5-F+SMAKPTJ^KLF=2&4!Y%9DG0 W%W_<KK116/!_]GB.6\]QY3D^X_E7; T<
M$^?*2:TYJC3M^]_-K\9!/,9X[0Y#Y1"+DCA,6K$C8,,6V+ W)%]-#HJD1P&X
ML$@OL99L'#X2@=BQ"NLM,?0%]$U/2$:MY]%W0U(*;(*<_8,E;WT"ECOVF!UE
MG*XX7&&_O-*4 ]&0EHH9!LX UGZ&AY'I!L\A$L;NR"4M_J07/_8S[%8"VX52
M(-)7@L4B-*=UG\S^PBY2O6 7XL2!>!1V,)\*)8$;\KB%/.Z%_  IIUJS-4MK
MF)A6F]T?38*M!5YBB[#]1O24]OB$0M0A>2HQ<'.<M!PGO1R_24,YD=\K:Q?:
MB2LK00?PJ5!\Y@D.@O>O0="+^;C_G MF8V1XW"A&<;?677)1$HW/%,_@X*,U
M^$&8A!JCV*HTME*(D41(C*XP2G)4WF"L#2C0[D?0>#OF,TJZ;!Q2T7ARADOX
MSB7\7USNBJ(4S+PNF+1E5."3P*D@?<XEST"Y^82G'3J9)$G<9>20BT:32;?P
M_8/YH@"UJ<8NC6A*8>I/<'O:CG:WU4#3.5_8D:^:6][-U/,B?F W3&C"88TF
M@^L$PZSJ$:S>&+FMIIB5-#@35<L<QU905@#OUU*:MXUUT ["\W\!4$L#!!0
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M0O*Z^0N>6ZPU LF^IJ1H@UD&158>/N.75HBS &CW!* V  T-L-L 6PA ?D^
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M]#&#Z%IGRVTWK9,9A3_H1@47VC,>;(47AX$3B@9% 12'^0+*GA8ZH<M.$^*
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MX?M<WZGG?XE.H;F9+U5YW?Q%SYUL-$'IOM:JZ 8#@D*6[7_^TAGB8 #,XQ]
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M9G4+M3>>\2SU%GPC;U+.CE=&H7.?1HF#E3(Z'RCD"N'E8N[7:-EKM QJ]%D
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M*IK+K>"9J(P _+Y1P#S=C7E!_UG*]=]02P,$%     @ T("N4E,K('\;#
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M6>.)UTN3;D6R]>86$1.KBBFPM,8K74#G7KPGVE>YL3H!FC-00V)-N0&?-O)
MN_W4."7<%OFIO$YJ)T#9"CZ&D9 X/A%-2+$G5Y"X/5#L3B8)J9- 9\H<17&Y
M ZV7\ 1%EGWA5&**M(L/F:K"W&E;.;9Z<YY.(^%5LBD8!,$'O<D)8K7J0\,^
M )BM#AQ6:[*R)N=(7[__ZP_S>+AXOHCYE:"D8$E!]WZF;U7KPKXJ-H3?]'&I
MO;P6EJCK]R?A$)E!.57 6R145IZ499": BX;4,*8>U@GEM;(-!()--")S/H
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M(J(EB/!!YT'H;#28_J6)YQ\"_:1F8=XF?QR<U65.R4^>]$N=:8\H%<__E%*
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M#XXS->@TP6,YICP\<2?/CC[SUNYE]L'6HX;$^</[>Y2LHRMJOANR?4,WDR%
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MMECJ-7F7)=$0&'2"YK]AE28N!.'"=!]U^ N> #>&\,[0<@'$!VL0;,U?OI9
MBT X? CO;#7SIVQCP$DH=JNOV)%.1BN< $[/V#(&A"Z1NPRA"4F #P051^R!
MJ6%QL@:.%]MT#L2(/1%')FOY<;'H>G_%)!YLE,10'2_R0;LU=N[ (K.V4I P
M?,%'U!#@!>31RE40NHNJD72"%G]=&)Q/8J%3!EUL6=VRALBW]T[S&]M7B%I
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M&6X(Q+G3A_VB4)!  T\C;')#U4D"5.KRUI$-%+YJO4$H,=A*O?:1UQK&L4K
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M+8$'KSI55W##LB2)%JOY\.\UW'6F"QS0[YA&;5O+BBB=%X3#:<JN],;=H#X
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M9'05?RP54N]I 7Y?.Q>[+W1 _U;]XM]02P,$%     @ T("N4O)4IU@U'
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M2TAN;]*\B>2UDHWIKUV#=,GB'I^Z)O0)I' ZJ(-E]+KT!KXPPR1:[FGS?BD
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ML1HMB5]T:I4T@,5-_VTF(=%!.(M.=W(N'"7@.%")NF;:_Y'TPM;W)KA8N&-
M0KO,>:C[.H0'1Q#<QBHU%P(HR".@ER;)KCMZJ'XD)2Y#91%6GGG(1K12A\V'
M)<74$CHUB-[ PM(E[33(6%PF&T0#Y'YA?..<]XS8QO9]VYY=]URG;1MTJL>Z
M"RJ$CFTX1@0@?D\C=2\@2B*.0F?W*.+;)FGLV0Q.\*@N"ND* 0^&U4R"JS19
M&:HW[A$LIX&)RP[UN7'< 'B[6+2DTVMR/4E!L"OVQ/8GWW>W)]<%I-R1 KRV
M%"G&*G-:A2[U E+IR+KE7CMURX!"U\F&NPS@+<5>MD'8AIG]K1^]6^'=]'YM
M^1 ]TU*]R B"PCY$Z(*(3_5-$$>^^[KH6)-X_M1$V-5V1(N(?,OVB@PKU-/X
MF:WT[A-GT&,O#>N'23/&>#0Z#^=V.DI^:P'7EC5%MGXER4GRQ%A.]]RVB0*P
M\#G"#(4U:&%P*.E9K0XE4T(Z;>J6"2/!E.RV)7[MIP_I!*FN!16ZY;KI;=P&
M#CVH6B%$9<#!<1%7U7.[[.JU_$#?S1CT'MFQR:4J+;6K.V/4![0JOGU+"DS>
M2IWBK*5GLOIHZWOUQA\43)3_8V_[2KV7C3,6<&(%?MMAY^' _J#^+I ZE#U:
M4CH^S0 EW9IVP#4O;/W$Y!J=4"IVH&9IF+JR&JTP>T)&;!81!;\\(,Y.M<S3
M>-=.@HX-U$^:KC5-V+SB01N[5V]PIF)NG[KE1TCUJ1O>&8UP[8D[/AO[]!2W
M!,&VIG#IB7L0Z=]_@0Z<C*L8BZ77B=@!-]U(6 :/[P^,P5RE0E3P*+;;8S<]
MYJ,U."/E#^%LW!=.T]APT%)456?A(M\FN,\V*M\!H(NV:"PYJO1NS5L-K&2_
M#^^&@H(XJ#KP@(,G_U"0\L^P>Y6"JSJ<F=(;B*B/&)+.R6)MS4',2K;H5ORP
M+D+W=9KH9C</DW+(D!Z)H]%'+SNH[Y,19_7K\@<>>,.#@C"=&1I[VQ8(?6]M
MWT,DHQD$=-GB=)L4!7BL$+-Q)ILF_.2J2N+>=#:MMJG9,\%[6Y':5@/UIG"5
MS6EP/%N;L ;+-AK'7P;JLZX1O38XGKB/E73_.]?:>D4A&FBC/+32N=L_8'O=
M-,5G-VDKPH+WI(F$[BT.X-0[.'TD;9^_DYJ(\#_I%2E_B=WQ@2B2.DS/_PYV
M\&=+6H*UOU(@HZ[5("+H!XY@;[I&0K@PK]Y>%0L?E03')AL]L,<N$GUP4I<J
M^?0H&GQ]+93&R96W26%06J]#=3<8$W>"2>-J_>*@W_1PL-7P<'#X>ZG)E&@1
M1P>?^;46<%?8\YP9'PEV%@Z:#\Z'ET+,P=GPVG_:&LGA)6\5$W\.K@_^@7^^
MEVM! ;QTMD_]O-PC6?MSD'5LD.S:;P\YR*+0 FG%T8N#3WR$.GW]1-?><< K
MW5K<;QMHQ9U1!]\<C >GY\_I[^G@^=7XX ^*8.2<5W+3Y>7EP=7YU<$GAS<(
M; Z_.CWCOY=GHX-;G,!=:BOM?UU/1E=WD@X5C>[E</A]&SU[0OSW+I[/"$]Y
M7I"X@>$U,^+R^37_/;NX.'@C!V"!FXMVX6F-1V'UCLZ:%)Z_.4_:9Y+\W2WC
M>0-)'!,%\U4$?T8RG")-LMV)X=.UCR@IU,A9Y(0M=])T3.Z4IV&!]KDH+]60
M1%9+=1=[QEEZ*+#1CT:.[R+<VQ!BPH7AP7^Q;1JI4"<V]B)A_#OA+V=UAUPI
MBAL!7WPAP!&)XV)P>GV&X>.#R\'5U34^GN'JV04^GA^<#2[I-_IX01]/K\X.
M/L44@+3S_.JYU]_I4Q(]&%\.+D;7!^],7;^0?)6"B8/SP?/KZX,/PN/NG0A/
M1  P"3*IT]'!V[2MD_5CTC:H_4A.DI[!B1KT8#;+*O* C=V5R]$%13SUW!<'
MM]Y.P@=')VA\D_&;)]?!R#-5XQ"R0<\D)W.[0PJ?'T7/0)^Y8X>"5_*4EB:#
M.2W[IYR>]&6R&Q&;(GVLU>*T#9Q!W-/B%T+XMZ1$W:*K_NQA3+ZP)[J,QQK%
MJIHX,>-1F1XM9*T[YM<4P.QV/>-L-%2OF*S0L!=:%.():I[<UENO!!@-SD8C
MU*I$KT5>W#A:MKS!)6_)P#QG_^CI "YQ79))2S9!4L^)I1/03).CN8/TWL )
MNI53E[#NP:XMDOA2D[A3YE]< ;_*?8E,4]=R%S):CQ"]6-C[LOIK(P6VTJ2*
M5+KN=+LDK'*6O>[A)Q%F'LE5=K:7G&+P92U7F^ZH.C2;B;D*HL,W1F!Y)Y#A
M]PIUY\C>6. AGG^'XG@XD-_W9']C*#UU.ZD4_[$5E>QJSCR]!H0'V.RGFO%(
M*_G#Q[F=V$9=7P_'@5.WTC9),L#N'_>9HX!ZA6QP=/WREY,;/SYFM7<F(UV2
M-(1(^2&\R(??Q%378<_D[H?;0;?/.);^\]/^"YL^F[@_*(4= ;1RK6H[*U&J
MUO(Z&2[ UW_K13&#6#GF+8$M@8N?ROA03BT=9B*NWHG!:117'<6U833>/G11
M.ZY8L/*[6._IJ.\U3W4!M:MFNO0[0[&35^[I,#&^RJ&+F$,EE:$GV3MV92P)
M1YF91TR7],'RQ94/LM+1LAT8MUF8U9:+<=XTTIO#.9+8F+6Q0;W#?K<LUZ+4
M%'N741,+#959HBG_;[;_MV:[Z]UO)\G;]KBQ'-374EJ6%^_%J_&UA3?RMK[N
M=GGG(9GN#&7UPDQIZ&CX_.*9E%;"E\8M^=U]$]<T;L$?YT:3M\(-]/O4D>C]
M%SP@OLSQ^_\%4$L#!!0    ( -" KE*A NEIF!4  )I.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;.5<6W/;1K)^YZ] ^3BGY"J(XD4DI<1QE2TG
M66=C6Q4YR</6>0"!(3EK ,-@ %'<7W^^[ID!!N!%M#?9]9[SD)@D@)F^]]?=
M SW?J.*C7@E1!@]9FNMOGZS*<OWUQ86.5R*+=%^M18XK"U5D48FOQ?)"KPL1
M)?Q0EEZ,!H/I11;)_,F+Y_S;;?'BN:K*5.;BM@ATE651L7TE4K7Y]LGPB?OA
M9[E<E?3#Q8OGZV@I[D3YR_JVP+>+>I5$9B+74N5!(1;?/GDY_/K5)=W/-_PJ
MQ49[GP/B9*[41_KR)OGVR8 ($JF(2UHAPC_WXD:D*2T$,GZW:SZIMZ0'_<]N
M]>^9=_ RC[2X4>EO,BE7WSZY>A(D8A%5:?FSVOQ%6'XFM%ZL4LW_#S;FWC%N
MCBM=JLP^# HRF9M_HP<K!^^!J\&!!T;V@1'3;39B*E]'9?3B>:$V04%W8S7Z
MP*SRTR!.YJ24N[+ 58GGRA<_BS0J11+<1D6Y#5XN"R$@\E(_ORBQ.MUS$=N5
M7IF51@=6&@=O55ZN=/!=GHBD_?P%J*I)&SG27HV.+O@V*OK!>!@&H\%H>&2]
M<<WJF-<;G\3JAR+*=<2FH8._O9SKLL"W_SFRSV6]SR7O<_D'B/3X2M?]X-!B
MP6\BB%6>5'$9S"N-![6&Z92K0(M[441I$"T6,I5X6 <5-%($FT*6I8 C-(M$
M>1+(G%T;#Q00R=)<Z0?LKX'$/<YA [4(X-:ZQ%,R7\(9TBB/A5DE@BOHN)!K
M]C7<J>4REPL91WD)YP43).B57.O@3.9!N5*5QG/ZV=<]Z#E>U8KNO1:QR.:@
MU_XRZ)W]DD=5(B&&9[W7E0@6A<K,FA#,F@7SW_]U-1H.OPG>8;M74O6>]H;A
MZ/JR_O>$Q]YG,M:]R?60_]O[@ 2S[I%?HT*"A]YP-NH-AU>]#ZJ$#),#CX&0
M43B8S,R_@S&O7ZHCY/Q&89GH'X6SZVOZ, BGD\'Q!U]7J=@&/ZLHZ8W#X72(
MS697L\<W(Y%=7X[YOZ,WO\FR*E?G[W/$';7<!C<P61GW)N!H-!L^OE%P$ZTE
M!-4;C2Y[?&'TS>-/W:XB6&AO"%;HOT;4G:>,H(>S\&I(DAY>AE?CJYYUH7.S
M;J[((];1-IJG8C]M>'("85]/6.K7X>AR>O(B;]5<IJ(WF86#V55O,@VGT\')
M#QN=3T90W:0W&8:34S>^N;OIC6?A^/*J-YZ&UX.AE5%Q^&&RQ.M9.+J:TJ?)
M93B>C'OOJR+X[D'$%:7*X&852<@]#]G#UX7,8[G&JDA*\<>52A%4PF"A*+HD
M?,LJHG"!L%06*DTI1LB\%(70)3XT'(;!9B7A\M+<G;H,C:B1(9G*=4JQ+5M'
M.3D<1PL1K$24EJLX*@1O58IXE1L;U.LH%OW@I;8A: YJYA2]L ^>B\")8#(H
MUL%B_#AG0J9'&:T=BZ($G/$C*$CS;L(BBRC&M1(7F;H$03=5:UJ3[LV!1I8B
M%R7B7YIN@TPEB(4@X-U?L7J::HBM0# M(%7%,7PMUX+"/_C8OVO G*=:=<BB
MW8VPMLXE[$\91&IU$<RWQ-D%-K47U"87!<7C1D4<WO?IO^]1\0NG$MJA^4W#
M/<&;%L6]Y'S@$DP@>"T6?/!.W9NX/AH,)R&2%BXO%H)16?"R6@+KV$O-RI#.
MO816076Q5@5X#EFNG-\HZR2 1))2-ZT2 ACE%3135@49'_\NEML0?J %9QEZ
MR-,575E6\!%5;(WJ.9YA];*0;.EN!;JHP#;AV35(*6MV^Y2*23DQQ+ $KZ1:
M$E CCQ+T@[MU6FEL&&F5L_O"-%1L$B,)7V3K5&V%@/'F8B%+&)JU,FF3K"$@
MD06D%F"7!?0#Z[+KL)CM1=I/@XK()M_:+MPF3K8D)Y_8/G)(X7XL5U DC)=A
MG6 W;R=KIHIR-+L:=E8%W?1TV+\"6$4((-R=\P\3]P-K8VWTGD*R, V =(H6
MQW0+4T(=HL5!5=8WO&1A[J%S!U@PT6I#;MEX&7RW#*(,48T]XFDP''69"8:#
M_NP0.Z1]*,1'67-1;H0P8:S<^ [L14($U[1*C*OL3VV!RJUK0Q/@-"%?GB-F
MT(=<JU0F?+O%90$7!3HP]DF!H]%/,.R/NSSUA_4OX!L5WCJ2B9.J"5BU1;-A
M<62=$V/K2!,Y,!=5+5=>".*HQ'C(D_ GZ*<M6B,K<C5?6#N4-IX25T5!ID'D
ME9\OOS<[P6O332G.4[=!"@&1&39!L)UB@I]^N@G)>?VDT\8^UHC6\- 'B<(3
MS ?7X60P0,U:$?L+JM8I7,.0B%!*@"2*FRH%]@]N)*UQ$Z42Z^0R<I*C],SZ
M KNXC_9CV@^Z5!K-*>BZX(AD_</;VTZ0=8SW@P\K(@+1"@[LI+#!EDV49TMX
M&VU9BK6YU'HGG:/P0(UM8@[89O6Y@%HO+N@6B#_C]9]> FP-R)M)T%&>5[@'
M%D*1UN3(\5?@>RGSW$"2X$=P0 4-R)BQ>N_$NFQH8/U&F0EXY4KZ&0T"$P^H
MHA+CS40#)V'<9,GJ<N5LO!_<(/4*8"@0X2BPUT)>K<6T8R"AW T&L/%3H#18
M03^XJ^9:_%Y9>G9V,JOY4I(4D*I2P9@L(L$>P"CD_6;;\U*=\P?J<4C".'A0
MFCP% H1DAS(XTLBYY!W*8#P(DFBK&8O.OB&8J)I:$Y"3+-1&!-4LPF*/$E1U
M'$,=4(M DC@O98:;32G9%KC'U"%!C[#T@CWT012QU :@'5OMT$+LIH2@9(Z
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M1EIIJRX],!V]JZ:"_)]P@I(6%G!GN\BPW(846A^C#:XRN988C-4V,[H"<WC
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M;<!-'C]+_#JQDPU8+ZP-NX$$V/^,S?\!4$L#!!0    ( -" KE+;,\BFKP4
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M)0:@0"X".K2*7![QLPI90E2RC$MZ[*%TFU/D[$5)1>>7+-P=:^24N#KQN.Z
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M59#!,CHC9S[,*W$7<*Q:.M(C(*E8BP8;1N3YRM!)[.J]MC)0D:+BAO\E#?S
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M#A!C'!$2[H)ZC*.0<1(%-*+^A $'LCV%&D^%&C]2J##H(,H 7Y0>:N]\RD>
M/TAW7X7NM_FT"AW]-Y-_N?-?2SC\FMI\)V&J;759S.GE08YI +-].(G)CIZ(
M\2".$\2B((7DG;6J+" ,BR@-DBP<_UY!N,ZT_?B%",'X!OAD$0]8R'W1,(8N
M]=K=".-K-(F!=P%+$_2F-;5RK0&^B:IY"75TZZ]\*89AZH\D1G\8;>U^W!"A
M,90;%"@0)@H9K-7:%_@TS]NJ[:D)E0;T5J+?(X"RJ+1QZGMW T51$$<QBDC
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M8^!"3SZ0I1RE09+PF<9>+N7:0OIATP(M-((FN'.5Z\JC-O2>@$498@'/R"0
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M>,MVPRE^UH"R!OA\+*5936R ^D.I_S=02P,$%     @ T("N4D;U"4;P!0
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MO2/5XAZI/MV%Z*GVZD7Q=&$Z=&MD]7$/V4@!%+V3CB+D[VRG#&^5R5[#\*U
M.)"\*Z/09[E'W=-U81&&;JM]US)%H64*1V2W;SIO0Q^C>[N16I->4*@.=K=*
M[R7Q+)UB^!'WPBQ81 9U3HLDG2-=H_NH @2XA[<[] />+.JSIX(^[%Q?0NVD
M2QJ5+?BKOLFT7]M[X&E]_;E;7E\BX0+8Y9@2*VP=#68(H*TO9O6+-^MP&5H:
MCZM5&!:XRPI+"S"_,B!V\T("VMOQR3]02P,$%     @ T("N4K7+65DP!
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MN<R9YM>R^"YRLSH?348TYPM6%^9!;K[P-I\8XV6RT/:7;EI;;T2S6AM9MLZ
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MV8[36MOI@?5]K&V@=8NU1*SP6F%6UG8[=YN.MJRM"(.MRZ8(P\+<M&Q7D_'
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M>=W<>IN.5?OZEG:O+-[YZN8._RF =@/P_58I^]1Q%[_NO\?\;U!+ P04
M" #0@*Y2/V]<I# #  !A"P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6S-5L%NXS80_15"IQ;81J(DV\K"-I XN^@"7<2(L=U#T0,CC2PB%*F25)S\
M_0XI158<Q\TMN5@D->_QS3Q:G/E.Z3M3 5CR4 MI%D%E;?,Y#$U>0<W,F6I
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M393)X(+:RH1.#1O4K7_L*XW4.GY9TW #XQSH?*TU'C8N0#\NBU]02P,$%
M  @ T("N4F:(ES 5 P  _0@  !D   !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&ULC9;?;]HP$,?_%2NKIE;:FE\D0 =(M*C:'M:ATG8/TQY,.(C5),YL ^U_
MO[.39A ,ZTL2._>]^]PY/F>PY>)9I@"*O.19(8=.JE1YY;HR22&G\I*74.";
M)1<Y53@4*U>6 NC"B/+,#3PO=G/*"F<T,'-3,1KPM<I8 5-!Y#K/J7B]AHQO
MAX[OO$W<LU6J](0[&I1T!3-0C^54X,AMO"Q8#H5DO" "ED-G[%_=^)X6&(LG
M!ENY\TQT*G/.G_7@VV+H>)H(,DB4=D'QMH$;R#+M"3G^U$Z=)J86[CZ_>;\U
MR6,R<RKAAF<_V4*E0Z?GD 4LZ3I3]WS[%>J$(NTOX9DT5[*M;+MHG*REXGDM
M1H*<%=6=OM2%V!'XG2."H!8$[Q6$M2 TB59D)JT)570T$'Q+A+9&;_K!U,:H
M,1M6Z&6<*8%O&>K4Z)85M$@8S<A,406X0(I,0%&62?*9_% I"#*6$I0DY]7\
M!<X_SB;D_.R"G!%6D(>4KR4M%G+@*B32?MVDCGY=10^.1/].Q24)_4\D\ +?
M(K\Y+9] TLB]?;F+=6B*$33%"(R_\(B_O73O>)&LA= %^36>2R7PB_M](DC8
M! E-D,Z1($_C!_S^$V ;.L_ 5K-*'QN]WH:;4<_']#:[A;'8Q)W&9@^LTX!U
M3H+- /-EZA5W0<DE4];UK%Q$.W%#O]]B.[2)PR-L4<,6G62;"B@I6Q#)EVI+
M!9",)=A+@"P!K)S1 4,0=%N<AS:=*+)SQ@UG?)+S'O!#88F"!4FH3&UD\4%4
MO]NNX&F;/;)N0]8]23998[$$S_';RZCF*ZE0KS; [D'PJ-/BLYCX=KQ>@]=[
MUP+C693@.Y9@1\*>0IH!EA6O$L0&5UZ2CQ]Z@>]_P6ZITOV4R/D=5T#Z%[;<
M>@?@[8UU:-$/[*GUF]3Z)U,S7<4&T[?LI;B%8[$)0CN/[_WK^=[_B0@U?<[:
MM+V#[N+WO:B%9K$*HGZO!>?NG$WZQP!;_HH5DF2P1)EWV<7<1'765@/%2W-<
MS;G"P\\\IOA_ D(;X/LEQ^6M!_H$;/YX1G\!4$L#!!0    ( -" KE*Q<\P3
M( 0  "H.   9    >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;(V7;8^C-A#'
MOXJ5GJI;:;M@($"N2:2]W9Y:J0^KVU[[HNH+!R;!.L"<;9+=;U_;L(2 27F3
M8)@9_SR,YV_6)\:_B@Q HI<B+\5FD4E9?7 <D610$'''*BC5DSWC!9%JR ^.
MJ#B0U#@5N>.Y;N@4A):+[=K<>^+;-:ME3DMXXDC414'XZT?(V6FSP(NW&Y_I
M(9/ZAK-=5^0 SR"_5$]<C9PN2DH+* 5E)>*PWRSN\8<''&D'8_$7A9/H72.]
ME!UC7_7@EW2S<#41Y)!('8*HOR,\0)[K2(KC6QMTT<VI'?O7;]$_F<6KQ>R(
M@ >6_TU3F6T6\0*EL"=U+C^ST\_0+FBIXR4L%^87G5I;=X&26DA6M,Z*H*!E
M\T]>VD3T'' PX>"U#MY<![]U\,U"&S*SK$<BR7;-V0EQ;:VBZ0N3&^.M5D-+
M_1J?)5=/J?*3VT^T)&5"28Z>)9&@7I!$CR )S07Z =TG":\A13^]J+(1(! I
M4_2'S("C7RG9T9Q*JNZ^;SQNE,>7YT?T_MT->H=HB?[,6"V4BU@[4K'J&9VD
MY?K8<'D37+\1?H=\?(L\U\,6]X?K[H^0=.[NI;NC,M2ER>O2Y)EX_D2\MT3T
M5_U0<Z[3]<_]3DBNZO'?*Q/YW42^F2CXGXEVK*RM:6O<0^.N]^AQ&ZZ":.T<
M^\D9&RV]..Z,+LB"CBR81992(=2R:7E (B-<O_[?F004W]APFYC+/FZ\# :X
M%J,H7-EQEQWN<A9NQ=D>A.XZJL9U^0K@1YH V@-8$[RTP'CQ@'AL%(7A1(+#
MCCB<20R)>D:3%K@;2*[W:<*$M(*'(Z8@7(8#<(N1[T^D.NK HUG@"2MTFR"Z
M/]L (\O<P6H .#;RXQ6V \8=8#P+4!4K$)YD)JTI')6(5:;C3>8T'M%XV/4'
MR&.CP'4]._*J0U[-S&FIFDO=:-XDYFI$@%<^'F".C5P[(W;/XN'.I=0-H4FE
MDO@4N*D"5)%7LLO!VO_=$4_L>0-FFU&OIB^Q>YJ'9V'G9,<4*..O"+[5M*D%
MTR/JJLJIO3^TL2];VC#7-J-@HHKQ682P=Y6[%6O5>=DNIX<FQ=]_%WL8_Z@.
M"XT<58Q/;< V?)]J&8W0QT8X\*;8S[J&KPO;(^Q! >I->(2RMI>$/]YNX7"W
MV8RBJ4H^BQN>IVY[KC*<40&W2) <Q"VJ!9B:4$)2 9>O2)*7B<H8ZQC&(WR+
M4:^C7.*?Q0[/4[N$5%0JD0!]8$NIK/D$ZEC \% J+#:^'TV0GD4.7U<Y<WJT
M(HVE*5H.U<%BA'$\U1#. H;G*1CTS[G,G'/S\XG/2AV-CEI^&*U&;]UJ%@UW
ME=,[R.NO*'4*/M!2H!SVRL^]B]3">?-AT@PDJ\S9?L>D^E(PEYGZF .N#=3S
M/5-'LW:@/Q>ZS\/M?U!+ P04    " #0@*Y2+\$+_.<"  #W!P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6R-E4M/XS 0@/^*%7$ "4B;]!%06XF6
M1<N!%:++[F&U!S>9-A:.76R' K]^QTYJ2IMVN;2V,X]OQN.9P4JJ)YT#&/):
M<*&'06[,\C(,=9I#0?6Y7(+ +W.I"FIPJQ:A7BJ@F5,J>!BU6KVPH$P$HX$[
MNU>C@2P-9P+N%=%E45#U-@8N5\.@':P/'M@B-_8@' V6= %3,(_+>X6[T%O)
M6 %",RF(@ODPN&I?3A(K[P1^,5CIC36QD<RD?+*;VVP8M"P0<$B-M4#Q[P4F
MP+DUA!C/M<W N[2*F^NU]1L7.\8RHQHFDO]FF<F'01*0#.:TY.9!KKY#'4_7
MVDLEU^Z7K&K95D#24AM9U,I(4#!1_=/7.@\;"FBG62&J%:)MA<X>A;A6B%V@
M%9D+ZYH:.AHHN2+*2J,UNW"Y<=H8#1/V%J=&X5>&>F9TPP05*:.<3 TU@/=C
MR#48RK@F9^16&%"@#:$BP\T++IW$K4AE :?D!Y;9<25^@N*/TVMR?'1"C@@3
MY&<N2XUZ>A :!+7NPK2&&E=0T1ZHF-Q)87)-OHD,LL_Z(0;HHXS648ZC@P;O
MJ#HG<?N41*VHW< S^;IZZP!.[),>.WOQ'GL[F72)_',UTT9A7?\]X*+C772<
MB\X>%X\"WS1G[Y"1!;YE38ZYU!KT"9DK61!X+IEY(QK24C'#H/&2*@\]Y\%V
M@Y=1DL3Q('S9S-RNT%G[(O%"G^"['KY[$-Z7'7/9:6*K#'0WW,;QQ19:@TP4
M-9/U/%GO/V3^YF@AE6'OU'4C>,6VJO%%"#!-N+T=E+,HZF[Q-@AUNLV\?<_;
M/\AKZ\H70E4!!'&9#Z/QXON[(-O7WB#2;D9-/&KRM4NWO>8#L*Z!O9E-=HOT
MHM/9HMT5ZF^7:+C10PM0"S=:-$EE*4S5:/RIGUY7KFEOG8]QJE5#Z,-,-1*Q
MC2SL4^0P1Y.M\SZF3U5CIMH8N72=>B8-]GVWS'$R@[("^'TNI5EOK ,_ZT?_
M %!+ P04    " #0@*Y2,SS:-6$$   Z$@  &0   'AL+W=O<FMS:&5E=',O
M<VAE970T,"YX;6RU6%MOFTH0_BLKJP^)E 86\*UR+.72M(Y.<ZRZ:1^J/FQ@
M;*, Z^XN<7+4'W]F,08<PX9&\HO-PGQSGV\71FLN'N020)&G.$KD66>IU.J#
M94E_"3&3IWP%"3Z9<Q$SA4NQL.1*  LR4!Q9CFWWK)B%26<\RNY-Q7C$4Q6%
M"4P%D6D<,_%\ 1%?GW5H9WOC:[A8*GW#&H]6; $S4'>KJ<"556@)PA@2&?*$
M")B?=<[IAQO'U8!,XGL(:UFY)CJ4>\X?]&(2G'5L[1%$X"NM@N'?(UQ"%&E-
MZ,?O7&FGL*F!U>NM]NLL> SFGDFXY-&/,%#+L\Z@0P*8LS127_GZ,^0!=;4^
MGT<R^R7K7-;N$#^5BL<Y&#V(PV3SSY[R1%0 U&L .#G :0MP<X#;%N#E *\M
MH)L#NFT!O1S0:POHYX!^6\ @!PQ> MP&P# '#-M:H/:V<G;609N29_URQ10;
MCP1?$Z'E49^^R)HNPV.;A(F>CYD2^#1$G!I__)V&ZIE,DD>0"OM>D3 AWT.!
M?<O(MR4(MH)4A;XD[\EY$(2ZJ5F$\IO1U"U^= 6*A=$Q2MS-KLC1NV/R3FOY
MMN2I9$D@1Y9"3[4]R\^]NMAXY31X=0WWI\3IGA#'=F@-_-(,OV')*7&IAM-A
M#?S*#)_!"N%V!A_4P#^^8CU-C/!K,_P+$UOG:V/_U!YNU\ _F^%7X!OAD]>L
M/YL2?]/:=]K?A5O8UT5S.T5S.YD^MZF0N)L$:03DWWFEPR7Y^0\*DHF"6/XR
MF'$+,VYFQFLP<\N3][BY/. 8W*,QV(Q46([4T2U70+SCNF;8J.YEJO5F]CC&
MM#]6"[8OT1]XPUVAFWVA0=<N->W$Y15Q><:X[A+<<:/P/PC( G=:27#8*W%*
M\%.!A !U WZ]4=VM.$2]79\_>7L^.VZ]Q]W"XZ[1XTFB0&#6"=).E=,FB<]C
M."&WH SU[A56>H=LJWYAIM\V_1&76?;W6JMNP/M[::5>4RL,"E\&1E_J=H03
MG=930Z##0OGPD/FD=KG7V8=KZ%QWM:-[O::\TLK^2XT^?6EMG];4M7'&:<F1
MU'EC:<D?<LGC&),T4]Q_P.4L34"&DDR7#'=_/Q-FT4;<5*&22:E[T%8HJ8V:
MN6V*QW 0 CM!9K%5V-KG>"T4/@H3Q7&9I2 3.R$2(Z^MSP6M8;QNS^G97D.%
M2E*C9E;3YPB2;2&:UGXP(1BZ.4V%O\0W W*^$ "9YW]J3VZOSBDMB8\>E/EH
M27W4S'U%<'R^K4>H1R3!+-0>Z/9)K\IY^;'-++3K:LF,U$R-?U&=&0@<;G)!
MRN[;3M;;"E<R+#THQ3HEQ3J'H]C+7/?.*::I0$[)L(Z98?^B0"_H[DU%<2JG
MTX,>3YV251WS 36/61)X N&'$HN#Q,9\/$T(:*:T2:ZV2FE.UZ7.RY)8E?=/
M_54%][2%KGT$<P3:IWW4(#8?*C8+Q5?9*^D]5_B*FUTN@04@M  ^GW,L5[[0
M;[G%YZ+Q_U!+ P04    " #0@*Y2Q>R8B3H%  !,&P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6R]65M/XS@8_2M6-0\STD 2.^EE5"I!66:18!?1
M9>9AM0^F<=MHDKAK.W08[8]?YT*<Q(G;B,(+-.GGS\>7<XZ_>KJC[ ??$"+
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M"^@!Y]82QO$M-^H5/BUQ??UL_=J)1S%CJJ$G^6<V,4G'._?(!*8TX^9.+C]
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M ?A\*J5YWMBIKICBNS\!4$L#!!0    ( -" KE)E19AE) 8  %DO   9
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MG<^\B4<RV-*ZT ]B_P5:AT9&7RH*97_)OI4-/)+62HNR!2.#DO'F29_;0)P
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M':01P.];(?1A80QT_PO,_P902P,$%     @ T("N4N<G\_#P!   WQ0  !D
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MD2$D"U#;4H2Y,MA(*3VNEK)&2YE;]][ 5>5QV*(J\ ?=1+%&,YE;Y(Y*%+I
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M*" 5S.F2VUNU^@I=/D/'5RIN_)>L.M\H(.726"4Z,"H03+8C?>GJL % GMV
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MO&GKAA<:0@=7=+;;G,F$MN&U?;4-GF.V3%OF!Y[0'_;;"M#P$J(;-T,1\+2
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MSUJ%W=;';J-U;?P! [>55( =XI!)6/]ND4RP%1HJ/ V=D0VO<#'$<7& X;N
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MFH\9FD:B#3.-"0<A@:47#Q>'A9&&K^'H;S/77V=.-"?V6]:?*7GTLM: -"2
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M?K=7?5!\6?ZH:\*5XHOR<4Z3C I= +Z?<J[6'_3OQ#:_GCS['U!+ P04
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MFBM3*J*T"\S\0@C]T+$&ZN)S\@=02P,$%     @ T("N4N5+H++9 @  O@D
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MFJ\ X@H06T=+9=:M2XITT)-B1:2QUFQF8&-CT=H;QLUGG*#4NTSC<##F,U$
M^4'7H,@7<I$DS(27YF3,RR0QP3ZY!*0L/]46]Y-+<O+AM.>C/MUP^+/JI&%Y
M4O3*23&Y$1PS1;[R!)*G>%^KKJ5'6^G#R$EX0V6#Q.%G$@51>$#/Z/WPP"$G
MKB,96[[XS4B2W]_U'ADC%.J/@[E9,S<M<]/-C)H9UOK_54!.IL A97CP.Y1L
M;<MF?N/'03L(M(N/^\%Y:11V]ZV>*&W52EM.I5>0@-2YHY#B$H7<6-&2(AS2
MZ>:*PD80?'2$KUV+:CN)1J)84+[YI BD*=AKPRG+S1:\H:I3J^HX>>XY0TC(
M1$<*E(.O6_-UCYQ^9S7SV5'3[^Q%9KV256&PNZ0"MP2D^<;A2KAWW85'#E,8
M[;BCHP:JHFN](U*[2RB,G1HFNE1GY)O0)=WET^[J"9O'CM?NL@C=?_A_QZOU
M9F;Y>Y6P #FW#8(B,['D6%:6>K5N0BYLZ7VV/C3-B:VP.YJRL]%U8\ZX(CFD
MFC)H=+0J638+Y03%PM;;J4!=O>TPTPT62&.@]U,A<#LQ!]0MV^ ?4$L#!!0
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MWR M"^ZG#87+FD+T!H5QJ7JD'QR1*(C"Q]DU.?AR^#^*CZ):95&K+'*P)V_
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M0TPP,;%AKKBT[(ZK6K"_!7>U%0=XF%IB<K<HQ=?&MEO:>N)+.#!D'W9Z;X6
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M@JOBVK+FHWM'(<N;M<1-K=1Y:/NJOQA>[M\NW+\9^?$_4$L#!!0    ( -"
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M&^IM!'H;ZFT$>AOJ;01ZVVRSA$!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O1[V=0&]'O9U ;T>]G4!O1[V=0&^?;783Z.VHMQ/H[:BW$^CMJ+<3
MZ.VHMQ/H[:BW$^@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VH=Q#H';.?E01Z!^H=
M!'H'ZAT$>@?J'01Z!^H=!'JWJ'=+H'>+>K<$>K>H=_N=>I?I\Y#+M>=KC<__
M3JJG\[WY^OC+\NOD[+U<<$ZW%>7Y+U!+ P04    " #0@*Y2_R>G=>,!  !L
M)   $P   %M#;VYT96YT7U1Y<&5S72YX;6S-VEU/PC 4!N"_0G9K6.G7_(AP
MH]ZJ%_Z!NAUD85N;MB#\>[L!)AHE&DQ\;UB@[7G/>I+GBNNGK:,PVK1-%Z;9
M(D9WQ5@H%]2:D%M'75J96]^:F+[Z%^9,N30OQ,1D4K#2=I&Z.(Y]C6QV?4MS
MLVKBZ&Z3?@ZU[::9IR9DHYO=QCYKFAGGFKHT,:VS=5=]2AGO$_)T<M@3%K4+
M9VE#QKY,Z%>^#]B?>UB3]W5%HT?CX[UITRZV:5B(VX9"?KS$%SW:^;PNJ;+E
MJDU'\N \F2HLB&+;Y+NB9\>38[IAVGWRD_.',L<"T\Y';UU($_/T^[C#2/K3
M8Y<*D8_U\5=\3TRE3WX_ZJ==4?7#['2]K]8OAWD$-CQ.O^./,WZO_\L^!$@?
M$J0/!=*'!NFC .GC'*2/"Y ^+D'ZX!.41E!$Y2BD<A13.0JJ'$55CL(J1W&5
MH\#*4605*+(*%%D%BJP"15:!(JM D56@R"I09!4HL@H4626*K!)%5HDBJT21
M5:+(*E%DE2BR2A19)8JL$D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM"
MD56CR*I19-4HLFH4636*K!I%5HTBJT:15:/(JE%D+5!D+5!D+?Y3UF=KEW\<
M/SSSUM3=(9\-?S*:O0%02P$"% ,4    " #0@*Y2!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( -"
MKE(-[/:([@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( -" KE*97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ T("N4CRQ7RM)
M!0  @Q4  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( -" KE+ H =KZ08  "$<   8              "
M@8P-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #0@*Y2
M@V(X])L"  !3!P  &               @(&K%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ T("N4B4J%Y?D!   ,!$  !@
M     ("!?!<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M -" KE)V%&[$LP,  !0+   8              " @98<  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    " #0@*Y2Q<-NK8 &  "?(   &
M            @(%_(   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ T("N4M$G&QHB"   HB(  !@              ("!-2<  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -" KE)3*R!_&PP  '(>
M   8              " @8TO  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    " #0@*Y2=&E&FVX5  "4/   &               @('>.P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ T("N4B_-&<72
M"   IA8  !D              ("!@E$  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    " #0@*Y2FP^FMM,&  "C$0  &0
M@(&+6@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( -"
MKE)0B8+BOP4  (X1   9              " @95A  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ T("N4E 0VO_'"   \Q<  !D
M         ("!BV<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    " #0@*Y2<0+C>2@)  !A%P  &0              @(&)<   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -" KE+R5*=8-1P  -A1
M   9              " @>AY  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ T("N4J$"Z6F8%0  FDX  !D              ("!5)8
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #0@*Y2G55,
M#-8%   R#@  &0              @($CK   >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( -" KE*PWD/)5PT  %,D   9
M  " @3"R  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
MT("N4AU4(/A\!   F D  !D              ("!OK\  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    " #0@*Y2VS/(IJ\%  "V#0  &0
M            @(%QQ   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( -" KE*=(LV)EQ@  %M)   9              " @5?*  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ T("N4OH@^#=?!
M> H  !D              ("!)>,  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    " #0@*Y2,L81SLL"  #F!0  &0              @(&[
MYP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( -" KE($
M\EO,EP8   82   9              " @;WJ  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ T("N4HXM6=%M!   - T  !D
M     ("!B_$  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -" KE)_310B!00  $P/   9              "
M@2H* 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ T("N
M4DMY 4BD!0  >AP  !D              ("!9@X! 'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    " #0@*Y2I>*T"84#  "'#   &0
M        @(%!% $ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( -" KE(_;URD, ,  &$+   9              " @?T7 0!X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ T("N4HV)KK'U P  I@T
M !D              ("!9!L! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    " #0@*Y2[+9DI9X#  #J#@  &0              @(&0'P$
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( -" KE(JE%0V
M10(  #H%   9              " @64C 0!X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ T("N4F:(ES 5 P  _0@  !D
M ("!X24! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #0
M@*Y2L7/,$R $   J#@  &0              @($M*0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -" KE(OP0O\YP(  /<'   9
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M970T,RYX;6Q02P$"% ,4    " #0@*Y29468920&  !9+P  &0
M    @(&]00$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M -" KE+XHV7:N0(  +L&   9              " @1A( 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ T("N4D_\H633 @  % <  !D
M             ("!"$L! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    " #0@*Y2N1;P*:(#   7#   &0              @($23@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( -" KE+G)_/P\ 0
M -\4   9              " @>M1 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ T("N4MF43X0_ @  FP4  !D              ("!
M$E<! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " #0@*Y2
MN@$\&X4"  !D!@  &0              @(&(60$ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( -" KE*7=!OY?@(  (D%   9
M      " @41< 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ T("N4B8VY/WQ @  _P<  !D              ("!^5X! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #0@*Y2^+4=CV@$   P%@
M&0              @($A8@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( -" KE*O_2@!-1(  +YW   9              " @<!F 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ T("N4I"V$T:^
M P  # X  !D              ("!+'D! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    " #0@*Y2U0R5X$0*  !).0  &0
M@($A?0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( -"
MKE)8XU,32@,  #@,   9              " @9R' 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ T("N4K9&AZEP!   3Q(  !D
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M=#8R+GAM;%!+ 0(4 Q0    ( -" KE+EMN"_0@,  /04   -
M  "  3^< 0!X;"]S='EL97,N>&UL4$L! A0#%     @ T("N4I>*NQS
M$P(   L              ( !K)\! %]R96QS+RYR96QS4$L! A0#%     @
MT("N4C8QN9^X!   G2D   \              ( !E: ! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( -" KE)W2W&%!@(  /$D   :              "
M 7JE 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -"
MKE+_)Z=UXP$  &PD   3              "  ;BG 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !& $8 (1,  ,RI 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>332</ContextCount>
  <ElementCount>432</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>116</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Combined Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Combined Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Combined Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Combined Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Combined Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Combined Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited</Role>
      <ShortName>Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited</Role>
      <ShortName>Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Combined Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Combined Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Financial Statement Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails</Role>
      <ShortName>Financial Statement Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Equity Investment in Viracta Therapeutics</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics</Role>
      <ShortName>Equity Investment in Viracta Therapeutics</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Party Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements</Role>
      <ShortName>Related Party Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders??? Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit</Role>
      <ShortName>Stockholders??? Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Description of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables</Role>
      <ShortName>Description of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Financial Statement Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables</Role>
      <ShortName>Financial Statement Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Related Party Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables</Role>
      <ShortName>Related Party Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Description of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail</Role>
      <ShortName>Description of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail</Role>
      <ShortName>Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail</Role>
      <ShortName>Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail</Role>
      <ShortName>Financial Statement Details - Property, Plant and Equipment, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Financial Statement Details - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail</Role>
      <ShortName>Financial Statement Details - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Financial Statement Details - Other Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail</Role>
      <ShortName>Financial Statement Details - Other Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail</Role>
      <ShortName>Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail</Role>
      <ShortName>Financial Statement Details - Interest and Investment Income, Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Equity Investment in Viracta Therapeutics - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail</Role>
      <ShortName>Equity Investment in Viracta Therapeutics - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail</Role>
      <ShortName>Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail</Role>
      <ShortName>Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Commitment and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Commitment and Contingencies - Summary of Information Regarding Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail</Role>
      <ShortName>Commitment and Contingencies - Summary of Information Regarding Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Commitment and Contingencies - Components of Lease Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail</Role>
      <ShortName>Commitment and Contingencies - Components of Lease Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail</Role>
      <ShortName>Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail</Role>
      <ShortName>Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail</Role>
      <ShortName>Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Related Party Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail</Role>
      <ShortName>Related Party Agreements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption</Role>
      <ShortName>Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail</Role>
      <ShortName>Stock-Based Compensation - RSUs Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ibrx-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ibrx-10q_20210331.htm">ibrx-10q_20210331.htm</File>
    <File>ibrx-20210331.xsd</File>
    <File>ibrx-20210331_cal.xml</File>
    <File>ibrx-20210331_def.xml</File>
    <File>ibrx-20210331_lab.xml</File>
    <File>ibrx-20210331_pre.xml</File>
    <File>ibrx-ex311_109.htm</File>
    <File>ibrx-ex312_108.htm</File>
    <File>ibrx-ex321_107.htm</File>
    <File>ibrx-ex322_106.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ibrx-10q_20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 35,
   "contextCount": 332,
   "dts": {
    "calculationLink": {
     "local": [
      "ibrx-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibrx-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ibrx-10q_20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ibrx-20210331_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibrx-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ibrx-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 630,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 18,
    "http://www.immunitybio.com/20210331": 12,
    "http://xbrl.sec.gov/dei/2020-01-31": 8,
    "total": 38
   },
   "keyCustom": 67,
   "keyStandard": 365,
   "memberCustom": 65,
   "memberStandard": 41,
   "nsprefix": "ibrx",
   "nsuri": "http://www.immunitybio.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentPeriodEndDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Financial Statement Details",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails",
     "shortName": "Financial Statement Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Equity Investment in Viracta Therapeutics",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
     "shortName": "Equity Investment in Viracta Therapeutics",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Financial Instruments",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapInvestmentTypeAxis_ibrxMarketableDebtAndEquitySecuritiesMember_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Fair Value Measurements",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Related Party Agreements",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements",
     "shortName": "Related Party Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders\u2019 Deficit",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit",
     "shortName": "Stockholders\u2019 Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock-Based Compensation",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Combined Consolidated Balance Sheets",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets",
     "shortName": "Condensed Combined Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Description of Business (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables",
     "shortName": "Description of Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Financial Statement Details (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables",
     "shortName": "Financial Statement Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Related Party Agreements (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables",
     "shortName": "Related Party Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Combined Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Combined Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210309",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Description of Business - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
     "shortName": "Description of Business - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
     "shortName": "Description of Business - Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_srtConsolidatedEntitiesAxis_ibrxNantCellIncMember_srtConsolidationItemsAxis_srtReportableLegalEntitiesMember_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapPlanNameAxis_ibrxNantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember_20210309_20210309",
      "decimals": "4",
      "lang": null,
      "name": "ibrx:MergerExchangeRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail",
     "shortName": "Summary of Significant Accounting Policies - Securities Excluded from the Computation of Potentially Dilutive Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail",
     "shortName": "Financial Statement Details - Prepaid Expenses and Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ibrx:PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail",
     "shortName": "Financial Statement Details - Property, Plant and Equipment, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Financial Statement Details - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail",
     "shortName": "Financial Statement Details - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValueAddedTaxReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Financial Statement Details - Other Assets (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail",
     "shortName": "Financial Statement Details - Other Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValueAddedTaxReceivableNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail",
     "shortName": "Financial Statement Details - Accrued Expenses and Other Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Financial Statement Details - Interest and Investment Income, Net (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail",
     "shortName": "Financial Statement Details - Interest and Investment Income, Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestAndOtherIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtAndEquitySecuritiesUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Combined Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "Condensed Combined Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Equity Investment in Viracta Therapeutics - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
     "shortName": "Equity Investment in Viracta Therapeutics - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20170331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail",
     "shortName": "Financial Instruments - Summary of Available-for-Sale Marketable Debt Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapInvestmentTypeAxis_us-gaapEquitySecuritiesMember_20210331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesEquitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
     "shortName": "Financial Instruments - Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InvestmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_deiLegalEntityAxis_ibrxViractaTherapeuticsIncMember_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesEquitySecurities",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
     "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
     "shortName": "Fair Value Measurements - Summary of Changes in Carrying Amount of Contingent Consideration Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:AnnualPaymentForSupportOfResearchActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapEquitySecuritiesByIndustryAxis_ibrxNationalInstitutesOfHealthMember_us-gaapTypeOfArrangementAxis_ibrxCooperativeResearchAndDevelopmentAgreementMember_20210201_20210228",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:AnnualPaymentForSupportOfResearchActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Commitment and Contingencies - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitment and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Commitment and Contingencies - Summary of Information Regarding Leases (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail",
     "shortName": "Commitment and Contingencies - Summary of Information Regarding Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited",
     "shortName": "Condensed Combined Consolidated Statements of Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Commitment and Contingencies - Components of Lease Expense (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail",
     "shortName": "Commitment and Contingencies - Components of Lease Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail",
     "shortName": "Commitment and Contingencies - Schedule of Cash Paid for Amounts Included in Measurement of Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail",
     "shortName": "Commitment and Contingencies - Summary of Future Minimum Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail",
     "shortName": "Related Party Agreements - Summary of Outstanding Balances of Related Party Agreements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DueToRelatedPartiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Related Party Agreements - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
     "shortName": "Related Party Agreements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DueFromRelatedParties",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_ibrxNantBioScienceMember_20210331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210309_20210309",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "ibrx:MergerExchangeRatio",
      "reportCount": 1,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Stockholders' Deficit - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
     "shortName": "Stockholders' Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "ibrx:NumberOfBoardOfDirectors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ibrxDirector",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail",
     "shortName": "Stock-Based Compensation - Stock Based Compensation Expenses Related to Statement of Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapStockOptionMember_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Stock-Based Compensation - Stock Option Activity (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
     "shortName": "Stock-Based Compensation - Black-Scholes Option-Pricing Model to Determine Fair Value of Assumptions Used for Employee Stock Options Granted (Detail) - Employee Stock Option",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited",
     "shortName": "Condensed Combined Consolidated Statements of (Deficit) Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-Based Compensation - RSUs Activity (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
     "shortName": "Stock-Based Compensation - RSUs Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:ExpectedClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_srtProductOrServiceAxis_ibrxWorkOrderOneMember_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_ibrxImmunoOncologyClinicIncMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210430",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ibrx:ExpectedClinicalTrialExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Combined Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Combined Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Description of Business",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ibrx-10q_20210331.htm",
      "contextRef": "C_0001326110_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 116,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_KR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KOREA, REPUBLIC OF",
        "terseLabel": "South Korea"
       }
      }
     },
     "localname": "KR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "verboseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "verboseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NameChangeEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table.",
        "label": "Name Change Event [Line Items]",
        "terseLabel": "Name Change Event [Line Items]"
       }
      }
     },
     "localname": "NameChangeEventLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NameChangeEventTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period.",
        "label": "Name Change Event [Table]",
        "terseLabel": "Name Change Event [Table]"
       }
      }
     },
     "localname": "NameChangeEventTable",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ibrx_ATMSalesAgreementWithJefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM sales agreement with Jefferies LLC.",
        "label": "A T M Sales Agreement With Jefferies L L C [Member]",
        "terseLabel": "ATM Sales Agreement With Jefferies LLC"
       }
      }
     },
     "localname": "ATMSalesAgreementWithJefferiesLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Line Items]",
        "terseLabel": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policies.",
        "label": "Accounting Policies [Table]",
        "terseLabel": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_AccruedCapitalExpenditures": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued capital expenditures.",
        "label": "Accrued Capital Expenditures",
        "terseLabel": "Accrued capital expenditures"
       }
      }
     },
     "localname": "AccruedCapitalExpenditures",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedDissentingShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued dissenting shares.",
        "label": "Accrued Dissenting Shares",
        "terseLabel": "Accrued dissenting shares (Note 8)"
       }
      }
     },
     "localname": "AccruedDissentingShares",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedLaboratoryEquipmentAndSupplies": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued laboratory equipment and supplies.",
        "label": "Accrued Laboratory Equipment And Supplies",
        "terseLabel": "Accrued laboratory equipment and supplies"
       }
      }
     },
     "localname": "AccruedLaboratoryEquipmentAndSupplies",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedPaymentForDissentingShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued payment for dissenting shares.",
        "label": "Accrued Payment For Dissenting Shares",
        "verboseLabel": "Accrual for dissenting shares"
       }
      }
     },
     "localname": "AccruedPaymentForDissentingShares",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedPreclinicalAndClinicalTrialCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued preclinical and clinical trial costs.",
        "label": "Accrued Preclinical And Clinical Trial Costs",
        "terseLabel": "Accrued preclinical and clinical trial costs"
       }
      }
     },
     "localname": "AccruedPreclinicalAndClinicalTrialCosts",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedReimbursableCostsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued reimbursable costs payable.",
        "label": "Accrued Reimbursable Costs Payable",
        "terseLabel": "Accrued reimbursable costs payable"
       }
      }
     },
     "localname": "AccruedReimbursableCostsPayable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AccruedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development costs.",
        "label": "Accrued Research And Development Costs",
        "terseLabel": "Accrued research and development costs"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCosts",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate market price of shares that may issue under a registered offering.",
        "label": "Aggregate Market Price Of Shares That May Issue Under Registered Offering",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "AggregateMarketPriceOfSharesThatMayIssueUnderRegisteredOffering",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AltorBioScienceCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altor BioScience Corporation.",
        "label": "Altor Bio Science Corporation [Member]",
        "terseLabel": "Altor BioScience Corporation"
       }
      }
     },
     "localname": "AltorBioScienceCorporationMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AltorBioScienceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Altor BioScience, LLC.",
        "label": "Altor Bio Science L L C [Member]",
        "terseLabel": "Altor BioScience, LLC"
       }
      }
     },
     "localname": "AltorBioScienceLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AmendmentToExtendLeaseTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to extend lease term.",
        "label": "Amendment To Extend Lease Term [Member]",
        "terseLabel": "Amendment to Extend Lease Term"
       }
      }
     },
     "localname": "AmendmentToExtendLeaseTermMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AmountOfAdvanceReceivedOnNote": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advance received on note.",
        "label": "Amount Of Advance Received On Note",
        "terseLabel": "Amount of advance received"
       }
      }
     },
     "localname": "AmountOfAdvanceReceivedOnNote",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AmountOfAdvanceReceivedOnNoteOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of advance received on note outstanding.",
        "label": "Amount Of Advance Received On Note Outstanding",
        "terseLabel": "Amount of advance received on note outstanding"
       }
      }
     },
     "localname": "AmountOfAdvanceReceivedOnNoteOutstanding",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AnnualPaymentForSupportOfResearchActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual payment for support of research activities.",
        "label": "Annual Payment For Support Of Research Activities",
        "terseLabel": "Annual payment for support of research activities"
       }
      }
     },
     "localname": "AnnualPaymentForSupportOfResearchActivities",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_AnnualPercentageIncreasesToBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual percentage increases to base rent.",
        "label": "Annual Percentage Increases To Base Rent",
        "terseLabel": "Percentage of annual increases of base rent"
       }
      }
     },
     "localname": "AnnualPercentageIncreasesToBaseRent",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_AnnualPercentageIncreasesToMonthlyFixedCharge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual percentage increases to monthly fixed charge.",
        "label": "Annual Percentage Increases To Monthly Fixed Charge",
        "terseLabel": "Annual percentage increases to monthly fixed charge"
       }
      }
     },
     "localname": "AnnualPercentageIncreasesToMonthlyFixedCharge",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_AtTheMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-The-Market offering program.",
        "label": "At The Market Offering Program [Member]",
        "terseLabel": "ATM Offering Program"
       }
      }
     },
     "localname": "AtTheMarketOfferingProgramMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_AvailableForSaleSecuritiesDebtSecuritiesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities debt securities period",
        "label": "Available For Sale Securities Debt Securities Period",
        "terseLabel": "Available-for-sale, Weighted- Average Remaining Contractual Life"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesPeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale securities period of unrealized loss positions.",
        "label": "Available For Sale Securities Period Of Unrealized Loss Positions",
        "terseLabel": "Available-for-sale securities, period of unrealized loss positions"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesPeriodOfUnrealizedLossPositions",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_BaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base monthly rent.",
        "label": "Base Monthly Rent",
        "terseLabel": "Base rent - monthly"
       }
      }
     },
     "localname": "BaseMonthlyRent",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_BioreactorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioreactor.",
        "label": "Bioreactor [Member]",
        "terseLabel": "Bioreactors"
       }
      }
     },
     "localname": "BioreactorMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and marketable securities.",
        "label": "Cash Equivalents And Marketable Securities [Abstract]"
       }
      }
     },
     "localname": "CashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.immunitybio.com/20210331",
     "xbrltype": "stringItemType"
    },
    "ibrx_ChangeInContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in contingent consideration.",
        "label": "Change In Contingent Consideration",
        "terseLabel": "Change in fair value of contingent consideration obligation"
       }
      }
     },
     "localname": "ChangeInContingentConsideration",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ClinicalTrialActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial activities.",
        "label": "Clinical Trial Activities [Member]",
        "terseLabel": "Clinical Trial Activities"
       }
      }
     },
     "localname": "ClinicalTrialActivitiesMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentValueRightsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights payable.",
        "label": "Contingent Value Rights Payable",
        "terseLabel": "Contingent value rights payable"
       }
      }
     },
     "localname": "ContingentValueRightsPayable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ContingentValueRightsPayableAtDecember312022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights payable at December 31, 2022.",
        "label": "Contingent Value Rights Payable At December312022 [Member]",
        "terseLabel": "Contingent Value Rights Payable if Certain Conditions are met by December 31, 2022"
       }
      }
     },
     "localname": "ContingentValueRightsPayableAtDecember312022Member",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ContingentValueRightsPayableBeforeDecember312026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights payable before December 31, 2026.",
        "label": "Contingent Value Rights Payable Before December312026 [Member]",
        "terseLabel": "Contingent Value Rights Payable if Certain Conditions are met on or before December 31, 2026"
       }
      }
     },
     "localname": "ContingentValueRightsPayableBeforeDecember312026Member",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ConvertibleNoteReceivableNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note receivable, non-current.",
        "label": "Convertible Note Receivable Non Current",
        "terseLabel": "Convertible note receivable"
       }
      }
     },
     "localname": "ConvertibleNoteReceivableNonCurrent",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_CooperativeResearchAndDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cooperative research and development agreement.",
        "label": "Cooperative Research And Development Agreement [Member]",
        "terseLabel": "CRADA",
        "verboseLabel": "CRADA"
       }
      }
     },
     "localname": "CooperativeResearchAndDevelopmentAgreementMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_CurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current assets.",
        "label": "Current Assets [Member]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "CurrentAssetsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DemandPromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Demand promissory note.",
        "label": "Demand Promissory Note [Member]",
        "terseLabel": "Demand Promissory Note"
       }
      }
     },
     "localname": "DemandPromissoryNoteMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DougStLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doug St LLC.",
        "label": "Doug St L L C [Member]",
        "terseLabel": "605 Doug St, LLC"
       }
      }
     },
     "localname": "DougStLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DrSoonShiongAndPelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Soon-Shiong and related party.",
        "label": "Dr Soon Shiong And Pelated Party [Member]",
        "terseLabel": "Dr. Soon-Shiong and Related Party"
       }
      }
     },
     "localname": "DrSoonShiongAndPelatedPartyMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DuleyRoadLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duley Road, LLC.",
        "label": "Duley Road L L C [Member]",
        "terseLabel": "Duley Road, LLC"
       }
      }
     },
     "localname": "DuleyRoadLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_DuleyRoadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duley Road.",
        "label": "Duley Road [Member]",
        "terseLabel": "Duley Road"
       }
      }
     },
     "localname": "DuleyRoadMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ElSegundoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "El Segundo, California.",
        "label": "El Segundo California [Member]",
        "terseLabel": "El Segundo California"
       }
      }
     },
     "localname": "ElSegundoCaliforniaMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_EmployeeBonusesPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee bonuses payment.",
        "label": "Employee Bonuses Payment [Member]",
        "terseLabel": "Employee Bonuses Payment"
       }
      }
     },
     "localname": "EmployeeBonusesPaymentMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_EquipmentDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment deposits current.",
        "label": "Equipment Deposits Current",
        "terseLabel": "Equipment deposits"
       }
      }
     },
     "localname": "EquipmentDepositsCurrent",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_EstimatedUnpaidResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated unpaid research and development expense.",
        "label": "Estimated Unpaid Research And Development Expense",
        "terseLabel": "Estimated unpaid research and development expense"
       }
      }
     },
     "localname": "EstimatedUnpaidResearchAndDevelopmentExpense",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_EtubicsCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Etubics Corporation.",
        "label": "Etubics Corporation [Member]",
        "terseLabel": "Etubics Corporation"
       }
      }
     },
     "localname": "EtubicsCorporationMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman and principal stockholder, and affiliates.",
        "label": "Executive Chairman And Principal Stockholder And Affiliates [Member]",
        "terseLabel": "Executive Chairman and Principal Stockholder and Affiliates"
       }
      }
     },
     "localname": "ExecutiveChairmanAndPrincipalStockholderAndAffiliatesMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ExpectedClinicalTrialExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected clinical trial expense.",
        "label": "Expected Clinical Trial Expense",
        "terseLabel": "Expected clinical trial expense"
       }
      }
     },
     "localname": "ExpectedClinicalTrialExpense",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FairValueOfContingentConsiderationObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration obligation.",
        "label": "Fair Value Of Contingent Consideration Obligation",
        "terseLabel": "Fair value of contingent consideration obligation"
       }
      }
     },
     "localname": "FairValueOfContingentConsiderationObligation",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_FinancialStatementDetailsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial statement details.",
        "label": "Financial Statement Details [Abstract]"
       }
      }
     },
     "localname": "FinancialStatementDetailsAbstract",
     "nsuri": "http://www.immunitybio.com/20210331",
     "xbrltype": "stringItemType"
    },
    "ibrx_FirstRSUAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First RSU award.",
        "label": "First R S U Award [Member]",
        "terseLabel": "First RSU Award"
       }
      }
     },
     "localname": "FirstRSUAwardMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ImmunoOncologyClinicIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immuno Oncology Clinic Inc.",
        "label": "Immuno Oncology Clinic Inc [Member]",
        "terseLabel": "Immuno-Oncology Clinic, Inc."
       }
      }
     },
     "localname": "ImmunoOncologyClinicIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ImmunoOncologyClinicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immuno-Oncology Clinic.",
        "label": "Immuno Oncology Clinic [Member]",
        "terseLabel": "Immuno-Oncology Clinic"
       }
      }
     },
     "localname": "ImmunoOncologyClinicMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10260.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in operating lease liability.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_InitialTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial term of agreement.",
        "label": "Initial Term Of Agreement",
        "terseLabel": "Initial term of agreement"
       }
      }
     },
     "localname": "InitialTermOfAgreement",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_InsurancePremiumFinancingAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance premium financing asset.",
        "label": "Insurance Premium Financing Asset",
        "terseLabel": "Insurance premium financing asset"
       }
      }
     },
     "localname": "InsurancePremiumFinancingAsset",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_InterestAndInvestmentIncomeNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and investment income net.",
        "label": "Interest And Investment Income Net [Member]",
        "terseLabel": "Interest and Investment Income, Net"
       }
      }
     },
     "localname": "InterestAndInvestmentIncomeNetMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_IosbioLtdExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "iosBio Ltd. Exclusive License Agreement.",
        "label": "Iosbio Ltd Exclusive License Agreement [Member]",
        "terseLabel": "iosBio Ltd. Exclusive License Agreement"
       }
      }
     },
     "localname": "IosbioLtdExclusiveLicenseAgreementMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_LeaseAgreementExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement extended period.",
        "label": "Lease Agreement Extended Period",
        "terseLabel": "Lease agreement extended lease period"
       }
      }
     },
     "localname": "LeaseAgreementExtendedPeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "ibrx_LeaseRelatedPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease-related payables.",
        "label": "Lease Related Payables",
        "terseLabel": "Lease-related payables"
       }
      }
     },
     "localname": "LeaseRelatedPayables",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LeaseholdImprovementPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leasehold improvement payables.",
        "label": "Leasehold Improvement Payables",
        "terseLabel": "Leasehold improvement payables"
       }
      }
     },
     "localname": "LeaseholdImprovementPayables",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_LicensingAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement.",
        "label": "Licensing Agreement [Abstract]"
       }
      }
     },
     "localname": "LicensingAgreementAbstract",
     "nsuri": "http://www.immunitybio.com/20210331",
     "xbrltype": "stringItemType"
    },
    "ibrx_LicensingAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement.",
        "label": "Licensing Agreement [Line Items]",
        "terseLabel": "Licensing Agreement [Line Items]"
       }
      }
     },
     "localname": "LicensingAgreementLineItems",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_LicensingAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensing agreement.",
        "label": "Licensing Agreement [Table]",
        "terseLabel": "Licensing Agreement [Table]"
       }
      }
     },
     "localname": "LicensingAgreementTable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_MarketableDebtAndEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable debt and equity securities.",
        "label": "Marketable Debt And Equity Securities [Member]",
        "terseLabel": "Marketable Debt and Equity Securities"
       }
      }
     },
     "localname": "MarketableDebtAndEquitySecuritiesMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_MergerExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger exchange ratio.",
        "label": "Merger Exchange Ratio",
        "terseLabel": "Merger exchange ratio"
       }
      }
     },
     "localname": "MergerExchangeRatio",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ibrx_MinimumAnnualPaymentsForSupportOfResearchActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual payments for support of research activities.",
        "label": "Minimum Annual Payments For Support Of Research Activities",
        "terseLabel": "Minimum annual payments for support of research activities"
       }
      }
     },
     "localname": "MinimumAnnualPaymentsForSupportOfResearchActivities",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_MinimumNetSalesMilestoneContingentValueRightsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum net sales milestone contingent value rights payable.",
        "label": "Minimum Net Sales Milestone Contingent Value Rights Payable",
        "terseLabel": "Minimum net sales milestone for contingent value rights payable"
       }
      }
     },
     "localname": "MinimumNetSalesMilestoneContingentValueRightsPayable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of stock options associated with postponement of termination date.",
        "label": "Modification Of Stock Options Associated With Postponement Of Termination Date [Member]",
        "terseLabel": "Modification of Stock Options Associated with Postponement of Termination Date"
       }
      }
     },
     "localname": "ModificationOfStockOptionsAssociatedWithPostponementOfTerminationDateMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ModificationOfStockOptionsAssociatedWithResignationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modification of stock options associated with resignation.",
        "label": "Modification Of Stock Options Associated With Resignation [Member]",
        "terseLabel": "Modification of Stock Options Associated with Resignation"
       }
      }
     },
     "localname": "ModificationOfStockOptionsAssociatedWithResignationMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ModifiedOptionsExercisablePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Modified options exercisable period.",
        "label": "Modified Options Exercisable Period",
        "terseLabel": "Modified options exercisable period"
       }
      }
     },
     "localname": "ModifiedOptionsExercisablePeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_NCSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NCSC.",
        "label": "N C S C [Member]",
        "terseLabel": "NCSC"
       }
      }
     },
     "localname": "NCSCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantBioIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Bio.",
        "label": "Nant Bio Inc [Member]",
        "terseLabel": "NantBio"
       }
      }
     },
     "localname": "NantBioIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantBioScienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantBioScience.",
        "label": "Nant Bio Science [Member]",
        "terseLabel": "NantBioScience"
       }
      }
     },
     "localname": "NantBioScienceMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCancerStemCellLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCancerStemCell, LLC.",
        "label": "Nant Cancer Stem Cell L L C [Member]",
        "terseLabel": "Nant Cancer Stem Cell L L C"
       }
      }
     },
     "localname": "NantCancerStemCellLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCapital.",
        "label": "Nant Capital [Member]",
        "terseLabel": "Nant Capital"
       }
      }
     },
     "localname": "NantCapitalMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCellIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCell, Inc.",
        "label": "Nant Cell Inc [Member]",
        "terseLabel": "NantCell, Inc."
       }
      }
     },
     "localname": "NantCellIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantCellTwoThousandAndFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantCell two thousand and fifteen plan.",
        "label": "Nant Cell Two Thousand And Fifteen Plan [Member]",
        "terseLabel": "NC 2015 Plan"
       }
      }
     },
     "localname": "NantCellTwoThousandAndFifteenPlanMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantKwestIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantKwest, Inc.",
        "label": "Nant Kwest Inc [Member]",
        "terseLabel": "NantKwest, Inc."
       }
      }
     },
     "localname": "NantKwestIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantKwestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nant Kwest [Member]",
        "terseLabel": "NantKwest"
       }
      }
     },
     "localname": "NantKwestMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantMobileMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Mobile.",
        "label": "Nant Mobile [Member]",
        "terseLabel": "NantMobile"
       }
      }
     },
     "localname": "NantMobileMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantOmicsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantOmics, LLC.",
        "label": "Nant Omics L L C [Member]",
        "terseLabel": "NantOmics"
       }
      }
     },
     "localname": "NantOmicsLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantPharma.",
        "label": "Nant Pharma [Member]",
        "terseLabel": "NantPharma"
       }
      }
     },
     "localname": "NantPharmaMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantWorksLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nant Works LLC.",
        "label": "Nant Works Limited Liability Company [Member]",
        "terseLabel": "NantWorks"
       }
      }
     },
     "localname": "NantWorksLimitedLiabilityCompanyMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantWorksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NantWorks.",
        "label": "Nant Works [Member]",
        "terseLabel": "NantWorks"
       }
      }
     },
     "localname": "NantWorksMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nantcell two thousand and fifteen plan and nantcell warrants.",
        "label": "Nantcell Two Thousand And Fifteen Plan And Nantcell Warrants [Member]",
        "terseLabel": "NC 2015 Plan and NantCell Warrants"
       }
      }
     },
     "localname": "NantcellTwoThousandAndFifteenPlanAndNantcellWarrantsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National institutes of health.",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institutes of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NewAgreementTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New agreement termination notice period.",
        "label": "New Agreement Termination Notice Period",
        "terseLabel": "Notice period to terminate new agreement"
       }
      }
     },
     "localname": "NewAgreementTerminationNoticePeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_NonCashInterestIncomeExpenseFromOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash interest (income) expense from operating activities.",
        "label": "Non Cash Interest Income Expense From Operating Activities",
        "negatedLabel": "Non-cash interest items, net (including amounts with related parties)"
       }
      }
     },
     "localname": "NonCashInterestIncomeExpenseFromOperatingActivities",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-employee director.",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non-employee Director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncurrent assets.",
        "label": "Noncurrent Assets [Member]",
        "terseLabel": "Noncurrent Assets"
       }
      }
     },
     "localname": "NoncurrentAssetsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_NumberOfAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of awards granted.",
        "label": "Number Of Awards Granted",
        "terseLabel": "Number of awards granted"
       }
      }
     },
     "localname": "NumberOfAwardsGranted",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_NumberOfBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of board of directors.",
        "label": "Number Of Board Of Directors",
        "terseLabel": "Number of board of directors"
       }
      }
     },
     "localname": "NumberOfBoardOfDirectors",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_NumberOfOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of officers.",
        "label": "Number Of Officers",
        "terseLabel": "Number of officers"
       }
      }
     },
     "localname": "NumberOfOfficers",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_NumberOfSquareFootOfFacilityLeased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of square foot of facility leased.",
        "label": "Number Of Square Foot Of Facility Leased",
        "terseLabel": "Number of square foot of facility leased"
       }
      }
     },
     "localname": "NumberOfSquareFootOfFacilityLeased",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "ibrx_OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease payments related to options to extend lease terms.",
        "label": "Operating Lease Payments Related To Options To Extend Lease Terms",
        "terseLabel": "Operating lease payments related to options to extend lease terms"
       }
      }
     },
     "localname": "OperatingLeasePaymentsRelatedToOptionsToExtendLeaseTerms",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_OperatingLeaseRightOfUseAssetNonCashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset non cash lease expense.",
        "label": "Operating Lease Right Of Use Asset Non Cash Lease Expense",
        "terseLabel": "Non-cash lease expense related to operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetNonCashLeaseExpense",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_OptionExpirationDateExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option expiration date extended period.",
        "label": "Option Expiration Date Extended Period",
        "terseLabel": "Option expiration date extended period"
       }
      }
     },
     "localname": "OptionExpirationDateExtendedPeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_OptionsToExtendNumberOfTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to extend number of terms.",
        "label": "Options To Extend Number Of Terms",
        "terseLabel": "Options to extend number of terms"
       }
      }
     },
     "localname": "OptionsToExtendNumberOfTerms",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_OutstandingStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options.",
        "label": "Outstanding Stock Options [Member]",
        "terseLabel": "Outstanding Stock Options"
       }
      }
     },
     "localname": "OutstandingStockOptionsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership percentage acquired on fully diluted bases upon consummation of merger.",
        "label": "Ownership Percentage Acquired On Fully Diluted Bases Upon Consummation Of Merger",
        "terseLabel": "Ownership percentage held by stockholders upon consummation of merger"
       }
      }
     },
     "localname": "OwnershipPercentageAcquiredOnFullyDilutedBasesUponConsummationOfMerger",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_OwnershipPercentageByKeyExecutives": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership percentage by key executives.",
        "label": "Ownership Percentage By Key Executives",
        "terseLabel": "Ownership percentage held by Executive Chairman upon consummation of merger"
       }
      }
     },
     "localname": "OwnershipPercentageByKeyExecutives",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_PayableOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable outstanding.",
        "label": "Payable Outstanding",
        "terseLabel": "Payable outstanding"
       }
      }
     },
     "localname": "PayableOutstanding",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PercentageOfSalesAgentCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sales agent commission.",
        "label": "Percentage Of Sales Agent Commission",
        "terseLabel": "Percentage of sales agent commission"
       }
      }
     },
     "localname": "PercentageOfSalesAgentCommission",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_PercentageOfWhollyOwnedSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of wholly-owned subsidiary.",
        "label": "Percentage Of Wholly Owned Subsidiary",
        "terseLabel": "Ownership percentage acquired"
       }
      }
     },
     "localname": "PercentageOfWhollyOwnedSubsidiary",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "ibrx_PeriodOfExtendedLeaseTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of extended lease term.",
        "label": "Period Of Extended Lease Term",
        "terseLabel": "Optional extended lease term"
       }
      }
     },
     "localname": "PeriodOfExtendedLeaseTerm",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_PrepaidBalance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid balance.",
        "label": "Prepaid Balance",
        "terseLabel": "Prepaid balance related to Clinic Agreement"
       }
      }
     },
     "localname": "PrepaidBalance",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid balance included in prepaid expenses and other current assets and other assets.",
        "label": "Prepaid Balance Included In Prepaid Expenses And Other Current Assets And Other Assets",
        "verboseLabel": "Prepaid balance included in prepaid expenses and other current assets and other assets"
       }
      }
     },
     "localname": "PrepaidBalanceIncludedInPrepaidExpensesAndOtherCurrentAssetsAndOtherAssets",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidEquipmentMaintenance": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid equipment maintenance.",
        "label": "Prepaid Equipment Maintenance",
        "terseLabel": "Prepaid equipment maintenance"
       }
      }
     },
     "localname": "PrepaidEquipmentMaintenance",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidLicenseFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid license fees.",
        "label": "Prepaid License Fees",
        "terseLabel": "Prepaid license fees"
       }
      }
     },
     "localname": "PrepaidLicenseFees",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid preclinical and clinical trial services with related party.",
        "label": "Prepaid Preclinical And Clinical Trial Services With Related Party",
        "terseLabel": "Prepaid preclinical and clinical trial services \u2013 with related party (Note 9)"
       }
      }
     },
     "localname": "PrepaidPreclinicalAndClinicalTrialServicesWithRelatedParty",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid preclinical and clinical trial services with related party in other assets.",
        "label": "Prepaid Preclinical And Clinical Trial Services With Related Party In Other Assets",
        "terseLabel": "Prepaid preclinical and clinical trial services \u2013 with related party (Note 9)"
       }
      }
     },
     "localname": "PrepaidPreclinicalAndClinicalTrialServicesWithRelatedPartyInOtherAssets",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid services.",
        "label": "Prepaid Services",
        "terseLabel": "Prepaid services"
       }
      }
     },
     "localname": "PrepaidServices",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidSoftwareLicenseFeesInOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid software license fees in other assets.",
        "label": "Prepaid Software License Fees In Other Assets",
        "terseLabel": "Prepaid software license fees"
       }
      }
     },
     "localname": "PrepaidSoftwareLicenseFeesInOtherAssets",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaidSuppliesWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid supplies with related party.",
        "label": "Prepaid Supplies With Related Party",
        "terseLabel": "Prepaid supplies \u2013 with related party (Note 9)"
       }
      }
     },
     "localname": "PrepaidSuppliesWithRelatedParty",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PrepaymentOfFundingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment of funding amount.",
        "label": "Prepayment Of Funding Amount",
        "terseLabel": "Prepayment for services amount"
       }
      }
     },
     "localname": "PrepaymentOfFundingAmount",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Promissory note.",
        "label": "Promissory Note [Member]",
        "terseLabel": "Promissory Note"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_PurchaseOfConvertibleNoteUponConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of convertible note upon conversion.",
        "label": "Purchase Of Convertible Note Upon Conversion",
        "terseLabel": "Purchase of convertible note"
       }
      }
     },
     "localname": "PurchaseOfConvertibleNoteUponConversion",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ReimbursementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursements.",
        "label": "Reimbursements [Member]",
        "terseLabel": "Reimbursements"
       }
      }
     },
     "localname": "ReimbursementsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party agreement renewal term.",
        "label": "Related Party Agreement Renewal Term",
        "terseLabel": "Related party, agreement renewal term"
       }
      }
     },
     "localname": "RelatedPartyAgreementRenewalTerm",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_RelatedPartyInstallmentPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party installment payment.",
        "label": "Related Party Installment Payment",
        "terseLabel": "Related party transaction installment payment"
       }
      }
     },
     "localname": "RelatedPartyInstallmentPayment",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_RelatedPartyNotesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related-party notes payable.",
        "label": "Related Party Notes Payable [Member]",
        "terseLabel": "Related Party Notes Payable"
       }
      }
     },
     "localname": "RelatedPartyNotesPayableMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_RelatedPartyTransactionConditionalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction conditional payment.",
        "label": "Related Party Transaction Conditional Payment",
        "terseLabel": "Related party transaction conditional payment"
       }
      }
     },
     "localname": "RelatedPartyTransactionConditionalPayment",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_RelatedPartyTransactionInitialTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related party transaction initial term of agreement.",
        "label": "Related Party Transaction Initial Term Of Agreement",
        "terseLabel": "Initial term of agreement entered into with the related party by the entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionInitialTermOfAgreement",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_ResearchAndDevelopmentExpenseRatablePaymentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense ratable payment period.",
        "label": "Research And Development Expense Ratable Payment Period",
        "terseLabel": "Research and development expense, ratable payment period"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseRatablePaymentPeriod",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "ibrx_SecondRSUAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second RSU award.",
        "label": "Second R S U Award [Member]",
        "terseLabel": "Second RSU Award"
       }
      }
     },
     "localname": "SecondRSUAwardMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SevenYearTermCommencingInJulyTwentyNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven-year term commencing in July 2019.",
        "label": "Seven Year Term Commencing In July Twenty Nineteen [Member]",
        "terseLabel": "Seven-Year Term Commencing in July 2019"
       }
      }
     },
     "localname": "SevenYearTermCommencingInJulyTwentyNineteenMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SevenYearTermCommencingInSeptemberTwentyNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seven year term commencing in September 2019.",
        "label": "Seven Year Term Commencing In September Twenty Nineteen [Member]",
        "terseLabel": "7-Year Term Commencing in September 2019"
       }
      }
     },
     "localname": "SevenYearTermCommencingInSeptemberTwentyNineteenMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award estimated benefit at grant date fair value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Estimated Benefit At Grant Date Fair Value",
        "terseLabel": "Estimated benefit at grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimatedBenefitAtGrantDateFairValue",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Price",
        "terseLabel": "Weighted-average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPrice",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption"
     ],
     "xbrltype": "perShareItemType"
    },
    "ibrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share-based payment award, options, aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "ibrx_SharedServicesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shared services agreement.",
        "label": "Shared Services Agreement [Member]",
        "terseLabel": "Shared Services Agreement"
       }
      }
     },
     "localname": "SharedServicesAgreementMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SixZeroFiveNashLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "605 Nash, LLC.",
        "label": "Six Zero Five Nash L L C [Member]",
        "terseLabel": "605 Nash, LLC"
       }
      }
     },
     "localname": "SixZeroFiveNashLLCMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SorrentoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sorrento.",
        "label": "Sorrento [Member]",
        "terseLabel": "Sorrento"
       }
      }
     },
     "localname": "SorrentoMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_SunesisPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sunesis Pharmaceuticals, Inc.",
        "label": "Sunesis Pharmaceuticals Inc [Member]",
        "terseLabel": "Sunesis Pharmaceuticals, Inc"
       }
      }
     },
     "localname": "SunesisPharmaceuticalsIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2018 Note and Warrant Purchase Agreement.",
        "label": "Two Thousand And Eighteen Note And Warrant Purchase Agreement [Member]",
        "terseLabel": "2018 Note and Warrant Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndEighteenNoteAndWarrantPurchaseAgreementMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen equity incentive plan.",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "Two Thousand Fifteen Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_VariousMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various.",
        "label": "Various [Member]",
        "terseLabel": "Various"
       }
      }
     },
     "localname": "VariousMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_VendorCostsPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vendor costs payments.",
        "label": "Vendor Costs Payments [Member]",
        "terseLabel": "Vendor Costs Payments"
       }
      }
     },
     "localname": "VendorCostsPaymentsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_ViractaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viracta Therapeutics, Inc.",
        "label": "Viracta Therapeutics Inc [Member]",
        "terseLabel": "Viracta Therapeutics, Inc."
       }
      }
     },
     "localname": "ViractaTherapeuticsIncMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_VivaBioCellMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VivaBioCell.",
        "label": "Viva Bio Cell [Member]",
        "terseLabel": "VivaBioCell"
       }
      }
     },
     "localname": "VivaBioCellMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants.",
        "label": "Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_WorkOrderOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work order one.",
        "label": "Work Order One [Member]",
        "terseLabel": "Work Order 1"
       }
      }
     },
     "localname": "WorkOrderOneMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ibrx_WorkOrderTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Work order two.",
        "label": "Work Order Two [Member]",
        "terseLabel": "Work Order 2"
       }
      }
     },
     "localname": "WorkOrderTwoMember",
     "nsuri": "http://www.immunitybio.com/20210331",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r364",
      "r365",
      "r556",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r364",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationEliminationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in consolidating a parent entity and its subsidiaries.",
        "label": "Consolidation Eliminations [Member]",
        "terseLabel": "Intercompany Eliminations"
       }
      }
     },
     "localname": "ConsolidationEliminationsMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r158",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r158",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r267",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r455",
      "r516",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r267",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r455",
      "r516",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r174",
      "r251",
      "r254",
      "r456",
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r174",
      "r251",
      "r254",
      "r456",
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r256",
      "r267",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r455",
      "r516",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r256",
      "r267",
      "r270",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r455",
      "r516",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableLegalEntitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal entities of the consolidated entity reporting separate financial information in the entity's financial statements.",
        "label": "Reportable Legal Entities [Member]",
        "terseLabel": "Reportable Legal Entities"
       }
      }
     },
     "localname": "ReportableLegalEntitiesMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Schedule Of Condensed Income Statement Table [Text Block]",
        "terseLabel": "Schedule of Impact of Change in Reporting Entity on Unaudited Condensed Combined Consolidated Statements of Operations"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r175",
      "r176",
      "r251",
      "r255",
      "r518",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r175",
      "r176",
      "r251",
      "r255",
      "r518",
      "r543",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r232",
      "r268",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r178",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable And Other Accrued Liabilities Current",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of net premiums and discounts on marketable debt securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "auth_ref": [
      "r11",
      "r44",
      "r313"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrual For Taxes Other Than Income Taxes Current",
        "terseLabel": "Accrued franchise, sales, use and property taxes"
       }
      }
     },
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses Current",
        "terseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance Current",
        "terseLabel": "Financing obligation \u2013 current portion"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "totalLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Accrued professional and service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrentAndNoncurrent": {
     "auth_ref": [
      "r20",
      "r22",
      "r472",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements.",
        "label": "Accrued Rent Current And Noncurrent",
        "terseLabel": "Rent payable"
       }
      }
     },
     "localname": "AccruedRentCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r225"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "terseLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r63",
      "r64",
      "r65",
      "r496",
      "r524",
      "r525"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r68",
      "r121",
      "r122",
      "r123",
      "r363",
      "r520",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Financial Statement Details"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r304",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Adjustments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Net share settlement for RSUs vesting"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r271",
      "r273",
      "r310",
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r273",
      "r300",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r62",
      "r65",
      "r68",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Aoci Including Portion Attributable To Noncontrolling Interest [Member]",
        "verboseLabel": "Total ImmunityBio Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r163",
      "r166",
      "r172",
      "r203",
      "r357",
      "r364",
      "r383",
      "r470",
      "r494"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r58",
      "r115",
      "r203",
      "r357",
      "r364",
      "r383"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Available-for-sale, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r186"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Available-for-sale, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r183",
      "r213"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Available-for-sale, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investments in debt and equity securities in an unrealized loss position categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Continuous Unrealized Loss Position Fair Value Table [Text Block]",
        "terseLabel": "Accumulated Unrealized Losses on Debt Securities Classified as Available-for-Sale in Continuous Loss Position"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r180",
      "r184",
      "r213",
      "r476"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Available-for-sale, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity securities categorized neither as held-to-maturity nor as trading.",
        "label": "Available For Sale Securities Equity Securities",
        "terseLabel": "Investments in marketable equity securities with readily determinable fair values",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesEquitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.",
        "label": "Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1",
        "terseLabel": "Number of available-for-sale securities in unrealized loss positions"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r370",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r266",
      "r269",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the business acquisition agreement was executed, in CCYY-MM-DD format.",
        "label": "Business Acquisition Date Of Acquisition Agreement1",
        "terseLabel": "Date of agreement and plan of merger"
       }
      }
     },
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1": {
     "auth_ref": [
      "r339",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.",
        "label": "Business Acquisition Effective Date Of Acquisition1",
        "terseLabel": "Effective date of acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionEffectiveDateOfAcquisition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r345",
      "r346",
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Business combination, consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.",
        "label": "Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High",
        "terseLabel": "Maximum milestone payment due if certain conditions are met"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r344",
      "r347"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Current",
        "terseLabel": "Accrued contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r112",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy",
        "terseLabel": "Accounting Treatment of the Merger"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "negatedLabel": "Property and equipment purchases included in accounts payable, accrued expenses, and due to related parties"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r35",
      "r105"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash, end of period:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r98",
      "r105",
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r98",
      "r384"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Operating Activities Lessee [Abstract]",
        "terseLabel": "Cash Flow Operating Activities Lessee [Abstract]"
       }
      }
     },
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r113",
      "r115",
      "r133",
      "r134",
      "r135",
      "r137",
      "r139",
      "r144",
      "r145",
      "r146",
      "r203",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Exercise price of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants exercised to acquire shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Outstanding",
        "terseLabel": "Number of warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r231",
      "r480",
      "r501"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r228",
      "r229",
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r234",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments And Contingencies Policy [Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Total shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r25",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized; 383,067,321 and 382,243,142 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs Policy [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r83",
      "r486",
      "r510"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive loss attributable ImmunityBio common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r82",
      "r355",
      "r356",
      "r369",
      "r485",
      "r509"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r71",
      "r73",
      "r81",
      "r354",
      "r369",
      "r484",
      "r508"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r150",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionPayableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Construction Payable Current",
        "terseLabel": "Accrued construction costs"
       }
      }
     },
     "localname": "ConstructionPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r249",
      "r250",
      "r252"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r107",
      "r108",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Shares Converted1",
        "verboseLabel": "Preferred stock investment converted into common stock, shares"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r257",
      "r265",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt and equity securities.",
        "label": "Debt And Equity Securities Realized Gain Loss",
        "terseLabel": "Realized gains or losses on sales of equity securities"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtAndEquitySecuritiesUnrealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in debt and equity securities.",
        "label": "Debt And Equity Securities Unrealized Gain Loss",
        "terseLabel": "Unrealized gains (losses) from equity securities"
       }
      }
     },
     "localname": "DebtAndEquitySecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r20",
      "r21",
      "r471",
      "r473",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r21",
      "r235",
      "r473",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "Amount of note borrowed"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Note interest rate per annum"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt Instrument Interest Rate Terms",
        "terseLabel": "Note interest rate term, description"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r193",
      "r215",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer",
        "terseLabel": "Available-for-Sale Investments, More than 12 months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r193",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss",
        "negatedLabel": "Available-for-Sale Investments, More than 12 months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r193",
      "r215",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months",
        "terseLabel": "Available-for-Sale Investments, Less than 12 months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r193",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss",
        "negatedLabel": "Available-for-Sale Investments, Less than 12 months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r116",
      "r324",
      "r329",
      "r330",
      "r331"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "terseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities Net",
        "terseLabel": "Deferred income tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r103",
      "r161"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r119",
      "r415",
      "r477",
      "r505"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due From Related Parties",
        "terseLabel": "Net receivable"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r2",
      "r13",
      "r26",
      "r117",
      "r415"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due From Related Parties Current",
        "terseLabel": "Due from related parties",
        "verboseLabel": "Total due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r36",
      "r119",
      "r415"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).",
        "label": "Due From Related Parties Noncurrent",
        "terseLabel": "Due from related party"
       }
      }
     },
     "localname": "DueFromRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r41",
      "r119",
      "r415"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due To Related Parties Current",
        "terseLabel": "Due to related parties",
        "verboseLabel": "Total due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r48",
      "r119",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.",
        "label": "Due To Related Parties Noncurrent",
        "terseLabel": "Total related-party notes payable"
       }
      }
     },
     "localname": "DueToRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per ImmunityBio common share \u2013 basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "terseLabel": "Company's effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r320",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation cost related to non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation cost related to unvested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r125",
      "r130",
      "r132",
      "r143",
      "r206",
      "r239",
      "r246",
      "r304",
      "r305",
      "r306",
      "r325",
      "r326",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Issued Or Issuable By Type [Axis]",
        "terseLabel": "Equity Interest Type"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued Or Issuable Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Ownership Percentage",
        "terseLabel": "Percentage of ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities By Industry [Axis]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r200",
      "r511"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni Unrealized Gain Loss",
        "negatedLabel": "Unrealized (gains) losses on equity securities",
        "terseLabel": "Unrealized gains (losses) from equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities Industry [Member]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r14",
      "r19",
      "r197",
      "r493",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities Without Readily Determinable Fair Value Amount",
        "terseLabel": "Non-marketable equity investment (Note 4)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities Without Readily Determinable Fair Value Downward Price Adjustment Annual Amount",
        "verboseLabel": "Unrealized loss on equity investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r372",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r373",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r372",
      "r373",
      "r375",
      "r376",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r257",
      "r258",
      "r263",
      "r265",
      "r373",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r257",
      "r258",
      "r263",
      "r265",
      "r373",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r373",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r377",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Summary of Changes in Carrying Amount of Contingent Consideration Obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement Inputs Disclosure [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings",
        "terseLabel": "Net change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r428",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r379",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInCarryingAmountOfContingentConsiderationObligationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r189",
      "r190",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r216",
      "r217",
      "r218",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtMember": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities (such as bonds) issued by a national, local, or municipal government not within the country of domicile of the entity.",
        "label": "Foreign Government Debt [Member]",
        "terseLabel": "Foreign Bonds"
       }
      }
     },
     "localname": "ForeignGovernmentDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture And Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r78",
      "r163",
      "r165",
      "r168",
      "r171",
      "r173",
      "r469",
      "r481",
      "r488",
      "r512"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes and noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r327",
      "r333",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r162",
      "r319",
      "r328",
      "r334",
      "r513"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Income tax expense",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10230.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase Decrease In Accounts Payable Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10250.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase Decrease In Due To Related Parties Current",
        "terseLabel": "Related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10240.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase Decrease In Other Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10220.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceSettlementsReceivableCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy.   For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Insurance Settlements Receivable Current",
        "terseLabel": "Insurance claim receivable"
       }
      }
     },
     "localname": "InsuranceSettlementsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r222",
      "r223"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible asset, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and income classified as other.",
        "label": "Interest And Other Income Table [Text Block]",
        "terseLabel": "Interest and Investment Income, Net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r76",
      "r160",
      "r393",
      "r394",
      "r487"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense (including amounts with related parties)"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r96",
      "r99",
      "r106"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable Current",
        "terseLabel": "Accrued interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r479",
      "r504"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable Current And Noncurrent",
        "terseLabel": "Accrued and unpaid interest on note"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable Current",
        "terseLabel": "Interest receivable \u2013 marketable debt securities"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r86",
      "r159"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income Interest And Dividend",
        "terseLabel": "Interest and investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterestAndDividend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r85",
      "r88"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income Net",
        "totalLabel": "Interest and investment income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income Net [Abstract]"
       }
      }
     },
     "localname": "InvestmentIncomeNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "terseLabel": "Investment amortization expense, net"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r197",
      "r201",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r409",
      "r411"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease Cost Table [Text Block]",
        "terseLabel": "Summary of Information Regarding Leases"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseIncentiveReceivableCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the current receivable for an incentive or inducement contractually stipulated between parties to a lease whereby the lessor has committed to provide the entity (lessee) with a cash payment as inducement to enter the lease.  The receivable is due within one year. For classified balance sheets, this element represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Lease Incentive Receivable Current",
        "terseLabel": "Tenant improvement receivables \u2013 with related party (Note 9)"
       }
      }
     },
     "localname": "LeaseIncentiveReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Period of agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2021 (excluding the three months ended March 31, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r410"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "terseLabel": "Less: Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Optional extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Initial term of lease arrangement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r42",
      "r115",
      "r167",
      "r203",
      "r358",
      "r364",
      "r365",
      "r383"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r115",
      "r203",
      "r383",
      "r475",
      "r499"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r115",
      "r203",
      "r358",
      "r364",
      "r365",
      "r383"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "negatedLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r43"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities Noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r55",
      "r115",
      "r203",
      "r383",
      "r474",
      "r498"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Minority Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Minority Interest Ownership Percentage By Parent",
        "terseLabel": "Percentage of ownership interest by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MutualFundMember": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective.",
        "label": "Mutual Fund [Member]",
        "terseLabel": "Mutual Funds"
       }
      }
     },
     "localname": "MutualFundMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature Of Expense [Axis]",
        "terseLabel": "Nature of Expense"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r147",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r98",
      "r101",
      "r104"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "negatedLabel": "Net cash used in operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r79",
      "r104",
      "r115",
      "r124",
      "r126",
      "r127",
      "r128",
      "r129",
      "r131",
      "r132",
      "r136",
      "r163",
      "r165",
      "r168",
      "r171",
      "r173",
      "r203",
      "r383",
      "r482",
      "r506"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "Net loss attributable to ImmunityBio common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r72",
      "r131",
      "r132",
      "r361",
      "r368"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income Loss Attributable To Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r246",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)",
        "verboseLabel": "Other (expense) income, net (including amounts with related parties)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity Table [Text Block]",
        "terseLabel": "RSUs Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r48",
      "r119",
      "r415"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).",
        "label": "Notes Payable Related Parties Noncurrent",
        "terseLabel": "Related-party notes payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r163",
      "r165",
      "r168",
      "r171",
      "r173"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r403",
      "r411"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "verboseLabel": "Present value of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfFutureMinimumLeasePaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities (including amounts with related parties)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, less current portion (including amounts with related parties)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r399",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesScheduleOfCashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net (including amounts with related parties)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r408",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesSummaryOfInformationRegardingLeasesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r44"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsAccruedExpensesAndOtherLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Other Assets Miscellaneous Noncurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets (including amounts with related parties)",
        "totalLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets Noncurrent [Abstract]"
       }
      }
     },
     "localname": "OtherAssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax",
        "terseLabel": "Net unrealized losses on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r75",
      "r80",
      "r239",
      "r385",
      "r390",
      "r391",
      "r483",
      "r507"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10040.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Total other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive (loss) income, net of income taxes:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r196"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income Loss Reclassification Adjustment From A O C I For Sale Of Securities Net Of Tax",
        "negatedLabel": "Reclassification of net realized losses on available-for-sale securities included in net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income, net (including amounts with related parties)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other than temporary impairment (OTTI) losses on equity securities, OTTI related to credit losses on debt securities, and OTTI losses on debt securities when the entity intends to sell the securities or it is more likely than not that the entity will be required to sell the securities before recovery of its amortized cost basis. Additionally, this item includes OTTI losses recognized during the period on investments accounted for under the cost method of accounting.",
        "label": "Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net",
        "terseLabel": "Other than temporary impairment losses"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "auth_ref": [
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.",
        "label": "Payments For Merger Related Costs",
        "terseLabel": "Merger related costs"
       }
      }
     },
     "localname": "PaymentsForMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Net share settlement for RSUs vesting"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments To Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable debt securities, available-for-sale"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r33",
      "r34"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets (including amounts with related parties)",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense And Other Assets Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r478",
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense Current And Noncurrent",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r4",
      "r7",
      "r219",
      "r221"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r5",
      "r7",
      "r220",
      "r221"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPrepaidExpensesAndOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r90",
      "r91",
      "r181"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities",
        "terseLabel": "Maturities of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds From Related Party Debt",
        "terseLabel": "Proceeds from issuance of related-party promissory notes"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds From Sale And Maturity Of Marketable Securities",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r93",
      "r303"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options",
        "verboseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r69",
      "r72",
      "r97",
      "r115",
      "r124",
      "r131",
      "r132",
      "r163",
      "r165",
      "r168",
      "r171",
      "r173",
      "r203",
      "r354",
      "r360",
      "r362",
      "r368",
      "r369",
      "r383",
      "r488"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited": {
       "order": 10030.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfComprehensiveLossUnaudited",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r224"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r226",
      "r500"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r514"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_InvestmentIncomeNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains Losses",
        "terseLabel": "Net realized losses on investments"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsInterestAndInvestmentIncomeNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r264",
      "r414",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r414",
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction Amounts Of Transaction",
        "verboseLabel": "Estimated cost for new agreement with clinic"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r264",
      "r414",
      "r415",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": {
     "auth_ref": [
      "r119",
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction Due From To Related Party",
        "terseLabel": "Due between the parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Purchases From Related Party",
        "terseLabel": "Laboratory equipment purchased"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r264",
      "r414",
      "r418",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r412",
      "r413",
      "r415",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Agreements"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r314",
      "r557"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development (including amounts with related parties)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research Development And Computer Software Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r9",
      "r17",
      "r105",
      "r110",
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "verboseLabel": "Restricted cash (Note 3)"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r9",
      "r17",
      "r110",
      "r544"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Outstanding RSUs",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r246",
      "r307",
      "r497",
      "r523",
      "r525"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r125",
      "r130",
      "r132",
      "r206",
      "r304",
      "r305",
      "r306",
      "r325",
      "r326",
      "r520",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r77",
      "r115",
      "r157",
      "r158",
      "r164",
      "r169",
      "r170",
      "r174",
      "r175",
      "r177",
      "r203",
      "r383",
      "r488"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r406",
      "r411"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]",
        "terseLabel": "Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Securities Excluded from the Computation of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Available-for-Sale Marketable Debt Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r192",
      "r193",
      "r194",
      "r195",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r273",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r273",
      "r299",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Stock Based Compensation Expenses Included on Operations Statement"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Investments [Line Items]",
        "terseLabel": "Schedule Of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule Of Investments [Table]",
        "terseLabel": "Schedule Of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of noncurrent assets.",
        "label": "Schedule Of Other Assets Noncurrent [Text Block]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule Of Other Current Assets Table [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r39",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r118",
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsSummaryOfOutstandingBalancesOfRelatedPartyAgreementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions Table [Text Block]",
        "terseLabel": "Summary of Outstanding Balances of Related Party Agreements"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r274",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r279",
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summarizes Stock Option Activity and Related Information Under Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Weighted Average of Fair Value of Options Under Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r51",
      "r113",
      "r144",
      "r145",
      "r236",
      "r237",
      "r238",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Selling, general and administrative (including amounts with related parties)",
        "verboseLabel": "Selling, general and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessScheduleOfImpactOfChangeInReportingEntityOnUnauditedCondensedCombinedConsolidatedStatementsOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling General and Administrative Expenses",
        "verboseLabel": "Selling, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Shares, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "positiveLabel": "Number of Shares, Granted",
        "terseLabel": "Grants of restricted stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, Unvested, ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, Unvested, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments",
        "terseLabel": "Deemed dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common stock reserved for future grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock option exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Stock Options,Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Stock Options, Options granted",
        "verboseLabel": "Stock options, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r281",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Stock Options, Ending Balance",
        "periodStartLabel": "Stock Options, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding Ending balance",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Stock Options, Vested and Exercisable",
        "verboseLabel": "Stock Options, Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r272",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationRsusActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Options granted",
        "verboseLabel": "Weighted average exercise price, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r294",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationBlackScholesOptionPricingModelToDetermineFairValueOfAssumptionsUsedForEmployeeStockOptionsGrantedDetailEmployeeStockOption"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Life, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Life, Vested and Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Share-based compensation arrangement by share-based payment award options vested number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Shares Paid For Tax Withholding For Share Based Compensation",
        "negatedLabel": "Net share settlement for RSUs vesting, Shares"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software And Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsPropertyPlantAndEquipmentNetDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r113",
      "r115",
      "r133",
      "r134",
      "r135",
      "r137",
      "r139",
      "r144",
      "r145",
      "r146",
      "r203",
      "r239",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r54",
      "r121",
      "r122",
      "r123",
      "r125",
      "r130",
      "r132",
      "r143",
      "r206",
      "r239",
      "r246",
      "r304",
      "r305",
      "r306",
      "r325",
      "r326",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r143",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeutics",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstruments",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r24",
      "r25",
      "r239",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r239",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock units (RSUs), Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r24",
      "r25",
      "r239",
      "r246",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Stock Options, Options exercised",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r24",
      "r25",
      "r239",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted stock units (RSUs)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r54",
      "r239",
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Stock Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpensesRelatedToStatementOfOperationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program Authorized Amount1",
        "terseLabel": "Total amount authorized for repurchase"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program Remaining Authorized Repurchase Amount1",
        "terseLabel": "Remaining authorized repurchase amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r24",
      "r25",
      "r239",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased And Retired During Period Shares",
        "terseLabel": "Repurchase of common stock, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r25",
      "r30",
      "r31",
      "r115",
      "r179",
      "r203",
      "r383"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "totalLabel": "Total ImmunityBio stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r115",
      "r121",
      "r122",
      "r123",
      "r125",
      "r130",
      "r203",
      "r206",
      "r246",
      "r304",
      "r305",
      "r306",
      "r325",
      "r326",
      "r352",
      "r353",
      "r367",
      "r383",
      "r385",
      "r386",
      "r391",
      "r521",
      "r522"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheets",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfDeficitEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r246",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r392",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r392",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r392",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r392",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements allowance"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r189",
      "r190",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAccumulatedUnrealizedLossesOnDebtSecuritiesClassifiedAsAvailableForSaleInContinuousLossPositionDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialInstrumentsSummaryOfAvailableForSaleMarketableDebtSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r53",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock Shares",
        "terseLabel": "Treasury Stock, Shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureRelatedPartyAgreementsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain Loss On Investments",
        "terseLabel": "Unrealized gains on marketable debt securities",
        "verboseLabel": "Unrealized gains on marketable securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureEquityInvestmentInViractaTherapeuticsAdditionalInformationDetail",
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRisksAndUncertaintiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risks And Uncertainties [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "UnusualRisksAndUncertaintiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.",
        "label": "Value Added Tax Receivable Noncurrent",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureFinancialStatementDetailsOtherAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r357",
      "r358",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity Primary Beneficiary [Member]",
        "terseLabel": "VIE"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r404",
      "r411"
     ],
     "calculation": {
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureCommitmentAndContingenciesComponentsOfLeaseExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding Related Party Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSecuritiesExcludedFromComputationOfPotentiallyDilutiveSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share \u2013 basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.immunitybio.com/20210331/taxonomy/role/StatementCondensedCombinedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e639-108305"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL6283291-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82921835-210448"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6419918&loc=d3e35281-107843"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e845-128460"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868678&loc=d3e848-128460"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.11)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "http://asc.fasb.org/topic&trid=2155941"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.23)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611133-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r559": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r561": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r562": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r563": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r564": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r565": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r566": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r567": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r568": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "i",
   "Publisher": "SEC",
   "Section": "3",
   "Subsection": "10"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001564590-21-028010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-028010-xbrl.zip
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MB?R<9;F2X'/6'P++=J@S&N.31IC3@.DVRJNKRLX+T70>W[LRK2'1Z2+DLAJ
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M@)5E[K1KQQFWHJ@5F(S+/.A3N -R15$Q8&O:_&G=X:?K"J.*&5@0YTX_4?O
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M1<^%=XV*G@U%7Q46:OIF35]7VY5/>KHF.NSQ7KU%4-QW!H\ZE)I7D-W<ZVR
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MK1$&?FQ,77,R)<;LB,B[!8.&S%NBZI!:+YI"[5S6&0ZQB[1S,M]1N!!/M*N
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M8RDZ@GKQ%!T4HB?DP PFFF+G.NBZ6]-7QU]8YP44IA]-U8L%ZJCJQ\V<VWZ
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M:Q]394%S1%#K<^V:94CK<\L7Z*#M,+X\NVEH?.D;'P1G+8%,M':>-S:/G1(
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M4.\L4Z$JQU!$3$1,/, *:QAX@#7J8V*E@A"5"OH/@_N#:A3,BA0,1K_U[K%
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M&2N"9+AM6H3C\CF#6FKI3"NX>G&CYXK3Y=1@\#-5_*L,!LC%ND(D:#6KIIN
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MKT"A'!D5A!@*9@S(J "%$F'9VH!-J::B1?GY>)>W<KO4*N-N+31MQ\5MVA)
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M+G)SI,] D09I%X08T!@@2 %I-P+M!FJX981VPQQ&1R;.D8H#!1]D8A!B0&.
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M8B=7Z/6T?WQ3Z5PMF82#-@F$=B3:1TIL0KL2:%=HR;1_M%/\Y"M9B8.V$@2
M)-I'2FP"P#+QS$(')040<&<C;"G@20'/8[<)A( G0VQ"P!);P$+;H_T#H'HG
M1<DP'+1A(,PCT3Y28A/FE=GU%9H1;0?T:"MV"/*3VXK1.-9=DY]'^4&',F%^
MS>%Q?IK,NF_>*-JZX,0,E*)<(->CQ':[T))I69+SBQ^&5RRZ'H$;<EQ'0LA0
MG)BAH.VW$FP@95"!"X2:)5"ST':)4),,Q9$;"D)-)=A RJ "%P@U2Z!FH>_.
M#E'SS*;YJF0T"$&)#:0,2G"!$'1]!.T4^OKL$$%5.O9)UN+$K 5!IQ)L(&50
M@0L$G26@L] H:)>;S^K.D,XJM-H] D_%I%)1>T'@J00;2!E4X *!9PGP+'0A
MVB5X[NSX*2&J<J*JJ!$A1%6"#:0,*G"!$+4$HA8Z'>T04=4[STHVX\1L!@&H
M$FP@95"!"P2@)0"TT"AI0P"E?>(AR\^.YYKF#L-J0S^P69#0,?1=Q];$#S6^
M^JD9 ,&.^M L#CMU0=&V/.4SZSR4(SL=C]WF,?WG>)*0Y[3-TNY[<53"$_(]
MLKY'H4?53>"/G.C+\Z/4#_"0SX:&^@6+D+729!6VPH&*H/+H=)Z0DAA"2+E]
MI"PTMB*D)*14S"H04NZ=!824A\(00LHM(66A$5/E2*G@$5A"S8.U$(2:>V<!
MH>:A,(10<TN=DSN%3DR5PV;9<Z\A%ZU:'CB]>&+[D?QA-J?<ZNF-5I]@5"%I
MW/9('$)0=0TV(:AB#"$$W=*^L]"4J?I]YY%.4"7PW+>U( 3=.PL(00^%(82@
M6]J#=@M=F:J'T&V?@:6]ZF%++>U53]>P$](JQA!"VFTA;:&)4^5(6Q&.9L"R
M/R"D5$CJ""E/US 34BK&$$+*;2%EH6/32DA9_4:QW2Q[6);@[TB'RSYW>-;V
MXZ'+M&:]PL.S:C/DH^F:GL4T,]3\D?;5#*RQUC)T#35P7P-GG_%A5F00';/=
MRY'_A%E(TX4P^APWR?U1AI5YOVB[W#QFQ^D9O^G7,'"=< S&*\PY3H7&7)D#
M1K?\Y]=Q%$:FAYS;[AFF.?_K\NKS<WX7>%M-O6%T]$:SI4Q_DF6^V%(8(>.S
M6]94!/)'9SD4!0;"^/59^7?EN$CPOJ=JMVZA:Q@'W;'O IU# =%E\NP[]0/R
MS<A:ZC0C([!7%E ([-7E#8$]@3V!_1; OM"F2RFP7^$X]@L5\$OS+H;>;G3U
M5J=LY0&Y!B<$/^0:J,L;<@W(-2#78!OU$87&9$KY!L^=.=^X*@.\@U9#;QEE
M*_C).U"Q8)$< W(,R#$@QX <@\T<@T(?-J4<@S7/TJ]V1*'=($_@$*29/ $E
MV4*>P-&PDCR!8U72$IY H;6<6IY !2T!-@XE-%OZH-LD[^$0-("\!R790M[#
MT;"2O(=C5=+UG8="6SVEG(=2KL%J1S[U9K=##L$A"#65'1!OR"L@KX"\@IW%
M%'J%5H%;=PLJVN@W].Z 3AH<A%@N:O'PEHL/?&H[#^N]=^XU?\N\EM'<&R9N
MV&E@T2L]]P[B=1O)ZU;X2G=CIIF6!3ZZZ3V!C,,W$3P?9%8S/<V!U[D/3%<#
M(8ZP.T0T9B%#58>EA\R&OR9#+!/"C[@)Q[R@-G(\T[,<N"Y,]@)A?66R(9$X
M:XMD5(=N;?DZXV#6+>:>U88!,W_6S!&\SCO3?32?PE?:VZK$O;%C<?^'J8T#
M-.=_NSO[^.7BQ_GUU=W%U=TM? -VS,LQ$BRV'YAHDM^!E64!8 -#\4*E1\$Y
M1W0 ,?C'6[P4S(#Y85X@MJ@U>=7=@O)*J@\!1M>6RK+LN9Q,$.Z?/CJ^K@%F
MUT%C;>TV'H:.[<"O6;@E2[6'E^4>S.7=Q=<?QH_/MS_.SV[_^\?G+]=_@BR>
MI\;H/#%&YUECE(8C>'N;<S,<:Y]=__&(B//AM>.!9?;C$ 0@?'-,+_;=,\$3
M!386WNJ ,#;G-DCWAWM#TG?\_14XY19S7?0. 8/3?TN_D_\[]]KOS#CRWTO/
M$[P^UYR&[%WRQWM->J<->.]7"_MKO>@??^;_WZ;^<;=;'_3+=J&LP"%6@NEE
MMB?5D-^H=U7O :H0<V!UZ)O\_JK[:G>,6AHB:37JK1=4)R'D#AJ?%1!@V5:S
MOXJ/6GZS$C"F?84OQZ%V <NS9^WJ]JQIO^UD@Z\&&XK:LZR-XXG S$9<(,PA
MS/G]55,%S#%:]7Y__;C\:8-2L]$T"'SV"#[[MG&EU&3O1E =@"(;>/!*^4RK
M:+*!^W3 M]M'?7E^7SCD>R'_#L*2UU.&N0[O7L,L](,3.2Q\MT3^]\0! 5';
M1Q9%./*L5[ O%JR (GNJ"E!H![1O)C57@WMBU+X9M1N )QXH "K$!(*5 V<2
MP<J!,.KD8:7<UG%K\9=M;1V5X< 5BS37#\-2>K"]L!=!^RZ#5F2/-CV;LCT.
M".A6Y5S)?MA2XF!)N<G8F#U+YGT:FY\2Z3?T=M^H[)0(J?F66S\0VA':G9 :
M$-HIR982:'?XTZU)S7>#=B>2FE6&^&?VO^,P$@=^(E\+&&BCY;A,\^3&&S_%
MORT\"A3CP2''TWQ*Z2K'275;4)R4-5.5#>2YJ,L;4A&""Z680+IPZFP@N%"7
M-R>O(D>7A#5:]9[:3.!]KVI#4[:QF3(OY/U+-/8+_V84L59,1RB416P@--^D
M)W"O56C^-S8#]A%MX'G&!&Z2KUUM &!';PZJF_Y'VK[_?2PAW[&;7-(%)=A
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M>_G<N_Z6?;?FWEYNB2FP&#83?-D6+'JE_:CZW9CQ\P&3J>D]88+=\R-XOAG
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MT]2<E"51U>(3T!+0*L G MJ#9-OZ0%N8X%<1T%9ZHGU5I&U65VI/0'OD%I^
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M9O=8XU+@VN5D@G[DTT?'UP5++SVKKIG\RT_,XB$8\47+D+] OU S/7OY]\9
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MR0P>3!:Y:8F1/DA^\,!Y.L6<7'J^!-D!_C\>6N4A>,P8R<)7,,IH9I"K/IY
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MR==&YX]Q\20->&>S8W$^1K&8.3LA)8Z!2T+*#4NZ[@+QL@$M_B@1B>.EX^+
M5::R>FX;P5(&BA#HE)]Q32HHXXB#LYY9RNP(A%24[*Y(>%SW>)K+2R*#]H,3
M^H&3[C- $1QKUMPBS*\NO5G^Y1.&9XF0/^@@G-C9]?Q$&=!"N(=/W.\<@TG
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MVZT.Y;<4%"!5=9O ;7]5(J0 "G""(AMET*U='MW*!S ,O3EH$[HI*$!4O:$
M$Y( A@LZZ&&[958^B$&IE",+X!/9J6[CI#E!08P2;EYGD9OW1>#+9[;-.$:K
M.:!4E8(RI*IZ$[Y1A<9)<X+B&&4 KKL1P"T,9<Q0K-]09_@J81B56RC%A"1:
MX20E4<K%\<BG(+*?$MDI5*$()RA44<*3*XQTD0"3EMQN+U;1;"V:*ZR85)&?
MIPHG"."HYN*T.4&QBC((U]\,X3:INVAUJ:I012&BN@L%F##KFC$-V,2))\G
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MDC^"G_/X$MPDT*:!/^0M6UP?5!NN,D/-S': >1PS3PMC:YRYMUC,D,$WYGW
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MH,^R8F4/(6CU"+IZ3^07$;1\T*?7U#MM@Q!T?3$3HI1(TG-"MXN8S]O(!.K
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MQP7+E?"/'P: R&#5D1&"_0),X_O((@72+KF^H\,<=:7S6!P\F*XT[9ECXE#
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M$D]R[[H7C"6,9@Q(@EA*A-&/$<=,*7!/=V8B, RPADMH\9R.N_C+9+BA8IX
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MOH*3?V*Z6/& G**= P:$8@R&E&P*X N+RY#O./# 0#PO'T@/S5:06%"/+6%
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M+W=$;2CND<M13)/Z>5Y*,4WJYWDBXM0^9Q,J9?;H+[*6IC)6J5[B.P&Y8@A
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M;,8IZ@R)"I#U5U<-1 6*4(%RE&T\#16@V@T*N[^SY#Y0[89]O-'GP ^8I4U
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M.5 <H&0S3E%G2%2 K+^Z:B J4(0*M(D*5"/WH>SN[RRY#U3?81]OA&E*_OP
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MYEHT787>4W,VT;VXU/6WJP]7M:BA"]=^;]PWX.NP )%-)8#G_),SRY?7^6<
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MB6K-N1HT:;5!;L]D T/N&>#&;XZI %YWC?51>-<@:!5;4</R]/D1K)SHVBJ
M%Z$P#K:$\V$C08&W3E0=LZ!NGGN!ZA"%,JU@PW0/G<2B!\OJXD (GYM=YTB7
MYZWX>#$LJ"(6@W(X;0YW) 8%D&RU(I-&;#I=9 DFH4;A%.8WPHHO%E,*;1&'
MM;^&C2Y92!ELQ1Z=>08V 37N<""UA7FQQ]@#8[-CW)\DL>^6UDGH]*=V.26
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M4H:O/O1;6:N9O2@@Q<3W<=A)%,]6;'86_)/0TW"P>7@>Q9NKGJ("3!WXT+:
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M[K7,,<MUH9>80I8;W4XDT"XWNITDYF2F2A T2)A+Y2+Q))7+.6%.ID&E.U9
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MP6!WNATK.+=B1 </HKEN.GJQ):AZ65"%;WQDXBC:>KOE&_>/]L:%0=NB2M^
M*)I1$IR=.!G;#[0_K8L+^YJ/-96#!9=K*FS<421FPO=;QD'W&P:N_EYU!<L/
M'Y$MIOA$+F&-+Q8+WE:B]\-5NO+ CD\'ANAD:;M8,!.\#O<HZ8;?;;S*<2;
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MZL,QM/BM,Y&A!\_6?N+Z9.*X-Y2?4+=\,ES-M%WP?A[A;3^:<,T&Q9>SD8"
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MGD/_JV,%".BV?[QB[QG>=+HN7LD/T#3)S*-@"#[X3HFCW1H-8A\^(JS81^P
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M3TOU=1!^^INC"^NS$\+7M[?MV^L]4#*7R[5#1YR^V76)#][9]&Y;8MT;2IB
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M@U>\ T$-J+N?4=%R/PL%R[;>\N>[VX2[W'2)AB[S"Z@]EUBO/G@O]AK,XZ]
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MVW'W]^:*%OQH ?\M)(O$<YZ 0'&[1*7#?3>T>67 7>F:K?UL5#J=[3LE'Q*
M8&Z0LI +*.87T7S/>"XD3?8KNQR=\5K"V<S0B--05+@2WEZQ:61$43&$4NY&
M*2B^+N;9X!?_];=QMQMR/HO)5(+^'T@;]"Z=]V^J'=.SJUV_]!T@*;<D#@+(
M52YG&=?>ATIA% X<_L.Q7;?V"!J_X)NI6G=P>/HC8^K\>GRQ'^>V[ZJ6?FN
M64:LF__XAK?Z;*'5"12-OXA'X;KM0?A'M9WG[0:\138,5UT!,9S4+0NK"(U.
MGFZJJL\H-U<F<=<'8MDO(Y67F/P'W79GP#"$U-*J]N/'TL*HDA0:9,50)0H
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ML"^4%\MAT]4UY?\/KK[7HF<6I7>*$-7C !%P@)_#6[DTL([TNINBWYSG-_5
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M2^8-", YP^/E2>\7OB);."\$8,])S<RQ)G"P=4,9O!@(#RVY2C.?RA$O (@
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MVNN6Y=4F_0W5>]N=)ZZ<H^(J[2 '-*8S_+UYOOE!N3#.U&Q=:*_*-3I5-A>
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M]2E%V8BA56>>'Y,YJ'3H0,;%?CB>&\=S2AJ;(O"SQB=>$)&?)B]\-^26IV(
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M'L[$%(.GP-(+MI\.+DXHF]5#24,2(&M4ZZ #3.2NHW+'IR)S+YM>O"N3]U2
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M*KPX2)'?.FI"^%$BOI&>0(RIA$'1KX(BAP'R:GRP&S@3X?H>[#N!M0B?,8V
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M&%!H2=NXN\K8ZQX[>F,+$J/@)?$$#@18$.SU9,CC,-?#@=[/)#8;F@%\]X<
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M;18.I*^5-T-U<,D5K*Y(%;V<*HYV72F[Q),1AB#J$*0<Y4*%U /VI#(M^3P
MHX6(F--IG(M_?E4..;A-$$[;-RY(?SYD $!"(& CTF&M"<@X$:OLB4@5<?0#
M3)Y$@(A_<= [K"(Y!?,$13HJQ:,TX#M (31T]?;C.6AHF3&2JXM$LR9C \A\
M]<D>,)G46TH>X?+P-;ZKSQ;O$K:]^CW'*%\TM*(X\&\EF'0AV"AH #%0]'+Q
M0%#BF5G"4"_A)2$((,NZBZ%1>"[)$80S!J%4II*"HH/PXW ?P%M'NCB6Q1QS
M] MPMEA;>U>@HNU?3>#;L0Z!J8KC!W%8!=;@Y*S*;K6FY(Z!'L9HE6+L XE&
MFU9S)A<X%A-'@HYY$R%SF!?H1[/+PHY*N\% -FQ#81Y0;LO)F-Y"]G91/55"
M?"]RL(*=;ZPLO(H>R&0+CRG*7]1::=G((UQO(D'5]9]:,._ !O-L,._9!?,N
MD'5^ #5'/8E0S'7)A#">$I 6<*>6[NQEG&=<D%0C9=@A0 -E)ZB-,O(QH.%C
M<HCP5YD@/X&V==X^;X:K'G[;Z^TYG@@"K&N G69_ZXH)^KNTT%=NFD2O=<V$
M!Q!R9TJ\,K^\=G013$^/=WNLWF3'Q]VS!NW^[KV2XS%IMPU54/WN\6-V)5U@
M@P68GU9.1@%(  +D7;_M'>^UH*SYH-<]J-D>>67-6%F!>NAN>QE\-U/_UGP9
MH]"?V%OPGKP%_QC&H$B1S\ !2^'1"\I^1J'8-O3]R-TB'YLCMX-^+6^^,V\>
MM($W8S7;%CTGGC?S1B?NH[/G-O45WO(H/"J_V(K4+4.Q#.5A&$K/,A2K%^X^
M);>/SS\^(JS-_C1H^^6?H9OZP/S\QVYA]8R9]8/-\-+\^^GVPKG@E.+H1J*W
M:3AW7J:<YO3+J]8-5&,6_C-P49]MM,:S_9 3!Y]5=ZBVHF% )M3S;JG65MS8
M(](*-"R1#S_I.%B!84]#V]!@!49[<?,3 ZG-LVD>W7?V@.98_Z![TFZ2_;*D
M *5U3>FM*?9($QV>E61MWS &*U31Y7G<ZQP>G[4/.<_L>#R:P]E:8%9.M.D@
M6#G12K2\/.AW^KU'FQUGC\<R.?$48VSM-^HNJ;7+_1AU-KYF?4$[S(W:B@8K
ML??>@, ^/=QZ:I$](D_\B%CKKA5HL*>A%6BP F/O3?^@<W:V]4C573\B-KZV
M@Z;8!V[E:>-K.RM9K6/HB:/!2E8PQ4X[AV?6=_K8:&CK$;&F6"O08$]#*]!@
M!<;>FY?]P4'[,//,#D@[0FT_N_:X_4;?>QZ^$(VP<2JVPA<T_(_;XF-7NW#5
MQ([&'>UV"S#,T?EG:>B$X.D*C^7::471]M/0?A[2RU:G%/Q9"8"VHFI0:L!R
M)W0]<2VJMW5BZSWQO';5\;<&,UMGNSZ^*+*6N95-+3A!;465E4WU\'=J)=-3
MB+ZNL\[]*,7^Y8/N8]@VCT/5GT6BS7 SI&35W,Q[,DT?L)_8HZ)O!\7_0_H=
MFS:;+.'N6>H'K2VC^3FH?-*ZPUGGY'CK/*V':E"WDET^JV/7VNZ8-:69M6ZM
M>-N%<V;%V],5;R_[)YW^X:.E2UD!US0H_BL-ZH)/]=RNEDS#:_<PO+PUT'DI
M=7G%9G9@$MT'G(A:=UAR:1HT3D7-)WC+</G@;IST?-Q;'/0<*JG0CP#?NZ41
M@X%($CB_>F(<G._!$5&.HP?_P6O77U^^?/VU/;XXT!='2JV__KC\\&BT_O+#
MTM4O3G,XU%J6U#<2S#HTV[71?>LNWL^N=K>!5#!?=WF_BK2HUL-'^NJ1VH3C
MT_+CAVM7 WC8@B9>] ]S;/%]2+RU[HT,K:X'4K^T*KGVZE[WH+P)UZ^UE'_I
MR],-E*TO3_3E-+MX_>I/2LO9<!(J@(F;'.&P'O6$^O)]<DVN77KY7((B,-T
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MN+(>EMKJ*2.9IVP+#2!,FKG &CHM$N:,'>=%WZ3%/O2!?@"/IQ$FV^A8C3V
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MC7>XMFZ(577P+=GR.3ZS\KSLY4#[.&@M(=B&</Z<_J!4 #X")8OHCJX R*>
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M6N..J-L_+-QH.T./"W&@'TV@,#P8M3&YVM)0O@8O]FGI*#_U#;8],%OB*V"
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M*H.@V[/7>EM;0:EGT-SI:E.[>]K\I"J,6.'II;&J0BB$7X2J#)\0B=Q0KGC
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M7,O^Z21!OF7.VP389''@!K I@KXT-3I1+7^QCQ?[>+&/9V@?3U#U6)H7,=X
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M67-)^DO,W3?"^Y#CA:A%GH]SINVK' !JIX.&71)(A9B)IAUR^2S%]CX@M#I
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MD*;7C5^1]N-1-$;L[1=^*L3(_M93JJ)ZB!P5K 2I+X_;H>V%%W'C&+U1T&<
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M0J'RQ$@43WVC?<+6T'58V>0>Z&/\!80 P/!)3]W$9\X:H/B8_9@:.SW((B[
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M+?(X BA@61L2*929J(OT:&"9625E4.,1IW5"\ P&M4(H3+!J.J^Q9='FP#O
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ML1$-MUA+ CB_;/;#M=6(#%H3:'^>(Z=%^?$P@B&HK[&,-YB(!MU1<+"/<EW
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M"FVSF!.2$:;+A[V(-*'!+#YTR47 61(E1B*K'6(PM+XHIL%YFU8HU0\<YF*
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M(RP+>Q!"X(6/0"F\E]\O,E&)P L'[YTY8L[14TWT\Q\&>/54%]&!5S^K3^G
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MZ/F#/TYYL)_[WYB#H L3/@)3]O'/W_ V/,#F5W@J0W\@]D(OO_^1O-"/%9R
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M% \90?^]2?)T@]N"I@SX8"UH,Q.PQ!88LYR60CT%Y)*'J>>9: S&.J9('_:
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M:?M[=>^;@RLA1!CPB QC1 0\WX 31SWV]U87RMLG59L^"3H?BSJ%<BRBL8;
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M@MX/KAM<0D(HX\)NV<$JKL\BF3>T8U9U.D))B-H')1&ZL(OTH8Y%TRCZK2L
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M"X83<9-4PH),*R#>>\.;["[:=_4Q/0T;.73:=T%%-ST4.3JN\AR$RKQ.['C
M T$) Q\7C-0HZ.U _NPJ_IFY8M(:NCR3W1I,=<<<@$)B"ONY\9XM3V5.\=^,
M\ 93;<I-N>&5L&8 C<04$<$TGD+A -C@G#';?'R?QY3C9L,+6M[T'O\6OS?I
M#ELL!^SR]-3<?I>C^YVSQJI&>+*,=O+#$RS*W;W9+JQ&2),D0F\B> -369;*
M(T>]JX3GA=BBWUB7$7ALN:R4;A#@HF@WI*\E"Z6*LEJ'X&&'/.\P^]R*#>C
M'W>:!F^A5!WUG["6!0U WB:9.7=>))>@=Q+SW5A6Y)FER!@1Q>UB=31K(#+U
M[WEIA;J?GU7I-L[3E78!L52CR+98MHJ(\'<NU\J&&)D%$05H: 7JF=)^W@*9
MA"($$PG952"H*!J+.B' _S>:I]#^W ZL]N\>],=)]_2E>5&A""J+B1!<A_I'
MU5K=TK5,$_"B@A=OPSD(2NQFK4"/Q(50/Q ,BX;?;39U)J_>9[%,Y<JF%PS
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MX(:Z!J/UWP_X]@*4GHM6;A,U\+EZ4+/F*FU'8<\'7$,:(97.D[4"FMW@@FV
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M:=?=S5T8)# T58PU,C164C3 <9KZG9.N*K4^P<GYI/)(?6T+><4MEF'D@CO
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M.Q6)7_QRJQC4'W]O924V(K^'---)"7LASI&>78_GYJ:,/X:O7RCCJI&)5)]
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MN9#:#$;/8/0,1O\!*]2F!Z-Z-",$1YW/4._.D,Z>H*P\=,F2QXE G*UZMSQ
MA5$_=8"C!J^^62F]@.)=@2=M>MT/F2>%'BQ7PZMQEJRN?RHX938VZF\LHH1
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M558L6%2UUUR<?#B8DVVM(_44S7?&W"=,F[[OE<*FS(157QN[56S(G3IJJ48
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M+:WT ,D".YME43>/0WOEE0A>T G.R@Y?T?FY!R(:W+@6-X_;,OC-0XL;/.8
M9VHIP?6G^]4;C> @L3MEJ-HQWH@T.LO X;(J$I&VE:B?!$[<_1"^>$;F=1/G
MB4!K0;Q8:8BB$_<@T&/'H,KN738]\-'WVQ4^9([S#U%2Y V, #C;> VPE:@
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M,=+O<W$R=!3,O)/.LHG8MEW/S0WF7JHAI<3M+**8L_]=QH)16=MIT]1;'74
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M4E'&5=-6HBO.(\/ZPJHOC'TH-ILBSVPNX>?\Y>^O<VWU'DT'533K(B7U*JW
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MEF;5]N\G:7DFB7S;5J$%=5E<4HJDVO#2YE4-S:H)LL'PE352I\X"4'<6;=[
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M2]59UB2UYML.N]-+QHEW0LO<&Z/>3ZH1__+%BW_TO!GY1Z[^4-"$_/](W%Y
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M-@$WO2]&PJ7@M^IK\M+FHF0S$8OR[K%**[@O?>#KS)0^\/3+3D+ +(VC_70
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M:L@RM:U/)"-[25 *(G ZHBO.]$.X1A'K,5O[G*=']O1IN;]Q:A:G_1'GI':
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M>VH9R\N[>XA$H=@OB/+JH/'4K]RSK%Y,\X>!L5/+6,E:\/Q6A/#2,(;?Y3-
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MGKV.$I*RS_W.1EHO.16H<70'6%VM:WEY%T%T_AUX7<$3\5(AE8GGK7;6?G?
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M<#^)@N)N=9_"X)"@%@KFM)^NO7JX0T(O,O<PJ O4 DKA4J^DM:AB,-X(-HA
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MQ@8L4/)R;_G864)RP^AC:W0 RK$B-3>;&H6\L[#&\K!0(XAY6#2'1,,S*K^
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M$LXF[6.T17'O;;FEU^02?#9!PK3 U(-;O')'Y!,G3=>Z79N_RU=![FJE,$C
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M&W2ZGC/SY^OQQ&!VY#8H73O0O;$D%3"1"6H@4#39@RX9=,_1YDFCWTH./I;
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M'@99^:T\(N*Z237(%*\DM&:BM*P0:'/N+O' 0(!<] BZAVC)XTY;@7";!?5
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M*J_ 7G68<Q<,_(\K"<[F+.D,N3NJY.C5O8X\$-6]O8M[C1412RWI00B-ISZ
M+$I@"T[)*PQ2[![;UG8DTFE7#="H;=G&2[.VOAUD%$X18F E8T-WLGEVF:$7
M*4YRYO1O)QX_[MZZH1@)8G?D<3R=Y HK#GAP]BG0[%9SUSIE;F!E_\ :"Q,S
M><4^O(_:3TQG44Z\=!8?9VHN-4A,!QMT9IZA\5 1H]W%9C762!AE!K(\HP:U
ME.IY8:XV/..0RE*TQ1I.4PCF!)1*=X+"'U0\\=@]6Y.CMW8ONJY>Q,&MCZ
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MR=3_W*[-"9&\:<[%BH/7Q;+(\NTQ7SZ_^/;@WG<T3KU]_?N3J^WCC'G'+0O
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M+!DEWXX0LOZZ"IY'FCX+F!FQYG/U;,]7$[/[.#N\)VZ$B1OA[MHF;H21<",
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M,LDS0K89C&Z[I:#5^%U(5&1C2MI!9^LV!14\@<P?J^DK$2%=9Y,"!J894H*
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M1>0-ZKJW@P:]J9T*)GH?59-&XEYL49_2V-':CYNYE@@QI<S*4W,UA)Y;KFH
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M$5[K8ZJ%MR=4*T[M'%3S#>TA:MF/T]G]]#T1X )Y,%N24@7JBHD1 Q>D#I:
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MN3IJMM1/GIM.-LIA22HWOT(C]!::3!CMR>F%:A! '8+R&PZ2+?3OK[-$;=8
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M3H#"9$%3!WMD&G?PTQ0#G4G^Q]79MD_0 Y> 'I@.TM>=BYY EO]WH-UFNP]
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M,VIY6A +IL+<1F4YS5H8S=OJF[O?)ODNDW,WO4V7DGFKM)F3T:*42YY2<:1
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MSFMF=KKF1ME$EX[B]OE%0 >4.Q#8%M>T! J#\<'[=J8HVZD@6$XZ+ 1-4")
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MA&G1]D%IEQ &W,K\BV"B(V[?/#HY.F-.'YR-0@,X(^)<7+ADV>>(+.MN)SV
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MZ)1'A0-0K<:3K)!N,N\X:,HY4*DS Z"],ST.*Q87OJ4^O(UY,<LI732]:*I
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MM$1&P4==E^0\5G]+5-!6U=@\%D\4L#[!C'DQ28KT'9\;@V 4UKO31UM[0<2
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M,<@EG#C04B=HMW/"+"M[&R(;G'_2U;NZQUC=_\7Q*9NTT]@Y'<Y:G1M$M _
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M^P*IY^Z8+R M]CM,[;^V7K36H4URP][GOML_K\^?EM%,#3UUSMJ+&9/E PA
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M+:##\:D%V@INEZNB5W"[@ML5W,X0W$Z>N?!'D4 -7F?L8GL@")6)!_%-30Q
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M8>)TP']5$HLD]55)K$IB51)S5!)IED.A_Q$]I.0-%TIHDH/_WI^:/E8Q)KN
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M8E!G=4!IV1C2/9&Q]:U8'$1.FVD-V#,CAC(V8UHUO;BYL\T!1<:SP*&)NWP
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M092_XW0;E&%O,7N98 _JZZ,LI[)C)UYD"N$H2 2]A?>=*PB]Y"UI3Z(V_P[
MWC!" ;VIZ*VC[P<IH*OPU)/I<*UZ#\IC&>P**2F-=N(F/ MF/:'!/!*<0+K
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M!['!5]/H 1L$KLO%B WW)86BNNRD;C@A5)>-XXLPC6.VT9FCM**Q9D@T%FC
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MG5CJ;A+ PGI]UK-&.FM]V',;M31FFB:E"4;"6O>(X%L89X6Q]':JJ[*H9";
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M4.S*-*SV%M7 >L.>#QIG5.5QG'9#!6#*[8Y\%=LQF C@5LH NO0;NFLL9$*
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M<61)KLAT KKV25NX>"(N)DSOM@8<\\7!1!V:U &C)E"?@,@B!U7U\3QF[1B
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M+$*5BH: =K2)S1:[J7"5F,#GP<T.!3J@66R-0>6T.ER'F*!V)G!B87O131#
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M!<T;.')BE9B$%9C,98I>1KAMW\?+H"D'\>\31O2"UWW;(HL]8_*(WA$0R:.
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M^_K>G!U3#]J:A,&(904U\P9'N?U-)6JF $5Z Y;V"LP[-L/:6_8:C(?40!R
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M)A7>D>.2G"RY+(]*7#NK&X:+"6\J:ZS%"9X["A,NG+J/Y+3L/-VYW!JM 0G
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M_?#5>^2W>_ !I+98/WT-O?:NBT_8&-W*!>L*!LI.U#;857"?86KE@[6DKH1
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MG,\)A&7"VUPB-Z,[Y0_8[69B\;I48<UDG.U;@WD?[]+^&^Y(J)U,8S4N]*#
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MQ_'@6N6)F>C,1;,HN>6]GST:G^Z59=YWRFZG)@K^EM@-NFM#6A1>#KE/6=F
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M\GB#FC5%ZXC,[^_X,D!-!.6602H <$P\Z :<.S.P4)H=83F>@Y)TSQBP%[^
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MI+QOL?!_W@8LML,O9%EG\V;\FG=G5X9)_]%8[:+!+Y;/BFSYW/988$0XD:B
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M(Z7DVC_:_^)>QS<O7_8?^HGWH8_=]6%'^Z'YL>MO*?L4=.%=\*T3IJ,D>\7
MM/W;_BVACU;IPH*D$)6NF2)R_\"[0:"(GEZA?D^UT660]00]?ETD+!?>$96'
M+CRF()G:N\LYB;,J+=)!&6KKLE[POO^7PP>8"BYEGLU(0HOQ7+&_AS*#H-L%
M:N6"$C%GZ5>5OL)^H7G3D*[),$&[194,JBTP0?Z)^?T*>[2=IN>Z IUYJYB)
MC8HI;NUFN_H:%4-<NQH1"J-.'D(XWV]C"$6'!6YRB8KBW<R2"0M292T!YF&A
M@KJ4A6J'44'F\^".LRZF?].DZX[N!77=G;W_]/&?-Q^8+V,5)HRA7@,G@],]
M/MC!@'80Y(RP?J$#O;$=%_=H45=$T-[%\ /&O?A%II@34.F$+XB=5*FBM+GS
M/4^/YOU/%=:R@L:;3"C_Z3=E5Q5J*D_F\AVQJN/:W)O20R46AGO]62:T[4/S
M\4[^C+7\[BA_S[6=.M=6,D^T6_X&4O6@BV[^.223!]J?4 >%MYFN,L=-+KYR
MKF_/VDM7H,_VBJP:.8<U7@HY4<&,EZ=PJ@]@J52.?^"(MQB> *'TYBM';T([
MB2&^\.TB%EZD4M!NZ> 3X[6L(]J!NC[8L+L?X-93G: "SOMA)]O6(D&7OV79
MQC[3,*$@-[@KY%ZHC-9 SH&!^4$<0U$P8!'#%RNPPJI("EG6&0B*&,]#^S]"
M!JM.<3A?B;TNQ(+TQUV+0$8] Q= ;\D,PB27A-ZW\_4!U4+L$PR'Q+%_?6TQ
M1D>F7QQEU8:K>X=%^8'* 0KT45\=L[-PMHA.'PQM)FHR44?! N A%:)7]-M
MK+C_MC%5D('!%6XHQ]].8$!SKRDI@^JJIA3SB5AK[\2?F7?IR'E +PA[BBES
MH]W![)@ZOOM^V@:&^23]1?'^O"MS4\Z(5Y](2%42]K"ZR\VP1-#WHU'I$8,)
M?3LF\W:07M+P1"!ZBN$5.=I\U$OW$8:+2I#VXB5T94?# *K2Y:@W524ICEMF
M[7S1Z5Q,4'.=7\G/:5;;^;[4;K[V0KI"DIC)H;>S5HP4R? C*%J4J<NZG,UV
M)RM5:;+D[<!VP?1(V\@-73L'KNY$@"&A5IK*$DL-@1$S$?G[.5!!1C2.@NY3
M!?3F7[L>3?.,X;1T3<+HO2B*E!=756!"SU KSB\<\E"8808=3%)4W-H^YE=\
MPJQ.62]*T'/)N04%KEMW[0H@[%*C82RJJ@I])S(P-MN)NVW;780\I'?Y78*B
M 2TWVTH7<JU1.Q+P1!H^^O,Y$5MA_ED)2F1&VN&H(&.YEP48U4H3=)(E<==#
M!G-*QJ0GH\"^_A/=G&\C]<9,?9FL5"[R=/318$_RB";-NXE\R+6T&4C,D**R
MKT>+7GY4Q )=O)JD+':%+G=&7FQ?X>,-A=_LJ(;"%W\8M @N=+9\V""H*F%,
M-=)PB R0!*]!!*@M*_'Z-D=192;T-&=FO93QFS^\QPXXPO!H D! CJH# ,G#
M/"GH$S0-Q+;J"=X2LZ %%DE=>$M"MVDY/_1+7:AR"=I]CD(:'O/I.[.NW6O!
MC 0-17$ND,X13(I+4FU#/ZQXPCS3#O9E+"GO QW4CRD5^VXYS"1B1\ UIJ3?
MD#KZXDW?[S<B7Z,=UN:)2L6(OMV8$NT3"U"AF;C%PBF\IX679>L!6M #4A8A
MM"MDQ2EZ@;# J4U[N:I06_O1PO? U/ 3I(' &D>=5P6: T)5_])VQZMR%'SF
M^QAH'D\L5,;H+9N6<##^:V7<U\3Z9_>30[Y,V@3RE\EH0L*+-(CB]Y&_!]NM
MH6\'91.*+7*BO\Y/7&"1$0R+8YY\MWZP^@9]-^C9U60"P&T@*/1.,JKG 1@D
M7[V1%8ZA)M%@(6@M<UF(++L#'T) &44$)#9@U!JS,M>G)LBHQLT8)*@:Y>)]
MH#;$P&>$=F?23\-'^@0\#=2MRD51:+ 1 FUL*%.S$R+-<"S+ *8EJ)1$2"'#
MJ["P?H"?NW!3ST0[5;^DOI^*RE*'=/W^W-=M*+=H^.V%+'>G;EIV7:)DP?2*
MNA.BMM#)1 \&OH+K&+P_!Q):H)2^G/@.;/"39<:@T#K*S;4==!1F6=%T3CJ.
MV_1.F,SF>&#CI0([YVXWDA'^O)ZD-B<F,I/Q8YZL#6$%W5%?@9VU=">D*RYU
M49B#RT#+N:N+LC;_E-RJ#*Q\GCRE>ZJ,+G2A=/;W6-]WG0E*#H;Z[!?>0775
MLB;!G#*R,I, S[SW[*%:P%1.PT>'MD"CT'[L$GF7T1G')VK8XKQ UP[MU5(F
M9;U:J531:M.W8S9UPL"[#S\'-[:TB7H<HX6Z]:SDG"/,3\$HBKFK-^0#.^(_
MH\9?ES*M\:MO>AW*,E%E(C_O+):%!AVZ;$9J*Z]28ZIKR]!)??C-)&MM!2^3
MGS$@ .IZ@AY'0--! C:!8RF,Q4F1O/ZK7"EFDJ'+29#L,YXL8]\/I3V9_=P]
MSPY(G0/BY=C-66=)4/M':;/(8.L!%C6!'@U3TGKR0G"W:#>, "UZ+JUV%04&
MR4;-Y%*6BOD1H/_CE%$<&"N=I[?C/L$C2IW#;:"I)J&J?IL*W-L)YC"QY\&K
MG?6I9##TQ"IS.2\;TD/G2)]KN)@?0!E29"'&403C).%^ *'+4J&O#LP1@NV5
MH)_#3*_WI$=,U=U[%4S15YAE2.[)'Q5(ULHUS7WC%8K0MBJ5H8;<3OP&W8D9
ME#,7+0I92E&D(/P =?Z7<B\SO=NB/)6ZKG9D"[_;V9S8L 93]R#:C=41-QW2
M=)\4(%L!AK_U+JLV>M1;[N5@S:Q2>%3UB;2()33-CVG>W,+'RS33)4W&_S4J
MH6Y>)%\IB\Q3@@&4<>)HL2ZDW#*R3,[G;M$"%Z\IS9&\VPT8)>*=&B%];\G#
M(Z<N=Y*3S5?7;HJ<HZ^GM2&PWD/77@FB%9BZW0V4T.XZIG(_8JLJ7@]&EXFO
ML.1168]O?3+*'46/R.TNXRG #F,L)3IB*-7%3A<,)ESG4UDF%O9SO/5U&55Z
M=>Z-EXJ<F^#T&3;9=+525(+@Z(Y89KW;C;!9<?"\W__/A_&/0"_^7L9Z#&I>
M%8*L#;L0U+Q>F0_Q/(!N]Q+>>Y,YSBIA[![X2;'<JY)QV%,KQ+8(D; *"Z[%
M:.PLEA]#*U]PMR;OSWM6>S)#YE53L:#U#,CHX887W,)[3[T"FCH4$&'\/"P.
ME2!)#NU!3J*F(9^/FYULG6\PTPK;75:4YPQ)DRL:'>M$WU-'A6 W V:E[.Q"
M$A_L VIASI!?I#8/?:E^5><F5V6T'/@J#HQ42BFIH4JG*- RH_#A@?V T6^)
M):]3.H3/AA<_!%WAL<".1Q@T+5[?FE_ ?V5O@GOL=^!H2#9U. G7*!C3*QR4
M(1B9+J6E%4;!/V 1A =C<@G*4!C34JT.9-I@PF4AB1"U5<JW??@%*GV\GZ#K
MDH)D!?6#\?Y+.XL,>R<%:EBSC(3]NT4YO)$IZ'C!;##:BQU8/=![&%"%3D-F
MW#HRO.3*BS$KDIMO^/5_JPNK3FPG%)9IV-4+;@4;@CL>]Y'MU<!T6:=OVQVZ
M1EB>@=ER<!^H*'0X)78-W!Z('NQ3@%.XZL)V!('<F-B5\0 G77"V3A9RHT W
M"-;L@M-DX9G;7L2Q5P@3X 2,8\<B8!O-80^#BVCIY!PE"8I@J,_U0,9!?Y?5
MZ8^7&/P\'O83!V*8=)QRSHN04$<,;0VI[G;&+&4D/L?Q*V%^&*RP8FQEN0&[
MPFIC C!$W?4W[>3AK<ZK#<BMO:IHSA$WGZ)H2#,T//&8?XF99'J\@-NO(4JT
MVDN+BGNV&/3(""_HQ-W8--4*=N$"FO3HO;M91/ G9('G'/#1>R"Z"V[- (-4
M;MN<LV\FZ*Q'"8+(=] ,KNS40#"]BO*M"I!"%7-8P0VS8U^7#,*VB(&VX.1]
M?@%S SL+CG,)8A^ %L,@*70\G2+ATB@?2RJ 6!441R-SQMP7?T(K)^7&1FZ.
M3#(#P0@P_]=)0;I'1!%3RV=K?W;U.#V/8"K=&TLYNU4&6S$#?^8<TWQ]/J&@
M1DX0YTO56,=RH;-FEV7,"S["_8*I1;CA.0DHWD &-E2J8!6$C_H Z]QP)'O?
M48T&S8M""[*D/DT'DTE0T"*XA/8T]@+UK-S]GK2](%"#/B+J8+>D91UL"M:8
M6WTZ5]3_;IWLN FBGH7VM&K$8TQ)6/=W/^6+.1JX<]^X$QXJS3A0'VYZAKM:
MA2R$]]7]5!SHDK +XJUDRUF)'Y)CF?(3#_=P\NJLE?\*W0_TU=V+H\(?IP^%
M]=UET+*WS //!/,^0YY/)^,%W*,'G3JF=WDY_[[" Y;#L+7P7EP*??>F)QKC
MC'1V/ 24/J?0RYHF)_-RL4NU9!2&G)0O/E4&)L)OI[B0OJ13YVGH3N5RYISO
M-)W-"9H6=:G@N;V@&[I0FCW1'*X\.B>P$>;P4EE7MFZ'Z7Y+>2-R!C!D\*F>
MQ1=+P6)AV,;(%$H24.>'^@?HF*M\K[,]6B,^\ 5A'\KD&M7F*/!TQ4)0##_S
M[UJ6 1E*=&D;428+&K.(9^N<@'SQRZE)5J<H \P#IO-F(?Q-'2<S";5P7+@U
M"%JB]6J(#]<SSR9@>TN*&@=F=J+[?E&0?&W#VWI7)C"C#$]Q=E")C&Q"[7Z
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M><<:,Z^/K@M]RV7>B%20=H4N=\8^WU>ZYCW)^V8C,9?5DO@:PT)]RM%B1GM
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M;Y<YRU+IHX4?E>-D=BO!8+%_>L+@!TR&V%Q@!GN'%QHEO%1=5^8_&WN'P\@
MYG/0(UXT?X"EC'B_L.C4'W@36-RLDY*K[KN/T%PB<&(E8 -]BP6X>@R=&,!1
MDD0XG@+;\ZASX>5EL5P"F,8,-9NL'2R"=L"A+G'QE-"!2DQCX>1EHSUJWNET
M%H0DJ!G^"I--Q3/8#=,):*WLJSMGM_LQXGIXHCWHNNQU>FJ?=Q*@*Q5Y:CQ*
MO JI5^<ME(FMS)=;E#NSTFB<&C0=&JP^@5)"46(= 8+=DOX0CE'WR&=1ND9H
M#YG.UZ!>:=I^SGS=Y^S)\0="/.R:>9Z@"01=5RGMX;O<NEFF;VE#[*PUH'VN
M!_&@QX+Y:H$X6'1P_32\.=A,4^>[PMC \7.X'OC/E04_@(7[GQFP'\]D[F!"
M$W3"P7D"C7UW\0$(VG_7LN34D!S<CGG@M@"UR\#A"^/=0<=,.DV5._P%,CQV
MDQSF)=/QHFM <(MSYG&OH(DZJ!9.XL[-:BLZ6'.T94&/MY^B)CG-$EZ3&NCQ
MH>FVKOT;A?"BOX-FA4/W\<<OOGEY_:=OL< EJ/VYSDMRF-TT8C>8.;;=AU5X
MO,]M^T=&^G2O7+E$U42="^;T[9[\"1X%C";W$;S=X(/CE!)' JN$0Q;@ FGA
MR@%^*V YR[A$>Z' \8<@F9I(PAQ=UH_<DW2BR/9SN<0A?9BOG)<U=(LI5?[&
M%1I,EF^I+,^1,!.D[!.5D0%!HW]\D"J8B8")?7>RX/(N[9A9<J<?/\O0;,JI
M\?PG:/\VBK62#>HA.2V5HK\ZWF:.HI>H)""'X^V1+ 08!5*3M8XI25V6B5XE
M/-_EL>O!DBS0Z3%RP=.2[QC%S=:FT%&^<-:&>Z P=Z@1)(S];"SH;-1VQYCH
M#)CI(QX]^%(7=:G(EC\?#A T8B5EICMZ;G3%22UX7/*,29/^=#_6]COCT4Q=
MH]-W_AQPT*W334ZI].!?#?3*.#+K_*V)K\R7?(L!PEY<% UV_>+U84.;HMO1
M3JSEU:*0XM.56)D-O179K;@KGR5?'<.]/=C6@XT_MDMG)V.;/N$N_RR232%7
M?WGVQ<V[O_[]^W^]__#CS?<_WGQ\-E0PS3<N9:I;D7I;F[47F7F2YBMN;.;2
M6I/WYB>:6LM!0WTEOGL$$8B=#._^GWWWQR^NW[SX]BE8=L_#ISLX\8NMX@;*
MRAY%'UQL[4>!WJ=)/Q\=(G:QC9;,G3H&,8[%:VC$6F1KG['06$)L9/6/MTU<
M8O6<>2JQZJ4<$YLLJL5;1G36ZE^-/%@J_L%<[C@.9CEC'=SA)%@[&.L(O9P^
MN$=M3);.RVVBR8?RG)88U[_3%<<3F<C[%<=>%::KXE+B&5.'OXY0R%*=KS).
M2_/]X1]U%BZV :::I5J%+['TAEEHOOK)%BRFAH27\]>;7JZ$%2Y%NH6F0:_\
M<L:.DDV'SG?U#7+@JD4#\/1_C+LXD.CP?-4(U\]]P5&*T*"#=;8^1-=-FRC,
M!85258_37%SFXM8'ZK'9WMI6E6)GK\[\ Y:[.NHN7DX!,(7N381WH*&*<V1K
M;_@!YIOCV"M]Z/2:[QZZ:4JS#8%JEO\:J?]=,\4_RN=[/UYLML+#TIZQGC]/
M>B)=?*JS3"PL8($M0%$&/Y8Y8[;QO\5\R^.4=K^_W_,7J&3&%9XH70=V]B[2
MT]]#M9&X"@9ZMV4_W"CUILB7=N0])$!'__IB.Y!%.NN:D_H5B%W>Q"A#LT[<
MS=OW_\\#*/R.GIF-< YH/WJX\YSGG'^HB\9:0F:2;/QUJO%T)\8P"5W6HUU#
M_@_(\4Y.+TA:2F8+6$^X3XYI<EF=H?780AWT ;A!CK?=SG \ 7\ !!NRN:!#
MDSZ&1D";6N"M#+(-O"4Z7C./E\:C9DG$7I-CFSUZJV8:L?D/.$AN4(]19,.\
M.[05O02;O;^EQ[0XR+Y#TCQ?)R@131!7&-P&C),6WY=@(:^ 5+9>8V<PX3!X
M B #0AC_@:([:9V]W# (;)R; 2FZP0&V#XB#L3<@MG;,-+9[L!?<,@%G\C/V
M&RV'..MW>EI6? SX7F=[6CN]"GG[X--_Z;]\A!+<X]H_UP,%O9:)A%\+I7<;
M83S/5-:5HGR\:TBI_<G9R;(NJ^(.G,[S 242T%9X\$;C,"YM720!Q/?GF<+F
M:';;AX_-/;%9TDQ3;KBKJHI$I,TX7.QS 5Q-(1,)XGSB[ILEV=T\0BE0&/ )
MU*PYZJ[_M::)[1PZ!(QKKQYW(SP10/F=8*+6)<:"5XY3[!Y;#Q:UHB1 #*TR
M-!?@]Q\F96,C=$$R*Y%5<5#9/D8B PX<W8%WDC'-=I\X*6F'S)W\+ND1C:Y5
M2*6@IWI.S%H<+!:'ZGI:_&O\ Y(<V$G86+*3KNPR_D&GWB+22NW5.-&YGPX#
MF8$Y8ZK=IQS$5PM'_NSYPYZYGO!$L<-#^=B'.>KQCR(&;'K:;]JI)6T[&"H4
M#-F;/(O\#-.K7+[<,SN6#DM1@%\)9A&Z!B'H-V"^_2;X@>P5N.N0(5(,QE'G
M(R'<EN0[<0#S#+XHW_T&Y^"-3SJ:/(F"=+1<,_L@=0\FQ%N$JH3=K;*V!D>.
M!_Z3#R*MRTIO&>_+V573;\5:62<UJ"0OQ5:LT6P$ZC^9>_G$\#I=WT'FOVB:
M*MT-:?)Z9=Y:0R-,3E;]VGD-8'R#GL-6%)\DHUSCS7%@N%'NTE8K8YS047\'
MA\!GD)O9 -%W6;71]9KR,Y!A ?X1,Z@N7?V6V],%X^$54]=T!E,NN>B!J_ZI
M75F?Q+A9(.DPJ@;_=O,!RX"(7&1W):J>\*I62'42TF:9415E*G9@!17VE4/#
M-!PQ( 58" R--5@"TV&8&-'<Y%Q ;C1XC0Z\TPFO9-QSF=HY(9_ 7S'O"S5@
M3_&^T'S;P(93&LD5LE26)>$%3@^<W^6?*K6G:LC^'.'P:!MCM0T1:KG=98(V
M3DYJL#:W!.;Y^DLZM;/E*AS>]S_D"2?]<V_^,&?XY;'Z=G)(=.$SY<>+#OZY
MT1.-^"R<'K-QO<A4":825ZC;</U-2RB[-5*Z00,\]"GPKM2KX:%CH%HB#>A'
M6!?323.HHD/& W02?.JTAG.!1@6"P?9&Y&OL3>H])T\1.+*7F\OOP;Q8W3[7
MR=]X/] 1"E-.@I.1;WP$$E_EYN'06Z,'J;D6JU3&21JW5]ZOR,\;\[J-[:8G
M_ T^]_.9*ZL,)0T>EVL];P6(J /SQT&031C[P(BYW4DLA8E40!C'0H*%=U66
M->DY3?1GX+,"(8[W("CH99R_U/(D0[>8*9/.BJTWJ+%DG5*'BV& ;YR[AN<]
MMLAS,!>U &<EHY$?;S;-43+O1]?25>2+,Q<16:%04$X$.*->,#J49O0E;J;[
M>*]I$Y&55 CD'+,N2[4@$06O)MHF-'\<4JH$?V*E:]+*N%>I$WB&4Y@R"0%Z
MZ]L<M;/C.NMT+0XG=*[\37"&SKH?P68?PQ:D\2BQM-2B!E][T*Q=["= #"?M
MJ'MQ3:8DZK22=^$!+3.Y%VB?24C>GV>RW&Q'_$@K<+KIDCEK[%3I0NQB@W.+
M=-3N^N9TC<(M@>>8/KZ3@NS*<)$#H$N!N>:\.DZ7*Z(DQ+,^T+>C.IL9Y73.
MXXG1X4X&IRYX#G:/7*XR,*C;2:-W4+1S2"H4<LGMX^3=0]=-SXSD'S3J8<^>
M+#([<@&>#MR\1$'KW.6@&85VZ".D5+#T0)ZT&:&$)1A=,87E#WO)$3I*F1:3
M'RQ^<@DC3DGQM*0K3_%W%7FFQ]ZE&VP\1'8]#Y;SM[JPR;&MIMWJU[C&0AMF
MCS  8'J4UROOO^9X^O2<[8!^O]*])%.K<[73UB)YL8@!RU=+7F.VZU86DK)$
MPS.#X4O6.TP*57XZ,S:@SE.+KS$BRH@4'"WS#H,*6X@\AD8Y=Q??Z6M-;F:
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MJ<\4 A:78!P2SJ86P&*( D/6A105:4D=Y-+XD_%>6)ZBP_P*6;:6%,L4C3,
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M.FLZG^<))&(!JKRE#JCJH.THC:<!ICW C"W,G'P&>M5C6>&@5 3K(3YX*"!
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MILIW!,$94RN4]N',D0>71:FG>&3Z4-WQ7#;/U!WF48C>8T>/3<KASBM[@G#
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M1:!#)HP%2\?#%<_UP;8/^R)8+4E4E4@_@0*&2M=>9&JI4'01/.B<@D%>#^T
M;&S0Z>[-H[H2RX9ZVOPI&=;^R9$MNDAR^,4KY!DRZ4T=.:0=:6_V2"KETOP;
MV>SYFJ]\^Y_I._IM8$,;J]?>P5ZM"SL-M9![)6^Q[I_!'_N\D)9H^2@#I?^G
MCUW1XW3$SB\=97LE?P??T>YH/92_(>8Z'Z&/Q@\.!*B$2,%9ZZ-+6:@]*[G\
MV*.CO%;/:1U'G'B525V@DTC/U/_G47MQ\B\.M!;-OX#.A2+7XV9:N>.X^O8%
M2YS$D1>O1$Y"*SV$2UI(FD05OGOG9WIFMPHNX.?+Q!+>88BHLBX*7><,4S(5
M)F^'<C$]VFE!#)SFOB6:-R?7255^U>:ZP?FRH?EGUF;N"0LX^3&W@HDV\H-9
MO);Y5)Y[)/A2KNRMG-4_AVN2N#SROK_C:#^;\+J-)&59RV4W/P0TF@+MJT.U
M!&>L)E0.&=(-XMC]L F<$A^J*5AS,IW&_X"\YFGG9/HWV _*A'Z&.U33HY)E
M#M4<:O!BW(AW5]JE2.CYFQZ\%3OC?OXF^AQ#)G"REH8U3O=LGOYH3VR0Y^7G
M _2)-YJAV+&^A4SA',Y/O//M9B]\' VC/+GZ6.\*29:CG2?UWKQXE(2TMNA%
MK,@,Z]5<%#S@36=0;VF2L6G>4)F:AWM6)X7G::)%3 =W0PX#\%'EH);:,PL^
M??,^E\FBCS>A^!H%Z*1<ZB9HV!@?;.JL!CO+(AWEJ;K_0,>KP<P-]%Q[.7-!
MW%S8Q)#F5@JJ?N 2"H#X+MOT4%B#@X7TJ"<<$&7:$*4 !]R0;9;(4W 'AP@0
M25VJJN:!M$)F ?:0**R0<_ (P P35O?BY0:Z[&V3\J)30X]-)Z#+W,,7A8X<
M:IDP,*T&GA>:3.I&N2'":('+S3P9T/Z:=\N3Q[Y1%AT*<^J4H!N+U17S>#L5
MBA(U6U9^O07IJO)S<WCJ%:>UV[%_J->+L@UP>;$"V71 ZUJCUIX,)3QO"*6S
MYZ@G-U K2;_=#6R9MW9/L12"2JC!CX2Y%/ $-$8S[/ #HP_;]R"5\<">)_^G
MF7]&6S6W20*SYDN9JE+Q\/,Y\XF[+ 88L\![G:\+*E\6$JRZ6ETN[:QEHWA-
M?$]3ZY^]LG ,G8+E#)F/DDL3[[9!B%M05Z.S:8R?5&>L.H\C86M+J */N6.V
M9N E6?<C#68=^XS*DSK?%7*ITDHLR,X]QP*(._"F8*:H6\8QN)4,$XB"/#%P
MKMVXM:P7TW<(PBXPJ/@9[K*C*')YFSQ%TQ"XE4.E\[S7)S^K<4A=?UJ]#PSR
M;(2<+*K&>+_AYE#0!PAJ[]%^ B]26&]04DE68'CFL,UIP^:VE_1M@1)L)?@9
M'E4"-KHOP:81FCC [0?*E"3+#@&L@JX?@#62HVX\[%N%O% ]RK?K^<A@U)GH
M(N'"%Z8XUR 1U=D[S%86U(5]1.4-7AT3VH5 #Q:,H_#P0QMW5YM_.R6;R)%\
M"8=.Q+%?K=N)Y7'&G\<C.35,>1Y"59#"">T*8(6?TXU3&WR"@03K)[IRKXUJ
M02..Y9##0EK0;1%WB=J:?SXW!S$GVS2)^P'G_#@,<1\#D'RSHP D+_XP@(0L
M=+;\UL?K P 3 #OR =UR0!41#&.6QMW)-(7>AGK5?)6KM^,8$Z_MPN*\S %#
M0?ZY.&0\\\$TSUWHP&*<0?-$[J4#%#+#7V)/U>"D.KT(@EG ^:4+=T&@"9@1
M10,LV_"+)EW!  4UDV#QAODBN,@.+XRQG0LY/#X>LMJ@=P,:(7"2,EC;8LI;
MSQ91)DV3'TZ@!<D0RF>..HP- ]:HF7Y#6NF+PSQ_!ME+T+BPD.2X>2<' "JO
M0_ ,9MUT0F/9G&F,0?@'$+=$^T$!24J_SVE7*%F) B1YZ(TO^#F<K3F,,9SV
M"5[R;8Q7-$.9A%"'PP0[NJCH;FZW)HV%;KE,38A+7[T_#! NXQ\\;J9'G',N
MQ7/K+'MVMM2?=5$O5$H^T&E5RH,?#98H96[+>&?-[<$1P9T4)>KQ-51EK&4M
M^T\PR[(W_9O9ZK6D.U@>CPG(YNKA1_^&UL[D9['=96B#-0@M_7]U=M?/B?D3
M.(@431,:"\4@P/"*U+0K-OS$N."T[ZPGY$+OA.FM=K5?KE_8.<-DG63X>-&!
MW-9[2<2ZD)QN4B<GC )2W]]5__,94GKO=6'LDL [R]"GU2P-2XGOZL+R<H,6
M$XPBD#[,6V:SF O#8ZG5[KM'I=W[:[6'1QMAVDJ.RI,G[5E=JI,^*.\73ABZ
M^I'K>;,DV-46."3;^$O-.V,RVOIJ'SM<;H\TY]D$WC/4B=2E\P+(QG82GM)G
M0F.C5^EA!ZXG/O!XN1R^?<M'\O]$7IL H/,P7KXXI8/A6V>6,NF]?XXO KLB
MF'KSW8L@G95RB!N&*POS 3!GIMHD_S?3"_G#=EOGI"/K^,L_Y.ES,&Q W8#P
MQ9W)&W#%G^,.. _FT#US%M*,WFEFCC+N5.W%G>:0N<T]>A/SL"&K2K]:G];S
MC,L!&VYICV!2&>'!ZV2Z$%][+H1D.@7<EF:W0:4&IS)9XXV]'=C2\[[^*!<?
M)1_,P^R;HAC^QM-4^A13P*^/YHBP.-'X6;80@FX\X?GC707/9H:8[-WL.<=.
M3!U0^@_+]3<9PN0^XT^ZF8Z7";ED[^IU75;W#NE)4UZA&:^)":^SN9E'JU]@
MA/\TR2:EF3[#7_L/0)?R]VI)>Z.#3U@E( NR(.D<5R[0P3<?J[;-6I*NXO!]
M_Y67Z>@4SFYCM"'%*/(:/S/7@T_,3?Y5Z9DFY]PZ1K,72-""P H@X!J=\GW6
ML/2,6:QCWA3FPJ!]57IUD-^PI!<6]C#)N.\39#)E.*QAZ:;AU0= "X(25%B\
M<G+GTOG QW?_\_'JO?[_KEXF%L55UJFM?X-%\[U(S3^ KX8]A<^YW/\RG\-8
M)%1NT6FYD21TOC7#I#NT-,3P]\?0.6"3->C1!>EGEAUP\,"0;<IU?L75TB=P
MZD*SR3 'MEC*7.]506:$W&F#.B^K@@&@\(8FPX-8=X4,&?>.]_874E0<1]JU
M2)!X,^]GTZN#=0;/% ?I,P.F?JM\1<*>AYQ92M,B-OB)I2HY#.C#*V0R\D')
MF6Z2AT0;<<Q[1!OIMK5Q('B_TH^1 @.@)E[$ F842PN_<![>SQ7!9*W)">EN
MOYI@9IO[Z:W_/7?JU[^S[,\K7T:VG.9:1WP%!@^F>QK]%-@>2DC2,]Q.$(AA
M2H?CNON:I":OT W<) M2<,Q709TOUHW<5X6?,$Y"4:%\5+2KBV@*>0]*+[D$
MLEPXK7,O*S5>G?$PGB!5">;XP *,WEU["8GYFT)5NJ -RC1@9P"E/Q@)T=K4
MJ4VKDEK0Y+;+\0U<.^4LLA;G(IK BDC3HUD\2=]EH&8(@J6SI(3+X3=4B*&)
M#/.X^.F:;GI50PY %9N<ZA&8:$T*6=89"7]'V!<"WJ%+_H2Z-6B8P. 2<SHP
M=7((HR%I-.]K)RNK3<%>8# G%Q"!<KJ*@J*,H0F%NYT.C3(8\S$V6!'5*0^U
M))U3^MI3L8T(T#ZQ!\0(Z*^!";1X\P'OQW<G=:6LL4#GO7*U_]3]H!T?=MY$
M8H<F894-Z^:S3JZG-O+"X"8$-2*USM^F317^6RPP?G'1J/CZQ9O#AC9%MZ.=
M6,NK12'%IRNQ,AMZ*S++P?@L^>I8_/]@6P\V_M@NG9V,;?J$N_RS2#:%7/WE
MV1<W[_[Z]^__]?[#CS??_WCS\=DP9&V^<2G30VO(V]JLO<B4^=YGW]U86Y-8
MJ+GYB28C<(AYOQ+?/9(9P4Z&=__/OFL1)3-/Q@R._8+K^(%#<#8.8KW@ZKO9
M!5_R\B]C-> +[J*L%[_8,6>\/42YA4KS5G\=Y^HWV#BPZ-8OBVW)O( X=Z!7
ML[X RX@YX]?+D1VOFRJ6Q:>;68M.APJ8L?C<%XF8=OAUE-M@M?E&*T=+I@4&
MVI&\[$0L>]55THQ7G/&;8;L<<2Z_@1W.VN6;M<.:FO^[T-F<)8C] "+U6'>%
MW(F.08-G]>+<R$K9X;;SCJ#MW&>9U@TTD+6/5W'NPR;T9ZR6MG;XHK2#SN67
MR<SW,F]OT%8J9WSXMFXZYZ".[YW&>?YS-\Z >QJI=_0?Y)[&*4)SSPD?!GS9
MM,R\_5.V'Q'G2U[*U=SS>S-/SG?3H69\ S/WI0^4V7/V*,1NES$' (SQ EUR
M!^T@UCF;@M3.A;7 -5Z,'^4>^*YUG,N_Q[_-.='2P/'FK(]N9<+TK\>FEUSR
M+0->49Q78"'!28L^GK,D'=#0SV=]%S_/.U@[3'6<\PTLYITQLG-C@'SOT;NZ
MI'.GF(6/..,;OCF.<_VVB6S&U0+;-M U_,X8P*-G?0FZQFH>5Y&M'Y2@."_A
M]US1I9?_6\D5I;^!?,O<S;*=UC9G03K4T3*N4HTSX[5@IHJBM<NS=BM:LVS[
MMN><KYNW:W=PC<Q/-H-6YZR29A[F-ZA-2!T=%;P+[D N9]UDL5(9>P?1RE +
M-F7O(U*=VJ UFP$V\P:(') N[-N(<A,<I11M/\Z\"R -0F<Y[]07-_T;9\PO
M$O,C.2L#'VVLF;):#[S1D[$L7Y7\M$ND%:B&]GS&$C1WT/5"EK/.%JEF@E#)
MSO[&>0LS!VN>(MOB_7%K]1:1;;4NC>]=LH 7T5[7#[]+V\7S2O//[26G@-92
MQ'6Q;)=5$XIV]7+>/$,<=>6-IHIE\8J;.H[RZ+DM;9'J6IOUF_QP9],LP,*B
M1*NDYIU?WLY:1[&2"!$O?WH6>2ZOI$V;<XD_HGPJOX7>T%GOH)D<.&NSW@+^
MYDU_,W-TA.8V L7IV!:*TY#H#?2+9?DSSW?.FRFCVK"%/]+S_PT@IEGJ,W83
M-N<+> "8GG,-==XPFKD3WAPFH<_X&; HY^*]@+F3GG4-3 F;/"].,9HY1+>0
MRSKEHK$B=8IF[E'(3&U5+O@(USA!<3.O[O['<&Q'>OZ' 7ZS1A6S>T'CO(+A
M6%?63KX>V<FCHO<NLGWGGRJU9_:IQ.F$S%WRV!-](ET_"P88K>HUECLYS V=
ML_I],&-YS@"M_Y@V\$A?PV]@/N"\U='LJYP8-TND076;X$M276?SWLC,$S1B
MN9=%*3,N VB<FUBM) ]&W,;6L1&^L5,SD;Z!F;,4S3Q5_Y\R'B92#3IW [#(
M9CW/H-(FN)3[F1?-4[W=R4I5<V__L33*LWX.6_%)S7V GNU%9-+J1[J#F4.!
MN6U542+)LXPM/7$Z% ==RIXL$><3.&1,N53N(T7;1QW9'R+;,H07B^V^Q'*I
M@/FQD4J==:3F_/9O-[*0R;S'?<X=>C5WZI/?YTU>FGMI[N/0?P.TU_ 0[DA1
M8[,N5?T&VC'XD5S,5S#K&_BM$-C?RH3O&L5Y%UCI-M(8H=+)S L^L\]2(H/J
MHMS 84[=K%E^YQUESKQJ6%:_D^_' 1Q)&O1%-7,\TLR;?':%_*5>*G:K5:2N
M!6NZ3+27(%+ R8[309WY,U"YX$)KQR8I/R9P1_-J%]PN6];BO*UY)V=X#8GQ
MOI5^CM&LG?#?QBVP83^1ON29YP-X%:MQFW'!Y<]\U$9MM! SE(M3!\V]I:K2
M^M.<G^\N$^F\@^E=H;B>=Z0[J'0R=\XAV]LYZPW4.XQR*[;UWVX4MS4OTE<P
M\TX249;U5BZ3WP $0^^Y$\@BM6F_*0A)#V+]:O?=__Y??]YUJ]N*8JWRJTKO
MWEY;.3K\[X6N*KU]:Q?5_)[*E^8PWKY^_O7K/WQ[P1W]K2Z,D2NVNI!?8C5T
M&Z8B*EG?YG*)*1$;@R$OU9QSIEB+ZEHKV](UX:$/%]4A6*"HUI:F((E?2.B-
MES5KVT='3#UZ#;]TAY16V.(K#=YS4LA2%ON681.Z#;W"?NK P@A=WF+T[GQ!
MS[&[TZ/OR-^"?:O8!MK:.K*F0S'[.?3\_C:^$V\C\K/8[C)2[PPCY%06=B@P
M=@#C4N+?8%TDC2Y).?KAM:.#*IEEYLG4(H,^:&S+SNR-TA/.SFX%)<S.WE9U
M,TL6.7*5)U8>(%D WXP-M!#Y_.GYQ^=__.+ZS8MOU]8MRK=&)5/".OS%=V4B
M0-4A1X^Z__OZ\/=914FV>PBLK^_""?S 6%_?GNKA4_>'"XGREK6TCC^,DGCG
ME!K '"**3(WQN,/YZ)).P:S_Z)=WGC)IK":97M;"NTS^J)-QY3E7F_ PY?'B
M9@X]%BQX[<)#2G$#7^X=2L4\1)&YAH'2;T.E_?-&@D8RE[>8SI;I)M>97JMQ
MQ>B'#H)T8!R'TE)=LM;6W: Y,<S&-<.9D8=&*53_J;&5:< +[<K.QK@KV^N-
M;)VVO<Y&^%OWC<GX;EJ-T#UQ^*C6,I>%R#+*H@SWKQ?6/% B'.2%>J''.54_
MN1PON@9C4N, U9GM0D[ZJ43(F:D\S6HKGEB$)Y)<YU?RL_EPJ4C3[VB:@PN/
M*4+!5-'=-6UTH7ZE]^4L+:)G=_A8\+LCG8ZAI:_'+R0D./C:D31+GL+()0!Q
MN+\JT--B^*U.7L FYC 58$XV04,I[F$-7?SQ/_<VK\B<BY?_VHALA>4?;C8R
MF1KG_/&+;UY>_^E;:K5^4NF<FIV1/1PJL*PD7Z23U)3%5I$1OGNG"?H&EJI,
MFW%JT _!FI*5XW"-Y^$5D*[LI QU[S-3%_K:T34))X<W_*U##@_Z#+V?:W=A
M\K-E0$?OE/4K74>3*-+-%9KS8V5ZT<0U9,A\P=1%8MQ3/1IG^3+#R=ZZ-0K6
MU;N;3\Y@F</$W_$!;\%SAFTM,]7K*2:!946);*VO+]L1#V LVY)E03LYED^%
M--2JC3S)',7P9V](^0D-N@/3F!.K=O(SECD*4)RC]<TCCD:RY6G/5].UIUHE
MQB=8RLHZ$SFI?E[!C\GQ<E*&U^HND=R2DQ)+95F* DLH+&0J:-/@%G)DLA**
MRCQZUE>D&T4DQ_S?VA7V[%*R0(79;&=D^H.9B9 <H!5=.#J\UP97+$?QS2-I
MSSL4,('%EP<I,C>,O7CZP!W/MTS(@K63PX92[YSWX[EA"29K&9BQWS.UJ.CO
M'%( W'BE7SZ8>P8EJ13,)]4=#UV$=K0D]O5+,G$84AGJY%\G5/GQY6 U$@2W
M%/+?M2KDE@$">CU)L:VX<*G>FZ 5NK.3=9VU+"JD*CMKIFQXW6LZR^N 50JY
MDH7,4S(Y#"[K,1]9Y<NZK JZ(C?\@A^PG-D]_2*B>RQV)<AY,W]JQXA (LK.
MFC@G<7HXG*OR#B-ID.< BFE0"0C0'9/>T%;D]4J,'X '6"&KLAY@J:%SQ9Q(
MN5WHY1T=H Y_"T/>G$V,7:@7YJVCCNI/.9F2'?(M8_G!C]5XP.5[<F"DFB>C
MKJMOOWC+$0^^7Q5IO2TK870_^*!,L%IMP'"P?;Z848:+:=8?U]1'' &^%<9F
M+D%S]&Z\_GL$KAF2Z!T' H:$<R<LBP;DA$ H*6Y30Q#*:&@)W@F-%#A)QAKT
M"<";H$N0/MY3%GNT/2#D^IJ180D,;*3PJZY+8/Y9D2'"T)L\4"*!6="&/0F\
M3!"\@G:?=--(& B2H5SJTGR(]5,=E0KHL"]LNEZ6XR&8'QRJW!@]]#I3S:SO
M=7P >/S1@H2PJB,:&5L\I&"%'8X:PXJ;ZT+?DID99VFV0VR'>0BL>^>DWOQ<
M".NK.W3O\[%6MF]V5"O;BS\,FM,6.EL^;$U3E<A4BK2Z 5UL/X "1-83AX+
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M.4WG!K,">FQV@J*.8&'SB+ C]H%MA(=K>%]PS4)*C&)+HHC.T5K],T!#_7L
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MFQ=@XE8;7@K5=8F@M7AI++?8?4H(O3 L='U#&0U/&^Y% T/+H@Z&M$%I[27
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MZ)Q _WO6O8G:@98KPHC<&-3+K2C6A&K<P.3&!GFH!76K08,U/EDI".^*CMG
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M;S?]^B206A6:V@Z^<3W[2V=/EF6>2!TXTK?L8 $J1HN=_K&VK#)<\ZB()5E
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MF'(L"B(,7L1-*/'Z8LS=<_AN H4E#F6I/0*!R;4@YN;U%'HRAUD<D(=G.5V
M-;M'6S&UB*,](_O>_0#!=F D"@**>E4.U,!V*F85G#F&*T_X%\?]V!T=P:=
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M(B)ND6M!L^EC35#J'53V 77<=^%?!DFZ5%*[K @1/ENZ'+35$0=X[M8,\-Y
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MY"QC<>C6CT[I1S96_I&-59(T7"I69T1EU5"(E5[=?&F#YJLO4H\=4$+F'N:
M0,A&-2JF-2<:M5@0$ G+DO\C'-?9.J&Q# :SD@0B%2:=ZN5JTVA(!H$_B63%
MP%7-^13DZ5*B3!G9!C= *2XM4D3!04C>GU14F>U/H02-=B7<N%0HE;)@^<JJ
M93 KXX.60;0,[K=E</&4L.:$(,!V=DA8! >!L1!B#$> :&TCSD3DPP>9+DOX
M#"&'OJZA<\/A9%9?LYJJQ7B<)R!>Y1?P;#YY+);8D@>;92A\7D23NC5H.I]F
M7QR!_E8]S9\99WN4ACDK@A*!!($$@233.^>#@:1)GUR']*@]C#2*7"8UPC0
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M>;PC$R ><R0BFMA#-0XHPU"&R7Y\VB,1UO8=D%W\(OXS7_XBFPEL >#>L-5
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M"E%1F%':@(I"5!2BHA 5A4I1V*1/_"4;!=*C]C#*()G PP,>'E!1^*&$ "5
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M672[:<"ZV+BN@LFBFEU"%2G!SJ);G<SV75>)**.@](A8%(DVG^'6,3%9OIS
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MSR7SGPD/*+"]9P%Y) ZASUC]\N/+7I+>:$1JB^XN&9M4EV)C,4L. T<>-Y[
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M]REW$C]YJ+U;:BL<]]1;I"\XQ+KD)7KM=0Y"3V?I&Q&?7$]BWG0Y+G,8I(K
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M,*)U\HX9W=\-Z&YBFY?7 X$7!Z+/.1@;S\.7"+*6_!45+ITM0 2+*R8#[&T
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MI%LI &2C]\89N-W<NMJH,^!#X[5WL.H;=&TCJT(B6_'\DFJ1,?0"0"F:HN3
MWJ'_WSCQ;[A/.;P=75UB<@\">#O-Y>-I'*SQBDQ8VQ,I89\QQP9SFJ7D+1\(
M""GPA""A+_X*ML1J&D 3#MI&;_@$4"!R_)(^SGHXXS99QY2K2>,:V3!3;6/<
M-#QV)7,C@EL U0JFIB/MQDVUC,=KGWO2>-,MX]60[%UPN&6DQ*_8DTYO.#0'
MWE]A,^*U#%#M5I:#&Q 6L%*M67<PPU_)!9.$IF%/U.D-C]? UV3IY/2VQVN
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M+XFWZ1:%W,=TE>$EJXR3F_HZ%VGL'CUVC^ZZ1W-[7=;!7R'UO%+'A\3,E&(
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MQC7S;S"E7..L-NU!E[G.@VX5=2;IO+NO(Y]J"XL29IWR2[ !%>P]6M3J7(+
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M!5]NLG]IJ8"E$&KK>NXE()8RN 9VM&G/3LCJS\)5+7+@6Z?E(L@]Z+1%.LI
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M%E3=8K!R-2K-CGZK9SRQ%J?S.3D,B/^NVE^HXIWG#?!T="O_VRT!(._[25]
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M%W:E)Q!5T GM**+\!-"K:P,LIMU4 .@?SEUJ9-N'3M'VD2(*6?%:.>T!1AY
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M.)U%[N.8BG%,Q3BFHDEOT'%,15,.CF,JQC$5"GO\U]S&Q@RO4'\L2G0I-B%
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ML_+[2<<92IXIN@WRZY2<]K1#3"2J+S=7GH5QO@\,SZ&M J-$NZ'/VSY]WQG
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MM,B5^C011C9WT7]9EM+V<_H/[8'_K_\?4$L#!!0    ( -" KE+D8_V+9ID
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MTE93B97E_IGES7("<)%N\5?M.KJL^W;Y7!=^;*A[?[9]NG*S.0IE.E0F/@E
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M?0W2Z*=4\6T+309N@GDO0_ON_3-A14$GWIU67 M'I^<9&7AU>_?%EP> S<Q
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M.CBY.'X"'N!"(AH$JE)6>K>F_7Z\=T\]V# <;!&I!1L)$NR#%G9^H4^845%
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M-;H0X.H)K:^N:O[9[#)($S*[9C<P945>!GXW2LK@NLDP:3=;Y"&;LBYBM*>
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M/":=H2#\[92,"M,'2_B_G=ZD<4B7@)]P!)&_\<F"[8W$*E-DORT[&XEAA7B
MR=<*8I6(0)!Q_HCV&;-K%S"Z)?^?&#WY$Y.;#<M""J5'WZ"!GP8_!PT:[[[4
MTY8?X<,(:&Q#P4L$M7#X2@!02U#X-Y?!2HX2/Z0OU$_?O?U0>"G]R=_7Z6-
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M1*BS2<P-&4&2JZ3_2F3U4T@%-O8-7&AK0P(@KMK=Q&5.^7"@97GD5_Q8'^A
MC0UTO2!8"R<N^=;+@KXF1C<CN#KQU<M_[(EPGV#^A$DN]TSDHU-SAW)4/%6!
MJ#Z@TDRF]U(_?%,=6JRMW<7 6'@EYPHX6U#S[73.J3>.PR<8[>E[B"NR0&5-
M2.-G> ?#?<H6.9<OM&H;1A\)VN=XN]N7KT:4RTPB.4L0I(MH77$VV"ZU*HF#
M/>Y"/E91)D@(:A%!*2.@0@)!2OI1*2<U,Y[.^=$ERK$18K<0?UL&AV:T-3>E
MCV:J/3MT$U MO7 JAD%=G3NQ'.P$=QNB'\%K"CO#$P+W#=L4&C0GY;A&EE%]
MI.8I]NY4'[UDJ%XD,T[+MIW4M"<+("> ,O4YC'2 -QH+VHKT':@1KV279&VU
M65CO\RP/$GH-E;TYO-XIWGZ0H:+;(WZ(JIN._C5'WNP=8,[3A[,-.:BPO/+\
MA:71<5W A/$#!4,+_=/=CP2-#&*N.J%;F.5I'.8P8N)\2>(\N[W[HEX6-$)(
M/]8.$G9K9H2-)[FT'$Q826M>0U+X2\VI<!?&"]R"._!E+I?YA5UUTB@E;7VH
MK_\&(<<N4'2AN G2_  *QIXX13<0>%!/7BF],/*"\ESV;+@ZO5;I(F*?YVRK
M\FN'!7ZV]A>O?>E:Y,S6[&T 79MV1_+3KBQO[<SXS+BA7E>LN=*$0:ID.)LE
M<0$<AZ>LMB58VA+U>1 *MH0W ):VM".VQ&H*3XI^5]]$9&I9E[VP)(+X35B2
MY8"T&K$A-X^-$8W3[3?5,Z_F=P9O5@ET'!36$.H>;0!W*AL/*<,GQ:*63N<Y
M 2G'I7[>T?[27+>NSC(\-=O^4XHNA?BEWF/CM=C5.80(W7_%]T]XGP5)M$JB
MC_$FAS"A[&A+F^)WRDT'C>[/NBP,6A?KL73639JR OE7#/)"(-:8:<-% CL*
M+/U!4O[JUT(L'PXZ+!@)MH3,0@VBT=3X'+Q_^^Z/X*;$G#(^IYC+[>HM8;Q%
MO*H,G\@!2D%8HZI"%*Z$5:&$4%2"M7Y5-RG<!7%$_A.27X[# !%^Y\4?[],X
M0'<P?8Y#F/T2YT_%/BO;9I4.<28L-"U:GZ63$%>( W:U/,RVJ[_D5"2R2.4R
M'7=6/O@0Z"R8"K:$CU;GX()I25G5?NOOS(RRI./4TDI3\LANCO2.A_1B@O U
M(9-D\"-4![GQJ1G. BFG4"/.!VR@5W!W@8!'-*0%^E62[<F<&$)"=1OOMQ]C
MDB:&](YYED&IG50I,IK&,$S6B6%4+.E\0WF21+I@"@+*U0<KD40-*ZA1RWKH
MY9X=5=X%W.$LSK/S?2I[V72$@*;%]!%T8BL5,Q 5W$#(V?E@)*/@8"F=F<PE
M%>5/ ;VQ1ZU._JV!01IFLTL73:?3#*PL95MS],%(9(#"LLHS2BSWNQV*S1=*
M_70,$\\>NFX3T8*IWVN:4>C:N>J@*H>-R-)6>6')_*T>LGIBG<O9;%@&O]5#
MEJ=!J'28K$368!=8GHW=+>+"*@O&;&^%MWSGO$'!'/Q:LO>D(D4';FR@[X7N
MNS0.6A0W7?[U7WYX_^[=7SL"%7CU&><0_#CPN-52%-3R T$.Y@NE)(") DI9
M !6F660Y\<E@E?_?P3Q'O*?_+0QA_$SOIBKD[(H$]4.<% ,7CXV7B[\0!?&6
M&'+)TH] I@8DUM+G(D!#;;P$EJ#F6<Y(UD*/W>W'KH!;1E1/16Z%P#O;TEK?
M]^O2L;CIYZ_D+547],''0:%=ILN5MVGDQ,*WQHEO1<N=A<0E"S_B?B\ QUEJ
M2SF^*;MEU%=R>O9EK[@[5^C9*%[&D(YFTH(7J)CQU=T\(>=6,3%M?&9L^[=N
M.@\6MN]/;\$N91]'EEL+*:)UQ;;BR:V59,_M(8)H"\<G"+Y+C]J"EUS&<VTG
M@>(:!AF\2F@#N?@9&JUJ1TGIV_T(:?N&=4_WY7,0;W<I?N8O]M6+60O;-5.%
M)EEXL:*N/8>R\#+&"U3,7*YLW1V)=<U]G>=A"QA+>R>\&L8GF6$XVMSCK5 -
M-_1ZB9CL!_40=9&,%RU_ZR!7Q3C>[)[]*((/N7";S8\0-PX@EM:IMV"A%DXN
M]^B<GM1V[MF5Q[13GH*X'69[GZ\<X>QG&<=G;RIQKNMK?9\YIN:@40?EX4>@
M&E ]'E>*?VI&@H9;1]A6GO&1.#>V9"\X#U [P^)<,W9JB]D0B]HTOCLU]1YR
MW?;W)J4/"N4'>C\C)UJIDBB#+MIC-&VT*Q[FX;;S=<F;76K)V6ESG7MZVLY:
M$N?.1M4RNEX*IL@VG(XV7'LT<7:X/Z@_NBU%SF0?<92\?8>\QLGCZ359AT?@
MGD@8T^1U9&]\VEU<>02QABH7@%:5M0ZXU]EAQC>\^^/-0><U;RER#G"KR?^7
MEPT@*.-E;54N "T9+^,N-L][X&S7] FCZ*K>_5;H+"!%QG#_N)NL V<JF0&1
MFQ^>) -3>UM_2&\>0X*&T)BK)V2]2Z[L&D>?FKU*)9!R>,3JA]7W:1V/J,0S
M#1\= \]DQ&?[&-$FMNHVW/Y27\%-2O8MN*3O2=SN43D>5HA?ZD5-S<YEO><X
MR?)T']);7U<)2:@>R6 T4I5A.OJJ'Z)KW\Y%;O3=\9*?'V8OA156T9W/N* .
M2*YJ2.9RF#N\R;_29I5)5/[Q CY#A-DD=(XSG41?@:C!GJ,L$P<;R04_/_Q(
M'4*LK<7%P(6:2+'%=/47@3%@G.?ROH_[-(GS/=/*Q_B%_DG#W8:HZ /63]6^
M0U6\BGYCG)L?[B6!$9;7FK]XH"$HYG*0WBVX:YT'%&2H.=@NO';WZ,'PN=>U
M;R\9*, IL]5[;>OU@:F@D]GHG?&Q@%XU_)3BS(ZG%90<0,4HN_.P$];W-6?5
M'U6Q[0EXI%P]=ZXF>C*.)>C2;Z1D'.JG88C</+L1AOOMGA7U74#:\B%FC6C(
MGQ&D?R 2KK8XS>-_LI_WJDK%Y^SQ-'@RP9(,+@YNLNPO0)"/7A"J!&1N'0B2
M^>'2ULT(NX+J6S&9(J"(=B)*!2JQ6) 1!1NL0;)4_M@S],_6KN,VZAX')[Y$
MX0;K2*.R8EDNW/>_2H3*3ID8J$;/L''9"'VW#<S*/0RQY0+=V^45J;P2U:=6
M9K+@MEN:22G9I#^>1M,C([,TYS=Y%ZSIS%J_%;G'MF_-PLS[E"O[CO6[)9^)
MSO0; 8X0LG(5XIBPNUL1-2_O>OO)8=9]/Z5/A5/8VL\!VL-5%,'H/GBI;\/5
M(JG8FP0Q?9L;)6Y_]?/SZMZ[WFOR@&%EW7D/3A$4&#? V '"3[S%67.<^DB8
M7^<]%'THE Y^VY\:G!<V23DXQ"T82#8*F>PTMT?[>$0UGFD:M91<$+=W67>2
M15CGW>2N%=C"QH6:0ZH.QL66>+0Z1<Q9)HY"MY D$'%($MCS('O2F\7[:>A[
M2Q]-^P97<P(A8>5'>!J%!<NJRE<(T)'V*9?YIN.+/:2O^@JKN1AF>OXP2DH?
MDQ'2]KV#,.1/9C=V _QP$EG(L*+^/(<'U<BP=ZC%KA:TU86,"RUR4^L;[O/N
M/OG0;_H^<X8B*.93G-'W,(,$XKUF;):A9F6;JX?Z[Z71RAA4W1M;@TKS'Y:N
M+<@&0UNQ>7!/T/X9Y5K8^#<]C5R%8;J'T45,J"5YG#S>/9$ED?PQ3^_WFL<V
M/?2<',,4O$!4,0,9X^;#:<H8,%A&85HGA07%@6F358^KFL@X/3.3&:/OU(1&
M\IZ0"N"154ECBW5T;&)U9 $*R6">"/GV10E5@QLD969K Z2=FEE:\&4V%@GW
M.7PS,!D8L:).3<R*S)PXI?9RJ,J'Z)6<HAVAJF6-43,SKF'J3NT+5:R%UKK4
MULK6E!Z9F"2D6%VY)H9V'NQBDJFQ9GT1NU&B;%V=),Q,JH.D4SL*.3_>/;!@
MZ)'I#(&$)34WQ>%^:;-Q\! CUFK8X%5)"6)&Y:S#Q&W7J3(S$]AY^VBD/(98
M69T3VN 93O89U.F5VT/ V-::!.UOY)1&]D#Y>&5+/5@<VT^7BKS4>\NO"Q;V
M6GH[W57H,IJC+85B6_L'"]O:3@?30J)F CB7Z6\4\74GWL L(SE&@.@IO7X8
MZJ5D[!<]E-W9V$Y@R)-T?F@@49HQ<< :@^\X<@TJTV^H6AXD\N(5)K:CVC0;
M7]T6.+[KM;!A'J$W>$QW/CQ"ER'Q+D!!&IN$PB,*QG[5HNC.\$*\I6WI_;JS
M.(3*<83KU)6?"+1\HN1A/9 YWU7M,J7A+=7EC*T%4LF/1:VCSC\S]J>["0Z:
MCTL-4;'3 ZU)U67X$MJA2=C9'+WI>G#JZ4S7I3E_,2E\I=&5KN ST_.39_LL
M3DB:>(ZW#W'"YC4B'5UWL2B19'$$4_;C<D_HH.%!)EQ,&F_J<G7J@84 S!DK
M"<".FX$?_FC!*K ]')9K 86_EV( 00Y0"P(:DE2;RP?K><X4!WQ=1C]ZNK>H
M$;;/ NK!U4UP6/_#T<&Y7*95#Z+KK]..21@O$]HD'?0VK)Y]QP\H?N0N55;]
MEI> =[2/B&<KN%[ CI=PW5KT%)R6NU1,9DIX:-BE!UFTOOE\G^5X"],JXBJN
M"H8(&26A_80=W.R &TB H O29YCL/<E Y&#"2EKS&I)Z:< X\?K[DE>=$\PQ
MF03H(T[O@Q>8L0+@^Z<@N4I"(A?[F>[\(DG5,*I)<7&7^6QHJ'N*,W@"L@#!
M[ 3L,\A2GUW9OBJG@OCA=!IHMR<G!7TO!UEQ"J.'*3@%C$EQ'8:R!IQW\7/;
MB;NS,JK.)6I'#97_(VFE&04?<"DU"(<7EOH*:E3BY1@ETQLQ?91_!Y>41N$Y
MNJ TK"R_H4 ""F"@F&V>):N9DSCQ#]>N(5RN*N'H>/@:U>S]\!TEMW'F,=,X
MBS]N<I4\PRRG^TL\V?@,M>IQ!\GHHS% UBH>-9\RYR*<O*N^E<$**RAOBHK;
M"_A0]KG-#T4K(6+M7Y(4!BC^)XQ^"N+D6K$UO0)1@WX+LDSL9S0U#_!(F&3@
M%2)\8/8];Y<!F4@@JV3RPSS5H<;:VEX,K*C<$'NHVTD3[&K&0 ";L@;7T[>Z
M;T>*JX18(_F)R0Q0T[ 7_DN:]CVNI QBQL@/AQJ%92#8-U7E*P2]TV_)QH-L
M2.@/O]Y<Q%F(]^P \":%VWB_-<V21LG;S9Y&V+GPK I;\7&&<DDRTH5^[O1*
M%OR1M$M*ZPL$>C!];KRLL-Z 4@@V#Q9B3-Z1D,^TM<!TRLVN67:EXLDCA$P:
MXPT0MN^=%*<J_>!))F /S9;</<DMY8##2GKT&J3"LTI.0' QQ@MP9O//CX;S
MG^6P9W\+K<H,Z=99[1=%HNCW]"4Y/3F8?MQ/+U-WU Z?8+1'<+VII<GN:76E
MB@,,43'H_MQ+U4'+[8(7G= %;N!7QL^3C3()L+"\^OP%!AEBXFS'[XK5HK-*
MR9=8>6NO_;799D^3FHM:IP<:ETHF?GC   AX7#W^*1QUZAK\2CG,:^"?@RV\
MP%N2D^F;N4C#ENYKFLY-_@109CX:?@<XO>;?5IBO0/2X F4#?N6,Y#VBI__3
M_5=\_X3W&<EYZ5YY_/B40YC0I@_DK[\$:1HD^0T1_"G(X.HQA9"*(/_JO3D/
MS0Y2!CR=M)AZ__;=#X#UTJ"KBT( 4$H *A%\:#=EPR:P+1R6BK\8167!-Z^3
MFWW81<PB<H!2$'X:5HC"U; :5 /XE4LT]71_1YR5"7".@BQ;;^YR'/ZFFM8.
M$#%87O01M6^KC / &\!X^#'5CP.#I77E+0CE$J_D C@2ZP*)>3)@<:CJN6_7
MUP;7*(ZH_3ZL?P #/*X=__2-1%77YJV:T%J*^9#V!#F[28M[3$P8^?Q6BHS)
M:V^]9%V\L<?:HYR!BIU/7B #%%;0G,>@H&$\U-.CGK5?>>!!LK&.C7W%19X<
M,<UL7H:XDV7;\)D0/1+R8<&F!"16UJGWH'76=U'$CLZ33H8/E/P;&FJ-:M4U
M*E[#/,^BB9<YEO)=9=D>1NN4_I<>29P=[LG05==0\C3UH[@L#_L66A2&5I!2
M3G[,L<I88EU]+@4WU T99PO6*2@9@[,# W*>9=JP4JA<ZHLW>9JNP*QYN'?"
M E%<(WJR&,?LP%?:,=LZ7@J6\H[)O=+2<<G=/H%9G-T\!>DV".$^IUU5,S(+
M*V;+HW0T<ZX1NDYRY((G:#$]H<F)#]FQ+&9818<^X]-8U ^ 8YX'3S(<-#@2
M.I#9#@RZJGZNXP1>Y7"K=FHP0LER95)%><*R,<H3,*8^UXX=HS=6/];2I=](
M(1L@R4V5Y;G>>G.."8LTC\EL3$__ONQ8'T7R(]I>7GK*E*:G&9HEZ3N90JLS
M4+RAC3U+[B"AAZ7['6NW6PK@PY2JBBW6T?$2<&P\)CX HH57P:<<%FJ-B(0)
M@2L_PZ=\0<W8RDO$QW=SUXD0G^P,C@C\@/MO8)-1;8/T-YBSU8/,U6N7)Z]%
ME<0ZO:4%%)_W-,U9;^I+Q><!0C Z.Q2_EQ6_J)1\&+,R/F/496W?B4L. +[
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MQ:U-WV4.?"+"EYW4>8F_#M<+YXC'=:MU"= -^EPFY))S-2JN9_?JC_\>PY0
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M@&MU.%RZ;8ZIE&Y GQ1VK4;NB"\SF">*O_\/SLA-_(;OHOS%_IC2#L!5[5H
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M+8H87O:.62*&$$L8BX]8<1.TJ'0[-Y'3<&,?9UW)T9*66\31(8X/7;4O2?^
MNNW?Z(?J(_H'>UG_7_\/4$L#!!0    ( -" KE*$/GMH=64  +^?!P 5
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M_Q;,9C[OD-48$L%C7O%Q!VS.R#!.A(EK<6O-@X\Z1.^)<"+L@XJ^Z4)XHQ>
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MN+E&^-%R =&'K&2\8CA:,M$WAH0Y8D$DQ:?MW1.V/)^8&G0BGA/]S3V8EFH
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MV;*M9E1>N2:=Y]Y.79 +R-5R"32*!PG.M 291V/-E]GQY]Y0=_L0N-5BY8.
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MH?ID=O>$9O\XXO;GIYA],3.V00HSWH<=!IZ95SSILYE]VV,!>>H%& HL]]A
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MD)]F'S/,\S"S[7 31BTQ?\?$)F16(K40S\$285K.L\WT)0<<,C;4@M:*S<&
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M_%!$<=)'TOJ(IV&WV?6HE#?L-KP:E;*&W8;7GU+9L/ML)'JB"PG77&OOL['
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MCRK2>CI^E1IK<O'\',1ZG)-<'#X',15:0#YSLYG0U,WOV+KY5?;Q?+'(2E\
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M=@6Y=S')*TE&04M:(P'XVD6_4AY8\=+8UR:5TLA/=$K=/*;438&%'<N=6_P
M51IL[.0S\#1$(@Q'^>[=IM=A0'XQ><',0=.5\YEWQ&-0GMQSTJX<TZ ;>>V8
M(=%7;=24A>^>DWC, .V;0Z/#(QM%[*XI-4#O<T^W4BA1QH&'IEQ?54[RLR41
M@_\.+'R-0OZ*(Y+4A[16(G.6ISVT&3^1@3O9IAGB@YOS+]39C"GI(<WWGNC7
MIU_ ?0%W1!.N)8INRHPQ& 3B-R]B,1*=3_2%Y=)%4HY!Q2CZ?="96WY6Z$K<
MW\3H3E?58[JJBJWM6+S 4B>I(1"-5U)TZ5$>'<:E&HDA;/9;CRZ$4V.' 6MV
MOHY68&.[F4$[25Y5T,:W,(:LV>E,LLBVN=.SVDV3+E.Q:[.(JM==A?=F4Q&M
M=A@R>"<Q*WYMR.8^GRF7IF7I/9H?97+%<O9="-E30J;=X+GE6A[96;3=9=DW
M4B\T70T_F.<:Y1/4X(L@)^4)99@@A^@>>7:(L6"60 ,A'7Z5$A8NE$SD0O,L
MKHFT4S&/&CH]=@:YE6F;U$Q+ZBWI_N)1M(M-]A.Y,2TON$-$Y0AT%:KX4'K\
M"VL+B;TDP<#!E](</*PMO+$D&,A_*#7^#97L:.[9R$6KW07Y -J"G-21D.MF
M%+I@MT"6(]J[Z/ [Z17Y$^&?OL2"Y+Z3ZP]A$3,K%!W[X"OI><\WT/;%NUF5
M?2K-PSE$-Y[H'BQ^V*-4;]>PJH10CW-1U*Q*7_\-%DO+5RI3N#.'Y !]]A^3
M>4!KIM7[W9=[NJCUZHVE34>[T]-<NW<<#3U$9&HS9F/I^B&F55&EYA]+)Q!Q
MG YM-/9B8G8%&C&D#HQI!I+9HE]\.^5N.PPFLRORB,%4N)(RF"8ASF"J<R&,
MI>6.^/G+NW_&TEY''*<#/QT#:I)4>:#R'E6&TV1'97#*^+S'TE>HZUOA;4FU
M<L.;"W$_""'>9RR&G/*8O8'5XY3$KO(IDW464![<9"9RV==L5L79O-3=\HB$
MF>/ >$*9<H<*PT XZ \\SJ-N!AK<X#<>V3G #Y(JSQ(! U44I!ZUXI"T^7+F
MO-!(EP6P 7P!SMR[1P'(1,)P/W;Q$U3/KQHF-86/@.?@QO,#'-)=N5]36NTO
MJ7G+OR$:2>F83_FNG'F.7)@2%SD=\Z([8E^2747\%1\]_3OPPL)X1RMF"&?-
MU]/I]RP]!A' :3<=-<>J2+7'!]2'$-MK6FKTP/P6JNL@3EO'C)^ 1R[^-YLM
M1B] N))3V==ZTD:C31,!>.,]8$1,#]__'2-?B/U:,GVE.^?JW///I9&4EN +
M0,0KL1\OP1;Y4$C$%3Z5+(@133LY19$&X-H1-1_+\[%&KI,Y&W+\5!+I:W\>
MMK%HMT4/J?4UJTQWA;93RI&2VCT';1KN0^ING"^YK58.(CIP3IK(+*C)TM)6
M;20E=]/QO-!RF9%QX]DX*BG^A*(48W=W#5^!<[&V,)]=(T.UST#%V*&8<^^H
ML&DJZ$JM$<$1(F>^O$I\%ZG4X%Z/&@J])3$(&<GE!#3969%<_A,&ZXO0#] &
M8*FB9@V$>I_+ KP +Z1>"K3RX#^9BZSUY$HH2YV#4D^;H*W(24C':MQ!+_(2
M[^]\M/<J]M=PR^3F^>[!$M430F3EY!$&6PLZ2=H:J\Z;_#SI T"+N,R#-<![
M;47,A"#]8?PW?@&F<$CY.>_BPL/78>1;Y/=A-%&0/ T^L,C%F4SODAPP%VTI
M[02)A150&SG)@(W%O\#Q$*;<^CQG5.>-!P,8'\3Y,CV>4H>;@ZJ"$R"YBV43
M1,"OE'TZFZ1C[CT*H T$5YJ+ELJU)7IB_RZ2[*"VZUI&L37'U"%GN6YRVY1F
MLXQ,GXDL<3EU<@%B/U-@ZI:3E4O%:W?TE9[Q_6UQOER2PX#Y=57Q0_T%\Q)A
M+;*Z%03D?3_I NQO'8+"J9Z(EG-$>V7-E]\)&]1VF#\'%O2HV7'U:D<-LJ\1
M5E#NN-4PJF_]Y['3E/_0<=&2XI)^GK@+A#@J?-?J_#_^%1)C^1HA:K=9=@1[
MM @":I:#E([]G+>6VSJD>*A-A1[X=7:-T2VFI6L)Z7D#<0G-U>_D1HTMES R
M<XAI"6E*8@!?9)03+\6ID$5RT4 ;Z/L([V@@@& B>?G'QUG<HJ>"'OT53\AN
MJ&P0B" S363DBEJ C>4YK?9F'0G],2#WU@:(5SJHIJ%_!J*U#<J^GLK.Z+'=
M$+D"!+L'UXJLK*N_0AAI=G[NN4E)S,?'068NY&^'\R _^O%(K@@TL_2[YV^!
M#9<0./S'IX% 9SS3*"P*SGYLWB-3\['4?GV$K_\/8'1-S)U[RU^+EZBI)B#'
M#WW5B:KZ KRAM=MIJ79O=>/][]#=/?TBD][=$S,F , 3952<LMH9/()M$!'N
M9AH-Y-L5C!+?%V6?2O%PY3Z"5>@YZ,)RX1)A#XJ*UAH*<JB@</482$!R^-W1
MEI/Z Q T,>WOFI9#%2VL54U!;I=LMB[: 7".O-!/B[2*;I1:(KIO@>VJ70V@
MQ-5!\J*BBE>E5.4\@1!A0(@B++A/BA]V92<0H\H)[>BU^1'@%V@#7\RVJ2'0
M,<]SG PH8MJ4?RNGAU'D9T.B^O7@LV:4_#U,/K#?K=#+>P? &"7RAT. R(]^
M7'D!%#G>Q6\Z8.H6K"PW'H5WP4H_ZVI7T9!RY$*''OQH/"AZ%.HHZ.1:Y#Q4
M?]\5QVE@CQBXA<\ZYT\$QH./6O@6/!O@1V)G7P#7E3/ *FGH?ZLICVR2N?KS
M4]4QRR04YG$-0'!+.9>J'5I'I:]9B-I0U33:E)%]M"&Y=<IXWXL?=R4GDG;%
M_#R6?-09;]:K!&_YC[KB;4%# \0XRWW2*5\B,C_S@82Y%/4^P;N8K^0OAVPE
M/_YQ,>/A*?O;G;D5P8K>6'\':(6M[1K:EBOH"JTFT+DK-#NHE#NT2$!9Y7;Q
MPMD-5'I__!?7\ESD]*3KVV@#TF67U_ -A'J<BZB>KR4C6:P">$X4P9ODN:79
M/8('H9F0GM1$,N@^GR2,HSG%-TP=E;YF(;I5JFE(A@; S7.(?2#C!2[_6$MZ
M?INN CUU$L@,^T2X%%WXTL_E7&MK"X/4GY@&TXIZVNJI:$FDQ9A:B?ONT/?(
ML]A/LCYG<6TI3%K+#B*,SY<9UH3W4#F!=B%-MW # ^"DX<<7:+.UO)ULI%,#
MN3[3@J?^)5/_DJE_"1MIZE]R+&55I_XE4_^2@:+6U$BAP1X82U<392>XP@;,
MG]TS8W&LMZ%1BQO 6#I]R-ZZ$-_%<2R=0-0=Z#+'0/XX?S06Q3JG2CE&!;5K
M>$7]9E5;[L9C^$SGD.L<5GMF\X?QL[%0-OJW&] J',TO9K<VXGC50-S/, RT
MZ2K+=5YK']WR1_:KL6CR/& V8U8\N&9?QOB>L',N ([']Q2]KV:+O?8]\,JZ
MFGZ=S)1:L=<0:Y,3>*?FX<@7JX0:XZA2G+Z9>4CYXM!0/B".@3+9'HV',!/9
MF#]TYCG=RB,_44G<Z1Z)4T-;!E;%YJ+2Z&"&AIF^B28T\G'<# VS5;Q4@_>#
M>/P4JR]F[ASEM\#J%(N\<#;7A=J8J-* UJ%E=&JX)<Z1GI1!3"2YBB%H]O59
MIE5U1=9="MFW2=XU6IX'>91Y 6>>6[HZW_00CT,1=F9H*$9=AK#0<3N;HBV:
MCUMU]G?^Y)GG7>;*G:]!J7 >#0VIX*R,P&?RGTT!$_5GLK3@1>XHGIF'7EUQ
M$%16G"3=3F=F.C@K2[B@BA(R#! S75-*=5YY!:#\(3/3SUE;-RF/3EDY)[;+
MS)3B?.6P4&6)+H;/9'FVB=0OK;^6/Y_FNKHD*MU5(%HXMH9ZZCDJ&W):IY/S
M/H-5?:G*%+./$V8,LYJ:HPPPLY4#YRD\+!*;PO-I/$*J>3\5ZOFF,'TV\]AQ
MAW8TE5U.@?IJ]HU(<#^5E,Q.D3+\>4(@DEFV OH>R@^&RW@54%;7Q$]1_&2F
M=T?NZ%9W04CQ^FRVJ%,;7IKO;)&_79KYSEC?$62/3W6GDG2?&9J]P=?I1<#V
M^&!X@)-HE$E#]YX4MF]FVK;RH27YKDU[G#Z>3OKQ,"8@UUZ+ 66V.:;,'UO6
M)2VO&<V+ ZB;>Q-"V1YXZ68SW/G?V$DPO6O6M#Q,P?I@M@CCTY!<G2M3R#Z:
M:7VU+,%3@&FZ/&9ARC2'31$R/ %6?"/E&_?N<?ID:*"EL$"O%^6?/II]V>GZ
MT?N6M<Y.(34\59&[(7FVB")G0W6&H?(Z?R\ /Z/C1K$VUS\+WI<)O.(=( 1/
M*/,A!'Z2*L.0^WQBMC24P2V?9K3/+HJJL]D%_$Y/)_QR]DE(U>U\^?A72(A?
M(Q3,E]>6'96;C)YCG"QXH[3LJL$[)_C<(2]8NT1%Y[:9X?&RPDC-/"^TW >
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M(QL )\K^;[U].(@->K=$_T</-]GY\6U>GR5_,.P@<*I\#R_5-G\"RCL1E2\
M6RN0\Y/HB9>68&L0.!^=37'D]G \DVN$DQ_1WQ.ZM.OF[*C1SFJ"08"<9TC.
M4X(<N(3@0)]'K16X+[&<A+1)J.=F$?%<:R.G33O%4U0[&;^5?^8<4?++2XB)
MT8\PUW0:"$CQ$\^0W#T@CA^3K  <=@3DY(R'E):T(C=B,GOESRY[VK6/?__P
M4ARTML]OW]F+!5TJ!X@RB#2P%I7?R,.@$2R^\'>)U2UO6FG%R=Z_' KFL1U^
MIF5%N-K0"\Q$DK"FU-?J_DE2";#-Y'3,Z\:ST2:N3D<YN*5<4R4@G('80*C'
MN8CF)]:2D9B'CX/,',C?#ODG/_IQ9[W"3;CAWTDE'W7&&SE[XKSE/^J*MP65
MQV*<Y3[IE"_>G7?P0:O$:+)[)5.@,U_J.*WGH4]4I>_/[/BQFAXQ^D<,)/*?
M.8CU-2=!Z5-)PJ1T^:KX%7(9]YS%X_?(DA)DK?QC*3ZN(?8#239*OYV*<TAZ
MG8ZX6,I48.0H"XS$KK?8Y$M"Q!-WTLSWD0VI/X&V8GM ?K!%'HC;@&8Z(%/_
MB:#,4#IFI[,FL@&NXC$[FF/)"'KN#@' <!,[O*A[F,8TQPZD9U?B]/'1TS&S
M>XLF*-"F;M'E4O1,E7XN9XL@;R^2]^Y/4>NCFD)7=OP3#&BVZHWGT!#=T'+C
M/>I&&Y1V57U"5UY >X)P;Q$ILMKF)W)GJ?A8:G=D+,K$G-Q'X]&*^? %2%BK
M0C2G D]&%'B2MGK:E(-J.Z@.C%@>#FTJQMA,2D5'.JKPG.;+%)MJ.U+O^8&*
MH"HO9M5VKXRP])6B,ST5RIH*9=7B4E$H2\B,&&&Q+'7'L\:H-+V\5K,Q7H5/
MT]6!E7(R4V&TN::AYILE@\_L'H^=ZMM2+T+^2'\T%MDZ#\QA_Y5&EU&'A=D&
M!9J00PZU=S)V6(-M/+AR.:C'4KVM4X%:6WSTL[&8]EU\],SLB]"@:F&:K=^&
M5N?UB]EJK^&*7QJUD6+S;=38E ?6,'#,UN+*BZA_,URN=6GU5 ;'Y>V?K\:B
MVQ1@V(#504CD'K73$[-=&_RAIH?'.A,3R\ RW ;LRK&;B7#.'==3\[ LCP!'
M)?'GZ:XZ-=/&J(K11Z59 @P-,XV*)C3R^1P,#;/%<Z<F0VTV3UX.F?>H))(9
MU8Q9P6PPW@7-DQN7OVLW9_6EZ!GO:!9$3S#KD^%HIJ[0Y2@J31].P=51Q=Q4
MU:,BAYPMA.$V@+KL?A4KT%CQ@*V+V:T2NED7WLH<*<J?S=:5:E'F+NO"X)V$
MBR"\U?5\&*B&^XFZD]C*:SZQ-3'[QM+!1F\N19:":_@38C<;7E,].[9(D[TR
MH$6JJ.S(5NO;M%KZK/ZZTJ;IDGQ5GB,RM!ZM_2R*ROJ];+&4-U6<%DNT:'6Z
M&-_,;LK8S5)P5$]G (^^5W<O^H*O;O]^E<B4IV,@OD82/2@8XH8[L0=Y*O@[
MI+!U,KL%\C#7J:8Y4+HPAH9C'.FED5&JZHG%%FXZ41I/E'#_N'2=QI[L(.^
M/^AYF"+Z8;*R%%M9F1Z7#.5),8CZT\LZHJ9X?C2[ ,G Y'5]LURV*)-P%MSD
M\AJ4JP5TNC+38X;.XR+6P9PMTF2#BB_2A6OY_GR9Q.7-<>1,G8>!'UB>0Q1S
M!M^ODPY6A&_N%2']1S_Y5S^K$[Y.$3/BH.\!)1?:1Q $+J!>H!OOPO+7J6QA
MM?>R:&L(I?G[^P+89#(_XW^+_HE^N #+-_2_WQ<WN2'@9A-ZA+-GB-[9:/-^
M7^#T?6"](@]M=O&P;':1J5U N/RG^]#GI/[@$TJCJN?+^1;$ 5[^)0@LZ.YQ
MKRJVNB!L_-#'1KQ+?;C9LCJ7Q5U-@<Y] ))(M3V9PL8>#MY3:S15Q?[K_&0)
MPY#6GSD,GXBJV!0%CZIFDB)#3XT>! OWMFGP,#5VF!H[=+?*4W.[J;D=)Z$1
M-[<3/U=IQI4:Y=NB;+M2!J82[J,IX:YTWXROG'L7YUXJX=]@M+M)^#>]#GRW
M"?^F5X37E?!_HKY4SM#"7'7)RMHJLN:60^F[BJSI]7PTE3:MJQY[:K:F&EKU
M6/65@,8JDI6[I,=2V+ZK9X0692OHF]2(WBUC43RSB?%&.ZTH?HZLHWX,KXRE
M_.MZKFA=4:$NC^,@%W,!J#8AAOT%\B)O2FBYM!7$J? CQT"XUO:HU&*^F= @
MSHF=Z5P.*?8&\9C7D#TS<QP82W(F!*0\KATS<@Q8-I_9V6J%P8IHX,/D2GTX
MMV#R&-8@<U#[P[B2B7UBVH1D>R:DNG2WEE+E9T-$8.KAXQAV6(4HJM:U!U4R
M>A>:W)P>PVH,$'9.E@8E59O*P%PCO 20-E3DK 6C([!*EK>C0+Q0WF(P> MR
M=A1HBY0YT@BU"%N#P-E8:6T4O@ODNDN$Z8<#A#K'W3&@SE]SI7?;KX2G8T X
MLW/T0UD8?%"6F[AQI!.[TN&UI3@(5JX2S($0I'X,NZ6T!J>^W5(Z_#'@-BSY
M='2848U_W:L]DN-@T.@5G\J[1.I6;Y)=38=J_LG6$!G$RDZ):B8DJBEO8224
M1--ZT"EQ9C2),ZWWROB2952=:=Z@;W,Q[3OHV_#<&5T1R34VU5@2;8ZF:>')
M5-:4]^JDL*!SU662K<K45*:%.Z";E3JLA7[R4?DB;6//8&#A8%HJI3V!3CY-
M)TK1,K5H\W#R6=TJ?(M7P8MBQ)P1KD,7KRWI0BGL:C8M5$=/BNEB?>U($5UY
MQ[]<G=IQX@U43KXI7ZNAI6$.<J5DPDG2IEU3;Y6N HGTKW!F6=5W1C#;?N]R
M<3MI+?EQ.K='L+2"(<+IZGZ:5O<(5E<XX)XU@I_6=P#KJS9_A77-[DCW3E>6
MCO.\6-_FZ7CRKYZ>C$C69=C,ICM:\UN[$9*5+8=/E2_9@"XCQBU<H?WJ64?+
M-^FS[HH]L!:)9HK+82]<0S64J;6?RNHVA^OVW#S@L[#%7U,G*%W-S]-J2AZU
M%DNFLM(6:_BE824'43COW+7LGX_VFORN'P-*KT($G#OD /<)70+"^(:L7]H@
M;;[,M%_\3LA=(UP2%+=OB1P7FBOYA?U>:%69KW_V!U[ZKT> M-;W*>L-RIU!
MW]G0@\BR:=-.=4$L2RWI5?S,'"VF?R"7D'')F1X$JH?L'!VN"^C_O,: WGP
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MBZMOM%T]SFGT=50XK66OM3ZM92_0_C]02P,$%     @ T("N4H$.J[(H"0
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M=%V!_R.9,:@3$+'BJ\N %X&11 H>'N&$T))R29_<\9NUI@%PS*6IRRB121
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MX0M(\<35@_O1R\!G-7C27%)'DCS]M:1!.0^L\*& ( AT,4H*1JU3=& $$S#
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M+FAT;5!+ 0(4 Q0    ( -" KE)(/_>CNAD  ,TB 0 1              "
M 2T6!P!I8G)X+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( -" KE*/._>2(!,
M !TN 0 5              "  18P!P!I8G)X+3(P,C$P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " #0@*Y2F]-Y?$=$  !:N00 %0              @ %I0P<
M:6)R>"TR,#(Q,#,S,5]D968N>&UL4$L! A0#%     @ T("N4N1C_8MFF0
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M97@S,3)?,3 X+FAT;5!+ 0(4 Q0    ( -" KE*F7I1T1P4  &8@   2
M          "  <>9" !I8G)X+65X,S(Q7S$P-RYH=&U02P$"% ,4    " #0
M@*Y2=/WY83P%   +(   $@              @ $^GP@ :6)R>"UE>#,R,E\Q
<,#8N:'1M4$L%!@     *  H C@(  *JD"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
